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In developed countries, human cytomegalovirus (CMV) is the major infectious cause of 
congenital birth defects including microcephaly, mental retardation, sensorineural hearing 
loss, and intrauterine growth restriction. Nonetheless, because of the potential for 
teratogenicity and toxic effects, no prenatal therapeutic treatment is currently approved by the 
Food and Drug Administration for congenital CMV infection. Therefore there is great interest 
in understanding CMV growth and blocking or altogether preventing CMV infection.  
 
When I received the email from the Viruses Editor-in-Chief, Eric Freed, about editing a 
Special Issue of Viruses on Recent CMV Research, I debated with myself and my husband (a 
Pediatric Infectious Disease physician) about the need for another dedicated CMV issue. 
There were several recent books, chapters and special issues on CMV including the 
comprehensive “Cytomegaloviruses From Molecular Pathogenesis to Intervention” edited by 
Matthias Reddehase with the assistance of Niels Lemmerman (Caister Academic Press, 2013) 
as well as a recent supplement (Supplement 4) of Clinical Infectious Diseases (2013, volume 
57) on Prenatal Therapy of Congenital Cytomegalovirus Infection. Nonetheless, having 
participated in the 4th Congenital CMV Conference in San Francisco and then being 
interviewed by Kayla Dufrene, a young woman who had suffered congenital CMV infection 
convinced me of the vital importance of continued efforts to understand the CMV life cycle 
and for developing new approaches to preventing and treating CMV diseases. With this in 
mind, I accepted serving as Guest Editor for the Viruses Special Issue on Recent CMV 
Research. Following my husband’s advice, I asked Kayla if we could use her autobiography, 
which she wrote following our meeting for her writing class at Gallaudet University, as the 
Introduction for our Special Issue. She accepted and it is the first paper in this book (Dufrene 
et al., 2014). Her autobiography is the backdrop for this issue and should serve as inspiration 
for many CMV investigators. Tellingly, Kayla has also been invited to speak about her life’s 
story at the 2014 Cytomegalovirus Public Health and Policy Conference in Utah. She 
provides an unparalleled perspective for the CMV field.    
 
I am very pleased with this Viruses Special Issue. Of particular interest to families and 
caregivers affected by CMV diseases are several papers: addressing prevention of CMV 
infection of trophoblast cells (Zydek et al., 2014), CMV latency (Sinclair and Reeves, 2013), 
as well as of CMV lung infections in non-HIV infected children (Restrepo-Gualteros et al., 
2014). Our ability to enhance immune responses for controlling CMV infection (Hanley and 
Bollard, 2014) and new strategies for CMV vaccine development guided by non-human 
primate studies (Deere and Barry, 2014) are discussed in two excellent reviews. Several 
articles address the CMV manipulation of the immune system, both innate and adaptive 
immune responses (Stevenson et al., 2014, Fink et al, 2013, 2014, Raghavan et al., 2014) and 
of DNA damage responses (E and Kowalik, 2014; Kulkarni and Fortunato, 2014). 
  
The CMV life cycle itself is the subject of several papers, including demonstration that the 
UL97 protein interacts with cell cyclins (Graf et al., 2014), the UL34 early and late proteins 
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are required for infection (Rana and Biegalke, 2014), the intracellular trafficking of CMV 
proteins (Niemann et al., 2014), the roles of CMV tegument proteins in virion assembly 
(Smith et al., 2014), and the effects of US28 protein on cell-to-cell spread of CMV (Noriega 
et al., 2014).    
 
Development of new drugs for CMV depends heavily on the generation of novel 
understanding of CMV lifecycle and the mechanisms it uses in its progression. With this in 
mind, many studies in this book has made significant contributions of state-of-the-art 
technologies to the field including the use of mass spectrometry (Reyda et al., 2014; 
Gnanandarajah et al., 2014), protein arrays (Puerta Martínez and Tang, 2014), adenofection 
for efficient transfection of CMV genomes (Elbasani et al., 2014), superresolution microscopy 
(Bhuvanendran et al., 2014), next generation sequencing (Sijmons et al., 2014) and targeted 
ribozymes (Yang et al., 2014) to enhance our understanding of CMV infection.  
 
Finally, I want to thank all the colleagues who contributed papers to this Special Issue, which 
has impressed the publishers and the readers alike. In fact the publisher selected two of the 
papers from this special issue (Zydek et al., 2014; Deere and Barry, 2014) to highlight in the 
MDPI Magazine. It is my hope that this special issue provides a valuable resource for the 
families and investigators in the CMV field.  
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1. Foreword 
This Viruses Special Issue on Recent Cytomegalovirus (CMV) Research is dedicated to the 
patients who have suffered CMV infection and to their parents, families and caregivers. We are 
including as a Preface to this issue the insights of a young college student, Kayla Dufrene, who 
suffered congenital CMV infection and contacted me and Dr. Roberta DeBiasi, to interview us to 
learn more about CMV. As I was just returning to the DC area from the 4th Congenital CMV 
Conference in San Francisco, I was particularly receptive to her request. When we met Kayla, we 
were both impressed with her personal strength and ability to cope with her disabilities and needed 
medical treatments. Despite it all, Kayla has an exceptionally positive outlook on life, feeling even 
lucky. She has not only coped, but has transcended her difficulties. I am proud to say that she was 
on the Dean’s List (Figure 1) at Gallaudet University. Ultimately, her hope lies in our fields’ efforts 
to develop a vaccine to prevent CMV disease in other children.  
Her autobiography (in her own words) is our Preface. For those of us who work on the virus and 
anyone interested in the consequences of CMV disease, it is a touching and inspiring read (Figure 2).  
2 
Anamaris Colberg-Poley, Guest Editor, Viruses, Special Issue, Recent CMV Research and  
Roberta L. DeBiasi, Professor of Pediatrics, GWU, Acting Chief, Division of Pediatric Infectious 
Diseases, Children’s National Medical Center. 
Figure 1. Kayla finding out that she made the Dean’s List at Gallaudet University. 
 
2. Preface: Cytomegalovirus — Patient Monograph — Kayla Dufrene 
Prior to writing a research paper for a college assignment, I never felt the need to learn more 
about Cytomegalovirus (CMV). I didn’t know a lot about CMV, I just grew up hearing my Mom 
tell doctors that it’s what I was born with. It’s the reason why I have hearing loss, bad eyesight, and 
muscle problems in my legs, and also the cyst in my brain. It’s also why I have had to endure two 
eye surgeries and surgery on both my hips. When I was born, I was very sick. Besides having CMV 
I had an enlarged liver (when the liver swells beyond its normal size) and yellow jaundice 
(yellowing of the skin). I was very tiny and had to stay in the hospital for a month. The doctors told 
my birth parents I would either die or not have a good quality of life. The decision was then made to 
put me up for adoption. 
Figure 2. Kayla enjoying the cherry blossoms. 
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It turns out I definitely DID want to know more about CMV. What are the symptoms? Is there a 
cure? Is this a genetic disease? Is there genetic testing? How does it affect my body? How does 
someone get CMV? Is it an STD? How is it diagnosed? Can I get it later in life? Is there a vaccine 
for infants? Is there a test for CMV? Is it contagious? Who can get CMV? How many people are 
diagnosed with cytomegalovirus? How has it affected me? Do I still have it in my system? How 
does my case compare to others? How will it affect me later in life? Could it affect my sex partner? 
Could I really have died? Did it affect my birth mom? Is it a genetic disease and something I have 
to worry about in the future? 
After reading texts and online references on Gallaudet’s library webpage, I had a foundation for 
my search and I was ready to start building from there. I developed a desire for more knowledge 
and answers to a more of my questions. I learned that CMV is a more popular subject than I 
thought. When I read about the impact it can have on the family, it made me understand a little 
more why my birth parents put me up for adoption. They couldn’t have known the extent that I 
would be affected yet here I am, 19 years later, a student at Gallaudet University. I was very 
excited to continue my search and learn more about the disease that has made me the person who I 
am today.  
My reading taught me that development of a CMV vaccine was a national top priority and I 
wanted to learn more about the efforts that doctors and researchers are going through to make a 
vaccine a reality. I know firsthand the effects of CMV: Knowing a vaccine could have prevented a 
lot of what I had to go through and could prevent newborns in the future from being affected by 
CMV I believe is worthwhile. CMV is very common and the effects it can have on a child and the 
family can be very hard. I know these from my own experiences of being picked on in school for 
wearing a hearing aid and being “the girl who walked a little funny”. I was excited to read about 
clinical trials that are testing potential vaccines for CMV. One of the articles explained a clinical 
trial to develop a vaccine to prevent CMV among mothers and infants. The possibility of a vaccine 
is very real. CMV has affected my life from the surgeries to the teasing in school and the thought that 
a vaccine could have prevented all of that is mind-boggling. My life could have turned out differently.  
My reading sparked my interest in interviewing someone knowledgeable about CMV research 
and disease. The deadline for having an interviewee was quickly approaching. I thought long and 
hard about where I could find someone whom I could interview. I then thought that since CMV is 
found in babies, maybe I should ask a pediatrician. I found out that the Children’s National Medical 
Center was just a few metro stops from Gallaudet and I was lucky to identify both a scientist (Dr. 
Colberg-Poley) and a doctor (Dr. Roberta DeBiasi) who focus their careers in this very area. They 
were both more than happy to meet with me. On the day of the interview, I was really nervous and 
wanted to make sure I had everything I needed prepared. I explained to them that I was writing a 
paper on a topic that had to relate to me so I chose CMV. I told them how I was born with CMV 
and of how it was the reason I had two eye surgeries when I was a kid, a hip surgery on both hips, 
and why I wear glasses and a hearing aid. They were thrilled to have me there, eager to share their 
knowledge about CMV, and just as excited to meet and speak with me as I was excited to meet 
with them.  
Dr. DeBiasi shared that in her entire career, she had never met someone as an adult who had 
been diagnosed with CMV as a baby. She said it was a good experience for her and an honor to 
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meet me. I shared many of my frustrations, such as the fact that no one figured out I was deaf until 
third grade, and I was able to ask if I born deaf or if it was detected late. I learned that even though 
the virus is latent in my body (just like anyone else who is infected with CMV at any time in their 
life); it is not something I have to worry about when I have a sexual relationship or children. I 
learned that it is not a genetic illness, and not something that I am going to pass on to my children 
genetically. I also learned that it is hard for doctors to accept that there are diseases they can 
diagnose, but for which they can’t do anything about, and they want to help change that. 
The one big thing that I took away was that I’m going to be okay and I do not have to stress 
about my future like wondering if CMV was going to affect my future children. I also realized that, 
when my birth mom put me up for adoption, she couldn’t have known what the future held for me. 
I’m glad that she’s okay. My adoptive mom did a very brave thing of adopting a baby that she knew 
was sick and never bat an eye and, over the last 19 years, I have not once heard her complain. 
Hearing Dr. Colberg-Poley and Dr. DeBiasi describe how there are even worse possible outcomes 
for people with CMV makes me feel extremely lucky. Something so small created a lot of 
problems for me growing up but it has made me a stronger person and more understanding of other 
people who have other problems. If it wasn’t for cytomegalovirus I wouldn’t have hearing 
problems and I wouldn’t be at Gallaudet University and I never would have had the chance to find 
out all of this information about CMV.  
Doing the interviews was the most beneficial thing to me because I have never had anyone to 
answer my questions. I was not sure where my search would lead me and what I would find out. I 
have always lived with the fear of not knowing how Cytomegalovirus would affect my future. I 
have always had questions like: What are the symptoms? Is there a cure? Is this a genetic disease? 
Do I still have it in my system? How does my case compare to others? How will it affect me later 
in life? Could it affect my sex partner? But I never had any answers. Now I have all the answers to 
all the questions I have ever asked. The search was hard and stressful but I’m glad I had the 
opportunity to finally learn about CMV. I have now made contact with people of whom I can ask 
questions that may arise later. During the interviews I learned things that I could not get through 
any article or any book and I got real answers. It’s amazing that something as small as a tiny virus 
could have such a huge impact and effect on my life.  
After my reading and interviews, I left feeling much more knowledgeable about CMV.  
Dr. Colberg-Poley and DeBiasi answered all of my questions and made me leave with a new-found 
confidence. I’m going to be okay in the future and so will my kids. CMV affected me as a baby and 
growing up it caused me a lot of problems, but it’s because of having Cytomegalovirus that I’ve 
had the experiences I’ve had and why I’m at Gallaudet University. When I started my research, I 
was not sure where it would lead me or what I would find. I have learned a lot about the virus and a 
lot about myself and just because the past was tough, it doesn’t mean the future has to be.  
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Abstract: Primary infection with human cytomegalovirus (HCMV) results in the 
establishment of a lifelong infection of the host which is aided by the ability of HCMV 
to undergo a latent infection. One site of HCMV latency in vivo is in haematopoietic 
progenitor cells, resident in the bone marrow, with genome carriage and reactivation 
being restricted to the cells of the myeloid lineage. Until recently, HCMV latency has 
been considered to be relatively quiescent with the virus being maintained essentially as 
a “silent partner” until conditions are met that trigger reactivation. However, advances 
in techniques to study global changes in gene expression have begun to show  
that HCMV latency is a highly active process which involves expression of specific 
latency-associated viral gene products which orchestrate major changes in the latently 
infected cell. These changes are argued to help maintain latent infection and to 
modulate the cellular environment to the benefit of latent virus. In this review, we will 
discuss these new findings and how they impact not only on our understanding of the 
biology of HCMV latency but also how they could provide tantalising glimpses into 
mechanisms that could become targets for the clearance of latent HCMV. 
Keywords: cytomegalovirus; latency; immune evasion; apoptosis; gene expression; 




Human Cytomegalovirus (HCMV) remains a major cause of disease in a number of patient 
populations who have compromised immune systems, as well as providing an increasing threat to 
critically ill immuno-competent patients [1–4]. These pathologies associated with opportunistic 
HCMV infections can be, in part, associated with a key characteristic of the virus: the ability to 
establish lifelong latent infection of the human host and, crucially, reactivate [2,5]. A wealth of 
studies from a number of laboratories using naturally latently infected cells has led to an informed 
consensus that the cells of the myeloid lineage represent at least one important site of HCMV 
latency, persistence, and reactivation (reviewed in [6]). Thus, at a cellular level, there is a clear and 
intimate link between myeloid differentiation and natural HCMV reactivation [7–14]. Furthermore, 
the use of experimental infection of non-permissive primary cells and cell lines in vitro are generating 
snapshots of the complex regulation of HCMV gene expression at a molecular level [15–25]. 
However, these studies have focussed predominantly on the regulation of major immediate early 
(MIE) gene expression because the critical switch to a reactivating phenotype is dependent on the 
triggering of MIE gene expression from quiescence. 
In many cases, the species specificity of HCMV has driven these analyses to be performed in 
experimental cell culture models and, ultimately, on tissue derived from healthy HCMV seropositive 
individuals which has then been analysed ex vivo. As a result, the mechanisms that control HCMV 
latency and persistence in vivo, at an organism level, have relied on the extrapolation of studies 
performed in vitro or using animal model surrogates such as murine CMV [26]; guinea pig  
CMV [27] and, more recently, non-human primate CMV strains [28]. Consequently, the inability to 
perform analogous studies in humans has likely contributed to the perception that HCMV latency is 
essentially a relatively quiescent infection. However, as techniques for studying HCMV at a 
molecular level have become increasingly powerful, it is now emerging that latent HCMV infection 
profoundly modulates the latently infected cell and the surrounding cellular environment. These 
effects act in concert to maintain latent carriage and this depends on, at least in part, the expression 
of a subset of virally encoded gene products.  
In this short review, we will examine our current knowledge of HCMV latency with particular 
emphasis on recent data which suggest that HCMV imparts a distinctive signature on latently 
infected cells. These latency-associated changes underpin the successful persistence of this virus  
in vivo and, importantly, could direct novel therapeutic strategies to target latency and reactivation 
of this important human pathogen.  
2. Background—HCMV Latency and Reactivation 
Following primary infection, HCMV establishes a latent infection of the CD34+ haematopoietic 
cell population in the bone marrow [29,30]. The prevailing view is that, ultimately, the major 
immediate early promoter (MIEP) is profoundly suppressed in these cells [6] and that this is 
achieved through cellular transcriptional repressors directing histone-modifying enzymes to impart 
repressive post-translational modifications of MIEP-associated histones [6]. During latency, the 
chromatin structure of the MIEP bears all the hallmarks of transcriptional repression: tri-methylation 
of histone H3 (lysine 9 and 27) and recruitment of heterochromatin protein-1 (HP-1) coupled with a 
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concomitant absence of histone acetylation on histone H4 [11,16,17,25]. Consequently, HCMV 
MIE gene expression, and lytic gene expression in general, is profoundly repressed in CD34+ 
progenitor cells. This chromatin phenotype is maintained in the monocyte cells derived from these 
progenitors [11,31] and it is only upon cellular differentiation that robust IE gene expression is 
observed [7,8,11,12,32]. The detection of IE gene expression in dendritic cells (DCs) is consistent 
with the histone modifications present at the MIEP in these terminally differentiated myeloid  
cells [11,31]. For instance, HP-1 is no longer associated with the MIEP—likely due to extensive  
de-methylation of histones at lysine residue 9 (methylation at this residue being important for HP-1 
binding to chromatin [33]) and, in these cells, the MIEP is associated with predominantly acetylated 
histones. Thus, the presence of repressive or activatory chromatin marks around the MIEP 
correlates with the expression of viral major IE RNA and the latency/reactivation phenotype of the 
virus [11,31]. Importantly, and consistent with molecular analyses, infectious HCMV progeny 
cannot be recovered from myeloid progenitor cells i.e., CD34+ cells or granulocyte–macrophage 
progenitors (GMPs) unless they are co-cultured under conditions that promote cellular differentiation 
or activation [9,11,34]. Analogous models of histone-mediated regulation of viral lytic gene 
expression also underpin studies of herpes simplex virus and Epstein–Barr virus and thus represent 
a common unifying theme in the biology of herpesvirus latency and reactivation [35,36].  
The molecular model of HCMV latency in the myeloid lineage, derived from analyses of natural 
latency, has been reviewed extensively elsewhere [6,37,38] and has helped provide an initial 
understanding of the underlying mechanism for the differentiation-dependent reactivation of 
HCMV. It is worth noting, however, that other studies using experimental infection models of 
latency and reactivation have essentially recapitulated the key observations made with natural 
models of latent infection and this gives confidence that wider studies involving experimentally 
latent models will have in vivo relevance. 
2.1. The Transcriptional Landscape of Latent HCMV 
HCMV encodes anywhere between 170 and 751 ORFs all of which are believed to be expressed 
at some stage during lytic infection [39,40]. Furthermore, the virus also encodes a number of 
microRNAs (miRNAs) which, during lytic infection, have been shown to target and regulate both 
cell and viral gene expression [41–43]. In contrast, the transcriptional landscape in latency is less 
clear. The earliest studies identified a number of transcripts arising from the MIE region of HCMV 
but no function was assigned to them [44,45]. Furthermore, deletion of the putative ORFs encoded by 
these latency-associated transcripts appeared to have little effect on HCMV latency in vitro [46]. As 
such, it was speculated that HCMV could exist in latency in a relatively quiescent state and that the 
normal transit and differentiation of latently infected CD34+ cells into the periphery was sufficient 
to trigger HCMV reactivation. Indeed, transcriptional quiescence during latency would provide the 
ideal mechanism for evasion of the robust immune responses known to be present in HCMV 
seropositive individuals [47]. However, a number of aspects of the known biology of HCMV are at 
odds with the view that HCMV is maintained in a totally quiescent state. For instance, if virus is 
carried long-term in the myeloid lineage, how is the latent genome maintained in cells which will, 
at least at some stage of their lifespan, proliferate? Although no latent origin of replication has been 
definitively identified for HCMV, it has been suggested that a mutation in the MIE region had a 
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carriage defect during latency in GMPs [48] and more recent work has suggested UL84 may act to 
maintain viral sequences [25]. Furthermore, an overt characteristic of HCMV latency is the 
carriage of the viral genome in the cells of the myeloid lineage and, particularly, the monocyte 
lineage [49–51] but not lymphocyte or polymorphonuclear cells [50] despite the fact that latent 
infection is seeded in a pluripotent progenitor cell type [29,30]. Potentially, this could be explained 
in alternative ways: the virus actively promotes myelopoiesis of infected CD34+ cells or, HCMV 
may preferentially promote the survival of myeloid committed progenitors or, finally, HCMV 
cannot combat anti-viral mechanisms in cells committed to the lymphoid lineage. Arguably, all 
these scenarios suggest an active process involving viral latency-associated functions during  
latent infection. 
A number of studies over the last 10 years or so have applied increasingly sensitive techniques 
to determine whether viral gene expression occurs during latent infection. Two independent microarray 
analyses identified a number of transcripts expressed during experimental latency [34,52] and, 
importantly, some have been subsequently confirmed during natural latency; including UL138, 
UL81-82ast (LUNA), as well as a splice variant of UL111A, which encodes a viral interleukin 10 
(vIL-10) termed LAcmvIL-10 [24,53–55]. These, and subsequent studies, have also shown that the 
initial infection of undifferentiated myeloid cells with HCMV to establish experimental latency 
results in a burst of temporally dysregulated viral transcription from a number of gene loci, 
including MIE gene expression, at very early times post infection [25,32,34]. However, it remains 
unclear what this means in the context of latent infection. It is tempting to speculate that this gene 
expression is important for preparing the cell for latency—akin to that proposed for the 
establishment of EBV latency [56]. However, there is no evidence, as yet, that cells which initially 
express lytic antigens go on to establish long-term latency. It is possible that the extremely high 
MOIs used to establish latent infections in vitro results in a sub-population of lytically or abortively 
infected cells which are, ultimately, unviable and die, leaving the true latent population.  
Regardless, what is generally accepted is that HCMV has a very distinct transcriptional profile 
during latent infection, quite different from lytic infection. The expression of a number of viral 
genes has now been described during latency and these are summarised in Table 1. For the 
remainder of this review, we will focus on emerging stories regarding the manipulation of latently 
infected cells by HCMV and how, in some instances, viral gene products may contribute to this. 
Table 1. Gene products and functions during latency and lytic infection. 
Gene Product  Latent Function Lytic Function References 
CLTs Unknown Regulation of anti-viral 2’5’ OAS 
expression (ORF94) 
[44–46,57] 
UL138 Regulation of TNFRI (up) and MRP1 
(down), repression of the MIEP(?) 
Regulation of TNFRI (up) and 
MRP1 (down), virus maturation 
(133-138 locus) 
[53,58–61] 
UL81-82ast Promotes UL138 gene expression.  Unknown [24,55,62] 
LAvIL-10 Down-regulation of MHC class II 
expression, immune evasion 
Unknown—cmvIL-10 expressed 
during lytic infection 
[54,63] 
Lnc4.9 Binds Polycomb repressor complex 2, 
Silencing of the MIEP 
Unknown [25] 
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Table 1. Cont. 
Gene Product  Latent Function Lytic Function References 
UL84 Genome maintenance DNA replication, UTPase activity, 
transcriptional regulation 
[25,64–67] 
US28 Unknown GPCR, induces cell signalling and 
cell migration, agonist of the MIEP 
[68–74] 
UL144 Unknown TNF superfamily member, hijacks 
NF-kB signalling, immune evasion? 
[75–78] 
3. Mechanisms Targeted during HCMV Latency 
3.1. Viral Evasion of Cell Death 
Pro-death signals in response to infection represent a very significant obstacle for many 
pathogens. Consequently, key players in the cellular apoptotic response become important targets 
for the virus—and HCMV is no exception. HCMV encodes an impressive armoury of anti-apoptotic 
functions that it expresses throughout lytic infection and which all contribute to efficient virus 
infection [79–84]. However, there is no evidence that any of these already-described anti-apoptotic 
viral genes associated with lytic infection are also expressed during latency. Clearly, if the virus 
was to be carried truly silently during latency then, arguably, there would be little requirement for 
any increased protection from cell death. However, it is becoming increasingly evident that HCMV 
does actively modulate multiple functions of the latently infected cell and that these, in effect, 
stress the cell to the point that viral functions are needed to protect the latently infected cell from 
such stress-induced pro-death signals.  
In the context of infection, be it latent or lytic, the initiation of cell death can arise at the earliest 
point of infection: at entry [85]. Pathogen recognition receptors (PRRs) can detect pathogen-associated 
molecular patterns (PAMPs), triggering cell death—and this is an important part of an intrinsic 
immune response [85]. Clearly, during lytic infection, the rapid expression of virally encoded  
anti-apoptotic proteins could quickly provide protection against such extrinsic death response 
signals [80]. However, during HCMV infection of cells destined to become latently infected with 
the associated suppression of the lytic transcription programme, it appears that virus binding, in 
itself, activates cell survival signals [86,87]. This occurs in both CD34+ cells and CD14+ cells, 
albeit with the employment of different signalling pathways in the two cell types as well as  
cell-specific differences in the duration of the survival response. Nevertheless, the up-regulation of 
an important cellular anti-apoptotic protein, MCL-1 [88], appeared to be important for protection in 
both cell types [86,87]. Thus, although the exact mechanisms of protection varied in these different 
cell types, the outcome was the same.  
The transitory nature of the ERK-MAPK dependent survival signal observed in CD34+ cells [86] 
argues that is likely to be important for overcoming the initial death signals triggered by cellular 
recognition of virus shortly after binding and/or entry. Consequently, it could be argued that long-term 
anti-death signals may not be required by a virus which is truly silenced in latency. However, 
recent work suggests that long-term anti-death signals may be important during latent infection 
with HCMV (Figure 1). For instance, experimental latent infection of granulocyte–macrophage 
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progenitors has been shown to result in long-term up-regulation of PEA-15 RNA [89]. As PEA-15 
is an anti-apoptotic factor that blocks both TNFR1 and Fas-L triggered apoptosis [90], clearly its 
up-regulation could be part of a protective response mediated by latent infection. Consistent with 
this, latently infected CD34+ cells are protected from FAS-L induced cell death [91]. Furthermore, 
given that it has been shown that the UL138 gene product up-regulates TNFR1 expression during 
lytic [59,60] and latent infection [61], potentially sensitising latently infected cells to TNFR1 
mediated apoptosis, the concomitant up-regulation of PEA-15 would be a sensible pro-survival 
strategy. Other preliminary data from the Sinclair laboratory has also shown that a number of other 
cellular proteins with potent anti-apoptotic function are up-regulated in latently infected CD34+ 
cells (J.S. unpublished data) and this includes the PEA-15 protein, further supporting a model by 
which induction of PEA-15 during latent infection, at least in part, protects latently infected cells 
from pro-death signals. Furthermore, it is likely that these effects are driven by secreted products in 
the latency-associated secretome [92], since inhibition of latency-induced cellular IL-10 was 
sufficient to block this survival effect [91]. 
Figure 1. Protection of latently infected cells from cell death. CD34+ cells latently 
infected with HCMV down-regulate the expression of mir92a. A key target of miRNA 
is the GATA-2 transcription factor which, consequently, is up-regulated. This promotes 
increased transcription of cellular (IL-10) and viral (LUNA) genes. LUNA expression 
promotes UL138 gene expression—a gene product shown to up-regulate cell surface 
levels of TNFRI, a potentially pro-apoptotic signalling factor. However, HCMV also 
up-regulates a number of anti-apoptotic factors including PEA-15. This occurs, in part, 
via the expression of IL-10 and potentially could provide a mechanism to protect cells 
from extrinsic cell death signalling. 
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3.2. Viral Evasion of the Immune Response during Latent Infection 
HCMV infection is known to generate a robust T cell response in vivo with between 0.5 and 
10% of all cytotoxic T lympohcytes (CTLs) recognising HCMV antigens [47]. The CTL response 
to HCMV is dominated by two abundant viral antigens—pp65 and IE72 [47], although CTLs 
which recognise most, if not all, lytic antigens have been detected [93]. Pertinent to this review is 
that significant T cell responses against antigens also expressed during latency are present in 
healthy HCMV carriers [94,95] and thus, in theory, a latently infected cell should be visible to 
these T cells. However, recent work suggests that latent infection results in a number of 
mechanisms which act in concert to disrupt these T cell responses, thereby preventing clearance of 
latently infected cells by the adaptive arm of the host immune response (Figure 2). 
A recent analysis of experimentally latently infected CD34+ cells detected a unique cell secretome 
signature associated with latency [92]. Intriguingly, this secretome was observed to promote the 
migration of Th1 CD4+ T cells to the latently infected cell. However, the anti-viral effector 
functions of these recruited cytotoxic T cells was countered by the concomitant latency-associated 
expression of two key cellular cytokines, transforming growth factor—beta (TGF- ) and 
interleukin-10 (cIL-10). Both TGF-  and cIL-10 have profound immune-modulatory capacity [96] 
and, consistent with this, blocked the CD4+ T effector functions [92]. Although the exact 
mechanisms that resulted in up-regulated expression of TGF-  and cIL-10 during latency are 
unclear, elevated cIL-10 production was observed to be, at least partly, dependent on the up-regulation 
of the cellular GATA-2 transcription factor resulting from a concomitant down-regulation of the 
cellular microRNA mir92a [91]. Furthermore, other recent work has illustrated that a proportion of 
the CD4+ T cell response directed against latent antigens consists of T regulatory (Treg) cells [95]. 
This study in healthy donors showed that, whilst cytotoxic CD4+ T cell responses against latent 
antigens were detectable, they were dominated by IL-10 expressing Treg cells. Consequently,  
the recruitment of Treg cells to a latently infected cell (74) would augment the effects of the 
immune-suppressive secretome around the latently infected cells dampening down CTL effector 
cell function [92]. Given the extremely low frequency of latently infected cells in a healthy 
seropositive individual [97], it is likely that the microenvironment around a latently infected cell 
would have little overall impact on the normal immune homeostasis of the bone marrow but may 
be locally sufficient to ensure latently infected cells evade elimination by the immune system. 
Induction of cIL-10 by latent virus clearly appears to be of real import for latent carriage and 
this view is, perhaps, reinforced by the fact that HCMV also encodes an IL-10 homolog, known as 
cmvIL-10, which is expressed solely during lytic infection, as well as an alternatively spliced form 
(LAcmvIL-10) expressed during both latent infection and lytic infection [98,99]. Interestingly, lytic 
infection-associated cmvIL-10 has retained many of the immune-suppressive functions associated 
with its cellular counterpart [100–102] and, indeed, signals via the human IL-10 receptor [98,103]. 
Consistent with a role for cmvIL-10-mediated immune evasion are studies in rhesus CMV that 
have demonstrated a role in viral dissemination [104]—presumably via a temporary dampening of 
the immune response. It is tempting to speculate that failure to evade the immune response during a 
primary infection could profoundly impact on the set point of latency but, unfortunately, this has 
not been possible to analyse. 
12 
Figure 2. Evasion of the immune response to HCMV. The up-regulation of IL-10 in 
latently infected CD34+ cells is concomitant with TGF-b up-regulation via an unknown 
mechanism. However, the expression of two potent immune-suppressive cytokines 
inhibits the effector functions of CD4 Th1 cells recruited to a latently infected cell. 
Furthermore, both cellular IL-10 and viral IL-10 (LAcmvIL-10) act in concert to 
promote the down-regulation of HLA-DR MHC class II molecules on the surface of 
latently infected cells. Although the mechanism used by LAcmvIl-10 is not yet 
understood but is known not to occur via binding to the cellular IL-10 receptor. 
 
As stated above, the cmvIL-10 gene encodes a number of biological properties that could 
impinge on HCMV latency and reactivation. Multiple studies have shown that cmvIL-10 promotes 
MHC class I and II down-regulation [102], prevents DC maturation and function [105,106] and 
promotes the polarisation of macrophages to an M2c phenotype [107]—which is considered to be a 
relatively inactive macrophage phenotype compared with the classic inflammatory M1 phenotype. 
As such, all these functions would be consistent with a role in immune evasion. However, the 
alternatively spliced LAcmvIL-10, though also detected during lytic infection, is the isoform expressed 
during latent infection [54] but does not exhibit many of the properties of cmvIL-10 [63]—presumably, 
in part, due to its inability to bind the cIL-10 receptor [63]. Crucially, however, both latently 
infected GMPs and monocytes have been shown to exhibit a dramatic decrease in cell surface 
expression of MHC class II [32,108]—a function associated with LAcmvIL-10 [63]. Importantly 
the deletion of the UL111A locus from the virus (and thus LAcmvIL-10) has illustrated that 
latently cells become sensitive to CD4+ recognition and killing [109] as well as impacting on the 
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normal differentiation of myeloid progenitor cells to a DC phenotype [110]. Thus despite a loss of 
many of the functions associated with cmvIL-10, the LAcmvIL-10 isoform has retained biological 
properties that could contribute to successful persistence during latency in vivo. 
3.3. Viral Regulation of Immediate Early Gene Expression 
As already discussed, the regulation of HCMV MIE gene expression during latency involves the 
action of higher order chromatin structure. As such, it has been hypothesised that the assembly and 
modification of histones at the MIEP is an intrinsic response dictated by the cellular environment. 
Indeed, at low MOIs during lytic infection, there appears to be pre-immediate early gene 
expression event where the MIEP is associated with methylated histones [111]. This may well 
represent an anti-viral response to foreign DNA that is mediated by ND10 bodies and their 
components and is overcome by the action of incoming viral pp71 tegument protein and, 
subsequently, newly expressed IE72 which has been reviewed extensively elsewhere [112–114]. In 
contrast to lytic infection, the intrinsic repression of the MIEP is not overcome in non-productive 
myeloid cells. One study has proposed that unknown mechanisms that exclude pp71 from the 
nucleus in CD34+ cells contributes to this [23], although the high levels of transcriptional repressors 
present in these cells is also likely to be important; consistent with this, the transfected MIEP is 
intrinsically less active in undifferentiated myeloid cells [115]. Indeed, a number of transcriptional 
repressors of the MIEP have been identified (such as YY1 and ERF) and these are believed to 
recruit histone methyltransferases [116,117] to the MIEP in undifferentiated myeloid cells and this 
is important for generating the signature repressive chromatin phenotype associated with the MIEP 
of latent HCMV [11].  
However, more recent work suggests that HCMV gene products themselves may be actively 
helping to manage MIE regulation during HCMV latency. Although the prevailing view of the 
MIEP during latency in CD34+ cells is a promoter predominantly associated with repressive 
chromatin marks (i.e., histone methylation and HP-1 binding), chromatin and its post-translational 
modification is highly dynamic. Studies analysing the chromatin state of well-characterised 
silenced cellular genes, in e.g., stem cells, suggest that all cellular promoters bear at least some 
hallmarks of transcription [118]. Histone methylation at lysine 4 (a marker of a recently transcribed 
promoter) has been identified at “silent promoters” and, consistent with this, small RNA fragments 
were identified which would correspond to aborted transcription events [118]. Thus the notion of 
“chromatin breathing,” even at repressed promoters, is not uncommon. Given the potent activity of 
the MIEP, there is a strong argument that the MIEP is unlikely to be completely transcriptionally 
repressed, even in the most undifferentiated myeloid cell, and that this will call for additional 
mechanisms to eliminate any residual low level, uncontrolled MIE expression (Figure 3). 
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Figure 3. HCMV mediated repression of IE gene expression. Latent infection of 
CD34+ cells is characterised by a repression of the major immediate early promoter 
(MIEP). Classically, the MIEP has been shown to be repressed by multiple cellular 
transcriptional repressors known to interact with components of the histone modifying 
enzyme families. However, these events may be augmented by the activity of further 
viral mechanisms. The expression of LUNA during latency has been shown to be 
important for UL138 expression—a protein postulated to repress the MIEP. 
Furthermore, the expression of the long non-coding 4.9kb RNA (lnc4.9 RNA) during 
latency has been suggested to promote the recruitment of polycomb repressor complex 
2 (PRC2) to the MIEP via direct binding of the RNA. Recruitment of PRC2 would 
promote a chromatin structure inhibitory for MIE transcription. Finally, the expression 
of a viral miRNA, mir112.1, has been hypothesised to be important for silencing 
translation from MIE transcript UL123 during latency. 
 
During lytic infection, HCMV expresses a virally encoded microRNA (mirUL-112-1) that 
specifically target IE72 encoding UL123 transcripts [119,120] and inhibits IE72 translation [120]. 
Deletion of mirUL-112-1 has no overt phenotype in infected fibroblasts, likely due to the 
substantial levels of IE72 transcript accompanying lytic infection [120]. However, it has been 
postulated that low levels of IE72 RNA may be targeted efficiently and, hence, miRUL112-1  
may have more of a role during latency [119]—where untimely IE72 expression could be 
problematic but where the less abundant levels of IE72 RNA could be more effectively controlled 
by a miRNA-mediated mechanisms. In effect, the microRNA acts as a safety net to ensure that the 
functional impact of any sporadic activity of the MIEP, and any resultant IE transcripts, are 
minimised during latent infection.  
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A more recent study [25] that used a deep sequencing approach to re-visit latent gene expression 
in experimental as well as naturally latent tissue samples, identified the expression of a number of 
viral transcripts including a 4.9 kb long non-coding RNA (lnc4.9). Interestingly, this transcript was 
observed to associate with the polycomb repressor complex 2 (PRC2)—with direct analogy to the 
KSHV PAN RNA species that also bind this complex [121]. Indeed, the PRC2 complex has also been 
shown to regulate HSV latency, although this is thought to occur independently of direct binding to the 
LAT RNA [122]. Furthermore, the binding of components of PRC2 and also the lnc4.9 RNA was 
observed in experimentally latently infected cells [25]. The net result of such interactions would be 
to augment the silencing of the viral MIEP linked with histone tri-methylation at lysine 27 on 
histone H3. The overall contribution of the lnc4.9 RNA to HCMV latency remains to be 
determined; however, analysis of whether virus mutants that fail to express lnc4.9 are defective in 
their establishment and maintenance of latency could help determine whether this interaction is as 
an essential component of the mechanisms required to maintain HCMV latency.  
Finally, other recent work has also suggested that the MIEP may repressed by a virally encoded 
factor during latency [23]. Treatment with histone deacetylase inhibitors (HDACi) is insufficient to 
promote the reactivation of IE gene expression in CD34+ cells latently infected with clinical strains 
of HCMV [23]. Conversely, however, CD34+ cells latently infected with laboratory isolates are 
responsive to HDACi. Consequently, this has suggested that a viral factor present in clinical 
isolates is involved in chromatin-mediated suppression of MIEP activity during experimental 
latency [23]. The likely candidate is UL138, which is expressed only in clinical isolates [39] and is 
known to be expressed during latent infection [34,53]. However, published studies suggest that the 
importance of UL138 for latency is not due to any direct effect on MIEP activity as a 
transcriptional repressor [58], thereby remaining in line with the predominant localisation of 
UL138 protein to the Golgi apparatus during lytic infection and transfection [58]. One caveat to 
this, though, is that the localisation of the UL138 protein has not been extensively analysed during 
latent infection and hence, at this stage, a role for UL138 in the repression of the viral MIEP during 
latency awaits further analyses.  
3.4. Viral Regulation of Latent Gene Expression 
In addition to the regulation of MIE gene expression, there is emerging evidence that HCMV 
also expresses functions to ensure efficient latent gene expression during latent infection (Figure 3). 
This, in itself, argues that latent viral gene products are likely to have important functions during 
latency and, importantly, that these could act as potential therapeutic targets for latent infection. 
The modulation of the cellular miRNAome during latent infection could provide potent fine-tuning 
mechanisms to optimise both viral and cellular gene expression [91]. As discussed earlier, the  
down-regulation of cellular hsa-miR-92a by HCMV is important for the increased cIL-10 
production that results in downstream effects on viability and immune modulation [91,92]. 
However, the down-regulation of hsa-miR-92a also results in an increase in the levels of the 
GATA-2 transcription factor [91]. The GATA family of proteins are considered key regulators of 
haematopoiesis and myeloid cell production [123,124] and, thus, the targeting of this transcription 
factor in the knowledge that HCMV persists in the myeloid lineage appears more than coincidental. 
However, a more direct effect of GATA-2 regulation is observed on latent gene expression. A 
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number of promoters of latently expressed genes contain consensus sequences for GATA-2 binding 
sites [77,91,125,126] and two of these, LUNA and UL144, have been directly demonstrated to be 
GATA-2 responsive [77,126]. Recent work has shown that the down-regulation of the hsa-mir92a 
observed in HCMV infected CD34+ cells results in increased GATA-2 levels during latency, 
subsequently leading to increased levels of GATA-2-dependent latent gene expression [91].  
Although we are far from completely elucidating the function of viral gene products during 
latency, observations, to date, strongly argue that latent infection with HCMV results in a  
latency-associated transcription profile of viral gene expression, resulting in an orchestrated change 
in the cell to support latent carriage. The regulation of latent viral gene expression, as well as the 
role of latent viral functions and their effects on cellular gene expression, are clearly inextricably 
linked. For instance, recent work from the St Jeor laboratory has shown that the expression of 
LUNA during latent infection is also important for latency-associated UL138 gene expression [62]. 
Consequently, a pathway of interactions appears to occur during latency which is exemplified by 
latency, thus resulting in the targeting of cellular hsa-miR92a; this, in turn, up-regulates cellular 
GATA-2 expression [91], leading to a downstream impact on latency-associated LUNA gene 
expression [77,91] and ultimately ensuring the expression of UL138 [62], which has been proposed 
to be a key determinant of latency [23,53]. 
Clearly, this simplified example of a linear pathway of viral and cellular interactions is likely to 
give way to far more complex networks of host–virus interactions as we begin to understand the  
multi-functional role of viral proteins, non-coding RNAs, and miRNAs during HCMV latency and 
their impact on the latent cell.  
4. Concluding Remarks 
The advances in molecular techniques for performing large-scale analyses at the cell level are 
allowing ever more detailed analyses of aspects of HCMV biology which, previously, were all but 
impossible due the limitations of sensitivity and the availability of tractable primary cell models. 
These approaches have already begun to illustrate the complexity of HCMV latency and to provide 
an intriguing view of the concerted efforts HCMV employs to maintain the latent state.  
It is evident that the reductionist approach of these types of studies, as well as the difficulty in 
further examining in vitro findings in vivo, warrants necessary caution to prevent overinterpretation. 
Accordingly, a key development in the future of HCMV studies of latency and reactivation will be 
the tractability and applicability of the humanised mouse model to studies of HCMV [127]. 
Caveats with this system also remain; although the humanised mouse can be used to assess HCMV 
reactivation in the myeloid lineage in vivo, this is still occurring in the background of mouse tissue 
that does not support extensive HCMV replication [128]. Consequently, such analyses are, 
arguably, restricted to the very initial events of HCMV reactivation occurring within a specific 
niche of human cells. Furthermore, the extent to which the human haematopoietic system develops 
from engrafted human CD34+ cells in the mouse (for instance, murine and human cytokines do not 
crosstalk unequivocally) is unclear and, more generally, the extent to which mouse models of 
disease truly reflect the human condition is an area of ongoing debate [129,130]. Nevertheless, the 
humanised mouse model could provide the potential to examine a number of predictions regarding 
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HCMV latency derived from in vitro studies, as well as certain aspects of the development of the 
immune response to latent HCMV.  
These cautionary notes aside, the identification of viral gene functions expressed during 
experimental latency (many of which, importantly, can be validated in naturally latent cells ex vivo) 
is beginning to provide a tantalising glimpse into the once-perceived “black box” of latency. As we 
begin to understand the functions of these latency-associated gene products, and assess their precise 
role in HCMV latency and reactivation, they are also likely to become potential targets for 
therapeutics. These approaches could range from the targeting of factors important for HCMV 
reactivation (our own unpublished work suggests that the LUNA gene product may encode a 
function that could be a future therapeutic target) or for the direct targeting of latently infected cells 
using chemotherapeutic or immunotherapeutic means [61].  
Anti-viral strategies for HCMV have, to date, relied on targeting of replicating virus during lytic 
infection. However, understanding the complex interplay between the virus and the host during 
latency will give important insights into how to explore potential therapeutic options that target 
latent virus in what was previously considered to be in an “untargetable state.” 
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Abstract: Human cytomegalovirus (HCMV) is the major viral cause of congenital 
infection and birth defects. Primary maternal infection often results in virus 
transmission, and symptomatic babies can have permanent neurological deficiencies 
and deafness. Congenital infection can also lead to intrauterine growth restriction, a 
defect in placental transport. HCMV replicates in primary cytotrophoblasts (CTBs), the 
specialized cells of the placenta, and inhibits differentiation/invasion. Human 
trophoblast progenitor cells (TBPCs) give rise to the mature cell types of the chorionic 
villi, CTBs and multi-nucleated syncytiotrophoblasts (STBs). Here we report that 
TBPCs are fully permissive for pathogenic and attenuated HCMV strains. Studies with 
a mutant virus lacking a functional pentamer complex (gH/gL/pUL128-131A) showed 
that virion entry into TBPCs is independent of the pentamer. In addition, infection is 
blocked by a potent human neutralizing monoclonal antibody (mAb), TRL345, reactive 
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with glycoprotein B (gB), but not mAbs to the pentamer proteins pUL130/pUL131A. 
Functional studies revealed that neutralization of infection preserved the capacity of 
TBPCs to differentiate and assemble into trophospheres composed of CTBs and STBs 
in vitro. Our results indicate that mAbs to gB protect trophoblast progenitors of the 
placenta and could be included in antibody treatments developed to suppress congenital 
infection and prevent disease.  
Keywords: HCMV; congenital; trophoblast; progenitors; neutralizing; placenta; 
development; neutralization; pentamer; hyperimmune globulin 
 
1. Introduction 
Human cytomegalovirus (HCMV) is the major viral cause of congenital infections and affects  
1%–3% of live births in the U.S. [1]. Virus transmission to the fetus occurs in 40%–50% of cases 
of primary infection and can result in birth defects, including severe neurological disorders, 
impaired hearing, vision loss and intrauterine growth restriction (IUGR), a defect that results from 
compromised placental function [2–4]. In contrast, due to immunity from maternal antibodies, 
recurrent infection is associated with a reduced viral transmission rate (0.1% to 2%) [5]. Although 
recent studies indicate that the frequency of hearing loss is similar in pregnancies complicated by 
primary and recurrent infection, the severity is greater in cases of primary infection [6,7]. 
Currently, there are no approved therapeutics for congenital HCMV infection in cases of 
primary maternal infection due to concerns over the toxicity and teratogenicity of available antiviral 
drugs (reviewed in [8,9]). A recently developed therapeutic approach is the administration of 
hyperimmune globulin (HIG), a pooled immunoglobulin preparation from donors with high-avidity 
anti-HCMV antibodies. In initial (non-randomized) clinical studies, treatment of pregnant women 
with HIG within 4 to 6 weeks after seroconversion was found to improve fetal outcome [10–13]. 
Analysis of placentas revealed that viral replication was reduced and compensatory development 
enabled growth of chorionic villi increasing the placental surface perfused by maternal blood [12,14]. 
However, reported studies were small and the results should be confirmed by double-blinded 
clinical trials [15]. To date, administration of HIG has been approved by the Food and Drug 
Administration only for transplant recipients [16–18]. As promising novel therapeutics, human 
monoclonal antibodies (mAbs) specific for epitopes on HCMV proteins have been developed using 
technological advancement of human B-cell cloning from highly seropositive donors [19–23]. 
Chorionic villi, the functional units of the placenta, are composed of a stromal core that contains 
blood vessels continuous with the fetal vasculature. The core is surrounded by a basement membrane 
populated by villus cytotrophoblasts (vCTBs), covered by a multinucleated syncytiotrophoblast 
(STB) layer. At the tips of the villi, vCTBs differentiate and switch their adhesion phenotype to that 
of invasive cytotrophoblasts (iCTBs), which penetrate the decidua and remodel uterine arteries, 
providing maternal blood to the placenta [24,25]. STBs, which are bathed in maternal blood, 
mediate transport of nutrients and oxygen to the fetal bloodstream. In contrast to CTBs, whose 
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proliferative potential is limited [26,27], trophoblast progenitor cells (TBPCs), resident in the 
chorion, proliferate and differentiate into the mature trophoblast populations [28]. 
Previous studies from our lab suggested that during the course of transmission, HCMV first 
replicates in uterine blood vessels, then spreads to differentiating iCTBs, where infection 
downregulates cell-matrix adhesion molecules and impairs cell differentiation/invasion [29–33]. 
Studies of congenital infection in placentas from early gestation and at term indicated a central role 
for high-avidity, neutralizing antibodies in suppression of infection [34–36]. We recently reported 
that some cases of IUGR have underlying primary or recurrent maternal infection, which impaired 
placental development [4]. In a case of IUGR associated with preterm delivery, chorionic villi 
contained unusual clusters of extravillous, cytokeratin 7 (CK7)-positive CTBs, suggesting arrested 
differentiation. In cases of symptomatic congenital infection, infected cell proteins were detected in 
TBPCs in the chorion, suggesting that virus replication could interfere with TBPC self-renewal and 
differentiation [37]. 
HCMV encodes several glycoprotein complexes in the virion envelope that function in attachment 
and penetration of host cells. A highly studied envelope protein important for virion entry into all 
cell types is gB [38,39]. gB facilitates attachment to the cell surface by binding to heparin sulfate 
glycosaminoglycans [40,41], cellular receptors [42,43] and integrins [44,45] and, in cooperation 
with gH/gL complexes, mediates membrane fusion [46]. In contrast to the fibroblast-adapted 
(attenuated) strains AD169 and Towne, clinical strains, such as VR1814 and TB40/E, are 
pathogenic and express the pentamer glycoprotein complex gH/gL/pUL128-131A, which is 
required for virus entry into epithelial and endothelial cells [47,48] but not fibroblasts [49,50]. 
AD169 and Towne have acquired mutations in the UL128-131A locus, lack a functional pentamer 
and are impaired in infection of epithelial and endothelial cells [51,52]. 
Recently, TBPCs were isolated from the chorions of human placentas, and lines of continuously 
self-renewing cells were established [27]. These TBPCs express the trophoblast marker CK7, 
factors for stem cell self-renewal, including HMGA2 (high-mobility group AT-hook 2), and 
proteins required for trophoblast fate specification, GATA-3, GATA-4, Eomes (Eomesodermin) 
and GCM-1 (glial cell missing homolog 1). When cultured under differentiation conditions, TBPCs 
aggregate and form spheres (trophospheres) that upregulate HLA-G, a marker of differentiating 
iCTBs, and increase expression of human placental lactogen and human chorionic gonadotropin 
(normally secreted from STBs) [27], in accord with differentiation in utero. 
Here, we have identified glycoproteins involved in entry of HCMV virions into TBPCs 
established from first and second trimester placentas and measured the extent to which neutralizing 
mAbs to gB and the pentameric complex block infection. We found that TBPCs are susceptible to 
infection with both the pathogenic VR1814 and the attenuated AD169 strain and that both strains 
undergo lytic viral replication in TBPCs. In addition, we found that virion entry into TBPCs was 
independent of the pentamer complex, as shown by infection with a UL131A-deficient 
mutant [53,54] and confirmed by failure of anti-pentamer mAbs to block VR1814 infection. 
Importantly, virion entry was found to depend on gB function. Consequently, neutralization of 
infection with an anti-gB mAb (TRL345) was found to preserve the ability of TBPCs to 
differentiate and form trophospheres. 
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2. Results and Discussion 
2.1. TBPCs from First and Second Trimesters Are Permissive for Pathogenic and Attenuated  
HCMV Strains 
TBPC expression of markers for trophoblasts (CK7), stem cell self-renewal (HMGA2) and 
trophoblast fate acquisition (GATA-4 and GATA-3) was confirmed by immunostaining. Over 90% 
of TBPCs in culture expressed these markers (Figure 1). 
Figure 1. TBPCs express markers of trophoblasts and pluripotency. TBPCs from 7.3 
weeks (left panel) and 15.6 weeks (right panel) of gestation were immunostained for 
CK7 (A,E), HMGA2 (B,F), GATA-4 (C,G) or GATA-3 (D,H). Nuclei were 
counterstained with DAPI. Scale bar = 100 m.  
 
To determine whether TBPCs isolated from placentas at 7.3 and 15.6 weeks of gestation were 
susceptible to infection, suspensions of VR1814 and AD169 were adsorbed to TBPCs and the cells 
immunostained at the indicated time points for expression of immediate-early protein IE1, early 
proteins pUL112/pUL113 and late protein pp28. We found that viral proteins were expressed at 
comparable levels in VR1814- and AD169-infected cells (Figure 2), indicating that TBPCs were 
susceptible to lytic HCMV infection. In 15.6 weeks TBPCs, nearly all cells expressed IE1 in nuclei 
at 1 day post infection (dpi), and pUL112/pUL113 were detected at 2 dpi. pp28 was present in most 
cells at 4 dpi (Figure 2A) suggesting viral DNA replication [55]. In 7.3 weeks TBPCs, fewer cells 
expressed viral proteins. Approximately 70% expressed IE1 at 1 dpi and 85% at 4 dpi (Figure 2B). 
pUL112/pUL113 and pp28 were expressed in nearly all cells by 7 dpi, suggesting delayed viral 
gene expression. Nonetheless, almost all TBPCs from both gestational ages expressed late  
infected-cell proteins within a week. Altogether, our results indicate that first and second trimester 










TBPCs are permissive for pathogenic and attenuated virus strains. Because results for first and 
second trimester TBPCs were similar, only TBPCs from 15.6 weeks of gestation were used for 
subsequent experiments. 
Figure 2. VR1814 and AD169 replicate in TBPCs. Cells from 15.6 weeks (A)  
or 7.3 weeks (B) of gestation were infected (MOI 2) and immunostained for HCMV 
IE1, pUL112/pUL113 or pp28 at the indicated time points (green). Mock-infected 
controls were immunostained for CK7 (red). Nuclei were counterstained with DAPI 
(blue). Scale bar = 100 m. 
 








pp28 DAPI pp28 DAPI pp28 DAPI 
DAPI UL112/UL113 DAPI UL112/UL113 DAPI UL112/UL113 
CK7 IE DAPI IE DAPI IE DAPI 












CK7 IE DAPI 
DAPI 
pp28 DAPI 
IE DAPI IE DAPI 
IE DAPI IE DAPI 
UL112/UL113 DAPI UL112/UL113 DAPI UL112/UL113 
pp28 DAPI pp28 DAPI 
pp28 DAPI pp28 DAPI pp28 DAPI 
CK7 IE DAPI 
32 
2.2. HCMV-Infected TBPCs Produce Infectious Progeny Virions  
To determine if TBPCs were fully permissive and produced progeny virions, the cells were 
infected with either VR1814 or AD169, conditioned medium (CM) was collected at 48 h intervals, 
and viral progeny were quantified by titration on human foreskin fibroblasts (HFFs). For 
comparison of virus yield, HFFs were infected and analyzed in parallel. We found that relatively 
high levels of progeny virions were released from infected TBPCs (total ~106 PFU per 2 cm2 plate 
on peak day), about 10- to 15-fold lower than the amount released from HFFs (Figure 3A). 
Consistent with the comparable levels of IE, early and late protein expression (Figure 2A), no 
significant differences were found between the levels of VR1814 and AD169 progeny released. 
The results indicate that, following virion entry into TBPCs, both pathogenic and attenuated 
HCMV strains complete the lytic infectious cycle. 
Next, we determined whether viral progeny released from TBPCs retain tropism. CM harvested 
from VR1814- and AD169-infected TBPCs (8 dpi) were adsorbed to human retinal pigment 
epithelial cells (ARPE-19) or HFFs. Immunostaining for IE proteins showed that AD169 progeny 
failed to infect ARPE-19 cells (Figure 3B) whereas VR1814 progeny from infected TBPCs 
retained the ability to infect ARPE-19 and HFFs. These results suggest that progeny virions 
released from TBPCs in the infected chorion retain tropism and hence could spread to other 
placental cells—vCTBs, iCTBs, stromal fibroblasts in the villous core and endothelial cells in 
blood vessels—thereby promoting viral dissemination in utero. 
Figure 3. (A) Infected TBPCs release progeny virions. CM from VR1814- and  
AD169-infected TBPCs and HFFs (MOI 0.1) were collected at the indicated time 
points and titrated on HFFs. (B) Progeny virions from TBPCs retain tropism. CM from 
VR1814- and AD169-infected TBPCs (8 dpi) was added to HFFs and ARPE-19 cells, 
and IE1 was immunostained (1 dpi). Nuclei were counterstained with DAPI. Scale  
bar = 200 m. 
 
2.3. Viral Entry into TBPCs Is Independent of the Pentamer Complex 
The finding that TBPCs can be infected with AD169 suggested that the pentamer complex is not 
required for virion entry into these cells. To test this hypothesis, we performed experiments with 
the TB40/E parent virus and its UL131A-deficient mutant ( UL131A) [53]. The mutant has an 
early stop codon in the UL131A ORF, does not express a functional pentamer, and fails to enter 
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epithelial and endothelial cells [53]. We confirmed the phenotype of parental TB40/E and UL131A 
by infecting ARPE-19 cells and HFFs. As expected HFFs supported infection with both viruses as 
determined by IE protein expression at 2 dpi (Figure 4G–L), whereas ARPE-19 cells were only 
permissive for the parental virus TB40/E (Figure 4C,D), but not UL131A (Figure 4E,F). To test 
TBPCs, we incubated the cells with TB40/E and UL131A and found that in both cases >90% of 
cells expressed IE proteins at 2 dpi (Figure 4M–S). The results confirmed that the pentamer 
complex is dispensable for virion entry into TBPCs. These data also suggest that virion entry into 
TBPCs follows the pathway described for fibroblasts, which involves gB-mediated fusion at the 
plasma membrane at neutral pH [56], as opposed to the entry pathway into epithelial and 
endothelial cells, where virion uptake entails endocytosis [57,58]. 
Figure 4. HCMV pentamer complex is dispensable for virion entry into TBPCs. 
ARPE-19 cells (A–F), HFFs (G–L) and TBPCs (M–S) were mock infected or infected 
(MOI 2) with parental TB40/E and UL131A-deficient mutant ( UL131A) and 
immunostained for IE1 proteins (2 dpi). Nuclei were counterstained with DAPI (blue). 
Scale bar = 100 m. 
 
2.4. TBPC Infection Is Blocked by mAbs to gB But Not mAbs to the Pentamer Complex 
Unlike HIG preparations, human mAbs to viral glycoproteins are epitope specific and can have 
especially high affinity. Among the important HCMV proteins that have been targeted by human 











M O R 
N P S 
G   I   K   
H J L
A C E 
B D F 
34 
lacking a functional pentamer infects TBPCs at levels comparable to those of the parent, which 
expresses a functional pentamer, suggested that the pentamer is dispensable for virion entry. 
Consequently, we expected that mAbs that prevent HCMV entry into a broad range of cells  
(e.g., gB-specific mAbs) would block TBPC infection, whereas mAbs to the pentamer would not. 
To test this hypothesis, we carried out neutralization assays with human mAbs to the pentamer 
component pUL130/pUL131A (mAbs 5A2 and 1F11) and a human mAb to gB (TRL345). These 
mAbs were selected by B-cell cloning and reported to have potent HCMV neutralizing titer in 
epithelial cells (anti-pUL130/pUL131A and anti-gB) and fibroblasts (anti-gB) [19,23]. First, we 
verified that the mAbs and the HIG preparation blocked VR1814 infection of ARPE-19 cells in a  
dose-dependent manner (Figure 5). The control mAb (Synagis) lacked neutralizing activity  
(Figure 5A). Next, we found that mAbs to the pentamer (mAbs 5A2 and 1F11) failed to block 
VR1814 infection of TBPCs (Figure 5B), whereas anti-gB mAb TRL345 exhibited a dose-dependent 
neutralizing activity, almost completely blocking VR1814 infection (99% reduction) at 10 g/mL 
(Figure 5B). HIG showed some neutralizing activity in TBPCs at high concentrations (~42% mean 
reduction at 10 g/mL, ~81% at 100 g/mL), but the efficiency was highly variable. It is difficult 
to compare HIG with HCMV neutralizing mAbs because the former is a polyclonal antibody 
mixture prepared from seropositive donors and contains mostly antibodies without antiviral 
activity. In contrast, each mAb recognizes a specific functional epitope on a single viral protein. 
Nonetheless, anti-gB mAb TRL345 blocked infection of TBPCs at 1 g/mL to a greater extent than 
HIG at 100 g/mL. These results indicate that a mAb to gB efficiently neutralizes HCMV infection 
of TBPCs as compared with HIG.  
2.5. Neutralization of VR1814 by Anti-gB mAb TRL345 Restores TBPC Differentiation 
When cultured under differentiation conditions, TBPCs form trophospheres and express markers 
of differentiated iCTBs and STBs [27], a process that mimics early differentiation in utero. In 
contrast, infected TBPCs fail to differentiate and form trophospheres [37]. We therefore examined 
whether TRL345-mediated virus neutralization could preserve the ability of TBPCs to differentiate 
and form trophospheres. For these experiments, TBPCs were infected with VR1814 or a  
virus-antibody mixture containing 20 g/mL anti-gB mAb (TRL345), 20 g/mL anti-pentamer 
mAb (5A2) or 20 g/mL negative control mAb (Synagis), or they were left uninfected. At 3 dpi, 
culture conditions were changed to induce differentiation (see Experimental Section). At 4 dpi, 
differentiating TBPCs (uninfected) formed trophospheres with diameters of approximately  
200–250 m (Figure 6A,F). In contrast, infected TBPCs generally failed to form spheres, and the 
few spheres that assembled had diameters of approximately 50 m or less (Figure 6B,G). TBPCs 
incubated with anti-gB mAb-treated VR1814 retained the capacity to differentiate and formed large 
trophospheres (Figure 6D,I). In contrast, TBPCs incubated with VR1814 treated with mAbs to the 
pentamer or the negative control mAb failed to form large trophospheres (Figure 6C,E,H,J), consistent 
with the failure of pentamer-specific mAbs to block infection (Section 2.4). Thus, neutralizing  
anti-gB mAb TRL345 precludes HCMV infection of TBPCs and rescues differentiation. 
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Figure 5. Infection of TBPCs is blocked by a mAb to gB but not mAbs to the pentamer 
complex. (A) VR1814 (MOI 0.01) was pre-incubated with medium alone, a serial log10 
dilution of the indicated mAb (0.01–10 g/mL) or HIG (0.1–100 g/mL). Virus-antibody 
mixtures were then applied to ARPE-19 cells. At 2 dpi, IE1 was immunostained and 
numbers of infected cells were counted. Data were normalized to the no Ab control. 
Error bars indicate standard deviation. (B) TBPCs were incubated with virus-antibody 
mixtures and analyzed as described for panel A.  
 
2.6. Discussion 
The studies presented here show that HCMV undergoes lytic replication in TBPCs and that viral 
entry into these cells depends on the functions of gB but not those of the pentamer complex. 
VR1814-infected TBPCs release significant levels of progeny virions that retain epithelial cell 
tropism. These findings suggest infection of TBPCs could inhibit villous growth and differentiation 
and promote viral spread among various cell types in the placenta. Infection could decrease the 
population of TBPCs (Figures 2–4) and impair differentiation (Figure 6), thereby reducing the 





























































































































































Figure 6. Neutralizing anti-gB mAb TRL345 precludes VR1814 infection and rescues 
TBPC differentiation. VR1814 was pretreated with 20 g/mL of the indicated mAbs, 
and the mixtures were adsorbed to TBPCs. At 3 dpi, the cells were reseeded on matrigel 
and cultured in differentiation medium for 24 h followed by light microscopic analysis. 
Lower magnification photographs (upper panel), higher magnification photographs 
(lower panel). Scale bars = 200 m. 
 
 
These findings could also explain the observation that CTBs failed to differentiate into STBs in 
cases of IUGR with congenital HCMV infection, suggesting infection and paracrine effects could 
subvert placental development [4]. Passive immunization with HIG enables compensatory growth 
of chorionic villi, increasing STB surface area and exchange [14], suggesting that neutralizing 
antibodies reduce virus replication and improve outcome. HIG was reported to prevent virus 
transmission to the placenta and fetus when administrated soon after maternal seroconversion [10–13]. 
In accord with these findings, HIG reduces viral spread in the decidua in an ex vivo tissue 
model [59]. Animal models that simulate congenital infection are rare because of the unique anatomy 
and biology of the hematogenous human placenta. However, the guinea pig has been used to measure 
efficacy of guinea pig CMV (gpCMV) antibodies in reducing transplacental infection [60]. When 
pregnant guinea pigs were infected and passively immunized with gpCMV neutralizing antiserum, 
fetal survival increased significantly, and placental inflammation and IUGR were reduced [60]. 
Likewise, a gpCMV gB subunit vaccine elicited protective neutralizing antibodies in dams, 
resulting in lower rates of fetal infection and reduced pup mortality [61]. 
HCMV entry into fibroblasts requires gB and gH/gL [46,49,50], whereas entry into epithelial  
and endothelial cells requires gB and the pentamer complex gH/gL/pUL128-131A [47–51,62]. 
Consequently, anti-gB antibodies neutralize virus entry into all cell types, whereas antibodies to the 
pentamer components pUL128, pUL130 and pUL131A selectively block infection of epithelial and 
endothelial cells [19,63]. Interestingly, antibodies to the pentamer complex are the major active 
component of HIG [64], and delayed development of these antibodies correlates with transplacental 
transmission to the fetus [65]. Our results suggest that anti-pentamer mAbs may reduce but not 
prevent virus spread in the developing placenta, as they fail to protect TBPCs, and other cell types, 
including stromal fibroblasts from the villus core [29] and uterine smooth muscle cells (data not 
uninfected 
no antibody 
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shown). Importantly, anti-gB mAbs, but not anti-pentamer mAbs, preserve the ability of TBPCs to 
differentiate. Moreover, we found that anti-gB mAb TRL345 had a higher efficiency and consistency 
as compared to HIG (Figure 5A,B). This high potency of mAb TRL345 is a consequence of the 
targeted, highly conserved AD-2 (Site I) epitope on gB [66], which the antibody binds to with high 
affinity [23]. While this neutralizing epitope is essential for gB function, it is poorly immunogenic, 
which explains why antibodies to this epitope are rare in human blood and consequently not 
present in HIG preparations [19,23,66]. HCMV infection inhibits TBPC self-renewal, proliferation 
and differentiation, which are required for proper villous development [37]. High affinity, potent 
human mAbs to gB, which functions in virion entry into a broad range of cell types, should be 
considered as a potential biotherapy for congenital HCMV infection, alone or in combination with 
pentamer complex targeting mAbs that more efficiently block infection of epithelial and endothelial 
cells. Additional advantages include a well-defined composition that reduces lot-dependent effects 
and increases consistency, suggesting mAbs could have considerable efficacy in clinical trials. 
3. Experimental Section 
3.1. Cells 
TBPCs (from 7.3 and 15.6 weeks of gestation) were established as reported [27]. Cells were 
grown on gelatin-coated plates in DMEM/F12 supplemented with 10 ng/mL basic FGF (R&D 
Systems, Minneapolis, MN, USA), 10% FCS, 10 M SB431542 (Tocris Bioscience, Minneapolis, 
MN, USA), 100 units/mL penicillin, 100 g/mL streptomycin and 0.25 g/mL fungizone. To 
exclude the presence of placental fibroblasts in the TBPC cultures, cells were immunostained for 
cytokeratin 7 (CK7), GATA-3 and GATA-4 as described in Section 3.3. These proteins are 
expressed in TBPCs but not in placental fibroblasts. ARPE-19 cells and HFFs were cultured in 
DMEM supplemented with FCS and penicillin/streptomycin as described previously [67,68]. 
3.2. Viruses and Infections 
VR1814 (an endothelial and epithelial cell-tropic pathogenic strain of HCMV) [69] was  
propagated in HUVEC [70], followed by a single passage in HFFs to obtain high titer stocks. 
AD169 (attenuated laboratory strain), TB40/E-derived parental virus (vBAC4-luc) and UL131A 
mutant (vBAC4-luc/UL131Astop) were propagated in HFFs [53]. For infection (MOI is indicated 
in figure legends), virus was diluted in DMEM, 1% FCS, 100 units/mL penicillin, 100 g/mL 
streptomycin and adsorbed for 2 h. Virus suspensions were aspirated, cells washed with PBS and 
provided with fresh medium. 
3.3. Immunofluorescence 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 and 
blocked with normal serum. Cells were incubated with primary antibody, followed by fluorescein 
isothiocyanate (FITC) or rhodamine red-X (RRX) labeled secondary antibodies (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA). For detection of TBPC markers, 
antibodies to cytokeratin 7 (CK7, monoclonal rat IgG, clone 7D3 [71]), GATA-3 (polyclonal goat 
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IgG, R&D Systems, Minneapolis, MN, USA), GATA-4 (polyclonal goat IgG, R&D Systems) and 
HMGA2 (polyclonal rabbit IgG, Abcam, Cambridge, MA, USA) were used. Murine monoclonal 
antibodies used to detect viral proteins were CH433 (anti-IE1, immediate-early protein), CH19 
(anti-pp28, true-late protein) [72] and M23 (anti-pUL112/pUL113, early proteins) [73]. Nuclei 
were counterstained with DAPI (Sigma-Aldrich, St. Louis, MO, USA). Analyses were performed 
with a Nikon Eclipse TS100 inverted fluorescence microscope equipped with a Nikon DS-F12 
camera controlled by Nikon NIS Elements 4.0 imaging software [74]. 
3.4. Detection and Quantification of Viral Progeny 
To quantify viral progeny, TBPCs or HFFs were infected with VR1814 or AD169 (MOI 0.1). 
Conditioned media (CM) was collected every 48 h. Subsequently, virus titers in CM were 
determined with an immunofluorescence-based infectivity assay in HFFs at 24 hpi [70]. For 
quantification, at least six representative pictures were taken and IE1-positive cells counted using 
Fiji Image J software [75,76]. 
3.5. Virus Neutralization Assay 
HCMV neutralizing assays were performed as described before [36]. Briefly, TBPCs or ARPE-19 
cells were seeded in 24-well plates. Diluted mAbs (final concentration 0.01 g/mL, 0.1 g/mL,  
1 g/mL or 10 g/mL) or HIG (Cytotect, Biotest, Boca Raton, FL, USA, final concentration  
0.1 g/mL, 1 g/mL, 10 g/mL or 100 g/mL) were incubated with VR1814 (MOI 0.01, in 300 L 
total volume) for 1 h at 37 °C with moderate agitation. Virus-antibody mixtures were adsorbed to 
cells for 2 h, followed by a wash step with PBS. The cells were then supplemented with fresh 
growth medium. At 2 dpi cells were fixed, permeabilized and immunostained for IE1 and analyzed 
by immunofluorescence microscopy (Section 3.3). IE1-positive cells were quantified as described 
in Section 3.4. Alternatively, viral titers were adjusted to give a total of 600 to 800 IE1-positive 
cells/well in 24 well plates. To target gB, human mAb TRL345 (Trellis Bioscience, LLC, South 
San Francisco, NC, USA [23]) was used. To target the pentamer, human mAb 1F11 or 5A2 (cloned 
from a published sequence [19] by Trellis Bioscience) directed to pUL130/pUL131A was used. 
Synagis [77], reactive with respiratory syncytial virus, was used as negative control mAb.  
3.6. Trophosphere Formation 
TBPCs were mock infected or infected with VR1814 or a mixture of virus and mAb as 
described above. The corresponding mAb used for pretreatment was present throughout the 
experiment (20 g/mL). At 3 dpi, TBPCs were dissociated and reseeded in matrigel-coated plates 
(100,000 cells per 2 cm2) in differentiation medium (Knockout Serum Replacement Medium, 
Gibco, Grand Island, NE, USA) supplemented with 10% FCS, 100 units/mL penicillin, 100 g/mL 
streptomycin, 0.25 g/mL fungizone, 10 ng/mL FGF4 (Sigma-Aldrich, St. Louis, MO, USA) and 
40 ng/mL EGF (Invitrogen, Grand Island, NE, USA) [27]. Formation of trophospheres was 




Human TBPCs in the chorion differentiate into CTBs and STBs, the two major cell types of 
chorionic villi required for placental development. The HCMV pathogenic strain VR1814 and the 
attenuated strain AD169 replicate fully in TBPCs, and the infectious progeny released retain 
tropism. Infection is blocked by a human mAb TRL345 to gB but not mAbs to the pentamer 
complex. Infected TBPCs are functionally impaired and fail to develop into large trophospheres 
comprised of cells that express the properties of differentiated CTBs and STBs. Altogether, our 
results suggest that congenital HCMV infection could be suppressed with a broadly effective 
neutralizing mAb to gB to prevent infection of TBPCs and, together with mAbs that protect 
specialized placental cells, could reduce virus transmission at the uterine-placental interface.  
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Abstract: Cytomegalovirus (CMV) is a prevalent pathogen in the immunocompromised 
host and invasive pneumonia is a feared complication of the virus in this population. In 
this pediatric case series we characterized CMV lung infection in 15 non-HIV infected 
46 
children (median age 3 years; IQR 0.2–4.9 years), using current molecular and imaging 
diagnostic modalities, in combination with respiratory signs and symptoms. The most 
prominent clinical and laboratory findings included cough (100%), hypoxemia (100%), 
diffuse adventitious breath sounds (100%) and increased respiratory effort (93%). All 
patients had abnormal lung images characterized by ground glass opacity/consolidation 
in 80% of cases. CMV was detected in the lung either by CMV PCR in bronchoalveolar 
lavage (82% detection rate) or histology/immunohistochemistry in lung biopsy (100% 
detection rate). CMV caused respiratory failure in 47% of children infected and the 
overall mortality rate was 13.3%. Conclusion: CMV pneumonia is a potential lethal 
disease in non-HIV infected children that requires a high-index of suspicion. Common 
clinical and radiological patterns such as hypoxemia, diffuse adventitious lung sounds 
and ground-glass pulmonary opacities may allow early identification of CMV lung 
infection in the pediatric population, which may lead to prompt initiation of antiviral 
therapy and better clinical outcomes. 
Keywords: CMV; lung; pneumonia; children; ground glass 
 
1. Introduction 
Cytomegalovirus (CMV) is one of the most important causes of opportunistic lung infection in 
the pediatric population [1]. Risk factors include human immunodeficiency virus (HIV) infection 
and immunocompromised status after bone marrow/stem cell transplantation (BMT/SCT) and solid 
organ transplantation [2]. Despite being a life threatening condition, if diagnosis is made in a 
timely manner, CMV pneumonia can potentially be cured with appropriate antiviral therapy (i.e., 
ganciclovir) [3]. Unfortunately, the clinical diagnosis of CMV lung infection is challenging in 
children and often requires a high-index of suspicion, especially in non-HIV infected cases and 
patients not severely immunocompromised [4]. 
Most of the literature about CMV lung infection in children focuses on the epidemiology of this 
condition in the pediatric immunocompromised population [1]. There are few reports that address 
the specific clinical and pulmonary imaging findings that may suggest this difficult diagnosis. 
Smith et al. in 1977 described the clinical respiratory findings and radiological appearance of CMV 
pulmonary infection in children using plain X-ray films [5]. This seminal work enhanced the 
awareness of the atypical course of CMV infection in the lungs, often described as “CMV 
pneumonitis” [5], which includes non-specific pulmonary findings such as interstitial patterns with 
increased bronchopulmonary markings and bronchiolar disease (diffuse air trapping) [5]. 
Interestingly, there has been a dramatic change in both the epidemiology of CMV infection and 
diagnostic techniques available for its diagnosis in children over the last 30 years [6]. Now-a-days 
we have an increasing population of non-HIV infected infants and children who have received 
different modalities of immunomodulators (i.e., steroids) for various conditions including BMT/SCT, 
solid-organ transplant and systemic autoimmune/inflammatory disorders that put them at risk for 
CMV lung infection [7]. In addition, better molecular diagnostics (i.e., CMV qualitative real-time 
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PCR) as well as great progress in performing pediatric bronchoscopy and detailed lung imaging 
(i.e., high-resolution computerized tomography, HRCT) have improved our ability to detect CMV 
pulmonary infection, re-defining the concept of CMV pneumonia, which is now known to occur in 
children that are not severely immunocompromised [8]. 
The goal of this article is to characterize CMV lung infection in non-HIV infected children 
using current molecular and imaging diagnostic modalities, in combination with traditional 
respiratory signs and symptoms. To this end, we present a case series of 15 children with CMV 
lung infection focusing on their clinical presentation, radiological patterns, bronchoscopic findings 
and the molecular approaches used. Our results highlight that the diagnosis of CMV pneumonia in 
children is challenging but the common clinical and radiological patterns such as hypoxemia, 
diffuse adventitious lung sounds and ground-glass pulmonary opacities, can provide critical clues 
to allow early identification of CMV lung infection in the pediatric population. 
2. Experimental 
2.1. Patients 
Fifteen cases of CMV pulmonary infection in non-HIV pediatric patients were studied. 
Neonates, infants and children (0–14 years) of both genders were included. All patients were seen 
at La Misericordia Children’s Hospital in Bogota, Colombia, which is the largest University-based 
Pediatric Hospital in the country. Cases were collected between January 2010 and November 2013. 
Children with HIV infection were not included. No other medical conditions were considered as 
exclusion criteria. CMV lung infection cases were defined as positive pulmonary detection of CMV 
by polymerase chain reaction (PCR) or immunofluorescence (lung biopsy) and clinical evidence of 
lung involvement on exam and from radiographic images of the chest. 
2.2. Clinical Assessment 
Clinical variables were obtained by electronic medical record review (EMR) and included 
symptoms involving the respiratory system, such as cough and signs/symptoms indicative of 
increased breathing effort including tachypnea, retractions, nasal flaring and/or dyspnea. Other 
respiratory variables included abnormal breath sounds (rales, wheezing, rhonchus, etc.), 
pulsoximetry values and the need/duration for mechanical ventilation. General symptoms like fever 
and weight loss were also recorded. Duration of disease, time to diagnosis and length of 
hospitalization were included as well. 
2.3. Diagnostic Studies 
Clinical specimens used for the diagnosis of CMV lung infection included serum and 
bronchoalveolar lavage (BAL). CMV detection was performed using real time PCR methodology 
(Light Cycler CMV Quantitative Kit, Roche Diagnostics, Indianapolis, IN, USA), which is 
routinely conducted in our institution. CMV viral culture is not available and not routinely 
performed in our hospital. BAL was obtained via fiberoptic bronchoscopy from the right middle 
lobe, lingula or affected site according to ERS guidelines [9]. Neutrophilia in BAL was defined as 
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>3% based on prior studies and bronchoscopy guidelines for children [9]. In five patients, open 
lung biopsy was also performed and the lung tissue was submitted for histopathological analysis to 
identify typical CMV features (i.e., inclusion bodies) and for immunohistochemistry studies using 
CMV-specific antibodies. Chest radiographs and high resolution CT scans (HRCT) were performed 
in all patients using pediatric protocols and general anesthesia if appropriate. Radiological findings 
were analyzed using standardized Fleischner Society [10] terminology by pediatric radiologists and 
independently by at least two pediatric pulmonologists. Other tests performed included CMV 
serology (serum IgM by enzyme-linked immunosorbent assay) and follow-up studies for CMV 
infection including serum CMV PCR/viral load measurements as well as ongoing monitoring of 
hemogram and liver function testing for drug toxicity. 
3. Results 
The baseline characteristics of the study subjects are presented in Table 1. The median age of  
the 15 children with CMV lung infection was 3 years (IQR 0.2 4.9 years.), which most likely 
reflects the population treated by the authors and not necessarily the group that is more likely to be 
affected by CMV. The majority were immunocompromised (13/15, 87%) according to immune cell 
counts, immunoglobulin levels or concomitant use of immunosuppressant agents (steroids). 
Specifically, children on systemic steroids (11/15, 73%) had low values for age of either IgG (6/11, 
54%), absolute lymphocyte counts (8/11, 73%), absolute neutrophil counts (1/11, 9%), or total CD4 
counts (2/11, 18%). Other important risk factors included malnutrition, hypogammaglobulinemia, 
hematologic malignancy and bone marrow/solid organ transplantation (Table 1). All transplant 
patients included had prior record of negative serology for CMV (donor and recipient). 
Table 1. Baseline characteristics for pediatric subjects. 
N 15 
Male, n (%) 8 (53) 
Age (year), median (IQR) 3 (0.25–4.9) 
Comorbidity  
Immunocompromised, n (%) 
Systemic steroid use, n (%) 
Hypogammaglobulinemia 
Malnutrition, n (%) 
Acute leukemia, n (%) 
Autoimmune disease, n (%) 
Allogeneic bone marrow/stem cell transplant, n (%) 










IQR, interquartile range. 
3.1. Clinical Characterization of CMV Lung Infection 
Clinical presentation of CMV lung infection was variable among pediatric subjects (Table 2).  
The median time of symptom onset was 14 days (IQR 3–20 days) with a median time to diagnosis  
of 26 days (IQR 11–37 days). All subjects presented with cough and 93% had increased respiratory 
effort/dyspnea as reported by the parent and/or patient. Other non-specific symptoms included 
fever and weight loss, which were present in 10 (67%) and 8 (53%) subjects respectively. The two 
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most prominent abnormal laboratory findings were anemia (53%) and abnormal liver function 
(47%), which has been previously reported as a hallmark of acute CMV infection [11]. Other 
common hematologic abnormalities included thrombocytopenia (40%), leukocytosis (40%) and 
leukopenia (27%). 
The clinical respiratory assessment was abnormal in all children with CMV pulmonary infection 
(Table 3). Physical examination findings included diffuse abnormal breath sounds (100% of patients) 
including wheezing (80%), rales (73%) and rhonchus (67%). All subjects showed hypoxemia at 
presentation and 47% required mechanical ventilation for respiratory failure. The median duration 
of mechanical ventilation was eight days (IQR 7–26 days). Overall mortality rate was 13% (n = 2). 
One subject died due to severe CMV infection and one due to massive central nervous system 
bleeding, secondary to severe thrombocytopenia associated with systemic lupus erythematosus. 
Table 2. Clinical presentation of Cytomegalovirus (CMV) lung infection in children. 
Duration   
Onset of symptoms (days), median (IQR) 
Time to diagnosis (days), median (IQR) 
14 (3–20) 
26 (11–37) 
Presenting symptoms  
Cough, n (%) 
Increased breathing effort, n (%) 
Fever, n (%) 





Laboratory findings  
Anemia, n (%) 
Thrombocytopenia, n (%) 
Leukocytosis, n (%) 
Leukocytopenia, n (%) 






IQR, interquartile range. 
Table 3. Respiratory Manifestations of CMV lung infection in children. 
Clinical variables  
Abnormal lung sounds, n (%) 
Wheezing, n (%) 
Rales, n (%) 
Rhonchus, n (%) 
Hypoxemia, n (%) 
Mechanical ventilation (MV), n (%) 
Days of MV, median (IQR) 









Radiological variables  
Abnormal lung images, n (%) 
Ground-glass opacity, n (%) 
Consolidation, n (%) 
Atelectasis, n (%) 
Air trapping, n (%) 
Nodular pattern, n (%) 
Reticular pattern, n (%) 









IQR, interquartile range. 
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3.2. Radiological Findings in CMV Lung Infection 
All patients had abnormal lung images. The most prominent radiological findings on plain chest 
radiographs and chest CT were consolidation and ground-glass opacity (80%) (Figures 1–5), 
indicating partial filling of alveolar air spaces, interstitial thickening and/or partial collapse of the 
alveoli during CMV pulmonary infection [10]. The result of these alveolar lesions is lung haziness 
in chest-X-ray (CXR) and ground-glass opacity on the CT scan [10,12]. In our pediatric case series, 
ground-glass opacity and consolidations were diffuse (Figures 1–5) and co-existed in eight patients 
(53%). In cases where CXR showed minimal abnormalities, the use of high-resolution CT scan 
(HRCT) enhanced the ability to see ground-glass opacity and consolidations (Figure 4). Atelectasis 
was present in 40% of cases and air trapping in 33%. Other radiological lung patterns were rare and 
included nodular (20%), reticular (6%) and tree-in-bud pattern (6%) (Table 3). 
Figure 1. Cytomegalovirus (CMV) lung infection after steroid therapy. Three year old 
girl treated with systemic corticosteroid for autoimmune lymphoproliferative syndrome 
(ALPS). Chest-X-ray (CXR) shows diffuse haziness more prominent in the left base (A), 
which correspond to ground-glass images in CT scan (B). H&E staining revealed monocyte 
infiltration with cytomegalic changes in lung biopsy (black squares in panel C). 
Immunohistochemical detection of CMV (brown staining in D) showed typical CMV 
inclusion bodies (squares). Slides shown with 100× magnification. 
 
Figure 2. Ground-glass pattern in CMV lung infection after stem cell transplant 
(SCT). Four year old boy with acute lymphoid leukemia presenting with hypoxemia 
and bilateral rales after allogeneic SCT. Diffuse haziness is seen in CXR (A), and CT 
scan (B). There are interspersed airway lumen marks known as “dark bronchus” signs 
indicating ground-glass pattern (arrows in B). 
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Figure 3. Ground-glass/Consolidation pattern in neonatal CMV lung infection. One 
month old term baby with lung haziness in CXR (A). CT scan revealed diffuse 
ground-glass and consolidations in both lung bases (B). Cytomegalovirus polymerase 
chain reaction) (CMV PCR) was (+) in serum but ( ) in bronchoalveolar lavage. Lung 
biopsy revealed dense monocyte infiltration with cytomegalic changes (black squares in 
panel C). Immunohistochemical detection of CMV in the lung (brown staining in D) 
revealed characteristic inclusion bodies (arrows). Slides shown with 40× magnification. 
 
Figure 4. Ground-glass pattern in CMV lung infection detected with high resolution 
CT scan (HRCT). Four year old boy with hypoxemia and diffuse rales/wheezing after 
bone marrow transplant. Plain CXR revealed non-specific mild increased lung markings. 
HRCT identified subtle ground-glass pattern in both bases. CMV diagnosis was 
confirmed by (+) PCR in bronchoalveolar lavage. 
 
Figure 5. Consolidation pattern in CMV lung infection. Fourteen year old boy with 
history of renal transplant. A retrocardial consolidation is seen in CT scan along with 
scattered opacities with lower density resembling ground glass pattern (arrows). 
Bronchoalveolar lavage of the left lower lobe revealed a (+) PCR for CMV. 
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3.3. Diagnostic and Treatment Approaches of CMV Lung Infection in Children  
The diagnostic approaches included a combination of CMV IgM serology, CMV serum 
PCR/viral load, bronchoscopy with bronchoalveolar lavage (BAL) with quantitative CMV PCR 
and lung biopsy (Table 4). The most common diagnostic modalities used were CMV serum 
PCR/viral load (14/15), which yielded a positive result in 50% of cases with a median CMV viral 
load of 268 copies/ L (IQR 20–20,000 copies/ L), and BAL (12/15) which gave positive CMV 
PCR in 82% of cases (Table 4). Most children with CMV lung infection had neutrophilia in BAL 
cellularity (92%) (Table 4). Lung biopsy was performed in five subjects and CMV was confirmed by 
histopathology and immunohistochemical detection (Figures 1, 3 and 6). A number of patients 
(14/15) were treated with IV ganciclovir during 14 to 21 days at dose of (5 mg/kg every12 h), 
which is the standard CMV treatment in our institution. Patients were followed for an average 
period of 2–3 weeks after therapy. One patient was not treated because of full resolution of CMV 
infection before starting antiviral therapy. Four subjects also received oral valganciclovir treatment 
after IV ganciclovir. Antiviral therapy was effective in 13/14 patients (one patient died due to 
severe CMV infection) and no significant side-effects were reported. 
Table 4. Diagnostic and treatment approaches of CMV lung infection in children. 
Intervention   
Bronchoalveolar lavage (BAL), n (%) 12 (80) 
CMV PCR (+) in BAL, n (%) 
Neutrophilia in BAL, n (%) 
9/11(82) 
11/12(92) 
Lung biopsy, n (%) 5 (33) 
Biopsy confirmed CMV, n (%) 5/5 (100) 
CMV serum PCR viral load, n (%) 14/15 (93) 
CMV PCR viral load (+) in serum 
CMV copies/ L, median (IQR) 
7/14 (50) 
268 (20–20,000) 
CMV serology, n (%) 5/15 (33) 
CMV IgM (+) in serum 4/5 (80) 
CMV treatment, n (%) 14/15 (93) 
Ganciclovir, n (%) 
Valganciclovir, n (%) 
14/14 (100) 
4/14 
IQR, interquartile range; PCR, polymerase chain reaction. 
Figure 6. Cytopathic changes in CMV pulmonary infection after steroid therapy. 
Thirteen year old boy treated with systemic corticosteroid for bronchiolitis obliterans 
and severe asthma presenting with acute hypoxemia and diffuse rales/wheezing. Lung 
biopsy revealed diffuse cytopathic changes in pneumocytes infected by CMV (squares 
in A and magnified image in B) including cellular enlargement and abnormal nucleus. 




CMV is a herpes virus that can produce life-threatening pulmonary infections in 
immunocompromised hosts [4]. Although effective antiviral therapy for CMV is available [11,13], 
timely diagnosis remains a major challenge for this condition, particularly in the pediatric 
population where CMV often presents with atypical patterns of lung infection [5,14]. The diagnosis 
of CMV pneumonia can be even more difficult in situations when there is no high-index of 
suspicion, for instance, in patients that do not have an underlying immunodeficiency syndrome (i.e., 
HIV-infected patients). Indeed, a detailed clinical characterization of CMV lung infection in this 
age group is critical to select patients that may warrant invasive procedures to obtain lung samples 
(i.e., pediatric bronchoscopy or open lung biopsy) and may benefit from prompt CMV therapy 
before confirmatory testing is available. Given the paucity of data about the clinical features of 
CMV pulmonary infection in children, this paper aims to fill this gap in the literature detailing the 
clinical and radiological features of this condition in a case series (n = 15) of non-HIV infected 
pediatric patients with pulmonary CMV infection. Our data illustrates that despite significant 
variability in the clinical presentation, there are specific features consistently present in pediatric CMV 
pulmonary infection, including hypoxemia, diffuse adventitious sounds and ground-glass 
consolidation pattern in lung CT scan, which together may offer crucial clues in the diagnosis of 
this condition in children. 
As previously reported in the adult literature, we found that the majority of children that 
developed CMV pneumonia were immunocompromised (87%) and 73% of patients were on 
systemic steroid therapy for different conditions including asthma, systemic lupus erythematous, 
leukemia treatment, renal transplant and allogeneic bone marrow/stem cell transplant. In addition, 
8/15 of the subjects (53%) had hypogammaglobulinemia, which was mostly secondary to steroid 
treatment and/or malnutrition in our case series. These risk factors have been previously reported in 
the literature [15], and reflect the need to have proper humoral and cell-mediated immunity to clear 
CMV infection in the lungs [3,16,17]. During the study period we did not identify children with 
HIV and pulmonary CMV in our institution. This may reflect the population treated by the authors 
and not the overall trend of CMV infections in pediatric HIV. In this regard, it is important to 
emphasize that children with HIV may have different patterns of CMV lung disease. For instance, 
HIV itself is often associated with non-malignant lymphocytic infiltrative disorders, including 
nonspecific interstitial pneumonitis and lymphocytic interstitial pneumonitis (LIP) [18], which 
could potentially change the radiological appearance and the clinical manifestations of opportunistic 
lung infections like CMV. In addition, HIV patients might have more extra-pulmonary 
manifestations of CMV (retinitis and hepatitis) as well as other opportunistic lung pathogens such 
as Pneumocystis Jirovecci [19] that may lead to more severe disease and worse prognosis. 
In terms of the clinical presentation and respiratory compromise, the onset of symptoms had a 
mean time of 14 days however there was considerable variation ranging from three days in a 
patient that required early mechanical ventilatory support, and up to three weeks in one child with 
nonspecific symptoms, a feature that has previously labeled CMV as an unpredictable respiratory 
infection [5]. Overall there was also great heterogeneity in the severity of the respiratory compromise. 
While one patient had self-limited clinical course that did not required therapy with ganciclovir, 
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another had severe CMV infection and died despite antiviral therapy. In contrast, there was a 
consistent homogenous pattern of initial respiratory symptoms/signs that included a combination of 
cough, hypoxemia, increased breathing effort (i.e., retractions or dyspnea) and diffuse abnormalities 
in lung auscultation, which were present in virtually all cases (Table 3). The diffuse adventitious 
lung sounds identified were described as either wheezing, rales and/or rhonchus, which suggests 
variable degrees of involvement of lung parenchyma and conductive airways during CMV infection, 
compatible with what is generally described in CMV lung pathology [20]. In association with 
respiratory symptoms, about half of the patients had constitutional manifestations (fever or weight loss) 
and accompanying laboratory abnormalities that included anemia (53%), thrombocytopenia (40%), 
leukocytosis (40%), leukopenia (27%) and elevated liver enzymes (47%). These abnormal laboratory 
findings are in overall agreement with prior reports of CMV lung infection in children [11,21]. 
One of the most important findings of our study was the current difficulty/delay in establishing  
the diagnosis of pediatric CMV lung infection. There was a median time to diagnosis of 26 days  
(IQR 11–37 days), which could be explained by the low clinical suspicion in the initial 
management of these non-HIV infected neonates and children. Indeed, relatively prompt diagnosis 
was obtained in those individuals with BMT, SMC and bone marrow transplantation (Figures 2, 4 
and 5), which are well-known risk factors for CMV and therefore bronchoscopy/BAL was performed 
early. On the other hand individuals without underlying immunodeficiency (i.e., steroid-dependent 
asthma; Figure 6) or malnutrition were subject to longer time to diagnosis. Another factor that 
contributed to CMV diagnosis delay was the turnover time for the molecular studies. The CMV 
molecular diagnostic approach was performed using several modalities, including CMV viral load 
in peripheral blood, CMV qualitative PCR amplification in bronchoalveolar lavage (BAL) fluid 
and IgG serology for CMV. Prior reports have been found in which measurements of CMV viral 
DNA done in samples of BAL or sputum are better to make a diagnosis of CMV pneumonia, 
compared with the gold standard demonstration of cytomegalic inclusions in lung tissue [22].  
Honda, J., et al. studied 363 CMV adult patients with 882 samples of sputum, BAL, peripheral 
blood and urine, showing a positive predictive value (PPV) and negative predictive value (NPV) of 
100% and 98.8% for BAL samples, 95.5% and 99.7% for sputum samples; and a sensitivity 90.9% 
and specificity 100% for BAL and 95.5% and 99.7% for sputum [22]. In our pediatric case series, 
CMV PCR in BAL was obtained in 11/15 and was positive in 82% of the cases (9/11); which may 
reflect the technical difficulties of obtaining a proper BAL specimen in the pediatric population, 
particularly in neonates [9]. Interestingly, most children with CMV lung infection had neutrophilia 
instead of lymphocytosis in BAL cellularity, which has been described in the adult literature [7,23]. 
The later may be attributed to bacterial superinfection, immunosuppression (affecting lymphocyte 
function and proliferation) or differences in the airway immune response to CMV in the pediatric 
population. In addition to bronchoscopy, four patients also underwent lung biopsy, two of these had 
PCR negative for CMV in BAL and the other two had a PCR positive in BAL but biopsy was 
performed due to additional concerns about other pulmonary infectious/inflammatory processes 
(i.e., persistent hypoxemia and alveolar hemorrhage). There was one patient who did not undergo a 
flexible bronchoscopy with BAL before open lung biopsy. In all five cases, lung biopsy  
confirmed the diagnosis of CMV, demonstrating cytopathic changes (Figure 6) and positive 
immunohistochemistry (Figures 1 and 3). Additional pathological findings in lung biopsies were 
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diffuse monocytic infiltration (Figures 1, 3 and 6) alveolar hemorrhage and pulmonary vascular 
disease in a patient with history of hemosiderosis and pulmonary hypertension. Because not all 
patients had the same CMV testing done (i.e., viral load) we could not do correlations of laboratory 
values with clinical parameters or the severity of CMV lung infection.  
The initial imaging diagnostic approach consisted of chest radiography and later chest CT to 
further characterize the parenchymal involvement and to help in the decision making for further 
testing such as flexible bronchoscopy and/or lung biopsy. One hundred percent of patients had 
abnormalities on radiological exams; the most frequent findings were consolidation, usually 
compromising the dependent lung regions (bi-basal consolidation; Figure 3) and ground-glass 
opacities caused by the partial displacement of air due to filling of alveolar spaces, interstitial 
thickening and/or partial collapse of alveoli leading to enhanced small airway lumen marks, which 
is a radiological sign known as “dark bronchus” [10] (Figure 2). The ground glass/consolidation 
pattern has been previously identified in adults with CMV infection [24,25]. These radiological 
findings underlie the clinical presentation of CMV lung infection in our pediatric series that 
included increased respiratory effort, abnormal breath sounds and hypoxemia secondary to 
diminished alveolo-capillar gas diffusion and abnormal ventilator (V)/perfusion (Q) match in the 
lungs [25,26]. Importantly, CT scan was superior to CXR in detailing the radiological pattern of 
CMV lung infection in our pediatric case series. This is in agreement with Smith et al. who 
previously reported children with CMV pulmonary disease having minimal non-specific 
abnormalities in CXR [5]. In this context, it is noteworthy to mention that newer CT scan lung 
modalities (high-resolution) are now being proposed to diagnose different pediatric pulmonary 
conditions and thus avoid open lung biopsies [27]. For instance, some types of children’s interstitial 
lung disease (chILD) such as neuroendocrine cell hyperplasia in infancy (NEHI), have specific 
patterns of disease in CT scan that may be sufficient to make a diagnosis when combined with a 
specific set of clinical features [27]. Based on our case series, we propose a group of clinical criteria 
(Table 5) based on risk factors (immunosuppression), symptoms/signs and lung imaging that when 
present must raise concern for CMV pulmonary infection in children and should prompt further 
confirmatory investigation (i.e., bronchoscopy) or empiric therapy depending on the clinical situation. 
Table 5. Key features of CMV lung infection in non-HIV infected children. 
Immunosupression 
Systemic steroid use  
Malnutrition  
Hypogammaglobulinemia  




Increased breathing effort  
Hypoxemia  




CMV PCR in BAL 
BAL, Bronchoalveolar lavage. 
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5. Conclusions  
In summary, CMV infection of the lung is a prevalent condition in the immunocompromised 
host with a variable clinical presentation. Clinical clues that should prompt suspicion of CMV 
pneumonia in this population are the presence of respiratory symptoms and abnormal lung exam. 
The initial diagnostic approach should include a chest-X ray which can shows signs consistent with 
alveolar air displacement, however these changes can be subtle and easily missed on interpretation, 
thus making a chest CT a better radiological tool to evaluation the lung involvement in the 
immunocompromised host. The best test to confirm the diagnosis is a CMV PCR performed in 
BAL, bronchoscopy. The prompt identification of CMV lung infection in children without 
underlying immunodeficiency syndrome (i.e., non-HIV infected) requires a high-index of suspicion 
based on common respiratory sign/symptoms/images (Table 5) and is crucial to institute early 
antiviral therapy, which can significantly impact the clinical outcome of neonates and children with 
this potentially life-threatening infection. 
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Abstract: The natural history of human cytomegalovirus (HCMV) is inextricably 
associated with mucosal surfaces. The vast preponderance of primary infections occur 
following mucosal exposure to infectious virions, and the high seroprevalence of 
HCMV throughout the world is due to long-term excretion of HCMV in bodily fluids 
from multiple mucosal sites. Accumulating evidence presents a model where the 
earliest virus-host interactions following infection dictate the long-term pattern of 
infection, alter innate immune responses that skew adaptive responses to enable 
persistence within an immune host, and are essential for reinfection of a host with prior 
immunity. HCMV has evolved a complex repertoire of viral functions fine-tuned to 
manipulate the immune environment both locally at the sites of infection and 
systemically within an infected host. Collectively, viral immune modulation represents 
a significant impediment for an HCMV vaccine. As HCMV can disseminate beyond 
mucosal surfaces to reinfect immune hosts, it may not matter whether prior immunity 
results from prior infection or immunization. A better understanding of the earliest  
virus-hosts interactions at mucosal surfaces may identify elements of the viral proteome 
that are especially susceptible to vaccine-mediated disruption and prevent challenge 
virus from disseminating to distal sites, particularly the maternal-fetal interface. 
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Herpesviridae are a family of ubiquitous pathogens with ancient origins, dating back 400 
million years, and they have co-evolved with their radiating host species since the progenitor 
herpes virus species arose [1]. The extent of co-evolution is such that herpes simplex virus (HSV-1) 
sequences have been used to track human global migration out of Africa [2]. If evolutionary 
longevity and the percentage of infected hosts measure the success of a pathogen, this family is 
very successful. While the classification of Herpesviridae is based on virion structure, all herpes 
viruses share the phenotype of establishing a lifelong persistence within the infected and, usually, 
immune-competent host. Mechanisms of persistence remain an active area of research into herpes 
virus natural histories. While large gaps in our knowledge of persistence remain to be filled, it is 
becoming clear that there are common themes amongst all herpes viruses layered onto virus-specific 
functions that modulate host cell signaling, trafficking, activation, antigen presentation, and 
lifespan. Based on our current understanding, some viral immune modulation mechanisms can be 
sub-grouped by family (alpha-, beta-, or gamma- herpesvirinae) or can be species-specific. One 
unifying feature of all herpes viruses is the central role of epithelial cells in the infectious cycle in 
mediating the initial portal of entry during infection of an individual in addition to serving as the 
exit site for secretion into bodily fluid to maintain the virus within the larger population of 
susceptible hosts. In between these points of the HCMV infectious cycle, herpes viruses 
disseminate to family-specific cell types of persistence for the alpha-, beta-, or gammaherpesvirinae, 
including neurons, CD34+ and other cell types, and B cells, respectively. It is highly likely that the 
raison d’être for sites of persistence is to provide a privileged site for viral genomes, resistant to 
immune-mediated clearance, that can occasionally or subliminally reactivate to produce infectious 
virions that can traffic back to mucosal epithelial cells and be secreted in bodily fluids. Analysis of 
the central role of mucosal epithelial cells in the life cycle of human cytomegalovirus (HCMV) 
illustrates the complexities and the challenges confronting development of HCMV vaccines designed 
to prevent primary infection and, hopefully, reinfection of those with preexisting HCMV immunity. 
2. HCMV Natural History 
2.1. HCMV Shedding in Bodily Fluids 
HCMV is the prototypical betaherpesvirus with a complex natural history, a large and 
incompletely defined genetic coding capacity, and a seemingly contradictory virus-host 
relationship. HCMV is ubiquitous throughout the world, and seroprevalence rates range from ~50% 
in the U.S. to close to 100% in some developing countries [3]. Primary HCMV infection in 
immune-competent individuals is generally associated with either transient and mild clinical 
outcomes or inapparent seroconversion. Based on the reported rate of congenital infection (~0.7%), 
primary infections result almost exclusively following mucosal exposure to horizontally 
transmitted virions in bodily fluids. Despite mucosal epithelia serving as the entry point for the 
preponderance of HCMV infections, there is virtually nothing known about the virological and 
immunological cascade of events within the mucosa and submucosa. 
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Like all herpes viruses, HCMV establishes a lifelong persistence characterized by the presence 
of cells harboring latent viral genomes that periodically reactivate to produce infectious virions. 
The frequency of shedding varies dependent in part on age, health, the particular bodily fluid, and 
physiologic status. In children under the age of five years infected congenitally or within the first 
years of birth, the frequency of HCMV in saliva and/or urine has been reported as high as 80% 
with rates declining as the children age (12%–23%) [4,5]. In healthy non-human immunodeficiency 
virus (HIV)-infected adults, cross-section surveys of HCMV excretion in cervical swabs, saliva, 
and/or urine indicate rates of detection between 7%–24%, with higher rates observed in the context 
of HIV coinfection (non-HAART treated) or sexually transmitted diseases [4,6–9]. Longitudinal 
studies of seroimmune healthy women demonstrate that 83% exhibited at least one positive urine 
sample with HCMV [8]. Rates of HCMV reactivation during pregnancy lead to the conclusion that 
HCMV is exquisitely suited for shedding in breast milk. Three studies have observed frequencies 
of HCMV detection in breast milk from 89%–100% [10–12]. While it is well established that 
HCMV can establish near complete latency in certain cell types (e.g., CD34+ myeloid progenitor 
cells), characterized by an extremely limited pattern of HCMV transcripts [13–18], long-term 
shedding in mucosal fluids is the norm during persistent infection. Even more pronounced than 
primary infection, persistent HCMV shedding is not associated with disease in those infected 
individuals with functional immune systems. As with the large gaps in our knowledge of initial 
virus-host interactions at mucosal surfaces during primary infection, the mechanistic basis for the 
frequency and magnitude of mucosal shedding are virtually unexplored for HCMV. 
2.2. HCMV Immune Responses 
The general absence of HCMV clinical sequelae associated with primary infection and the almost 
complete absence during persistent infection emphasize the protective nature of host antiviral 
immune responses. Primary HCMV infection stimulates robust immune responses, including broadly 
neutralizing antibodies to multiple envelope glycoproteins [19–21] and especially prominent 
antiviral T cell responses [22,23]. The protective efficacy of these immune responses is emphasized 
by the fact that declines in functional immunity, either by iatrogenic immunosuppression or 
immune deficiency, is associated with significantly increased risks of HCMV morbidity and 
mortality. Similarly, congenital HCMV infection is a leading infectious cause of hearing loss and 
developmental disorders in infants in the U.S. [21,24]. Primary HCMV infection in the mother puts 
the infant at greater risk of symptomatic disease [19]. Likewise, the immunological immaturity of 
fetuses portends increased risk of developmental deficits following congenital HCMV infection 
(reviewed in [25]). Due to the severe diseases that HCMV can cause in people with limited 
functional immunity, an HCMV vaccine has been a public health priority for the past several 
decades [24,26–30]. An overriding theme of HCMV vaccine development has been to recapitulate 
through vaccination the dominant immune responses generated during primary infection. 
A potential limitation of this approach is that peripheral immune responses (e.g., neutralizing 
antibodies, antigen-specific T cells) constitute the vast majority of immune responses analyzed in 
infected individuals. While informative, limitation of immune responses to the periphery may result 
in failure to identify critical tissue-specific immune responses. In particular, mucosal immune 
responses in situ, including innate responses, to HCMV are notably understudied relative to 
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peripheral B and T cell responses. A limited number of studies have detected very low but 
detectable binding and/or neutralizing antibody responses to HCMV in saliva following either 
natural infection and, importantly, immunization with live attenuated virus or recombinant gB 
subunit vaccination [31–33]. Saliva antibody responses, which are not detectable in all those with 
serum antibodies to HCMV, include IgG, IgA, and sIgA. Neutralizing antibodies have 
differentially been associated with the IgA and IgG fractions. 
Three features of these studies that may be relevant to vaccine design include the following.  
(1) Vaccination can lead to detectable increases in saliva antibodies [33]; (2) Saliva IgG titers are a 
fraction of serum antibody IgG titers but generally correlate with peripheral IgG [31,33]; (3) There 
is no apparent association between cessation of HCMV shedding in saliva of young HCMV-infected 
children and development of detectable neutralizing antibodies in saliva [32]. As mucosal surfaces 
represent the first line of defense against HCMV infection, it stands to reason that a more thorough 
understanding of the earliest host-pathogen interactions at mucosal surfaces is critical for the future 
development of vaccine strategies designed to disrupt the natural pattern of infection, persistence, 
and shedding. Enhancement of innate immune responses at the site of infection might tip the 
balance in favor of the host and allow for viral clearance or reduced viral shedding from mucosal 
surfaces later in the replication cycle. 
2.3. HCMV Persistence 
The preceding discussion about the mostly protective immune responses resulting from primary 
infection presents something of a conundrum about the quality of the antiviral immune responses. 
Like all herpes viruses, HCMV persists for the lifetime of immune-competent hosts, and the 
longitudinal shedding of virus in bodily fluids demonstrates that viral gene expression occurs in the 
presence of the very same immune responses that protect against viral sequelae. Simply put, 
HCMV stimulates immune responses that effectively limit infection and mostly protect the host 
from disease, yet are insufficient to clear persistent reservoirs of infected cells. The chronicity of 
antiviral immunity following primary infection strongly implies chronic viral gene expression at a 
level sufficient to maintain antibody and T cell responses [23]. There is no solid evidence that 
lifelong HCMV infection and gene expression result in overt HCMV pathology, which leads to the 
conclusion that HCMV has evolved a lifecycle to maximize its potential to excrete infectious 
virions that can disseminate to susceptible hosts. Beyond the potential for spreading virus 
horizontally and vertically, there are numerous reports in the last several years suggesting that 
chronic HCMV infection may be associated with increased risk of some age-related diseases. It 
should be stressed, however, that the linkages are statistical associations without conclusive proof 
of HCMV causality [24,34]. It may turn out that, as human lifespan increases well beyond historic 
levels, chronic HCMV infection may have adverse effects in the context of an aging immune system. 
2.4. HCMV Reinfection 
Another aspect of the restricted immune protection conferred by primary infection is the failure 
of preexisting immunity to fully protect from reinfection with a different strain of HCMV [21,35,36]. 
Multiple studies have documented that HCMV can reinfect individuals with prior HCMV  
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immunity [8,21,37–43]. Congenital infection rates of 1% have been reported in populations with 
100% seroprevalence of HCMV. The demonstration that seropositive women who give birth to a 
congenitally infected infant acquired new antigenic reactivity to HCMV antigens between 
pregnancies is strong evidence that prior immunity is incompletely protective against reinfection 
with antigenic HCMV variants. This is particularly remarkable because, in healthy long-term 
HCMV carriers, ~10% of memory T cells are HCMV-specific, and neutralizing antibodies are 
generated against multiple viral glycoproteins including gB [23,44–48]. In another study, 30% of 
seropositive women that were longitudinally evaluated developed novel HCMV antibody 
specificities, equivalent to an annual rate of HCMV reinfection of 10% [49]. Studies of reinfection 
indicate a viral mechanism to surmount preexisting immune memory to initiate a new infection, 
leading to the clinical ramification that infection of an immune host is probably independent of 
whether prior immunity is from prior infection or prior vaccination. The reinfection studies also 
suggest that the true disease burden might be underestimated, particularly so since the reinfection 
studies to date are based on looking at an extremely limited number of epitope variants. 
2.5. HCMV Immune Modulation 
The ability of HCMV to persist in an immune-competent host and reinfect immune individuals 
is undoubtedly related to the extraordinary devotion of HCMV coding content to viral proteins that 
modulate host immune cell function. Based on the number of open reading frames that can be 
deleted without impairing replication in fibroblasts, it is likely that ~50% of viral ORF are involved 
in an extensive repertoire of immune modulating functions [50,51]. Given the protracted evolution 
of herpes viruses, in general, and HCMV, in particular, it is highly likely that evolution of viral 
functions that modulate innate and adaptive immunity define the mechanistic basis for the 
phenotypic features that define HCMV as the virus that it is. Consistent with this interpretation, it 
is, perhaps, noteworthy that there have been no descriptions of immune escape variants arising 
during subclinical persistent infections, or fulminant outcomes associated with immunosuppression 
or immunodeficiency. In contrast, drug-resistant variants readily arise after initiation of anti-
HCMV chemotherapies [52], which, based on recent estimates of sequence variation occurring 
during HCMV infection, should come as no surprise [53]. One interpretation of these discordant 
responses to immune-mediated and antiviral-mediated selective pressures might be the result of the 
protracted evolution of herpes viruses in hosts possessing innate and adaptive immune systems. 
HCMV evolved the broad repertoire of immunomodulatory functions that presumably confers a 
selective advantage over genetic drift as a means to persist within a host and disseminate 
throughout the population. In contrast, anti-HCMV chemotherapies are very recent treatment 
modalities, and therefore, there are no apparent HCMV-encoded functions that can directly 
counteract the different anti-HCMV drugs in clinical use. 
2.6. Future Directions for HCMV Vaccine Development 
One of the earliest calls for development of an HCMV vaccine stemmed from the clinical 
recognition of the grave infectious threat that intrauterine HCMV represents to fetal growth and 
development [27]. Based on his 15-year retrospective analysis of congenital HCMV cases, 
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Hanshaw concluded that, “… any thoughtful program aimed at prevention or treatment deserves 
consideration”. Multiple lines of reasoning, focusing on (1) lifelong viral gene expression and 
shedding; (2) the magnitude of host cell immune responses required to prevent sequelae; and (3) 
reinfection of immune hosts, lead to the argument that HCMV is unlike any other virus for which 
vaccines have been clinically approved. Accordingly, “any thoughtful program aimed at prevention” 
of HCMV infection is likely to require adjuncts to the current paradigm of preventing attachment 
of HCMV virions to susceptible cells by gB-mediated neutralization. There are numerous challenges 
confronting HCMV vaccine development including a complex natural history, incompletely 
defined correlates of immune protection, and financial and logistical challenges in sufficiently 
powered clinical trials. Recent studies using the rhesus macaque model of HCMV demonstrate that 
infection of rhesus macaques with rhesus CMV (RhCMV) offers novel insight into vaccine 
strategies that have clinical relevance for development of HCMV vaccines. The remainder of this 
review will focus on the mechanisms of RhCMV infection, transmission, persistence, and 
reinfection and how the results of these studies inform new HCMV vaccine modalities. 
3. RhCMV Natural History 
3.1. Endemic RhCMV Infectious Cycle in Rhesus Macaques (Macaca mulatta) 
Development of the RhCMV model of HCMV persistence and pathogenesis has benefitted by 
characterization of RhCMV natural history in large breeding cohorts to establish normative 
parameters of endemic infections to guide experimental studies. One unifying element of 
population studies is the central role of mucosal surfaces in the infectious cycle of RhCMV. Studies 
have demonstrated that the kinetics of RhCMV dissemination throughout mixed cohorts of 
uninfected and infected animals is a function of the persistent shedding of virus in bodily fluids of 
infected animals and the repeated mucosal exposure of uninfected animals to virus. RhCMV is 
endemic in breeding cohorts of rhesus macaques, as well as in native populations of wild 
macaques, and almost 100% of naive animals seroconvert by one year of age, well before the onset of 
sexual maturity around four years of age [54–57]. There are no known clinical sequelae associated 
with primary RhCMV infection in immune competent animals, which stands in contrast to the 
severe pathogenic outcomes following SIV immunodeficiency [58–60] or iatrogenic 
immunosuppression [56]. Seroconversion of previously naïve animals is often, but not always, 
contemporaneous with the detection by TaqMan real-time PCR of low quantities of RhCMV 
genomes in plasma [61,62]. The quantities of viral DNA detected in plasma are lower than those 
detected in saliva later in infection, consistent with hematogenous spread of progeny virions from 
local portals of entry to distal sites throughout the body. Like HCMV, RhCMV can be detected in 
multiple cell types throughout the body [58,60], and the virus efficiently seeds those anatomic sites 
where virus can be shed. 
Recapitulating the virus-host relationship for HCMV, RhCMV persists, and chronic RhCMV 
gene expression is the norm during the life of the infected animal, despite the presence of 
neutralizing antibody and T cell responses [63–65]. Key sites of persistence include the salivary 
glands and genitourinary tract. Infected animals can persistently and asymptomatically shed virus 
in bodily fluids (e.g., saliva and urine), often in high quantities, for years after primary  
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infection [66–69]. Multiple genetic variants have been detected in fluids of naturally infected 
animals [69–71], although there are no reports of deep sequencing to quantify the extent of 
sequence diversity. Because of persistent shedding in bodily fluids and the social dynamics of large 
macaque cohorts, RhCMV rapidly spreads through the cohort. In fact, RhCMV has an exceedingly 
high force of infection in naïve hosts. Two studies of mixed cohorts of infected and uninfected 
macaques demonstrate that the doubling rate of seroconversion of uninfected animals is five to nine 
weeks [54,61]. 
There have been no reports to date of vertical transmission of RhCMV, possibly due to the 
universal seroprevalence of RhCMV in breeding age female macaques [56]. Consequently, the high 
seroprevalence of RhCMV in large cohort is the direct consequence of repeated mucosal exposure 
of uninfected animals to horizontally transmitted virions in bodily fluids of infected animals. As 
such, this aspect of RhCMV natural history reflects the challenges that confront HCMV vaccine 
trials, namely repeated close contact of vaccinated/uninfected women to those shedding potentially 
antigenically variant HCMV in bodily fluids. One implication from the studies of RhCMV in 
mixed populations is that there are at least two strategies to minimize the risk of primary infection:  
(1) vaccinate those at-risk for primary infection; and (2) vaccinate those who may become the 
source of horizontally transmitted virus to minimize the potential for shedding of virus in bodily 
fluids (such as young children). While detailed molecular and virological investigations of RhCMV 
infection following natural exposure have not been reported, experimental data regarding cellular 
tropism and the virally encoded genes that are essential in this process provide insights into parts of 
the viral proteome that may be especially susceptible to vaccine-mediated disruption. 
3.2. Early Virus-Host Interactions during Experimental Infection 
Early virus-host interactions within the mucosa following natural exposure to RhCMV have not 
yet been explored. However, several studies using experimental inoculation via subcutaneous (SC) 
delivery of virus have revealed a salient aspect about early virus-host interactions relevant to 
HCMV vaccine design. In particular, the acute virus-host interactions following SC inoculation 
determine the long-term patterns of RhCMV infection. 
Several strains of RhCMV have been described in the literature, and strain-specific differences 
depend on the extent of fibroblast adaptation. RhCMV strain 68-1 is the prototypical strain that was 
isolated after co-culture of urine from a rhesus macaque on human fibroblasts [66,67]. Sequence 
analysis of the 68-1 genome after serial passage in human and/or rhesus fibroblasts revealed that 
the UL/b’ region of the genome had undergone rearrangements and loss of coding capacity, in 
particular RhUL128, RhUL130, and three CXC chemokine-like ORF [69,72]. Based on precedence 
with the HCMV gH-based pentamer [73,74], the loss of RhUL128 and RhUL130 results in severe 
attenuation of RhCMV tropism for epithelial and some endothelial cells in culture [75,76]. RhCMV 
strains UCD52 and UCD59 were also isolated initially on human and macaque fibroblasts, and 
subsequently passed exclusively on primary monkey kidney epithelial cells [61,77]. Sequence analyses 
of both UCD52 and UCD59 demonstrated that the UL/b’ regions of both strains retain the full 
coding capacity of wild-type RhCMV (i.e., never passed in culture) [69], and both retain epithelial 
cell tropism in vitro. Of particular note for vaccine strategies, strain-specific differences in the 
UL/b’ coding content result in distinct phenotypes of acute infection in vivo following SC inoculation. 
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Skin biopsies of the SC inoculation site obtained seven days after infection with either UCD52 
or UCD59 are noted for prominent neutrophilic infiltration with extensive infection of endothelial 
cells (CD31-positive), fibroblasts (vimentin-positive), and macrophages (CD68-positive) [60]. In 
contrast, biopsies from animals infected seven days prior with 68-1 were noted for a predominant 
mononuclear cell infiltrate, and infected cells were predominantly fibroblasts and a reduced 
infection frequency in macrophages was observed (compared to UCD52/UCD59). Notably, no 
endothelial cells infected with 68-1 were detected (infection of epithelial cells was not evaluated in 
this study). This study confirmed that the expanded tropism conferred by the gH-anchored 
pentamer (in UCD52 and UCD59) observed in vitro is also observed in vivo. In addition, 
investigation of the earliest virus-hosts interactions highlights how RhCMV acutely alters local 
innate host responses, presumably due to the presence (UCD52/UCD59) or absence (68-1) of viral 
CXC chemokine-like ORF. As will be discussed below (Sections 3.3 and 3.4), differences in UL/b’ 
coding capacity also result in distinct long-term parameters of RhCMV infection. 
3.3. Rapid Emergence of RhCMV Variants with Complete UL/b’ Coding Capacity during 
Experimental Infection 
The strong positive selective pressures conferred by a full complement of UL/b’ coding capacity 
was recently described in a serendipitous finding with another annotated strain of RhCMV [78]. 
RhCMV strain 180.92 was isolated from a simian immunodeficiency virus (SIV)-infected monkey 
and serially passed on human and monkey fibroblasts without plaque purification [79]. Sequence 
analysis of overlapping cosmid clones generated from cells infected with the 180.92 stock revealed 
a large rearrangement in UL/b’ that resulted in the deletion of most of UL/b’-encoded ORF, 
compared to 68-1 and wild-type RhCMV, but left intact the RhUL128-131 coding regions. 
RhCMV 180.92 exhibits greater epithelial/endothelial cell tropism than 68-1, consistent with 
retention and expression of the complete gH-anchored pentamer in 180.92, although the ability to 
infect epithelial/endothelial cells is reduced compared to a repaired version of 68-1 (BRh68-1.2) in 
which the RhUL128 and RhUL130 genes were engineered back into 68-1 [75]. Reduced growth of 
180.92 in epithelial/endothelial cells compared to BRh68-1.2, is likely due to other UL/b’ ORF 
distinct from RhUL128-131. Stocks of RhCMV 180.92 were prepared from bulk infected cell 
cultures, and plaque purification was never done during serial passage. PCR analysis of the 180.92 
stock subsequently revealed the presence of a minor sequence variant comprising <15% of the total 
RhCMV genomes within the 180.92 stock. PCR amplification and sequencing of molecular clones 
determined that the minor sequence variant was, in fact, a full-length RhCMV genome, presumably 
representing the remnant of the original unrearranged genome prior to fibroblast adaptation. 
Reexamination of tissues from these animals and other animals unexpectedly revealed that there 
was a rapid emergence of the full-length variant despite it being a minor constituent in the virus 
stock [78]. 
Six RhCMV uninfected macaques, including one that was SIV-infected, were inoculated 
intravenously with the RhCMV 180.92 stock, and longitudinal plasma, saliva, and urine samples 
were collected and analyzed for RhCMV. Using primer sets that distinguished the truncated and 
full-length genomic variants, it became apparent that the full-length variant rapidly became the 
dominant genomic form (>95%) in blood by three weeks post inoculation. Analysis of RhCMV in 
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the tissues from the SIV/RhCMV coinfected animal similarly demonstrated high-level genome 
copy numbers of the full-length in tissues. In contrast, the truncated genomic variant exhibited 
significantly lower genome copy numbers in plasma, tissues, urine, and saliva. These data 
demonstrate that the truncated 180.92 variant is severely attenuated in vivo, despite the presence of 
the RhUL128-131 ORF. The results emphasize that additional UL/b’ ORF are essential for optimal 
replication and dissemination of RhCMV in vivo, and accordingly, these particular viral proteins 
represent potential vaccine targets to minimize hematogenous spread to tissues throughout the body. 
3.4. Long-term Parameters of RhCMV Infection during Experimental Infection 
The preceding rationale about vaccine-mediated targeting those UL/b’ ORF outside of 
RhUL128-131 can also be applied to RhUL128-131, based on differences in long-term infections 
of variants containing or lacking RhUL128-131. In addition to an apparent defect in cell tropism 
during acute infection (described above), 68-1 is significantly attenuated for shedding in bodily 
fluids [60,61]. Uninfected animals inoculated SC with UCD52 and UCD59 are noted for persistent 
detection of RhCMV in the saliva and urine of most animals (~75%) beginning six to eight weeks 
after inoculation [61]. The prolonged detection of RhCMV following experimental inoculation 
reflects the pattern of RhCMV shedding in animals naturally exposed to RhCMV [66–68]. In 
marked contrast, 68-1 DNA is either below the limit of PCR detection, or infrequently detected at 
low copy numbers in either bodily fluid [80–82]. All of these studies used PCR detection of 
RhCMV DNA as a surrogate for virus isolation to assess virus shedding. As a measure of the 
biological relevance of PCR detection, animals inoculated with UCD52 or UCD59 can transmit 
virus to uninfected cage-mates, whereas horizontal transmission of 68-1 has not been observed [61]. 
This finding is particularly relevant for vaccine development strategies aimed at reducing viral 
shedding as a means to control horizontal infection. Together, these observations suggest impaired 
dissemination and shedding of 68-1 in vivo and demonstrate the essential nature of mucosal tissues 
in CMV infection and the requirement for broad cellular tropism. It should be noted that RhCMV 
68-1 is not replication impaired in vivo due to the absence of a functional gH-anchored pentamer 
and the CXC-chemokine-like ORF. The pattern of acute infection with 68-1 (described in  
Section 3.2) [60] demonstrates that 68-1 can utilize, presumably, gB-mediated entry into 
permissive cells, and 68-1 can disseminate throughout the body [83]. Moreover, studies using 
RhCMV 68-1 as a vaccine vector to express SIV antigens have observed some excretion of the 
engineered 68-1 vectors in urine of inoculated animals [22,84]. 
Although the mechanisms involved in mucosal transmission are poorly understood, disruption 
of the natural pattern of mucosal shedding through vaccination, by either reducing the incidence of 
shedding in infected people or enhancing mucosal immune responses to prevent infection or 
reinfection, is a novel strategy that is supported by recent observations in macaques. A better 
understanding of the early interactions between RhCMV and its host, and the mucosal immune 
responses involved in RhCMV infection, are essential for this vaccine development strategy. 
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3.5. RhCMV Immune Modulation 
It is an accepted precept of vaccinology that the quality and quantity of adaptive immune 
responses are dependent on the quality and quantity of innate responses [85]. Accordingly, there is 
increasing effort in designing adjuvants that direct adaptive immunity in a direction that increase 
protective efficacy. Acute differences in innate immune responses at sites of inoculation following 
SC exposure to either UCD52/UCD59 or 68-1 (described above) [60] imply that RhCMV (and by 
extension HCMV) similarly exerts an adjuvant-like effect on the local innate effector cells to direct 
adaptive immune responses towards a situation that favors viral persistence at the expense of 
immune-mediated clearance of RhCMV-infected cells. The RhCMV functions that presumably 
mediated the relative differences in the nature of the inflammatory response (polymorphonuclear 
cells for UCD52/UCD59 and mononuclear cells for 68-1) is due to the presence of the CXC-like 
ORF in UCD52/UCD59, although no functional activity for these ORF has been reported [69]. The 
concept that a critical step in early RhCMV-host interactions involves rapid manipulation of innate 
responses is bolstered by studies investigating the role of the virally encoded interleukin-10 like 
protein of RhCMV. 
Primate CMVs, with the exception of chimpanzee CMV, encode a viral IL-10 gene that is an 
evolutionary remnant of a transduced cellular IL-10 (cIL-10) gene by a progenitor primate CMV at 
some point after the split of rodents and primates [56,86,87]. Despite extensive genetic drift of  
the HCMV and RhCMV viral IL-10 proteins (cmvIL-10 and rhcmvIL-10, respectively) from the 
cIL-10 proteins of their respective hosts, these viral orthologs retain high affinity for the cognate 
cIL-10 receptor [50] and nearly identical immunosuppressive properties in vitro to those exhibited 
by cIL-10 [56,87]. The conservation of functionality of cmvIL-10 and rhcmvIL-10 to that of cIL-10 
leads to the proposition that expression of an IL-10-like protein in the context of viral infection 
suppresses acute immune responses to viral infection. 
The role of rhcmvIL-10 in primary infection was analyzed in macaques following SC 
inoculation with 68-1 or a 68-1 rhcmvIL-10 knockout virus (68-1 IL-10) [81]. Tissue biopsies 
taken from animals seven days after inoculation with 68-1 had markedly reduced cellularity at the 
inoculation site, but greater numbers of tissue macrophages, than 68-1 IL-10 inoculated animals [81]. 
In addition, there were fewer myeloid dendritic cells and decreased priming of naïve CD4+ T cells 
in the draining lymph nodes of 68-1 infected animals versus 68-1 IL-10 infected animals. Animals 
inoculated with 68-1 also showed impaired RhCMV-specific IgG responses and lower IgG avidity, 
compared with 68-1 IL-10 infected animals. In sum, the functional absence of rhcmvIL-10 in  
68-1 IL-10 resulted in increased innate immune recognition of viral antigens and increased 
adaptive immune responses. These results lead to a model whereby a critical step in RhCMV 
infection is the immediate manipulation of the local immune environment mediated, in part, by 
rhcmvIL-10. Based on this premise, secreted proteins, such as rhcmvIL-10, should represent 
reasonable vaccine targets to induce, particularly, antibodies that neutralize their function. 
A recent survey of RhCMV-infected macaques revealed that one consequence of the extensive 
genetic drift of rhcmvIL-10 from the cIL-10 protein of its host is that what was once a self-protein 
soon after transduction of the cIL-10 gene has become highly immunogenic in the context of viral 
infection [88]. All RhCMV-infected animals develop high avidity binding antibodies to rhcmvIL-10, 
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and almost 100% of the animals also exhibit some level of antibodies that neutralize rhcmvIL-10 
function in bioassays. Importantly, the rhcmvIL-10-specific neutralizing antibody responses 
generated in these macaques did not cross-react with cIL-10. The cmvIL-10 protein is also 
immunogenic in HCMV-infected humans [89]. Together, these data provide proof-of-concept for 
targeting viral IL-10, an immune modulator, as a vaccine strategy to interrupt viral persistence. 
To accomplish antigenic stimulation without triggering the cIL-10 receptor, a non-functional 
rhcmvIL-10 has been designed, cloned into an expression cassette, expressed, and purified [90]. 
Immunization of naïve macaques with a DNA prime/protein boost immunization strategy stimulated 
antibody responses that neutralized wild-type rhcmvIL-10 function without cross-neutralization of 
rhesus cIL-10 [90]. SC challenge of vaccinated animals with UCD59 resulted in significantly lower 
frequencies and loads of RhCMV DNA in plasma, saliva, and urine, compared to mock-vaccinated 
control animals [91]. These data are unprecedented for CMV vaccine strategies in that targeting a 
single viral immune modulator (i.e., rhcmvIL-10) elicited immune-mediated protection against viral 
challenge without inducing antibodies that neutralized RhCMV infection of cells. Given the large 
devotion of the HCMV coding capacity to immune modulating proteins (discussed in Section 2.5), 
the results targeting rhcmvIL-10 offer a compelling rationale to explore additional viral antigens 
involved in immune modulation. 
3.6. RhCMV Reinfection 
A considerable challenge to reducing congenital infection is the ability of HCMV to reinfect 
women with pre-conceptional immunity and subsequently cross the maternal-fetal interface 
(discussed in Section 2.4). The challenge arises because the mechanism for reinfection is unknown 
and, consequently, there are no prevention strategies short of absolutely minimizing exposure to 
virus shedding contacts. Fortunately, a study of RhCMV sheds light on viral mechanisms to 
overcome prior immunity. 
Evidence for RhCMV infection of immune competent hosts is suggestive from natural history 
studies but incontrovertible from experimental studies. As described above (Section 3.1), multiple 
genetic variants of RhCMV have been amplified by PCR from RhCMV-immune animals. While 
these reports are consistent with reinfection, given the repeated exposure to infectious virus in 
bodily fluids of infected cohorts, it cannot be ruled out that the animal, from which saliva samples 
were analyzed, was not infected with more than one variant during primary exposure to RhCMV. 
In contrast, experimental inoculation of immune animals with genetically tagged variants of 
RhCMV is exceedingly efficient. Engineered variants of RhCMV 68-1 that express the SIV proteins 
(gag, retanef) have been used to reinfect RhCMV immune animals [84]. Animals inoculated with 
the RhCMV vector expressing the SIV protein uniformly develop SIV protein-specific T cells 
responses, and the RhCMV/SIV vector can be recovered in the urine of reinfected animals. 
Reinfection can be observed following inoculation with as little as 100 PFU, highlighting the 
ability of RhCMV to overcome existing antiviral immune responses [22]. 
Based on this, Hansen et al. reasoned that an essential step in reinfection is overcoming  
“an initial immunological checkpoint”, and they addressed whether the RHCMV orthologs of the 
HCMV proteins disrupting MHC-I antigen presentation mediate RhCMV reinfection (US2, 3, 6, 
and 11) [22]. Engineered deletion of the RhUS2-11 genes did not impair the ability of the deletant 
70 
variant to replicate in cultured fibroblasts, compared to the unmodified parental vector. 
RhCMV US2-11 expressing SIV gag was also able to establish infection in RhCMV-uninfected 
macaques, as demonstrated by recovery of RhCMV US2-11 in the urine of infected animals and 
development of RhCMV-specific and gag-specific T cell responses. Notably, RhCMV US2-11 
was incapable of reinfecting RhCMV-immune animals following SC inoculation with 107 PFU. 
These results demonstrate that manipulation of the host immunity is essential for reinfection, and, 
together with studies of acute RhCMV infection, illustrate the role RhCMV immune modulating 
proteins play in the infectious cycle of RhCMV in vivo. 
4. Conclusions 
The results of the Phase II gB vaccine trial [29] represents an important step towards meeting 
the clarion call of Hanshaw to develop a vaccine that protects against the devastating consequences 
of intrauterine HCMV infection [27]. This clinical trial now represents the “gold standard” against 
which subsequent HCMV vaccine trials will be compared, and yet, it is not certain at this time 
whether the level of observed protection compels a Phase III trial. Key issues about how best to 
move forward include (1) optimization of gB immunization to induce greater protective neutralizing 
responses; (2) inclusion of additional envelope glycoproteins to induce broader neutralizing responses 
against other virologically relevant cell types (i.e., gH pentamer-mediated infection of epithelial 
and endothelial cells); and/or (3) targeting other parts of the HCMV proteome not involved in 
attachment/entry of susceptible cells. The vaccine potential for broadening neutralizing antibody 
responses beyond gB has been demonstrated recently by restoring the gH pentameric complex in 
the AD169 vaccine strain of HCMV [92,93]. While still in an early developmental stage, this 
strategy may help to address the difficult problem of the broad cellular tropism of HCMV. HCMV 
persistence in immune competent hosts and, in particular, the ability of HCMV to reinfect immune 
individuals leads to the proposition that HCMV is unlike most every other virus for which 
protective vaccines have been developed. Varicella zoster virus (VZV), an alphaherpesvirus and 
the only herpes virus for which there is a commercially available vaccine, persists in the infected 
host in a truly latent state, and recurrent disease is the result of reactivation of this latent virus after 
host immune responses have waned or become impaired. The attenuated VZV vaccine strain, Oka, 
was generated via serial passage in cell culture of a clinical VZV isolate. Similar strategies for 
HCMV have failed to generate a successful vaccine candidate (e.g., Towne) [94,95]. In addition, 
prior immunity to HCMV does not protect from reinfection despite robust adaptive immune 
responses. The ability to overcome extant neutralizing antibody responses and extraordinarily large 
HCMV-specific T cell responses emphasize the unprecedented role of HCMV-encoded immune 
modulating functions in HCMV natural history. Given the expense involved in conducting 
sufficiently powered clinical Phase II and Phase III trials, there is an essential need for rigorous 
pre-clinical studies that can inform which vaccine modalities should advance to human testing. 
Recent studies of RhCMV point to multiple ORF that can be targeted to change the course of 
acute infection, dissemination via the blood to tissues throughout the body, and the ability to seed 
distal sites where progeny virions are shed into bodily fluids. These antigens include: gB, pp65,  
the gH-pentamer complex, CXC chemokines, rhcmvIL-10, and other ORF in UL/b’ besides 
RhUL128-131. However, multiple RhCMV vaccine studies using a variety of antigen delivery 
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modalities have demonstrated partial protection, at best, and the results are consistent with the 
complexities of HCMV vaccine design. It should be stressed that all RhCMV vaccine studies, and 
to our knowledge all animal vaccine models of HCMV vaccines, use direct parenteral introduction 
of challenge virus. This bypasses the potential for mucosal immunity in the vaccinee to control 
primary viral challenge, and subsequent studies in animal models should work to recapitulate the 
repeated mucosal exposures to HCMV that vaccinees will encounter. 
Acknowledgments 
This manuscript was made possible by grant support from NIH to PAB (AI063356, AI097629, 
AI049342) and the California National Primate Research Center (OD011107), and the Margaret 
Deterding Infectious Disease Research Support Fund. 
Author Contributions 
J.D.D. and P.A.B. contributed equally to this review. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References and Notes 
1. McGeoch, D.J.; Gatherer, D. Integrating reptilian herpesviruses into the family herpesviridae.  
J. Virol. 2005, 79, 725–731. 
2. Kolb, A.W.; Ane, C.; Brandt, C.R. Using HSV-1 Genome Phylogenetics to Track Past Human 
Migrations. PLoS One 2013, 8, e76267. 
3. Cannon, M.J.; Schmid, D.S.; Hyde, T.B. Review of cytomegalovirus seroprevalence and 
demographic characteristics associated with infection. Rev. Med. Virol. 2010, 20, 202–213. 
4. Cannon, M.J.; Hyde, T.B.; Schmid, D.S. Review of cytomegalovirus shedding in bodily fluids 
and relevance to congenital cytomegalovirus infection. Rev. Med. Virol. 2011, 21, 240–255. 
5. Noyola, D.E.; Valdez-Lopez, B.H.; Hernandez-Salinas, A.E.; Santos-Diaz, M.A.;  
Noyola-Frias, M.A.; Reyes-Macias, J.F.; Martinez-Martinez, L.G. Cytomegalovirus excretion 
in children attending day-care centers. Arch. Med. Res. 2005, 36, 590–593. 
6. Berntsson, M.; Dubicanac, L.; Tunback, P.; Ellstrom, A.; Lowhagen, G.B.; Bergstrom, T. 
Frequent detection of cytomegalovirus and Epstein-Barr virus in cervical secretions from 
healthy young women. Acta Obstet. Gynecol. Scand. 2013, 92, 706–710. 
7. De Franca, T.R.; de Albuquerque Tavares Carvalho, A.; Gomes, V.B.; Gueiros, L.A.;  
Porter, S.R.; Leao, J.C. Salivary shedding of Epstein-Barr virus and cytomegalovirus in people 
infected or not by human immunodeficiency virus 1. Clin. Oral Investig. 2012, 16, 659–664. 
8. Arora, N.; Novak, Z.; Fowler, K.B.; Boppana, S.B.; Ross, S.A. Cytomegalovirus viruria and 
DNAemia in healthy seropositive women. J. Infect. Dis. 2010, 202, 1800–1803. 
72 
9. Gautheret-Dejean, A.; Aubin, J.T.; Poirel, L.; Huraux, J.M.; Nicolas, J.C.; Rozenbaum, W.; 
Agut, H. Detection of human Betaherpesvirinae in saliva and urine from immunocompromised 
and immunocompetent subjects. J. Clin. Microbiol. 1997, 35, 1600–1603. 
10. Hayashi, S.; Kimura, H.; Oshiro, M.; Kato, Y.; Yasuda, A.; Suzuki, C.; Watanabe, Y.; 
Morishima, T.; Hayakawa, M. Transmission of cytomegalovirus via breast milk in extremely 
premature infants. J. Perinatol. 2011, 31, 440–445. 
11. Hamprecht, K.; Maschmann, J.; Vochem, M.; Dietz, K.; Speer, C.P.; Jahn, G. Epidemiology 
of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 
2001, 357, 513–518. 
12. Jim, W.T.; Shu, C.H.; Chiu, N.C.; Chang, J.H.; Hung, H.Y.; Peng, C.C.; Kao, H.A.; Wei, T.Y.; 
Chiang, C.L.; Huang, F.Y. High cytomegalovirus load and prolonged virus excretion in breast 
milk increase risk for viral acquisition by very low birth weight infants. Pediatr. Infect. Dis. J. 
2009, 28, 891–894. 
13. Maciejewski, J.P.; Bruening, E.E.; Donahue, R.E.; Mocarski, E.S.; Young, N.S.; St Jeor, S.C. 
Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood 1992, 80, 170–178. 
14. Mendelson, M.; Monard, S.; Sissons, P.; Sinclair, J. Detection of endogenous human 
cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol. 1996, 77, 3099–3102. 
15. Kondo, K.; Kaneshima, H.; Mocarski, E.S. Human cytomegalovirus latent infection of 
granulocyte-macrophage progenitors. Proc. Natl. Acad. Sci. USA 1994, 91, 11879–11883. 
16. Kondo, K.; Xu, J.; Mocarski, E.S. Human cytomegalovirus latent gene expression in  
granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc. Natl. 
Acad. Sci. USA 1996, 93, 11137–11142. 
17. Goodrum, F.; Reeves, M.; Sinclair, J.; High, K.; Shenk, T. Human cytomegalovirus sequences 
expressed in latently infected individuals promote a latent infection in vitro. Blood 2007, 110, 
937–945. 
18. Cheung, A.K.; Abendroth, A.; Cunningham, A.L.; Slobedman, B. Viral gene expression 
during the establishment of human cytomegalovirus latent infection in myeloid progenitor 
cells. Blood 2006, 108, 3691–3699. 
19. Fowler, K.B.; Stagno, S.; Pass, R.F.; Britt, W.J.; Boll, T.J.; Alford, C.A. The outcome of 
congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 
1992, 326, 663–667. 
20. Rasmussen, L.; Matkin, C.; Spaete, R.; Pachl, C.; Merigan, T.C. Antibody response to human 
cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis. 
1991, 164, 835–842. 
21. Boppana, S.B.; Rivera, L.B.; Fowler, K.B.; Mach, M.; Britt, W.J., Intrauterine transmission of 
cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med. 2001, 
344, 1366–1371. 
22. Hansen, S.G.; Powers, C.J.; Richards, R.; Ventura, A.B.; Ford, J.C.; Siess, D.; Axthelm, M.K.; 
Nelson, J.A.; Jarvis, M.A.; Picker, L.J.; et al. Evasion of CD8+ T cells is critical for 
superinfection by cytomegalovirus. Science 2010, 328, 102–106. 
  
73 
23. Sylwester, A.W.; Mitchell, B.L.; Edgar, J.B.; Taormina, C.; Pelte, C.; Ruchti, F.; Sleath, P.R.; 
Grabstein, K.H.; Hosken, N.A.; Kern, F.; et al. Broadly targeted human cytomegalovirus-specific 
CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 
2005, 202, 673–685. 
24. Griffiths, P.D. Burden of disease associated with human cytomegalovirus and prospects for 
elimination by universal immunisation. Lancet Infect. Dis. 2012, 12, 790–798. 
25. Crough, T.; Khanna, R. Immunobiology of human cytomegalovirus: From bench to bedside.  
Clin. Microbiol. Rev. 2009, 22, 76–98. 
26. Elek, S.D.; Stern, H. Development of a vaccine against mental retardation caused by 
cytomegalovirus infection in utero. Lancet 1974, 1, 1–5. 
27. Hanshaw, J.B. Congenital cytomegalovirus infection: A fifteen year perspective. J. Infect. Dis. 
1971, 123, 555–561. 
28. Plotkin, S.A. Vaccines for varicella-zoster virus and cytomegalovirus: Recent progress.  
Science 1994, 265, 1383–1385. 
29. Pass, R.F.; Zhang, C.; Evans, A.; Simpson, T.; Andrews, W.; Huang, M.L.; Corey, L.; Hill, J.; 
Davis, E.; Flanigan, C.; et al. Vaccine prevention of maternal cytomegalovirus infection. N. 
Engl. J. Med. 2009, 360, 1191–1199. 
30. Stratton, K.R.; Durch, J.S.; Lawrence, R.S. Vaccines for the 21st Century: A Tool for Decision 
Making; National Academy Press: Washington, DC, USA, 2000; p. Appendix 4:165–172. 
31. Saccoccio, F.M.; Gallagher, M.K.; Adler, S.P.; McVoy, M.A. Neutralizing activity of saliva 
against cytomegalovirus. Clin. Vaccine Immunol. 2011, 18, 1536–1542. 
32. Tamura, T.; Chiba, S.; Chiba, Y.; Nakao, T. Virus excretion and neutralizing antibody 
response in saliva in human cytomegalovirus infection. Infect. Immun. 1980, 29, 842–845. 
33. Wang, J.B.; Adler, S.P.; Hempfling, S.; Burke, R.L.; Duliege, A.M.; Starr, S.E.; Plotkin, S.A. 
Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural 
infection and immunization with human cytomegalovirus vaccines. J. Infect. Dis. 1996, 174,  
387–392. 
34. Simanek, A.M.; Dowd, J.B.; Pawelec, G.; Melzer, D.; Dutta, A.; Aiello, A.E. Seropositivity to 
cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the 
United States. PLoS One 2011, 6, e16103. 
35. Bale, J.F., Jr.; Petheram, S.J.; Souza, I.E.; Murph, J.R. Cytomegalovirus reinfection in young 
children. J. Pediatr. 1996, 128, 347–352. 
36. Chandler, S.H.; Handsfield, H.H.; McDougall, J.K. Isolation of multiple strains of 
cytomegalovirus from women attending a clinic for sexually transmitted disease. J. Infect. Dis. 
1987, 155, 655–660. 
37. Sohn, Y.M.; Park, K.I.; Lee, C.; Han, D.G.; Lee, W.Y. Congenital cytomegalovirus infection 
in Korean population with very high prevalence of maternal immunity. J. Korean Med. Sci. 
1992, 7, 47–51. 
38. Gaytant, M.A.; Rours, G.I.; Steegers, E.A.; Galama, J.M.; Semmekrot, B.A. Congenital 
cytomegalovirus infection after recurrent infection: Case reports and review of the literature. 
Eur. J. Pediatr. 2003, 162, 248–253. 
74 
39. Gaytant, M.A.; Steegers, E.A.; Semmekrot, B.A.; Merkus, H.M.; Galama, J.M. Congenital 
cytomegalovirus infection: Review of the epidemiology and outcome. Obstet. Gynecol. Surv. 
2002, 57, 245–256. 
40. Gandhoke, I.; Aggarwal, R.; Lal, S.; Khare, S. Congenital CMV infection in symptomatic 
infants in Delhi and surrounding areas. Indian J. Pediatr. 2006, 73, 1095–1097. 
41. Yamamoto, A.Y.; Mussi-Pinhata, M.M.; Boppana, S.B.; Novak, Z.; Wagatsuma, V.M.; 
Oliveira Pde, F.; Duarte, G.; Britt, W.J. Human cytomegalovirus reinfection is associated with 
intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am. J. 
Obstet. Gynecol. 2010, 202, 297.e1–297.e8. 
42. Ross, S.A.; Fowler, K.B.; Ashrith, G.; Stagno, S.; Britt, W.J.; Pass, R.F.; Boppana, S.B. 
Hearing loss in children with congenital cytomegalovirus infection born to mothers with 
preexisting immunity. J. Pediatr. 2006, 148, 332–336. 
43. Wang, C.; Zhang, X.; Bialek, S.; Cannon, M.J. Attribution of congenital cytomegalovirus 
infection to primary versus non-primary maternal infection. Clin. Infect. Dis. 2011, 52, e11–e13. 
44. Britt, W.J.; Mach, M. Human cytomegalovirus glycoproteins. Intervirology 1996, 39, 401–412. 
45. Revello, M.G.; Gerna, G. Human cytomegalovirus tropism for endothelial/epithelial cells: 
Scientific background and clinical implications. Rev. Med. Virol. 2010, 20, 136–155. 
46. Cui, X.; Meza, B.P.; Adler, S.P.; McVoy, M.A. Cytomegalovirus vaccines fail to induce 
epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26, 
5760–5766. 
47. Macagno, A.; Bernasconi, N.L.; Vanzetta, F.; Dander, E.; Sarasini, A.; Revello, M.G.;  
Gerna, G.; Sallusto, F.; Lanzavecchia, A. Isolation of human monoclonal antibodies that 
potently neutralize human cytomegalovirus infection by targeting different epitopes on the 
gH/gL/UL128–131A complex. J. Virol. 2010, 84, 1005–1013. 
48. Britt, W.J. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the 
envelope of human cytomegalovirus. Virology 1984, 135, 369–378. 
49. Ross, S.A.; Arora, N.; Novak, Z.; Fowler, K.B.; Britt, W.J.; Boppana, S.B. Cytomegalovirus 
reinfections in healthy seroimmune women. J. Infect. Dis. 2010, 201, 386–389. 
50. Dunn, W.; Chou, C.; Li, H.; Hai, R.; Patterson, D.; Stolc, V.; Zhu, H.; Liu, F. Functional profiling 
of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. USA 2003, 100, 14223–14228. 
51. Yu, D.; Silva, M.C.; Shenk, T. Functional map of human cytomegalovirus AD169 defined by 
global mutational analysis. Proc. Natl. Acad. Sci. USA 2003, 100, 12396–12401. 
52. Hakki, M.; Chou, S. The biology of cytomegalovirus drug resistance. Curr. Opin. Infect. Dis. 
2011, 24, 605–611. 
53. Renzette, N.; Gibson, L.; Bhattacharjee, B.; Fisher, D.; Schleiss, M.R.; Jensen, J.D.; Kowalik, T.F. 
Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive 
selection. PLoS Genet. 2013, 9, e1003735. 
54. Vogel, P.; Weigler, B.J.; Kerr, H.; Hendrickx, A.; Barry, P.A. Seroepidemiologic studies of 
cytomegalovirus infection in a breeding population of rhesus macaques. Lab. Anim. Sci. 1994, 
44, 25–30. 
75 
55. Andrade, M.R.; Yee, J.; Barry, P.; Spinner, A.; Roberts, J.A.; Cabello, P.H.; Leite, J.P.; 
Lerche, N.W. Prevalence of antibodies to selected viruses in a long-term closed breeding 
colony of rhesus macaques (Macaca mulatta) in Brazil. Am. J. Primatol. 2003, 59, 123–128. 
56. Früh, K.; Malouli , D.; Oxford, K.; Barry, P. Non-Human-Primate Models of Cytomegalovirus 
Infection, Prevention, and Therapy. In CYTOMEGALOVIRUSES: From Molecular Pathogenesis 
to Therapy; Reddehase, M., Ed.; Caister Academic Press/Horizon: Norfolk, UK, 2013; Volume 2. 
57. Jones-Engel, L.; Engel, G.A.; Heidrich, J.; Chalise, M.; Poudel, N.; Viscidi, R.; Barry, P.A.; 
Allan, J.S.; Grant, R.; Kyes, R. Temple monkeys and health implications of commensalism, 
Kathmandu, Nepal. Emerg. Infect. Dis. 2006, 12, 900–906. 
58. Baskin, G.B. Disseminated cytomegalovirus infection in immunodeficient rhesus monkeys.  
Am. J. Pathol. 1987, 129, 345–352. 
59. Kaur, A.; Kassis, N.; Hale, C.L.; Simon, M.; Elliott, M.; Gomez-Yafal, A.; Lifson, J.D.; 
Desrosiers, R.C.; Wang, F.; Barry, P.; et al. Direct relationship between suppression of  
virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J. Virol. 
2003, 77, 5749–5758. 
60. Assaf, B.T.; Mansfield, K.G.; Westmoreland, S.V.; Kaur, A.; Oxford, K.L.; Diamond, D.J.;  
Barry, P.A. Patterns of acute rhesus cytomegalovirus (RhCMV) infection predict long-term 
RhCMV infection. J. Virol. 2012, 86, 6354–6357. 
61. Oxford, K.L.; Strelow, L.; Yue, Y.; Chang, W.L.; Schmidt, K.A.; Diamond, D.J.; Barry, P.A. 
Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission 
of rhesus cytomegalovirus in rhesus monkeys. J. Virol. 2011, 85, 5105–5114. 
62. Wussow, F.; Yue, Y.; Martinez, J.; Deere, J.D.; Longmate, J.; Herrmann, A.; Barry, P.A.; 
Diamond, D.J. A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces 
Broadly Neutralizing Antibodies in Rhesus Macaques. J. Virol. 2013, 87, 1322–1332. 
63. Yue, Y.; Zhou, S.S.; Barry, P.A. Antibody responses to rhesus cytomegalovirus glycoprotein 
B in naturally infected rhesus macaques. J. Gen. Virol. 2003, 84, 3371–3379. 
64. Yue, Y.; Kaur, A.; Zhou, S.S.; Barry, P.A. Characterization and immunological analysis of the 
rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower 
matrix phosphoprotein (pp65). J. Gen. Virol. 2006, 87, 777–787. 
65. Pitcher, C.J.; Hagen, S.I.; Walker, J.M.; Lum, R.; Mitchell, B.L.; Maino, V.C.; Axthelm, 
M.K.; Picker, L.J. Development and homeostasis of T cell memory in rhesus macaque.  
J. Immunol. 2002, 168, 29–43. 
66. Asher, D.M.; Gibbs, C.J., Jr.; Lang, D.J. Rhesus monkey cytomegaloviruses: Persistent 
asymptomatic viruses. Bacteriol. Proc. 1969, 69, 191. 
67. Asher, D.M.; Gibbs, C.J., Jr.; Lang, D.J.; Gajdusek, D.C.; Chanock, R.M. Persistent shedding 
of cytomegalovirus in the urine of healthy Rhesus monkeys. Proc. Soc. Exp. Biol. Med. 1974, 
145, 794–801. 
68. Huff, J.L.; Eberle, R.; Capitanio, J.; Zhou, S.S.; Barry, P.A. Differential detection of B virus 
and rhesus cytomegalovirus in rhesus macaques. J. Gen. Virol. 2003, 84, 83–92. 
69. Oxford, K.L.; Eberhardt, M.K.; Yang, K.W.; Strelow, L.; Kelly, S.; Zhou, S.S.; Barry, P.A. 
Protein coding content of the UL)b' region of wild-type rhesus cytomegalovirus. Virology 
2008, 373, 181–188. 
76 
70. Alcendor, D.J.; Barry, P.A.; Pratt-Lowe, E.; Luciw, P.A. Analysis of the rhesus 
cytomegalovirus immediate-early gene promoter. Virology 1993, 194, 815–821. 
71. Barry, P.A.; Alcendor, D.J.; Power, M.D.; Kerr, H.; Luciw, P.A. Nucleotide sequence and 
molecular analysis of the rhesus cytomegalovirus immediate-early gene and the UL121–117 
open reading frames. Virology 1996, 215, 61–72. 
72. Hansen, S.G.; Strelow, L.I.; Franchi, D.C.; Anders, D.G.; Wong, S.W. Complete sequence and 
genomic analysis of rhesus cytomegalovirus. J. Virol. 2003, 77, 6620–6636. 
73. Wang, D.; Shenk, T. Human cytomegalovirus virion protein complex required for epithelial 
and endothelial cell tropism. Proc. Natl. Acad. Sci. USA 2005, 102, 18153–18158. 
74. Ryckman, B.J.; Rainish, B.L.; Chase, M.C.; Borton, J.A.; Nelson, J.A.; Jarvis, M.A.;  
Johnson, D.C. Characterization of the human cytomegalovirus gH/gL/UL128–131 complex 
that mediates entry into epithelial and endothelial cells. J. Virol. 2008, 82, 60–70. 
75. Lilja, A.E.; Shenk, T. Efficient Replication of Rhesus Cytomegalovirus Variants in Multiple 
Rhesus and Human Cell Types. Proc. Natl. Acad. Sci. USA 2008, 105, 19950–19955. 
76. Carlson, J.R.; Chang, W.L.; Zhou, S.S.; Tarantal, A.F.; Barry, P.A. Rhesus brain microvascular 
endothelial cells are permissive for rhesus cytomegalovirus infection. J. Gen. Virol. 2005, 86, 
545–549. 
77. Abel, K.; Martinez, J.; Yue, Y.; Lacey, S.F.; Wang, Z.; Strelow, L.; Dasgupta, A.; Li, Z.;  
Schmidt, K.A.; Oxford, K.L.; et al. Vaccine-induced control of viral shedding following 
rhesus cytomegalovirus challenge in rhesus macaques. J. Virol. 2011, 85, 2878–2890. 
78. Assaf, B.T.; Mansfield, K.G.; Westmoreland, S.V.; Strelow, L.; Barry, P.A.; Kaur, A. Limited 
Dissemination and Shedding of the UL128-Complex-Intact, UL/b’-Defective Rhesus 
Cytomegalovirus Strain 180.92. J. Virol., submitted. 
79. Rivailler, P.; Kaur, A.; Johnson, R.P.; Wang, F. Genomic sequence of rhesus cytomegalovirus 
180.92: Insights into the coding potential of rhesus cytomegalovirus. J. Virol. 2006, 80,  
4179–4182. 
80. Yue, Y.; Kaur, A.; Eberhardt, M.K.; Kassis, N.; Zhou, S.S.; Tarantal, A.F.; Barry, P.A. 
Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus 
glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J. Virol. 
2007, 81, 1095–1109. 
81. Chang, W.L.; Barry, P.A. Attenuation of innate immunity by cytomegalovirus IL-10 
establishes a long-term deficit of adaptive antiviral immunity. Proc. Natl. Acad. Sci. USA 
2010, 107, 22647–22652. 
82. Abel, K.; Strelow, L.; Yue, Y.; Eberhardt, M.K.; Schmidt, K.A.; Barry, P.A. A heterologous 
DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. Vaccine 2008, 
26, 6013–6025. 
83. Lockridge, K.M.; Sequar, G.; Zhou, S.S.; Yue, Y.; Mandell, C.P.; Barry, P.A. Pathogenesis of 
experimental rhesus cytomegalovirus infection. J. Virol. 1999, 73, 9576–9583. 
84. Hansen, S.G.; Vieville, C.; Whizin, N.; Coyne-Johnson, L.; Siess, D.C.; Drummond, D.D.; 
Legasse, A.W.; Axthelm, M.K.; Oswald, K.; Trubey, C.M.; et al. Effector memory T cell 
responses are associated with protection of rhesus monkeys from mucosal simian 
immunodeficiency virus challenge. Nat. Med. 2009, 15, 293–299. 
77 
85. Pulendran, B.; Ahmed, R. Immunological mechanisms of vaccination. Nat. Immunol. 2011, 
12, 509–517. 
86. Lockridge, K.M.; Zhou, S.S.; Kravitz, R.H.; Johnson, J.L.; Sawai, E.T.; Blewett, E.L.;  
Barry, P.A. Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 
2000, 268, 272–280. 
87. Slobedman, B.; Barry, P.A.; Spencer, J.V.; Avdic, S.; Abendroth, A. Virus-encoded homologs 
of cellular interleukin-10 and their control of host immune function. J. Virol. 2009, 83,  
9618–9629. 
88. Eberhardt, M.K.; Chang, W.L.; Logsdon, N.J.; Yue, Y.; Walter, M.R.; Barry, P.A. Host immune 
responses to a viral immune modulating protein: Immunogenicity of viral interleukin-10 in 
rhesus cytomegalovirus-infected rhesus macaques. PLoS One 2012, 7, e37931. 
89. De Lemos Rieper, C.; Galle, P.; Pedersen, B.K.; Hansen, M.B. Characterization of specific 
antibodies against cytomegalovirus (CMV)-encoded interleukin 10 produced by 28% of  
CMV-seropositive blood donors. J. Gen. Virol. 2011, 92, 1508–1518. 
90. Logsdon, N.J.; Eberhardt, M.K.; Allen, C.E.; Barry, P.A.; Walter, M.R. Design and analysis of 
rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human 
cytomegalovirus. PLoS One 2011, 6, e28127. 
91. Eberhardt, M.; Deshpande, A.; Chang, W.-L.; Barthold, S.; Walter, M.; Barry, P. Vaccination 
Against a Virally-Encoded Cytokine Significantly Restricts Viral Challenge. J. Virol. 2013, 
87, 11323–11331. 
92. Fu, T.M.; Wang, D.; Freed, D.C.; Tang, A.; Li, F.; He, X.; Cole, S.; Dubey, S.; Finnefrock, A.C.; 
ter Meulen, J.; Shiver, J.W.; Casimiro, D.R. Restoration of viral epithelial tropism improves 
immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human 
cytomegalovirus. Vaccine 2012, 30, 7469–7474. 
93. Freed, D.C.; Tang, Q.; Tang, A.; Li, F.; He, X.; Huang, Z.; Meng, W.; Xia, L.; Finnefrock, A.C.; 
Durr, E.; et al. Pentameric complex of viral glycoprotein H is the primary target for potent 
neutralization by a human cytomegalovirus vaccine. Proc. Natl. Acad. Sci. USA 2013, 110, 
E4997–E5005. 
94. Plotkin, S.A.; Furukawa, T.; Zygraich, N.; Huygelen, C. Candidate cytomegalovirus strain for 
human vaccination. Infect. Immun. 1975, 12, 521–527. 
95. Plotkin, S.A.; Starr, S.E.; Friedman, H.M.; Gonczol, E.; Brayman, K. Vaccines for the 
prevention of human cytomegalovirus infection. Rev. Infect. Dis. 1990, 12, S827–S838. 

79 
Immune and DNA Damage Responses Linked to CMV 
 
Reprinted from Viruses. Cite as: Hanley, P.J.; Bollard, C.M. Controlling Cytomegalovirus: Helping 
the Immune System Take the Lead. Viruses 2014, 6, 2242-2258. 
Review 
Controlling Cytomegalovirus: Helping the Immune System 
Take the Lead 
Patrick J. Hanley * and Catherine M. Bollard 
Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute  
for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Children’s 
National Health System, Washington, DC 20010, USA; E-Mail: CBollard@childrensnational.org 
* Author to whom correspondence should be addressed; E-Mail: PHanley@childrensnational.org;  
Tel.: +1-202-476-6368; Fax: +1-202-476-5808. 
Received: 4 February 2014; in revised form: 9 May 2014 / Accepted: 13 May 2014 /  
Published: 27 May 2014 
 
Abstract: Cytomegalovirus, of the Herpesviridae family, has evolved alongside 
humans for thousands of years with an intricate balance of latency, immune evasion, 
and transmission. While upwards of 70% of humans have evidence of CMV infection, 
the majority of healthy people show little to no clinical symptoms of primary infection 
and CMV disease is rarely observed during persistent infection in immunocompetent 
hosts. Despite the fact that the majority of infected individuals are asymptomatic, 
immunologically, CMV hijacks the immune system by infecting and remaining latent 
in antigen-presenting cells that occasionally reactivate subclinically and present antigen 
to T cells, eventually causing the inflation of CMV-specific T cells until they can 
compromise up to 10% of the entire T cell repertoire. Because of this impact on the 
immune system, as well as its importance in fields such as stem cell and organ 
transplant, the relationship between CMV and the immune response has been studied  
in depth. Here we provide a review of many of these studies and insights into how 
CMV-specific T cells are currently being used therapeutically. 
Keywords: Cytomegalovirus (CMV); Adoptive immunotherapy; T cell; 




1. Biology of Cytomegalovirus 
The virus family Herpesviridae consists of three subfamilies of viruses, alpha, beta, and gamma. 
Betaherpesviruses contain the four major components of this family: the core, the capsid, the 
tegument, and the envelope and establish latency in cells of the myeloid lineage and CD34+  
cells [1–3]. The tegument contains the majority of virion-associated proteins [4,5]. Tegument 
proteins have two reported functions, though the proteins that facilitate them are not mutually 
exclusive [6]. The first function is the disassembly of the virion during entry and assembly of the 
virion during egress [7]. The second function is inhibiting the host immune response to infection, 
though as discussed later, they may also promote the response as well [6]. Many of these proteins 
are associated with immune evasion, and are therefore packaged within the virion and delivered to 
the host soon after uncoating of the virus. The most abundant tegument protein is the lower matrix 
phosphoprotein of 65 kDa (pp65), or Unique Long (UL)83 [5]. One important function of pp65 is 
immune evasion. Other tegument proteins devoted to immune evasion include the upper matrix 
protein pp71, UL36, UL38, and IRS1/TRS1 [8,9]. 
Immediate early (IE) proteins are translated within 2 h of infection and do not require the de 
novo synthesis of viral proteins for their translation [10]. These IE proteins then control subsequently 
gene expression and virus replication. As such, suppression of IE proteins is thought to contribute 
to CMV latency whereas the expression of IE genes is associated with reactivation [11]. The 
laboratories of both Hahn and Fietze have shown that proinflammatory cytokines such as GM-CSF 
and TNF-  can induce the differentiation of monocytes into macrophages or dendritic cells, which 
is thought to activate the IE1 promoter and stimulate reactivation [12–14]. However, how cytokines 
cause HCMV reactivation is still mostly unknown [12,14]. Because IE proteins are expressed first 
after reactivation, T cells targeting these proteins are of paramount importance, as highlighted in 
the field of transplantation where T cells IE proteins are important for protection after solid organ 
transplant [15]. 
2. CMV Infection in the Immune Compromised Host 
CMV has long been one of the most problematic pathogens after stem cell transplantation (SCT) 
and organ transplant [16–19]. While effective antiviral drugs, viral monitoring, and donor/recipient 
matching have lowered the likelihood of disease after SCT, the mortality rate in patients who 
develop CMV-associated pneumonia remains strikingly high (around 80%–90%) [17,18]. Additionally, 
the recipient’s CMV-seropositivity remains an independent risk factor for morbidity and mortality 
after SCT. In the case of SCT, the highest risk of CMV reactivation is when the recipient is 
seropositive and the stem cell donor is seronegative [20,21]. This is because the recipient has latent 
(or active) CMV that can no longer be controlled by the recipient’s immune system after it is 
depleted with conditioning regimens and the stem cell donor graft does not contain protective 
CMV-specific memory T cells. In contrast, the risk of CMV-related complications, including death, 
after solid organ transplant (SOT) is greatest when the organ donor is CMV-seropositive and the 
recipient is CMV-seronegative, though the severity tends to vary based on the organ being 
transplanted [22–25]. With the advent of CMV prophylaxis, an unexpected complication has 
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emerged with an increased incidence of late-onset CMV disease; after day 100, late CMV disease 
may be as high as 17% in CMV-seropositive recipients undergoing SCT [26]. 
3. Innate Immunity to CMV 
An in-depth review of the immune response to CMV can be found here [9]. Some of the best 
evidence for the role of the innate immune system in mice is in experiments using beige mice that  
have known defects in Natural Killer (NK) cell-mediated cytotoxicity and are highly susceptible  
to murine Cytomegalovirus (MCMV). However, protection against MCMV can be restored by 
transferring NK cells from normal mice [27]. Despite the elegant studies suggesting the importance  
of NK cells in controlling MCMV, similar studies in humans are lacking for HCMV [28]. However, 
Biron et al. have reported in the New England Journal of Medicine NK cell-deficient individuals 
who are susceptible to herpes virus infections, including HCMV. In vitro experiments using IL-2 
activated human NK cells have also demonstrated that NK cells can inhibit CMV replication in 
CMV-infected fibroblasts by inducing IFN-beta release from infected fibroblasts [29]. Activated 
NK cells also released IFN-gamma which can impede viral replication [9]. Boehme et al. have 
shown that HCMV glycoproteins B and H also activate Toll Like Receptor (TLR) 2 on fibroblast, 
resulting in NF B activation and subsequent inflammatory cytokine secretion, suggesting that NK 
cells are not the only innate cell responsible for protection from CMV [30]. Indeed, monocytes, 
macrophages and dendritic cells are cells permissible for viral reactivation and once infected 
release inflammatory cytokines, in addition to presenting antigen to T cells [31]. 
4. Humoral Immunity to CMV 
The importance of an antibody response to CMV is demonstrated in guinea pig models where 
antibodies protect the animals from reaching a lethal infective dose, but do not prevent infection, 
suggesting a role for the humoral immune response in limiting the severity of the disease by 
controlling CMV viral load [32]. After a primary infection in humans, antibodies against a number 
of proteins from HCMV are detectable in the serum. These antibodies recognize an array of 
proteins from different parts of the virus, including pp65 and pp150 from the tegument, the 
glycoproteins gB and gH from the envelope, as well as proteins involved in transcription such as 
IE-1 [33]. Most CMV-seropositive humans have antibodies directed against gB, with over 50% of 
all neutralizing antibodies recognizing an epitope of gB [33,34]. The importance of humoral 
immunity is also demonstrated in congenital CMV infection where pregnant women who develop 
primary CMV infection carry a 40% chance of HCMV transmission to the fetus [35,36]. In cases 
where the mother is able to provide transplacental IgG antibodies, the severity is less [37]. 
Moreover, identifying a successful vaccine that elicits functional neutralizing antibodies to CMV 
and can prevent congenital CMV has become a priority [40]. Relevant articles discussing the role 
of the humoral immune response can be found here [39–41]. 
5. Cellular Immunity to CMV 
CMV infection commands an overwhelming response from all facets of the immune system.  
As discussed above, the humoral response and innate response to CMV are indeed significant and 
82 
contribute to controlling the infection, but the cellular immune response is necessary to control 
latency and impede viral replication in latently infected individuals (Figure 1) [42]. The most 
compelling evidence for the immunogenicity of CMV involves the cellular arm of the immune 
system where up to 10% of all circulating CD8+ T cells can be directed towards CMV—a 
staggering number given the plethora of pathogens we encounter in our lifetime [43]. With the 
extraordinary percentage of T cells targeting CMV, it has been postulated that over time, immune 
surveillance is less effective in CMV+ individuals and, although controversial, CMV-seronegative 
individuals have been reported to live longer than their CMV-seropositive counterparts [44]. 
Recent reports on the “aging” of the immune response to CMV have begun to shed light on the 
mechanism behind this observation [45,46]. 
Figure 1. Cellular and humoral immunity to Cytomegalovirus. 
 
6. CD8+ T Cell Response to CMV 
The most studied, understood, and manipulated facet of the immune response to CMV is the 
cellular response, in particular the protective role of CD8+ T cells. The presence of CMV-specific  
T cells was first reported in a SCT study noting that the majority of patients without CMV-specific  
T cells had overwhelming CMV disease [47]. This led to studies evaluating the ex vivo expansion 
of CMV specific T cells from CMV-seropositive individuals [48] and the extensive evaluation of 
the CMV-specific T cell response in healthy individuals versus immune compromised populations.  
The importance of CD8+ T cells has been reported in solid organ transplant as well [49]. In renal 
transplant recipients, the presence of CD8+ T cells coincides with protection from CMV [50–52]  
and in both heart and lung transplant recipients, the presence of IE-1-specific T cells correlated  
with protection from CMV disease [15]. 
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The protectiveness of CD8+ T cells was first shown in a study by Riddell et al. where T cells 
were expanded ex vivo using CMV-infected fibroblasts [48]. Expanded T cells were then infused 
into patients after SCT. Riddell et al. reported that prior to the infusion of the T cells, the CMV-specific 
immunity was undetectable in these patients. However, as early as 48 h after infusion there was a 
detectable CMV-specific response and after three weeks the CMV-specific T cells response was as 
great or greater than CMV-specific immune responses detected in immunocompetent donors [48,53]. 
The cell mediated immune response targets proteins in all three of these stages of the viral 
replication cycle: immediate early, early, and late. By targeting immediate-early and early genes,  
T cells can protect against reactivation from latent viruses [54]. Although targeting late proteins 
would typically delay the cellular response to CMV since these proteins are not expressed until  
24-h after infection, many of the late proteins are structural proteins such as the tegument protein 
pp65 which is already present within the virion and can be immediately presented to T cells by 
infected APCs. 
In spite of the plethora of CMV antigens targeted by the CD8+ T cell response, a hierarchy of 
antigenic frequency exists, though it varies on the method of detection. Collectively, pp65 and the 
immediate-early 1 (IE-1) are two of the most targeted antigens of CMV by CD8+ T cells [55,56]. 
7. CD4+ T Cell Response to CMV 
As is the case with CD8+ T cells, approximately 9% of all circulating CD4+ T cells recognize 
CMV, an astounding number given the immune repertoire devoted to protection from one  
pathogen [56]. These T cells recognize at least 125 open reading frames of CMV or 59% of all 
open reading frames. Antigen recognition by CD4+ T cells is similar to CD8+ T cells in that T cells 
recognizing pp65 are some of the most abundant but T cells recognizing other antigens such as gB, 
UL86, pp28, IE-2, UL36, UL48, pp10, UL113, and IRS-1 are also highly abundant [56]. 
The importance of CD4+ T cells is apparent in a model of CD4-T cell-depleted mice where 
mice infected with MCMV had an increased incidence of MCMV reactivation [57]. It has also been  
reported that CD4+ T cells contribute to controlling MCMV in mice depleted of CD8+ T cells, but 
viral clearance is significantly delayed in most tissues and is never cleared from the salivary glands 
where a persistent infection develops [58]. 
The significance of CD4+ T cells is better understood and supported in HCMV. Lung transplant 
recipients with low frequencies of CMV-specific CD4+ T cells have difficulty clearing CMV [49].  
In a parallel to the finding in mice, children with CMV who have few CD4+ T cells have prolonged 
shedding of CMV in the salivary glands, and dysfunctional CD4+ T cells have been reported 
during primary infection [59,60]. Studies from SCT recipients suggest that CD4+ T cells are linked 
with protection from disease and are necessary for the recovery of donor-derived CD8+ T cells [61]. 
What is perhaps more interesting is that the persistence of adoptively transferred T cells has been 
reported to depend on the presence of CD4+ T helper cells [53]. 
In the first study of adoptively transferred CMV-specific T cells (predominantly CD8+), no 
patients developed CMV viremia but only patients who had detectable CD4+ T cell responses 
showed persistence of the transferred CD8+ T cells [53]. In other words, the highly successful trials 
mentioned above that utilized CD8+ T cells specific for various antigens of CMV required not only 
the transferred CD8+ T cells, but endogenous CD4+ cells as well. 
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A compelling argument for the role of CD4+ T cells in immunity to HCMV derives from a  
study conducted by Einsele et al. in which CD4+ T cells (without CD8+ cells) were transferred to 
antiviral-resistant SCT recipients with CD4+ T cell deficiencies. Remarkably, all patients exhibited 
rapid antiviral activity and the cells then persisted at levels similar to immunocompetent healthy 
donors. Einsele et al. observed that the presence of CD4+ T cells allowed endogenous CD8+  
CMV-specific T cells to expand, in contrast to transferring CD8+ T cells that eventually decline 
without CD4+ T cell help [61]. 
8. CMV Evasion from the Immune System 
Through thousands of years of evolution, CMV and humans have reached a balance whereby 
CMV is able to transmit virus from host-to-host yet not cause significant pathology to 
immunocompetent individuals. One way CMV is able to persist is by employing numerous 
immune evasion genes that are expressed in both the unique short (US) and unique long (UL) 
region of the genome (Table 1) [62]. As with all herpes viruses, CMV interferes with MHC class I 
presentation to CD8+ T cells in a number of ways. Interestingly, CMV also appears to stealthily 
modulate the immune response to itself by using decoys and choosing which epitopes and antigens 
it allows the immune system to target. More specifically, phosphorylation of IE-1 by pp65 blocks 
the processing of IE-1 in the proteosome [63]. This evasiveness is likely a reason why IE-1 was not 
identified earlier as an important immunogen of CMV. 
Table 1. CMV genes involved in immune evasion. 
Mechanism of evasion CMV Gene product Effect on immune system 
MHC Class I down-regulation [64] 
US2, US3, US6, 
US11 
Decreased presentation of CMV 
antigens to CD8+ T cells 
CMV-IE-1 sequestration [63] UL83 (pp65) 
T cells cannot target first genes 
expressed upon reactivation 
MHC Class II down-regulation [65–67] IE/E product 
Decreased presentation of CMV 
antigens to CD4+ T cells 
MHC Class I homolog [68] UL18 Inhibition of NK cell lysis 
Inhibitory receptors, downregulation of 
ligands [69,70] 
UL40, UL16, UL142 Evasion of NK cells  
Chemokine receptor [71] US28 Immune homing interference 
IL-10 homolog [1] UL111a Immune suppression 
Inhibitors of apoptosis [72,73] UL36, UL37 
Decrease in phagocytosis of 
infected cells by APCs 




Decreased recognition by NK cells 
and T cells via NKG2D 
Another way CMV disrupts antigen presentation is by disrupting the transporter associated with 
antigen processing (TAP). US6 binds with high affinity to the ER-lumenal side of the transporter, 
effectively altering the affinity of TAP for ATP. Overall, at least four US genes are involved in 
down regulation expression of MHC Class I: US2, US3, US6, and US11 [64,76]. 
85 
Dendritic cells play an important role in the primary immune response to CMV as they 
orchestrate the priming of naïve T cells in the lymph nodes. Not surprisingly, CMV targets 
dendritic cells and halts their maturation, forcing them into a state of functional paralysis and 
preventing them from presenting CMV antigens to T cells [62,77]. What’s more unexpected is that 
DCs infected with MCMV are not just unresponsive to MCMV, but MCMV-infected DCs do not 
secrete IL-12 or IL-2 even after treatment with the potent stimulus lipopolysaccharide (LPS) [77]. 
It has been suggested that CMV not only evades the immune system, but it also suppresses it. 
Secondary CMV-associated diseases exist and are a result of CMV modulation of the immune 
response in ways mentioned above. Additional immunomodulatory genes expressed by CMV and 
their function are listed in Table 1, but for a more comprehensive review of immune evasion by 
CMV see the reviews cited here [78–80]. 
9. Immunotherapy: Adoptive Transfer of CMV-Specific T Cells after Transplant 
As discussed above, some of the most insightful data about the role of T cells in protection from 
CMV came from adoptively transferring T cells to patients who received stem cell transplants. 
Since the first method of generation CMV-specific T cells that was utilized almost 20 years ago by  
Riddell et al. using CMV-infected fibroblasts to expand T cells, numerous other methods have  
been developed to offer protection after SCT [81]. The most common and perhaps most simple is 
pulsing antigen presenting cells—typically dendritic cells—with overlapping peptides spanning the 
entire pp65 antigen [82]. Although efficacious, this technique requires the lengthy and difficult 
generation of DCs, a non-trivial amount of donor-derived blood, and requires highly trained 
technicians and expensive equipment and manufacturing facilities. 
In 2006, Leen, Bollard, and Rooney et al. generated T cells specific for three viruses (CMV, 
EBV, and adenovirus) by using a recombinant adenovirus that expressed pp65, hereafter named  
Ad5f35pp65 [83]. This approach utilized monocytes and EBV transformed LCL transduced with  
the Ad5f35pp65 vector as APCs, thus obviating the need for high volumes of donor blood and 
targeted 3 viruses in a single culture. While this strategy was effective in vivo and less labor 
intensive, the expansion of virus-specific T cells is still a lengthy process that takes upwards of one 
month, not including the months it takes to generate EBV-LCL [83]. 
To circumvent the need for multiple expansions and a lengthy expansion process, Peggs et al. 
recently described a method where they pulsed leukocytes with overlapping peptides for pp65. 
Activated T cells are then selected based upon their secretion of IFN-gamma and then frozen  
for infusion. Including QA/QC testing, total time to infusion was less than two weeks and the entire 
selection process took <24 h. However, the risk of such a rapid manufacturing strategy is GVHD 
since alloreactive T cells may be still present in the infused product. Indeed, in the Peggs study, 
most patients were protected from CMV at a dose of only 1 × 104 CD3+ cells/kg but 8 of 18 
patients developed acute GvHD, three of which were grade II or higher. Six patients also 
experienced chronic GvHD [84]. 
Memory T cells are critical in non-T cell depleted grafts because the virus-specific memory T 
cells present in the grafts confer protection against viral infections and reactivation. For this reason,  
CMV-reactivation is highest when the transplant recipient is CMV-seropositive and the transplant 
donor is CMV-seronegative, as is often the case in cord blood transplantation and CMV-seronegative 
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donors [85]. Memory T cells are also a valuable resource when expanding virus-specific T cells  
ex vivo from seropositive donors as these T cells can be expanded by simply culturing virus-specific 
memory T cells with antigen-presenting cells loaded with the antigen of interest. When transferred 
to transplant recipients after transplant, these cells have been protective against CMV, EBV, and 
adenovirus without severe adverse events (Table 2) [83,86]. The challenge, however, has been the 
ex vivo generation of antigen-specific T cells from antigen-inexperienced sources of T cells such as 
cord blood. Instead of expanding the pre-existing memory T cell population, naïve T cells need to 
be primed in vitro to respond to the antigen of interest [19]. 
Table 2. Studies of adoptively transferred CMV-specific T cells. 
Group Method of Expansion/Selection 
Riddell, 1992, 1995 [48,53] Expansion using CMV-infected fibroblasts 
Einsele, 2002 [61] Expansion with CMV lysate 
Cobbold, 2005 [87] Tetramer Selection using magnetic beads 
Leen, 2006 [83] 
Antigen-presenting cells (Dendritic cells, EBV-LCL) transduced with 
an adenoviral vector encoding CMVpp65 
Micklethwaite, 2008 [86] 
Antigen-presenting cells (Dendritic cells) transduced with an 
adenoviral vector encoding CMVpp65 
Peggs, 2011 [84] Selection of T cells secreting IFN-  after exposure to CMV antigen 
Hanley, 2012 [88] 
Antigen-presenting cells (Dendritic cells, EBV-LCL) transduced with 
an adenoviral vector encoding CMVpp65 
Blyth, 2013 [89] 
Antigen-presenting cells (Dendritic cells) transduced with an 
adenoviral vector encoding CMVpp65 or Dendritic cells pulsed with 
HLA-A02-restricted peptide NLVPMVATV 
Because of these challenges, only a few reports document the generation of single antigen-specific 
T cells from naive donors [90–93]. In an attempt to target 3 viruses simultaneously, our group 
reported the ability to generate CMV, EBV, and adenovirus-specific CTL from the 20% fraction of 
a cord blood unit by using dendritic cells transduced with an Ad5/f35-CMV-pp65 vector as well as 
the cytokines IL-7, IL-12, and IL-15 [94]. Responding T cells were shown to be derived from the 
naïve T cell population and responded to typical and atypical, novel CMV-pp65 epitopes. A clinical 
trial using CB-derived multi-virus specific T cells for the prevention and treatment of viral infection 
after CBT is open and has started to accrue patients. (Clinical Trial #: NCT01017705) [81,88]. 
Recently, we and other groups have also reported the ability to generate CMV-specific T cells from 
CMV-seronegative donors; [95,96] the clinical efficacy of these T cells will be tested in a Phase 1 
clinical study (Clinical Trial #: NCT01945814). 
Another option for recipients of CB and CMV-seronegative donors is the use of third party,  
CMV-specific T cells. Thirdy party virus specific T cells have been evaluated clinically in several 
trials with promising results [97–101]. Leen et al. recently published a multi-institutional study of  
best-matched, MULTI virus-specific T cells and reported that responses with third party CTL were 
similar to those from donor-derived CTL in their previous studies [83,100]. This study highlights  




The human body has done an exquisite job over thousands of years to prevent or impede the 
manifestations of CMV and as a result, the majority of the population can live with CMV without 
knowing they have it. However, when the balance shifts towards CMV reactivation, usually as a 
result of treatment modalities or in some cases other infections, options are available to treat CMV 
infection, and the use of immunotherapy is rapidly becoming one of the favored options. The use of 
third-party, epitope-targeted CMV-specific T cells provides a unique platform similar to other 
pharmacotherapies in that they are rapidly available, are short lived, are effective, and are not 
associated with significant toxicities. However, for chronically suppressed patients, such as those 
undergoing SOT, the use of autologous CMV-specific T cells might be the ideal solution as  
long-term protection is necessary. Overall, improvements to T cell manufacturing technologies will 
provide a new and widely used treatment for CMV infection after transplant. 
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Abstract: The wide range of disease pathologies seen in multiple organ sites associated 
with human cytomegalovirus (HCMV) infection results from the systemic hematogenous 
dissemination of the virus, which is mediated predominately by infected monocytes. In 
addition to their role in viral spread, infected monocytes are also known to play a key 
role in viral latency and life-long persistence. However, in order to utilize infected 
monocytes for viral spread and persistence, HCMV must overcome a number of 
monocyte biological hurdles, including their naturally short lifespan and their inability 
to support viral gene expression and replication. Our laboratory has shown that HCMV 
is able to manipulate the biology of infected monocytes in order to overcome these 
biological hurdles by inducing the survival and differentiation of infected monocytes 
into long-lived macrophages capable of supporting viral gene expression and replication. 
In this current review, we describe the unique aspects of how HCMV promotes 
monocyte survival and differentiation by inducing a “finely-tuned” macrophage cell 
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type following infection. Specifically, we describe the induction of a uniquely polarized 
macrophage subset from infected monocytes, which we argue is the ideal cellular 
environment for the initiation of viral gene expression and replication and, ultimately, 
viral spread and persistence within the infected host. 
Keywords: HCMV; monocyte; macrophage; polarization; survival; signaling;  
receptor-ligand; viral persistence; viral dissemination 
 
1. Introduction 
Human cytomegalovirus (HCMV), a ubiquitous betaherpesvirus that infects 60%–90% of the 
population worldwide, establishes a lifelong infection of the host [1]. The disease manifestations 
associated with HCMV infection are dependent upon the immune status of the host. In healthy 
individuals, primary infection with HCMV is typically asymptomatic, although mononucleosis-like 
symptoms have been reported [2,3]. Long-term infection with HCMV, however, is associated with 
chronic inflammation, which links HCMV infection to the development of cardiovascular diseases 
and some types of cancers in otherwise immunocompetent individuals [3–5]. In contrast, HCMV 
infection causes severe morbidity and mortality in immunocompromised individuals, including 
AIDS patients, transplant recipients, and developing fetuses [3,6]. In these susceptible populations 
lacking normal immune control of the virus, HCMV infection can lead to a severe disease state that 
is characterized by multi-organ system involvement [7].  
The ability of HCMV to establish persistent infection within the host and the wide range of 
associated disease pathologies in multiple organ sites are a result of the systemic dissemination of 
the virus following primary infection. The dissemination strategy of HCMV involves a 
hematogenous step that is mediated predominately by infected peripheral blood monocytes. There 
are multiple lines of evidence supporting a specific role for monocytes in the hematogenous 
dissemination of HCMV. An HCMV cell-associated viremia is known to occur early after  
infection [8,9] and HCMV viral DNA is found predominately in peripheral blood monocytes and 
polymorphonuclear leukocytes (PMNs), rather than in lymphocytes [10–12]. Both monocytes and 
PMNs have been shown to play a role in the transfer of HCMV to blood vessel endothelial cells, 
suggesting a role for both cell types in the spread of HCMV [11]. Neither cell type is able to 
support viral replication [11]; however, viral gene expression and replication have been identified 
in monocyte-derived macrophages [13–16]. Furthermore, monocytes are the most prevalent 
infiltrating cell type found within HCMV-infected tissues [11,17], and a critical role for monocytes 
in the dissemination strategy of HCMV has been clearly defined in an animal model using  
the related murine CMV [18]. Based on these studies and others (reviewed in [19,20]), our 
laboratory focused on primary HCMV infection and the specific role monocytes play in viral 
dissemination [20,21]. We argue that monocytes serve as “Trojan Horses” to carry HCMV to 
multiple organ sites in the absence of de novo viral gene expression, as monocytes are initially  
non-permissive for viral gene expression and replication and only become permissive upon their 
differentiation into macrophages [20–27].  
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Monocytes/myeloid cells are not only key to viral spread following primary infection, but are 
central to the entire viral persistence strategy, as myeloid progenitors have been shown to be 
critical for the establishment of viral latency within the bone marrow [8,10,28–30]. Furthermore, 
reactivation of the virus occurs in these latently infected myeloid precursor cells that then leave the 
bone marrow as differentiated monocytes—thus also serving as a source of life-long periodic viral 
shedding [31–33]. Therefore, cells of the monocytic lineage play a defined and crucial role in the 
overall success of the virus in establishing a productive and persistent infection within the host and 
also in the transfer of HCMV to new hosts. Our recent studies have focused on determining how 
HCMV is able to manipulate the biology of newly infected monocytes during primary infection in 
order to promote the viral dissemination required for productive and persistent infection. 
2. HCMV Rapidly Changes the Monocyte Cellular Environment Following Primary Infection 
to Establish a Pro-Viral Inflammatory Phenotype that Mediates Viral Dissemination 
Due to the immune surveillance function of peripheral blood monocytes, this cell type can 
readily migrate through the blood vessel endothelium and infiltrate into peripheral organs, making 
infected monocytes ideal candidates for widespread delivery of the virus to nearly all organ tissues. 
Monocytes possess, however, a short lifespan of approximately 1–3 days within the  
bloodstream [34,35]. As previously mentioned, newly infected monocytes do not support de novo 
viral lytic gene expression or replication [36], thus new viral gene products are not synthesized that 
can alter the cellular environment to favor the success of the virus within the cell, as seen in other 
cell types infected by HCMV [37–41]. Despite this lack of new viral gene expression, our 
laboratory has observed rapid signaling and activation-induced changes in infected monocytes 
following viral binding that result in the production of a pro-inflammatory monocyte phenotype 
that favors viral spread [21–23,27,42–44]. Furthermore, we have shown that these phenotypic 
changes are mediated by the signaling that results from viral engagement of the epidermal growth 
factor receptor (EGFR) and the 1 and 3 integrins on the surface of monocytes [20,24–26,45,46]. 
Based on our recent studies [20,25,26,45,46] and the work of others [47–49], we have gained a 
better understanding of the early binding events that occur during HCMV infection of monocytes 
and how these events translate into the activation of cellular signaling pathways and functional 
changes in infected monocytes that promote the viral dissemination and persistence strategy [20,21]. 
During primary infection of monocytes, initial viral tethering likely occurs through engagement 
of glycoprotein M (gM)/gN to heparin sulfate proteoglycans [50]. This initial viral tethering event 
is then followed by the binding of the gH/gL/UL128-131 complex to specific proteinaceous 
receptors, the 1 and 3 integrins [26,46] and the binding of other viral glycoprotein(s), such as gB 
to EGFR on the surface of monocytes [45]. These receptor-binding events then trigger the 
activation of signaling cascades downstream of EGFR and integrins. Our data suggest that there are 
both distinct and overlapping signaling events that mediate viral entry into monocytes and that 
initiate specific monocyte biological changes [20,25,26,45,46]. For instance, the binding to and 
activation of both EGFR and integrins are required for viral entry into monocytes [26,45,46]. 
Moreover, the activation of both EGFR and integrins by HCMV is required for increased monocyte 
cellular motility, which is essential for the overall dissemination strategy of HCMV [26,45]. 
However, although both EGFR and integrin signaling are required for HCMV-induced enhanced 
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monocyte motility, our data indicate that HCMV activation of EGFR alone promotes the 
upregulation of an actin cytoskeletal regulator, N-WASP, which we showed to be required for 
enhanced monocyte motility [45]; while activation of integrins alone promotes the activation and 
upregulation of the actin cytoskeletal regulator, paxillin, which we show also induces monocyte 
motility and plays a key role in the viral entry process [26]. These data suggest that EGFR and 
integrin signaling events overlap to promote HCMV-induced monocyte motility through actin 
cytoskeletal rearrangement, although the specific signaling cascades downstream of these receptors 
regulate distinct cellular molecules. We also note that the requirement of both EGFR and integrin 
signaling for actin cytoskeletal rearrangement in the process of viral entry into monocytes links the 
receptor-mediated activation of cellular motility to the viral entry process, as the cytoskeletal 
events regulating enhanced motility also regulate viral entry [26,45,46]. The EGFR- and  
integrin-mediated enhanced motility of infected monocytes, when paired with a virus-induced 
increase in monocyte adhesion molecules and in monocyte transendothelial migration, likely allows 
the infected monocyte to exit the bloodstream and to enter peripheral organ tissues [22,23]. 
Furthermore, HCMV-induced activation of EGFR alone results in the prolonged survival of 
infected monocytes by altering the normal cellular apoptotic machinery through the prolonged 
expression of Mcl-1, providing the virus with a longer-lived cellular host [22,25]. The enhanced 
survival of infected monocytes is also potentiated by HCMV-induced differentiation of infected 
monocytes to naturally long-lived tissue macrophages within the organ tissues [21,24].  
Following the differentiation of infected monocytes to macrophages, viral replication can then 
commence [21,51,52], resulting in progeny virions capable of infecting the necessary surrounding 
cell types required to promote viral shedding to other hosts [13,21] or capable of infecting myeloid 
progenitor cells within the bone marrow to establish the latent infection required for lifelong viral 
persistence within the host [19,28,29,32].  
These earlier studies highlight the ability of HCMV to alter the biological function of infected 
monocytes to promote changes that are critical for the outcome of the viral life cycle and for the 
viral persistence strategy. Furthermore, our studies demonstrate that the HCMV-induced changes in 
infected monocytes are initiated by cellular surface receptor binding-induced signaling in the cell, 
in the absence of de novo viral gene expression. In fact, newer studies have uncovered that a high 
degree of regulatory control is utilized by HCMV during infection of monocytes through the 
utilization of these two separate cellular receptors, EGFR and integrins, to promote a “finely-tuned” 
monocyte/macrophage cell type that is required for viral spread, replication, and persistence.  
3. Precise Regulation of the Monocyte/Macrophage Apoptotic Program Is Required for  
HCMV-Induced Monocyte-to-Macrophage Differentiation 
We have shown that HCMV effectively initiates molecular changes that reprogram infected 
monocytes to establish a pro-viral phenotype that mediates viral dissemination. We suggest that for 
the virus to successfully have evolved to infect monocytes and utilize them as “Trojan Horses” for 
the spread of HCMV to target organs, the virus had to overcome at least two significant biological 
obstacles. First, HCMV had to adapt to the naturally short lifespan of monocytes of around 48 to  
72 hours in circulation [34,35], a scenario that is particularly problematic for HCMV, with its slow 
DNA replication cycle of several days to weeks in vivo [53]. Second, the virus had to adapt to the 
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differentiation barrier, because as stated previously, monocytes are not initially permissive for  
de novo viral gene expression and replication [14,52,53], while their differentiated counterparts, 
macrophages, are permissive [21]. We have evidence that HCMV navigates these biological 
hurdles by extending the lifespan of infected monocytes and directing their differentiation into 
long-lived macrophages, which are capable of supporting viral replication and the production of 
progeny virions [21,24,25,44]. In this manner, it appears that HCMV has evolved a mechanism to 
molecularly bridge the survival-differentiation hurdle in order to generate a long-lived cell type that 
serves as a reservoir for viral persistence in host organ tissue.  
In order to promote the extended survival of HCMV-infected monocytes, HCMV must escape 
both the intrinsic programming that causes monocytes to die within 48–72 hours of entering 
circulation [34,35] and the cellular antiviral pro-apoptotic response [54]. Because monocytes are 
not productive for viral gene expression and replication, viral immediate early proteins do not 
participate in the rescue of infected monocytes from various apoptotic mechanisms. Accordingly, 
the virus appears to have evolved a mechanism whereby it relies on cellular Bcl-2 family  
anti-apoptotic proteins in order to navigate critical cellular checkpoints and to escape apoptosis. 
The Bcl-2 family of proteins consists of multiple mitochondrial membrane permeabilization 
regulators that function to either promote or inhibit apoptosis [55]. Anti-apoptotic Bcl-2 members 
(Mcl-1, Bcl-2, and Bcl-xL) have been reported to mediate survival of myeloid cells under some 
conditions [56–61]. Our laboratory recently reported that Mcl-1 functions to mediate the early 
survival of infected monocytes [25]. Monocytes have a biologically limited lifespan of about  
48–72 hours in the circulation, during which they must make a cell fate decision to either undergo 
monocyte-to-macrophage differentiation [24,25] or to fulfill their natural “default” biological 
programming and undergo apoptosis. Under homeostatic conditions, monocytes exhibit high levels 
of Mcl-1 upon entry into circulation and upon isolation in our system, followed by a significant 
reduction in Mcl-1 protein levels over their 48–72 hour lifespan [25]. The decline of pro-survival 
Mcl-1 between 48 and 72 hours post infection is consistent with the in vivo lifespan of these cells 
and appears to constitute a potential molecular viability gate, which monocytes must negotiate in 
order to escape their intrinsic apoptotic fate [25]. Furthermore, this expression pattern suggests that, 
under homeostatic conditions, Mcl-1 may function as a molecular clock to ensure a controlled 
population of unstimulated short-lived monocytes [25]. These data are consistent with what is 
known about Mcl-1 and its anti-apoptotic function in myeloid leukemia cells [62–64]. The Mcl-1 
gene was originally identified as being over-expressed in a human myeloid leukemia cell line 
during monocyte-to-macrophage differentiation [62]. Mcl-1 has since been identified as a member 
of the Bcl-2 gene family that, under homeostatic conditions, serves to regulate two important 
myeloid cell processes: survival and differentiation [63,65]. Because of its pro-survival function in 
cells, over-expression of Mcl-1 enhances the survival of cancerous cells and contributes to drug 
resistance in a variety of cancers [66–69]. Our data suggest that HCMV usurps the pro-survival 
function of Mcl-1 to promote the enhanced survival of infected monocytes. In contrast to 
uninfected monocytes, Mcl-1 levels remain stable through the first 24 hours following HCMV 
infection; after 24 hours, Mcl-1 levels in infected monocytes decline until expression finally 
reaches the same levels as those observed in mock-infected cells at 72 hours post infection [25].  
By extending the expression of Mcl-1 in HCMV-infected monocytes when compared to their 
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mock-infected counterparts, HCMV infection allows these cells to navigate the cell viability 
checkpoint at 48 hours post infection. Thus, HCMV appears to upregulate Mcl-1 expression in 
infected monocytes to overcome the intrinsic apoptotic clock that controls the monocyte population 
under homeostatic conditions, in order to extend the lifespan of the infected cell [25]. In support, 
siRNA-mediated knock down of Mcl-1 levels leads to a reversal of the apoptotic resistance 
observed in HCMV-infected monocytes, confirming that Mcl-1 is responsible for the enhanced 
survival of monocytes during the initial 24–48 hours following infection [25].  
Molecularly, survival and differentiation are distinct processes in monocytes that are, 
nonetheless, intimately linked. Prolonged survival of monocytes is necessary to afford the time 
required for differentiation to occur; however, an excess of pro-survival signals can block 
differentiation [70]. Thus, the survival and differentiation programs in monocytes appear to 
represent a “Goldilocks” phenomenon whereby only precise expression levels of the cellular products 
involved in both survival and differentiation will result in effective monocyte-to-macrophage 
differentiation. In fact, myeloid cell differentiation has been shown to require low level expression 
of multiple “pro-apoptotic” players, particularly the caspases [70]. For example, caspase-3 and 
caspase-8 play a significant role in monocyte-to-macrophage differentiation induced by stimulation 
with macrophage colony-stimulating factor (M-CSF): both caspases are required for differentiation 
to occur [70]. However, the expression of caspase-3 and caspase-8 is lower during differentiation 
than during apoptosis [70], suggesting a threshold level of caspase expression exists that is 
necessary for differentiation, while remaining low enough to avoid triggering apoptosis. These 
studies implicate that the process of monocyte-to-macrophage differentiation may represent, 
molecularly, an incomplete apoptosis-like program.  
In support, recent work from our laboratory has shown that HCMV controls  
monocyte-to-macrophage differentiation through the partial activation of caspase-3 [24]. 
Furthermore, we demonstrated that, prior to the 48-hour cell fate checkpoint, Mcl-1 acts to inhibit 
the cleavage and activation of caspase-3, which in turn promotes monocyte survival [24]. However, 
once infected monocytes survive to and through the 48-hour viability gate, the loss of Mcl-1 allows 
a basal activation of caspase-3 that is required for monocyte-to-macrophage differentiation [24]. 
Thus, by differentially regulating Mcl-1 expression levels, HCMV walks a fine line between 
survival and death; between differentiation and non-differentiation, to create the long-lived 
macrophage that is central to its viral survival/persistence strategy.  
Our more recent studies investigating the prolonged survival of HCMV-infected monocytes 
have further illustrated the involvement of a possible incomplete apoptosis-like program in  
HCMV-induced monocyte-to-macrophage differentiation. During our analysis of a panel of assays 
to identify apoptotic cell death, we identified that despite the well-characterized enhanced survival 
of HCMV-infected monocytes [24,25], HCMV-infected cells did not exhibit a decrease in the 
expression of several apoptosis-associated markers as would be expected, but rather showed an 
increase in some quantifiable phenomena associated with apoptosis (Figure 1). Flow cytometric 
analysis of Annexin V and propidium iodide (PI) staining in HCMV-infected versus mock-infected 
monocytes at 72 hours post infection revealed a greater than two fold increase in the percentage of 
Annexin V positive, PI negative cells in HCMV-infected monocytes (Figure 1A). Cells staining as 
Annexin V positive, PI negative are prototypically considered to be in the early stages of apoptosis, 
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because Annexin V binds to phosphatidyl serine (PS), an inner membrane component that flips to 
the outer membrane of cells during apoptosis [71]. However, the presence of PS on the outer 
membrane of cells is also a natural occurrence during monocyte-to-macrophage differentiation, and 
PS on the outer membrane is required for the phagocytic function of macrophages [72]. With an 
already documented increase in cell viability during HCMV infection of monocytes [45] and in the 
absence of an increase in PI staining, which would represent true cell death; the increase in the 
number of cells expressing PS (by Annexin V staining) in HCMV-infected monocytes likely 
represents the larger number of cells undergoing monocyte-to-macrophage differentiation that we 
have previously documented [21,24]. Furthermore, quantification of fluorescent cells in images 
captured by an IncuCyte ZOOM™ analyzer of HCMV-infected versus mock-infected monocytes 
that were treated with CellPlayer™ 96-well Caspase-3/7 reagent (which fluorescently labels cells 
containing activated or cleaved caspase-3/7) over a timecourse of 72 hours indicated an increase in 
the number of cells containing cleaved caspase-3/7 in HCMV-infected cells compared to  
mock-infected cells (Figure 1B). We previously showed that HCMV-infected monocytes had 
increased levels of the full-length 32 kDa and partially cleaved 20-kDa forms of caspase-3, while 
showing similar levels of the fully-cleaved 17 kDa form of caspase-3, when compared to mock-infected 
monocytes by three days post infection [24]. Additionally, we have observed an increase in caspase-7 
expression and cleavage in infected monocytes 3–5 days post infection [73]. Although the activation 
of caspase-3/7 is typically indicative of an apoptotic process in cells, our previous data showed that 
caspase-3 activity was required for HCMV-induced monocyte-to-macrophage differentiation [24]; 
however, we have not yet addressed a potential role for caspase-7 in the differentiation of infected 
monocytes to macrophages. With a defined role for caspase-3 activation in myeloid cell 
differentiation [24,64] and the recently documented role for caspase-7 in the differentiation of 
dental hard tissue producing cells, such as odontoblasts and ameloblasts [74], we suggest that the 
increase in the number of cells expressing activated caspase-3 and -7 in HCMV-infected monocytes, 
again reflects a greater number of cells undergoing monocyte-to-macrophage differentiation, rather 
than apoptosis. To verify that HCMV-infected monocytes exhibited lower amounts of apoptosis 
than their uninfected counterparts despite the measurable increase in PS expression and caspase-3/-7 
activation, we performed a DNA laddering assay to detect the presence of fragmented DNA  
(a hallmark of complete apoptosis) at 72 hours (data not shown) and 120 hours post infection  
(a time that we could identify any cellular apoptosis that may potentially be initiated at 72 hours) 
(Figure 1C). We observed a small amount of DNA laddering in HCMV-infected monocytes 
(Figure 1C, Lane 3), indicating that some HCMV-infected cells had undergone apoptosis. 
However, we identified that uninfected monocytes (Figure 1C, Lane 2) had an increased amount of 
DNA laddering when compared to HCMV-infected monocytes (Figure 1C, Lane 3), indicating the 
presence of increased apoptosis in uninfected monocytes. Therefore, it appears that although 
multiple biological changes occur during HCMV infection of monocytes that have been linked to 
the initiation of an apoptotic cascade, full apoptosis does not occur in the majority of HCMV-infected 
monocytes. We argue that the process of macrophage differentiation likely requires the specific 
regulation of a partial apoptotic-like cascade (involving multiple steps including the activation of 
caspases and the surface expression of PS) that drives the myeloid differentiation process to a 
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“point of no return” for the macrophage, but that does not result in a full apoptotic response that 
would result in cell death. 
Figure 1. Human cytomegalovirus (HCMV) induces the upregulation of  
apoptosis-associated markers in the absence of increased apoptosis. Primary human 
peripheral blood monocytes were isolated as previously described [22,44]. Monocytes 
were mock- or HCMV-infected (Towne/E p.41 MOI 5) for 72 hours at 37 C in 5% 
CO2, and kept either in suspension (A and C) or adherent in a 96 well plate (B) in 1% 
human serum RPMI 1640 (Cellgro). (A) At 72 hours post infection, monocytes were 
harvested, stained with Annexin V-FITC and PI, and analyzed by flow cytometry. The 
average percentage of Annexin V positive, PI negative cells in each sample from three 
separate donors is represented. Student’s paired t-test was used to determine statistical 
significance (* p < 0.05). (B) At the time of infection, triplicate samples were treated 
with 5 M CellPlayer™ 96-Well Caspase-3/-7 reagent. Samples were placed in an 
IncuCyte™ Zoom live imaging system at 37 C and 5% CO2. Phase contrast and green 
fluorescence images of each sample at identical areas were acquired every six hours for 
72 hours. The number of green objects detected per image was normalized to the number 
of cells detected by phase contrast per respective image. The resulting green object 
count for each sample is represented. (C) At 120 hours post infection, fragmented DNA 
was harvested from samples using a Calbiochem® Suicide Track™ DNA Ladder 
Isolation kit. Isolated DNA was run on a 1.5% agarose/TAE gel at 50 constant volts. 
The gel was then stained with ethidium bromide and apoptotic DNA was visualized by 
UV illumination. All samples were run on the same gel under the same conditions; 
however, a lane containing an irrelevant treatment option was removed for the final 
figure. Lane 1 contains the 1 kb DNA standard ladder, Lane 2 contains DNA from 
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4. HCMV-Induced Monocyte-to-Macrophage Differentiation Is Required for Viral 
Replication and for Long-Term Persistent Infection 
Infection of monocytes by HCMV was initially thought to represent a non-productive and 
abortive infection for the virus because monocytes do not support viral replication [8,12,36]. 
However, as previously discussed, HCMV-infected monocytes are clearly implicated in the overall 
dissemination of HCMV within the infected host [8–12,17,18]. The circulating surveillance 
function of monocytes within the bloodstream makes this highly motile cell type ideal for delivery 
of the virus to multiple organ tissues, but in the absence of viral replication, infection of monocytes 
by HCMV would appear to serve no productive function for the overall viral persistence  
strategy. On the other hand, viral replication has been shown to occur in monocyte-derived 
macrophages [13–16,75] and in macrophages from infected individuals [13,76]. However, 
differentiated macrophages are not found within the bloodstream and can, therefore, not play a 
predominant role in the hematogenous dissemination strategy of HCMV during primary infection. 
Our laboratory demonstrated that HCMV is able to promote the transendothelial migration of 
infected monocytes to facilitate their exit out of the bloodstream and entry into the surrounding 
tissues [21,22]. Studies of a mouse model of CMV infection support the extravasation of infected 
monocytes out of the bloodstream and their movement into organ tissues [77]. In this model, a 
primarily mononuclear cell-associated CMV viremia was identified in the infected mice; that  
was then followed by a dissemination of the virus to the liver and spleen [77]. Furthermore, we 
showed that primary infection of monocytes by HCMV drives the differentiation of infected 
monocytes into macrophages that can then support viral replication and the release of infectious 
virions [21,24,78,79]. Although infected monocytes appear to be driven towards differentiation  
into macrophages within hours following infection [78,79], the complete productive  
monocyte-to-macrophage differentiation process appears to take up to two weeks post  
infection [21]. HCMV-infected monocytes exhibit gene expression changes that are associated with 
macrophage differentiation as early as four hours post infection [78,79] and have an upregulation 
of macrophage markers, such as CD68, as early as 24 hours post infection [21]. HCMV-infected 
monocytes gain an increase in macrophage-associated phagocytosis function by three days post 
infection [21]. The infected monocyte/macrophage begins to express the macrophage differentiation 
marker, HLA-DR, in low levels by four days post infection, with increasing expression levels that 
peak around two weeks post infection [21]. The HCMV immediate early (IE) gene products, IE1 
and IE2, and the late gene product, gH, can then be detected within these fully differentiated 
macrophages between 2–3 weeks post infection, which coincides with the release of infectious 
virus into the macrophage supernatant [21,46]. Together, these data demonstrate that primary 
infected peripheral blood monocytes not only serve as viral carriers for hematogenous dissemination, 
but that they also serve as sources of viral persistence through their production of progeny virions. 
The release of newly produced infectious virions by HCMV-infected monocytes that have 
undergone differentiation into tissue macrophages would allow the virus to establish a long-term 
infection within peripheral organ tissue. It is likely that this viral persistence in macrophages links 
HCMV infection to the overt organ pathology observed in immunocompromised hosts. Newly 
released infectious virions within various host organs would then be able to infect additional 
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recruited myeloid cells and nearby epithelial cells at sites of bodily fluid excretion in order to 
facilitate chronic viral shedding and passage to new hosts [20,22]. In support, following the 
initiation of viral gene expression around two weeks post infection, we detect the release of 
infectious HCMV into the cellular supernatant at around three weeks post infection, which we 
showed continues through five weeks post infection [21]. Furthermore, we now have data 
indicating that HCMV-induced differentiation of infected monocytes results in a long-lived 
macrophage phenotype that becomes a long-term persistent source for the production of infectious 
HCMV (Table 1). In fact, HCMV-infected monocyte-derived macrophages secreted infectious 
virus into the cellular supernatant for at least 16 weeks post infection, albeit at very low levels 
(Table 1). Therefore, when paired with our previous data indicating that HCMV drives the motility 
and transendothelial migration [21,26,45] and the prolonged survival [25] and differentiation of 
infected monocytes [21,22,24], these data suggest that primary infected peripheral blood 
monocytes serve a critical role in the overall long-term persistence strategy of HCMV. Through the 
induction of these highly specific biological changes in infected monocytes, HCMV promotes the 
establishment of a long-lived macrophage phenotype that supports the chronic production of 
infectious virus, likely contributing to continuous shedding of the virus for months after initial 
infection. Clinical data support that chronic shedding of the virus following primary infection is a 
common occurrence, particularly among children in daycare settings, who have been shown to shed 
the virus for up to 23 months [80]. Furthermore, because monocytes/macrophages are the primary 
cell type involved in carrying reactivated HCMV, the replication of reactivated HCMV within these 
cells may contribute to the observed chronic shedding of HCMV in the breast milk of postpartum 
mothers [81]. Therefore, the replication of HCMV within differentiated monocytes/macrophages 
likely serves as a critical component for the long-term production and shedding of HCMV in both 
primary and reactivated infections. 
Table 1. Long-term release of HCMV from infected monocytes/macrophages. 
Monocytes were mock- or HCMV-infected (Towne/E MOI 5) and then cultured for 16 
weeks. At the indicated times post infection, cell supernatants were collected and added 
to fibroblasts. The presence or absence of detectable IE1 expression was determined by 
immunohistochemistry staining using an anti-IE1 antibody (Millipore MAB810), 
Histostain-Plus Kit (Invitrogen cat. 859043), and AEC Substrate Kit (Invitrogen cat.  
00-2007) at 24 hours post infection, as an indication for productive virus release by  
the long-term infected cells. “-” represents the absence of released virus and the 
numbers represent the calculated plaque forming units per 500 macrophages (averaged 
from two donors).  
Treatment 2 weeks 4 weeks 8 weeks 12 weeks 16 weeks 
Mock - - - - - 
HCMV - 20 26 30 10 
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5. HCMV Reprograms the Polarization of Infected Monocytes towards a Unique 
Macrophage Phenotype in Order to Promote Viral Replication and Persistence 
Recent advances in macrophage biology research have uncovered that the differentiation of 
monocytes into macrophages can result in a wide spectrum of resulting phenotypes that have a 
variety of biological functions [82–85]. These macrophage phenotypes have been categorized 
broadly into “M1”, or classically-activated, pro-inflammatory macrophages, and “M2”, or 
alternatively-activated, anti-inflammatory macrophages, although the phenotypes classified within 
these categories are broadly pleotropic [82–85]. Differentiation towards an M1 macrophage 
phenotype typically occurs following activation by interferon-  (IFN- ), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF), or lipopolysaccharide (LPS), 
resulting in a host defense or tumor resistance phenotype [83–85]. M1 macrophages are 
characterized by their secretion of large amounts of proinflammatory cytokines, including 
interleukin (IL)-6, IL-12, IL-23, and TNF [84,86,87]. On the other hand, differentiation towards an 
M2 macrophage phenotype typically occurs following activation by IL-4, IL-10, IL-13, or M-CSF, 
resulting in a regulatory, anti-parasitic, wound healing, or tumor promotion phenotype [83–85]. M2 
macrophages are characterized by the secretion of very low levels of inflammatory cytokines and 
the production of high amounts of IL-10 [84,86,87]. Moreover, M2 macrophages have been further 
classified into three subcategories (M2a, M2b, and M2c), which differ by stimulating cytokines, 
upregulated macrophage markers, cytokine production, and distinct biological function [84]. For 
example, M2a macrophages are stimulated by IL-4 and IL-13, express scavenger receptors on their 
surfaces, and function primarily in anti-parasitic activity or allergic inflammation; M2b macrophages 
are stimulated by Toll-like receptors or IL-1 receptors, express CD86, secrete TNF, IL-1, and IL-6, 
and are involved in the regulation of immune responses; and M2c macrophages are stimulated by 
IL-10, secrete TGF- , and are involved in tissue remodeling [84]. Therefore, the specific activating 
ligand involved in the stimulation of monocytes can greatly influence the overall differentiation 
and polarization of monocytes to macrophages.  
Regardless of stimuli, the process of monocyte-to-macrophage differentiation results in a series 
of cellular phenotypes that have some degree of shared functional and/or cytokine expression traits 
along with distinct characteristics. Thus, due to the wide range of potential differentiation-inducing 
ligands, the overall resulting macrophage cell type under various stimuli represents a diversity of 
potential cell types. Our laboratory was among the first to demonstrate that a virally-induced 
monocyte-to-macrophage differentiation process occurs and that it is likely required for viral 
replication and long-term viral persistence [21,24,78,79]. Because macrophages can be polarized to 
function generally as either pro-inflammatory/anti-microbial or anti-inflammatory/pro-tumorigenic, 
the specific type of macrophage polarization that results during HCMV infection of monocytes 
would have significant implications for viral dissemination and persistence. Our laboratory’s data 
indicate that HCMV induces the pro-inflammatory activation of infected monocytes, which we argue 
is critical for viral spread within the host [21,23,45]. However, the induction of a pro-inflammatory 
or M1 phenotype typically results in an anti-microbial functional that is characteristic of a host 
immune response [83,84,88], which would likely be detrimental to the viral life cycle. Nonetheless, 
because of the plasticity of macrophage differentiation along with our data that the stimulation of 
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macrophage differentiation by LPS results in a macrophage phenotype that is distinct from  
HCMV-induced macrophage differentiation [21], we suggest that HCMV utilizes this plasticity to 
regulate the polarization of infected monocytes/macrophages towards a distinct phenotype that 
ensures successful viral survival and persistence. One mechanism to test this notion of a distinct 
cell type is global transcriptome microarray analyses. We used this global transcriptome approach 
paired with an analysis of secreted chemokine analysis to decipher the distinct polarization of 
HCMV-infected monocytes/macrophages [78,79]. These studies identified that HCMV-infected 
monocytes exhibit a unique reprogramming of their differentiation and polarization in which both 
M1- and M2-associated genes are expressed and chemokines are secreted [78,79]. Specifically, we 
identified that subsets of M1-associated gene transcripts (65%) and M2-associated gene transcripts 
(4%) were upregulated during HCMV infection of monocytes, and subsets of M1-associated 
chemokines (44%) and M2-associated chemokines (33%) were more abundant in infected 
monocytes. These data implicate that HCMV-infected monocytes/macrophages fall somewhere 
along the macrophage polarization continuum to resemble a more “M1-like” pro-inflammatory 
phenotype [78,79]. We propose that HCMV specifically modulates the polarization of infected 
monocytes/macrophages to induce an activated, mostly M1-like phenotype in order to promote the 
pro-inflammatory changes (such as adhesion, motility, and survival) that are required for effective 
viral dissemination while dampening a potential anti-viral immune response by promoting the 
upregulation of key M2-associated genes (such as IL-10 and CCL18).  
To expand our microarray analyses, we have focused on the identification of specific gene 
expression changes that occur during monocyte-to-macrophage differentiation and polarization 
under various stimuli. These studies were designed to allow us to determine specific genes that are 
key to the overall differentiation of monocytes to macrophages, regardless of stimuli, and moreover, 
to identify the specific subsets of gene expression changes that are shared among HCMV-infected 
and M1 or M2 polarized macrophages. We hoped from these studies to gain a better understanding 
of the similarities and differences of HCMV-induced macrophage polarization versus traditional 
M1 or M2 polarization. To address this question, monocytes were mock- or HCMV-infected, or 
treated with LPS (to induce M1 polarization) or M-CSF (to induce M2 polarization), for two 
weeks. At two weeks, RNA was harvested for microarray analysis. These new microarray analyses 
have uncovered the differences in the overall gene expression profile and the changes that occur 
during the differentiation of HCMV-infected versus LPS-treated (M1) versus M-CSF-treated (M2) 
macrophages, when compared to mock-infected monocytes/macrophages (Figure 2A,B). Our data 
indicate that the general ligand-induced monocyte-to-macrophage differentiation process includes a 
subset of gene expression changes that is present regardless of stimulating ligand or polarization 
(upregulation of 2,455 genes; downregulation of 450 genes) (Figure 2A,B). That is, there is a core 
set of likely “pan” macrophage genes induced and/or reduced. However, the differentiation of 
monocytes towards an M1 or M2 macrophage phenotype also resulted in a large pool of distinct 
gene expression profiles. That is, we observed a large number of gene expression changes  
that appear unique to the specific macrophage polarization phenotype (upregulation of 739  
M-CSF-specific genes and 588 LPS-specific genes; downregulation of 961 M-CSF-specific  
genes and 685 LPS-specific genes) (Figure 2A,B). Furthermore, these analyses revealed that 
HCMV-induced monocyte-to-macrophage differentiation results in subsets of gene expression 
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changes that are shared with either M1 or M2 macrophages, with more genes shared with the M1 
macrophage polarization phenotype (upregulation of 936 LPS-shared genes; downregulation of 634 
LPS-shared genes) than the M2 macrophage phenotype (upregulation of 422 M-CSF-shared genes; 
downregulation of 305 M-CSF-shared genes) (Figure 2A,B). We also observed a distinct subset of 
gene expression changes in infected monocytes/macrophages that were not observed in either M1 
or M2 polarized macrophages (upregulation of 1,371 HCMV-specific genes; downregulation of 
1,263 HCMV-specific genes) (Figure 2A,B), suggesting that the HCMV-induced differentiation 
program of infected monocytes truly represents a unique differentiation phenotype.  
Figure 2. HCMV infection of monocytes induces a unique subset of gene expression 
changes when compared to monocytes polarized towards an M1 or M2 phenotype. 
Monocytes were mock- or HCMV-infected (Towne/E p.41 MOI 5), or treated with LPS 
(100 ng/mL) or M-CSF (100 ng/mL) for two weeks at 37 C and 5% CO2 under 
adherent conditions. At two weeks, RNA was harvested from each sample. Harvested 
RNA was used to perform microarray analysis on Affymetrix U133 Plus 2.0 genechips. 
Probe sets to represent individual genes were selected by using JetSet [89]. The genes 
that were upregulated (A) or downregulated (B) ( 2 fold change when compared to 
mock-infected monocytes) were compared between treatments and the number of 
unique or shared genes among samples is represented. 
 
In support of our gene array analyses, flow cytometric analysis revealed an increase in the 
expression of both M1- and M2-associated macrophage markers in HCMV-infected monocytes 
when compared to mock-infected monocytes at five days post infection (Figure 3). Of note—although 
uninfected monocytes are programmed to die between 48–72 hours in circulation, a certain 
percentage of cells (~40%) receive enough stimuli in our in vitro culture system to survive and 
undergo a small degree of differentiation. However, when compared to the percentage of cells found 
in HCMV-infected monocytes (>80% survival), it is clear that infection serves as both a survival 
and a differentiation stimuli. Analysis of co-staining with CD71 (a general macrophage marker), 
CD86 (a cell surface marker that is typically expressed on M1 macrophages), and CD163 (a cell 
surface marker that is typically expressed on M2 macrophages) revealed that HCMV infection of 
monocytes induces the upregulation of specific macrophage markers, resulting in a larger number 
of cells within the doublet staining macrophage subsets. In addition, the macrophage marker expression 
profile of HCMV-infected monocytes was distinct from that seen with M-CSF- or GM-CSF-treated 
monocytes, suggesting that various stimulating ligands induce distinct macrophage phenotype 
A. B. 
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populations (data not shown). Furthermore, analyses of the expression of select M1- and M2-associated 
genes in monocytes/macrophages at 24 and 72 hours following treatment with M-CSF, GM-CSF or 
LPS or infection with HCMV supported the finding that HCMV infection of monocytes/macrophages 
results in a distinct polarization profile that shares some characteristics with M1 and/or M2 
macrophages (data not shown). However, further studies involving additional donors are required to 
effectively decipher gene profile changes that occur during macrophage polarization between 24 
and 72 hours. Taken together, these data demonstrate that HCMV-infection of monocytes/macrophages 
drives their differentiation/polarization towards a macrophage phenotype that shares some 
characteristics with M1-polarized macrophages and M2-polarized macrophages, but that, overall, 
represents a distinct polarization phenotype; that is, the specific HCMV-induced polarization 
phenotype does not fall into the category of strictly “M1” or “M2”, but exists somewhere along the 
M1/M2 continuum, skewed towards a more M1-like phenotype. 
Figure 3. HCMV infection of monocytes induces a macrophage polarization phenotype 
that is distinct from M1 or M2 polarization. Monocytes were mock- or HCMV-infected 
(Towne/E p.41 MOI 5) at 37 C and 5% CO2 for five days. Monocytes/macrophages 
were washed with PBS, blocked in 5% fetal bovine serum and stained with Alexa  
fluor-conjugated antibodies specific for CD14 (a myeloid specific marker), CD71 (a 
macrophage specific marker), CD86 (an M1 macrophage associated marker), or CD163 
(an M2 macrophage associated marker). Cells were then analyzed by flow cytometry 
and gated by forward and side scatter and for CD14 positive cells. Scatter quadrant plots 
were generated indicating the number of cells expressing the various staining profiles.  
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Overall, we propose that this unique macrophage polarization phenotype uncovered by our 
studies reflects the manipulation of the differentiation and polarization program of infected 
monocytes by HCMV to promote a macrophage phenotype that is required for the overall persistence 
strategy of the virus. We predict that the early pro-inflammatory phenotype of HCMV-infected 
monocytes/macrophages regulates the motility and migration of the infected cells in order to 
promote their exit out of the bloodstream, and it helps to trigger the pro-survival signals necessary 
to overcome the cell’s intrinsic apoptotic program (inflammatory activation is known to induce 
prolonged monocyte survival [90]). However, because some inflammatory cytokines have also 
been linked to apoptosis in Mycobacterium-infected monocytes [90], the expression of some  
M2-associated anti-inflammatory genes in HCMV-infected monocytes likely helps to dampen the 
cell’s intrinsic apoptotic host response to infection. Through the specific regulation of the 
differentiation and polarization of infected monocytes/macrophages, we argue that HCMV 
promotes the specific cellular environment that is required for viral replication and overall persistence. 
This notion is supported by studies involving the infection of already differentiated M1 or M2 
macrophages by HCMV, which indicate that although both macrophage phenotypes are susceptible 
to HCMV infection, HCMV is able to infect a higher percentage of M2 macrophages than M1 
macrophages, indicating that M2 macrophages are more susceptible to HCMV infection [91,92]. 
These studies also indicated that HCMV induced the secretion of pro-inflammatory cytokines and 
chemokines in both M1 and M2 macrophages following infection, but that infected M2 
macrophages released a higher amount of infectious virus [93]. These data suggest that HCMV not 
only induces the polarization of differentiating monocytes, but also alters the polarization profile of 
already differentiated macrophages by inducing the expression of pro-inflammatory molecules. 
Furthermore, these data suggest that the expression of specific M2-associated molecules confers 
some type of advantage for the virus during infection, indicating that the specific macrophage 
polarization phenotype in infected cells may determine the overall outcome of HCMV replication 
and gene expression. In support, it was shown that the specific phenotype of differentiated 
macrophages resulting from infected monocytes strictly affected HCMV replication and the 
production of infectious virus from infected monocytes/macrophages, as the absence of IFN-  and 
IL-2 nearly abolished viral replication [52]. Moreover, IFN-  and TNF-  were shown to be 
required for the differentiation of HCMV-permissive monocyte-derived macrophages, and the 
presence of these cytokines during the differentiation process conferred HCMV resistance to these 
antiviral cytokines [93]. Taken together, these studies illustrate the requirement of a very distinct 
macrophage phenotype, expressing specific proinflammatory (M1-associated) cytokines and/or 
cellular factors (such as IFN-  and TNF- ) and certain anti-inflammatory (M2-associated) cytokines 
and/or cellular factors (such as IL-10), for the establishment of the ideal tissue environment for 
effective HCMV replication within monocyte-derived macrophages. Therefore, we propose that the 
“fine-tuning” of the infected macrophage polarization phenotype likely produces a cellular 
environment that expresses all of the cytokines and cellular factors that are required for the 
hematogenous spread of HCMV and for the initiation of HCMV replication in macrophages, while 
avoiding certain detrimental outcomes like a robust antiviral immune response. Specifically, we 
predict that the expression of M1-associated cytokines likely promotes the required biological 
changes for enhanced motility, transendothelial migration, and survival to promote viral spread and 
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replication and to help provide resistance to any later production of these pro-inflammatory 
cytokines, while the expression of M2-associated cytokines promotes an environment that is  
better-suited for viral replication and that helps to dampen immune detection of the virus. 
6. Discussion 
The hematogenous dissemination strategy of HCMV allows the virus to spread throughout the 
entire body of the host and to gain access to nearly every organ tissue. This systemic spread is 
critical for the establishment of viral latency within the bone marrow and the life-long persistent 
infection that is associated with HCMV infection [19,28,29]. Because peripheral blood monocytes 
play an immune surveillance role within the host and can, therefore, easily transition out of the 
bloodstream to enter into peripheral organ tissues, monocytes represent ideal candidates to serve as 
viral carriers for the spread of HCMV during infection. Furthermore, the clinical disease 
manifestations associated with HCMV infection are thought to result from the infiltration of 
infected monocytes during the hematogenous spread of the virus [94]. However, because peripheral 
blood monocytes have a short lifespan [34,35] and do not support de novo viral gene expression or 
replication until differentiation into macrophages [36], HCMV must first overcome these biological 
hurdles in order to utilize monocytes for viral spread. 
Our laboratory has demonstrated that the binding of HCMV glycoproteins to EGFR and the 1 
and 3 integrins on the surface of monocytes triggers the activation of multiple signaling cascades 
that mediate the pro-inflammatory activation of infected monocytes [26,45]. We propose that this 
pro-inflammatory monocyte activation is required for the induction of multiple monocyte 
biological changes that are critical for viral spread and persistence, including an enhanced motility 
and transendothelial migration, which help to facilitate the extravasation of infected monocytes out 
of the bloodstream and into the surrounding tissues [21–23,45]. However, due to the natural short 
lifespan of these cells, in the absence of a viral-induced pro-survival signal, infected monocytes 
would likely represent an “end-point-cellular-host” for the virus. Our data have shown that HCMV 
promotes the extended survival of infected monocytes through the prolonged expression of the 
cellular anti-apoptotic molecule, Mcl-1 early after infection, which promotes the survival of 
infected monocytes through a 48-hour viability checkpoint, a time at which uninfected monocytes 
appear to be programmed to die by apoptosis [25] (Figure 4). Although the prolonged survival of 
infected monocytes is critical for providing a longer-lived cellular host for the virus, in order for 
HCMV replication to occur, differentiation of infected monocytes into long-lived macrophages is 
also required [8,13–15,95] (Table 1). Further complicating this scenario, cellular differentiation can 
by blocked by an abundance of pro-survival signaling [70], suggesting that the survival and 
differentiation programs in infected monocytes must be intimately linked and tightly co-regulated 
during HCMV infection in order for viral replication to occur. That is, the virus must regulate the 
precise expression of pro-survival signals in order to navigate through critical cell fate decision 
checkpoints to promote survival, while simultaneously ensuring that differentiation also appropriately 
commences in the presence of these pro-survival signals. Based on our studies, we have developed 
a model describing this link between HCMV-induced monocyte survival and differentiation. Early 
after infection, following the extravasation of infected monocytes into the surrounding tissues, the 
primary hurdle for HCMV is the “ticking clock” of monocyte pre-programmed cellular death around 
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a 48-hour viability gate (Figure 4). Therefore, HCMV regulates the prolonged expression of Mcl-1 
to drive the survival of the infected cell through this 48-hour viability gate (Figure 4). Following 
the successful navigation through this cell survival “crisis point”, the primary hurdle for HCMV 
becomes the inability to initiate viral gene expression and replication, thereby necessitating a switch 
from a primarily cell survival program to a primarily cellular differentiation program (Figure 4). 
During the cellular differentiation phase of infection, Mcl-1 expression levels are depleted to allow 
for differentiation, while a low level increase in other pro-survival signals (including Bcl-2 
expression) is observed, which we believe allows the infected cell to maintain survival throughout 
the differentiation process without directly interfering with the differentiation process (Figure 4). 
In an effort to identify the molecular mechanisms for how HCMV effectively regulates the distinct 
processes of survival and differentiation during infection, we initiated studies to molecularly define 
the players involved in driving the monocyte-to-macrophage differentiation process that may also 
be linked to alterations in the cell survival program. We have shown that Mcl-1 expression early 
after infection serves to inhibit the apoptosis of infected cells through the inhibition of caspase-3 
cleavage/activation, prior to the 48-hour viability gate (Figure 4) [24]. Furthermore, we showed 
that once Mcl-1 levels are depleted after the 48-hour viability checkpoint, HCMV utilizes the 
partial activation of caspase-3, a typically pro-apoptotic molecule that has also been shown to 
regulate macrophage differentiation [64], in order to drive differentiation of infected monocytes 
(Figure 4) [24]. Our new studies confirm an increase in the activation of caspases during HCMV 
infection of monocytes (Figure 1B) and indicate that HCMV infection also induces the expression 
of PS on the surface of infected monocytes (Figure 1A). Although these findings are typically 
associated with enhanced cellular apoptosis, we nonetheless observe a prolonged survival [25] and 
a lower amount of DNA laddering in infected monocytes (Figure 1C), indicating that HCMV 
promotes resistance to apoptosis in infected monocytes. Moreover, both the activation of  
caspases [24,64,70,74] and the expression of PS [96] have been shown to occur during the 
differentiation of monocytes to macrophages. Therefore, we argue that following the successful 
navigation of infected monocytes through the critical 48-hour cell fate decision checkpoint (which 
is mediated by the increased expression of cell survival signals, including Mcl-1 [25]), HCMV then 
initiates the expression of a series of “pro-apoptotic” signals in precise quantities that help to drive 
the differentiation of infected monocytes to macrophages, but that does not fully activate the 
apoptotic response (Figure 4). Furthermore, the expression of PS has recently been found to have 
an anti-inflammatory effect by inducing the expression of anti-inflammatory cytokines that can 
counteract the effects of pro-inflammatory cytokines within inflamed tissues [97–100]. These data 
suggest that the surface expression of PS in infected monocytes may not only indicate the 
differentiation of infected monocytes into macrophages, but may also aid in the distinct 
polarization of infected monocytes/macrophages by enhancing the expression of anti-inflammatory, 
or M2-associated cytokines to counteract any potential negative or anti-viral effects of  
pro-inflammatory, or M1-associated cytokines that are expressed during infection.  
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Figure 4. HCMV regulates the distinct processes of survival and differentiation during 
infection through the precise expression of specific pro- and anti-apoptotic molecules. 
Our data have shown that HCMV infection induces the enhanced expression of Mcl-1 
in infected monocytes in order to mediate their prolonged survival through a 48-hour 
viability checkpoint, a time in which uninfected monocytes are programmed to die [24,25]. 
Mcl-1 levels gradually decrease through 48 hours after infection, before becoming 
undetectable. Following 48 hours, HCMV induces the enhanced expression of Bcl-2 
and phosphatidyl serine (PS) membrane expression and an increase in the partial 
activation of caspase-3 in infected monocytes. The expression of low levels of Bcl-2 
helps to support the survival of infected monocytes after the 48-hour viability gate, 
while precise regulation of the membrane expression of PS and the partial activation  
of caspase-3 help to drive the differentiation of infected monocytes towards  
replication-permissive macrophages. Overall, through the tight regulation of pro- and 
anti-apoptotic molecules, HCMV is able to overcome critical biological hurdles, such 
as the short lifespan of monocytes and the limit of de novo viral gene expression and/or 
replication in monocytes. 
 
7. Conclusions 
Although the precise mechanisms for how HCMV directs the polarization of infected 
monocytes/macrophages remain undetermined, our data clearly indicate that HCMV serves as a  
unique ligand that induces the differentiation and polarization of infected monocytes/macrophages  
towards a distinct phenotype that shares common characteristics with both M1 and M2 polarized 
macrophages [78,79] (Figures 2 and 3). In this manner, HCMV appears to specifically regulate the 
polarization of infected monocytes/macrophages in order to achieve an effective balance between 
pro-inflammatory and anti-inflammatory signals, which may establish the cellular environment that 
is conducive for dissemination and persistence of HCMV (Figure 5). Furthermore, we suggest that 
the specific polarization of HCMV-infected monocytes into distinct macrophages allows the virus 
to reprogram its cellular environment to achieve effective viral replication within a now naturally 
long-lived tissue macrophage (Figure 5). Combined with our polarization data, our identification of 
the ability of infected monocytes/macrophages to serve as long-term sources of productive viral 
release (Table 1) suggests that HCMV specifically manipulates monocyte cell biology to utilize this 
cell type not only as a vessel for successful dissemination, but to also promote long-term persistence 
within infected tissues. Furthermore, these studies strengthen previous studies indicating that infected 
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macrophages do, in fact, serve as a critical cellular component in the production of HCMV within 
tissues, tying infected monocytes/macrophages to viral spread, persistence, and pathogenesis within 
organs [13,101]. Overall, it seems that in order to successfully reach the point of viral replication, 
HCMV must orchestrate the precise expression of multiple pro-survival and pro-apoptosis signals, as 
well as pro-inflammatory and anti-inflammatory mediators, to achieve optimal “Goldilocks” expression 
levels of these critical cellular signals in infected monocytes/macrophages. Furthermore, as evidenced 
by the partial activation of caspase-3 and the extracellular membrane-associated expression of PS 
on infected monocytes/macrophages, HCMV has likely evolved to utilize multiple molecular 
mechanisms that link the survival and differentiation/polarization programs of infected cells. 
Figure 5. HCMV polarizes infected monocytes/macrophages towards a distinct phenotype 
possessing aspects of both M1 and M2 macrophages in order to promote viral spread 
and replication. Our current data indicate that HCMV induces the simultaneous expression 
of M1-associated molecules (IL-6, TNF- , CD86) and M2-associated molecules (IL-10 
and CD163), suggesting that HCMV-infected macrophages fall somewhere along the 
macrophage polarization continuum between an M1 and M2 phenotype (with a skewing 
towards a more M1-like phenotype) with an expression of more M1-associated genes 
and chemokines than M2-associated genes and chemokines [78,79]. We propose that  
through tight regulation of the expression of specific M1 (pro-inflammatory) and M2 
(anti-inflammatory) macrophage markers and chemokines, HCMV is able to utilize key 
pro-viral aspects of both polarization phenotypes, while simultaneously avoiding potential 
detrimental anti-viral effects. Specifically, HCMV likely utilizes M1-associated 
macrophage markers and chemokines to promote the pro-inflammatory activation of 
infected monocytes/macrophages to ensure proper cellular motility, migration, and 
monocyte recruitment, while utilizing M2-associated macrophage markers and 
chemokines to dampen the tissue-damaging effects of the pro-inflammatory response 
and any potential anti-viral responses. Overall, through the precise regulation of 
macrophage polarization, HCMV likely induces an ideal cellular environment that can 
support effective long-term viral replication, which ensures the overall success of the viral 
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Abstract: The MHC-class I (MHC-I)-like viral (MHC-Iv) m152 gene product of 
murine cytomegalovirus (mCMV) was the first immune evasion molecule described for 
a member of the -subfamily of herpesviruses as a paradigm for analogous functions of 
human cytomegalovirus proteins. Notably, by interacting with classical MHC-I molecules 
and with MHC-I-like RAE1 family ligands of the activatory natural killer (NK) cell 
receptor NKG2D, it inhibits presentation of antigenic peptides to CD8 T cells and the 
NKG2D-dependent activation of NK cells, respectively, thus simultaneously interfering 
with adaptive and innate immune recognition of infected cells. Although the m152 gene 
product exists in differentially glycosylated isoforms whose individual contributions to 
immune evasion are unknown, it has entered the scientific literature as m152/gp40, 
based on the quantitatively most prominent isoform but with no functional justification. 
By construction of a recombinant mCMV in which all three N-glycosylation sites are 
mutated (N61Q, N208Q, and N241Q), we show here that N-linked glycosylation is not 
essential for functional interaction of the m152 immune evasion protein with either 
MHC-I or RAE1. These data add an important functional detail to recent structural 
analysis of the m152/RAE1  complex that has revealed N-glycosylations at positions 
Asn61 and Asn208 of m152 distant from the m152/RAE1  interface. 
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1. Introduction 
Murine cytomegalovirus (mCMV) encodes a set of MHC class I (MHC-I)-like molecules 
(MHC-Iv) from the “mCMV-private” m145 gene family that are involved in evasion of natural 
killer (NK) cell recognition of infected cells by interfering with cell surface expression of  
MHC-I-like cellular ligands of the activatory NK cell receptor NKG2D. Specifically, m145 
interferes with MULT1 [1], m152 with RAE1 family members [2], and m155 with H60 [3,4] (for 
reviews, see [5–9]). 
Besides representing the first confirmed MHC-Iv type immune evasion molecule of a  
CMV [10–12], m152 is special in that it targets not only RAE1 family ligands of NKG2D for 
subverting innate immune recognition of infected cells but also classical MHC-I allomorphs for 
inhibiting the recognition of infected cells by virus epitope-specific CD8 T cells, hence subverting 
also adaptive immunity ([13–15]; for reviews see [16–18]). 
Mechanistically, regarding its interference with the classical MHC-I pathway of  
antigen-presentation, m152 is thought to interact transiently with nascent peptide MHC-I 
complexes (pMHC-I) in the ER and disconnects them from the constitutive vesicular flow to the 
cell surface by retaining them in the ER-Golgi Intermediate Compartment (ERGIC)/cis-Golgi [11,12], 
which classifies m152 as the prototype of a “retainer”-type immune evasion molecule (for reviews, 
see [16,19]). Accordingly, the frequent statement that MHC-I cell surface expression is 
“downmodulated” by m152 may be somewhat misleading. More precisely, the function of this 
immune evasion molecule is to interfere with trafficking of newly generated pMHC-I from the ER 
to the cell surface, while loss of virus-specific as well as overall cell surface pMHC-I rather results 
from cell-surface MHC-I turnover in absence of resupply [20]. Transient interaction between 
pMHC-I and the luminal portion of m152, which is a type-I transmembrane protein, proved to be 
sufficient for catalyzing durable pMHC-I retention, while dissociated m152 passes the Golgi apparatus 
and eventually becomes degraded in the lysosome [21]. Regarding m152’s interference with cell 
surface expression of NKG2D ligands of the RAE1 family, the association with m152 varies between 
different RAE1 isoforms, with the greatest affinity observed for RAE1  [22]. RAE1  appears to be 
special in that its nascent form is effectively retained by m152, whereas loss of the mature,  
surface-resident form is prevented by absence of a PLWY motif [23]. Based on the high affinity of 
m152’s interaction with RAE1 , Wang and colleagues [24] succeeded in resolving the X-ray 
crystal structure of the m152/RAE1  complex, and they defined intermolecular contacts showing 
that m152 interacts in a pincer-like manner with two sites on the 1 and 2 helices of RAE1 . 
In infected cells, m152 is found in differentially glycosylated isoforms, of which a 40 kDa 
molecular species is most prominent [12]. This has led to equate m152 with gp40 in its 
immunoevasive functions, both in innate and adaptive immune recognition of infected cells, 
although the isoform(s) actually interacting with and catalyzing retention of classical MHC-I and 
RAE1 molecules as well as a possible contribution of carbohydrate moieties to the retention 
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function have never been established. The crystal structure of the m152/RAE1  complex indeed 
revealed electron density for two single N-acetyl glucosamine residues at Asn61 and Asn208 [24], 
which shows that the N-glycosylation does at least not interfere with the physical association 
between m152 and RAE1 . Whether or not it is actually needed for the immunoevasive function is 
the question that we have pursued here. 
2. Results and Discussion 
2.1. Impaired Immune Evasion Function Coincides with Quantitative Underrepresentation of 
Glycosylation Isoform gp48 of m152  
Our original interest in the role of glycosylation isoforms of m152 was based on the incidental 
observation of inconsistent reduction in overall cell surface display of classical MHC-I molecules 
in two mCMV mutants deleted for immune evasion gene m06 [25] but supposed to be identical in 
the expression of the two remaining mCMV-encoded class-I trafficking regulators m152 and m04, 
namely mutants mCMV- m06L [18,26] and mCMV- m06W [27]. Identical expression of 
m04/gp34 [28] by these two mutants has been documented previously [18], so that suspicion 
focused on a possibly aberrant expression of m152. 
As shown in Figure 1, left column, infected cultures of mouse embryo fibroblasts (MEF) consist 
of two cell populations with clearcut distinction between “uninfected” cells characterized by 
missing expression of the ER-resident viral early (E) phase glycoprotein m164/gp36.5 [29] and 
high cell surface expression of classical MHC-I, and infected cells characterized by expression of 
the infection marker m164/gp36.5 and levels of MHC-I cell surface expression that vary depending 
upon the expression of immune evasion genes [18,26,30]. As a side aspect for clarity, it should be 
noted that at an MOI of 4 all cells present in infected cell cultures likely have virus attached, but 
apparently not all cells are permissive for the viral gene expression program. Notably, these cells 
also fail to express a fluorescent reporter, such as GFP, even under the control of the human CMV 
IE promoter-enhancer in a respective recombinant virus mCMV-GFP [31] (Appendix Figure A1), 
which suggests immediate silencing of incoming viral genomes. 
After infection with virus mCMV- m06m152, infected m164pos cells (arrow-marked) showed 
an intermediate level of cell surface MHC-I, which was strongly reduced by expression of m152 in 
cells infected with mCMV- m06L. Surprisingly, although mCMV- m06W, which is the prototypic 
m06 deletion mutant used in several publications by a number of investigators, was expected to 
show the same phenotype, immune evasion was found to be alleviated [30], corresponding to an 
only moderate reduction of cell surface MHC-I expression (Figure 1, left column). Notably, these 
findings for the three viruses were paralleled by cell surface levels of RAE1 in the respective 
m164pos cell populations (Figure 1, right column), which clearly points to m152 expression as being 
the key to this phenomenon, since RAE1, unlike classical MHC-I, is targeted by m152 selectively. 
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Figure 1. Inconsistent effects of m152 expression in cells infected with m06 mutants. 
Left column panels: Cytofluorometric analysis of cell surface MHC-I (H-2 Kd) expression 
(abscissa; FL-2, PE fluorescence intensity) and expression of the ER-resident, E-phase 
infection marker m164/gp36.5 (ordinate; FL-1, Alexa Fluor488 fluorescence intensity) 
in BALB/c MEF infected with the indicated immune evasion gene deletion mutants of 
mCMV. Data are displayed as density plots (color-coded with red and blue representing 
highest and lowest density, respectively). The arrows point to the population of actually 
infected MEF present within the infected cell cultures beyond to cells that are  
non-permissive for productive cycle infection and express high levels of MHC-I not 
downmodulated by immune evasion gene expression. Right column panels: Cell surface 
expression of pan-RAE1 (abscissa; FL-4, APC fluorescence intensity) by the gated 
population of infected MEF. To serve as a reference for an easier comparison, the 
dashed line marks the peak RAE1 expression in absence of immune evasion molecules 
m06 and m152. 
 
We therefore studied the expression of m152 by these two m06 deletion mutants in  
comparison to mCMV-WT.BAC. Generally, as shown by us previously in Western blot analyses, 
the amount of the 40 kDa molecular species of the m152 protein is strongly reduced in cells 
infected with mCMV- m06W compared to cells infected with WT virus or mCMV- m06L [18]. 
That the protein is not completely absent has been shown by Western blot in the original report on 
mCMV- m06W [27], and we could confirm this by sensitive immunofluorescence analysis of 
infected cells as well as by immunohistological detection of m152 protein [18] in tissue sections of 
mice infected with mCMV- m06W [32].  
127 
Here we have modified the approach of detecting m152 proteins in that they were first enriched 
by m152-specific immunoprecipitation before their analysis by Western blot (Figure 2). For WT 
virus and mutant virus mCMV- m06L, this more sensitive analysis revealed m152 isoforms of  
48 kDa and 40 kDa, whereas the 48 kDa molecular species proved to be severely underrepresented 
selectively in cells infected with virus mCMV- m06W (Figure 2A). In accordance with previous 
work by Ziegler and colleagues describing the more abundant 40 kDa molecular species [21], both 
isoforms turned out to be resistant against treatment with endoglycosidase H (Endo H), while removal 
of all N-linked carbohydrates using PNGase F identified them as differentially N-glycosylated 
isoforms gp48 and gp40 that, according to their Endo H resistance, must have passed the Golgi 
apparatus, and led to a deglycosylated (more precisely: N-linked carbohydrate-deprived) isoform 
p36 (Figure 2B). As indicated by increasing abundance of gp48 corresponding to decreasing 
abundance of gp40 over time in absence of further protein synthesis, gp40 is apparently a precursor 
of the higher-glycosylated isoform gp48. It should be noted that the reason for the difference 
between the two m06 mutants is still unknown, as sequencing did not reveal any mutation in the 
coding region, the 3' and 5' untranslated regions (UTRs), and the promoter region of transcription 
unit m152 of the two m06 viruses (data not shown). 
Based on these findings we surmised the gp48 glycosylation isoform of m152 might be the 
functional isoform of m152 in immune evasion.  
2.2. Mapping of N-glycosylation Sites in m152 and Generation of a Recombinant Virus Expressing 
only Isoform p36 of the m152 Gene Product 
There exist three potential N-glycosylation sites in the amino acid sequence of the m152 protein, 
namely at amino acid positions Asn61, Asn208, and Asn241. Transfection of COS7 cells with 
expression plasmids carrying single mutations N61Q, N208Q, and N241Q revealed a predicted  
ca. 2 kDa molecular mass shift from 40 kDa to 38 kDa only after mutations N61Q or N208Q  
(Figure 3), indicating that the site Asn241 is not used in presence of either of the other two sites, at 
least not in COS7 cells. Interestingly, as mentioned above, the crystal structure of the m152/RAE1  
complex, for which the ectodomain of His6-tagged m152 was expressed in Drosophila S2 cells, in 
fact revealed usage of both Asn61 and Asn208, but not of Asn241 [24]. In accordance with these 
structural data, double mutation N61/208Q revealed a molecular species of 36 kDa consistent with 
p36 found after de-N-glycosylation with PNGase F. In line with non-usage of Asn241, mutation of 
all three sites also revealed p36 as the most prominent band. A minor signal at lower apparent 
molecular mass turned out to be visible only upon transfection (see below) and, therefore, we did 
not pursue its identity any further. 
For analyzing any functional impact of N-glycosylation on the immune evasion function of 
m152, we constructed and characterized mutant virus mCMV-m152 3Glyc. Fidelity of triple 
mutagenesis N61Q, N208Q, and N241Q is verified by sequencing (Figure 4A), and Western blot 
analysis revealed a single molecular species of 36 kDa, that is the p36 isoform of m152  
(Figure 4B). Note that a lower molecular mass species, whose existence was suggested by 
transfection with the triple-N/Q expression plasmid (see above), is not seen in cells infected with 
the corresponding virus mCMV-m152 3Glyc. 
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Figure 2. Protein expression and glycosylation analysis of molecular species of m152 
after infection of BALB/c MEF with mCMV- m06W or - m06L compared to  
mCMV-WT. BAC (WT). MEF were infected with the indicated viruses and, from 6 h 
p.i. onward, further translation was blocked with cycloheximide (CHX) for the indicated 
times to reveal shifts to higher glycosylated isoforms over time. To increase the sensitivity 
of detection by enrichment of m152 isoforms prior to Western blot analysis, 430 g of 
total cell protein lysates were subjected to immunoprecipitation (IP) by using magnetic 
Dynabeads incubated with monoclonal antibody 152.01. (A) Molecular identification of 
m152 isoforms. Solubilized IP-precipitates were subjected to SDS-PAGE (12.5%)  
and molecular species of m152 were detected by Western blot using monoclonal 
antibody M3D10; (B) Glycosylation analysis. Prior to SDS-PAGE and Western 
blotting, bead-bound IP-precipitates were mock treated (upper panel) or were treated 
with either Endo H (centre panel) or PNGase F (lower panel) for 60 min n.i., not 
infected; no precip., IP procedure performed without a precipitating antibody.  
 
Log-linear growth curves in organs of immunocompromised mice revealed identical, exponential 
growth of mCMV-WT.BAC and mutant virus mCMV-m152 3Glyc in the spleen but suggest some 
growth attenuation of the mutant virus in lungs and liver as indicated by a somewhat prolonged 
virus doubling time in these organs (Appendix Figure A2). Although some residual innate 
immunity from NK cells remains in BALB/c mice immunocompromised by a 6–7 Gy dose of  
-irradiation [33,34], a link of growth attenuation of mCMV-m152 3Glyc to a potentially impaired 
innate immune evasion of NK cell control is considered less likely, as one would not expect this to 
apply to liver and lungs but not to the spleen where NK cells are, in principle, operative as well. 
Furthermore, the log-linear growth curves of virus mCMV- m152 that activates NK cells through 
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its failure to prevent RAE1 cell surface expression did not reveal an attenuation in liver and lungs 
(unpublished data), which excludes attenuation of mCMV-m152 3Glyc due to NK cell control; 
hence, the reason for the slight growth attenuation of mCMV-m152 3Glyc in liver and lungs 
remains to be revealed but is most likely unrelated to m152 and its glycosylation status. 
Figure 3. Mutational analysis of N-glycosylation sites in m152. Western blot analysis  
of m152 isoforms (not enriched by a preceding IP) expressed in COS7 cells transfected 
with expression plasmids carrying single or combined N/Q mutations at potential  
N-glycosylation sites. In essence, COS7 cells were transfected with 4 g of the indicated 
expression vectors. After 48 h, total protein extraction was performed and 30 g of the 
protein lysates were subjected to SDS-PAGE (12.5%) followed by Western blot 
analysis using monoclonal antibody M3D10 for detection. 
 
2.3. The 36 kDa Isoform of m152 Expressed by Virus mCMV-m152 3Glyc is Sufficient to Inhibit 
Antigen Presentation to CD8 T Cells 
One function of m152 is to retain peptide-loaded classical MHC-I molecules in the ERGIC,  
thereby reducing the number of pMHC-I complexes displayed at the cell surface for recognition by 
CD8 T cells. The presentation of pMHC-I complexes can be evaluated by quantitating the number 
of virus epitope-specific but polyclonal CD8 T cells sensitized to secrete IFN-  upon contact with 
infected cells. As shown in Figure 5 for memory CD8 T cells derived from latently infected  
BALB/c and C57BL/6 mice representing haplotypes H-2d and H-2b, respectively, recognition of 
WT virus-infected MEF was low compared to cells infected with the immune evasion gene deletion  
mutant mCMV- m152. Importantly, in this respect, the m152 N-glycosylation-deprived mutant 
virus mCMV-m152 3Glyc behaved like WT virus, with no noticeable difference in the degree of 
immune evasion. Thus, N-glycosylation of m152 is not critically involved in the immune evasion 
function of m152 in antigenic peptide presentation by classical MHC-I molecules of two different 
MHC haplotypes. 
2.4. The 36 kDa Isoform of m152 Expressed by Virus mCMV-m152 3Glyc is Sufficient to Inhibit 
Activation of NK Cells through RAE1/NKG2D Interaction 
Although it is proposed that the identified crystal structure of the complex formed between 
m152 and the MHC-I-like NKG2D ligand RAE1 is a paradigm for MHC/MHC interactions, including 
the interaction of the MHC-I-like m152 molecule with classical MHC-I [24], N-glycosylation 
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might nonetheless modulate m152/MHC-I and m152/RAE1 interactions differently and possibly 
with different functional consequences. We therefore also studied the impact of N-glycosylation of 
m152 on RAE1 cell surface expression by comparing cells infected with mCMV-m152 3Glyc 
with cells infected with WT virus, known to downmodulate cell surface RAE1, and mutant virus 
mCMV- m152, known to leave RAE1 untouched (Figure 6). Again, analysis was restricted to 
infected (arrow-marked) cells characterized by expression of the infection marker m164/gp36.5 and 
low cell surface expression of classical MHC-I that, in the case of these three viruses (and different 
to the viruses used in Figure 1), was mediated primarily by immune evasion protein m06, which is 
known to be the main regulator of overall cell surface MHC-I expression [18,26,27]. Importantly, 
m152 3Glyc, that is the m152 isoform p36, proved to be fully competent in downmodulating cell 
surface RAE1. 
Figure 4. Verification of N/Q mutations in the m152 coding sequence of recombinant 
BAC plasmid and virus m152 3Glyc. (A) Chromatograms of BAC plasmid sequencing. 
Upper panels: WT.BAC (WT) sequence regions of interest with Asn (N) at aa positions 
61, 208 and 241 (positions defined by protein start). Indicated are nucleotide positions n 
of the WT.Smith genome [35]. Lower panels: m152 3Glyc.BAC sequence regions of 
interest with Gln (Q) at the respective aa positions. Signals from nucleotides A, T, G, 
and C are shown in green, red, black, and blue, respectively; (B) Western blot analysis 
of m152 protein expression. BALB/c MEF were infected with mCMV-WT.BAC (WT) 
or mCMV-m152 3Glyc. At the indicated times p.i., proteins were extracted and 30 g 
of whole protein lysates were subjected to SDS-PAGE (12.5%) followed by Western 
blot analysis using monoclonal antibody M3D10 for detection of m152 isoforms. 
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Figure 5. Inhibition of antigen presentation to CD8 T cells by m152 independent of its  
N-glycosylation status. Polyclonal memory CD8 T cells derived from the spleens of 
latently infected BALB/c (left panel) and C57BL/6 (right panel) mice at seven months 
after intraplantar infection with mCMV-WT.BAC were used as effector cells in an  
IFN-  ELISpot assay for sensing the presentation of antigenic peptides on BALB/c and 
C57BL/6 MEF, respectively, infected with the indicated viruses either expressing all 
isoforms of m152 (WT), lacking m152 ( m152), or expressing just the unglycosylated 
p36 isoform (m152 3Glyc). n.i., uninfected MEF. Bars represent numbers of 
responding CD8 T cells, error bars represent 95% confidence intervals. 
 
Figure 6. Inhibition of RAE1 cell surface expression by m152 independent of its  
N-glycosylation status. Cytofluorometric analysis of pan-RAE1 cell surface expression 
(right column panels: abscissa; FL-4, APC fluorescence intensity) on BALB/c MEF 
infected with the indicated viruses either expressing all isoforms of m152 (WT), lacking 
m152 ( m152), or expressing just the unglycosylated p36 isoform (m152 3Glyc). To 
serve as a reference for an easier comparison, the dashed line marks the peak RAE1 
expression in absence of immune evasion molecule m152. The analysis was restricted 
to actually infected cells (left column panels: arrow-marked population) by electronic 
gating on cells expressing E-phase infection marker m164/gp36.5 (ordinate; FL-1, 
Alexa Fluor488 fluorescence intensity) and low levels of MHC-I (H-2 Kd, abscissa;  
FL-2, PE fluorescence intensity). For data display, see legend to Figure 1. 
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The effects on RAE1 cell surface expression were functionally reflected in vivo by the antiviral 
activity of NK cells in spleen and lungs in an established 3-day NK cell assay (for a review, see [6]) 
(Figure 7A). Specifically, NK cell control of virus replication, which is effective after infection 
with the m152 deletion virus mCMV- m152, was significantly alleviated in BALB/c mice infected 
with either the WT virus (p < 0.0001) or the mutant virus mCMV-m152 3Glyc (p < 0.0001). The 
somewhat lower replication of mCMV-m152 3Glyc compared to WT virus in the lungs likely  
relates to its slight growth attenuation already seen in Appendix Figure A2 for the lungs of 
immunocompromised mice (see the discussion above). This definitively does not indicate a  
reduced NKG2D ligation-specific NK cell evasion of virus mCMV-m152 3Glyc since, in contrast 
to mCMV- m152, its replication in the lungs was not increased by pan-NK cell depletion or by 
antagonistic anti-NKG2D antibody blocking the activatory RAE1/NKG2D interaction (Figure 7B). 
In conclusion, N-glycosylation of m152 does not appear to be critical—and is definitively not 
essential—for m152/RAE1 interaction that prevents NKG2D-dependent activation of NK cells. 
3. Experimental  
3.1. Cells, Viruses, and Mice  
Primary BALB/c or C57BL/6 mouse embryo fibroblasts (MEF) were cultivated in modified 
Eagle’s medium (MEM) supplemented with 10% fetal calf serum (FCS) and antibiotics. For 
transfection experiments, COS7 cells were cultivated and seeded 24 h prior to transfection in 
DMEM medium supplemented with 10% FCS and antibiotics. 
Virus derived from BAC plasmid pSM3fr [36] was used as “wild-type” virus, mCMV-WT.BAC 
(WT). Recombinant viruses mCMV- m06W and mCMV- m06L are described in references [26]  
and [27], respectively. Virus mCMV-GFP has been described by Angulo and colleagues [31]. 
BALB/c mice were bred and maintained under SPF conditions at the “Central Laboratory 
Animal Facility (CLAF)” of the University Medical Center Mainz. All experimental procedures 
were performed in compliance with the ‘International Guiding Principles for Biomedical Research 
Involving Animals’ guidelines. The experiments were approved according to German federal law 
under permission number AZ 1.5 177-07-04/051-61. 
3.2. Infection Conditions and Virus Growth Kinetics in Immunocompromised Mice 
For in vitro assays, 3rd-passage MEF were infected with the indicated viruses at a multiplicity 
of infection (MOI) of 4 by using the method of centrifugal enhancement of infectivity ([37,38] and 
references therein). 
For the in vivo NK cell assay (see below), 8–10 week-old BALB/c mice were infected  
intravenously (i.v.) with 2 × 105 PFU (non-enhanced) of mCMV-WT.BAC or the indicated  
BAC-derived recombinant viruses, all diluted in 50 L of PBS. 
Priming of mice for the generation of memory CD8 T cells was performed by intraplantar 
infection with 1 × 105 PFU (non-enhanced) of mCMV-WT.BAC. 
Log-linear in vivo virus growth curves were determined by intraplantar infection (see above) of 
BALB/c mice immunocompromised by hematoablative treatment with a single 6.5 Gy dose of  
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total-body -irradiation and subsequent monitoring of organ infection on days 2, 4, 6, 8, and 10. 
Infection of lungs and spleen was quantitated by determining virus titers (see above) in the 
respective organ homogenates. Infection of the liver was quantitated by immunohistochemistry 
(IHC) and counting of infected liver cells, which are predominantly hepatocytes, in representative 
10 mm2 areas of tissue sections, based on detection of the intranuclear immediate-early (IE) protein 
IE1-pp89/76. Virus doubling times (vDT) and their 95% confidence intervals (CI) were calculated 
from the slopes of regression lines determined by linear regression analysis with the statistics 
software Mathematica [39]. All methods were described in greater detail previously [38]. 
Figure 7. NK-cell evasion by m152 independent of its N-glycosylation status.  
(A) Modulation of the in vivo NK cell control of virus replication by m152 expression 
in spleen (left panel) and lungs (right panel) of mice infected with viruses expressing 
all isoforms of m152 (WT, black-filled circles), lacking m152 ( m152, open circles), or 
expressing just the p36 isoform (m152 3Glyc, gray-filled circles); (B) Replication of 
mCMV-m152 3Glyc in the lungs is not influenced by NK cells. Left panel: Growth 
attenuation of virus mCMV- m152 dependent upon activation of NK cells through 
ligation of the activatory receptor NKG2D. Right panel: NK cell-independent growth of 
mCMV-m152 3Glyc. The day-3 NK cell assay was performed with BALB/c mice left 
undepleted (control), BALB/c mice depleted of pan-NK cells with anti-asialo GM-1 
antibodies administered 24 h before infection, or BALB/c mice in which ligation of 
NKG2D on NK cells was blocked by antagonistic anti-NKG2D antibodies administered 
6 h before infection. Throughout, symbols represent virus titers (determined as  
plaque-forming units, PFU, by virus plaque assay performed under conditions of 
centrifugal enhancement of infectivity) for individual BALB/c mice infected i.v. three 
days before with 2 × 105 PFU of the indicated viruses. Median values are marked by 
short horizontal bars. The dotted lines indicate the detection limit. The statistical 
significance of differences was tested based on log-transformed ordinate values by the 
unpaired, two-tailed Student’s t test with Welch’s correction not assuming equal 
variance. Differences are considered non-significant for p > 0.05, significant for  
p < 0.01, and highly significant for p < 0.001. 
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3.3. In Vivo NK Cell Assays 
On Day 3 after i.v. infection (see Section 3.2), virus titers in homogenates of spleen and lungs 
were determined under conditions of centrifugal enhancement of infectivity. The involvement of 
NK cells was tested by NK-cell depletion with polyclonal rabbit antibody directed against mouse 
asialo GM1 (20 L in 500 L of PBS i.v., WAKO Chemicals, Richmond, VA, USA) administered 
on day-1, ca. 24 h before infection. For the specific blockade of NK-cell activation through 
RAE1/NKG2D ligation, hamster monoclonal antibody (clone C7) directed against mouse  
NKG2D [40] was administered i.v. (300 g in 500 L of PBS) 6 h before infection. 
3.4. ELISpot Analysis 
An IFN- -based enzyme-linked immunospot (ELISpot) assay was performed to quantify 
responding memory CD8 T cells after stimulation with infected MEF. Polyclonal memory CD8 T 
cells were immunomagnetically purified from spleen cell populations of latently infected mice at  
7 months after primary intraplantar infection with mCMV-WT.BAC. The assay has been described 
in detail previously ([41] and references therein). In brief, graded numbers of CD8 T cells were 
incubated in triplicate cultures for 18 h with 1 × 105 MEF infected with an MOI of 4 (centrifugal 
infection) for 90 min prior to the cocultivation during which infection proceeds. Frequencies of 
IFN- -secreting cells and the corresponding 95% confidence limits were calculated from the spot 
counts by intercept-free linear regression analysis with the statistics software Mathematica [39]. 
3.5. Cytofluorometric Analysis 
At 16 h p.i. (MOI 4, with centrifugal enhancement), BALB/c MEF were stained for cell surface 
MHC-I with PE-conjugated monoclonal antibody mouse anti-mouse H-2 Kd (FL-2, clone SF1-1.1; 
BD Pharmingen, catalog no. 553566, Heidelberg, Germany), for cell surface RAE1 with APC-labeled 
monoclonal antibody rat anti-mouse pan-RAE1 (FL-4, clone 186107; R&D Systems, catalog no. 
FAB17582A; Wiesbaden, Germany), and for intracellular expression of m164/gp36.5 indirectly 
with a rabbit anti-m164 antiserum [30] and Alexa Fluor488-conjugated goat-anti-rabbit IgG (FL-1, 
Life technologies, catalog no. A11008; Darmstadt, Germany). GFP fluorescence was measured in 
fluorescence channel 1 (FL-1). Analysis was performed with a Beckman Coulter FC500 
cytofluorometer and CXP software [42]. 
3.6. Construction of Expression Plasmids 
To generate expression plasmids, PCR was performed using mCMV-WT.BAC genomic DNA 
with oligonucleotides m152-HpaI_for/rev (Appendix Table A1) amplifying the full length 
ORFm152 with the following protocol parameters: 5 min at 95 °C; 18 cycles of 30 s at 94 °C, 90 s 
at 62 °C, and 2 min at 68 °C; 12 cycles of 30 s at 94 °C, 2 min at 45 °C and 2 min at 68 °C; 
followed by final extension for 10 min at 68 °C. The PCR product was subcloned into vector 
pcDNA3.1 within the EcoR I restriction site. To insert nucleotide exchanges CAT-GCG at nt 
positions 211.131–211.129, 210.690–210.688, and 210.591–210.589, the construct was subjected 
to site-directed mutagenesis using the Quick Change II Site-Directed Mutagenesis Kit (Agilent, 
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catalog No. 200524, Böblingen, Germany) with the oligonucleotide pairs m152_N61Q_for/_rev, 
m152_N208Q_for/_rev, and m152_N241Q_for/rev (Appendix Table 1), respectively. The 
mutagenesis resulted in constructs pcDNA-m152N61Q, pcDNA-m152N208Q, and pcDNA-
m152N241Q. Plasmid pcDNA-m152N61Q was subjected to a second round of mutagenesis using 
the respective oligonucleotides resulting in the constructs pcDNA-m152N61/208Q and  
pcDNA-m152N61/241Q. Plasmid pcDNA-m152N208Q was used as template for the construction 
of pcDNA-m152N208/241Q, and, in a third round, mutagenesis of pcDNA-m152N61/208Q 
resulted in the generation of pcDNA-m152N61/208/241Q (m152 3Glyc). The successful 
replacement was confirmed by sequencing (GATC; Konstanz, Germany). 
3.7. Generation of Recombinant Viruses 
To generate recombinant virus mCMV-m152 3Glyc, BAC mutagenesis was performed. In a 
first step, mCMV-WT.BAC DNA was used as template for PCR with the oligonucleotides 
m152_BAC-for/rev (Appendix Table A1) to amplify ORFm152 with the following protocol 
parameters: 5 min at 95 °C; 35 cycles of 15 s at 94 °C, 1 min at 55 °C and 7 min 40 s at 68 °C; 
followed by final extension for 10 min at 72 °C. After Sac I/Xma I restriction, the product was 
subcloned into pBluescript, resulting in pB-m152_flank. The m152_208/241 fragment from 
pcDNA-m152N208/241Q (see above) was inserted into pB-m152_flank by Nhe I/Sph I subcloning. 
The thus modified m152 sequence was inserted into the shuttle vector pST76K_SR by Sac I/Xma I 
restriction, resulting in pST76K-m152_N208/241Q_flank. This construct was used for allelic exchange 
of ORFm152 in BAC plasmid pSM3fr as described [43], resulting in BAC-m152_N208/241.  
For replacement of the third glycosylation site, BAC-m152_N208/241 DNA was introduced into 
E. coli GS1783 and recombination was performed by Red-mediated markerless DNA recombination 
as described by Tischer and colleagues [44]. In brief, oligonucleotides pEPKan-S_m152N61Q_for/rev 
(Appendix Table A1) were used for a PCR with plasmid pEP-kanS as a template. The resulting 
products were transformed into GS1783 cells carrying BAC-m152_N208/241Q. After Red-
recombination, arabinose-induced I-SceI expression, and a second round of Red-recombination, 
m152_N61/208/241Q (m152 3Glyc) BAC DNA was purified and successful mutagenesis was 
confirmed by sequencing (GATC; Konstanz, Germany). 
The generation of recombinant BAC plasmid pSM3fr_ m152 was performed in E. coli strain 
SW105 as described by Warming and colleagues [45] by PCR-based deletion of ORFm152 
between the nucleotides 211,378 und 210,245 [35]. For this, a kanR cassette flanked by 
homologous viral sequences was amplified from plasmid pKD46 using oligonucleotides 
m152_del_for/rev (Appendix Table A1) and inserted into the viral genome by ET-recombination. 
The kanR cassette was subsequently excised by FLP recombinase [45]. 
Virus reconstitution and purification of a high titer virus stock were performed as described [38]. 
3.8. Protein Extraction and Analysis 
MEF were seeded in 10 cm cell culture dishes and infected with an MOI of 4 under conditions 
of centrifugal enhancement of infectivity. At defined times p.i., cells were washed with ice-cold 
PBS and scraped-off. After centrifugation (5 min, 3,000 rpm, 4 °C), the cells in the pellet were 
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lysed for 15 min on ice in 200 L Lysis Buffer/dish (0.2 M NaCl, 1.5 mM MgCl, 4 mM EDTA,  
4 mM EGTA, 1% Triton-X100, 20 mM HEPES; with complete proteinase inhibitor (diluted 1:25; 
Roche, catalog No.11697498001) and 1mM DTT added shortly before use). After centrifugation 
(10 min, 14,000 rpm, 4 °C), supernatants were collected and the amount of protein was determined 
by BCA-Assay (Thermo Scientific, catalog No. 23225, Dreieich, Germany). 30 g of total protein 
was separated on an SDS-PAGE followed by Western blot analysis. Isoforms of m152 were 
detected with monoclonal antibody M3D10 (1:250) [21]. 
3.9. Transfection 
5 × 105 COS7 cells per 10-cm dish were seeded and 4 g DNA was transfected with Polyfect 
(Qiagen, catalog No. 301105, Hilden, Germany) following the manufacturer’s instructions. 48 h 
later, cells were harvested and total protein was extracted. 30 g of protein lysates were separated 
on a 12.5% SDS-PAGE followed by Western Blot analysis. 
3.10. Immunoprecipitation 
MEF were infected at an MOI of 4 (centrifugal enhancement) and translation was blocked by 
cycloheximide (CHX) (100 g/mL) from 6 h p.i. onward. At the indicated times after addition of 
CHX, protein extraction was performed and 430 g of protein lysates were incubated overnight 
with anti-m152 monoclonal antibody (clone 152.01; 1:100)-pretreated Dynabeads (Life technologies, 
catalog no. 11201D, Darmstadt, Germany). Unbound proteins were removed by repetitive washing 
with PBS. Precipitated m152 protein isoforms were identified by SDS-PAGE separation and 
Western blot analysis.  
3.11. Deglycosylation with Endo H and PNGase F 
Immunoprecipitated, bead-bound m152 isoforms were mock treated or incubated with either 
750U EndoH (NEB, catalog no. P0702S, Frankfurt, Germany) or 1000U PNGase F (NEB, catalog 
No. P0704S, Frankfurt, Germany) for 60 min at 37 °C, followed by SDS-PAGE separation and 
Western blot analysis. 
4. Conclusions  
The recently established crystal structure of the m152/RAE1  complex has revealed two single  
N-acetyl glucosamine residues at Asn61 and Asn208 of m152 [24]. As these two positions are 
distant from the identified m152/RAE1  interface, Wang and colleagues proposed that these  
N-glycosylations are unlikely to affect that interaction. Here we show functional data confirming 
this view experimentally. In a transfection system with single mutations of the three potential  
N-glycosylation sites of m152, namely Asn61, Asn208, and Asn241, evidence of usage of the 
respective site was provided only for Asn61 and Asn208, precisely the two sites actually found to 
be N-glycosylated in the crystallized m152/RAE1  complexes. Lack of m152 N-glycosylation in an 
N61Q-N208Q-(N241Q) triple mutated virus mCMV-m152 3Glyc did not prevent downmodulation 
of RAE1 from the surface of infected cells, indicating that N-glycosylation at Asn61 and Asn208 is 
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not needed for m152/RAE1  complex formation nor does it alter the complex in a mode relevant 
for its function in NK cell evasion. Interestingly, the same also applied to the interaction between 
m152 and classical MHC-I in the inhibition of pMHC-I cell surface trafficking for antigen 
presentation to CD8 T cells. This supports the title notion by Wang and colleagues that the 
structural basis of m152 interaction with RAE1  may reveal a paradigm for MHC/MHC interaction 
in immune evasion [24]. 
In addition, these data have shown that absence of the higher glycosylated isoform gp48 of 
m152 has no functional consequence in immune evasion and thus cannot explain the impaired 
immune evasion capacity of virus mutant mCMV- m06W compared to mCMV- m06L. Since the 
Asn61/208 dually N-glycosylated isoform gp40 is Endo H-resistant, it must have reached the Golgi 
apparatus, whereas pMHC-I complexes and RAE1 stick in the ERGIC/cis-Golgi. Unless we 
assume retrograde trafficking of gp40 back into the ER, for which there exists no evidence and for 
which there is no rationale as glycosylation is not needed for function, the Endo H-resistant isoform 
gp40 is unlikely the molecule that mediates immune evasion by interacting with and catalyzing the 
retention of pMHC-I and RAE1. Since N-glycosylation takes place in the ER, it remains open to 
question if nascent p36 interacts with pMHC-I and RAE-1 before or after the glycosylations at 
Asn61 and Asn208. In either case, our data have revealed that unglycosylated p36 can interact and 
that the two N-glycosylations are not required for the innate and adaptive immune evasion 
functions of m152. 
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Appendices 
Figure A1. Reporter virus revealing cells non-permissive for the viral replicative cycle 
within infected mouse embryo fibroblast cell cultures. Cytofluorometric analysis of cell 
surface MHC-I (H-2 Kd) expression (abscissa; FL-2, PE fluorescence intensity) and 
expression of the fluorescent reporter protein GFP (ordinate; FL-1) in BALB/c MEF 
infected with reporter virus mCMV-GFP. Data are displayed as a density plot  
(color-coded with red and blue representing highest and lowest density, respectively). 
The red arrows point to three prominent cell populations. Population 1: Cells not 
expressing the GFP reporter under control of the human CMV promoter-enhancer but 
expressing a high level of cell surface MHC-I, which indicates lack of immune evasion 
gene expression. Population 2: Infected cells expressing high levels of reporter protein 
GFP but low levels of MHC-1 due to the action of the immune evasion proteins. 
Population 3: Putatively infected cells, in which GFP expression became silenced  




Figure A2. Comparative growth kinetics of mCMV-WT.BAC and mCMV-m152 3Glyc 
in immunocompromised mice. Prior to intraplantar infection with 1 × 105 PFU of the 
viruses under comparison, BALB/c mice were immunocompromised by hematoablative 
total-body -irradiation with a single dose of 6.5 Gy. At the indicated times p.i., virus 
multiplication was quantitated in host organs. (A) Virus titers (plaque forming units, 
PFU) in spleen (upper two panels) and lungs (lower two panels), determined by virus 
plaque assay under conditions of centrifugal enhancement of infectivity; (B) Infection 
of the liver quantitated by counting the number of infected liver cells, which are mostly 
hepatocytes, stained by IHC specific for intranuclear IE1 protein. Symbols represent 
individual mice. Median values are marked by short horizontal bars. Virus doubling 
times in hours (vDT, with 95% confidence intervals in parentheses) were calculated 
from the slopes of log-linear regression lines determined by using the statistics software 
Mathematica [39]. Note that slopes, unlike the absolute ordinate values, reflect virus 
growth within the respective tissues/organs, independent of possible differences in the 
spread to these organs and not influenced by unintentional systematic error or statistical 
variance in inoculum virus doses. 
 
143 
Table A1. Oligonucleotides used in this study; nucleotides inserting aa substitutions are 
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Abstract: Viral CD8 T-cell epitopes, represented by viral peptides bound to major 
histocompatibility complex class-I (MHC-I) glycoproteins, are often identified by 
“reverse immunology”, a strategy not requiring biochemical and structural knowledge 
of the actual viral protein from which they are derived by antigen processing. Instead, 
bioinformatic algorithms predicting the probability of C-terminal cleavage in the 
proteasome, as well as binding affinity to the presenting MHC-I molecules, are applied 
to amino acid sequences deduced from predicted open reading frames (ORFs) based on 
the genomic sequence. If the protein corresponding to an antigenic ORF is known, it is 
usually inferred that the kinetic class of the protein also defines the phase in the viral 
replicative cycle during which the respective antigenic peptide is presented for 
recognition by CD8 T cells. We have previously identified a nonapeptide from the 
predicted ORFm164 of murine cytomegalovirus that is presented by the MHC-I 
allomorph H-2 Dd and that is immunodominant in BALB/c (H-2d haplotype) mice. 
Surprisingly, although the ORFm164 protein gp36.5 is expressed as an Early (E) phase 
protein, the m164 epitope is presented already during the Immediate Early (IE) phase, 
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based on the expression of an upstream mRNA starting within ORFm167 and 
encompassing ORFm164. 
Keywords: antigenic peptides; antigen presentation; CD8 T cell epitope; gene 
expression; immediate-early protein; murine CMV ORF m164; open reading frame; 
RACE mapping; reverse immunology; transcription start site; translation start site  
 
1. Introduction  
In listings of antigenic peptides identified in viral open reading frames (ORFs) by “reverse 
immunology” [1–3], annotated viral proteins are usually co-listed under the implicit inference that 
the antigenic peptides are derived by antigen processing when the respective proteins are synthesized, 
and, thus, belong to the same kinetic class in the cascade regulation of viral gene expression. 
Although such a “canonical” expression and presentation of an antigenic peptide as a peptide-MHC 
(pMHC) complex almost certainly applies, because, as far as we are aware of, no viral protein or 
even self protein is exempt from becoming degraded in one of the antigen processing pathways, the 
kinetic class assignment of an antigenic peptide and its corresponding protein can nonetheless 
differ due to “noncanonical” entry into a processing pathway. One mechanism of noncanonical 
antigen deployment and pre-immediate early presentation is delivery of virion structural proteins 
during the viral entry process [4–6], whereas canonical expression and presentation would occur 
not before the late (L) phase, close to the time of virion assembly and release and, thus, possibly 
too late for antiviral immune protection. A second virion entry-associated mechanism could be the 
delivery of viral RNA enclosed in virions [7], leading to pre-immediate early gene expression 
independent from the canonical kinetic class of the respective viral RNA. Such mechanisms can be 
of functional relevance for cell surface presentation of antigenic peptides prior to the expression of 
viral immune evasion proteins that would otherwise interfere [8–10]. Here, we report on an 
example for a third mechanism of noncanonical antigenic peptide presentation. 
We have previously identified an antigenic peptide in ORFm164 of murine cytomegalovirus 
(mCMV) by employing the strategy of “reverse immunology” [11]. CD8 T cells derived from 
infected BALB/c (haplotype H-2d) mice were found to respond to MHC (H-2 Dd) gene-transfected 
L cells (fibroblasts of the unrelated haplotype H-2k) exogenously loaded with high performance 
liquid chromatography (HPLC)-separated naturally processed peptides derived from mCMV-
infected BALB/c mouse embryo fibroblasts (MEF). This was the first indication of the existence of 
mCMV peptide(s) presented by MHC-I Dd, as the only antigenic mCMV peptide known at that time 
was the Immediate Early (IE) peptide IE1 presented by MHC-I Ld [12]. Algorithms predicting H-2 Dd 
binding nonapeptides were applied to the viral genome-wide coding sequence and predicted a panel 
of high-scoring peptides of which a peptide with the amino acid sequence AGPPRYSRI encoded by 
ORFm164 was functionally verified by the response of CD8 T cells. Along with the IE1 epitope and 
with more recently identified epitopes from ORFs M105 and m145 [13], the m164 epitope proved to 
be immunodominant with respect to the frequency of CD8 T cells responding to it during the 
immune response to acute infection. In addition to the IE1 epitope, which is the prototype of an epitope 
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that induces expansion of the memory CD8 T-cell pool at extralymphoid sites of latent mCMV 
infection [14], a phenomenon known today as “memory inflation” ([15], reviewed in [16–18]), the 
m164 epitope turned out to be the second inducer of memory inflation in the H-2d haplotype, a 
property that it shares with three epitopes in the H-2b haplotype [19] and that is thought to indicate 
episodes of limited viral gene expression during latency (for recent reviews, see [20,21]). As the 
ORFm164 protein, a non-essential ER-resident type-I glycoprotein of 36.5 kDa, is expressed as an 
Early (E) phase protein [22], it was assumed that the m164 peptide is presented not until the E 
phase. Interestingly, cytolytic T lymphocytes (CD8+ CTL) of an m164-specific CTL line  
(m164-CTLL) recognized infected fibroblasts in the E phase despite all immune evasion molecules 
being expressed, a finding that was explained by high numbers of pMHC-I (m164 peptide-Dd) 
complexes exhausting the inhibitory capacity of the immune evasion proteins, thus allowing the 
escape of some of the pMHC-I complexes to the cell surface sufficient for recognition [23]. 
Importantly, in an experimental approach of CMV immunotherapy (for reviews, see [24,25]), 
m164-CTLL proved to protect against multiple organ CMV disease upon adoptive cell transfer into 
infected, immunocompromised recipient mice [11]. 
Here, we report the astounding finding that this “E phase peptide”, as well as a transgenic 
peptide replacing it in a recombinant mCMV, are recognized by CTLL of the respective cognate 
specificities on infected cells metabolically arrested in the IE phase, thus representing a case of 
“noncanonical presentation”. This presentation is not explained by virion entry-dependent delivery 
of antigenic virion protein or epitope-encoding virion-associated RNA, but is based on IE phase 
expression of an unrelated mRNA originating in ORFm167 and encompassing the epitope-encoding 
sequence in ORFm164. These data call for caution in assigning epitope presentation to a kinetic 
phase based just on the kinetic class to which the corresponding viral protein belongs. 
2. Results and Discussion 
2.1. Antigenic Sequences Encoded by the Predicted ORFm164 Are Presented on Infected Cells 
Metabolically Arrested in the IE Phase as Well as in the E Phase 
MEFs were infected under established conditions of IE phase or E phase arrest (Figure 1A). For 
IE phase arrest, infection was performed in the presence of the reversible protein synthesis inhibitor 
cycloheximide (CH) that becomes replaced after 3 h with the irreversible transcription inhibitor 
actinomycin D (ActD). This allows for selective and enhanced transcription from IE genes followed 
by IE protein synthesis, and prevents transactivation of E gene transcription. E phase arrest is achieved 
by 16 h of infection in the continuous presence of the DNA synthesis inhibitor phosphonoacetic 
acid (PAA) preventing, by definition, the transition from the E phase to the L phase. The mutation 
strategy for manipulating antigenicity and immunogenicity of ORFm164 (reviewed in [26]) is 
sketched in Figure 1B. In a first approach, MEF were infected either with BAC-cloned wildtype 
(WT) virus mCMV-WT.BAC coding for the authentic ORFm164 epitope AGPPRYSRI or with a 
mutant virus mCMV-m164Ala, in which the C-terminal amino acid isoleucine of the antigenic 
sequence is genetically replaced with alanine. This strategy prevents C-terminal proteasomal cleavage 
of the antigenic peptide in the first place. In addition, it reduces binding affinity to the presenting 
MHC-I molecule Dd in case that inefficient, residual proteasomal cleavage might still generate 
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some AGPPRYSRA peptide. We have previously introduced C-terminal residue mutagenesis as an 
ideal control for testing epitope specificity of the CD8 T cell response [13,27–30], leaving other 
parameters of infection bona fide untouched. In a second approach, referred to as “orthotopic 
peptide swap”, the authentic antigenic peptide AGPPRYSRI was replaced at precisely the same  
site with the ovalbumin-derived model peptide sequence SIINFEKL in recombinant virus  
mCMV-SIINFEKL [29]. This peptide swap is associated with a switch in the presenting MHC-I 
molecule, namely from H-2 Dd to Kb. For serving as an epitope specificity control, recombinant 
virus mCMV-SIINFEKA was generated based on the rationale already explained above [29].  
Figure 1. Presentation of intrinsic and transgenic m164 peptides in the IE and E phase.  
(A) Scheme of the experimental protocol for selective arrest of viral gene expression in 
infected fibroblasts by metabolic inhibitors. For arrest in the IE phase, MEF are infected 
under conditions of centrifugal enhancement, resulting in an MOI of 4, in the presence of 
cycloheximide (CH, 100 g/mL) that becomes replaced at 3 h post-infection (p.i.) with 
actinomycin D (ActD, 5 g/mL). For arrest in the E phase, MEF are infected likewise for 
16 h in the continuous presence of PAA (250 g/mL). At 5 h and 16 h p.i., respectively, 
these cells are used in an IFN- -based ELISpot assay as stimulator cells for CTL from CTL 
lines (CTLL) of defined antigenic peptide specificities; (B) Scheme of the mutagenesis 
rationale for modification of m164 protein antigenicity and immunogenicity in recombinant 
viruses. Shown is an overview map of the mCMV genomic region encompassing ORFs 
m163-m165. ORFs are symbolized by boxes, with the blue box representing ORFm164 
encoding protein gp36.5 that comprises the intrinsic antigenic peptide AGPPRYSRI, which 
is presented by the MHC-I molecule H-2 Dd. Hatched boxes indicate overlaps with 
neighboring ORFs. Amino acid sequences of the intrinsic and the replacing transgenic CD8 
T-cell epitope, which is presented by H-2 Kb, are shown in blue and green one-letter code, 
respectively. The C-terminal residue mutation to Ala is highlighted by red capital letter. 
Epitope-flanking residues are shown in smaller font; (C) Frequencies of cells of the 
indicated CTLL that respond in an IFN- -based ELISpot assay to sensitization by MEF of 
the presenting MHC haplotype infected with the indicated viruses under the indicated 
conditions of gene expression phase arrest. (Left two panels) Bars represent most probable 
numbers determined by intercept-free linear regression analysis based on triplicate assay 
cultures and graded numbers of CTL seeded; error bars indicate the 95% confidence 
intervals. n.i., no infection (uninfected MEF); ActD, MEF infected for 5 h in the presence 
of ActD preventing transcription from the very beginning; UV-IE, IE conditions applied to 
cells mock-infected with virus inactivated by UV-light (254 nm, ca. 4500 J/m2). IE and E, 
MEF infection under conditions of IE and E phase arrest, respectively, as explained above. 
(Right panel) Bars represent median values of absolute spot counts from triplicate assay 
cultures for CTL seeded in graded numbers as indicated. Variance bars show the range.  
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Figure 1. Cont. 
 
In the experiment to the first approach (Figure 1C, far left panel) m164-CTLL recognized WT 
virus-infected target cells in the E phase, as it was to be expected. Surprisingly, however, a 
significant proportion of the m164-CTL, supposedly those with the highest functional avidity [25,31], 
also recognized target cells arrested in the IE phase. Recognition in both the IE and the E phase 
was abolished after infection with the epitope deletion virus mCMV-m164Ala, thereby excluding 
the theoretical possibility that inhibitor treatment of infected target cells might have induced T cell 
receptor (TCR)-independent, non-epitope specific signaling that activates CTLL. Known noncanonical 
modes of epitope presentation were also ruled out: (i) infection in the presence of inhibitor ActD 
prevented presentation of the m164 epitope. This revealed the requirement for de novo transcription 
and thus excluded a noticeable contribution of virion-associated RNA, and (ii) UV-inactivated 
virus did not lead to the presentation of the m164 epitope, which was not unexpected in light of the 
fact that no ORFm164-encoded protein was detected in the virion proteome [32]. These findings were 
corroborated by the experiment to the second approach (Figure 1C, center and far right panels). 
Although the response of SIINFEKL-specific CTL to the Kb-presented epitope was lower 
compared to recognition of the authentic m164 peptide by m164-specific CTL, which is not 
unusual as processing rates and MHC-I binding affinity differ between different epitopes, the key 
message of presentation in both the IE and E phase was reproduced, and epitope-specificity was 
confirmed for both phases by missing recognition of cells infected with mCMV-SIINFEKA. 
In conclusion, antigenic peptides naturally present or experimentally placed in the sequence of 
the E phase protein m164/gp36.5 are noncanonically expressed and presented in the IE phase, an 
obvious paradox that needed to be resolved. 
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2.2. Detection of Distinct mRNA Species in the IE and E Phases by m164  
Sequence-Specific Hybridization  
As virion proteins and virion-associated RNA, apparently, did not account for presentation of 
m164 peptide in the IE phase (recall Figure 1C, left panel), and as recognition by CD8 T cells was 
clearly epitope-specific (recall Figure 1C, all panels), there must exist an IE mRNA encoding a 
protein that encompasses the antigenic sequence. Northern blot analysis (Figure 2), using a  
DIG-labeled m164-specific single-strand RNA-probe for hybridization with total RNA, revealed 
only an E phase RNA of slightly more than 2 kb in size present 3 h after infection in the absence of 
protein synthesis inhibition by CH but absent in the presence of CH. When sensitivity was 
increased by using poly(A)+ RNA for hybridization with the riboprobe, this mRNA species was far 
more prominent but remained absent in cells infected in the presence of CH, thus identifying it as a 
true E phase transcript. The nature of a low-abundance CH-sensitive E phase transcript of ca. 4 kb, 
which is present only in infected cells, was not pursued further as our interest was focused on  
the existence of an IE RNA. Conversely, however, this sensitive analysis indeed revealed an 
mRNA species of >5 kb that became visible only after infection in the presence of CH, thus 
identifying it as an IE phase transcript. The blot did not reveal splice products that would be 
expected to be more stable and, thus, more prominent than a long splice precursor. In conclusion, 
m164 sequence is indeed present in distinct mRNA species of ca. 2 kb and >5 kb expressed in the 
E and the IE phase, respectively. 
Figure 2. Identification of m164 transcripts by Northern blot analysis. Total cellular 
RNA or poly(A)+ RNA were isolated at 3 h p.i. from MEF infected in the presence (+) or 
absence (–) of CH (100 g/mL) and were analyzed by Northern blotting using a  
DIG-labeled m164-specific RNA probe. The arrow highlights a specific band of >5 kb 
representing an IE mRNA.  
 
2.3. Mapping of the m164 E Phase Start Sites of Transcription and Translation 
It was obvious to predict that the ca. 2 kb mRNA that is abundantly expressed in the E phase 
codes for the previously identified E phase protein m164/gp36.5 [22], which is considerably 
smaller than the gp48.6 (includes 2 kDa from the identified single N-glycosylation [22]) predicted 
for a protein starting at the first of three AUG (Met1, Met27, and Met91) translation start sites in 
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the predicted ORFm164 [33,34]. In fact, relative to Met1, the N-terminus of the mature protein was 
definitively identified by mass spectrometric sequence analysis to be Ser108. We, therefore, 
originally speculated that the translation start site might be the third AUG (Met91). Accordingly, we 
proposed a 17-aa signal peptide of which existence was bioinformatically supported by the SignalP 
3.0 algorithm [35] predicting signal peptide peptidase cleavage between Ala107 and Ser108 [22]. 
With the initial aim to verify this assumption, mutational analysis was performed by transfection 
of COS7 cells with a complete set of expression plasmids comprising all possible combinations of 
ATG to GCG mutations of the three proposed start codons (Figure 3A). This analysis revealed that 
all three AUG start codons can be used, at least upon transfection of COS7 cells, when usage is 
enforced by absence of competing start codons. Unexpectedly, however, the different-lengths 
primary translation products were all co- or posttranslationally processed to yield the 36.5 kDa mature 
protein (Figure 3B), which also showed the typical ER and nuclear rim/outer nuclear membrane 
localization (Figure 3C) described for protein m164/gp36.5 previously [22]. Translation was prevented 
only by mutation of all three ATG in expression plasmid ATG (Figure 3B), thus showing that no start 
codon other than AUG is used. 
Figure 3. Mapping of AUG start codon usage by comprehensive mutational analysis 
through cell transfection with a complete set of expression plasmids. (A) Overview 
scheme of combinatorial ATG to GCG mutations for the three ATG codons present in 
the predicted ORFm164; (B) Western blot analysis of gene products of mutated m164 
ORFs. COS7 cells were transfected with 4 g of expression plasmids carrying single or 
combined ATG to GCG mutations at potential start sites. After 48 h, total protein was 
extracted and 30 g of the protein lysates were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (12.5%) followed by Western blot 
analysis for detection of m164 protein species by using polyclonal antibody directed 
against a C-terminal peptide; (C) m164/gp36.5 localization in the ER, independent of 
usage of the 1st, 2nd, or 3rd AUG as start codon. COS7 cells were seeded on glass 
coverslips and were transfected with 0.4 g of pcDNA_m164_ATG_1/2/3, _1, _2, or _3. 
At 24 h after transfection, cells were fixed and protein m164/gp36.5 was detected with 
the polyclonal antibody. DNA was stained by Hoechst-dye.  
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This analysis, however, did not reveal the start AUG that is actually used when any of the three 
can be chosen, although increased signal strengths with expression plasmids containing ATG_1, 
alone or in combinations, indicated preferential usage of the first AUG (Figure 3B). Translation 
start at the first AUG is also strongly suggested by ribosome profiling, showing reads beginning at 
position -12 relative to the AUG, which is the correct distance from a start site [36,37]. To finally 
settle this question under the more real conditions of infection, we constructed recombinant virus 
mCMV-m164_ ATG_1, with only the first start codon mutated, to infect MEF. As revealed by 
Western blot analysis, this mutation abolished expression of gp36.5 (Figure 4A). 
Figure 4. (A) Verification of the 1st AUG as start codon. MEF were infected with  
mCMV-WT.BAC or mCMV-m164_ ATG_1, and at 6 h p.i. proteins were extracted and  
30 g of whole protein lysates were subjected to SDS-PAGE (12.5%) followed by 
Western blot analysis detecting protein m164/gp36.5; (B) Verification of the E phase 
mRNA encoding the ORFm164 product. The in vitro transcribed RNAs (see Appendix 
Figure A1) were used as templates for in vitro translation. Shown is the autoradiograph 
of [35S]-labeled translation products separated by SDS-PAGE. Lane 1: proteins 
translated from the RACEm164 in vitro transcript. Lane 2: proteins translated from the 
ORFm164 in vitro transcript. Lane 3: BMV (Brome Mosaic Virus) RNA control 
supplied in the Ambion MEGAscript SP6 kit (Life Technologies, Catalog No. 
AM1330, Darmstadt, Germany); (C) Map of the m164 mRNA and its localization as 
revealed by 5'- and 3'-RACE shown in Appendix Figure A1. 
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Having, thus confirmed ORFm164, the slightly more than 2 kb length of the predominant E 
phase mRNA exceeded the calculated 1281 b of the ORF, which is difficult to explain just by the 
poly(A)+ tail and rather suggests the existence of UTRs. To address this issue, rapid amplification 
of cDNA ends (RACE) analysis was performed and in fact identified 3' and 5' UTRs of 537 bp and 
186 bp, respectively (Appendix Figure A1). This result defined a length of the mRNA of 2,004 bp 
(polyadenylated tail not included), which is compatible with the length revealed by Northern blot 
analysis of poly(A)+ E phase m164 transcripts (recall Figure 2). Finally, in vitro transcribed ORF 
RNA as well as RACE RNA (Appendix Figure A1C) were translated in vitro and both resulted in a 
dominant product of ca. 47 kDa (Figure 4B) in accordance with the calculated molecular mass of 
the unprocessed 46.6 kDa primary translation product starting at Met1 (see above). Thus, in 
conclusion, the ca. 2 kb E phase poly(A)+ RNA is, in fact, the one that codes for the E phase 
protein m164/gp36.5. To sum these results up, Figure 4C shows a revised map of m164 and its 
neighboring genes with which it largely overlaps.  
2.4. Confirmation of an Upstream IE Phase RNA Encompassing the Complete m164 E Phase  
RNA Sequence 
What, finally, is the >5 kb IE phase poly(A)+ RNA detected with the m164 sequence-specific 
riboprobe in the Northern blot (recall Figure 2)? RACE mapping of the complete m164 E phase 
transcript allowed us to design RT-PCRs with one primer placed at the 3' terminus and a second 
primer placed either to the left (RT-PCR I) or to the right (RT-PCR II) of the 5' terminus, that is 
inside or outside of the E phase transcript, respectively (for the strategy, see Figure 5A). 
With total RNA from infected cells, the inside 5'-end primer resulted in the expected amplificate 
of 2,001 bp in RT-PCR I, corresponding to the RACE-mapped E phase mRNA. Notably, in RT-
PCR II, the outside 5'-end primer also gave an amplificate, thus indicating the existence of an RNA 
that initiates upstream of the 5' end and includes the complete m164 E phase transcript sequence 
(Figure 5B). As RT-PCR I detects both transcripts, the signal was only in part sensitive to CH 
treatment of the infected cells, with the remaining signal coming from IE RNA. In contrast, an 
enhanced signal seen by RT-PCR II after CH treatment shows that it results from IE RNA. 
Upstream “walking” of the 5'-end primer (Appendix Figure A2) located the start site of this IE 
mRNA between nucleotides n226,549 and n226,903 within ORFm167 (for a summarizing map, see 
Figure 6), resulting in a length of >5 kb compatible with the length seen for the IE phase poly(A)+ 
RNA detected by the Northern blot analysis (recall Figure 2). As this RNA ends before the start of 
the predicted ORFm167, it cannot be the regular m167 transcript, whereas ORFm166 [38] is 
completely included. Notably, in accordance with IE gene expression upstream of m164, by using 
an mCMV ORF microarray, the group of T.E. Shenk has defined a cluster of IE genes within 
restriction fragment Hind IIIE, namely genes m166-m169 [39–41]. 
As the full-length m166 mRNA with a putative 5' UTR has not yet been mapped, it might 
overlap with ORFm167 so that the transcription start site of m166 mRNA remains a candidate. 
Alternatively, the long m164 epitope sequence-encompassing IE phase mRNA might represent a 
new transcript using an alternative start site within ORFm167. Theoretically, as no in-frame 
translation start sites are present upstream of ORFm164, the IE mRNA might represent a 
polycistronic transcript using the ORFm164 start site, either directly or with an upstream internal 
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ribosomal entry site (IRES). Bioinformatical analysis [42] indeed revealed a putative group 4 IRES 
[43] 1,044 bp upstream of the confirmed m164 AUG. Though IRES sequences are rarely described 
for herpesviral transcripts, it remains to be tested if this IRES is functional. 
Figure 5. Verification of the m164 IE phase mRNA by RT-PCR. (A) Schematic map of 
the RACE-defined m164 mRNA with its 3'- and 5'-UTRs. RACE analysis (see 
Appendix Figure A1) predicted an mRNA of 2004 b. Positions of oligonucleotides 
binding inside or outside of the RACE product are indicated. Calculated sizes of the 
respective RT-PCR products are shown in lines I and II; (B) MEF were infected with 
mCMV-WT.Smith in presence (+) or absence (–) of ActD (5 g/mL) or CH  
(100 g/mL) as indicated. At 1.5 h or 3 h p.i. total RNA was isolated and subjected to 
RT-PCRs using oligonucleotides for product I or II (see Appendix Table A1). 
Amplificates were analyzed on a 1% agarose gel. M, marker; n.i. not infected; bp, 
basepairs. Controls with no RT step were negative throughout (not shown).  
 
As Western blot analysis with antibodies directed against a C-terminal peptide of ORFm164 did 
neither detect m164/gp36.5 nor larger or smaller isoforms expressed in the IE phase ([22], and data 
not shown), translation from the long IE mRNA and consequent m164 epitope presentation in the 
IE phase may result from a smaller isoform or even oligopeptide lacking the C-terminus. 
In any case, this study has revealed the existence of an IE phase mRNA that starts upstream of 
the E phase m164 transcript and that spans the complete m164 sequence, including the sequence 
that encodes the CD8 T-cell epitope of which presentation was, so far, assigned only to the E phase.  
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Figure 6. Provisional map of the >5 kb m164 IE mRNA and its localization within the 
mCMV genome. Positions of oligonucleotides binding inside or outside of the IE 
transcript are shown. Unmapped sequences are indicated as hatched boxes. A predicted 
IRES is indicated.  
 
3. Experimental Section  
3.1. Cells, Viruses, and Mice  
Primary BALB/c or C57BL/6 mouse embryo fibroblasts (MEF) were prepared as described 
previously [44] and cultivated in modified Eagle’s medium (MEM) supplemented with 10% fetal 
calf serum (FCS) and antibiotics. For transfection experiments, COS7 cells were cultivated and 
seeded 24 h prior to transfection in DMEM medium supplemented with 10% FCS and antibiotics. 
The m164 peptide (AGPPRYSRI)-specific, polyclonal cytolytic T-lymphocyte (CTL) line  
(m164-CTLL), and the SIINFEKL-specific CTLL were generated and tested for functional avidity 
as described previously [44,45].  
High virus titer stocks of mCMV Smith strain (mCMV-WT.Smith; ATCC VR-194/1981  
re-accessioned as VR-1399), mCMV.WT.BAC [46], mCMV-m164Ala [13], mCMV-SIINFEKL [29], 
and mCMV-SIINFEKA [29] were prepared from infected MEF according to standard  
procedures [44,45]. Unless stated otherwise, infection was regularly performed with  
mCMV-WT.Smith. 
BALB/c and C57BL/6 mice were bred and maintained under SPF conditions at the “Central 
Laboratory Animal Facility (CLAF)” of the University Medical Center Mainz. All experimental 
procedures were performed in compliance with the “International Guiding Principles for 
Biomedical Research Involving Animals” guidelines [47]. The experiments were approved 
according to German federal law under permission number AZ 23 177-07/G 09-1-004.  
3.2. Infection Conditions 
Confluent MEF were infected in the second or third cell culture passage under conditions of 
centrifugal enhancement of infectivity with 0.2 PFU/cell of the indicated viruses, resulting in an 
effective multiplicity of infection (MOI) of ~4 PFU per cell. For viral transcriptional arrest in the 
IE-phase, cells were infected in presence of cycloheximide (CH; 100 g/mL; Sigma-Aldrich, 
Catalog No. C7698, Steinheim, Germany) and, 3 h later, CH was replaced with Actinomycin D 
(ActD; 5 g/mL; Sigma-Aldrich, Catalog No. A9415, Steinheim, Germany). For E phase arrest, 
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cells were infected in the presence of phosphonoacetic acid (PAA; 250 g/mL, Catalog No. 
284270, Steinheim, Germany) [44]. 
3.3. Construction of Expression Plasmids 
To amplify the full-length sequence of ORFm164, PCR was performed using mCMV-WT.BAC 
genomic DNA as template with oligonucleotides m164_rev_BamHI and m164_full_Hind III 
(Appendix Table A1) with the following protocol parameters: 5 min at 95 °C; 35 cycles of 10 s at 
94 °C, 30 s at 60 °C, and 40 s at 72 °C followed by final primer extension for 10 min at 72 °C. The 
PCR product was subcloned into vector pcDNA3.1 after BamH I/Hind III restriction. To insert 
nucleotide exchanges ATG to GCG at nt positions 223, 649–223, 647; 223, 571–223, 569 and 223, 
379–223, 377 the construct was subjected to site-directed mutagenesis using the Quick Change II 
Site-Directed Mutagenesis Kit (Agilent, Catalog No. 200524, Böblingen, Germany) with the 
oligonucleotide pairs m164_1stATG_for/rev, m164_2ndATG_for/rev, and m164_3rdATG_for/rev 
(Appendix Table A1), respectively. The mutagenesis resulted in constructs pcDNA-m164_ATG_2/3, 
pcDNA-m164_ATG_1/3, and pcDNA-m164_ATG_1/2. Plasmid pcDNA-m164_ATG_2/3 was 
subjected to a second round of mutagenesis using the respective oligonucleotides resulting in the 
constructs pcDNA-m164_ATG_3 and pcDNA-m164_ATG_2. Plasmid pcDNA-m164_ATG_1/3 
was used as template for construction of pcDNA-m164_ATG_1. A third round of mutagenesis 
using pcDNA-m164_ATG_3 as a template resulted in pcDNA-m164_ ATG. The successful 
replacement was confirmed by sequencing (GATC; Konstanz, Germany). 
3.4. Construction of Recombinant mCMV 
To generate recombinant virus mCMV-m164_ ATG_1, BAC mutagenesis was performed by  
Red-mediated markerless DNA recombination as described by Tischer and colleagues [47]. In 
brief, oligonucleotides pEPKan-S_m164_1stATG__for and pEPKan-S_rev (see Appendix Table A1) 
were used for a PCR with plasmid pEP-kanS [48] as a template. The resulting products were 
subjected to a second round of PCR using oligonucleotides pEPKan-S_m164_1stATG_rev and 
m164_1stATG_short. The resulting product was transformed into GS1783 cells carrying  
WT.BAC. After Red-recombination, arabinose-induced I-SceI expression, and a second round of  
Red-recombination, m164_ ATG_1 BAC DNA was purified, and successful replacement of the 
ATG was confirmed by sequencing (GATC; Konstanz, Germany). 
3.5. Protein Extraction and Analysis 
MEF were seeded on 10-cm diameter cell culture dishes and infected with an MOI of 4 under 
conditions of centrifugal enhancement of infectivity. At defined times p.i., cells were washed with  
ice-cold PBS and scraped-off. After centrifugation (5 min, 3,000 rpm, 4 °C), the pelleted cells were 
lysed for 15 min on ice in 200 L Lysis Buffer/dish composed of 0.2 M NaCl, 1.5 mM MgCl,  
4 mM EDTA, 4 mM EGTA, 1% Triton X-100, 20 mM HEPES; with complete proteinase inhibitor 
(diluted 1:25; Roche, Catalog No. 11697498001, Mannheim, Germany) and 1 mM DTT added 
shortly before use. After centrifugation (10 min, 14,000 rpm, 4 °C), supernatants were collected 
and the amount of protein was determined by BCA-Assay (Thermo Scientific, Catalog No. 23225, 
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Dreieich, Germany). An amount of 30 g of total protein was separated on an SDS-PAGE  
followed by Western blot analysis. Detection of m164 proteins was performed with polyclonal 
affinity-purified rabbit antibodies directed against a C-terminal peptide (1:500) [49] and an  
HRP-conjugated anti-rabbit antibody as secondary Ab (DakoCytomation, Catalog No. P045001, 
Hamburg, Germany). 
3.6. Transfection 
A total of 5 × 105 COS7 cells per 10-cm diameter dish were seeded and 4 g DNA was 
transfected with Polyfect (Qiagen, Catalog No. 301105, Hilden, Germany) according to the 
manufacturer’s instructions. Forty-eight hours later, cells were harvested and total protein was 
extracted as described above. An amount of 30 g of protein lysates were separated on a 12.5% 
SDS-PAGE followed by m164 protein-specific Western blot analysis. 
3.7. Immunofluorescence Analysis 
COS7 cells seeded on glass coverslips and transfected with 0.4 g DNA were fixed with 4% 
(wt/vol) paraformaldehyde in PBS supplemented with 4% (wt/vol) sucrose. After incubation for 1 h 
in blocking buffer (PBS with 0.3% (vol/vol) Triton X-100 and 15% (vol/vol) FCS), intracellular 
m164 protein was detected by polyclonal affinity-purified rabbit antibodies (1:100) [49] and Alexa 
Fluor 546-conjugated goat anti-rabbit antibody (Life Technologies, Catalog No. A11010, 
Darmstadt, Germany) as secondary antibody. Cell nuclei were stained by 5 min incubation with the 
DNA-binding blue fluorescent dye Hoechst 33342 (1:5,000; Life Technologies, Catalog No. 
H3570, Darmstadt, Germany). 
3.8. Northern Blot using RNA Probes 
MEF were treated 15 min before infection either with 100 g/mL CH or 5 g/mL ActD, or were 
left untreated. Cells were infected under conditions of centrifugal enhancement. Highly purified 
polyadenylated RNA was isolated from the cell lysate at 1.5 h (untreated and ActD treated cells) or 
3 h (untreated and CH treated cells) p.i. by using oligo(dT)-coated superparamagnetic 50-nm diameter 
microbeads ( MACS mRNA isolation kit; Miltenyi Biotec Systems, Catalog No. 130-075-201, 
Bergisch-Gladbach, Germany). To generate two complementary hybridization probes, a 431 bp 
DNA fragment of the m164 sequence (nt 222,625–nt 223,055) was amplified by PCR using the 
primers mRNAint_for and mRNAint_rev and the plasmid pSM3fr [46] as template. The resulting 
PCR product was subcloned into pDrive cloning vector (Qiagen, Catalog No. 223122, Hilden, 
Germany) resulting in pDrive-m164probe. After linearization of the plasmid with BamHI for 
transcription with T7, the MAXIscript Kit SP6/T7 (Life technologies, Catalog No. AM1320, 
Darmstadt, Germany) was used to synthesize single strand RNA probes labeled by random-priming 
with the DIG RNA Labeling Mix (Roche, Catalog No. 1277073, Mannheim, Germany) in the 
presence of DIG-UTP:dTTP (1:3). Amounts of 4 g of poly(A)+ RNA or 2 g of total RNA per 
lane were separated in 1.2% Agarose/37% formaldehyde gels and transferred onto positively 
charged nylon membranes. An amount of 700 ng of the DIG-labeled RNA-probe (T7) was diluted 
in 70 mL DIG Easy Hyb buffer prior to hybridization, which was performed as described above. 
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3.9. Mapping of mRNA by 5'/3'RACE 
To map the full-length m164 transcript by 5'/3' RACE (rapid amplification of cDNA ends) [50], 
the 2nd generation kit (Roche, Catalog No. 03353621, Mannheim, Germany) was used for the analysis 
of poly(A)+ RNA isolated in the E phase of the viral replicative cycle at 6 h post-infection (p.i.). 
In brief, poly(A)+ RNA was enriched from total RNA by the Oligotex mRNA Mini Kit (Qiagen, 
Catalog No. 72022; Hilden, Germany) according to the manufacturer’s instructions. 5' RACE 
analysis started with an RT-step transcribing m164 mRNA partially into cDNA by using the 
Flank_1 primer (see Appendix Table A1), followed by digestion of residual poly(A)+ RNA with 
RNase H. The transcription start site of gene m164 was identified by tailing the cDNA at its 3' end 
using terminal deoxynucleotidyl transferase with substrate dATP. The 3' region of the cDNA 
[corresponding to the 5' end of the poly(A)+ RNA] was then amplified using a standard PCR 
protocol with the provided oligo-dT anchor primer and the antisense primer Nested_Flank_2 (see 
Appendix Table A1) designed to bind internally within the predicted ORFm164. 
3' RACE analysis started with the synthesis of cDNA using the oligo-dT anchor primer, 
followed by digestion of residual poly(A)+ RNA with RNase H. The 5' region of the cDNA 
(corresponding to the 3' end of the poly(A)+ RNA) was then amplified by using the provided PCR 
anchor primer and the ORFm164 sequence-specific internal primer Nested_Flank_3 (see Appendix 
Table A1). Reaction products were analyzed by 1.5% agarose gel electrophoresis and were sequenced. 
3.10. Primer Walking  
Fifteen minutes prior to infection, MEF were either treated with 100 g/mL CH or 5 g/mL 
ActD, or were left untreated. Infection was performed under conditions of centrifugal enhancement. 
Highly purified polyadenylated RNA was isolated from the cell lysate at 1.5 h (untreated and ActD 
treated cells) or at 3 h (untreated and CH treated cells) p.i. by using oligo(dT)-coated 
superparamagnetic 50 nm-diameter microbeads ( MACS mRNA isolation kit; Miltenyi Biotec 
Systems, Catalog No. 130-075-201, Bergisch-Gladbach, Germany). For reverse transcription 
reactions, the OneStep RT-PCR Kit (Qiagen, Catalog No. 210210, Hilden, Germany) was used 
according to the manufacturer’s protocol. Reactions were carried out with an automated thermal 
cycler (GeneAmp PCR System 9700; Life technologies, Darmstadt, Germany), using the primer 
pairs shown in Appendix Table A1. The time-temperature profiles were as follows: reverse 
transcription for 30 min at 50 °C, initial PCR activation step for 15 min at 95 °C, 35 cycles of 
denaturation for 30 s at 94 °C, and annealing for 30 s with annealing temperatures and elongation 
conditions specified in Appendix Table A2. Final extension was performed for 10 min at 68 °C or 
72 °C, dependent on the respective elongation temperature. Amplification products were visualized 
by standard procedures of 1% (wt/vol) agarose gel electrophoresis with ethidium bromide. 
3.11. In Vitro Transcription and Translation  
To introduce the SP6 promoter sequence [51] in front of the RACEm164 and the ORFm164 
sequence, PCRs were performed with primer pairs SP6_m164RACE_for and SP6_m164RACE_rev 
or SP6_m164ORF_for and SP6_m164ORF_rev (see Appendix Table A1), respectively. An amount of 
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1 g of purified PCR product was used as template for in vitro transcription according to the 
manufacturer’s protocol for “Transcription Reaction Assembly” of the Ambion MEGAscript SP6 
kit (Life technologies, Catalog No. AM1330, Darmstadt, Germany). After 3.5 h of incubation at  
37 °C for transcription, DNA template was removed by digestion with DNase, and the RNA was 
cleaned with RNeasy Mini Elute Cleaning kit (Qiagen, Catalog No. 74134, Hilden, Germany) and 
analyzed on a 1% agarose/formaldehyde gel. 
In vitro translation of the in vitro transcripts was performed with the Promega wheat germ 
extract (Promega, Catalog No. L4380, Mannheim, Germany). The reaction conditions were 90 min 
at 25 °C with 80 ng of template RNA. The resulting protein was labeled with Redivue L-[35S] 
methionine (Amersham Biosciences, Catalog No. AG1094, Little Chalfont, UK) and analyzed by 
12.5% SDS-PAGE followed by autoradiography. 
3.12. ELISpot Assay 
Presentation of the m164- and SIINFEKL-epitope was determined after endogenous antigen 
processing in infected MEF (BALB/c, haplotype H-2d and C57BL/6, haplotype H-2b, respectively) 
by using cognate CTLL as responder cells in a standard IFN- -based ELISpot assay. For selective 
arrest of the viral gene expression in the IE or E phase, MEFs were treated with inhibitors as 
described previously [44]. The assay was performed as described ([52,53] and references therein) 
and frequencies of IFN- -secreting cells and the corresponding 95% confidence intervals were 
calculated by intercept-free linear regression analysis using the software Mathematica [54].  
4. Conclusions and Outlook 
These data have revealed a paradigmatic example of a CD8 T-cell epitope that is encoded by 
two overlapping mRNAs expressed in different phases of the coordinately regulated gene expression 
program in the productive viral cycle [55,56]. As overlapping genes are a more general feature of 
CMV genomes [33,57], more such cases might be found in the future and lead to a revision of the 
assignment of antigenic peptides to a certain kinetic class in epitope listings. This is of relevance 
for the order in which epitopes are expressed relative to immune evasion proteins or for discussing 
viral gene expression during CMV latency. In the specific case of the memory inflation-inducing 
m164 peptide of mCMV it was assumed that the expansion of the m164 epitope-specific memory 
CD8 T-cell pool indicates E gene expression during latency [11,20,21]. With the new knowledge 
presented here, future experiments will have to address the question of whether the m164 peptide 
that is supposed to drive m164-specific memory inflation during latency indeed results from the E 
phase transcript or, alternatively, results from the here identified IE phase transcript. Sporadic 
expression of IE genes from the major IE locus during viral latency has been documented [27,58–60]. 
Thus, “noncanonical” expression and presentation of the m164 epitope from the long IE phase 
transcript could explain m164-specific memory inflation during viral latency in absence of 
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Figure A1. Mapping of the E phase m164 transcript with its 5' and 3' untranslated 
regions (UTRs). (A) Hind III restriction map [61] of the mCMV-WT.Smith genome 
(GenBank Accession No. MCU68299), and map position of the predicted ORFm164 [34] 
located within the Hind E fragment on the C (complementary) strand. It overlaps with 
neighboring ORFs m163 and m165 by 45 bp and 366 bp, respectively; (B) Schematic 
illustration of the strategy of 5' and 3' RACE for identifying UTRs. For 5' RACE, 
poly(A)+ mRNA is reverse transcribed using an internal primer Flank_1. An oligo-dA 
sequence is appended to the 3' end of the resulting m164 cDNA fragment. PCR 
performed with an oligo-dT anchor primer and an internal primer Nested Flank_2 will 
reveal the expected 965 bp of predicted ORF sequence (up to the complementary start 
codon CAT) plus an additional unknown number of 5' bp (5' X; dashed line). For 3' 
RACE, poly(A)+ RNA is reverse transcribed by using an oligo-dT anchor primer. The 
resulting cDNA is amplified by using the PCR anchor primer and an internal primer 
Nested Flank_3 to reveal the expected 984 bp of predicted ORF sequence (up to 
complementary stop codon TCA) plus an additional unknown number of 3' bp (3' Y; 
dashed line); (C) Left two panels: Ethidium bromide-stained 1% agarose gels identifying 
1,151 bp 5' and 1,521 bp 3' RACE products, allowing the calculation of 5' X and 3' Y, 
respectively. Sequencing revealed 2,004 bp of non-overlapping sequence representing a 
2,004 base-long mRNA, referred to as RACEm164 RNA. Right panel: in vitro 
transcripts. Ethidium bromide-stained agarose/formaldehyde gel showing the in vitro 
transcription products (1 g RNA per lane) obtained with DNA templates representing 
either the full-length mRNA [except the poly(A) tail] as determined by RACE analysis 
(RACEm164) or the sequence of only the predicted ORF (ORFm164), both 5' extended 
with the 20-bp SP6 promoter sequence ATTTAGGTGACACTATAGAA. CUU, 








Figure A2. RT-PCR primer walking for searching the 5' end of the long IE m164 
mRNA (A) Map indicating relative positions of ORFs m164 to m166. I-IV show 
predicted lengths of RT-PCR products and the positions of the oligonucleotides on the 
mCMV genome (map not drawn to scale); (B) MEF were infected with mCMV-WT.Smith 
in presence (+) or absence (–) of ActD (5 g/mL) or CH (100 g/mL). At 1.5 h p.i. (for 
ActD) or 3 h p.i. (for CH), total RNA was isolated and subjected to RT-PCR. Products 
were analyzed on a 1% agarose gel stained with ethidium bromide. M, marker; n.i., not 
infected; (C) Left panel: map indicating relative positions of oligonucleotides and  
RT-PCR products (map not drawn to scale); right panel: MEF were infected with 
mCMV-WT.Smith in absence (–) or presence of CH or ActD, and total RNA was 
isolated at 3 h p.i. (for CH) or 1.5 h p.i. (for Act.D) and subjected to RT-PCR using 
oligonucleotides for products I-VIII (see Appendix Table A1). DNA isolated from 




Table A1. Oligonucleotides used in this study; nucleotides inserting ATG to GCG 














mRNAin_for  5'-GTTTAGTCGGGAGCGTG-3' 















Nested Flank_2 5'-GACGACGCACGATACGCAGAC-3' 















Table A2. PCR cycling conditions used in this study. 
Product Primer rev Primer for Annealing  Elongation  Size [bp] 
Figure 4 
I m164mRNA_rev m164mRNAin_for 51.7 °C 1 min 30 s; 72 °C 2,001 
II m164mRNA_rev m164mRNAout_for 51.7 °C 90 s; 72 °C 2,023 
Figure A2A 
I m164mRNA_rev m164mRNAout50_for 51.7 °C 2 min10 s; 68 °C 2,081 
II m164mRNA_rev m164mRNAout100_for 51.7 °C 2 min10 s; 68 °C 2,123 
III m164mRNA_rev m164mRNAout300_for 51.7 °C 2 min 18 s; 68 °C 2,299 
IV m164mRNA_rev m164mRNAout1000_for 51.7 °C  3 min; 68 °C 3,048 
Figure A2C 
I m164mRNAin_rev m166_ORF_end_for 55 °C 1 min 30 s; 72 °C 1,744 
II m164mRNAin_rev m166_ORF_end250_for 55 °C 1 min 30 s; 72 °C 1,986 
III m164mRNAin_rev m166_ORF_end500_for 55 °C 2 min 18 s; 68 °C 2,254 
IV m164mRNAin_rev m166_ORF_end1000_for 55 °C 3 min; 68 °C 2,732 
V m164mRNAin_rev m166.5_ORF_end_for 55 °C 3 min; 68 °C 3,086 
VI m164mRNAin_rev m166.5_ORF_end250_for 55 °C 3 min 20 s; 68 °C 3,346 
VII m164mRNAin_rev m166.5_ORF_end500_for 55 °C 3 min 30 s; 68 °C 3,576 
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Abstract: Interferons (IFNs) activate the first lines of defense against viruses, and 
promote innate and adaptive immune responses to viruses. We report that the immediate 
early 1 (IE1) protein of human cytomegalovirus (HCMV) disrupts signaling by IFN . 
The carboxyl-terminal region of IE1 is required for this function. We found no defect in 
the initial events in IFN  signaling or in nuclear accumulation of signal transducer and 
activator of transcription 1 (STAT1) in IE1-expressing cells. Moreover, we did not observe 
an association between disruption of IFN  signaling and nuclear domain 10 (ND10) 
disruption. However, there is reduced binding of STAT1 homodimers to target gamma 
activated sequence (GAS) elements in the presence of IE1. Co-immunoprecipitation 
studies failed to support a direct interaction between IE1 and STAT1, although these 
studies revealed that the C-terminal region of IE1 was required for interaction with 
STAT2. Together, these results indicate that IE1 disrupts IFN  signaling by interfering 
with signaling events in the nucleus through a novel mechanism.  
Keywords: human cytomegalovirus; interferons; interferon ; immediate early 1; IE1; 





After primary infection, human cytomegalovirus (HCMV) persists for the lifetime of the host, 
avoiding elimination by the host immune system [1]. In congenitally infected infants and 
immunosuppressed persons, HCMV can cause serious diseases [2]. Aspects of both HCMV disease 
and persistence in human populations are suspected to be linked to the multiple mechanisms this 
virus has evolved to modulate human immune responses.  
Interferons direct intrinsic cellular defenses and early immune responses against HCMV and 
other viruses. IFNs are classified into three categories: type I (IFNs- , , , , ), type II (IFN ) 
and type III (IFN ), though type I and II interferons are the best studied with respect to their 
antiviral functions [3]. IFNs have intrigued virologists for over 50 years, not only for providing 
insight into viral biology and the molecular combat that occurs in infected cells, but also for the 
potential promise of exploiting the IFN system for therapeutic control and prevention of viral 
diseases. IFNs function to limit virus replication and pathogenesis through stimulation of intrinsic 
cellular defense mechanisms that contribute to innate immunity [4,5], and by promoting and 
regulating adaptive immune responses [6,7].  
The antiviral functions of IFNs are initiated by binding with their receptors [4,8–10]. The type I 
receptor is composed of two proteins, IFN Alpha Receptor 1 (IFNAR1) and IFN Alpha Receptor 2 
(IFNAR2). The cytoplasmic tails of the receptors associate with protein tyrosine kinases, Janus 
Kinase 1 (JAK1) and Tyrosine Kinase 2 (TYK2). Binding of Type I IFN to its cognate receptor 
leads to phosphorylation of JAK1 and TYK2 and tyrosine residues on the cytoplasmic tails of the 
receptors. Phosphorylation of the receptors enables docking of Signal Transducer and Activator of 
Transcription 1 and 2 (STAT1 and STAT2) via Src Homology 2 (SH2) domains and tyrosine 
phosphorylation and heterodimerization of the STATs. The STAT1-STAT2 heterodimers forms 
complexes with interferon regulatory factor (IRF)9 that translocates to the nucleus and binds Interferon 
Stimulated Response Elements (ISRE) in the promoters of type I IFN induced genes [8,9]. Type II 
IFNs bind to a different receptor composed of Interferon Gamma Receptor 1 and 2 (IFNGR1 and 
IFNGR2) proteins, associated with the tyrosine kinases JAK1 and JAK2. IFN  signaling results in 
formation of phosphorylated STAT1 homodimers that translocate to the nucleus and bind Gamma 
Activated Sequence (GAS) elements in the promoters of type II IFN inducible genes [3,9,10]. 
Interferons can stimulate the expression of over 300 cellular genes known as Interferon Stimulated 
Genes (ISGs) [11]. The proteins encoded by ISGs have antiviral and immunomodulatory activity. 
These gene products interfere with the viral life cycle by degrading viral nucleic acids, inhibiting 
viral protein synthesis, interference with viral protein trafficking, or inducing apoptosis leading to 
death of virally infected cells [10]. In addition to their direct antiviral role, IFNs can control viral 
pathogenesis by enhancing adaptive immune responses, enhancing antigen presentation to cells of 
the immune system, and recruiting immune cells to sites of infection [6,7]. In particular, type II 
IFN is important in stimulating the activity of NK cells, macrophages, T lymphocytes and dendritic 
cells (DCs) [7].  
The cytomegaloviruses employ multiple mechanisms to disrupt IFN induction [12–14] and IFN 
signaling [15–20]. HCMV targets the type I pathway by disrupting STAT1 and STAT2. Paulus and 
colleagues demonstrated that HCMV immediate early 1 (IE1/IE72) encoded by the UL123 gene 
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forms a physical complex with STAT1 and STAT2 thereby blocking signaling after nuclear 
translocation and before DNA binding [21]. Binding of IE1 to STAT2 requires the short acidic and 
serine/proline-rich low-complexity motifs in the carboxy-terminal region of IE1 [22]. Huh and 
colleagues demonstrated that disruption of IFN  activity related to binding the acidic domain of 
immediate early 1 (IE1) to STAT2 in a sumoylation-dependent manner [23]. Le et al. further 
reported that STAT2 is targeted for proteasome-mediated degradation at early to late times of 
infection that was dependent on expression of an early gene [24].  
The type II IFN signaling pathway has been studied in both MCMV- and HCMV-infected cells.  
A blockade in IFN -mediated regulation of several genes is observed in murine cytomegalovirus 
(MCMV) infected macrophages [25], and the MCMV M27 protein has been shown to disrupt IFN  
signaling through a novel, STAT2-dependent mechanism [26]. Initial reports that HCMV also 
targets type II IFN signaling derived from the observation that IFN -induced CIITA induction  
was disrupted downstream of STAT1 nuclear translocation as early as 6 hours after HCMV 
infection [27]. This appeared to be due to impaired binding of STAT1 to GAS elements at very 
early times in HCMV infected cells [28]. Subsequently, it was reported that IFN  signaling in 
HCMV infected cells is also disrupted through degradation of JAK1 [29]. Furthermore, Baron and 
Davignon described impaired STAT1 tyrosine phosphorylation in response to IFN  in the 12 to  
24 hour time period after infection with HCMV [30]. This was found to be linked to activation of the 
SH2 domain-containing phosphatase 2 (SHP2) acting on phosphorylated STAT1. Remarkably, 
Knoblach and colleagues described an activation of a type II interferon-like host response in cells 
induced to express IE1 [31]. The activation ISGs by IE1 in this report was attributed to activation 
of STAT1 and was independent of IFN . Altogether there is a lack of clarity on how HCMV 
influences type II IFN signaling and the viral gene products involved. 
Here we report that expression of the HCMV UL123 gene that codes for IE1/IE72 also 
interferes with IFN  signaling in human primary fibroblasts. IE1 is a promiscuous transactivator of 
viral and cellular genes [32] and, as discussed above, is known to antagonize type I interferon 
signaling [21,23,24]. Our findings suggest that IE1 can disrupt signaling by both type I and Type II 
interferons. Furthermore we have determined that the carboxyl-terminal region of IE1 that includes 
the acidic domain is required for this function. We found no defect in the initial events in IFN  
signaling in IE1-overexpressing cells, nor did we observe an association between disruption of 
IFN  signaling and ND10 disruption. Moreover, IE1 does not interfere with nuclear accumulation 
of STAT1. However there is reduced binding of STAT1 homodimers to target GAS elements in the 
presence of IE1. This activity does not appear to require a direct interaction of IE1 and STAT1 and 
suggests that IE1 disrupts IFN  signaling in the nucleus and through a novel mechanism.  
2. Results and Discussion 
2.1. The HCMV IE1 Gene Disrupts Signaling by Type II Interferon 
To identify the HCMV genes involved in disruption of IFN signaling a cDNA library of the 
HCMV laboratory strain AD169 was constructed [33]. The human fibrosarcoma cell line 2C4 was 
used in a preliminary screen for HCMV cDNA clones that have a role in regulating IFN signaling. 
2C4 is a fibrosarcoma cell line engineered to express the T-cell antigen CD2 under the control of 
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the promoter element of the Interferon Induced Transmembrane protein 1 (IFITM1) gene (a.k.a.  
9-27, IFI17, CD225) which respond to both type I and II IFNs by increasing cell surface expression 
of CD2 [34]. 2C4 cells transfected with any HCMV cDNA clone involved in disruption of IFN 
signaling would thus be expected to exhibit reduced accumulation of cell surface of CD2. Using 
this system we observed that transfection of cDNA clone pIE622, harboring the full length cDNA 
sequence for the HCMV UL123 gene, was associated with diminished CD2 cell surface levels 
relative to empty vector-transfected cells after exposure to IFN , and to a lesser extent, IFN  (data 
not shown). This suggested a role for IE1 in disruption of both type I and type II IFN signaling. 
The UL123 gene codes for the HCMV major transcriptional transactivator protein, IE1. In addition 
to its role as a promiscuous transactivator of viral and cellular genes, IE1 is known to have multiple 
functions including disruption of ND10 nuclear bodies [35], antagonism of histone deaceytlase 
(HDAC3) [36], anti-apoptotic function [37], chromatin tethering [38], and interference with 
signaling by type I interferons [21].  
To confirm a role for IE1 in disruption of type II IFN signaling, we examined the effect of IE1 
in a more physiologically relevant human fibroblast cell line. Basal expression of MHC II 
Transcriptional Activator (CIITA) is very low in fibroblasts but becomes highly induced after IFN  
treatment. CIITA transcript levels were quantified by Real-Time RT-PCR in MRC5 fibroblasts 
after nucleofection with pIE622 expressing the full length IE1. In MRC5 cells, nucleofection 
resulted in greater than 90% transfection efficiency (data not shown). CIITA mRNA levels were 
compared in IFN  treated cells and untreated cells. In untreated cells, expression of IE1 was 
associated with a slight induction of CIITA or IRF1 (0.9 to 3 fold). In IFN  treated cells, we found 
that CIITA induction in IE1 expressing cells was only 39% of that observed in cells nucleofected 
with empty vector (Figure 1A). We also examined the IFN -induced expression of a second gene, 
IRF1, in IE1 expressing fibroblasts. We found that the increase in expression of IRF1 in response 
to IFN  is reduced by 52% in IE1 expressing cells as compared to cells nucleofected with  
empty vector (Figure 1B) relative to untreated cells. These findings confirm that IE1 is able to 
impair, but not completely block IFN -induced upregulation of CIITA and IRF1 transcript levels in 
human fibroblasts. 
2.2. Mapping of the IE1 Protein Region Involved in Disruption of IFN-Induced Gene Expression 
The HCMV IE1 protein is a multifunctional protein with various functions attributed to different 
domains of the protein (Figure 2A). We generated a series of FLAG epitope-tagged truncation 
mutants to identify the protein region required for attenuation of IFN -induced gene expression as 
described in Materials and Methods. We generated five different FLAG-tagged truncation mutants 
plus a full length FLAG-tagged version of IE1 (Figure 2A). These six different clones were 
nucleofected into MRC5 cells, followed by treatment with IFN  for 6 hours. RNA extracted from 
these cells was analyzed for levels of CIITA transcript induction by Real-Time RT-PCR. We found 
that there was a reduction in the IFN -induced expression of CIITA in cells expressing full length 
and truncated versions of IE1, with the exception of the C-terminal truncation missing residues 
345–491 ( AD) that includes the acidic domain and chromatin tethering domain (Figure 2B). We 
consistently observed higher levels of CIITA induction in cells expressing the 345–491 protein 
relative to our vector alone transfections. Although the reason for this is not clear, it may be that the 
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IE1 protein without the C-terminal domain provides a signal that amplifies IFN -induced CIITA 
gene expression. This may also relate to the report linking inducible IE1 expression to  
STAT1-dependent interferon-like gene induction [31]. One possibility is that IE1 may interact with 
cellular proteins that stimulate a type II interferon response, but this activity is masked by the 
dominant inhibitory role of the C-terminal 147 residues in our studies. These contradictory data 
may also reflect the different transfection systems or viral strains used in these two studies. 
Figure 1. Diminished interferon-induced gene expression in human fibroblasts expressing 
IE1. MRC-5 fibroblasts were nucleofected with plasmid pIE622 harboring the UL123 
gene specifying IE1, or the pFIN2 empty vector. At 24 hours post-nucleofection, the 
cells were exposed to 100 U/mL of IFN  or were left untreated. At 6 hours after 
treatment, total RNA was isolated and subjected to Real Time RT-PCR analysis as 
described in Materials and Methods. The fold increase in CIITA (A) (p value = 0.053) 
or IRF1 (B) (p value 0.017) transcript levels in IFN treated cells relative to untreated 
cells was determined by the Ct method. Data shown are the average of three 
independent experiments. 
 
Figure 2. The carboxy-terminal region of IE1 is required for disruption of IFN  
signaling. (A) Schematic of the IE1 protein and truncation mutants generated in this 
study. Top line: a schematic of the IE1 protein indicating the amino acid positions 
comprising the coding exons (below) and the positions of the known functional 
domains (above). The coding exons are shown in white boxes. The functional domains 
of exon 4 are shown in shaded boxes and include the leucine zipper (L), the zinc finger 
(ZF) and the acidic domain (AD). A schematic of the five different IE1 N-terminal 
truncation mutants generated in this study are shown below. The sixth mutant is a  
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C-terminal truncation mutant. The designation of the plasmids harboring the truncation 
mutants is based on the deletion of relevant exons or functional domains shown on the 
right, and the deleted amino acid residues are shown in parentheses. The gene 
sequences were inserted in frame to sequences specifying a FLAG epitope (depicted as 
a flag). (B) Interferon Stimulated Gene (ISG) induction in fibroblasts expressing 
truncated IE1 proteins. The indicated plasmids were nucleoporated into MRC5 cells 
and 24 hours after nucleofection the cells were treated with 100 U/mL IFN .  
At 6 hours after treatment total RNA was isolated. Real Time RT-PCR analysis was 
carried out for CIITA and 18S rRNA (endogenous control). The fold increase in CIITA 
transcript levels in IFN treated cells relative to untreated cells was determined by the 
Ct method. Shown is the average of two independent experiments. A film image of 
immunoblot analysis is shown below. In replicate cultures of the first experiment, cells 
were treated as above and solubilized. Equal amounts of protein from each lysate were 
subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins were transferred 
to nitrocellulose sheets and reacted with the indicated antibodies. Anti-FLAG antibody 
was used to detect the presence of FLAG tagged IE1 proteins and antibody to GAPDH 
was used to evaluate protein loading. 
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2.3. Disruption of IFN  Signaling by IE1 Does Not Involve Interaction with PML 
Promyelocytic leukemia protein (PML) is involved in transcriptional repression and is a master 
organizer of nuclear domain (ND)10 structures. Since IE1 has been reported to be involved in the 
disruption of ND10 structures in the nucleus [35,39–43] and because PML is known to mediate 
antiviral activities of IFNs in HSV-infected cells [44] and to confer intrinsic immunity against 
CMV [45,46], we set out to test the hypothesis that the function of IE1 in disrupting IFN -induced 
gene expression is linked to its role in disrupting ND10 structures by immunofluorescence 
microscopy. We found that in fibroblasts expressing the full length IE1 and the 345–491  
C-terminal deletion mutant of IE1, PML was dispersed throughout the nucleus, indicating 
disruption of ND10s (Figure 3). As expected, PML staining was in the form of punctate dots in the 
nucleus in the absence of IE1. Therefore, the C-terminal deletion mutant retains the ability to 
disrupt ND10s. We conclude that IE1-mediated disruption of the IFN  signaling pathway is not 
strictly linked to IE1-mediated dispersal of ND10s. 
Figure 3. Disruption of ND10 structures in cells expressing IE1 and the C-terminal 
truncation mutant. Immunofluorescence images of IE1 and Promyelocytic leukemia 
protein (PML) in fibroblast cells. MRC5 cells were nucleofected with the indicated 
constructs. At 24 hours after nucleofection cells were fixed in methanol and reacted 
with mouse monoclonal anti-IE1 antibody (Mab810) followed by anti-mouse alexafluor 
488 as secondary antibody. The cells were then exposed to rhodamine conjugated anti 
PML antibody (PGM3). IE1 reactivity is visualized in green (left column), PML 




Earlier there have been conflicting reports, one suggesting that the acidic domain is important 
for PML targeting and disruption of ND10 structures [41] and the other suggesting that the acidic 
domain is not involved in this function of IE1 [39]. Yet another study revealed an intermediate role 
for the acidic domain IE1 wherein it was required to target ND10 structures but could not disrupt 
them [47]. Our results indicate that a C-terminal truncation mutant that includes the entire acidic 
domain is able to disrupt ND10s similar to the full length IE1 protein in MRC5 cells. Our results 
are in agreement the findings of Wilkinson et al. [39]. Although these results to do not preclude a 
role for PML in IE1-mediated IFN signal disruption, they do demonstrate that this function of IE1 
does not involve disruption of ND10 structures. 
2.4. IE1 Does Not Perturb Initial Events in IFN -Mediated Signal Transduction 
We next examined the state and abundance of proteins involved in IFN  signaling in  
IE1-expressing cells. We found no difference in the levels of total JAK1, JAK2 and STAT1 in  
IE1-expressing cells as compared to cells expressing the 345–491 mutant or cells nucleofected 
with empty vector (Figure 4). Activation of STAT1 by IFN  was not affected by IE1 since similar 
levels of tyrosine 701-phosphorylated STAT1 were observed after 30 minutes of IFN  treatment in 
cells nucleofected with full length IE1, the 345–491 mutant ( AD), or empty vector (Figure 4). 
Similarly, no differences in accumulation of serine 727-phosphorylated STAT1 were observed 
(data not shown). We also found that translocation of STAT1 to the nucleus was not affected by 
IE1 when examined by immunofluorscence microscopy (Figure 5A). Consistent with the microscopy 
analysis, the accumulation of STAT1 protein in the nucleus of IE1 expressing cells was similar to 
that of cells expressing the 345–491 deletion mutant ( AD) and cells transfected with empty 
vector (Figure 5B). Thus, IE1 does not act by limiting the abundance of key IFN  signal 
transduction molecules, nor does it disrupt STAT1 phosphorylation and nuclear translocation. 
2.5. Type II Interferon-Induced Binding of STAT1 to GAS Elements Is Reduced in the Presence of IE1 
We next determined whether STAT1 molecules in the nucleus were competent to bind the GAS 
element derived from the promoter of the IRF1 gene by EMSA. The full length IE1, the 345–491 
mutant ( AD), and empty vector (FIN2) were nucleofected into MRC5 cells. These cells were 
either treated with IFN  for 30 minutes or left untreated. Nuclear extracts from these cells were 
incubated with a radiolabeled 22mer IRF1 GAS element probe. The amount of probe shifted in 
nuclear extracts from IE1-expressing cells is diminished relative to extracts derived from empty 
vector- or 345–491-nucleofected cells (Figure 6A, compare lane 6 to lanes 5 and 7). These bands 
could be supershifted using a STAT1 antibody indicating that the shift was caused by a complex 
containing STAT1 (lanes 11–13). This demonstrates that there is reduced binding of STAT1 to 
GAS elements in the presence of IE1. Studies were also conducted with nuclear extracts from 
HCMV-infected cells at 12 hours after infection. We could detect only a minor STAT1-shifted 
probe band in HCMV infected cells compared to uninfected cells (Figure 6B, lane 2), which may 
be related to the much higher levels of IE1 in infected cells relative to cells nucleofected with full 
length IE1 (data not shown). Together, these data indicate that expression of HCMV IE1 is sufficient 
to impair STAT1 binding to GAS elements, and that this activity requires the C-terminal region of 
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IE1 including residues 344 to 491. These data also suggest that the impairment of functional 
STAT1 dimer binding to GAS elements at 12 hours after infection is a result of IE1 expression.  
Figure 4. IE1 does not alter the state or abundance of key signaling molecules of the 
IFN  pathway. Film images of electrophoretically separated cell lysates reacted with 
antibodies to IFN  pathway signaling components. MRC5 cells were nucleofected with 
plasmid harboring full length IE1 (FL), the 345–491 C-terminal truncation IE1 ( AD) 
or empty vector (FIN2). At 24 hours after nucleofection, cells were exposed to IFN  for 
30 minutes or left untreated. Cells were solublized and equal amounts of protein from 
each lysate were subjected to electrophoresis in a denaturing polyacrylamide gel. 
Proteins were transferred to nitrocellulose sheets and reacted with the indicated 
antibodies. Anti-FLAG antibody was used to detect the presence of FLAG tagged IE1 
proteins and antibody to GAPDH was used to evaluate protein loading.  
 
IE1 has been reported to antagonize HDAC activity [36]. Although HDAC activity is typically 
associated with transcriptional repression, it is associated with transcriptional activation of  
ISGs [48]. It is tempting to speculate that antagonism of HDAC activity by IE1 is linked to 
disruption of interferon signaling. Further implicating a role for chromatin organization is that the 
C-terminal region of IE1 includes the region previously shown to be required for chromatin 
tethering [38]. However, this possibility is difficult to reconcile with the observation that IE1 
disrupts STAT1-binding to a GAS element probe used in our EMSA assays, which is not 
dependent on chromatin structure. We therefore propose that a novel function of IE1 impairs 
STAT1 binding to target GAS elements. 
  
180 
Figure 5. Nuclear translocation of STAT1 is not altered by IE1. (A) Immunofluorescence 
images of IE1 and STAT1 in cells with and without IFN  treatment. MRC5 cells were 
nucleofected with the full length IE1 (FL) or empty vector (FIN2). After 24 hours cells 
were exposed to IFN  for 30 minutes or left untreated. Cells were fixed in methanol 
and reacted with mouse monoclonal anti-IE1 antibody (Mab810) and rabbit polyclonal 
anti-STAT1 antibody followed by anti-mouse alexafluor 543 and anti-rabbit alexafluor 
488 as secondary antibodies. STAT1 reactivity is visualized in green (left column), IE1 
reactivity is visualized in red (middle column) and merged images are shown in the 
right column. (B) Film images of electrophoretically separated cell lysates reacted with 
antibodies to STAT1 and GAPDH (loading control). MRC5 cells were nucleofected 
with plasmid harboring full length IE1 (FL), the 345–491 C-terminal truncation IE1 
( AD) or empty vector (FIN2). At 72 hours after nucleofection, cells were exposed to 
IFN  for 30 minutes or left untreated. Cells were harvested and nuclear and cytoplasmic 
fractions were separated. Equal amounts of protein from the nuclear and cytoplasmic 
lysates were subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins 
were transferred to nitrocellulose sheets and reacted with the indicated antibodies.  
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Figure 6. Reduced binding of STAT1 to GAS elements in the presence of IE1. Film 
image of an Electrophoretic Mobility Shift Assay shows a reduction in the amount of 
IRF1 GAS element probe that is shifted upon mixture with nuclear extracts from MRC5 
cells ectopically expressing IE1 (A) and HCMV infected cells (B). In A, MRC5 cells 
were nucleofected with plasmid harboring full length IE1 (FL), the 345–491  
C-terminal truncation IE1 ( AD) or empty vector (FIN2). At 24 hours after 
nucleofection, cells were exposed to 100 U/mL of IFN  or left untreated. At 30 minutes 
after treatment, cells were solubilized and nuclear extracts were isolated as described in 
Materials and Methods. Nuclear extracts were mixed with the GAS element of the IRF1 
gene with or without addition of unlabeled probe and with or without anti-STAT1 
antibody. Resulting complexes were resolved by electrophoresis on a 4.5% native 
polyacrylamide gel. In a second experiment (B), MRC5 cells were exposed to 1 PFU 
per cell of the AD169 strain of HCMV or left uninfected. At 12 hours after infection, 
cells were solubilized and processed as described above. The black arrow indicates the 
shifted bands and the grey arrow indicates the supershifted bands. 
 
2.6. STAT1 Fails to Co-Immunoprecipitate with IE1 
In the EMSA studies, the size of the shifted band in the presence or absence of STAT1 antibody 
is the same whether or not IE1 is present. This argues against a scenario in which IE1 acts by 
directly binding to STAT1-bound GAS elements. In order to test this directly, we carried out  
co-immunoprecipitation studies. MRC-5 fibroblast cells were exposed to 3 PFU per cell of the 
AD169 strain of HCMV. At 12 hours after infection, cells were treated with interferon for  
30 minutes. Cells were solubilized and IE1 was isolated using an antibody that recognizes an 
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epitope in exon 2. Under these conditions, we found no evidence of an interaction between STAT1 
and IE1 (Figure 7A). Similarly, STAT1 failed to specifically co-immunoprecipitate with either the 
full length or the 345–491 mutant of IE1 in nucleofection studies (Figure 7B, left panel). We did 
observe a small amount of STAT1 isolated from cells expressing both the full length IE1 and the 
C-terminal mutant upon longer exposure (right panel). However, in several replicate experiments, 
similar amounts of STAT1 were also observed in immunoprecipitations performed using lysates of 
empty-vector-transfected cells (data not shown). We therefore conclude that the small amount of 
STAT1 isolated upon isolation of IE1 and the 345–491 mutant IE1 represents nonspecific 
binding. These studies suggest that IE1does not require a sustained interaction with STAT1 to 
disrupt IFN  signaling.  
A blockade in IFN -mediated regulation of several genes is observed in murine cytomegalovirus 
(MCMV) infected macrophages [25], and the MCMV M27 protein has been shown to disrupt IFN  
signaling through a novel, STAT2-dependent mechanism [26]. Therefore, we examined whether 
STAT2 co-immunoprecipitates with IE1 in IFN  treated human fibroblasts. As expected based 
previously published studies [21–24], we did observe an interaction of STAT2 with the full length 
IE1 in total lysates of nucleofected cells and HCMV infected cells. Similar to previously published 
results, this interaction maps to the C-terminal region of IE1 and the 345–491 mutant does not 
appear to interact with STAT2 under these conditions (Figure 7B). In addition, very little or no 
phosphorylated STAT2 accumulated in nuclei of MRC5 human fibroblasts in response to IFN  
treatment, though phosphorylated STAT2 was observed in nuclei after IFN  treatment (Figure 8). 
Our findings raise the possibility that IFN  signaling is different in murine and human fibroblasts. 
Specifically, it seems that murine, but not human fibroblasts, utilize phosphorylated STAT2 to 
transduce and amplify signals by IFN . Together, these studies suggest that IE functions via a 
novel mechanism in the nucleus to interfere with the type II IFN signal transduction pathway. 
An important question raised by our studies is whether IE1 employs the same strategy, or 
entirely different strategies to disrupt type I and type II interferon signaling. Relevant are the 
following observations: (i) co-immunoprecipation studies using total lysates indicate an interaction 
between the HCMV IE1 acidic domain and STAT2 in human cells consistent with other studies 
([21–24] and this report), and IE1 and STAT2 colocalize in ND10 structures and metaphase 
chromosomes [23]; (ii) in human fibroblasts, phophorylated STAT2 does not accumulate in the 
nucleus upon IFN  treatment ([24] and this report); (iii) there are conflicting reports of an 
interaction between IE1 of the Towne strain and STAT1 [21,23] and we were unable to find 
compelling evidence for a specific interaction between IE1 of strain AD169 and STAT1; and (iv) 
nevertheless, IE1 expression interferes with binding of STAT1 molecules to GAS elements. Based 
on these observations, it is tempting to conclude that an interaction between IE1 and STAT2 is 
necessary and sufficient to interfere with type I IFN signaling. However, such an interaction does 
not readily account for the activity of IE1 in attenuating binding of STAT1 molecules to GAS 
elements in response to type II interferon. On the other hand, the ability of IE1 to disrupt STAT1 
binding to target DNA elements through an indirect mechanism could impede signals transduced 
by both type I and type II interferons. We suggest further studies are needed to resolve the role of 
IE1 in these signaling pathways. 
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Figure 7. IE1 does not interact with STAT1 by co-immunoprecipitation. Film images 
of electrophoretically separated cell lysates and proteins isolated by immunoprecipation. 
(A) MRC5 cells were exposed to HCMV AD169 at 3 PFU per cell or left untreated. At 
12 hours after infection cells were treated with 100 U/mL of IFN  for 30 minutes. The 
cells were harvested and solubilized. 350 g of total protein from each sample was 
reacted with anti-IE1 antibody (mouse monoclonal Mab810). The isolated proteins 
along with the 10 g total lysates were resolved by denaturing PAGE and transferred to 
a nitrocellulose membrane. The membrane was reacted with antibodies for STAT1, IE1 
and STAT2 and the antibody reactive bands were visualized by chemiluminescence. 
The left panel shows films exposed for 10 seconds and the right panel shows films 
exposed for 5 minutes. The arrow indicates the position of the isolated, full length IE1. 
(B) MRC5 cells were nucleofected with full length IE1 (FL), the 345–491 C-terminal 
truncation IE1 ( AD) or empty vector (FIN2). 48 hours after nucleofection cells were 
exposed to 100 U/mL of IFN  for 30 minutes. The preparation of cell lysates, 
immunoprecipitations, PAGE and western hybridization and detection were carried out 
as above. The left panel shows films exposed for 10 seconds and the right panel shows 
films exposed for 5 minutes. The short and long arrows indicate the position of the 
345–491 IE1 in the total lysate and immunoprecipitates respectively.  
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Many DNA viruses encode proteins that target the JAK- STAT signaling pathway including 
adenovirus E1A [49,50], human papilloma virus (HPV) E7 protein [51], hepatitis B virus (HBV) 
terminal protein [52], and polyoma virus large T antigen [53]. Among the herpesviruses, the EBV 
immediate early protein BZLF1 has been shown to interfere with STAT1 phosphorylation and 
nuclear translocation in response to IFN , as well as IFN  receptor expression [54]. Similarly, 
herpes simplex virus (HSV) was shown to interfere with type I IFN signaling by decreasing the 
levels of several signaling molecules, including JAK1 and STAT2, which was in part mediated by 
the virion host shutoff protein encoded by UL41 [55,56], by inducing suppressor of cytokine 
signaling-3 (SOCS3) [57], and by the activity of the ICP27 protein in inhibiting STAT1 
phosphorylation and nuclear translocation [58]. HSV also targets the IFN  pathway by modifying 
the IFNGR1 through the activity of the US3 and UL13 protein kinases, and indirectly by the 
activities of virion host shutoff protein [59]. With the partial exception of HSV virion host shutoff 
protein, all of these viruses target early events in the signaling pathway, especially STAT1 
phosphorylation and nuclear translocation, to attenuate IFN mediated signaling. Our findings 
indicate that HCMV does not target these proximal events in IFN signaling but rather it reduces 
STAT1 binding to target promoter elements in the nucleus. Elucidating the mechanism and 
consequences of this novel immune evasion strategy may provide important insights into the 
pathogenesis of HCMV infections and the regulation of interferon-induced gene expression. 
Figure 8. Phosphorylated STAT2 does not accumulate in the nucleus of IFN -treated 
MRC-5 cells. Film images of electrophoretically separated nuclear lysates reacted with 
antibodies to p-STAT2 and Lamin (loading control). MRC5 cells were nucleofected 
with full length IE1 (FL), the 345–491 C-terminal truncation IE1 ( AD) or empty 
vector (FIN2). At 72 hours after nucleofection, cells were exposed to IFN  or IFN  for  
30 minutes or left untreated. Cells were harvested and nuclear and cytoplasmic 
fractions were separated. Equal amounts of protein from the nuclear lysates were 
subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins were 




3. Experimental Section  
3.1. Cells and Viruses 
Human embryonic lung fibroblasts (MRC5) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and maintained in ATCC-recommended complete media. 
Human fibrosarcoma cell line 2C4 was a kind gift from George Stark (Cleveland Clinic Lerner 
Research Institute, Cleveland, OH, USA) [34]. 2C4 cells were maintained in DMEM supplemented 
with 10% FBS, Glutamine and Sodium Pyruvate. HCMV strain AD169 was obtained from ATCC 
and propagated in MRC5 cells. Viral titers were determined by standard plaque assay [60]. 
Plasmids and vectors: Construction of the AD169 cDNA library is described elsewhere [33]. 
cDNA clones containing different truncated versions of the IE1 gene were selected from the cDNA 
library. The following clones were used in this study and harbor viral gene sequences with the 
indicated genomic coordinates: pie639 (173157-171814), pie535 (172658-171814), pie836 
(172436-171814). The sequences specifying the FLAG epitope tag were inserted at the 5' end of 
each truncation mutant by replacing the Nde I–Eco R1 fragment of each clone with the Nde I–Eco 
R1 fragment from the pCMV3TAG vector (Stratagene, La Jolla, CA, USA) that includes both the 
CMVIE1 promoter sequence and the sequences specifying the FLAG tag. The resultant plasmids 
specified 5' FLAG tag sequences in frame with different truncated versions of IE1. For the  
C-terminal deletion mutant, a Bgl II fragment from cDNA clone pie622 (a full length IE1 cDNA 
clone), was inserted into the pCMV3TAG vector containing a FLAG tag at the 5' end in the same 
coding frame. The genomic coordinates for the C-terminal deletion mutant are (173705-173626 + 
173511-173327 + 173156-172377). To generate a full length UL123 gene sequence in frame with 
FLAG sequences, the IE1 cDNA was PCR amplified from pie622 using the following primers: 
'AGAGTGACTCACCAAGCTTGACACGATG and CGAGGCTGATCAGCTTAATTAACC. The 
PCR products were digested with Hind III and Pac I and inserted into HindIII- and PacI-digested 
pCMV3TAG vector. To generate a UL123 construct missing exon 2 in frame with FLAG sequences, 
pie622 was used as template to PCR amplify the appropriate gene regions using the following 
primers: CCTTCCTCCAAGCTTCCACGGCC and CGAGGCTGATCAGCTTAATTAACC which 
begins at genomic coordinate 173,645. The PCR products were digested with Hind III and Pac I and 
ligated into HindIII and PacI digested pCMV3TAG vector. 
3.2. Transfection, Nucleofection and Infection 
40,000 2C4 cells were plated per well of a 12-well plate. Within 24 hours of plating cells were 
transfected with the cDNA clones specifically using the Fugene HD transfection reagent (Roche, 
Indianapolis, IN, USA) according to manufacturer’s recommendations (1 g plasmid DNA/well 
with 3 L of transfection reagent) [61]. Typically, this procedure resulted in 40%–50% transfection 
efficiency (data not shown). Transfections were optimized to reduce non-specific cellular interferon 
responses [61]. For nucleofections, 1.5 × 106 MRC5 cells were resuspended in 100 L of basic 
nucleofector solution for primary fibroblasts with 3 g of plasmid DNA and nucleofected using 
U23 program in the nucleofector device (Amaxa, Cologne, Germany). After nucleofection cells 
were immediately distributed equally in three wells of a six-well cluster. Nucleofection and 
186 
transfection efficiencies were determined by immunofluorescence microscopy analysis of IE1 
expression and/or immunofluorescence microscopy analysis of GFP expression in parallel 
transfections using plasmid pEGFP-N3 (Clontech, Mountainview, CA, USA). Nucleofection 
resulted in greater than 90% transfection efficiency (data not shown). For infections, confluent 
MRC5 cells in 75 cm2 tissue culture flasks were exposed to one or three plaque forming unites 
(PFU) per cell of HCMV strain AD169 and harvested 24 hours post infection. Wherever indicated, 
cells were treated with 100 U/mL of human recombinant IFN  or IFN  (Chemicon (now EMD 
Millipore), Billerica, MA, USA). All interferon treatments were performed 24 hours after 
transfection or nucleofection.  
3.3. Immunoblotting and Immunoprecipitation 
Infected or nucleofected cells were rinsed with versene (PBS + 1 mM EDTA) to dislodge cells. 
No trypsin was used in these studies. Harvested cells were pelleted by centrifugation at 1500 rpm 
for 5 minutes and resuspended in lysis buffer (25 mM Tris, 150 mM NaCl, 1% NP40, 10 mM NaF, 
0.1 mM NaVO4, 1 mM EDTA and 1% (vol/vol) protease inhibitor cocktail (Sigma, St. Louis, MO, 
USA). The cells were then sonicated in a Misonix (Farmingdale, NY, USA) Cuphorn Sonicator for 
100 seconds (5 s on, 5 s off) at setting 5. Sonicated cells were centrifuged at 13,000 rpm for  
5 minutes to pellet insoluble material. Protein was quantified using Bradford dye (Bio-Rad, 
Hercules, CA, USA) according to manufacturer recommendations. For immunoprecipitation, cell 
lysates were precleared by incubating with protein A agarose beads for 30 minutes at 4 °C. The 
precleared lysates were incubated with primary antibody at 4 °C overnight followed by incubation 
with Protein A beads for 2 hours at 4 °C. The isolated complexes were rinsed four times in lysis 
buffer and eluted by boiling in 2× Laemmli buffer with 5% -mercaptoethanol. Proteins were 
separated by SDS-PAGE, transferred to a nitocellulose membrane (Whatman (now GE Healthcare 
Bio-Sciences), Pittshburgh, PA, USA), reacted with primary antibodies overnight, exposed to 
HRP- conjugated secondary antibody, and detected by ECL (Amersham (now GE Healthcare  
Bio-Sciences), Pittshburgh, PA, USA). Antibodies to the following were used: JAK1 (Upstate 
(now EMD Millipore), Billerica, MA), JAK2 (Santacruz Biotechnology, Dallas, TX, USA), 
STAT1 (Santacruz), STAT2 (Cell Signaling, Danvers, MA, USA), phosphotyrosine STAT 1 (tyr 
701, Cell Signaling), phosphoserine STAT1 (ser 727, Cell Signaling), FLAG (Sigma), 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Chemicon), phosphoSTAT2 (Upstate), IE1 
exon 2 antibody (Chemicon), IE1 exon 4 antibody p63-27 (gift of Dr. William Britt, University of 
Alabama at Birmingham, Birmingham, AL, USA). 
3.4. Flow Cytometry 
2C4 cells were rinsed with versene and nonezymatically dislodged from wells at 24 hours after  
IFN treatment. Cells were resuspended in flow buffer (PBS with 1% FBS) and reacted with  
FITC-conjugated anti-CD2 antibody (Dako, Carpinteria, CA, USA) according to manufacturers 
recommendations. Cells were rinsed with flow buffer and CD2 fluorescence was measured in a 
Facscalibur Flow Cytometer (Becton Dickenson, Franklin Lakes, NJ, USA). The data were 
analyzed with the aid of CELLQuest 3.0 software (Becton Dickinson) [62]. 
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3.5. Real Time RT-PCR 
Total RNA from MRC-5 cells was isolated using Trizol (Invitrogen (now Life Technologies), 
Grand Island, NY, USA) according to the manufacturer’s protocol. Next, 1 g of total RNA from 
each sample was used to perform first strand cDNA synthesis using Superscript reverse transcriptase 
(RT) (Invitrogen) as per manufacturer’s recommendations. The cDNA was diluted 1:4 and 8 L 
was used per real-time polymerase chain reaction (PCR) of 25 L total volume. For reactions using 
SYBR green, the primers used for CIITA and GAPDH (endogenous control) are described 
elsewhere [63]. For reactions using TaqmanTM the following primer and probe sets were used: 
CIITA-Hs00172106_mL, IRF1-Hs00233698_mL and 18SrRNA-4310893E (Applied Biosystems 
(now Life Technologies), Grand Island, NY, USA). All Real-Time reactions were set up in 
triplicate in 96 well format and analyzed in an ABI prism 7900HT Real-Time instrument. Fold 
change in CIITA or IRF1 expression in IFN treated samples compared to untreated samples was 
calculated using the 2 Ct method after normalizing to the endogenous control (either GAPDH or 
18SrRNA) [64]. 
3.6. Microscopy 
Nucleofected or transfected cells were plated on 12 mm coverslips in 24 well plates. Wherever 
indicated cells were exposed to 100 U/mL IFN for 30 minutes. Cells were rinsed with PBS and 
fixed in methanol for 1 hour on ice. The cells were then air dried and stored at 4 °C. Cells were 
rehydrated in PBS for 5 minutes and incubated in blocking buffer (PBS, 10% human serum, 1% 
BSA) for 1hr. This was followed by incubation with primary antibody in blocking buffer overnight 
at 4 °C. Cells were rinsed three times for 20 minutes with PBS. This was followed by exposure to 
fluorescently labeled secondary antibody for 1 hour at 4 °C. Excess secondary antibody was rinsed 
off with three rinses with PBS. The coverslips were allowed to air dry and then were mounted on 
glass slides using the Prolong antifade kit (Molecular Probes (now Life Technologies), Grand 
Island, NY, USA). Microscopy was performed using a Zeiss LSM 510 instrument. Each 
fluorescent dye was scanned separately to avoid any spectral overlap. Images were prepared using 
Zeiss LSM 5 Software, Version 3.5 [65]. The following primary antibodies were used: anti-IE1 
exon 2 antibody (Chemicon), anti-IE1 exon 4 antibody p63-27 (gift of Dr. William Britt),  
anti-PML (Santacruz), anti-STAT1 (Santa Cruz). 
3.7. Electrophoretic Mobility Shift Assay (EMSA) 
MRC5 cells were plated at a density of 1 × 106 cells per 75 cm2 flask post nucleofection. Cells 
were exposed to 100 U/mL IFN  for 30 minutes or left untreated. Cells were rinsed with PBS, 
dislodged from the plates, and nuclear extracts were prepared using Nuclear extract kit (Activ 
Motif, Carlsbad, CA, USA). A 22mer Interferon Response Factor 1 (IRF1) GAS element probe 
(GATCGATTTCCCCGAAATCATG) was radiolabeled with  [P]32 ATP using T4 polynucleotide 
kinase enzyme (Invitrogen) according to the manufacturer’s recommendations. 4 g of nuclear 
extract was incubated with 1× binding buffer, 0.5 g poly dI:C, 0.1 g poly L-lysine and 2ng of 
labeled probe for 15 minutes at room temperature. For competition assays, a 200-fold excess of 
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unlabeled probe was added to the reaction mix. For supershift studies, 5 g of rabbit polyclonal 
anti STAT1 antibody (Santacruz) was added to the reaction and incubated for 15 minutes at room 
temperature prior to adding the labeled probe. The reactions were resolved on a 4.5% native 
polyacrylamide gel in 0.5× TBE buffer and visualized by autoradiography. 
4. Conclusions  
The major findings of this report are as follows: (i) IE1, the immediate early transcriptional 
transactivator of HCMV, was identified as a candidate protein that disrupts IFN signaling by 
screening a HCMV cDNA library using the 2C4 reporter cell line and primary human fibroblasts; 
(ii) Using a series of truncation mutants we assigned this function of IE1 to the C-terminal  
147 residues of the IE1 protein; (iii) IE1-mediated disruption of IFN  signaling appears to be 
independent of IE1-mediated ND10 disruption; (iv) IE1 does not inhibit the proximal events of 
type II IFN signaling; and (v) Although IE1 does not appear to directly interact with STAT1, 
expression of IE1 interferes with STAT1 binding to target DNA elements. Together our data 
indicate that a novel mechanism is employed by IE1 to interfere with the IFN  signal transduction 
pathway. In earlier studies, Miller et al. [28] have reported a reduction in STAT1 homodimer 
binding to GAS elements starting at 12 hours of infection and continuing up to 72 hours of 
infection. Furthermore, LeRoy et al. reported a defect in CIITA induction by IFN  that occurs 
downstream of STAT1 nuclear translocation in infected cells [27]. Our results suggest that these 
phenomena are mediated by IE1. Although only cells of the immune system including NK cells and 
T cells produce IFN , most or all nucleated cells in the body can express IFN  receptors and thus 
elaborate antiviral responses when stimulated by IFN . It is known that during a primary infection 
CD8+ T cells play an important role in controlling the spread of the virus. During this time it may 
be advantageous for the virus to be able to dampen signaling induced by IFN , which is produced 
abundantly by CD8+ T cells. This could not only counteract IFN –mediated antiviral responses, but 
also interfere with IFN -induced expression of MHC class I and MHC class II molecules, assembly 
of the immunoproteasome [66] and the presentation of viral antigens. Therefore, viral disruption of 
IFN -mediated signaling may promote virus replication by attenuating both intrinsic cellular 
defense mechanisms and adaptive immune responses. 
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Abstract: Viruses use different strategies to overcome the host defense system. Recent 
studies have shown that viruses can induce DNA damage response (DDR). Many of 
these viruses use DDR signaling to benefit their replication, while other viruses block 
or inactivate DDR signaling. This review focuses on the effects of DDR and DNA 
repair on human cytomegalovirus (HCMV) replication. Here, we review the DDR 
induced by HCMV infection and its similarities and differences to DDR induced by 
other viruses. As DDR signaling pathways are critical for the replication of many viruses, 
blocking these pathways may represent novel therapeutic opportunities for the treatment 
of certain infectious diseases. Lastly, future perspectives in the field are discussed. 
Keywords: HCMV; cell cycle; DNA damage response; DDR; ATM 
 
1. Introduction 
Human cytomegalovirus (HCMV) is a -herpesvirus and is genetically the most complex  
viral pathogen of humans. Though HCMV infection rarely causes symptomatic disease in 
immunocompetent individuals, it can establish lifelong latency/persistence following primary 
infection and can be reactivated under some conditions. In general, it is the causative agent of a 
variety of disorders in immunocompromised and immunosuppressed individuals. HCMV-associated 
pneumonitis and retinitis are among the most prevalent complications following primary infection 
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or reactivation of latent HCMV reservoirs. HCMV infections are serious threats to the health of 
HIV-positive individuals and transplant patients. Primary or reactivated HCMV infections can 
place pregnancies at risk as the virus can be transmitted to fetuses. In the United States, about 1% 
of newborns are congenitally infected with HCMV. Most congenitally infected infants and children 
do not present with health problems, but 22%–38% of infected infants are born with symptoms, 
including microcephaly and mental retardation [1–3]. HCMV is also the leading cause of 
nonfamilial hearing loss. A strong association between HCMV and glioblastomas has been 
established [4], but its direct role in tumorigenesis is, at this juncture, unclear. 
Many environmental factors and physiological processes can damage DNA. The presence of 
abnormal DNA structures can induce many types of DNA signaling pathways. Mammalian viruses 
use different strategies to antagonize host defense systems, including altering host DNA damage 
response (DDR) to facilitate their replication. This review concentrates on the effects of DDR on 
HCMV replication and draws comparison to other viruses that induce DDR.  
2. HCMV 
HCMV virions are structurally complex. It is an enveloped DNA virus that contains a dsDNA 
genome of ~235 kilobase pairs, which is the largest genome of any human virus [5]. The genome 
encodes approximately 200 open reading frames [6,7] although a recent study suggests that many 
additional, small open reading frames are also transcribed and translated [8]. Recent study shows 
that HCMV genomes exists as complex mixtures of variants in patients, which may add another 
layer of genetic complexity to viral infections [9]. The viral genome is encased within a capsid and 
surrounded by a protein layer called the tegument [10,11]. This structure contains proteins that are 
delivered to cells upon infection and can act before the onset of viral immediate early (IE) gene 
expression to help initiate a productive infection. As examples of tegument proteins with such 
activity, pp71, promotes the degradation of hypophosphorylated forms of pRB, p107, and p130, 
thus stimulating activities associated with cell cycle progression, whereas tegument delivered 
pUL69 arrests the cell cycle in a late G1/S-like state [12]. 
Productive HCMV replication and gene expression has been subdivided into three kinetic 
classes: immediate early (IE), early (E), and late (L) [13,14]. IE genes are the first to be expressed 
and do not require de novo protein synthesis for their expression. The IE proteins have many 
functions which collectively prepare the host cell and viral genome for E gene expression and viral 
DNA replication. In general terms, E gene products are associated with promoting viral DNA 
replication. The replication of viral DNA is closely associated with expression of L genes. IE and E 
gene products also regulate late gene expression [15]. The 72-kDa IE1 protein and 86-kDa IE2 
proteins are the first and, for IE1 at least, among the most abundantly expressed proteins during 
HCMV infection. Both proteins have long been recognized as transcriptional regulators, but they 
also interact with numerous cellular proteins including RB family members [16,17]. They are 
produced from differentially spliced transcripts under the control of strong promoter-enhancer 
element known as the major immediate early promoter (MIEP). 
HCMV early genes require prior de novo synthesis of viral IE and cellular proteins for their 
transcription. The earliest of the early gene transcripts appear and accumulate to peak levels by  
8 hours postinfection (e.g., UL112–113), while temporally later early transcripts can be detected 
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just prior to the onset of viral DNA replication (e.g.,TRL4) and accumulate to peak levels when 
viral DNA replication is allowed to proceed [18]. Most of the viral early genes function in one of 
two ways. Some of the early genes are directly involve in viral DNA synthesis, cleavage and 
packaging of the viral genome, and contribute to assembly of the virus particles. Some other genes 
function to produce cellular and extracellular environments that are suitable for viral gene 
expression and replication, either by modulating factors involved in the regulation of cellular DNA 
synthesis or by altering the host’s immune response to the virus. Some examples of the early genes 
are the UL112-113 nuclear phosphoproteins and HCMV viral DNA replication proteins, including 
DNA polymerase processivity factor (UL44) and single-stranded DNA binding protein (SSB) 
(UL57), which are localized in nuclear replication compartments [19]. 
Following viral DNA replication, delayed early and late viral genes are expressed which, in 
general, encode the structural components of the virion. UL55 (gB), UL75 (gH) and UL99 (pp28) 
as well as components of the capsid are products of late genes. While much study has been carried 
on the regulation of HCMV IE and E gene expression, little is known about the specific 
mechanisms of regulating late gene expression. 
A key biological property of HCMV is to maintain a lifelong relationship with its host by way 
of latent or persistent infections. During latency, only a subset of viral genes is expressed. The 
mechanisms governing the establishment and maintenance of latency and reactivation of HCMV 
from latency are complex and now coming into focus. HCMV resides latently in hematopoietic 
cells of the bone marrow. Several in vitro systems have been developed as models for HCMV 
latency. Nelson and colleagues [20,21] have used allogenic stimulation to study HCMV reactivation 
in monocytes that harbor viral genomes. CD4+ and CD8+ T lymphocytes, cytokines, IFN- , and 
tumor necrosis factor-  can facilitate viral reactivation [21,22]. Mocarski and colleagues [23,24] 
have studied HCMV latency in granulocyte–macrophage progenitors expressing CD33 and 
dendritic cell markers. They have identified several HCMV transcripts expressed during latency 
following in vivo or in vitro infection. Goodrum and colleagues have investigated a primary CD34 
(+) hematopoietic progenitor cell system as an experimental model to study HCMV latency and 
reactivation [25]. Using an HCMV gene array, they examined HCMV gene expression in these 
cells. CD34+ cells exhibit distinct patterns of viral gene expression from that observed during 
productive or nonproductive infections. Furthermore, pUL138 was identified as an HCMV protein 
that promotes an infection with the hallmarks of latency [26,27]. Sinclair and colleagues analyzed 
the secretome of cells carrying latent HCMV and have identified changes in several secreted cellular 
proteins known to be involved in regulation of the immune response and chemoattraction [28]. 
Their results identified a strategy by which sites of latent HCMV can firstly recruit CD4+ T cells 
and then inhibit their antiviral effector functions. All told, much more needs to be learned in order 
to develop a clear understanding of HCMV latency. 
In sum, HCMV infection strategies and viral replication are complex and reflective of the large 
genome, numbers of proteins (and miRNAs), and broad cell tropism.  
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3. Cell Cycle Checkpoints 
Cell cycle checkpoints are regulatory steps in pathways that govern the order and timing of cell 
cycle transitions to ensure completion of one cellular event prior to commencement of another. 
Checkpoints also offer the opportunity to repair damaged DNA. Most eukaryotic cells proceed 
through an ordered cell cycle, G1 S G2 M phase, during which the chromosomes and other 
cell material double in number with each of the daughter cells receiving one copy of the doubled 
genetic material. The cell cycle is completed when each daughter cell has its own intact  
outer membrane. Regulation of the cell cycle is the key for the normal development of multi 
cellular organisms. 
In the cell cycle, the G1 phase represents an organizing state prior to DNA replication and where 
decisions regarding cell cycle progress are made. Factors that influence progression through G1 
include cell size, metabolic state, cell signaling, and perhaps a need to repair damaged DNA. 
Inconsistency among these states or excessive DNA damage can lead cells to exit the cell cycle and 
undergo senescence or apoptosis. S phase is where DNA synthesis takes place resulting in the 
duplication of the cellular genome. In the G2 phase, the cell prepares for the process of mitosis, and 
the associated cell division to form two daughter cells. This stage provides another opportunity for 
recognition and repair of damaged DNA. Thus, under normal conditions, the progression of  
DNA replication and mitosis is signaled by the intracellular checkpoints primarily at the G1 and 
G2, respectively. 
4. DNA Damage Response (DDR) 
Many external and internal effectors, such as ionizing radiation and reactive oxygen species, can 
directly damage DNA. The presence of abnormal DNA structures, including single-stranded break, 
double-strand breaks, modification of incorporated nucleotides or aberrant replication fork structures, 
as well as alterations in higher-order chromatin structure, can induce one or more DDR. For a more 
complete review of DNA damage and responses, please refer to these publications [29–33]. 
Activation of the DDR plays a key role in avoiding or reducing errors. Although cells use 
different signaling pathways (Figure 1) to deal with different environment stresses, there are 
common elements. Signaling networks in response to DNA damage consists of sensors, 
transducers, and effectors. Sensors detect damaged DNA and signal to transducers. Transducers 
amplify and transfer the signal to effectors. Effectors then execute the cellular response to initiate 
cell cycle checkpoint activation, DNA repair or apoptosis. Cellular responses to DNA damage are 
crucial for maintaining genome integrity. Defects in the DDR system are also associated with 
several inherited human disorders [34–36] and cancers [37,38]. The DDR system tends to be more 
error prone than genomic replication and any remaining damage or incorrectly repaired damage 
may play a role in the development of pathologies such as birth defects, cancer or aging. 
DNA lesions trigger the activation of various kinases, which play important roles in DDR 
(Figure 1). The phosphatidylinositol-3-kinase-like family, including ataxia-telangiectasia mutated 
(ATM), ataxia-telangiectasia Rad3-related (ATR) and DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs) play central roles in DNA damage checkpoints. ATM is defective in  
ataxia-telangiectasia mutated disease (A–T), which is characterized by cancer susceptibility, 
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radiosensitivity and neurological defects [39]. ATM is the primary mediator of the response to 
DNA double strand breaks (DSBs); ATM has been traditionally considered a nuclear protein that 
functions in response to genotoxic damage though ATM also participates in the oxidative stress 
response and cytoplasmic signaling [40–44]. ATR activation is generally associated with  
single-stranded DNA breaks and stalled DNA replication forks. DNA-Pkcs is an important enzyme 
involved in the non-homologous-end-joining pathway of double strand break repair [45]. The 
phosphorylation of these proteins plays a crucial role in the activation of various effector proteins. 
A large-scale proteomic study on ATM and ATR substrates identified more than 700 proteins that 
are phosphorylated in response to DNA damage [46]. 
Figure 1. DNA damage-induced cell cycle checkpoint network. Schematic representation 
of ATM, ATR and DNA-PK signaling pathways. DNA-PK responds to DNA  
double-strand breaks and regulates nonhomologous end joining (NHEJ). The DNA 
ends are captured by the KU heterodimer. Ku regulatory proteins recruit DNA-PK to 
double-strand breaks; two DNA-PKcs molecules in concert tether DNA ends together 
and recruit the DNA Ligase IV–XRCC4 complex to rejoin broken DNA ends. ATM 
responds to DNA double-strand breaks; phosphorylates H2AX and NBS1, which 
localize to sites of DNA damage, where upon the MRN complexes form. ATM 
activation regulates cell-cycle checkpoints through the phosphorylation of CHK2 and 
p53. ATR is activated in response to single-stranded DNA (ssDNA). Activation of 
ATR requires TopBP1. ATR is recruited to RPA-coated ssDNA by its binding partner 
ATRIP. ATR regulates the cell-cycle through activation of CHK1. Both ATM and ATR 
are required to activate the p38MAPK/MK2 effector kinase complex downstream of 
TAO kinases in response to DNA damage. The three effector kinases, CHK1, CHK2, 
and MK2 are directly responsible for inhibitory phosphorylation on members of the 
Cdc25 family. Arrows indicate the flow of the respective DDR pathways. 
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5. The pRB-E2F Complex 
The RB protein family consists of three members—pRB, p107, and p130—which maintain cells 
in a quiescent state as well as regulate the transition from G0/G1- to S-phase by modulating the 
activity of the E2F family of transcription factors. E2F transcription factors are the major 
downstream targets of the RB family of proteins, and are necessary for the expression of many 
genes that are required for cell cycle progression [47–50]. RB family members exert their growth 
regulatory functions partly by inhibiting the transcriptional activity of E2F [51–55]. Conversely, 
disruption of the RB gene by deletion or mutation, or inactivation of pRB by phosphorylation or 
interaction with viral oncoproteins, cause the release of free or now depressed and transcriptionally 
active E2F1-3 resulting in cell cycle progression [56–58]. Sustained inactivation of pRB often results 
in apoptosis or deregulated proliferation. 
The E2F family, including E2F1-8, can be divided into two subgroups based on their primary 
function, activator E2Fs: E2F1, 2 and E2F3a, and suppressor E2Fs: E2F3b, E2F4-8. E2Fs 1–3a are 
required for the transactivation of target genes involved in the G1/S transition. E2F3 encodes two 
proteins, E2F3a and E2F3b that differ in expression pattern and function. E2F3a is a transcriptional 
activator mainly expressed during S phase, while E2F3b acts as a transcriptional repressor, which is 
constantly expressed during cell cycle. In contrast, E2F4 and E2F5 possess predominantly 
repressive activity. E2F4 and E2F5 bind to p107 and p130 with high affinity, and recent studies 
have demonstrated that they also interact with pRB [59–63]. E2F6 and E2F7 are also considered to 
be transcriptional repressors [64–69]. E2F6–8 are distinct from the other E2Fs in that they do not 
bind to pocket proteins. E2F6 is known to interact and form complexes with the Polycomb Group 
(PcG) proteins. It is not yet clear what the identity is of the interacting partners of these E2Fs. 
Deregulation of the pRB-E2F interaction results in hyperproliferation, lack of differentiation, 
genomic instability and can lead to cancer. 
6. The Link between Cell Cycle and DDR 
6.1. CHK1 and CHK2 Kinases Control the Cell Cycle in Response to DNA Damage 
DNA damage poses a continuous threat to genomic integrity in mammalian cells. In order to 
prevent the propagation of damaged DNA through the cell cycle, cells have evolved DDR that 
coordinate cell cycle progression and checkpoints with the repair of DNA lesions. Mammalian cells 
initiate cell cycle arrest at different phases of the cell cycle in response to various forms of 
genotoxic stress to allow time for DNA repair. Cell cycle arrest and apoptosis are two of the 
downstream consequences of DDR [70]. CHK1 and CHK2 are checkpoint kinases that are 
activated by ATM or ATR and phosphorylate cell-cycle components to cause the arrest of the cell 
cycle [71,72] (Figure 1). Although CHK1 and CHK2 have overlapping roles, CHK1 kinase is 
restricted to S and G2 where its activity is amplified in the presence of different types of DNA 
damage [73]. CHK2 is expressed throughout the cell cycle and is also activated in the presence of 
DNA damage [74]. Usually, CHK1 or CHK2 phosphorylated p53 and CDC25 propagate signals to 
arrest cells or to undergo apoptosis depending on cell type and extent of DNA damage. However, 
DNA lesions sometimes do not induce cell cycle checkpoint responses, such as DNA damage 
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during G2 phase of the green alga, Scenedesmus quadricauda [75]; or the level of DNA damage is 
low enough that the cell can deal with the lesions in the absence of a checkpoint response.  
6.2. A Novel Cell Cycle Checkpoint Kinase Pathway, MK2, that also Induced Cell Cycle Arrest 
Over the last decade, a number of publications point to a crucial role for the 
p38MAPK/MAPKAP-K2 (MK2) complex as an integral part of the DDR network [76,77].  
There are four p38MAPK isoforms denoted , ,  and  [78]. p38  and p38  have been  
shown to be activated by DNA damage-specific agents, such as cisplatin, doxorubicin, and 
temozolomiode [76,77,79–81]. p38  forms a nuclear complex with its downstream substrate MK2 
and that upon activation of p38MAPK in this complex, p38MAPK phosphorylates and activates 
MK2. p38MAPK/MK2 complex is a third checkpoint effect or module that operates parallel to 
CHK1 and is activated downstream of ATM and ATR [76,77,82] (Figure 1). More detailed 
information on this DNA damage checkpoint signaling pathways can be found elsewhere [82–84].  
7. Many Viruses can Induce DNA Damage Responses and Modulate Cell Cycle Progression 
DDR can be activated not only by external sources of DNA damage, but also by intracellular 
conditions, such as oncogene overexpression, loss of tumor suppressors, and viral infections. 
Recent studies demonstrate that infections by DNA viruses or viruses with a DNA genome stage 
during infection induce host DDR (Table 1) [85–89]. Somewhat unexpectedly, some viruses with 
RNA genomes can also induce DDR. The mechanisms responsible for DDR induction by RNA 
viruses are less clear and possibly indirect.  
The manipulation of the cell cycle by viruses is closely related to activation of the DDR and is 
usually associated with DNA double-strand break signaling pathways. As examples, oncoproteins 
of DNA tumor viruses, such as adenovirus E1A, simian virus 40 T antigen, and papillomavirus E7, 
each interact with the RB family of tumor suppressors, leading to E2F-mediated cell cycle 
stimulation, apoptosis induction, and cellular transformation. These proteins utilize a conserved 
LXCXE motif, which is also found in cellular proteins, to target the RB family. The subsequent 
induction of cell cycle checkpoints and activation of ATM/ATR/DNAPKcs pathways have been 
reported to accompany infection by a number of different viruses. Given that DDR usually results 
in cell cycle checkpoints and apoptosis, infection-associated DDR were initially considered to be 
antiviral, as in the case of adenovirus serotype 5 (Ad5) [90]. However, for many other viruses that 
induce a host DDR, the response appears to modulate the cell cycle at a precise point that favors 
virus replication [91–93]. Thus, manipulation of the cell cycle and the associated DDR may be a 
commonly employed strategy of viruses to create a favorable cellular environment for replication.  
Several mammalian viruses evolved mechanisms to manipulate DDR pathways for their own 
benefit by exploiting or actively inhibiting different parts of the pathways [91]. For example, 
simian virus type 40 (SV40), herpes simplex virus 1(HSV-1), HCMV, and Epstein-Barr virus 
(EBV) all activate ATM and downstream signaling during infection, which is accompanied by 
recruitment of ATM and other repair proteins to sites of viral DNA replication [94–97] (Table 1). 
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Table 1. A list of viruses that both induce and require host DNA damage responses 
(DDR) for productive infections. 
Virus that Induce DNA 
damage response (DDR) 
Abbreviation Virus type DDR factors activated 
DDR factors required 
for virus replication 
References 
Human cytomegalovirus HCMV 
dsDNA,  
-herpesvirus 
ATM, CHK2, p53, H2AX 
NBS1, CHK1 
ATM, p53, H2AX [94,98] 





ATM, CHK2, 53BP1, NBS1 ATM, Mre11 [95] 
Epstein-Barr virus EBV 
dsDNA,  
-herpesvirus 








ATM, H2AX, p53, CHK1 ATM, H2AX [100,101] 
Simian virus type 40 SV40 
dsDNA, 
polyomavirus 
ATM, CHK1, CHK2, p53 ATM, Rad51, FancD2 [97,102,103] 
Human papillomavirus HPV 
dsDNA, 
papillomavirus 
ATM, CHK2, H2AX, 
NBS1, CHK1, BRCA1 
ATM, CHK2 [104–108]  
Human parvovirus B19 B19V 
ssDNA, 
parvovirus 
ATM, CHK2, ATR,  
DNA-PKcs, CHK1, 
Ku70/Ku80, H2AX, RPA-32 
ATR, CHK1,  
DNA-PKcs, Ku70/ku80 
[109–111] 
Adeno-associated virus AAV 
ssDNA, 
parvovirus 
ATM, CHK2, DNA-PKcs, 
SMC1,  
H2AX, CHK1, RPA32 
DNA-Pkcs [112,113] 
Human T-cell 













ATM, H2AX, p53, NBS1, 
ATR, CHK1, P38MAPK 
ATM [120–122] 
Rift Valley fever virus RVFV 
ssRNA, 
arbovirus 
ATM, CHK2, H2AX, p53 ATM, CHK2, p53 [123,124] 
Hepatitis C virus HCV 
ssRNA, 
flavivirus 
ATM, CHK2, H2AX, CHK1 ATM, CHK2 [125,126] 
HSV-1, an alphaherpesvirus, has a complex relationship with the DDR, in that it activates many 
components of the ATM-dependent signaling pathway, such as phosphorylation of CHK2, 53BP1, 
and NBS1, while inhibiting the DNA-PKcs and ATR kinases [95,127–129]. MRE11-RAD40-NBS1 
(MRN) complex formation (Figure 1) and activated ATM promote HSV-1 replication [95]. HSV-1 
codes for an immediate early transcription factor, ICP0 that promotes cell cycle arrest by inducing 
the tumor suppressor p53 and its downstream target proteins (p21, GADD45, and MDM2). 
Epstein-Barr virus (EBV) is a gammaherpesvirus that induces the phosphorylation of ATM, 
NBS1, H2AX, CHK2, and p53 during lytic infection [99]. Phosphorylated ATM, NBS1 and Mre11 
proteins are recruited to EBV replication compartments. XPC, a sensor of DDR that functions in 
nucleotide excision repair, is required for EBV replication [96]. 
The murine gammaherpesvirus 68 ( HV68) latency-associated, anti-interferon M2 protein induces 
ATM activation and histone acetylation [100] presumably to limit the induction of a virus-induced 
DNA damage signaling cascade. However, HV68 protein kinase orf36 activates the DDR and 
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facilitates lytic replication in primary macrophages. H2AX, an orf36 substrate, can enhance 
MHV68 replication [101]. 
The large T antigen encoded by the SV40 polyomavirus, deregulates multiple DNA damage 
signaling and repair pathways [97]. ATM mediated phosphorylation of SV40 large T antigen is 
detected at the onset of viral replication, and is required for optimal viral DNA synthesis [102]. 
Inhibition of ATM activity decreases SV40 DNA accumulation [102,103], and delays the assembly 
of viral replication compartments and recruitment of cellular DNA repair proteins to these sites. 
Human papillomavirus (HPV) proteins induce a DDR characterized by the activation of the 
ATM kinase substrates CHK2, NBS1, and BRCA1 [104–108]. ATM kinase activity is required for 
HPV genome amplification in differentiating cells but not for episome maintenance in 
undifferentiated cells [106]. HPV does not induce degradation of MRN components but instead 
keeps them at high levels throughout differentiation [106].  
As a single stranded DNA virus, human parvovirus B19 (B19V) induces a broad range of DDR 
by triggering activation of all PI-3-like kinases associated with DNA repair pathways during 
infection [109–111]. Phosphorylated ATM, ATR, and DNA-PKcs, and their downstream targets 
(CHK2, CHK1, and Ku70/Ku80 complex, respectively) are all localized within B19V replication 
compartments. However, B19 virus apparently only uses ATR-CHK1 signaling to promote its 
replication [111]. 
Relatedly, adeno-associated viruses (AAV), another member of Parvoviridae, do not have an 
absolute requirement for ATM kinase activity. DNA-PK is the primary mediator of damage 
signaling in response to AAV replication [113]. Immunofluorescence revealed that some activated 
damage proteins are found in a pan-nuclear pattern (phosphorylated ATM, SMC1, and H2AX), 
while others such as DNA-PK components (DNA-PKcs, Ku70, and Ku86) and RPA32 accumulate 
at AAV replication compartments. DNA-PK enhances recombinant AAV (rAAV) replication 
through the interaction of Ku proteins and AAV-ITRs [112]. 
ATM protein can also enhance the replication of retroviruses and lentiviruses [120,121], such as 
human immunodeficiency virus type 1 (HIV-1) where ATM can enhance HIV replication by 
stimulating Rev function [120,122]. Similar observations have been made during human T-cell 
lymphotropic virus (HTLV1) infections [114–119].  
In most cases, ATM signaling has been demonstrated to be beneficial for DNA virus replication. 
It has also been suggested that RNA viruses activate DDR functions that can be beneficial. A study 
shows the induction of DNA damage signaling upon infection with Rift Valley Fever Virus 
(RVFV), an RNA virus, that results in cell cycle arrest and increased viral replication [124]. ATM 
and a number of its substrates, CHK2, H2AX, and p53, were phosphorylated following RVFV 
infection. The use of ATM and CHK2 inhibitors or p53-null cells demonstrates that they are 
required for RVFV replication [123,124]. Another recently identified example of an RNA virus 
that activates DDR is HCV, which replicates better in the presence of ATM and CHK2, and 
expresses viral proteins that bind ATM and sensitize cells to DNA damage [125,126]. Other studies 
observe that HCV NS2 protein inhibits DNA damage signaling by sequestering p53 in the 
cytoplasm while the viral core protein interacts with NBS1 protein, leading to inhibition of MRN 
complex formation thereby blocking ATM activation and signaling in response to DSBs [130,131]. 
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Clearly the association between RNA virus infection and DDR is complex, with additional study 
needed to better understand the molecular underpinnings and biology of this relationship. 
In contrast, some viruses do not use DDR signaling for replication [91]. Specially, serotype-specific 
inactivation of the cellular DDR during adenovirus infection has been found [132]. For example, 
human adenovirus serotype 5 (Ad5) encoded E4 proteins inactivate the MRN complex early in 
infection, either via E1b55K/E4orf6-mediated degradation of MRN [90,133] or E4orf3-mediated 
mislocalization of MRN into nuclear tracks [134,135] and cytoplasmic aggresomes [136,137]. In 
addition to preventing ATM and ATR-mediated damage signaling, inactivation of MRN promotes 
Ad5 DNA replication [134,138,139]. Likewise, Kaposi’s sarcoma-associated herpesvirus (KSHV) 
viral interferon regulatory factor 1 (vIRF1) compromises an ATM/p53-mediated DNA damage 
checkpoint by targeting both upstream ATM kinase and downstream p53 tumor suppressor [140]. 
Whether this activity is essential for productive or latent infection awaits further study. 
In summary, though there are some viruses that do not use DDR for their replication (i.e., Ad5), 
there are numerous viruses (Table 1) that induce DDR pathways and require ATM or other  
PI-3-like kinases for productive infection. For more detailed information of DDR and viruses in 
general, see the following reviews [85–89].  
8. HCMV Modulates the Cell Cycle and Checkpoints 
HCMV infection can alter the cell cycle status (Figure 2) and induce a DDR (Figure 3). Most 
cells infected with HCMV are driven into a unique G1/S-like state that provides enzymes and 
metabolites necessary for viral DNA replication [141–143]. At the same time, the virus directly 
suppresses competitive cellular DNA synthesis [144–147]. This unusual G1/S-like state is dependent 
upon several viral proteins including at least the tegument proteins pUL69 [148], pp71 [149], and 
pUL97 [150], pUL35 [151], the immediate early proteins, IE1 [152] and IE2 protein [153], and 
polymerase accessory protein pUL44 [154], while several other viral proteins prevent apoptosis 
signaling that would normally result from deregulating the cell cycle (Figure 2).  
The p53 checkpoint protein functions primarily as a transcriptional activator with target  
genes including the CDK inhibitor, p21, as well as Mdm2, a negative regulator of p53. The  
levels of p53 and its phosphorylation are increased during HCMV infection [94,98,141]. 
Phosphorylation-mediated activation of p53 induces an arrest of the cell cycle, which is mainly due 
to the induction of p21, sustained arrest leading to apoptosis. During HCMV infection, 
phosphorylation of p53 following DDR signaling prevents its interaction with MDM2, thereby 
stabilizing p53 by preventing its ubiquitin-mediated degradation [155], and contributing to the 
G1/S-like cell cycle arrest through the induction of p21 expression [152]. HCMV infection also 
activates several factors that normally induce cell cycle progression, including E2Fs [156]. In 
summary, the interaction between HCMV and cell cycle regulatory mechanisms is complex, with 
some viral factors eliciting cell cycle arrest and others promoting cell cycle progression. Thus, 
HCMV infection-induces a cell cycle arrest that leaves cells in a unique state that favors its 
replication, a theme that appears to be common to herpesviruses during productive infections [92].  
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Figure 2. The relationship between cell cycle and the DDR induced by HCMV. Lines 
depicted in green represent activities that promote cell cycle progression or prevent the 
cells from undergoing apoptosis. Lines depicted in red represent activities that can 
negatively affect cell cycle progress within the cell. 
 
Figure 3. Model of the host DNA damage response induced by HCMV infection. 
 
9. HCMV, Deregulation of the Cell Cycle, and DNA Damage Signaling 
HCMV infection induces a DDR that includes activation of ATM, H2AX, NBS1, CHK2, 
CHK1, and p53 [94,98,157]. How does HCMV induce DDR signaling? HCMV encode four 
proteins, IE1, IE2, pp71 and pUL97 that can either bind to or phosphorylate RB family members 
(Figure 2) [17,149,150,158–163]. Binding by these viral proteins to or phosphorylation of pRB 
causes the release of E2F proteins. Of these, the now de-repressed E2F1 can induce DSBs [164]. 
The resultant ATM activation and its downstream phosphorylation targets, including H2AX and 
206 
p53, contribute to HCMV replication [94]. These DDR phenotypes are similar to productive 
infection with another herpesvirus, HSV-1 [85,89,95,128]. In addition, HCMV pUL35 can active 
DDR, causing H2AX and 53BP1 foci formation and induce a cell cycle arrest [151] which likely 
supports viral replication [151].  
HCMV, in particular, encodes several proteins that both modulate cell cycle controls and the 
host DDR to promote viral replication. The following subsections focus on how some of these viral 
proteins, in particular, IE1, IE2, pp71, pUL97, pUL69, mediate these activities. 
9.1. IE1 Can Inactivate p107 and p130 
UL123, encoding IE1 (sometimes referred to IE1-72 or IE72), is the first transcribed HCMV 
gene. As a predominantly nuclear protein, IE1 is a promiscuous transactivator that also interacts 
and modulates the function of p107, a member of the RB protein family [17,165]. IE1 has been 
suggested to exhibit kinase activity [156,163]. In vitro kinase assays suggest that both p107 and 
p130 can be phosphorylated by IE1 and that phosphorylation of these two RB proteins is sufficient 
to disrupt their interaction with E2F4 [163]. These findings imply that IE1 specifically targets at 
least two RB proteins for inactivation, which causes the derepression of E2F-responsive promoters. 
Even with RB family member inactivation and derepression of E2Fs, IE1 expression is unable to 
induce S-phase entry in primary fibroblasts due to a p53-dependent arrest [152]. This ability of p53 
to block the IE1-mediated induction of S-phase is dependent on the p21 CDK inhibitor [157].  
IE1 also disrupts PML bodies [166–168] (also known as promyelocytic oncogenic domains 
(PODs) or nuclear domains-10 (ND-10)). PML is involved in cellular growth regulation, transcription, 
DNA replication and repair, and posttranscriptional regulation of gene expression [169]. PML body 
integrity is also a component of the host intrinsic antiviral defense and the displacement of PML 
protein from PML bodies by IE1 contributes for sustained viral gene expression [170,171]. 
9.2. IE2 Binds pRB and p53 
Studies have shown that the protein encoded by the largest transcript of UL122, IE2 (also known 
as IE2-86 or IE86) specifically interacts with pRB [16,160,172,173]. Expression of IE2 is sufficient 
to alleviate pRB repression of E2F-responsive promoters [16,47,160]. IE2 can also interact with  
p53 [174–176]. However, expression of IE2 in a human cell line blocked cell cycle progression in  
G1-phase similar to the phenotype observed when permissive cells are infected with HCMV [153]. 
Moreover, a study using DNA microarrays to analyze the effects of IE2 protein on cellular gene 
expression reveals that the 86kDa form of IE2 induces the expression of numerous factors 
associated with cell cycle regulation and bioenzymatic machinery necessary for DNA replication. 
For example, IE2 expression results in an increase in the mRNA levels of B-myb, cyclin E, cdk-2, 
E2F1, ribonucleotide reductase subunit-1 and -2, thymidine synthetase, MCM3, and MCM7, 
among other factors associated with S phase [177]. This study shows that most of the genes 
induced by IE2 are E2F targets. What is striking is that even though IE2 inactivates pRB, 
derepresses E2F activity, and can inhibit cell cycle arrest functions of p53, this viral protein does 
not induce S phase as measured by cellular DNA replication. This observation is in stark contrast to 
pRB and p53 targeting proteins encoded by other viruses such as SV40 lg T or the combination of 
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adenovirus E1A and E1B-55K proteins, which are potent inducers of cell cycle progression and S 
phase. A clearer understanding is needed as to why IE2 does not induce S phase. 
9.3. pp71 Binds to pRB, p107 and p130 
The pp71 phosphoprotein, expressed from the UL82 ORF, is a tegument protein that localizes to 
the nucleus immediately after virion entry during productive infections [178,179]. Functionally, 
pp71 is a transcription factor that is packaged within the viral tegument and is essential for the 
adequate accumulation of IE1 and IE2 by transactivating the major IE promoter and accelerating 
the infection cycle of HCMV [180]. Studies examining the relationship between pp71 and the cell 
cycle reveal that pp71 contains a sequence (LACSD) that is similar to the RB-binding motif 
(LxCxE) present in viral oncoproteins encoded by the small DNA tumor viruses. This motif is 
required for the induction of DNA synthesis in quiescent cells and for degradation of the RB family 
by viral oncoproteins [149,162]. pp71 binds to all three RB family members and promotes the G1/S 
cell cycle state during infection [149]. 
9.4. pUL97 Phosphorylates RB Protein 
pUL97, another tegument protein, is a multifunctional viral protein kinase which is required at 
multiple steps during viral replication. Deletion of the pUL97 region from the viral genome or 
pharmacological inhibition of pUL97 kinase activity drastically reduces viral replication. A number 
of cellular and viral interacting proteins and substrates of pUL97 have been described, including 
viral pUL69 [181], pUL44 [182], autophosphorylated pUL97 [183,184] , and, given its cdk-like 
activity, cellular RB family proteins are also phosphorylated by pUL97 [150]. In addition, pUL97 
is able to phosphorylate nuclear lamins, which contributes to the HCMV-induced reorganization of 
the nuclear lamina [185].  
9.5. pUL69 Modulates CDK Function 
As mentioned earlier, IE1, IE2 and pUL97 can interact or phosphorylate RB family members to 
inactivate protein function, which can, under certain circumstances, result in stimulation of cell 
cycle progression. However, during HCMV infection, cell cycle progression is blocked at multiple 
points, including the G1-to-S-phase transition. pUL69, a phosphorylated virion tegument  
protein [186], is reported to be a factor responsible for this cell cycle block [148]. Host CDKs and 
pUL97 phosphorylate pUL69 and modulate its nuclear localization and activity [181]. Although the 
mechanism by which pUL69 induces an accumulation of cells in G1 is not clear, these findings 
indicate that HCMV tegument proteins (pUL69, pp71, and pUL97) can have an immediate effect on 
the cell cycle. It seems that HCMV has developed a strategy to inhibit cellular DNA replication and, 
at the same time, alter the host environment in a manner that ensures the replication of viral DNA. 
9.6. E2F1-mediated DNA Damage Response 
In the normal condition, RB family members bind to E2F family members to limit cell cycle 
progression. During HCMV infection, at least four viral proteins (IE1, IE2, pp71 and pUL97) 
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inactivate RB family proteins resulting in the release of E2F proteins. These derepressed E2F 
proteins then alter the expression of S phase genes that contribute activities and substrates that 
support viral DNA replication. In addition, deregulated E2F1 induces DSBs and stimulates a robust 
host DDR [94]. The mechanism responsible for this phenomenon is unclear but it is specific to 
E2F1 as other RB-targeted E2Fs, namely E2F2 or E2F3, do not induce double strand DNA breaks 
(DSBs) or DDR [164]. This relationship between E2F1 and DSBs appears relevant to HCMV, as it 
is the only activator E2F that contributes significantly to viral replication [94]. Moreover, ATM, 
the signal transducing kinase of many DDR, functions downstream of E2F1 deregulation and is 
also required for HCMV replication [94].  
10. Which DDR Factors Contribute to HCMV Replication? 
ATM has been implicated as a target of several DNA viruses (Table 1), which activate or inhibit 
the ATM signaling pathway [85]. Depletion or inhibition of ATM by RNA interference or by 
pharmacological compounds, respectively, demonstrate that ATM is a key kinase in DDR and also 
the most common DDR factor contributing to virus replication [94]. ATM and at least some 
downstream targets, like H2AX [94], p53 [187] contribute to HCMV replication. In addition, at 
least one DNA repair factor, DDB2 [188], influences HCMV replication. 
11. Difference and Similarities in the DDR Induced by HCMV and Other Viruses 
11.1. HCMV Is Similar to Other Viruses that Use DDR (ATM Signaling) for Replication 
As listed in Table 1, many viruses can activate ATM, and most of them can use ATM signaling 
to promote viral replication [94,95,97,99–104,106,108–110,113,114,116,120,122,124,125]. HCMV 
infection as well as IE1 or IE2 transduction can activate ATM [94,98,157]. Using caffeine, a PI3 
kinase-like inhibitor, KU 55933, an ATM-specific inhibitor [189], AT cells derived from patients 
with ataxia telangiectasia, or siRNAs to deplete ATM, results in reduced or blocked HCMV 
replication [94]. Here, HCMV is similar to many other viruses with DNA stages in their replication 
strategy, such as HSV-1, HIV, MHV-68, SV-40, and HPV, in its requirement for ATM signaling 
for replication. 
11.2. HCMV is Different from Other Viruses Not Using ATM or that Block DDR for Replication 
HCMV is different from Ad5 and KSHV or B19V in its requirement for ATM signaling for 
efficient replication. Ad5 has evolved mechanisms to inhibit DNA damage signaling and repair 
during infection by degrading and mislocalizing components of the Mre11–Rad50–NBS1 (MRN) 
DNA damage recognition complex [135]. In addition, the Ad5 E3 ligase complex (comprised of 
E1B-55K and E4 adenoviral proteins) is able to target a number of cellular DNA repair proteins for 
proteasomal degradation including the RecQ helicase, bloom helicase (BLM) [190]. KSHV vIRF1 
protein compromises an ATM/p53-mediated DDR by targeting both upstream ATM kinase activity 
and also downstream p53 tumor suppressor function by facilitating its proteasome-mediated 
degradation [140]. However, a recent study shows that during early de novo infection of primary 
endothelial cells, KSHV induces DDR signaling and ATM kinase activation as measured by H2AX 
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phosphorylation, which are essential for KSHV’s latent gene expression and establishment of 
latency [191]. Taken together, it seems that KSHV is able to both inhibit, and induce the cellular 
DDR dependent upon its replication strategy. Infection with B19V induces a broad range of DNA 
damage responses by activating three upstream kinases: ATM, ATR, and DNA-PKcs. Disruption 
of either the ATR or DNA-PKcs, but not ATM, signaling pathways significantly reduced the 
efficiency of B19V replication without affecting the resultant cell cycle arrest [111]. Thus, it 
appears that B19V uses ATR and DNAPKcs, but not ATM to facilitate its replication. Likewise, 
DNA-PKcs contribute to the replication of adeno-associated virus (AAV), another parvovirus [112]. 
Interestingly, AAV and Ad5 coinfections activate a broad DDR that is different from that seen 
during Ad5 or AAV infection alone [113]. 
12. HCMV Infection Results in the Relocalization of DDR Proteins to Virus Replication 
Compartments (RCs) 
Viral RCs are sites of viral DNA replication and maturation. RCs begin as multiple, discrete 
structures early in infection, then move and coalesce into a single, large structure that can be  
referred to as a “mature” RC [94,192]. HCMV DNA replication happens in the RCs, similar to  
HSV-1 [95,193,194]. During HCMV infection, many DDR proteins are relocalized to the RCs 
including H2AX, p53, pATM, MRE11, CHK2, NBS1, Rad50, ATRIP, and CHK1 [94,98]. 
Although the mechanism(s) responsible for this relocation is unclear, these DDR proteins might 
interact with the viral DNA replication machinery in RCs to regulate viral DNA replication, gene 
expression, or recruit DNA repair proteins to repair damage to viral DNA. 
13. Does DNA Damage Exist in Cellular or Viral DNA During Infection? 
Many DNA viruses and retroviruses can tether or integrate their genome into the host DNA 
during infection [195,196]. It has been suggested that viral genetic material can be recognized by 
the host as damage DNA and stimulate cellular DNA repair mechanisms [197]. Given these 
observations, questions arise regarding whether host DNA is damaged during infections and 
whether DNA damage exists in viral DNA.  
Host chromosome breaks have been observed in HCMV-infected cells. Infection of cells during  
S-phase results in two specific breaks on chromosome 1 at positions 1q42 and 1q21 [198]. HCMV 
infection-associated damage to chromosome 1 appears not to be cell-type-or-strain specific. Cells 
infected with HSV also show an increased incidence of chromosome breaks [199,200]. Chromatid 
gaps and breaks were found to accumulate in region 3 of the X chromosome and in region 7 of 
chromosome 1 [201]. Adenovirus type 12 E1B protein can induce damage specifically at 17q21–22, 
lp36, 1q21, and lq42-43 and at random sites in cellular chromosomes [202]. For HCMV, it is not 
clear if infection causes extensive host DNA damage or whether the two DNA break is sufficient to 
initiate the observed host DDR. 
Some studies suggest that viral adsorption and penetration is required for inducing chromosomal 
breaks whereas viral protein expression is not required for induction of damage [198]. Alternately, 
a viral or cellular protein component of the incoming virion may be responsible for the induced 
damage. Our laboratory has observed DDR at very early times of infection, even before de novo 
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viral protein expression. Input tegument proteins have been suggested to be partly responsible for 
DDR soon after viral entry, perhaps by inactivating pRB and derepressing E2F1 [199].  
Another possible source of the DDR is that incoming, virion-delivered viral DNA or the nascent 
viral DNA generated during replication, is damaged or contains mutations. Evidence for these 
possibilities exists for HSV [194,200–204]. One can imagine that the oxidative state of virally 
infected cells, in particular HCMV infected cells [205] may result in oxidation of nucleotides such 
as guanines in viral DNA. It is also possible that, even though herpesviruses encode replicase 
complexes with proof reading activity, the high levels of (viral) DNA replication during infection 
may result in an accumulation of mutations that stimulate the relocalization of DDR proteins to 
viral RCs.  
Activation of DDR does not necessarily require DNA lesions. Prolonged binding of DNA repair 
factors to chromatin can elicit DNA damage response in an ATM- and DNA-PK dependent manner 
in the absence of DNA lesions [206]. The herpesviral genomes are synthesized in a rolling  
circle manner to produce head-to-tail concatemers that are subsequently cleaved into unit-length 
genomes [207] and either the replication complexes or the cleaved DNA may be recognized as 
damaged DNA and trigger a DDR. In addition, viral infections confront cells with large amounts of 
exogenous genetic material that might be broadly recognized as abnormal [197] or the physical 
interaction of DNA repair factors with chromatin can be sufficient to activate the DDR signaling 
cascade [206]. Another possibility is that infected cells recognize viral replication as a genotoxic 
stress and elicit a DDR. In the case of HCMV infection, the inactivation of RB family members by 
IE1, IE2, pp71, and pUL97 and subsequent deregulation of E2F1 appears to result in DSBs in human 
fibroblasts [94]. Thus, it is possible that a trigger of the virus-induced DDR is not necessarily the 
recognition of linear viral DNA as double-strand breaks or actual damage to DNA, but rather, it is 
the recruitment of DNA damage repair factors to RCs or, very likely, a combination of these 
possibilities. Clearly, much work is needed to understand the interplay of viral infection, the 
presence of viral DNA and proteins, the remodeling of host cells function and the resultant DDR. 
14. Future Perspectives 
Although it is well accepted that activation of host DDR is a common theme of infections with 
DNA viruses, many of which require DDR signaling to replicate, more detailed study is still 
needed to better understand the “hows” and “whys” of this relationship. Most small DNA viruses 
capable of infecting nondividing cells induce S phase in order to activate the host DNA replication 
machinery to provide the nucleotide triphosphates and host replication machinery necessary for 
viral DNA replication [93]. However, many large DNA viruses, such as herpesviruses, code for not 
only their own viral replicase enzymes, but also factors involved in deoxynucleotide synthesis and 
do not require a canonical S phase to support viral replication [92]. It has been thought that the host 
DNA polymerases do not play a role in herpesviral DNA replication. However, our unpublished 
studies suggest that host DNA polymerases may contribute to HCMV replication with the 
implication that theses enzymes may contribute activities that are different from the viral 
polymerase [208]. It should be interesting to explore the roles of host DNA polymerases in the 
replication of HCMV and other viruses. 
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Components of the ATM-pathway are activated and recruited to sites of viral DNA synthesis 
including HCMV infected cells. Although ATR- and ATM-mediated pathways are related and both 
can be activated by similar genotoxic events, HSV-1 distinguishes between these two pathways, 
inactivating ATR pathway and potentially using ATM pathway. In contrast, it has been noted that 
the steady-state levels of ATR increase in HCMV infected cells at 48 hpi accompanied by a shift in 
mobility [98]. The ATR pathway also responds to DSBs, generally more slowly than ATM [209]. 
Determining the contribution of ATR signaling in relation to ATM signaling during HCMV 
infection should provide important insight into the specifics of DDR signaling as it pertains to 
HCMV infection and viral DNA replication, 
HSV and HCMV infections, and the adenovirus type 12 E1B protein induce chromosome breaks 
in specific chromosome regions. The particular nonrandom distribution of chromosome aberrations 
in the HSV and HCMV infected cells raise a question as to whether virion genome deposition or 
early replication localized to particular chromosome regions are responsible for these effects. 
The mechanism by which E2F1 stimulates host DDR is not well understood. Inactivation of RB 
and the subsequent deregulation of E2F1, but not the related family members, E2F2 or E2F3, leads 
to an accumulation of DSBs in human fibroblasts as observed by the H2AX immunostaining and 
neutral comet assays [164]. The mechanism by which E2F1 stimulates host DDR needs to be 
further studied during infection by HCMV and other viruses. 
Ubiquitination and sumolyation is one of the most common mechanisms by which viruses target 
cellular proteins. Viruses can encode their own ubiquitin ligases, such as the ICP0 protein of  
HSV-1. ICP0 interacts with PML isoform I and induces its SUMO-independent degradation [210]. 
Other viral proteins, such as Ad-E1B55K/E4orf6, KSHV-LANA, HPV-E6, and HIV-Vpr, can 
recruit and redirect cellular ubiquitin ligase complexes to target proteins. A recent study shows that 
a DNA repair factor, DDB2, can contribute to HCMV replication [188]. DDB2 is a component of a 
Cul4A-Ub ligase complex. The DDB1-CUL4ADDB2complex is a cullin-RING (i.e., E3) Ub-ligase 
that targets histone H2A at UV-damaged DNA sites. Whether the ubiquitination ability of this 
complex is involved in HCMV replication needs further investigation. 
One wonders if the intimate relationship between the host DDR and HCMV infection can be 
leveraged to treat HCMV-associated diseases. For example, there are no licensed treatments for 
pregnant women who undergo primary infection with HCMV during pregnancy, which places the 
fetus at risk for symptomatic congenital infection. This is at least partly due to the fact that drugs 
that are effective against HCMV infection have serious teratogenic side effects, which make them 
inappropriate for use during pregnancy. HCMV is also a common complication during tissue 
transplantation. Here, ganciclovir is commonly used to treat HCMV disease. However, ganciclovir 
induces leukocytopenia, an unwanted side effect in patients already receiving immunosuppressants. 
Perhaps, ATM inhibitors or more appropriately, drugs that target ATM responsive factors can be 
used alone or as adjuvant therapies to prevent congenital CMV infections or other diseases associated 
with infection. Continued study of infection-induced DDR pathways is essential for a better 
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Abstract: Human cytomegalovirus (HCMV) is a ubiquitous pathogen capable of 
causing life threatening consequences in neonates and immune-compromised 
individuals. HCMV inflicts site-specific double strand breaks (DSBs) in the cellular 
genome. DNA damage infliction raises the corollary question of virus modulation of 
DNA repair. We recently reported HDR was stimulated in wt human foreskin 
fibroblasts (HFFs) during fully permissive infection or expression of the HCMV protein 
IE1-72 (IE72). These studies have been extended into semi-permissive T98G 
glioblastoma cells. T98Gs encode a mutant p53, which may contribute to their high 
baseline rate of HDR. We fully expected HCMV infection to increase HDR in T98Gs, 
similar to its effects in HFFs. Surprisingly in T98Gs HCMV infection, or sole 
expression of IE72, decreased HDR by two-fold. Transient expression of wt p53 in 
T98Gs also reduced HDR by two-fold. Dual transient expression of wt p53 and IE72 
restored high baseline HDR levels. GST pulldown experiments revealed that both IE72 
and wt p53 bound the important HDR protein, Rad51. We conclude that the expression 
of certain HCMV proteins can modulate HDR in an infected cell, dependent upon p53 
status. We propose a model of the protein interactions explaining this behavior. 




Human cytomegalovirus (HCMV) is a member of the -herpesvirus family and is endemic in 
the human population. HCMV can cause congenital birth defects, primarily of neurological  
origin [1–3]. It also causes severe systemic disease following reactivation in immunosuppressed 
individuals [4]. The virus’ role in oncomodulation of cancers has also recently been the subject of 
intensive investigation (for review see [5,6]).  
One of the direct effects of HCMV infection in human foreskin fibroblasts (HFFs), is the 
induction of two site-specific breaks at chromosome 1q42 and 1q23.3 in the host cellular  
DNA [7,8]. The physiological significance of HCMV-induced specific breaks or whether they can 
be repaired is unknown. However, the proximity of the 1q23.3 breakpoint to two hearing 
impairment (HI) loci, DFNA49 and DFNA7, and in the vicinity of the myelin protein zero (MPZ) 
gene [9], prompts speculation on this break’s correlation with the hearing loss observed in 
congenitally infected infants. 
Mammalian cells are exposed to both intrinsic (i.e., reactive oxygen species) and extrinsic 
(i.e., genotoxic chemicals) agents capable of inflicting cellular DNA damage. DNA damage triggers a 
cascade of complex protein signaling pathways. This combination of pathways constitutes the DNA 
damage response (DDR). Depending on the type and extent of DNA damage different repair pathways 
are activated. In the case of double-stranded breaks (DSBs), two repair pathways are principally 
activated (as reviewed in [10,11]). One is the error free homology-directed repair (HDR) pathway, 
which commonly involves strand invasion of a sister chromatid. The other pathway utilizes the 
more error-prone non-homologous end-joining (NHEJ) or single-strand annealing mechanisms. 
We recently reported interactions between HCMV and HDR in permissive HFFs [12]. HCMV 
infection caused a two-fold increase in HDR of an I-SceI induced site-specific DNA DSB, from a 
baseline level of 4% to a stimulated level of 8%. Expression of the HCMV IE72 protein on its own 
produced comparable results. Here the same DSB repair assay has found that HCMV regulates 
HDR in the semi-permissive T98G cells in a surprising and counterintuitive manner, hinging on the 
p53 status of these cells. A model to explain the interaction of HCMV IE72 with p53 and the HDR 
machinery is proposed.  
2. Results 
2.1. Introduction of the pDRGFP Substrate into T98G Cells to Assess HDR 
Our earlier study assessed whether HCMV infection affected HDR of an integrated substrate at  
I-SceI-induced DSBs in fully permissive HFFs. This work found that HDR, as measured by an 
increase in GFP+ cells, was stimulated in HFFs during HCMV infection and, further, that 
expression of the HCMV protein IE72 on its own also stimulated HDR [12]. The assay utilized a 
non-functional GFP reporter substrate susceptible to DSBs upon introduction of I-SceI [13,14] (see 
Figure 1A for diagram of the substrate). If the DSB was successfully repaired by HDR, functional 
GFP was reconstituted. HDR was scored by microscopic analysis for cellular GFP+. These 
fibroblast experiments have now been extended into the semi-permissive cell line T98G. Three 
different stable clones of T98Gs with an integrated pDRGFP substrate were generated. The results 
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obtained using all clones were consistent, therefore here we report only representative studies 
carried out in Clone 10.  
Clone 10 was synchronized in G0 and then infected with an Adenovirus (Ad) expressing the  
I-SceI endonuclease (NGUS24i), or an Ad control virus (dL70-3) [15,16] at various MOIs (5, 10, 
25, 50, 100, and 200) or were mock-infected. Cells were analyzed for efficiency of I-SceI 
endonuclease production after NGUS24i infection. The I-SceI endonuclease in this virus is tagged 
with hemagglutinin (HA), permitting detection of protein expression using an anti-HA Ab by IF. 
100% of the cells infected with NGUS24i displayed HA-positivity and no staining was observed in 
mock-infected cells (Figure 1B) or dL70-3-infected cells (data not shown). 
NGUS24i infection produced GFP+ cells. This indicated I-SceI-induced site-specific DNA 
breaks had been successfully repaired by HDR. In our hands NGUS24i infection effects were 
greatest using an MOI of 200 and continuous incubation for 72 h prior to harvest. Clone 10 was 
also examined for spontaneous HDR events. Figure 1B displays representative experiments 
depicting the absence of any GFP+ cells in mock-infected Clone 10. These results demonstrated 
that the Ad-based enzyme delivery system in conjunction with the integrated pDRGFP substrate 
worked as well in the T98G cells as had been previously observed in the HFFs [12]. 
Figure 1. Efficient expression of I-SceI from an Adenoviral vector based system in 
T98Gs with an integrated pDRGFP substrate. (A) Schematic diagram of reporter 
plasmid pDRGFP as described in [12]. (B) Representative IF staining of Ad-infected 
Clone 10. Cells were seeded onto glass coverslips and infected with Ad expressing  
I-SceI (NGUS24i). Coverslips were harvested at 72 h post infection. GFP+ cells were 
scored as HDR competent. Cells were stained with HA-specific Ab to detect HA-I-SceI 
expressed from NGUS24i. Scale bar = 5 m for all panels and all figures.  
 
2.2. HDR at I-SceI Induced DSBs Was Downregulated in HCMV-Infected T98G Cells 
Previously we showed that in a semi-permissive infection of T98G cells, although all cells take 
up virus, only a modest percentage (~30%–40%) of cells express IE72 antigen (Ag) in contrast to 
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100% Ag+ cells in a fully permissive infection [17]. Clone 10 was Go synchronized, released from 
synchronization and then mock-infected or HCMV-infected at an MOI of 10 for 48 h. These cells 
were subsequently superinfected with NGUS24i or dL70-3 and harvested at 72 h post Ad infection. 
Cells were stained for the expression of HCMV IE72 by IF to monitor initiation and progression of 
HCMV infection. Approximately 30% of cells were IE72+ at 120 h post infection (hpi), which 
agreed with previous experiments [17]. Cells were also scored for GFP+. Representative IF images 
for these infections are shown in Figure 2A.  
Figure 2. HCMV infection decreased HDR in T98Gs in the presence of stably 
integrated pDRGFP substrate. Cells were seeded onto glass coverslips and infected with 
HCMV or Ad individually or dually with HCMV and Ad in succession. Coverslips were 
harvested at 72 h post Ad superinfection with either I-SceI expressing (NGUS24i) or 
control (dL70-3) virus. GFP+ cells were scored as HDR competent. Clone 10 was 
stained by IF for the presence of IE72. (A) Representative IF staining for GFP+ + IE72+ 
cells in Clone 10. (B) Percentage of GFP+ cells in Clone 10 after infection.  
(C) Representative protein profile for steady state levels of HA-tagged I-SceI in Clone 
10 infected with NGUS24i alone or dually infected with HCMV and NGUS24i. Actin 
was used as a loading control. For IF studies at least 300 cells were scored for each type 
of infection. Values on top of the bar indicate fold decrease in percent of GFP+ cells in 
dually infected versus NGUS24i alone experiments. Error bars represent one SD.  
 
T98Gs displayed a very high baseline rate of HDR after DSB induction with I-SceI. Ad 
NGUS24i infection resulted in ~16% GFP+ cells (as compared to 4% in HFFs) [12]. No GFP+ cells 
were observed in either dL70-3-infected or mock-infected cells. An average of ~7% GFP+ cells 
were detected in HCMV-infected cells subsequently superinfected with NGUS24i to induce DSBs, 
an ~2 fold decrease (Figure 2B). Although not quite reaching a degree of statistical significance, 
this decrease was consistently reproducible (fold changes of 2.7 and 1.9 in two experiments). 
231 
Downregulation of HDR due to HCMV infection was not associated with changes in steady  
state levels of I-SceI expression. Immunoblot analysis found no decrease in I-SceI expression in 
HCMV-infected T98Gs compared to mock-infected T98Gs (Figure 2C). Actually, somewhat the 
reverse was found with slightly higher levels of I-SceI observed in lysates derived from an 
equivalent number of virus-infected cells. Thus lower expression of the I-SceI enzyme was not the 
cause of the somewhat paradoxical decrease in HDR. 
2.3. Transient Expression of IE72 Alone Was Sufficient to Downregulate HDR in T98Gs 
A number of studies have suggested that IE72 plays a vital role in fine tuning the host cell, 
including activating early gene expression needed for viral replication ([18] and as reviewed  
in [19]). We had previously shown that expression of IE72 alone was sufficient to enhance HDR in 
HFFs [12]. Having found that full HCMV infection reduced HDR in T98Gs, we repeated the IE72 
expression assays in these cells. Parallel experiments to those above were performed in Clone 10 
nucleofected with vector-alone (pSG5) or an IE72-expressing construct (pSGIE72). These cells 
were then Ad infected. Cells were subsequently scored for IE72 and GFP positivity. Approximately 
90% cells were IE72+ (data not shown).  
No GFP+ cells were observed in vector alone (pSG5), pSG5 + dL70-3-infected (control Ad), 
IE72 alone or IE72 + dL70-3-infected cells. In close agreement with the previous results an 
average of ~16 % GFP+ cells were detected in cells nucleofected with pSG5 and NGUS24i-infected 
(I-SceI expressing Ad). In cells nucleofected with the IE72 construct and NGUS24i-infected, an 
average of 9% GFP+ cells were scored, a 1.8 fold decrease (Figure 3A). This decrease was 
approximately equivalent to the reduction in GFP+ of HCMV-infected cells. Again, although this 
decrease was not statistically significant, it was consistently reproducible (fold changes of 1.9 and 
1.5 in two experiments). Therefore, as was seen in HFFs, transient expression of IE72 alone largely 
recapitulated the HCMV-infection results, however, with the same perplexing downregulation of 
HDR in T98Gs. 
2.4. Expression of wt p53 in T98Gs Caused the Same Decrease in HDR as IE72 
T98Gs have a mutagenic profile and harbor a mutation in p53 at R273H, in the DNA binding 
domain [20]. It is widely accepted that wt p53 suppresses HDR (as reviewed in [21]). Was the 
mutation in p53 responsible for the elevated levels of HDR (~16%, Figure 2B) in uninfected T98Gs 
compared to HFFs (~4%, [12])? If so, introduction of wt p53 would be expected to decrease HDR 
levels in uninfected T98G cells and, similarly, p53 DNA binding domain mutants would not be 
expected to alter HDR levels. Experiments parallel to those discussed for IE72 were performed in 
Clone 10. It should be noted that although all the constructs used in this study were GFP-tagged, 
the wt p53 and the mutant p53 genes were expressed from the weak wt p53 promoter and, as we 
have previously observed [22], no detectable GFP expression above background was observed in 
control populations of these cells (data not shown). Clone 10 was nucleofected with vector-alone 
(pCDNA3-T7) or constructs [22] expressing wt p53, a non-acetylatable p53 mutant (K382R), p53 
DNA binding domain mutants (R273H, R175H, R248W, G154V), or a p53 N-terminal multi-site 
phosphorylation mutant and subsequently Ad-infected. Cells were scored for GFP+ (Figure 3B). 
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Figure 3. Nucleofection with IE72 or wt p53 alone decreased HDR, whereas  
co-expression did not alter high level HDR in T98Gs. Cells were nucleofected with the 
indicated plasmids and then infected with either I-SceI expressing (NGUS24i) or 
control (dL70-3) Ad. Coverslips were harvested at 40 h post Ad infection. GFP+ cells 
were scored as HDR competent. (A) Percentage of GFP+ in Clone 10 after 
nucleofection of IE72 or pSG5 control. (B) Percentage of GFP+ in Clone 10 
nucleofected with either wt p53 or p53 mutants (K382R, N-term, R273H, R175H, 
R248W, G154V). (C) Percentage of GFP+ in Clone 10 nucleofected with wt p53 and/or 
IE72. At least 300 cells were scored for each type of infection. Error bars represent one 
SD. Values on top of the bars indicate fold decrease (or increase for the dual IE72/wt 
p53 nucleofection) in percent of GFP+ cells. *, ** and *** indicate increasing levels of 
statistical significance (see text for details). Error bars represent one SD.  
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Immediately evident was that introduction of even low levels of wt p53 into T98Gs resulted in 
accelerated cell death, with very few cells surviving until 72 h post Ad infection. The infection 
protocol was modified to overcome this technical problem. Ad infection MOIs were reduced 
from 200 to 5. An MOI of 5 still delivered I-SceI enzyme to the entire population, as detected by 
HA Ab staining (data not shown), however the lower MOI reduced baseline DSB-induced HDR 
events to a more modest, but still prevalent, ~11%. More importantly, the reduced MOI allowed 
sufficiently high cell survival for a long enough duration to obtain meaningful population counts. 
Eight hours post-nucleofection, cells were Ad infected and GFP+ was scored at 40 h post Ad 
infection. Following this modified protocol, control experiments using any of the constructs 
followed by infection with the dL70-3 control virus showed no GFP+ cells (data not shown). 
Nucleofection with no DNA, or introduction of vector alone (pCDNA3) followed by  
I-SceI-expressing NGUS24i-infection produced an average ~11% GFP+ cells (Figure 3B). Cells 
nucleofected with wt p53 or the p53 K382R mutant produced an average of ~6% GFP+, an ~2 fold 
decrease. This decrease was consistently reproducible and highly statistically significant for both 
constructs (p value < 0.0001 and 0.0004, respectively). The introduction of the p53 DNA binding 
domain mutants (R273H, R175H, R248W, G154V), or the p53 N-terminal multi-site 
phosphorylation mutant yielded no change in the percent of GFP+ from the vector alone. Thus, 
introduction of wt p53 into the T98G cells suppressed the high level HDR allowed by the 
endogenous mutant p53 [20].  
2.5. Co-Expression of IE72 and wt p53 Negated Their Individual Effects on HDR 
Surprisingly, in the T98G microenvironment, expression of either IE72 or wt p53 reduced HDR, 
therefore we tested co-introduction of both proteins. Using the modified protocol described above, 
once again control experiments using dL70-3 virus produced no GFP+ cells (data not shown). 
We observed that nucleofection with no DNA, or introduction of backbone vector (pCDNA3) 
followed by I-SceI-expressing NGUS24i produced an average ~9% GFP+ cells. Introduction of 
either IE72 or wt p53 alone reduced GFP+ to ~5%, an ~2 fold decrease as expected, both of which 
were statistically significant (p = 0.01 and p = 0.0014, respectively). Much to our surprise, dual 
introduction of IE72 and wt p53 produced an average of 13.6% GFP+ cells, an ~1.4 fold increase 
from the baseline rate of ~9%, an increase that was only marginally statistically significant (p = 0.043) 
(fold changes of 1.3, 1.7, 1.5 in three experiments) (Figure 3C). This suggested that in T98G cells 
interaction between wt p53 and IE72 negated their individual effects on the HDR machinery. 
2.6. In Vitro Binding Assays Found Both wt p53 and IE72 Bound Rad51 
T98G cells harbor a mutant p53 (R273H mutation) [20]. The mutation abolishes specific DNA 
binding. The p53 transient expression experiments established that an intact DNA binding domain 
and phosphorylatable N-terminus were required to decrease HDR in these cells. Previous studies 
have determined that recombination is controlled, at least in part, by p53 binding to the strand 
invasion protein Rad51, which modulates Rad51’s function (as reviewed in [21]). An intact DNA 
binding domain in the p53 protein is required for this interaction [23–25]. Further, T98G cells 
mount a DSB response [20] and express high levels of the DSB repair proteins, including  
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Rad51 [20,26]. Previous work had established that p53 could bind both Rad51 and IE72 [27], and 
that interaction between p53 and IE72 could negate p53’s normal DNA binding ability through its 
core region [27]. This information suggested that the effects noted in the above transient expression 
and co-expression experiments might be the result of IE72 binding either wt p53 or Rad51. In vitro 
mixing experiments of radiolabeled Rad51 and pGEX72, GST wt p53 or pGEX-KG (control GST 
alone) were performed. As can be seen in Figure 4, both p53 and IE72 were capable of binding 
Rad51, although IE72 appeared to be slightly less avid for the protein. While not excluding other 
possible explanations, this binding, in combination with the results from the expression 
experiments, have prompted us to propose a protein interaction model capable of explaining the 
observed behaviors (see Figure 5 below). This model may have significant bearing on questions 
entirely unrelated to HCMV-infection in the semi-permissive cell type T98G. 
Figure 4. GST pulldown experiments revealed IE72 and wt p53 bound to Rad51. GST 
proteins were incubated with radiolabeled Rad51 for 1 h as described in experimental 
details. Input lanes represent 1/10th the total starting reaction. Negative controls  
are incubations with in vitro translation mixture containing an equivalent amount  
of radioactivity.  
  
3. Experimental Section  
3.1. Cells and Virus Growth  
T98G glioblastoma cells and clones expressing pDRGFP were propagated in Earle’s minimal 
essential media (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS),  
L-glutamine (2 mM), penicillin (200 U/mL), streptomycin (200 g/mL), and amphotericin B 
(1.5 g/mL). Cells were grown in incubators maintained at 37 °C and 5% CO2. The Towne strain 
of HCMV was obtained from the ATCC (# VR 977), propagated under standard procedures and 
used at a multiplicity of infection (MOI) of 10 in all experiments. The recombinant Ad strains 
dL70-3, used as a control virus, and NGUS24i, encoding the I-SceI enzyme, (both kind gifts of 
Frank Graham and Philip Ng, McMaster University, Hamilton, ON, Canada [15,16]) were grown 
and titrated in replication-permissive human 293A cells. The MOI of Ad viruses used was 




Lipofectamine reagent (Invitrogen/Life Technologies, Grand Island, NY, USA) was used 
according to manufacturer’s instructions to introduce pDRGFP [13,14] into T98Gs. Following 
transfection, cells were grown in non-selective medium for 48 h. Subsequently, puromycin  
(1 g/mL) was added to the media to select for integrated pDRGFP. Cloning rings were used to 
isolate puromycin-resistant colonies. Colonies were separated and subjected to another cycle of 
puromycin selection prior to freezing and storage in liquid nitrogen. All colonies were tested to 
ensure the absence of GFP+ without DSB induction. Three stable clones of T98GpDRGFP were 
tested and produced comparable results in the assays described above. T98GpDRGFP clone 10 
(Clone 10) was used for all experiments reported here. 
3.3. Nucleofections 
Nucleofection of T98Gs was optimized using a protocol provided by Amaxa Biosystems  
(program O-016). Each nucleofection used ~5 × 105 cells. IE72 transient expression studies used  
either 6 g of control vector pSG5 (Stratagene/Agilent Technologies, Santa Clara, CA, USA) or  
6 g of pSGIE72 [28]. p53 transient expression experiments used the following constructs in the 
listed quantities: 6 g of vector pCDNA3-T7 alone (with the CMV promoter removed, as a control) 
or 6 g of p53 derivative vectors containing (1) a wt p53 promoter-wt p53-green fluorescent 
protein (GFP) cassette (wtp53pCDNA3-T7) or (2) an equivalent vector cassette containing one of 
the following p53 mutations: K382R, R273H, R175H, R248W, G154V or an N-terminal multi-site 
phosphorylation mutant [29]. All of these have been previously described [22]. After nucleofection, 
cells were immediately transferred to plates containing coverslips and pre-warmed medium.  
3.4. Molecular Cloning 
The pCDNA3-T7 vector was modified by insertion into its polylinker of a BamHI-NotI 
fragment containing DsRed2 (from pDsRed2-N1vector; Clontech Laboratories, Mountain View, 
CA, USA) to produce pCDNA3-DsRed. The wt p53 promoter-wt p53 coding sequence was cleaved 
from pCLNCX-p53pro-p53GFP [22] at the KpnI and AgeI sites. Finally, this fragment was  
inserted upstream of DsRed2 in the polylinker of pCDNA3-DsRed. This ultimately produced the 
pCDNA3-p53pro-p53DsRed construct. Dual transient expression studies with wt p53 and IE72 
used 3 g each of pCDNA3-p53pro-p53DsRed and pSGIE72. Alternatively, one of these constructs 
(3 g) was transfected along with the corresponding control backbone of the other construct (3 g). 
3.5. DSB Repair Assay 
The DSB repair assay was carried out as described previously [12]. The results reported were 
carried out in mock- or HCMV-infected Clone 10.  
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3.6. Virus Infection 
Clone 10 was synchronized in Go by serum starvation for 3 d. Cells were then washed with PBS, 
trypsinized and re-plated at a density of 5 or 10 × 105 cells/60-mm dish containing glass coverslips. 
After allowing 2 h for attachment, the cells were mock- or HCMV-infected. Twenty-four hours 
later the virus or mock inoculums were removed (unless otherwise noted). After an additional 24 h, 
cells were washed once with PBS and subsequently superinfected for 30 minutes in pre-warmed 
media. Super-infection was with control Ad dL70-3 or with I-SceI-expressing Ad NGUS24i [12]. 
Cells were then re-fed with complete media. Cells were fixed and permeabilized 72 h later unless 
otherwise noted. Coverslips were scored for GFP+ cells and IE72+ cells. 
3.7. Antibodies (Ab) 
Primary mouse monoclonal antibodies (mAbs) used were: anti-pan actin (IgG1) 
(Neomarkers/Thermo Scientific, Fremont, CA, USA); anti-hemagglutinin (HA)(12CA5) 
(IgG2b)(Abcam, Cambridge, MA, USA); anti-IE1 (IgG2a) (a kind gift from Bill Britt, University of 
Alabama, Birmingham, AL, USA); and anti-IE1 and -IE2 (Ch16.0; IgG1) (Virusys Corporation, 
Taneytown, MD, USA). Secondary Abs used were as follows: for immunoblot detection, horseradish 
peroxidase (HRP)-linked sheep anti-mouse (GE Healthcare Life Sciences, Pittsburgh, PA, USA), 
and for IF analysis, tetramethyl rhodamine isothiocyanate (TRITC)-conjugated anti-mouse IgG1, 
IgG2a and IgG2b (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).  
3.8. Immunofluorescence (IF) 
Cells were seeded into dishes containing glass coverslips. Coverslips were collected and processed 
at indicated times pi, as described previously [30]. 300–500 cells per coverslip were counted and 
scored for GFP+ and either HA+ or IE72+ cells in each experiment. All experimental results represent 
the average of at least two independent experiments. Error bars represent +/  one standard 
deviation (SD). Statistical analysis was performed using unpaired, two-tailed student t-tests.  
3.9. Immunoblotting  
Virus- and mock-infected cells were harvested at 48, 72, and 96 hpi and lysates were processed 
as previously described [22,31].  
3.10. GST Binding Studies  
Overnight bacterial cultures (100 mL in LB + 100 g/mL ampicillin) containing the GST fusion 
plasmids pGEX-human p53 (1-393) (Addgene plasmid #24860; [32]), pGEX72 [28] or pGEX-KG [33] 
were diluted 1:10 (to a final volume of 1 L LB/amp) and incubated an additional 1 h at 37 °C with 
shaking. Cultures were chilled to room temperature (RT), then 1 mL 0.5M IPTG was added. After 
an additional incubation at RT for 2 h, bacteria were pelleted at 5000 rpm for 10 min and cells were 
resuspended in 50 mL NETN + protease inhibitors (PIs) (20 mM Tris pH 8, 100 mM NaCl, 1 mM 
EDTA, 0.5% NP40, 2 g/mL aprotinin, 2 g/mL leupeptin, 100 mM DTT). This suspension was 
then frozen at 80 °C in 5 mL aliquots for future use.  
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Assays were performed using one of the 5 mL aliquots thawed on ice. Fifty L of a 10 mg/mL 
lysozyme solution was added and the cell suspension was incubated on ice for 30 min. The 
suspension was sonically disrupted to lyse the cells. Debris was pelleted at 10,000 rpm for 5 min 
and the supernatant transferred to a new tube. Sixty L of a 50% glutathione agarose bead slurry 
(vol/vol in NETN) was added and rocked at 4 °C for 1 h. Beads were then washed in 500 L 
NETN + PIs three times prior to final re-suspension in 500 L NETN + PIs. Fifty L of this bead 
suspension (25 L bead equivalents) were incubated with 20 L Laemmli reducing sample buffer 
(2% SDS, 10% glycerol, 100 mM DTT, 60 mM Tris pH 6.8, Bromophenol blue dye, aprotinin and 
leupeptin (2 g/mL each)), and then boiled for 5 min. The resulting supernatant was loaded onto a 
12% SDS-PAGE gel. The gel was stained with Coomassie dye to visualize the GST fusion proteins 
and to determine equivalent protein amounts for use in the following binding reactions. Roughly 
equivalent amounts of protein, as estimated from the Coomassie staining, were used in the 
reactions (approximately 30 L beads of pGEX72 and pGEX-p53 and 7.5 L of pGEX-KG were 
used in the reactions shown in Figure 4). 
Pet24d-Rad51 [34] was in vitro translated using the Promega quick-coupled TNT reaction kit 
per manufacturer’s instructions. In each binding assay, five L of translated Rad51 (or just TNT 
reaction mixture) was incubated while rocking for 1 h at 4 °C with the GST fusion proteins in a 500 
L reaction of NETN + PIs. After incubation, 40 L of a 50% Protein A Sepharose slurry (vol/vol 
in NETN) was added to each tube (to increase the bead volume). Ten percent of the total volume 
(54 L) was removed to serve as the input fraction (no washes of these beads followed). The beads 
in the remaining sample were pelleted and then washed four times with 500 L of buffer (the first 
two washes in NETN, the last two in RIPA (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 
0.1% SDS, 50 mM Tris (pH 8), 5 mM EDTA). After the final spin, 15 L of urea sample buffer 
was added to the beads and the samples were boiled for 5 min. The supernatants were run on a 12% 
SDS-PAGE gel. Gels were dried and exposed to Kodak X-omat film.  
4. Conclusions  
A cell’s ability to repair insult to its DNA is a process that is essential to its survival. The 
concept that virus infection may alter this capability has begun to be investigated. In theory a virus 
might benefit from manipulation of the repair processes, while simultaneously (and likely 
corollary) degrading the integrity of a host’s genome. Existing studies have examined a variety of 
different repair pathways in the context of expression of a single viral protein and have assessed 
that protein’s capability to influence the repair of exogenously introduced damage in the cellular 
DNA [35–46]. The effects on repair during a complete infection have also been examined [12,47–56]. 
A handful of these studies have looked specifically at HDR [12,35,37,45,49]. The very large majority 
of these studies found viral protein expression (or full infection) decreased cellular repair capabilities. 
Two cellular proteins, p53 and Rad51, are exceedingly important in the context of HDR. It is 
widely accepted that wt p53 regulates HDR, primarily through interactions with Rad51 (as 
reviewed in [21]). In vitro reactions have found p53 binds Rad51 and, by means of this interaction, 
inhibits strand exchange and branch migration of recombination intermediates [57]. An intact core 
DNA binding domain of the p53 protein is required for direct binding between the p53 and Rad51 
proteins (and inhibition of the latter’s activities) [23–25]. It has also been shown that following 
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induction of damage wt p53 inhibits transactivation of the Rad51 promoter, thereby acting as a 
repressor of Rad51 transcription and protein expression [23]. It has also been shown that a 
phosphorylatable N-terminus is important for regulation and binding of Rad51 [58]. Many tumors 
(and cell lines derived from them) have so called “hotspot” mutations in p53, including the T98G 
cells used in this study [20]. Reintroduction of wt p53 into these tumor cells reduced HDR via 
decreasing Rad51 activity [59]. 
Multiple viruses have been shown to interact with the Rad51 protein. Epstein-Barr Virus (EBV), 
a herpesvirus, and SV40 have both been found to require the presence of Rad51 within their viral 
replication centers. Knockdown of Rad51 in infected cells dramatically decreased viral  
replication [60,61]. The opposite was true for HIV; stimulation of Rad51 activity inhibited HIV 
replication, primarily due to an inhibitory effect of Rad51 on the virus’ Integrase enzyme [62].  
The context of the T98G cellular environment is important for consideration of HDR in these 
cells. Under normal stress T98Gs can complete HDR and have normal levels of Rad51 [20]. 
Baseline levels of HDR in T98G cells after insult are quite high, perhaps in part due to the large 
proportion of these rapidly dividing cells being in the S/G2 phases of the cell cycle, during which 
HDR is most common [25,59]. However, the higher rate of HDR may also be attributable to the 
presence of the mutation in the p53 DNA binding domain (R273H) within these cells [20], which 
prevents p53’s normal binding to, and regulation of, Rad51. 
The model in Figure 5 is proposed to explain the dichotomy of results between the T98G results 
reported here and our earlier HFF study. In wt cells p53 normally inhibits Rad51 activity. In the 
model, the prediction is that the mutant p53-containing T98G cells, where p53 cannot bind  
Rad51 [23–25], would have high baseline recombination rates, as seen. The model further predicts 
that, introduction on their own (indicated by the arrow in the figure) of either wt p53 or IE72 
(which we have shown can bind Rad51 in vitro) into these cells would decrease HDR by their 
binding to and inhibiting Rad51. Co-expression of both wt p53 and IE72 did not inhibit Rad51.  
We propose in these experiments wt p53 and IE72 bound to one another, inhibiting normal p53 
activity [27]. This seems a reasonable assumption, given previous reports that IE72 binds directly 
to p53 and inhibits core domain binding ability [27]. If the introduced wt p53 and IE72 were 
interacting and p53’s normal activity was inhibited, Rad51 would again be free to cause the high 
recombination rates observed. 
Also in our model, in wt cells p53 normally inhibits Rad51, establishing baseline HDR activity 
levels. HCMV-infection of wt fibroblast cells causes p53 to become tightly associated with the 
viral replication centers [63]. We believe in an infected cell this viral manipulation of p53 prevents 
the normal binding of p53 and Rad51. The disruption of this normal condition in turn frees Rad51 
to increase recombination in both the viral and cellular DNA. Experiments in wt cells found that 
expression of the single HCMV protein IE72 was sufficient to increase HDR levels [12]. The 
proposed model attributes the increase in HDR in wt cells to IE72 binding to wt p53, thereby 
inhibiting the ability of wt p53 to bind and regulate Rad51.  
The proposed model offers a mechanistic explanation for our previously reported results in wt 
HFFs [12]. The focus of the earlier HFF study was the recognition of viral manipulation of a 
cellular repair mechanism to its own ends in the context of a fully permissive infection. The 
experiments performed in T98G cells were expected to corroborate that data. Fortuitously, the 
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particular microenvironment of the mutant glioblastoma cells allowed elucidation of what we 
believe to be the protein interactions responsible. 
The results of this study may have implications for the initiation of glioblastomas. It has been 
reported that in excess of 90% of glioblastomas contain HCMV genetic material [64,65]. A latently 
HCMV-infected neural progenitor/stem cell which reactivated could, and most likely would, 
express IE72. We have found that expression of IE72 in a wt cell was capable of increasing 
unscheduled recombination, a hallmark of genetic instability and perhaps the first step toward 
hyperproliferation and gliomagenesis. The common perception of HCMV as a relatively harmless 
pathogen belie not only its capacity to cause serious birth defects, inflict direct DNA damage and 
downregulate repair of the cellular genome, but perhaps its capability to initiate an often lethal and 
devastating cancer. We have experiments underway to determine if the protein interactions found 
in this study are capable of intitiating oncogenic effects in tissue culture experiments. 
Figure 5. A model for the interactions between wt p53, Rad51 and IE72 in HFFs and 
T98Gs. Interactions between these three proteins and the ramifications to HDR depend 
completely on the cellular microenvironment and the presence or absence of wt p53. 
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Abstract: The human cytomegalovirus (HCMV)-encoded protein kinase, pUL97, is 
considered a cyclin-dependent kinase (CDK) ortholog, due to shared structural and 
functional characteristics. The primary mechanism of CDK activation is binding to 
corresponding cyclins, including cyclin T1, which is the usual regulatory cofactor  
of CDK9. This study provides evidence of direct interaction between pUL97 and  
cyclin T1 using yeast two-hybrid and co-immunoprecipitation analyses. Confocal 
immunofluorescence revealed partial colocalization of pUL97 with cyclin T1 in 
subnuclear compartments, most pronounced in viral replication centres. The 
distribution patterns of pUL97 and cyclin T1 were independent of HCMV strain and 
host cell type. The sequence domain of pUL97 responsible for the interaction with 
cyclin T1 was between amino acids 231–280. Additional co-immunoprecipitation 
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analyses showed cyclin B1 and cyclin A as further pUL97 interaction partners. 
Investigation of the pUL97-cyclin T1 interaction in an ATP consumption assay strongly 
suggested phosphorylation of pUL97 by the CDK9/cyclin T1 complex in a substrate 
concentration-dependent manner. This is the first demonstration of interaction between 
a herpesviral CDK ortholog and cellular cyclins. 
Keywords: human cytomegalovirus; protein kinase pUL97; cyclins T1, B1 and A;  
protein-protein interaction; substrate phosphorylation; interaction-mediated regulation 
 
1. Introduction 
Human cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), is a member 
of the -Herpesvirinae subfamily. It is a ubiquitous human pathogen of increasing seroprevalence 
in different populations (60%–90%) that causes severe systemic diseases in immunosuppressed 
patients and is the leading infectious cause of birth defects in developed countries [1]. Currently 
approved antiviral agents for systemic treatment (cidofovir, foscarnet, ganciclovir and valganciclovir) 
inhibit viral DNA synthesis by targeting the HCMV DNA polymerase, pUL54 [2]. However,  
drug-resistant virus variants emerge after prolonged therapy, and current antivirals cause frequent 
adverse side effects. Protein kinases are putative targets of novel antiviral drugs, given their 
important role in the regulation of HCMV replication [3–8]. Pharmacological cyclin-dependent 
kinase (CDK) inhibitors interfere with the replication of HCMV and other viruses and are currently 
being investigated in a number of clinical trials. Roscovitine, a purine analogue that preferentially 
inhibits CDK1, 2, 5, 7 and 9, has been shown to decrease viral DNA synthesis and production of 
late viral proteins and infectious virus [4]. Recently, we reported that a novel selective CDK9 
inhibitor, R22, exerts anti-cytomegaloviral activity in cell culture models [9]. CDKs are 
heterodimeric serine/threonine kinases phosphorylating a number of substrate proteins. Upon 
activation through binding to their regulatory cyclin subunits, CDKs regulate cell cycle 
progression, transcription, neuronal cytoskeleton organization, apoptosis and other cellular 
functions. These kinases are promising targets for anti-cytomegaloviral therapy, since the 
efficiency of HCMV replication is closely connected to CDK activity [4,8–11]. Moreover, HCMV 
is able to stimulate or suppress CDK activity in order to create an environment favourable for 
efficient viral transcription, genome replication and assembly of viral particles. At least four CDKs 
(CDK1, 2, 7 and 9) and their corresponding cyclins are required for efficient HCMV replication 
and are upregulated in HCMV-infected cells [3,12–15]. 
HCMV not only modulates CDK regulation of the host cell, but also mimics CDK activity 
through expression of the serine/threonine protein kinase, pUL97. HCMV pUL97 is considered a 
CDK ortholog, due to structural and functional similarities. Although pUL97 does not appear to be 
absolutely required for viral replication, deletion of the ORF UL97 from the viral genome or 
pharmacological inhibition of pUL97 significantly reduces virus replication, showing the 
importance of pUL97 activity for efficient virus replication [16,17]. pUL97 regulates HCMV at 
various stages of replication by phosphorylating viral and cellular proteins (Figure 1). Sequence 
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analyses and a three-dimensional pUL97 model suggested conservation of functionally important 
residues in ATP binding sites and the catalytic centre between pUL97 and CDKs [18,19]. Recently, 
it has been reported that pUL97 phosphorylates cellular retinoblastoma protein (Rb) at the same 
residues as CDKs, a protein which controls progression through the G1 phase of the cell  
cycle [20,21]. There are further shared substrates of CDKs and pUL97, including nuclear lamins A 
and C, RNA polymerase II and pUL69 (Figure 1). In addition, inhibition of CDKs potentiates the 
effect of the pUL97 inhibitor, maribavir, indicating that the functions of CDKs and pUL97 overlap 
to some extent [22]. Moreover, a yeast complementation assay demonstrated a pUL97-mediated 
rescue of the proliferation of a Saccharomyces cerevisiae mutant lacking CDK activity [20]. It has 
been suggested that pUL97 is regulated in a cyclin-independent manner, a conclusion based on the 
finding that cyclins did not copurify with pUL97 during tandem affinity purification, so that 
binding of pUL97 to cyclins was considered unlikely [20]. However, in the present study, we 
provide the first evidence for the interaction of pUL97 with cyclins, emphasizing the functional 
relation between the viral CDK ortholog pUL97 and cellular CDKs. The meaning of these 
interactions for phosphorylation-dependent regulatory processes during HCMV replication and 
possible functional consequences are discussed.  
Figure 1. Schematic illustration of the structure of pUL97. Kinase domain (amino acids 
337–651): subdivided into 11 subdomains (SD) that are conserved within herpesviral 
protein kinases and are similarly found in cellular protein kinases; mutation of the 
invariant lysine residue of SD II (amino acid 355) results in a complete loss of kinase 
activity [18,23,24]. Expression of three pUL97 isoforms: formation by the alternative 
initiation of translation with start codons at amino acids 1, 74 and 157 [25–27]. Nuclear 
localization signals (NLS1 amino acids 6–35 and NLS2 amino acids 190–213): 
mediation of the nuclear import of pUL97 isoforms by importin-  binding [26,28]. 
Self-interaction domain of pUL97 (amino acids 231–280): formation of dimers and 
oligomers [29]. Regulation of various processes during human cytomegalovirus 
(HCMV) replication by pUL97 via phosphorylation of viral and cellular substrates: 
protein synthesis (RNA polymerase II [30], EF-1  [18,31], pUL69 [32]), viral DNA 
replication (pUL44 [33]), nuclear capsid egress (lamins A and C, p32, a multi-ligand 
binding protein, also referred to as gC1qR and HABP1 [34,35], morphogenesis  




2.1. Interaction of the HCMV Protein Kinase pUL97 with Cyclin T1 
Yeast two-hybrid (Y2H) experiments revealed the interaction between pUL97 and cyclin T1 
(Figure 2a, row 3). The signal obtained in the filter lift assay was similar to the positive control 
(interaction between p53 and SV40 T-antigen, Figure 2a, row 1). This was considered specific, 
since the intrinsic autoactivation effects of the individual fusion proteins were excluded by vector 
controls (Figure 2a, rows 4 and 5). The interaction between pUL97 and cyclin T1 was confirmed 
using co-immunoprecipitation (CoIP) analyses with protein lysates from transiently transfected 
293T cells (Figure 2b). Endogenous cyclin T1 was specifically co-immunoprecipitated together 
with Flag-tagged pUL97 (Figure 2b, lane 1). Positive controls (pUL97 self-interaction, Figure 2b, 
lane 4) and negative controls (expression of RFP and pUL53, respectively, Figure 2b, lane 2, 3) 
confirmed the reliability of signals. Further CoIP analyses also demonstrated the pUL97-cyclin T1 
interaction in HCMV-infected human foreskin fibroblast (HFF) cells (Figure 2c). pUL97 was  
co-immunoprecipitated with cyclin T1 (Figure 2c, lanes 2 and 3) and vice versa (Figure 2c, lanes 4 
and 5). The intensity of the detected signals was independent of multiplicity of infection, when 
tested at multiplicity of infection (MOI) 0.5 and 1.0. The known interactions between cyclin T1 and 
CDK9 [37], as well as between pUL97 and the viral mRNA export factor, pUL69 [32], served as 
positive controls (Figure 2c, lanes 7–9). The weak signal of co-immunoprecipitated CDK9 in 
uninfected cells was a result of low expression and subsequent limited immunoprecipitation of 
cyclin T1. Interestingly, CDK9 did not co-immunoprecipitate with pUL97 (Figure 2c, lane 9), 
whereas both proteins were detected in the precipitate of cyclin T1. These findings provide the first 
evidence of the interaction of a herpesviral kinase with a cellular cyclin. 
2.2. Partial Colocalization of pUL97 with Cyclin T1 in Subnuclear Compartments of  
HCMV-Infected Cells 
In order to study the intracellular localization patterns of pUL97 and cyclin T1, the cell types, 
HFF, MRC-5, ARPE-19 and TEV-1 were infected with two different HCMV strains, AD169 and 
Merlin. The results of indirect immunofluorescence analyses are shown in Figure 3.  
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Cyclin T1 was found evenly distributed in the nuclei of uninfected cells, regardless of cell type 
(Figure 3, panels 10, 22, 34, 54). In HCMV-infected cells, however, cyclin T1 was concentrated in 
subnuclear compartments, partly colocalizing with the viral protein, pUL97 (Figure 3, panels 4, 16, 
28, 40, 48). This colocalization was most pronounced in viral replication centres. The kinase 
pUL97 is a known component of viral replication centres [33], here indicated by co-staining with 
the viral DNA polymerase processivity factor, pUL44 (Figure 3, panels 6, 18, 30, 42, 50). The 
pUL97-pUL44 colocalization, previously described in HFFs [33], was confirmed in MRC-5, 
ARPE-19 and TEV-1 cells. In summary, the subnuclear distribution patterns of pUL97 and cyclin 




Figure 2. Direct interaction between pUL97 and cyclin T1. (a) Yeast two-hybrid 
(Y2H) analysis: cyclin T1 fused to the GAL4 activation domain (AD) and pUL97 fused 
to the GAL4 binding domain (BD) were coexpressed in yeast cells, and colonies were 
stained in filter lift assays (FLA). (b) co-immunoprecipitation (CoIP) analyses using 
protein lysates of transfected 293T cells: the self-interaction of pUL97 served as a 
positive control (lane 4) and pUL53-Flag as a negative control (lane 2). (c) CoIP analyses 
showing the interaction between pUL97 and cyclin T1 in HCMV-infected cells: human 
foreskin fibroblasts (HFFs) were infected with HCMV AD169-GFP at a multiplicity of 
infection (MOI) of 0.5 or 1.0. At six days post-infection, infected and mock-infected 





Figure 3. Comparison of the pUL97-cyclin T1 intracellular localization in four human 
cell types infected with two different HCMV strains using immunofluorescence 
analyses. HFF, MRC-5, ARPE-19 and TEV-1 cells were infected with HCMV AD169 
or HCMV Merlin at various MOIs (1–8: MOI 0.5; 13–20: MOI 0.09; 25–32: MOI 0.03; 
37–52: MOI 0.01). Cells were fixed within a range of late time points post-infection (1–
12: 4 dpi, 13–36: 6 dpi, 37–56: 5 dpi) and immunostained with pAb(r)-cyclin (pAb, 
polyclonal antibody) T1, mAb UL97/pAb-UL97 (mAb, monoclonal antibody) and 




2.3. Mapping of the Sequence Domain of pUL97 Responsible for the Interaction with Cyclin T1 
CoIP analyses using Flag-tagged N- and C-terminal truncation mutants of pUL97 expressed in 
293T cells were performed to narrow down the sequence domain of pUL97 responsible for the 
interaction with cyclin T1 (Figure 4a). Initial CoIP analyses revealed that the N-terminus of pUL97 
was important for the interaction with cyclin T1 (i.e., amino acids 1–365; data not shown). Further 
CoIP analyses demonstrated that the first 230 amino acids of pUL97 were dispensable for the 
interaction with cyclin T1, since pUL97(231–707)-Flag was the smallest N-terminally truncated 
fragment that was still co-immunoprecipitated, whereas the correlating C-terminal truncation mutant, 
pUL97(1–230)-Flag, did not interact with cyclin T1 (Figure 4a, lanes 4 and 11). Together with 
pUL97(1–280)-Flag being the smallest C-terminally truncated pUL97 fragment still interacting 
with cyclin T (Figure 4a, lane 3), the protein domain of pUL97 responsible for the interaction with 
cyclin T1 could be mapped to amino acids 231–280. Deletion of the interaction region in construct 
pUL97( 231–280)-Flag prevented the co-immunoprecipitation of cyclin T1, confirming the 
finding of the mapping experiment (Figure 4b, lane 8). All three isoforms of pUL97 contain the 
cyclin T1 interaction region and interacted with cyclin T1, as shown by CoIP analyses performed 
with expression constructs encoding individual isoforms (Figure 4b, lane 4 (IF-1, pUL97(MX4)-Flag), 
lane 5 (IF-2 and IF-3, pUL97(74–707)-Flag) and lane 6 (IF-3, pUL97(157–707)-Flag) [25,26]).  
It should be mentioned that in CoIP analyses based on HCMV-infected cell lysates,  
co-immunoprecipitation of isoform 1 with cyclin T1 was mostly detected (Figure 2c, lanes 2 and 3), 
which, however, might rather refer to a limitation in detection sensitivity than to biochemical 
differences between pUL97 isoforms expressed in the two systems. Interestingly, the catalytically 
inactive mutant, pUL97(K355M)-Flag, also interacted with cyclin T1 (Figure 4b, lane 3), 
suggesting a mode of pUL97-cyclin T1 interaction independent of pUL97 activity. 
2.4. Interaction of the HCMV Protein Kinase pUL97 with Further Cyclins 
Further analysis revealed that pUL97 also interacted with cyclins other than cyclin T1. pUL97 
was detected in precipitates of cyclin B1, the regulatory cofactor of CDK1, in a CoIP analysis using 
protein lysates of transiently transfected 293T cells (Figure 5a, lane 1). Like cyclin T1, cyclin  
B1 also interacted with the three isoforms of pUL97 (Figure 5a, lanes 4 (IF-1), 5 (IF-2 and IF-3),  
6 (IF-3)). Importantly, the catalytically inactive mutant, pUL97(K355M)-Flag, was not  
co-immunoprecipitated with cyclin B1 (Figure 5a, lane 3). This finding may suggest that the 
interaction of pUL97 with cyclin B1 is dependent on the kinase activity of pUL97, in contrast to 
the interaction with cyclin T1. This points to a mechanistic difference between pUL97-cyclin T1 
and pUL97-cyclin B1 interactions. Additional CoIP experiments also indicated an interaction 
between pUL97 and cyclin A (regulatory cofactor of CDK1 and CDK2; Figure 5b, lane 1), albeit 
with a lower affinity, whereas cyclin H (a component of the CDK7/cyclin H/MAT1 complex) 
could not be identified as an interaction partner of pUL97 (Figure 5b, lane 3). These findings 
strongly suggest that pUL97 does not exclusively interact with cyclin T1, but additionally with a 
selection of further cyclins. 
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Figure 4. Mapping of the sequence domain of pUL97 responsible for the interaction 
with cyclin T1. Flag-tagged N- and C-terminal amino acid replacement and deletion 
mutants of pUL97 were transiently expressed in 293T cells. Recombinantly expressed 
RFP was used as the transfection control. At two days post-transfection, CoIP analyses 
were performed. Either (a) endogenous cyclin T1 was immunoprecipitated using 
pAb(r)-cyclin T1 or (b) Flag-tagged pUL97 mutants were immunoprecipitated using 
mAb-Flag. Specificity of precipitation was demonstrated by CoIP using Dynabeads® 
Protein A without antibody (a, lane 12) and by the negative controls with 
recombinantly expressed pUL53-Flag (a and b, lane 2). pUL97(MX4)-Flag, multiple 
amino acid replacement mutant carrying missense mutations in alternative start codons 
of pUL97 isoform expression: M38A, M74L, M111L and M157A. 
 
2.5. Phosphorylation of pUL97 by the CDK9/cyclin T1 Complex in an ATP Consumption Assay 
With pUL97 interacting with cyclin T1, we next examined whether pUL97-cyclin T1 interaction 
triggered phosphorylation of pUL97 by the CDK9/cyclin T1 complex. Sequence analysis of pUL97 
revealed that the mapped cyclin T1 interaction region (amino acids 231–280) did not contain the 
known, linear cyclin recognition motif, DOC_CYCLIN_1 ([RK].L.{0,1}[FYLIVMP]; ELM 
database [38]), which is found in many CDK substrates. Furthermore, no known CDK phosphorylation 
site (MOD_CDK_1; ...([ST])P.[KR]; ELM database)) was detected in the amino acid sequence of 
pUL97. In order to address the question whether pUL97 is phosphorylated by the CDK9/cyclin T1 
complex, an ATP consumption assay (ADP-Glo™ Kinase Assay, Promega, Mannheim, Germany) 
was performed (ProQinase, Freiburg, Germany). In this nonradioactive in vitro assay, ATP 
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consumption of CDK9 was measured as an indirect indicator of CDK9 substrate phosphorylation. 
Importantly, the results strongly indicate phosphorylation of the catalytically inactive mutant, 
pUL97(K355M)-Flag, by CDK9/cyclin T1 in a substrate concentration-dependent manner  
(Figure 6c). The detected signals were clearly increased compared to a background control (mAb-
Flag (mAb, monoclonal antibody) coated protein A sepharose beads; Figure 6d). Interestingly, an 
inhibitory, concentration-dependent effect of the control mAb-Flag coated protein A sepharose 
beads on CDK9 was observed (Figure 6d). If it were the case that CDK9/cyclin T1 was generally 
inhibited in the presence of protein A sepharose beads, the actual phosphorylation of 
pUL97(K355M)-Flag might be underestimated under these experimental conditions. RBER-IRStide 
(artificial fusion protein containing a fragment of human retinoblastoma protein 1, Figure 6a) 
served as the reference substrate to control the kinase activity of the CDK9/cyclin T1 complex. 
Bovine histone H1 (a substrate of multiple kinases, excluding CDK9) was used as a negative 
control to monitor background signals (Figure 6b). CDK9 autophosphorylation signals determined 
in the absence of substrates were clearly lower than substrate phosphorylation signals (Figure 6a–d, 
column 1), and substrate background signals measured in the absence of the CDK9/cyclin T1 
complex remained at a very low level, close to the detection limit (Figure 6a–d, panel no enzyme). 
These findings strongly suggest that pUL97 is phosphorylated by the CDK9/cyclin T1 complex. 
Considering the capability of pUL97 to interact with cyclins other than cyclin T1, the phosphorylation 
of pUL97 by further CDK/cyclin complexes seems also possible. 
3. Experimental Section  
3.1. Cell Culture, HCMV Infections and Plasmid Transfection 
Embryonic kidney epithelial cells (293T) and retinal pigment epithelial cells (ARPE-19) were 
cultivated in Dulbecco’s modified Eagle’s medium containing 10% FCS. Primary human foreskin 
fibroblasts (HFFs) and human foetal lung fibroblasts (MRC-5) were cultivated in MEM containing 
7.5% or 10% FCS, respectively. Human first-trimester extravillous trophoblast (TEV-1) were 
cultivated in Ham’s F 10 Nutrient Mix supplemented with 10% FCS. The HCMV infection 
experiments were performed at a multiplicity of infection (m.o.i.) of 1.0 (or lower as indicated for 
specific experiments) using HCMV strains AD169, AD169-GFP [39] and Merlin [40]. Transfection 
of 293T cells was performed using polyethylenimine reagent (Sigma-Aldrich, Taufkirchen, Germany), 
as described previously [29]. 
3.2. Antibodies 
The following polyclonal (pAb) and monoclonal (mAb) antibodies were used in the present 
study: mAb-UL44 (BS 510, kindly provided by Prof. B. Plachter, Univ. Mainz, Mainz, Germany), 
mAb-UL97 (AL-1, kindly provided by Prof. M. N. Prichard, Univ. Alabama, Birmingham, AL, 
USA), pAb-UL97 (06/09, kindly provided by Prof. D. M. Coen, Harvard Medical School, Boston, 
MA, USA), mAb-pUL69 [41], mAb-cyclin A (sc-271645), mAb-cyclin B1 (sc-7393), pAb-cyclin 
B1 (sc-752), mAb-cyclin H (sc-1662), mAb-cyclin T1 (sc-271348), pAb(r)-cyclin T1 (sc-10750), 
pAb(g)-cyclin T1 (sc-8127), mAb-CDK9 (sc-13130; all Santa Cruz Biotechnology, Heidelberg, 
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Germany), mAb-Flag (Sigma-Aldrich, Heidelberg, Germany) and mAb-HA (12CA5, Roche, 
Mannheim, Germany). The following fluorescent dye-conjugated secondary antibodies were 
applied in immunofluorescence analyses: Alexa 488-conjugated goat anti-rabbit IgG (H + L) and 
Alexa 555-conjugated goat anti-mouse IgG (H + L) (Life Technologies, Darmstadt, Germany). 
Figure 5. CoIP analyses used to reveal further cyclin interaction partners of pUL97. 
Flag-tagged amino acid replacement and deletion mutants of pUL97 were transiently 
expressed in 293T cells. At 2 days post-transfection, cells were lysed and used for  
co-immunoprecipitation analysis with (a) pAb-cyclin B1 (lanes 1–6) and the Fc 
fragments of rabbit antibodies as the control (Fc(r), Rabbit IgG Fc-Fragment, Jackson 
ImmunoResearch; lane 7), respectively; or with (b) mAb-Flag. CoIP analyses with 
recombinantly expressed pUL53-Flag (a, lane 2; b, lanes 2 and 4) served as a negative 





Figure 6. ATP consumption assay used to investigate the putative phosphorylation of 
pUL97 by the CDK9/cyclin T1 complex. The catalytically inactive mutant  
pUL97(K355M)-Flag was expressed in 293T cells and 2 days post-transfection, 
immunoprecipitated from cell lysates using mAb-Flag. Immunoprecipitates and  
mAb-Flag coated protein A sepharose beads (negative control) were used to determine 
luminescence signals (counts per second (cps)) as a measure for ADP generation by the 
active CDK9/cyclin T1 complex; the assay was performed in duplicate (n = 2).  
(a) Specific substrate RBER-IRStide (positive control); (b) substrate bovine histone H1 
(negative control); (c) pUL97(K355M)-Flag (substrate in question); (d) mAb-Flag 




293T cells were seeded in 10-cm dishes (cell number: 5.1 × 106) and transfected with expression 
plasmids coding for full-length pUL97 or mutants of pUL97 and pUL53, as described  
previously [23,26,29,42] using the polyethylenimine transfection technique [29]. Red fluorescent 
protein (RFP; pDsRed1-N1; BD Clontech, Heidelberg, Germany) was used as a transfection 
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control. HCMV AD169-GFP-infected HFFs cultivated in cell culture flasks were harvested at  
6 days post-infection. Both transfected 293T cells and HCMV infected HFFs were lysed in 500 mL 
CoIP buffer (50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM PMSF, 
2 g aprotinin mL 1, 2 g leupeptin mL 1 and 2 g pepstatin mL 1) and incubated with  
antibody-coated Dynabeads® Protein A (50 L per sample; Life Technologies, Darmstadt, 
Germany) for 2 h at 4 °C under rotation. The precipitates were washed five times (1 mL each) with 
CoIP buffer before the samples were subjected to standard Western blot analysis using tag- or 
protein-specific antibodies for the detection of co-immunoprecipitates and protein expression (ECL 
staining; New England Biolabs, Frankfurt/Main, Germany). 
3.4. Immunofluorescence Analyses 
HFF, MRC-5, ARPE-19 and TEV-1 cells were grown on coverslips and used for infection with 
various HCMV strains. At indicated time points, cells were fixed with 4% paraformaldehyde 
solution (10 min, room temperature) and permeabilized by incubation with 0.2% Triton X-100 
solution (20 min, 4 °C). Non-specific staining was blocked by incubation with 2 mg/mL human  
-globulin (Cohn fraction II; Sigma Aldrich, Taufkirchen, Germany, 30 min, 37 °C). Proteins were 
detected by incubation with primary antibodies for 90 min at 37 °C, followed by incubation with 
dye-conjugated secondary antibodies for 30 min at 37 °C. Cell samples were mounted with 
Vectashield Mounting Medium containing DAPI and analysed using a DMI6000 B microscope and 
a 63× HCX PL APO CS oil immersion objective lens (Leica Microsystems, Mannheim, Germany). 
Confocal laser-scanning microscopy was performed with a TCS SP5 microscope (Leica Microsystems, 
Mannheim, Germany). Images were processed using the Meta-Imaging series (Molecular Devices, 
Biberach, Germany), LAS AF software (version 1.8.2 build 1,465; Leica Microsystems) and Adobe 
Photoshop (version 8.0.1; Adobe Systems Incorporated). 
3.5. ATP Consumption Assay 
An ATP consumption assay (ADP-Glo™ Kinase Assay, Promega, Mannheim, Germany) was 
performed in order to measure the CDK9-dependent phosphorylation of pUL97 (ProQinase, 
Freiburg, Germany). The catalytically inactive mutant, pUL97(K355M)-Flag, was expressed in 
293T cells. Two days post-transfection, 293T cells were harvested and lysed in 400 L of RIPA 
lysis buffer (0.1% SDS, 1% Na-deoxycholate, 1% Triton X-100, 0.5% NP40, 1 mM EDTA, 10 mM 
Tris/HCl (pH 7.5), 150 mM NaCl) supplemented with protease inhibitors (Complete Mini, Roche; 
1 tablet for 10 mL). The lysate was incubated with mAb-Flag-coated protein A sepharose beads 
(200 L of antibody-coated protein A sepharose beads per sample) for 2 h under rotation. The 
immunoprecipitates were washed with RIPA lysis buffer three times. Washed mAb-Flag coated 
protein A sepharose beads, incubated with protein lysates from 293T cells not expressing 
pUL97(K355M)-Flag, were prepared as a negative control. The ATP consumption assay was 
performed as follows. The reaction cocktail, containing 7.5 L of 3.33× standard ATP consumption 
assay buffer (167 mM HEPES-NaOH [pH 7.5], 10 mM MgCl2, 10 M Na-orthovanadate and  
3.33 mM DTT), 7.5 L of a substrate (various amounts of RBER-IRStide (ProQinase, Freiburg, 
Germany), histone H1 (Sigma-Aldrich, Munich, Germany), pUL97(K355M)-Flag immunoprecipitates 
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or mAb-Flag coated protein A sepharose beads), 5 L of the purified kinase complex, CDK9/cyclin 
T1 (100 ng diluted in 1× kinase dilution buffer (50 mM HEPES-NaOH (pH 7.5), 0.25 mg/mL 
PEG20000, 1 mM DTT), ProQinase, Freiburg, Germany) and 5 L of ATP (UltraPure), was mixed 
in 96-well white flat bottom half-area plates and incubated for 30 min at 30 °C (measured in 
duplicate). Subsequently, 25 L of ADP-GloTM reagent were added, and the samples were 
incubated for 40 min at room temperature. After the addition of 50 L of ADP-GloTM Kinase 
Detection reagent, the samples were incubated for another 60 min at room temperature in the dark. 
Resulting luminescence (counts per second (cps)) as a measure for ADP-generation by the active 
kinases was determined using a VICTOR reader (Perkin-Elmer, Hamburg, Germany). 
3.6. Yeast-Two-Hybrid System 
Protein interactions were analysed using GAL4 fusion proteins (GAL4-BD, DNA binding domain; 
GAL4-AD, activation domain) in the yeast two-hybrid system, as described previously [9,34]. 
pUL97 fused to the GAL4-BD [33,34] and cyclin T1 fused to the GAL4-AD (kindly provided by 
Dr. Giuliana Napolitano, University of Monte S. Angelo, Italy [43]) were expressed in the 
Saccharomyces cerevisiae strain, Y153. pGAD424 and pGBT9 (Clontech) served as vector 
controls and pVA3 (p53) and pTD1 (SV40 large T antigen) as an interaction control. Selection for 
the presence of bait and interactor plasmids was achieved by cultivation on medium restricting growth 
to histidine/tryptophan/leucine prototrophy. Selected colonies were analysed for -galactosidase 
activity by filter lift tests. 
4. Conclusions  
Interactions between herpesviral kinases and cellular cyclins have not been described so far. 
This study provides the first evidence that the HCMV protein kinase, pUL97, interacts with cyclins, 
as demonstrated by well-established methods of yeast two-hybrid assay, co-immunoprecipitation 
and confocal microscopy-based colocalization studies. In particular, the sequence domain of 
pUL97, responsible for the interaction with cyclin T1, was between amino acids 231–280. This 
biochemically defined interaction region is located within the non-globular N-terminus of pUL97 
and is distinct from the pUL97 protein kinase domain, which is determined by subdomains I–XI 
comprising amino acids 337–651 [18].  
Although this cyclin T1 interaction region of pUL97 does not contain a known cyclin 
recognition motif and the entire pUL97 sequence does not comprise a known CDK phosphorylation 
motif, the results of an ATP consumption assay strongly suggest that pUL97 is recognized and 
phosphorylated by the CDK9/cyclin T1 complex. Due to the fact that kinase activity of 
CDK9/cyclin T1 was determined in an indirect approach by the quantitative determination of ATP 
consumption, additional in vitro kinase assays using radioactive ATP should be performed to 
demonstrate the phosphorylation of pUL97 directly and to confirm our conclusion. The detection of 
further cyclins (cyclin B1 and cyclin A) as interaction partners of pUL97 points towards a more 
complex mode of pUL97-CDK/cyclin inter-regulation. The question about whether CDK-mediated 
phosphorylation of pUL97 influences its kinase activity or multifunctionality has not been 
addressed and requires further investigation. Presently, we are working on the identification of 
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motifs in pUL97 mediating cyclin interaction, such as a putative zinc finger motif (see the 
interaction between cyclin T1 and that Tat protein of the human immunodeficiency virus [44]) or 
potential linear interaction motifs [45]. 
Importantly, the structural and functional similarities between pUL97 and CDKs, the 
phosphorylation of identical viral and cellular substrates [3] and the interaction between pUL97 
and cyclins described here suggest that multimeric complexes may be formed. Such complexes 
might consist of CDKs, cyclins, pUL97 and further viral proteins or substrates. pUL97 could only 
transiently be included, so that varying kinase activities might be involved in the regulation of  
phosphorylation-dependent processes during HCMV replication. They also may only form under 
certain conditions, as we showed that pUL97 did not co-immunoprecipitate with CDK9. This 
finding might indicate the lack of interaction or, more likely, a competitive mode of binding of 
CDK9 and pUL97 to cyclin T1 or the existence of a dynamic complex (trimeric or multimeric) that 
may only transiently include CDK9, pUL97 and cyclin T1. In the latter scenario, cyclin T1 may 
play the role of a bridging factor between pUL97 and CDK9, triggering phosphorylation events 
(see Section 2.5). Interactive regulatory steps of mutual phosphorylation between CDK/cyclin 
complexes and pUL97 seem probable in this scenario. The regulation of the activity of the viral 
RNA transporter, pUL69, is an example of such interplay between CDKs and pUL97. In this case, 
CDK9 and pUL97 contribute to an activating phosphorylation of pUL69 [9,32,46]. The protein 
region of pUL97 required for the interaction with pUL69 (amino acids 231–336 [32]) overlaps with 
the cyclin T1 interaction domain of pUL97 (amino acids 231–280), most likely indicating a putative 
role of cyclin T1 in pUL97-pUL69 interaction. This example of activating pUL69 phosphorylation 
emphasizes an interplay between CDK and pUL97 activities in phosphorylation-dependent 
processes during HCMV replication. Interestingly, the mapped region of pUL97 interacting with 
cyclin T1 is also responsible for the self-interaction of pUL97 (amino acids 231–280 [29]), so that 
the potential of pUL97 to oligomerize might also be linked to the formation of multimeric 
complexes. Future experimentation should substantiate this scenario, possibly also including 
further aspects of pUL97-cyclin interaction, such as a putative regulatory impact on viral DNA 
synthesis and late gene expression. Taken together, our present and previous findings support the 
hypothesis that pUL97 not only mimics CDK function, but actively associates with cyclins or 
CDK/cyclin heteromers to form functional complexes. Thus, the formation of such cyclin-based 
complexes may provide a platform for pUL97 and CDKs to undergo mutual trans-phosphorylation 
and fine-regulation. 
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Abstract: UL34 is one of the ~50 genes of human cytomegalovirus (HCMV) required 
for replication in cell culture in human fibroblasts. UL34 encodes highly related early 
(UL34a) and late (UL34b) proteins that are virtually identical, with the early protein 
containing an additional 21 amino terminal amino acids. The UL34 proteins are 
sequence-specific DNA-binding proteins that localize to the nucleus. The HCMV 
genome contains 14 to 15 UL34 binding sites; two of the UL34 binding sites contribute 
to transcriptional regulation of two other viral genes, US3 and US9. The roles of the 
remaining binding sites and the requirement for both UL34 proteins during viral 
infection remain unknown. We examined the contributions of the early and late UL34 
proteins to viral replication by generating HCMV-containing bacterial artificial 
chromosomes with the initiation codon for the early or the late protein mutated. Neither 
virus was able to replicate, demonstrating that UL34 expression is required throughout 
the viral replication cycle. A marked decrease in viral gene expression for each of the 
mutants suggests that UL34 proteins may contribute generally to transcriptional regulation. 
Intracellular localization studies demonstrated that UL34 colocalizes with the major 
immediate early protein, IE2, and the viral DNA polymerase processivity factor, UL44, 
to viral DNA replication centers. In conclusion, sustained UL34 protein expression is 
required for viral replication. The sequence-specific DNA binding ability of UL34 
proteins, their localization to viral DNA replication centers and their general effects on 
viral gene expressions suggests that UL34 proteins contribute to the establishment of a 
nuclear environment necessary for viral gene expression and DNA replication. 
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Human cytomegalovirus (HCMV) is predominantly an opportunistic pathogen, causing 
clinically significant disease in people who have inadequate immune responses, including neonates, 
transplant recipients, and people with uncontrolled HIV infections [1]. Viral replication initiates 
with the expression of the immediate early genes, the best characterized of which are IE1 and IE2. 
IE1 and IE2 initiate the cascade of viral gene expression, regulating the expression of the remainder 
of the viral genome, resulting in the expression of early and then late genes, and ultimately the 
production of new virions.  
HCMV has a very large genome of ~235 kb and encodes an estimated 176 genes [2]. Despite 
the large genome size, only ~50 genes are required for HCMV replication in cell culture, 
suggesting that the remaining 70% of the genes contribute to replication and latency in the human 
host [3,4]. The essential genes of HCMV can be grouped according to function: attachment of the 
virus to the target cells, transcriptional regulation, viral DNA replication, virion formation, and 
virion egress. Although there are a relatively small number of essential HCMV genes, to date the 
functions of several of the essential genes, including UL34, have been minimally characterized.  
The UL34 gene is essential for viral replication as determined by Dunn et al. [3] and Yu et al. [4] 
in their global analyses of the HCMV genome. The UL34 gene is transcribed throughout the viral 
replication cycle, resulting in the expression of early and late transcripts [5]. The early transcript 
becomes abundant by 3 hours post-infection (hpi) while the late transcript predominates from 48 
hpi throughout the remainder of the viral replication cycle. Two highly related proteins are encoded 
by the early and late transcripts, with the late protein (UL34b) identical to the early protein 
(UL34a) except for the absence of 21 amino terminal amino acids. Both UL34 proteins localize to 
the nucleus and are sequence-specific DNA-binding proteins that act as transcriptional repressors; 
the interaction of UL34 proteins with the UL34 binding sites in the US3 and US9 genes  
down-regulates their expression [6,7].  
In addition to the UL34 binding sites within the US3 and US9 genes, there are 12 to 13 
additional binding sites located in the viral genome. Six of the UL34 binding sites are located 
within protein coding regions, 3 or 4 binding sites (the number is strain dependent) are in a region 
flanking the lytic origin of replication, and the remaining 3 binding sites are located 5' of protein 
coding regions [6]. The positions of the UL34 binding sites relative to coding regions suggests that 
UL34 proteins may be multifunctional, contributing not only to transcriptional repression but also 
contributing to viral replication in as yet unidentified ways. The experiments described here were 
undertaken to identify the contributions of each of the UL34 proteins to viral replication and to 
examine the intracellular localization pattern of UL34 proteins during infection.  
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2. Results and Discussion 
2.1. Both UL34 Proteins Are Essential for Viral Replication 
Yu et al. [4] and Dunn et al. [3] identified UL34 as essential for viral replication in their global 
analyses of the HCMV genome. We extended their results by constructing and studying 
recombinant viruses using the bacterial artificial chromosome (BAC) that contains the HCMV 
AD169 genome, pHB5 [8]. HCMV-BACs that either entirely lacked UL34 ( UL34), contained 
UL34 with a mutation in the ATG initiating translation of the early protein [ATG mutated to ATC 
(methionine to isoleucine), E mutant], contained UL34 with a mutation in the ATG initiating the 
late protein [ATG mutated to GTG (methionine to valine), L mutant], or had the UL34 open 
reading frame restored (UL34 rescue, RUL34). The ability of each of the recombinant viruses to 
replicate was assayed following electroporation of the HCMV-BACs into primary human fibroblasts, 
along with a plasmid expressing the tegument protein, pp71. Following electroporation, cells were 
observed for plaque formation for 4 weeks. The parental BAC, pHB5, and the UL34 rescue BAC 
(RUL34) gave rise to plaques by 8 days post-transfection. No plaques developed in the cells 
receiving the UL34 mutant, the E UL34 mutant or the L UL34 mutant BAC during a 4 week 
observation period. From these results, we concluded that the expression of both UL34 proteins is 
essential for viral replication.  
2.2. Reduced Viral Gene Expression in the Absence of UL34 Proteins 
To examine the defect in viral replication associated with the absence of UL34 proteins,  
semi-quantitative RT-PCR reactions were performed on RNA samples extracted following the 
electroporation of the UL34-HCMV BACs into human fibroblasts. Levels of expression for the 
essential genes UL32, UL37, UL44, UL46, UL84 and UL123 (IE2) were assayed as were levels  
of expression of the non-essential UL36 and UL69 genes. IE2, UL36, and UL37 are immediate 
early genes; UL44 and UL84 are early genes; UL69 is an early/late gene and UL32 and UL46 are 
late or presumed late genes (Figure 1A). Levels of expression were analyzed at 6 and 8 days  
post-transfection; time points that correspond approximately to early and late times of infection, 
based on the time when plaques are visible. Viral transcript levels were normalized to the transcript 
levels of the cellular gene, glyceraldehyde phosphate dehydrogenase (GAPDH). At 6 and 8 days 
post-transfection, transcript levels for all genes asssayed were decreased in the UL34 mutant 
viruses when compared to the UL34 rescued virus (RUL34, Figure 1B,C).  
Six days post-transfection, expression of the major immediate early (mIE) gene, IE2, was 
decreased in the absence of the early, late or both UL34 proteins. Similar to the reduction in the 
level of IE2 transcripts, levels of UL44, UL84, UL32, and UL46 transcripts were detected at a 
reduced level for all of the UL34 mutant viruses at 6 days post-transfection (Figure 1B). In 
contrast, no UL69 or UL37 expression was detected for the UL34 mutant viruses; and UL36 
expression was detected only in the UL34 mutant virus expressing the late UL34 protein (UL34b). 
At 8 days post-transfection, only UL44 transcripts were detectable for the UL34 deleted-BACs, 
albeit at a much reduced level compared to the UL34 rescued virus (Figure 1C).  
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Figure 1. (A) List of genes assayed for expression in cells receiving the recombinant 
UL34 human cytomegalovirus (HCMV) bacterial artificial chromosome (BACs). (B) 
and (C) Relative transcript levels for the indicated genes at 6 and 8 days post-transfection. 
RT-PCR was used to amplify the transcripts for each of the listed genes along with the 
cellular gene, glyceraldehyde phosphate dehydrogenase (GAPDH). The amplification 
products were quantified; viral gene levels were normalized to the level of GAPDH 
amplimers obtained for each of the samples. RUL34 is the UL34 rescued HCMV BAC, 
L UL34 has the initiation codon for the late protein mutated, E UL34 has the 
initiation codon for the early protein mutated and UL34 has the entire UL34 open 
reading frame deleted.  
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There is no UL34 binding site within the major immediate early gene, and in studies utilizing 
transient expression assays, UL34 has no activating or repressing effect on the mIE promoter [9]. 
Consequently, the reduction in IE2 transcript levels seen in the absence of UL34 proteins suggests 
that UL34 proteins have a general effect on the level of IE2 transcripts. This is supported by the 
reduction in transcript levels for all viral genes assayed (Figure 1B,C). UL32 and UL37 contain 
UL34 binding sites within their open reading frames; however, the diminution in transcript levels is 
consistent for all genes tested, regardless of the presence of a UL34 binding site. Intriguingly, the 
inability to detect UL69 and UL37 transcripts in the absence of either UL34 protein suggests that 
both proteins are required for their expression, contrasting with UL36 expression, where transcripts 
are not detectable in the absence of the late UL34 protein, suggesting that the late UL34 protein 
(UL34b) is required for UL36 expression. 
At 8 days post-transfection, of the genes assayed, only UL44 transcripts were detected for the 
UL34 mutant viruses, in contrast to the transcripts detected for the UL34 rescued virus (Figure 1C). 
The lack of either UL34 protein results in a decrease in expression of IE2 and an absence of UL37 
expression; proteins critical for later gene expression. These data suggested that the effects of the 
UL34 mutations were cumulative, that is, a reduction in the expression of essential genes earlier in 
the infection cycle (day 6) results in very little viral gene expression by 8 days post-transfection, 
corresponding to the defect in viral replication.  
Some variations in transcript levels were seen when comparing the UL34 mutant HCMV BACs. 
Expression of only the late UL34 protein resulted in detectable levels of UL36 and an increase in 
the level of UL32 expression, relative to the other UL34 mutant viruses, suggesting that the late 
protein plays a significant role in the expression of these two genes. There are UL34 binding sites 
located within the coding regions of UL37 and UL32 that may directly influence gene expression. 
UL34 proteins have a known transcriptional effect, repressing expression of the US3 and US9 
genes [6,7]. However, the data presented in Figure 1 suggests that UL34 has a more general effect 
on viral gene expression given the lack of UL34 binding sites within the other assayed genes, 
coupled with the decrease in gene expression. Both forms of the UL34 protein are required for viral 
replication, with the early and late proteins differentially affecting the expression of other viral genes. 
2.3. UL34 Localizes to Viral DNA Replication Centers 
The UL34 proteins localize to the nucleus when visualized using a tag of enhanced green 
fluorescent protein (EGFP) or using indirect immunofluorescence [5]. Here, we examined the 
intracellular location of UL34 proteins during the viral replication cycle, using polyclonal rabbit 
anti-sera to UL34 and indirect immunofluorescence. Monoclonal antibodies to other viral proteins 
were used simultaneously to co-label the same infected cell population. Primary human fibroblasts 
were infected with HCMV strain Towne and fixed and stained at 3, 24, 48, 72 and 96 hours 
post-infection (hpi).  
As UL34 proteins are detectable by 4 hpi using either immunoprecipitation or western blot  
analyses [5], we initially compared the intracellular pattern of UL34 expression to that of the 
immediate early protein, IE2. At 3 hpi, UL34 was detected in a punctate staining pattern (Figure 2). 
Co-labeling with an antibody to IE2 demonstrated that UL34 colocalized with IE2 in the punctate 
dots at 3 hpi. UL34 continued to colocalize with IE2 throughout the remainder of the viral 
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replication cycle, with the staining of UL34 and IE2 increasing as viral replication progressed 
(Figure 2). At 3 hpi, UL34 was not detectable in all cells positive for IE2, as expected, with IE2 
expression activating the expression of other viral genes.  
Figure 2. Indirect immunofluorescence was performed on primary human fibroblasts 
infected with HCMV strain Towne at 3, 24, 48, 72, and 96 hpi using antibodies to 
UL34 and to IE2. UL34 staining is red, IE2 staining is green; the merged column is the 
combination of the green and red images. Colocalization is indicated by the yellow 
color in the merged images. The numbers indicate the time post-infection at which the 
cells were examined. Control slides, infected cells incubated only with secondary 
antibodies, are not shown. 
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As IE2 is found in viral DNA replication structures [10], the colocalization of UL34 with IE2 
suggested that UL34 localizes to viral DNA replication centers. To further examine the intracellular 
location of UL34, additional immunofluorescence experiments were performed, comparing the 
intracellular location of UL34 to that of UL44. UL44 encodes a viral DNA polymerase processivity 
factor; antibody labeling of UL44 is commonly used to identify viral DNA replication centers [11,12]. 
UL44 was detectable at 24 hours post-infection, localizing as bright nuclear foci with a low level of 
diffuse nuclear staining (Figure 3). UL34 colocalized with UL44 in the bright nuclear foci. The 
pattern of colocalization continued throughout the viral replication cycle, with UL34 colocalizing 
extensively with UL44. Although UL34 colocalizes with UL44 in viral DNA replication centers, 
UL34 was not identified in the proteins complexing with UL44 [11], suggesting that UL34 does 
not interact directly with UL44. 
Figure 3. Indirect immunofluorescence was performed on primary human fibroblasts 
infected with HCMV strain Towne at 24, 48, 72, and 96 hpi using antibodies to UL34 
and to UL44. UL34 staining is red, UL44 staining is green; the green and red images 
were merged with the DAPI-stained images (blue) at 24 hpi; for the other timepoints, 
only the red and green images were merged. An enlargement of one of the stained cells 
is shown in the insert at 24 hpi in the merged column. The extracellular bright green 
dots seen in the 48 hpi samples were an artifact associated with the secondary antibody. 
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The similar staining patterns of UL34, IE2 and UL44 again suggested that UL34 localizes 
predominantly to viral replication centers. To compare the intracellular location of UL34 with that 
of another viral protein found in the nucleus but not in viral DNA replication centers, infected cells 
were labeled with antisera to UL34 and with a monoclonal antibody to ICP22. The US22 gene 
encodes ICP22, a tegument protein that is found in the nucleus early in infection and in both the 
nucleus and cytoplasm at later stages of viral replication [13]. As shown in Figure 4, little 
colocalization of UL34 with ICP22 is seen, suggesting that UL34 specifically colocalizes with IE2 
and UL44 in viral DNA replication centers. 
Figure 4. Indirect immunofluorescence was performed on primary human fibroblasts 
infected with HCMV strain Towne at 24, 48, and 72 hpi using antibodies to UL34 and 
to ICP22. UL34 staining is red, ICP22 staining is green; the merged column is a 
combination of the red and green images.  
 
IE2 accumulates at the periphery of promyelocytic leukemia protein-associated nuclear bodies 
(PODs) [10], becoming incorporated into viral DNA replication centers, along with the core 
proteins including UL44, as the viral replication cycle continues. Our data demonstrate that UL34, 
along with IE2 and UL44, is also found in viral DNA replication centers. The contribution of UL34 
to viral replication is potentially mediated through the UL34 binding sites located in the viral 
genome near the origin of lytic replication. The interaction of pUL34 with the ori-lyt region and the 
localization of UL34 to viral DNA replication center along with the two essential proteins, IE2 and 
UL44, suggests that UL34 may contribute to the efficiency of viral DNA replication.  
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2.4. UL34 Colocalizes with Nucleolin 
At late stages of infection (96 hpi), UL34 was found widely distributed in the nucleus. The 
circular areas within the nucleus that did not contain UL34 (See Figure 2, 72 hpi as an example) 
were identified as nucleoli using an antibody to label the nucleolar protein, fibrillarin (data not 
shown). However, UL44 colocalizes partially with the cellular protein nucleolin, and the interaction 
of nucleolin with UL44 is essential for viral replication [11]. The colocalization of UL34 and UL44 
suggested that UL34 would colocalize with nucleolin. To examine the interaction of UL34 and 
nucleolin, infected cells were costained with antibodies to UL34 and to nucleolin. Early in infection 
(24 hpi), UL34 accumulated in bright nuclear foci adjacent to the nucleolin staining (Figure 5). 
However, at late times of infection, UL34 partially colocalized with the ring of nucleolin detected 
at the perimeter of the nucleoli (Figure 5, see inset). These data suggested that nucleolin and 
nucleoli contribute to organization of UL34 in the nucleus and to the formation and organization of 
viral DNA replication compartments. Strang et al. [11,12] found nucleolin predominantly dispersed 
in the nucleus following viral infection (using HCMV strain AD169), and further found that UL44 
partially colocalized with nucleolin at the perimeter of viral replication centers. In contrast, using a 
monoclonal antibody to nucleolin rather than polyclonal antisera, we detected no dispersal of 
nucleolin. The difference seen in nucleolin distribution following infection may be a result of 
utilizing different antisera, or alternatively, strain specific differences, with the localization data 
presented here obtained following infection with HCMV strain Towne. In summary, UL34 proteins 
are localized in close proximity to nucleolin early in infection; late in infection, UL34 proteins 
partially colocalize with nucleolin. 
Figure 5. Indirect immunofluorescence was performed on primary human fibroblasts 
infected with HCMV strain Towne at 24 and 96 hpi using antibodies to UL34 and to 
nucleolin. UL34 staining is red, nucleolin staining is green; the green and red images 
were merged with the DAPI-stained images (blue) in the merged column at 24 hpi as 
described for Figure 1; the DAPI-stained image was not included in the merged image 
for the 96 hpi timepoint. The arrowhead indicates the association of UL34 with nucleolin 
early in infection. The inset shows an enlargement of the colocalization of UL34 and 
nucleolin at 96 hpi.  
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3. Experimental Section  
3.1. Virus, Cells and Immunofluorescence 
HCMV strain Towne was propagated in primary human fibroblasts in Dulbecco’s minimal  
essential medium supplemented with glutamine, penicillin, streptomycin and 10% Nuserum. For 
immunofluorescence studies, primary human fibroblasts were plated on glass coverslips and 
infected with HCMV strain Towne at a moi of 1–2 pfu/cell. Prior to antibody staining, cells were 
washed with phosphate buffered saline (PBS), fixed with 4% paraformaldehyde and permeabilized 
using 0.2% Triton X-100 in PBS. Following four washes with PBS, cells were incubated with 10% 
normal human serum at 37 °C for 1 hour. Primary antibodies were diluted to the recommended 
concentrations in PBS containing 3% bovine serum albumin; cells were incubated with the primary 
antibodies for 1 hour at room temperature. Secondary fluorescent dye-tagged antibodies to mouse 
or rabbit antibodies were incubated with the cells for 30 minutes at room temperature. Nuclei were 
stained with 4',6-diamidino-2-phenylindole (DAPI); cells were visualized using a Nikon 
fluorescence microscope and photographed using a SPOT camera. The following primary antibodies 
were used: monoclonal antibodies to UL44 (ICP36) and to US22 (ICP22) were obtained from 
Virusys Corporation, Taneytown, MD, USA; the monoclonal antibody to IE2 was obtained from 
Millipore, Billerica, MA, USA; the monoclonal antibody to nucleolin was obtained from Abcam, 
Cambridge, MA, USA, and the fluorescent dye-tagged secondary antibodies were obtained from 
Life Technologies, Grand Island, NY, USA. 
3.2. Recombinant Virus 
The BAC plasmid, pHB5, which contains the HCMV AD169 genome was kindly provided  
by U. Koszinowski [8]. A mutated BAC lacking UL34 was constructed as described by  
Datsenko and Wanner [14] using primers (285, 5'CAGAACCCGTCGCCATTTCCCCTCATA-
TACGGTACACGTCCCC CTGATCTGTGTAGGCTGGAGCTGCTTC 3' and 286,  
5' AAACCAGAGCGGAACTTGAGAAATCAACGCTTTATTGTTCTCCAGTGACGCATAT-
GAATATCCTCCTTAG 3') which contain sequences complementary to the ends of UL34 and to 
the kanamycin gene [14]. Briefly, the primers were used to amplify the kanamycin and frt 
sequences from pKD13; the PCR product was then introduced into pHB5 using pKD46, which 
expresses the lambda Red genes. Following insertion of the FRT-kanamycin cassette and deletion 
of the UL34 open reading frame, the kanamycin gene was removed from the BAC using pCP20 
which expresses the Flp recombinase.  
Recombinant BACs were then constructed by replacing the deleted UL34 gene with either the 
wild type sequence or with a UL34 gene containing mutations of either the early or late translation 
initiation codons for the early and the late proteins. pBJ545, which contains the HindIII H fragment 
of HCMV strain Towne in pST76K_SR, was mutated using oligo pairs 328 and 329 (328, 5' 
CCTGCGAGCCGCCGAGGTGCGTGACAACGTGGC 3'; 329, 5' GCCACGTTGTCACGC 
ACCTCGGCGGCTCGCAGG 3') or 330 and 331 (330, 5' 
ACCGCCCCACCGCCGTCGTCGTCAT CAACTTCATCATCACCACC 3'; 331, 5' 
GGTGGTGATGATGAAGTTGATGACGACGAC GGCGGTGGGGCGGT 3') and the 
275 
Quickchange mutagenesis kit (Stratagene, Santa Clara, CA, USA) giving rise to pBJ598 (early 
ATG mutated to ATC) and pBJ599 (late ATG mutated to GTG). pBJ598 and 599 were 
electroporated into bacteria containing the UL34-BAC and pKD46. Resulting colonies were 
screened using PCR to identify BACs containing the replaced UL34 sequences.  
3.3. Quantitative Reverse Transcriptase Polymerase Chain Reactions 
The following pairs of oligonucleotides were used to amplify a portion of the indicated  
gene transcript: UL37 (368, 5' TCAGACGATCCGATGAACGT 3' and 369, 5' 
TCTCCTCCGAGCCAAAAGTC 3'), UL44 (370, 5' CTAGCCGCACTTTTGCTTCT 3'and 371, 5' 
ACGGTCTTTCCTCCAAGGAA 3'), UL69 (372, TTAGTCATCCATATCATCGC 3' and 373, 
GAGCTTAACTTGATGACGCC 3'), UL122 (374, GAGACTTGTTCCTCAGGTCC 3', and 375, 
5' CAACATGATCATCCACGCTG 3'), UL36 (376, 5' TCAGTTGTTCATGTAAACGT 3', and 
377, ACCACTTTGAACTCTCCTAC 3'), glyceraldehyde phosphate dehydrogenase (GAPDH; 39, 
5‘ AGAGACATCATCCCTGCCTCT 3', and 391, 5' TTTTTCTAGACGGCAGGTCA 3'), UL84 
(398; 5' GCAGACCATGGCTAAAGTGA 3' and 399, 5' TTAACCGTACTGGTGAGCGA 3')  
and UL32 (20, 5' TGCAGTTTATCGGTCTACAGCG 3'; and 21, 
5'CGRATCCTTGAGGTGCACAAAG 3'). RNA was extracted from human fibroblasts that had 
been electroporated with the indicated HCMV-BAC 6 and 8 days post-transfection. RNA was 
treated with RQ1 DNAse followed by DNAse stop solution. PCR reactions were performed 
following reverse transcription reactions or in the absence of reverse transcription to confirm the 
absence of contaminating DNA. Amplimers were quantified following gel electrophoresis. 
4. Conclusions  
The experimental results presented here demonstrate that both UL34 proteins play an essential 
role in viral replication. Viruses containing in frame point mutations substituted for the initiation 
codons for the early and the late proteins are replication defective. The absence of UL34 protein 
expression resulted in a diminution of viral gene expression, and most notably, the absence of 
UL37 and UL69 transcripts. With the exception of UL34 repression of US3 and US9  
expression [6,7], we have been unable to identify any direct effects of UL34 expression on viral 
gene transcription. This suggests that UL34 proteins are multi-functional, not only specifically 
repressing the expression of some viral genes, but also having a general effect on viral gene 
transcription. We postulate that the effects of the UL34 proteins may be to facilitate the 
establishment of an environment in the nucleus favorable for viral gene expression and viral DNA 
replication. This notion is supported by the localization of UL34 proteins to viral DNA replication 
centers. Furthermore, the proximal localization of UL34 to nucleolin suggests that UL34-nucleolin 
interactions may facilitate the intranuclear positioning of the replication centers. In summary, this 
work demonstrates the significance of both UL34 proteins, and raises questions about the viral and 
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Abstract: Human cytomegalovirus (HCMV) encodes four G protein-coupled receptor 
(GPCR) homologs, termed pUS27, pUS28, pUL33, and pUL78. In contrast to the 
extensively characterized vGPCRs pUS28 and pUL33, knowledge concerning pUS27 
and pUL78 is limited. Previous studies already demonstrated constitutive 
internalization of pUS27 and pUL78, as well as an association with the endosomal 
machinery, however, these results were mainly obtained using transiently transfected 
cells. To explore the subcellular localization of both receptors during viral infection, we 
constructed recombinant HCMVs expressing tagged vGPCRs. Colocalization analyses 
revealed a predominant association of pUS27 or pUL78 with the trans-Golgi network or 
the endoplasmic reticulum, respectively. Intriguingly, our data emphasize that protein 
sorting is highly regulated by viral functions as we detected dramatic changes in the 
colocalization of pUS27 and pUL78 with endosomal markers during progression of 
HCMV replication. Furthermore, we observed cell type-dependent differences in 
trafficking of both vGPCRs between fibroblasts and epithelial cells. Most importantly, 
infection experiments with a recombinant HCMV carrying tagged versions of pUS27 
and pUL78 simultaneously, revealed that these two proteins do not colocalize during 
viral infection. This contrasts to results of transient expression experiments. In conclusion, 
our results highlight the importance to investigate vGPCR trafficking in a viral context.  
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1. Introduction 
G protein-coupled receptors (GPCRs) act as key regulators of numerous cellular processes via 
transmitting the response of various signal molecules like chemokines, hormones, or 
neurotransmitters. Thus, it is not surprising that viruses have hijacked mammalian GPCRs during 
coevolution to ensure efficient viral propagation [1,2]. Thereby, virally encoded GPCRs (vGPCRs) 
illustrate an effective means to bypass the immune system, modulate cellular functions, and 
redirect cellular signaling networks [3]. Human cytomegalovirus (HCMV) encodes four GPCR 
homologs, termed pUS27, pUS28, pUL33, and pUL78 [4,5]. In contrast to pUS27 and pUS28, 
which are restricted to primate CMVs, pUL33, and pUL78 are highly conserved among all 
betaherpesviruses. While their expression is not crucial for virus replication in cell culture [6,7], a 
deletion leads to a significantly diminished pathogenesis in animal experiments [8,9]. 
The most comprehensively analyzed vGPCR of HCMV is pUS28. As a homolog of CCR1, 
CCR2, and CX3CR1, it can bind a broad spectrum of chemokines, such as CCL5/RANTES, 
monocyte chemoattractant protein-1 (MCP-1), and CX3CL1/fractalkine [10–12]. As pUS28 is 
rapidly internalized in a constitutive manner [13–16], it is believed to function as a chemokine  
sink to impair leukocyte recruitment thereby dampening the immune response at sites of  
infection [7,17–19]. Furthermore, similar to other vGPCRs, pUS28 constitutively activates several 
signaling pathways including PLC  [20,21], NF- B [10], NFAT, and CREB [22] via G q and G i-
dependent signaling. Due to the strict host specification of all CMVs, it is difficult to determine the 
role of pUS28 in a physiologically relevant situation in vivo. However, recent reports demonstrated 
a partial functional complementation between pUS28 and its mouse cytomegalovirus vGPCR 
homolog pM33 [23,24]. Nevertheless, it is still unknown whether pUS28 plays an essential role 
during HCMV pathogenesis [7,19].  
In contrast to pUS28, the vGPCRs pUS27, pUL78, and pUL33 are still orphan receptors. 
Interestingly, for pUL33 and its homologs in mouse (pM33) [11] and rat CMV (pR33) [25] a 
ligand-independent activation of several signaling cascades could be shown [26]. Whereas a 
functional analysis of pUL33 is difficult in vivo, rodent homologs have been reported to be critical 
for infection [8,27,28]. By means of gene-knockout viruses it was shown that deletion of M33 or 
R33 resulted in less virulent CMV variants, which neither disseminated nor replicated within the 
salivary gland. Intriguingly, both pUL33 and pUS28 were able to partially restore the replication 
defect of a M33-deficient virus indicating shared biological functions between the respective 
vGPCRs [23]. 
While pUS28 and pUL33 constitutively activate multiple signaling pathways, the functions of 
pUS27 and pUL78 are not yet fully understood. As pUS27 and pUS28 are directly adjacent and 
share 31% sequence identity, a gene duplication event may have occurred. Similar to pUS28, 
pUS27 is constitutively internalized and localized to cellular vesicles with endosomal markers 
(EEA1), to lysosomes (LAMP-1), as well as to Golgi compartments (GM130) [29,30]. A potential 
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di-leucine sorting motif in the cytoplasmic domain of pUS27 was reported to be necessary and 
sufficient for its intracellular localization [29]. The fact that pUS27 is heavily glycosylated [31] and 
possesses two conserved cysteine residues in the second and third extracellular loop indicates a 
possible involvement of pUS27 in chemokine binding and signaling in host cells. Notably, 
O’Connor et al. were able to demonstrate that pUS27 supports viral spread through the 
extracellular route late during infection in fibroblasts and endothelial cells, but not in epithelial 
cells [32]. Thus, this study suggested a cell type-dependent function of pUS27, which appears to 
involve interactions with one or more virus-encoded proteins at the site of virus assembly. 
Moreover, pUL78 was recently shown to support viral infection affecting a step after plasma 
membrane binding but before virus entry in epithelial cells [33]. This observation was also cell 
type-specific as pUL78 seemed to be dispensable for virus replication in fibroblasts and endothelial 
cells. Furthermore, the rodent variants (pR78, pM78) of pUL78 were used to demonstrate the 
importance of this vGPCR for viral pathogenesis in vivo [9,34,35]. In line with the three other 
vGPCRs of HCMV, pUL78 is constitutively internalized [36]. Wagner et al. could show that the 
process of internalization is dependent on dynamin. In addition, they could identify an association 
of pUL78 with the endoplasmic reticulum (ER), and its localization in the trans-Golgi network  
as well as early endosomes. Although pUS27 and pUL78 seem to lack constitutive signaling 
activity [11], they were demonstrated to colocalize and heteromize with the constitutively active 
receptor pUS28 in vitro. Thereby, pUL78, in contrast to pUS27, is able to silence pUS28-mediated 
activation of NF- B dependent gene expression [37].  
As there is a lack of antibodies against HCMV-encoded GPCRs, most reports assessing the 
subcellular localization of these proteins were based on transient transfection analyses using tagged 
receptors. In this study, we describe the construction of recombinant HCMVs expressing either 
singly tagged pUS27 and pUL78, or a virus, where both proteins were tagged simultaneously, thus, 
enabling live cell imaging. These viruses were used for a comparative analysis of the subcellular 
localization of pUS27 and pUL78 after infection of both fibroblasts and epithelial cells. These 
experiments revealed cell type-dependent differences in trafficking of pUS27 and pUL78. In 
addition, colocalization analyses with cellular markers showed a substantially different accumulation 
of both receptors in infected cells compared to transiently transfected cells. Thus, this study 
emphasizes the necessity to analyze vGPCRs in a viral context in order to obtain physiologically 
meaningful results concerning their functions during viral replication.  
2. Results 
2.1. Colocalization of pUS27 and pUL78 in Transiently Transfected Cells  
The viral GPCR pUS28 has previously been shown to colocalize and heteromize with pUL78 or 
pUS27 in vitro [37]. In order to investigate a possible colocalization of pUS27 with pUL78 in 
transiently transfected cells, we used tagged versions of both receptors due to a lack of specific 
antibodies for pUS27 or pUL78. Thus, a FLAG-tag was fused to the N-terminal extracellular domain 
of pUS27. The C-terminal intracellular domain of pUL78 was labeled with GFP. To analyze the 
intracellular vGPCR localization, receptors were transiently expressed in HeLa cells, either alone 
or in combination. After 24 h, cells were fixed, permeabilized, stained, and analyzed by confocal 
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microscopy. Both proteins were detected in a predominantly perinuclear distribution pattern. While 
pUS27 was only found in dot-like structures (Figure 1b, red), pUL78 showed an additional weaker 
signal distributed throughout the cytoplasm (Figure 1c, green) as already described in previous 
reports [30,36]. In co-transfection experiments, most of the pUS27 signal overlapped with the  
dot-like pUL78 signal (Figure 1d). Therefore, both receptors not only colocalize with pUS28 [37], 
but also show a distinct colocalization among each other presumably in endosomal structures. 
Figure 1. Colocalization analysis of FLAG-US27 and UL78-GFP in transiently 
transfected HeLa cells. HeLa cells were transfected with 1 g of an expression plasmid 
encoding N-terminally tagged wild-type TB40/E FLAG-US27 (b), C-terminally tagged 
wild-type TB40/E UL78-GFP (c), or both plasmids together (d). pcDNA3 was used as a 
negative control (a). Cells were fixed 24 h post transfection and permeabilized with Triton 
X-100. The primary antibody mAb-FLAG in combination with a secondary anti-mouse 
antibody coupled to Alexa-555 were used to detect pUS27. Cell nuclei were stained with 
4',6-diamidino-2-phenylindole (DAPI). 
 
2.2. Recombinant Viruses Harboring Tagged Versions of pUS27 or pUL78 Show Similar Growth 
Kinetics Compared to Wildtype HCMV Strain TB40/E 
To analyze whether the intracellular localization patterns of pUS27 and pUL78 as observed in 
transiently transfected cells [29,30,36] can also be detected during infection, recombinant 
cytomegaloviruses were engineered via homologous recombination. The two-step, red-mediated 
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recombination for markerless DNA manipulation, as described by Tischer et al., was used for the 
generation of recombinant CMVs [38]. The wild-type TB40/E-based HCMV bacterial artificial 
chromosome (BAC) TB40-Bac4 [39] was manipulated in order to fuse EYFP to the C-terminus of 
UL78 or US27, resulting in recombinant viruses termed TB40/E-US27-EYFP (US27-EYFP) or 
TB40/E-UL78-EYFP (UL78-EYFP), respectively (Figure 2a, upper panel). To enable 
colocalization studies with both vGPCRs in one cell, we additionally generated a recombinant virus 
carrying tagged versions of US27 and UL78 (Flag and EYFP, respectively), referred to as  
UL78-EYFP/Flag-US27 (Figure 2a, lower panel). In order to confirm the correct in-frame 
integration of all tags, BACs were analyzed using various independent methods. Distinct PCR 
reactions and subsequent nucleotide sequence analyses of all BACs, as well as restriction fragment 
length polymorphism analysis (RFLP) revealed a correct BAC recombination (data not shown). 
After reconstitution of infectious viruses, viral growth was analyzed by performing multistep 
growth curve analyses of wild-type and recombinant TB40/E viruses (Figure 2b). For this purpose, 
HFFs were infected at an MOI (multiplicity of infection) of 0.1 with either wild-type or 
recombinant viruses. The supernatants were harvested at 0, 3, 6, 9, 12, and 15 dpi (days post 
infection). After cell lysis and DNA extraction, real-time PCR was performed to quantify HCMV 
genome copy numbers. As depicted in Figure 2b, all recombinant viruses replicated with similar 
growth kinetics compared to the wild-type strain TB40/E. Therefore, the epitope tags do not alter 
HCMV replication capacities in HFFs. Thus, recombinant viruses can be used to analyze 
intracellular localization routes of pUS27 and pUL78 during the entire replication cycle, even by 
live cell imaging. 
2.3. Expression and Localization Patterns of pUS27 and pUL78 Differ upon HCMV Infection of 
Fibroblasts and Epithelial Cells 
While, up to now, pUS27 localization was only determined in detail in transiently transfected 
cells [29,30], the intracellular distribution of pUL78 was additionally analyzed at 48 hpi in HFF 
cells [36]. It has been demonstrated in previous studies that HCMV infection changes the entire 
morphology of infected cells [40,41]. One of these alterations is the development of a so-called 
cytoplasmic virion assembly compartment (cVAC). Usually, one cVAC per cell is formed by 
rearrangement of several cellular compartments including Golgi bodies, the trans-Golgi network 
and endosomal structures [41–43]. Thus, the dynamic nature of endocytic compartments during 
infection compels the use of multiple time points in analyses. Furthermore, it is important to 
analyze vGPCR localization in different cell types, as HCMV can infect a remarkably broad 
spectrum of different cell types with variable outcomes for the host in vivo [44].  
In a first set of experiments we aimed to determine the subcellular localization of pUS27 and 
pUL78 in human retinal pigment epithelial cells (ARPE-19) and HFFs over the entire replication 
cycle. For this, HFFs and ARPE-19 were seeded, infected at an MOI of 0.5 or 1, respectively, and 
fixed at 6, 24, 48, 72, and 96 h post infection (hpi). After fixation, infected cells were permeabilized, 
stained for IE1 detection, and analyzed using confocal microscopy. The progression of virus infection 
in HFF and ARPE-19 cells is shown in Figure 3. To verify that all detected vGPCR signals were 
specific for infected cells, IE1 staining was used as a control (Figure 3, red). At 6 h after HCMV 
infection, the IE1 protein was already present in the cell nucleus of HFF and ARPE-19 cells. As 
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described previously [36], pUL78 (Figure 3, green, middle and right panel) was produced between 
6 and 24 hpi. In contrast to that, pUS27 (Figure 3, green, left panel) expression was firstly visible 
48 h after infection. Thus, it appears to be expressed later during HCMV replication. During the 
entire replication cycle, pUS27 was present in the perinuclear region of the cell. Late in infection, 
however, pUS27 was not only detected in association with the cVAC, but was additionally found in 
dot-like structures all over the cytoplasm, which was both observed in HFF and ARPE-19 cells 
(data not shown). In contrast to the perinuclear distribution of pUS27 at 48 hpi, the pUL78 signal 
was spread over the entire cytoplasm including defined dot-like structures. As infection progressed 
(72–96 hpi), pUL78 was increasingly displaced from the cVAC formation site, both in HFF and in 
ARPE-19 cells. Nevertheless, in epithelial cells dot-like pUL78-positive structures remained in the 
perinuclear region over the entire replication cycle. This observation suggests that pUL78 may 
exhibit different functions during infection of epithelial cells versus fibroblasts. 
Figure 2. Construction and characterization of recombinant HCMVs expressing tagged 
US27 and/or UL78. (a) Schematic illustration of the US27 and UL78 genomic loci of 
HCMV strain TB40/E. Recombinant viruses were generated with C-terminal EYFP 
(US27 or UL78, upper panel) or N-terminal FLAG-tag (US27, lower panel);  
(b) Growth kinetics of recombinant TB40/E-derived viruses. HFF cells were seeded 
and infected three days later with wild-type and recombinant viruses at an MOI of 0.1. 
Virus supernatant samples were harvested at indicated times (dpi, days post infection) 
and digested with proteinase K. Viral DNA was quantitated via Taqman PCR to 
determine the release of viral particles from infected cells. Each infection was 
performed in triplicate, and the standard deviations are shown. 
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Figure 3. Subcellular localization of US27-EYFP and UL78-EYFP in infected HFFs 
and ARPE-19 cells. HFF (left and middle panel) or ARPE-19 cells (right panel) were 
infected with recombinant TB40/E viruses (MOI: 0.5 or 1) expressing fusion proteins 
of pUS27 (left panel) or pUL78 (middle and right panel) with EYFP and fixed at 
different time points during HCMV infection (6–96 hpi). Cells were stained with 
primary antibody mAb-IE1 (p63-27), and a secondary anti-mouse antibody coupled to 
Alexa-555. Cell nuclei were stained with DAPI.  
 
2.4. While Both Receptors Localize to the trans-Golgi Network in Virus Infected Cells, only pUL78 
Colocalizes with Calreticulin 
To better define the intracellular localization patterns of pUS27 and pUL78 during HCMV 
infection, we performed indirect immunofluorescence analysis using different cellular markers. In a 
first experiment, HFF and ARPE-19 cells were infected with either US27-EYFP or UL78-EYFP to 
identify a potential colocalization with proteins of the Golgi network or the endoplasmic reticulum. 
Since many vGPCRs, including pUS27, are predicted to be highly glycosylated [31], we expected a 
colocalization with the cis-Golgi marker GM130 in HFF as well as in ARPE-19 cells. In contrast to 
previous reports [29,45], we were not able to visualize any colocalization with GM130 in infected 
cells over the entire replication cycle (data not shown). However, in accordance with transiently 
transfected receptors [30,36], partial colocalization of pUS27 and pUL78 was detected with the 
membrane protein TGN46, a marker for the trans-Golgi network, during the progression of HCMV 
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infection (Figure 4a). Similar to GM130, the TGN46 signal showed perinuclear localization early in 
infection (Figure 4a, 24 hpi). After 48 h, the signal shifted to the cVAC formation site and started 
forming concentric circles around this virus-induced, cellular structure (Figure 4a, 72 hpi). Upon 
pUS27 expression, the vGPCR localizes to the trans-Golgi network (TGN) (Figure 4a, left panel), 
suggesting that the TGN serves as site of glycosylation. This expression pattern lasted until late 
stages of HCMV infection. Upon comparison of these findings to pUL78, we observed a slightly 
different pattern. As pUL78 was detected throughout the cytoplasm at early stages (Figure 4a,  
6 hpi, right panel) and was almost excluded from the virion assembly site late in infection  
(Figure 4a, 72 hpi, right panel), we detected a partial colocalization of TGN46 with pUL78 but not 
as striking as with pUS27. Next, we investigated a potential colocalization of both vGPCRs during 
infection with calreticulin, a marker for the endoplasmic reticulum (ER) (Figure 4b). At early 
stages of virus infection, calreticulin showed a typical lamellae structure formed around the cell 
nucleus. After approximately 48 to 72 h, the structure changed and was completely displaced from 
the site of cVAC formation. As pUS27 is associated with the cVAC, we did not observe any 
colocalization of this receptor with calreticulin. In contrast to pUS27 (Figure 4b, left panel), pUL78 
appeared to be associated with the ER over the entire replication cycle of HCMV (Figure 4b, right 
panel). The same results were obtained in ARPE-19 cells (data not shown). These results are in 
accordance with previous studies using transiently transfected cells [36]. 
Figure 4. Colocalization of US27-EYFP and UL78-EYFP with TGN46 and calreticulin 
in infected HFFs. HFFs were infected with recombinant TB40/E viruses (MOI: 0.5) 
expressing fusion proteins of pUS27 (left panel) or pUL78 (right panel) with EYFP and 
fixed at different time points during HCMV infection (24–96 hpi). Cells were stained 
with primary antibody (a) pAb-TGN46, diluted 1:300, or (b) pAb-Calreticulin (PA3-900), 
diluted 1:100, and the respective secondary anti-sheep antibody or anti-rabbit antibody 
coupled to Alexa-555 (1:400). Cell nuclei were stained with DAPI.  
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Figure 4. Cont. 
 
2.5. Endosomal Localization Patterns of pUS27 and pUL78 Diverge in Fibroblasts as Well as in 
Epithelial Cells during HCMV Replication 
Next, we determined whether there is any colocalization of pUS27 or pUL78 with endosomal 
markers during the time course of HCMV infection. In order to describe endosomal structures in 
detail, colocalization studies with different endosomal and lysosomal markers were performed. The 
main components of the endosomal system are early endosomes (EE), recycling endosomes (RE), 
maturing endosomes (ME), late endosomes (LE), and lysosomes. During cVAC formation, 
components of the host cell secretory apparatus are rearranged in concentric circles [41]. Thereby, 
early (EEA1) and recycling (CD71) endosomes were localized in the cVAC center and were 
enclosed with markers of the trans-Golgi and cis-Golgi network in HFFs (Figures 4 and 5). 
Markers of the late endocytic pathway (CD63, LAMP-1), however, were found in the cVAC 
periphery (Figure 6). For pUL78, a partial colocalization with EEA1 was already shown at 48 h 
post infection in a in previous report [36]. Here, we demonstrate that co-localization of pUL78 
signal with that of EEA1 is not restricted to the 48 h post infection time point, but in fact occurs 
throughout the HCMV replication cycle in HFFs (Figure 5, right panel) as well as in ARPE-19 
cells (data not shown). In contrast, the pUS27 signal colocalized with EEA1 in HFFs only at late 
times of infection (Figure 5, left panel). Intriguingly, no colocalization between pUS27 and EEA1 
could be detected in ARPE-19 cells, infected with the same recombinant virus (Figure 5, middle 




Figure 5. EEA1 staining of US27-EYFP and UL78-EYFP infected HFFs and ARPE-19 
cells. HFF (left and right panel) or ARPE-19 cells (middle panel) were infected with 
recombinant TB40/E viruses (MOI: 0.5 or 1) expressing fusion proteins of pUS27 (left 
and middle panel) or pUL78 (right panel) with EYFP and fixed at different time points 
during HCMV infection (24–96 hpi). Cells were stained with primary antibody  
pAb-EEA1 (H-300), diluted 1:200, and the secondary anti-rabbit antibody coupled to 
Alexa-555 (1:400). Cell nuclei were stained with DAPI.  
 
The endosomal machinery is a highly complex system. After internalization and bypass of early 
endosomes, cargo can enter a recycling circuit or a degradative system, in which endosomes mature 
to MEs, and later to LEs [46]. To further elucidate the fate of HCMV-encoded vGPCRs after 
internalization, we used markers for REs (CD71), MEs/LEs (CD63), and lysosomes (LAMP1). We 
expected a colocalization with recycling endosomes, as both receptors were shown to localize to 
the cell surface [29,30,36]. Unfortunately, no overlap of vGPCR signals with CD71 could be 
detected in any cell type (data not shown). This may suggest that pUS27 and pUL78 recycling is 
independent of CD71-positive endosomes occurring directly via EEs. Alternatively, both receptors 
might enter the cellular degradative system immediately after internalization. To address this 
hypothesis, we next focused on maturing endosomes, late endosomes and lysosomes. CD63, a 
marker for multivesicular bodies, appeared as dot-like structures (Figure 6a), which were widely 
spread over the cytoplasm early in HCMV infection (24 hpi). After 48 h, the signal began to 
concentrate in the perinuclear region. Interestingly, CD63 signal seemed to be downregulated 
during cVAC formation in HFFs (Figure 6a, left and middle panel), as described previously [43]. In 
ARPE-19 cells, however, we could not observe any changes in CD63 expression (Figure 6a, right 
panel). Similar to EEA1, pUL78 began to colocalize with CD63 at 24 hpi (Figure 6a, middle and 
left panel). This colocalization could be observed throughout the replication cycle in HFFs and 
ARPE-19 cells and was decreased with the reduction of the CD63 signal in HFFs late in infection 
(Figure 6a, middle panel). In contrast, pUS27 did not display any colocalization with the cellular 
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marker CD63 (Figure 6a, left panel), indicating that this receptor is not present in mature and late 
endosomes of infected HFFs and ARPE-19 cells (data not shown). Corresponding to CD63, 
LAMP1, a marker for lysosomes, could be recognized in dot-like structures widely spread 
throughout the cytoplasm at 24 hpi; at 48 hpi, the signal started to concentrate in the perinuclear 
region of the cell (Figure 6b). Furthermore, pUS27 was not observed in lysosomes in HFFs  
(Figure 6b, left panel) or ARPE-19 cells (data not shown). Nevertheless, pUL78 signal overlapped 
with LAMP1 (Figure 6b, middle and right panel). This pattern, however, differed strongly 
dependent on the cell type. While we could demonstrate that pUL78 was localized to lysosomes 
early in infection in HFFs (Figure 6b, middle panel), the dot-like signals of pUL78, located close to 
the nucleus, showed clear colocalization with LAMP-1 in ARPE-19 cells starting at 72 h post 
infection (Figure 6b, right panel).  
Figure 6. CD63 and LAMP1 staining of US27-EYFP and UL78-EYFP infected HFFs 
and ARPE-19. HFF (left and middle panel) or ARPE-19 cells (right panel) were 
infected with recombinant TB40/E viruses (MOI: 0.5 or 1) expressing fusion proteins 
of pUS27 (left panel) or pUL78 (middle and right panel) with EYFP and fixed at 
different time points during HCMV infection (24–96 hpi). Cells were stained with 
primary antibody (a) mAb-CD63 (MX-49.129.5) or (b) mAb-LAMP-1 (H5G11), each 
diluted 1:50, and the secondary anti-mouse antibody coupled to Alexa-555 (1:400). Cell 
nuclei were stained with DAPI. 
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2.6. pUS27 and pUL78 Do Not Colocalize in Infected Fibroblasts or Epithelial Cells throughout 
the Replication Cycle 
Finally, we set out to clarify whether there is any colocalization of both vGPCRs in one cell 
during HCMV infection. To that end, a recombinant virus carrying tagged versions of the US27, as 
well as the UL78 gene (Flag/EYFP), was engineered by means of BAC technology (Figure 2) and 
investigated by immunofluorescence analysis. Colocalization studies with variable cellular markers 
already revealed that localization patterns of pUS27 and pUL78 differ substantially. Here, we 
demonstrate for the first time that pUS27 and pUL78 do not display any colocalization throughout 
the HCMV replicative cycle. This observation was independent of the cell type, as both vGPCR 
signals did not overlap in HFFs or ARPE-19 cells (Figure 7). In conclusion, this strongly suggests 
that the localization patterns of virally-encoded GPCRs as determined in transiently transfected 
cells do not reflect the physiological patterns during infection. Our data highlight the importance to 
analyze vGPCR functions in a viral context. 
Figure 7. Colocalization analysis of Flag-US27 and UL78-EYFP in infected HFFs and 
ARPE-19 cells. HFF (left panel) or ARPE-19 cells (right panel) were infected with a 
recombinant TB40/E virus (MOI: 0.5 or 1) expressing fusion proteins of both pUS27 
(red) and pUL78 (green) with Flag or EYFP, respectively, and fixed at different time 
points during HCMV infection (24–96 hpi). Cells were stained with primary antibody 
mAb-Flag, diluted 1:400, in combination with the secondary anti-mouse antibody coupled 




Human cytomegalovirus (HCMV), as all herpesviruses, establishes a lifelong infection in the 
host. In order to maintain its persistent state, HCMV developed various mechanisms during 
coevolution with its host to modify the cellular signaling network and to evade the immune system. 
It is likely that the expression of four homologs of cellular seven-transmembrane receptors termed 
pUS27, pUS28, pUL33, and pUL78 contributes to the dysregulation of cellular signaling and to 
immune evasion [4,5]. While cellular G-protein coupled receptors (GPCRs) typically localize to the 
cell surface and induce intracellular signaling cascades upon ligand binding [47], several reports of 
viral GPCRs (vGPCR) showed a different receptor localization. For instance, in the absence of ligands 
pUS28 was predominantly found in an intracellular pattern in endosomal compartments [15]. 
Similar observations were made for the orphan receptors pUS27 and pUL33, where the majority of 
the protein was detected in the perinuclear region of cells [30]. Moreover, the vGPCR pUL78 
seemed to associate mainly with the endoplasmic reticulum (ER) [36]. Unfortunately, most of these 
results were obtained with transiently expressed receptors. To gain more insight into the subcellular 
localization of HCMV-encoded vGPCRs during viral infection we performed immunofluorescence 
analyses of recombinant HCMVs, based on the endotheliotropic strain TB40/E, expressing either 
EYFP- or Flag-tagged pUS27 and/or pUL78.  
In accordance with previous studies, we could confirm that pUL78 has an early/late expression 
pattern [48], whereas pUS27 is expressed later during infection. While pUS27 exhibits an intracellular 
perinuclear distribution and is recruited to the cytoplasmic virion assembly complex (cVAC), the 
early protein pUL78 is observed throughout the cytoplasm. Due to stable colocalization with the 
ER, which is known to be excluded from the cVAC formation site [41,42], pUL78 is completely 
displaced from the virus assembly zone in HFFs. Importantly, our results indicate pronounced 
variations in localization patterns of virally-encoded GPCRs compared to transiently expressed 
pUS27 or pUL78. Contrary to transiently expressed vGPCRs [29,45], we were not able to visualize 
any colocalization with the cis-Golgi marker GM130 in HFFs or ARPE-19 cells (data not shown). 
Similar to recent reports [30,36,45], a colocalization of pUS27 and pUL78, with TGN46, a marker 
for the trans-Golgi network (TGN), was obvious and stable over the whole replication cycle. Thus, 
in contrast to Stapleton et al. [29], we suggest the TGN as the site of receptor glycosylation for at 
least pUS27.  
Furthermore, we detected a clear colocalization of pUL78 with EEA1 immediately upon 
expression, whereas pUS27 started to colocalize with the marker for early endosomes (EEs) at late 
time points after infection (96 hpi) only in HFFs. This observation differed significantly from the 
pattern determined for transiently expressed receptors [29,36]. Our data provide evidence that 
protein sorting is a dynamic process leading to dramatic changes of receptor localization during the 
entire HCMV replication cycle. Thus, it is of obvious importance to investigate protein localization 
patterns in a viral context. A surprising finding was that neither pUS27 nor pUL78 signal 
overlapped with CD71, a marker for recycling endosomes (REs). Both receptors were reported to 
constitutively internalize [29,30,36]. Hence, we expected a colocalization with REs, which was 
previously shown for the pUL78 homolog pM78 [45]. However, this result does not necessarily 
exclude pUS27 and pUL78 recycling in infected cells, since receptor recycling may also occur via 
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a direct route from EEs, the so called fast recycling pathway [49], or, as shown for cellular GPCRs, 
via the TGN [50]. On the other hand, both vGPCRs could enter a cellular degradative system 
directly after internalization [46]. In contrast to transiently expressed pUS27 [30], we were not able 
to visualize any colocalization with the cellular markers CD63 and LAMP1. Only pUL78 
extensively overlapped with these late endosomal (LE) and lysosomal markers, contrary to a 
transiently transfected version [36]. Since Das et al. suggested that lysosomes do no longer act as 
degradation system in infected cells [42], we hypothesized that pUL78 is not degraded but may 
fulfill a so far unknown function within these structures. However, the colocalization pattern of 
pUL78 with LEs and lysosomes varied extensively when analyzing different cell types or time 
points post infection. Consequently, these data again emphasize the highly dynamic protein 
localization pattern during HCMV replication. 
Intriguingly, the most pronounced divergence was detected with our recombinant virus carrying 
tagged versions of pUS27 and pUL78 simultaneously. In general, it is important to keep in mind 
that heteromerization of vGPCRs can alter their functions [51]. For example, Tschische et al. 
showed that heterodimerization of pUL78 with pUS28 led to an almost complete block of  
pUS28-mediated constitutive NF- B activation [37]. Besides, pUL78 as well as pUL33 were 
shown to heteromize with the human CCR5 and CXCR4 receptors thereby modifying GPCR 
functions and cell surface localization [52]. Thus, we hypothesized that a closer investigation of 
pUS27/pUL78 heterodimerization might unravel novel roles during virus infection and 
pathogenesis. Unexpectedly, however, we were not able to visualize any overlap of pUS27 and 
pUL78 signals in infected cells whereas this was clearly detectable in transient transfection 
experiments (compare Figures 1 and 7). Consequently, recent heteromerization studies of  
HCMV-encoded vGPCRs have to be interpreted with caution since the subcellular localization of 
virally-encoded GPCRs as determined in transiently transfected cells may not reflect the 
physiological patterns during infection. 
In accordance with previous studies [32,33], comparative analyses of fibroblasts and epithelial 
cells revealed a cell type-dependent trafficking of both pUS27 and pUL78. Moreover, we 
demonstrate that the subcellular morphology changes not only during infection, but also varies 
between infected HFFs and ARPE-19 cells. Whereas, as described previously [43], CD63 was 
downregulated during cVAC formation in HFFs, we did not observe any changes in CD63 
expression in ARPE-19 cells. This observation was in agreement with a HFF-specific, decreased 
colocalization of CD63 with pUL78 late during infection. Similar results were obtained for 
LAMP1. In addition, not only the colocalization of pUL78 varied between cell types, but also its 
cytoplasmic distribution: at the beginning of HCMV replication, pUL78 signal was spread 
throughout the cytoplasm in both analyzed cell types; however, a displacement from the cVAC 
formation site was only observed in HFFs. In ARPE-19 cells additional dot-like pUL78-positive 
structures remained in the perinuclear region for the entire replication cycle.  
Surprisingly, no colocalization of pUS27 with any endosomal marker was detected in ARPE-19 
cells. This raises the question whether pUS27 is localized at the cytoplasmic membrane in epithelial 
cells. A possible explanation would be that pUS27 internalization occurs via EEA1-negative 
endosomes, for example APPL-positive ones [53], or in a retrograde manner via the TGN [50]. 
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Nonetheless, further investigations will be required to characterize the sorting abilities of pUS27 in 
more detail.  
In conclusion, the results of this study emphasize the importance of analyzing vGPCR sorting in 
a viral context. Furthermore, we observed an unexpected, cell type-dependent variation in vGPCR 
receptor localization and sorting suggesting major functional differences of these molecules in 
terms of their signaling capabilities in various cell types. 
4. Experimental Section  
4.1. Cells 
HeLa cells were cultivated in Eagle’s minimal essential medium (MEM) (GIBCO/BRL) 
containing 7% fetal calf serum at 37 °C and 5% CO2. Primary human foreskin fibroblasts (HFFs) 
and the human retinal pigment epithelial cell line ARPE-19 were maintained in MEM, 
supplemented with 10% fetal calf serum at 37 °C and 5% CO2. 
4.2. Construction of Vectors for Subcellular Localization Analyses 
For the FLAG-US27 construct, a FLAG-epitope was fused to the 5' region of the US27  
gene (based on TB40/E) after amplification of the US27 coding sequence with primers  
N-US27-BamHI-for (5'-CTA GGG ATC CAC CAC CTC TAC AAA CCA AAC CTT AAC-3') and 
N-US27-XhoI-rev (5'-CTA GCT CGA GTT ACA ATA GAA ATT CCT CCT CCC CG-3') 
followed by insertion into the pcDNA3-derived vector pHM971. For the UL78GFP construct, the 
GFP coding sequence was fused to the 3' region of the UL78 gene (based on TB40/E): after 
amplification of the UL78 coding sequence with primers UL78-EcoRI-for (5'-CTG AAT TCA 
TGT CCC CTT CTG TGG AGG AGA C-3') and 2.UL78-BamHI-2nt-rev (5'-TCG GAT CCT GTA 
ATG CCG TCA CCG TTG CGT CG-3'), the amplicon was inserted into pEGFP-C1 (Clontech, 
Heidelberg, Germany), resulting in the expression of a C-terminally GFP-tagged pUL78.  
4.3. Transient Expression Analyses and Protein Localization  
For immunofluorescence analyses, 4 × 105 HeLa cells/well were seeded in MEM medium 
without antibiotics on coverslips until they were grown to approximately 80% confluence. 
Transfection of DNA plasmids (2 g total, with or without pcDNA3/well) was performed by 
utilizing LipofectamineTM 2000 (Invitrogen, Karlsruhe, Germany) according to the manufacturer’s 
instructions. At 24 h post-transfection, cells were washed three times with PBSo and fixed by 
incubation with 4% PFA for 10 min at room temperature. After fixation, cells were washed again 
three times with PBSo and permeabilized with 0.2% Triton X-100 in PBSo at 4 °C for 15 min. 
After three additional washing steps with PBSo, the MAb-Flag (M2 F1804, Sigma-Aldrich, 
Deisenhofen, Germany), to stain FLAG-US27, diluted 1:400 in PBSo, was applied and cells were 
incubated for 1 h at 37 °C. Excessive antibodies were removed by washing three times with PBSo, 
followed by incubation with anti-mouse Alexa555-conjugated secondary antibody, which was 
diluted 1:400 in PBSo, and incubated with the cells for a further 45 min at 37 °C. Cells were 
mounted using the DAPI Hard-set (4,6-Diamino-2-phenylindol)-containing Vectashield mounting 
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medium (Vector Laboratories, Burlingame, CA, USA) and then analyzed using the Leica TCS SP5 
confocal laser scanning microscope (Leica, Wetzlar, Germany). Adobe Photoshop package [54] 
was used for processing of images. 
4.4. Viruses, Generation of Recombinant HCMVs, and Growth Curve Analysis 
All HCMV strains were reconstituted and propagated on human foreskin fibroblasts (HFF) as 
described previously [38,55] and were based on the HCMV bacterial artificial chromosome (BAC) 
TB40-Bac4, which was derived from the HCMV strain TB40/E, isolated on endothelial cells [39]. 
For C-terminal and/or N-terminal fusion of EYFP- or FLAG-tag to the coding region of US27 and/or 
UL78 (for details see Figure 2a) a markerless BAC mutagenesis according to Tischer et al. [55] 
was performed in the E. coli strain GS1783 (kindly provided by Tischer, B.K., Free University of 
Berlin, Berlin, Germany). For that purpose, linear recombination fragments were generated by 
amplification of an I-SceI-aphAI cassette from plasmid pEP-S/aphAI (for FLAG-fusion, kindly 
provided by Tischer, B.K., Free University Berlin, Berlin, Germany) or plasmid pHM3366 (based 
on pEP-S/aphAI, for EYFP-fusion) via Hot Start PCR with the polymerase Phusion Hot Start 
(Thermo Fisher Scientific, Waltham, MA, USA) and specific primer pairs (Table 1). For N-terminal 
fusion of the Flag-epitope, two consecutive PCRs had to be performed. Afterwards, the kanamycin 
cassette was removed by induction of I-SceI followed by a second Red recombination. Resulting 
BAC clones, termed TB40/E-US27-EYFP (US27-EYFP), TB40/E-Flag-US27 (Flag-US27), or 
TB40/E-UL78-EYFP (UL78-EYFP), were verified by distinct PCR reactions and subsequent 
nucleotide sequence analyses, as well as restriction fragment length polymorphism analysis  
(RFLP, using restriction endonuclease EcoRV-HF, NEB). To generate double-tagged  
TB40/E-UL78-EYFP/Flag-US27 (UL78-EYFP/Flag-US27), the parental BAC TB40/E-Flag-US27 
(Flag-US27) was used to transform E.coli GS1783. Recombination occurred as above with a linear 
recombination fragment of UL78-EYFP. For virus reconstitution, BAC DNA was isolated from 
bacteria using the BAC preparation protocol of the PureLink HiPure Plasmid Maxiprep kit 
(Invitrogen, Karlsruhe, Germany) and transfected into HFFs using X-tremeGENE transfection 
reagent (Roche, Mannheim, Germany) according to the manufacturer’s instructions. Transfected 
cells were incubated at 37 °C until plaques appeared, while medium was changed once a week. The 
supernatant was used for infection of fresh HFF cultures and preparation of virus stocks.  
In order to determine the replication capacities of all reconstituted recombinant viruses, 
multistep growth curve analyses were performed. Therefore, 3 days after seeding, 3.0 × 105 resting 
HFFs were infected with equal IE1 units (MOI = 0.1) of wild-type TB40/E or recombinant viruses. 
The viral supernatants were harvested at 0, 3, 6, 9, 12, and 15 days post infection (Figure 2b, dpi, 
days post infection). Aliquots of the supernatants were treated with proteinase K. Afterwards, to 
quantify the HCMV genome copy numbers, all samples were subjected to quantitative Real-Time 
PCR using fluorescence-labeled Taqman probes and the ABI Prism 7500 sequence detector 
(Applied Biosystems, Foster City, CA, USA) as well as the corresponding software SDS [56]. The 
viral load was determined by amplification of a region within the exon 4 of the IE1 gene locus 
(ORF UL123) using the primers CMV5' (5'-AAG CGG CCT CTG ATA ACC AAG-3') and 
CMV3' (5'-GAG CAG ACT CTC TCA GAG GAT CGG-3') together with the fluorescence labeled 
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probe CMV MIE FAM /TAMRA (5'-CAT GCA GAT CTC CTC AAT GCG GCG-3'). Each 
infection was performed in triplicate. 
Table 1. Oligonucleotide primers for generation of recombinant human cytomegalovirus 
(HCMV) strains. 




GAT TAC AAG GAT GAC GAC GAT AAG 
Flag-US27-rev 
CAT ATC AGA ATT GGT TAA TTG GTT GGT AAC ACT ACC TGT AAG 
GTG ATG GAT TAC AAG GAT GAC GAC GAT AAG ATG ACC ACC TCT 




TTT GTC ATG TTG CTC ACC TGT GTT 
Flag-US27-fw TGT TAT GCT TTT TAC AGG ACC GTT CAG CAG GTA ACA CTA 
CCT GTA AGG TGA TGG ATT ACA AGG ATG ACG ACG ATA AG 
US27-EYFP-fw 
US27-EYFP 
ATG ACA GAA AAA ATG CAC CTA TGG AGT CCG GGG AGG AGG 
AAT TTC TAT TGA TGG TGA GCA AGG GCG AGG AGC TG 
US27-EYFP-rev GTG CAA TGA GCA AAA ATA GAT GTG CGG CGG ACG CGT GAA AGA GGA TCG AAT TAC TTG TAC AGC TCG TCC ATG CCG AG 
UL78-EYFP-fw 
UL78-EYFP 
GCA CCG ACG GCG AAA ACA CCG TCG CGT CCG ACG CAA CGG 
TGA CGG CAT TAA TGG TGA GCA AGG GCG AGG AGC TG 
UL78-EYFP-rev GAC GTG ATT TAT CTG CCA CTT TTC TCC CCG CTG CCG TAC AGC GCC GCC GCT TAC TTG TAC AGC TCG TCC ATG CCG AG 
4.5. HCMV Infection and Protein Localization 
HFF (2 × 105 cells/well) or ARPE-19 cells (4.5 × 105 cells/well) were seeded on coverslips for 
infection with recombinant viruses. Indirect immunofluorescence analysis was performed as 
described before for transiently transfected cells. However, after permeabilization, an additional 
blocking step was performed. Therefore, cells were blocked with human or goat serum diluted 1:10 
in PBSo for polyclonal or monoclonal antibodies, respectively, and incubated for 15 min at 37 °C. 
Afterwards, cells were stained with specific primary antibodies (Table 2) for 1 h at 37 °C  
and appropriate secondary antibodies Alexa-555 anti-sheep, Alexa-555 F(ab)'2 anti-mouse, or 
Alexa-555 F(ab)'2 anti-rabbit (Invitrogen, Karlsruhe, Germany) for 45 min at 37 °C and mounted 
using the DAPI Hard-set-containing Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA, USA). Images were acquired as before, using a Leica TCS SP5 confocal laser 
scanning microscope and finally analyzed using Adobe Photoshop package [54].  
Table 2. Antibodies used in this study. 
Target protein Localization Dilution Nature of antibody (source) 
IE1 nucleus 1:4 MAb, clone p63–27 [57] 
TGN46 trans-Golgi network 1:300 
Sheep polyclonal antibody  
(AbD Serotec catalog No. AHP500G)  
calreticulin endoplasmic reticulum 1:100 
Rabbit polyclonal antibody  
(Thermo Fisher catalog No. PA3-900) 
EEA1 early endosomes 1:200 
Rabbit polyclonal antibody, clone H-300 





MAb, clone 4X-49.129.5  
(SCBT catalog No. 5275) 
LAMP1 lysosomes 1:50 MAb, clone H5G11 (SCBT catalog No. 18821) 
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5. Conclusions 
In conclusion, our data demonstrate that trafficking of the HCMV-encoded GPCRs pUS27  
and pUL78 occurs in a cell type-dependent manner suggesting that both receptors may exhibit 
functional differences in various cell types. Furthermore, we could clearly show that pUS27 as well 
as pUL78 trafficking are affected by additional viral proteins. Thus, analysis of pUS27 and pUL78 
in a viral context is mandatory in order to further decipher the functions of these two vGPCRs 
during HCMV replication. 
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Abstract: Like other herpesviruses, human cytomegalovirus (HCMV) contains a 
unique proteinaceous layer between the virion envelope and capsid, termed the 
tegument. Upon infection, the contents of the tegument layer are delivered to the host 
cell, along with the capsid and the viral genome, where they facilitate the initial stages 
of virus replication. The tegument proteins also play important roles in virion assembly 
and this dual nature makes them attractive potential targets for antiviral therapies. 
While our knowledge regarding tegument protein function during the initiation of 
infection has been the subject of intense study, their roles in assembly are much less 
well understood. In this review, we will focus on recent studies that highlight the 
functions of HCMV tegument proteins during assembly, and pose key questions for 
further investigation. 
Keywords: human cytomegalovirus; tegument; assembly 
 
1. Introduction 
Despite being near ubiquitous in the population [1], overt human cytomegalovirus (HCMV) 
disease in adults is typically restricted to the immunocompromised [2,3]. Even in the era of 
HAART, HCMV is associated with increased risk of progression to AIDS and immune 
reconstitution inflammatory syndrome in HIV-infected individuals [4]. HCMV also causes 
significant disease and mortality in transplant recipients [3]. Such patients frequently undergo 
prophylactic therapy to reduce HCMV-associated complications, leading to viral resistance and 
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development of late-onset HCMV disease [5,6]. HCMV is also the most common intrauterine 
infection in the U.S., with outcomes ranging from death to neurological impairment, sensorineural 
hearing loss, seizure disorder, cerebral palsy and chorioretinitis [7,8]. Significantly, permanent 
disability due to congenital HCMV infection is more common than other well-known conditions 
such as spina bifida and Down’s syndrome [9]. Currently available treatments for HCMV infection 
target the viral DNA replication machinery, and can be quite effective at diminishing the impact of 
HCMV disease [10]. However, strains resistant to these drugs are emerging at a rate of 5%–10% 
depending on the underlying condition and type of treatment [10], prompting the need to develop 
new antiviral strategies. The tegument proteins of HCMV have been proposed as potential 
therapeutic targets due to their key functions in the initiation of infection, virion assembly and 
particle stability [11,12]. While we know a considerable amount regarding the functions of the 
tegument proteins during the initial phases of virus replication [11,13], our understanding of the 
specific role of the HCMV tegument proteins in virus assembly lags behind. In this review, we will 
focus on the functions of tegument proteins in the assembly, egress and stability of virus particles.  
2. Overview of Replication and Assembly 
Replication of HCMV begins with virus binding to cell surface receptors and fusion of the viral 
envelope with the plasma membrane [14]. At that time, the viral capsid is released into the infected 
cell along with the components of the virion tegument, a layer of proteins located between the viral 
envelope and the capsid. The tegument consists of approximately 38 different viral proteins that are 
released into the host cell upon infection where they play critical roles during the initiation of virus 
replication [11,12]. The HCMV tegument also contains a number of cellular proteins [15] and 
mRNA’s [16], although it is unclear at this point if these play any role in virus infection, or if they 
are simply bystanders that are nonspecifically incorporated during the assembly process. During 
lytic replication, the tegument proteins function to enhance the efficiency of viral immediate early 
gene expression [11,12]. The immediate early proteins are essential for progression through the 
early phase of gene expression [17,18], which is followed by DNA replication, the late phase of 
viral gene expression [19] and virion assembly [20].  
HCMV assembly occurs in two phases; first, the capsid is formed within the nucleus and the 
DNA genome is encapsidated [20]. It is likely that at this stage, the initial components of the 
tegument are added to form the inner tegument, an organized net-like layer that encloses the capsid 
shell [21]. The capsids then bud through the nuclear envelope and final assembly, including the 
addition of the bulk of the tegument, occurs in a unique structure consisting of redistributed 
components of the cellular secretory apparatus known as the assembly complex (AC) [20,22–24]. 
The majority of the tegument lacks a defined structure [21], and as mentioned above, incorporates a 
number of cellular proteins and mRNA’s [15,16], suggesting that final tegumentation is a relatively 
nonspecific process. However, there is evidence pointing to a degree of specificity for at least some 
of the viral tegument components. For example, while three isoforms of the pUL69 protein can be 
detected in infected cells, only one specific isoform of pUL69 is incorporated into the tegument [25]. 
Likewise, it has been reported that a hypophosphorylated form of the pp28 tegument protein 
(product of the UL99 gene) is specifically incorporated into virions [26]. Another possibility to 
account for the difference in protein isoforms located within the virion versus those found in 
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infected cells is modification within the tegument. In that regard, viral and cellular kinases are 
known tegument components [27,28], and the cellular phosphatases PP1 and PP2A can also be 
detected in the virion [29]. This raises the possibility that fine tuning of tegument protein  
post-translational modifications can occur within the virion and have the potential to modulate 
virus infection. It should be mentioned here that the majority of the tegument proteins can be 
phosphorylated and the abbreviation “pp” denotes this fact.  
Additional studies support the notion that the HCMV tegument is added in an ordered step-wise 
fashion. For example, there is an abundance of evidence that addition of the pp150 tegument 
protein, encoded by the UL32 gene, initiates in the nucleus [30,31], and is the primary component 
of the structured tegument network surrounding the capsid [21]. While the pp150 network clearly 
plays a role in capsid stability [32,33], it may also provide a structural framework for the addition 
of subsequent tegument components. Consistent with this, pp150 has been shown by mass 
spectrometry analysis to interact with a number of capsid and tegument proteins, including the 
pp71 protein encoded by the UL82 gene [34]. This is of particular note in that pp71, along with the 
pp65 tegument protein encoded by the UL83 gene, has a relatively tight association with the capsid, 
suggesting that it may form a secondary, albeit less organized, layer of tegument [35]. Recent 
studies utilizing yeast two-hybrid analysis have revealed interaction networks centered on a number 
of hub proteins that may contribute to an ordered tegumentation process [36,37]. For example, the 
pUL45 tegument protein forms a network hub via interaction with itself, as well as the pUL25, 
pp150, pUL48, and ppUL69 tegument proteins [36]. Although the precise function of pUL45 is 
unknown, deletion of this gene causes a defect in plaque formation [38]. A more extensive yeast 
two-hybrid analysis revealed interactions amongst a number of tegument, capsid and envelop 
proteins, and also identified the pUL24, pUL25 and pUL89 proteins as network hubs [37]. 
Intriguingly, both studies showed that a number of the tegument proteins were capable of  
self-association [36,37]. Such extensive networks of cross-interactions and self-interactions are likely 
to be critical for efficient tegumentation during the assembly process. Perhaps surprisingly, other 
than pUL45, most of these hub proteins are not essential for efficient virus replication [39]. A 
generally accepted concept that accounts for this apparent discrepancy is that multiple overlapping 
interactions and functions ensures that efficient tegumentation and subsequent infectivity is less 
dependent on any one tegument protein [20,40]. 
While it is clear that the majority of the tegument proteins become associated with the virion 
particle in cytoplasmic assembly complexes [20,40], a number of these proteins contain nuclear 
localization signals and transit to the nucleus at the initial stages of virus infection [11,12,41–43]. 
Thus, the tegument proteins can be considered as belonging to three major classes; the inner 
tegument consisting of pp150, which likely initiates tegument incorporation in the nucleus [30,31] and 
pUL48 [21]; nuclear tegument proteins that initially transit to the nucleus of permissive cells and 
are later relocalized to the cytoplasmic AC, including pp71, pp65, pTRS1, pUL26, pUL35 and the 
ppUL97 viral kinase [11,12,44]; and the cytoplasmic tegument proteins that retain this localization 
throughout the course of virus infection, including pp28, pUL71 and pUL25 [45–47]. One of the 
key questions regarding tegumentation that remains unanswered is whether the nuclear tegument 
proteins associate with the capsid within the nucleus. Direct evidence for the association of the 
nuclear tegument proteins with capsids within the nucleus is lacking, although this possibility 
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cannot be definitively ruled out [20,40]. If the nuclear tegument proteins do not associate with 
capsids in the nucleus, how are they redirected to the cytoplasmic AC at the late stages of 
infection? For some of these proteins, including pp65, pUL94 and ppUL69, there is evidence for 
shuttling activity between the nucleus and the cytoplasm [48–50]. Thus, the relocalization of these 
proteins to the cytoplasm could result from modulation of the rate of nuclear import and/or export. 
For the pp65 protein, phosphorylation clearly plays a role in controlling this process, as inhibition 
of cellular cyclin dependent kinase (CDK) activity prevents the accumulation of pp65 in  
the cytoplasm at the late stages of virus infection [51]. In addition, the viral ppUL97 kinase  
affects the distribution of pp65, with inhibition of ppUL97 resulting in large pp65-containing 
aggregates [52,53]. However, the formation of these aggregates is more consistent with a role for 
ppUL97 is regulating the self-association of pp65, rather than a direct effect on trafficking, per se. 
With other nuclear tegument proteins, domains have been identified that can directly target the 
proteins to the cytoplasmic AC [43,54]. For example, in transfected cells, the pp71 tegument 
protein colocalizes with markers of the late-trans Golgi Network and early endosomal 
compartment if the nuclear localization signal is mutated [43]. However, the precise mechanism of 
this switch in trafficking during the process of virus infection has yet to be identified. Thus, 
significant gaps in our understanding of HCMV tegumentation remain. Despite this, continued 
research into the specific functions of the tegument proteins promises new insights into this 
process, and may yet reveal novel antiviral targets amongst this key class of viral proteins. In the 
remainder of this review, we will highlight the specific functions of components of the HCMV 
tegument during virion assembly (Table 1), with a focus on the most recent data. 







UL32 (pp150) 9.1% Essential [39,55] 
UL48 12.6% Essential [39]; Severe growth defect (>104 fold drop in titer) [55] 
Nuclear Tegument 
UL26 0.1% Non-essential, Small plaque phenotype with severe growth defect [39,55] 
UL35 0.5% 
Moderate growth defect (1,000-fold decrease in titer), Essential at low 
multiplicity [56] 
UL82 (pp71) 8.9% Non-essential, Severe growth defect at low multiplicity [57,58] 
UL83 (pp65) 15.4% 
Non-essential [59], Important for replication in macrophages [60], Slight 
growth defect (10-fold) at low multiplicity in fibroblasts [61] 
UL94 1.2% Essential [39,62] 
UL97 0.1% Non-essential, Severe growth defect [63] 
TRS1 0.6% Non-essential, Moderate growth defect (~200-fold decrease in titer) [64] 
Cytoplasmic Tegument 
UL71 0.1% Essential [39] 
UL99 (pp28) Unknown Essential [39,55,65] 
a Data on relative abundance obtained from Varnum et al. [15]. Note that the relative abundance of the 
pUL48 protein in this report includes the entire UL48-49 gene region. b Phenotype represents the ability 
of virus with a mutation in the indicated gene to replicate in fibroblasts unless otherwise stated. 
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3. The Inner Tegument Proteins 
3.1. pp150 (ppUL32)  
The product of the HCMV UL32 gene, pp150, is the primary component of the inner tegument 
and forms a filamentous net-like structure that surrounds the capsid [21]. The inner tegument can 
be distinguished from the outer tegument proteins by virtue of this relatively organized structure, as 
well as its tight association with the capsid [66]. Recent studies have revealed that pp150 can be  
co-purified from cells at the late stage of infection in association with capsid components including 
the major capsid protein (MCP, product of the UL86 gene), pUL46, pUL85, and pUL80.5 [34]. 
However, co-purification of proteins at this time point probably represents a more general capsid 
association as opposed to a direct interaction with any one specific component. Additional studies 
using cryo electron microscopy (cryo-EM) reveal that the smallest capsid protein, pUL48.5, likely 
makes direct contact with the inner tegument [67]. These studies also determined that the inner 
tegument is composed of an upper and lower helical bundle joined by a long central helix, with 
features of the helices consistent with the predicted structure of pp150. Moreover, reduced 
expression of pUL48.5 mediated by ribozyme inhibition significantly reduced viral yield and 
resulted in the accumulation of non-infectious enveloped particles (NIEP’s) that lack viral DNA [67]. 
However, this latter finding is distinct from what has been observed by either deletion or 
knockdown of pp150 directly [32,33]. In these studies, the number of A- (empty), B- (contain 
scaffold proteins) and C- (DNA filled) capsids within the nuclei of infected cells are comparable in 
the presence or absence of pp150 [32,33]. In contrast, very few DNA containing capsids or 
enveloped viral particles could be identified in the cytoplasm in the absence of pp150, suggesting 
that this protein stabilizes DNA-containing capsids as they progress from the nucleus to the 
cytoplasmic AC. The discrepancy between the effects of the pUL48.5 and pp150 viral mutants may 
result from the approaches employed e.g., cryo-EM of extracellular particles [67] versus 
transmission EM of particles within infected cells [32,33]. However, it is also possible that 
pUL48.5 has additional functions in virion assembly independent of the interaction with the pp150 
inner tegument protein [67]. What is clear is that the pp150 protein is critical for the efficient 
formation of enveloped capsids within infected cells and that the mechanism is likely related to 
effects on capsid stability during post-nuclear events.  
Another key question is the cellular site of inner tegument addition. The preponderance of 
current evidence supports an initial nuclear localization of pp150 derived from the tegument [30,31], 
perhaps due to the tight association with the capsid [66]. Indeed, this tight association was recently 
shown to facilitate a novel cis-mode of regulation during HCMV infection [68]. In this study, 
tegument-derived pp150 was found to be phosphorylated by a cyclin A2-dependent mechanism 
resulting in restriction of HCMV replication to the G0/G1 phase of the cell cycle. Mutation of the 
cyclin A2-dependent phosphorylation site blocked the cell cycle restriction effects, but in a 
genome-specific manner, suggesting that the tight association of pp150 with at least some capsid 
components is retained during the initial stages of lytic replication. Newly synthesized pp150 
protein appears to be both nuclear and cytoplasmic [34,69], but evidence also suggests that tegument 
addition begins in the nucleus, as pp150 can be found associated with nuclear B-capsids [31]. This 
finding would be consistent with formation of an initial inner tegument framework in the nucleus. 
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However, it is also clear that as infection progresses, the distribution of pp150 alters to become 
predominantly cytoplasmic and associated with the AC [30,69,70]. Whether this reflects the 
accumulation of capsids within the AC during envelopment, or an independent redistribution of 
pp150 to facilitate completion of the inner tegument remains an unanswered question.  
Another possible function for pp150 is the targeting of capsids to the site of virus assembly. Of 
note is that pp150 interacts with Bicaudal D1 [71], a protein involved in microtubule dependent 
cargo transport [72], consistent with an association with the AC [22–24]. Knockdown of Bicaudal 
D1 or inhibition of Rab6, a Bicaudal D1-interacting protein [73], resulted in decreased localization 
of pp150 to the AC, and reduced virus replication, although a direct effect on capsid recruitment to 
the AC was not examined [71,74]. Mass spectrometry analysis also identified clathrin components 
as pp150 interacting proteins, although a direct role for this interaction in virion assembly or 
localization to the AC could not be demonstrated [34].Thus the possibility that pp150 association 
with the capsid could participate in the recruitment of capsids to the AC still needs to be addressed 
experimentally. Finally, a role for the inner tegument as a scaffold that nucleates addition of the 
remaining tegument makes an attractive, but unproven, model. It is known that pp150 can interact 
with a number of tegument proteins including pUL48, pTRS1, ppUL69, ppUL97, and pp71 [34], 
although this may represent association with overlapping tegument interaction networks. Yeast 
two-hybrid analysis demonstrates direct evidence for pp150 interactions with pUL35, pUL45 and 
pp71 [36,37], and as already noted pp71 is thought to have a relatively tight association with 
capsids [35], consistent with pp150 nucleating additional tegument components. Further evidence 
for a role for pp150 as a tegument scaffold comes from a study examining the pUL96 tegument 
protein [31]. In this analysis, pUL96 was found to be added to capsids exclusively within the 
cytoplasm. However, mutation of pUL96 resulted in a similar defect in virus replication to that 
observed in the pp150 mutant viruses, with an apparent effect on the stability of capsids after or 
during transition from the nucleus. This data is consistent with the initial association of pp150 with 
capsids in the nucleus, and perhaps stabilization of the inner tegument network upon association 
with pUL96 in the cytoplasm, resulting in nucleocapsids capable of association with additional 
tegument and finally envelopment in the AC before virus egress from the cell. 
3.2. pUL48 
The protein product of the UL48 gene, pUL48, is a large tegument protein that is tightly 
associated with the capsid [75], is a component of the inner tegument [21], and localizes to both the 
nucleus and cytoplasm of infected cells [76]. The best characterized function of the pUL48 is in 
viral entry where it interacts with pUL47, pUL69 and the pUL86 major capsid protein and is thought 
to assist in release of the viral genome from the capsid during the initial stages of infection [77]. 
Like its homologs in other herpesviruses, the HCMV pUL48 has deubiquitinase activity, and 
mutation of the active site results in a 10-fold reduction in virus yield [78,79]. However, a specific 
role for the deubiquitinase activity in virus assembly has not yet been shown. In a more recent 
study, the nuclear localization signal of pUL48 was mapped, and disruption of nuclear trafficking 
resulted in a small plaque phenotype [76]. While the nuclear localization could clearly be involved 
in the established role for pUL48 in virus entry, it also raises an intriguing possibility that this 
localization could contribute to the initial stages of tegumentation along with pp150. The pUL48 
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protein has also been shown to interact with the cellular p180 ER membrane-associated protein [80], 
and thus could play a role in directing capsids to the cytoplasmic AC. Consistent with this, deletion 
of the herpes simplex virus (HSV) homolog (pUL36 or VP1/2) results in the accumulation of 
cytoplasmic unenveloped capsids [81]. Detailed analysis of the HSV pUL36 protein during 
assembly shows that the protein is added to cytosolic capsids and functions to link the inner and 
outer tegument [82,83]. It remains to be seen whether the HCMV pUL48 protein functions in a 
similar manner. 
4. The Nuclear Tegument Proteins 
It has been well characterized that a number of HCMV tegument proteins, including pp71 and 
pp65 (products of the UL82 and UL83 genes, respectively), initially localize to the nucleus of 
permissively infected cells [11,12,84,85]. Of note, both pp71 and pp65 contain nuclear localization 
signals that can independently target the proteins to the nucleus [41,43]. The nuclear trafficking of 
these proteins during the initial stages of virus infection is associated with their role in enhancing 
the efficiency of replication and viral gene expression [11]. For example, the pp71 protein has been 
shown to enhance the transcription of the major immediate early gene region via degradation or 
relocalization of transcriptional repressors such as Daxx and ATRX [13]. In a similar vein, the 
pp65 protein was recently shown to enhance activation of the major immediate early promoter via 
its interaction with the IFI16 protein [61]. It has also been observed that these initially nuclear 
tegument proteins relocalized to the AC at the late stages of virus replication. While the precise 
mechanisms of redistribution remain unclear, as noted above phosphorylation does appear to play a 
role in some cases [43,51,53]. What is perhaps surprising is that a number of these tegument 
proteins, including pp65 and pp71, are not essential for virus replication [12], emphasizing the 
apparent redundancy in tegument protein function [20,40]. Despite this, some of the nuclear 
tegument proteins have been shown to play important roles in virion assembly and stability. 
4.1. pUL26 
The pUL26 protein follows the standard pattern of nuclear tegument protein localization, with 
an initial nuclear distribution, followed by a perinuclear localization consistent with the AC [44]. 
When infections with a virus lacking pUL26 were carried out at low multiplicity, expression of the 
viral immediate early protein levels were reduced relative to the wild type virus, leading to a 
corresponding decrease in the efficiency of viral DNA replication. Of particular note with respect 
to assembly, this study showed that the levels of the pp28 and pp65 tegument proteins were 
diminished within the newly infected cells, although virion levels of both proteins were similar to 
wild type virus [44]. This finding suggested that the proteins in the mutant virus were somehow 
less stable, and may correspond to an altered hypophosphorylated form of pp28 being preferentially 
incorporated into the particles. In a separate study of a pUL26 deletion virus, the authors noted a 
decrease in particle stability [86]. Specifically, the wild type and revertant viruses were relatively 
stable (~50% infectivity) for at least two days at 20 degrees, whereas the pUL26 deletion virus 
retained only 5% infectivity over the same time period. Electron microscopy revealed 
nonenveloped extracellular particles derived from cells infected with the pUL26 deletion virus, 
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suggesting that the decrease in stability resulted from a loss of the viral envelope due to defective 
tegumentation. Such an interpretation would be consistent with a role for the tegument analogous 
to the matrix proteins of RNA viruses in which the tegument forms a critical link between the 
capsid and the viral envelope [87].  
The absence of pUL26 also resulted in the accumulation of immature particles in the cytoplasm 
associated with electron dense areas, possibly representing aggregates of tegument proteins [86]. 
This finding is consistent with other data suggesting that disruption of tegumentation leads to 
nonspecific aggregation of the tegument proteins [53,56], and implies that the interactions amongst 
the tegument proteins must be tightly regulated. The deletion of the UL26 gene also resulted in 
increased levels of pp71 in the virion particles [86]. As there is no direct evidence for interaction 
between pUL26 and pp71, the authors speculate that pUL26 and pp71 may compete for binding to 
the same capsid protein, and without pUL26, more pp71 becomes incorporated into the virion, 
perhaps as a compensatory mechanism. This may be one mechanism that accounts for the apparent 
redundancy of a number of the tegument proteins [20,40]. 
4.2. pUL35 
The UL35 gene codes for two isoforms that differ in size; the full-length protein that is 
expressed at the early stages of infection, and pUL35a consisting of the carboxy-terminal region 
that is expressed with late kinetics [88]. Both isoforms can interact with the pp71 tegument protein, 
although there are conflicting reports as to the effect of this interaction on viral gene  
expression [88,89]. Recent studies suggest a role for both pUL35 and pUL35a in controlling ND10 
reorganization [90], known to be important for viral replication and gene expression [91]. In 
addition, pUL35 can interact with and regulate the cellular DNA repair machinery [92]. Deletion of 
the UL35 gene from HCMV results in decreased numbers of both enveloped viral particles and dense 
bodies (subviral particles consisting primarily of tegument surrounded by the viral envelope [93]) 
in the cytoplasm under conditions where viral gene expression is unaffected, suggesting an 
additional defect in virus assembly [56]. The mechanism of the defect is likely related to the 
persistence of the pp65 and pp71 proteins in the nucleus, where they form large electron dense 
accumulations [56], suggesting that the lack of UL35 proteins disrupts the relocalization of these 
proteins to the AC. Further analysis showed that the smaller isoform, pUL35a, was largely 
responsible for this effect, as co-transfection of pUL35a with pp71 results in relocalization of both 
proteins from the nucleus to the cytoplasm [90]. Interestingly, the two proteins colocalized in the 
cytoplasm in distinct punctate perinuclear structures, similar to those observed when pp71 nuclear 
localization is abrogated by a specific mutation within the pp71 nuclear localization signal [43]. 
Together, these findings suggest that pUL35a disrupts recognition of the pp71 non-classical NLS, 
either through a conformational change or altered phosphorylation, resulting in the nascent pp71 
AC localization predominating [43]. It is less clear how deletion of the UL35 gene alters pp65 
redistribution, as there was no evidence of a direct interaction between these two proteins in the 
yeast two-hybrid assays [36,37]. However, recent studies in our laboratory show that affinity 
purification of the pp71 protein from cells at the late stages of infection results in the  
co-purification of a number of viral proteins, including pp65 (Table 2). These findings suggest that 
pp71 and pp65 may exist as a complex, and pUL35a could redistribute both proteins to the 
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cytoplasm at the later stages of virus infection [88]. Further, the phenotype of the UL35 gene 
deletion virus is consistent with sustained retention of the nuclear tegument proteins within the 
nucleus decreasing the efficiency of virion morphogenesis in the cytoplasm.  
Table 2. Viral proteins that co-purify with pp71 a. 
Protein 
Name Protein Function 
# of Peptides 
Matched 




pTRS1 Transcriptional Regulation/Immune Evasion [12] 78 2439 44% 
pIRS1 Transcriptional Regulation/Immune Evasion [12] 60 1809 41% 
pUL44 DNA Processivity Factor [94] 66 2413 82% 
pUL86 Major Capsid Protein [95] 5 339 8% 
ppUL97 Viral Kinase [96] 5 272 8% 
pp65 Tegument protein [12] 236 2580 71% 
pUL50 Nuclear Egress [97] 9 276 26% 
pUL52 Genome Cleavage and Packaging [98] 7 256 14% 
pUL56 Terminase Subunit [99,100] 11 385 26% 
pUL88 Tegument Protein [100] 7 135 10% 
pUL35 Tegument Protein [12] 6 289 29% 
a Proteins were purified using S-protein agarose (Novagen) from cells infected at 72 hpi with a virus 
expressing a S-tagged version of pp71 [101]. The resultant proteins were subjected to SDS-PAGE using  
a 4%–20% gel (Jule Biotechnologies, Inc., Milford, CT, USA). Protein bands were visualized by 
Coomassie Blue staining, excised and subjected to trypsin digestion prior to analysis on an LTQTM Linear 
Ion Trap tandem Mass Spectrometer (ThermoFinnigan, San Jose, CA, USA). Protein searches were 
performed using MASCOTTM. Only proteins identified in multiple experiments are included. b The ion 
score is based on the calculated probability, P, and provides a measure of the likelihood that the predicted 
peptide matches the indicated protein (Matrix Science, Boston, MA, USA). For the study shown, a score 
of >36 indicated identity or extensive homology (p < 0.05). 
4.3. pp71 (ppUL82) 
The pp71 tegument protein, encoded by the HCMV UL82 gene, plays a number of roles during 
the initiation of virus replication, including the degradation and/or inactivation of cellular proteins 
that would repress viral gene expression [13]. The majority of research on pp71 has focused on its 
functions during the establishment of infection, and it is unclear what role if any it may play during 
virus assembly. However, some studies are suggestive of a contribution. For example, as noted 
above delayed relocalization of the pp71 protein, along with pp65, to the cytoplasm due to the 
deletion of the UL35 gene results in a decrease in the efficiency of secondary envelopment [56]. A 
similar effect was observed upon deletion of the TRS1 gene [64]. Other evidence that points to a 
role in virion assembly is the possibility that pp71 interacts with a number of key virion components 
including pp150, pUL94, pUL35, pIRS1/TRS1 and the major capsid protein (Table 2) [36,37]. 
Despite these findings, a definitive role for pp71 in assembly remains to be demonstrated.  
However, analysis of pp71 trafficking and post-translational modifications have revealed insight 
into the mechanisms involved in nuclear tegument protein trafficking and redistribution [43].  
In this study, a large region from amino acids 94–300 termed the mid-region (MR) of pp71 was 
found to be necessary and sufficient for nuclear localization, suggesting the presence of a large  
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non-classical nuclear localization signal. Phospho-mapping of pp71 from transfected cells revealed 
a single phosphorylation site within the MR, at threonine 223 (T223). Mutation of T223 to a 
phosphomimetic resulted in a block in nuclear localization, and redistribution of pp71 in a punctate 
perinuclear region. Confocal analysis using intracellular markers demonstrated that cytoplasmic 
pp71 colocalized with markers of the late trans-Golgi Network and late endosomal compartments. 
Notably, these cellular components are reorganized along with other structural elements of the 
secretory pathway into the cytoplasmic assembly complex in infected cells [22–24]. Together, 
these findings are consistent with pp71 containing an integral signal that denotes trafficking to the 
AC that is regulated by phosphorylation [43]. Ongoing studies in our laboratory are directed 
towards determining the significance of these findings during virus infection.  
4.4. pp65 (ppUL83) 
The pp65 protein is the most abundant component of the tegument, and like the other nuclear 
tegument proteins initially traffics to the nucleus of permissively infected cells, and then relocalizes 
to the cytoplasm at the later stages of infection [42,70]. While initial reports showed that pp65 
played no role in virus infection in vitro [59], more recent studies show that pp65 is important for 
efficient growth in both monocyte-derived macrophages and fibroblasts [60,61,102]. The underlying 
cause of this growth defect likely involves pp65 functions during the initiation of infection as well 
as during assembly. For example, pp65 can enhance the activation of the major immediate early 
promoter through its interaction with the cellular IFI16 transcriptional regulator [61]. Disruption of 
pp65 expression can also influence the incorporation of other proteins into the virion tegument, such 
as pUL25, ppUL97 and ppUL69, suggesting that pp65 forms part of a protein interaction network 
that may be important for assembly [60]. This finding is consistent with yeast two-hybrid analysis 
that identified pUL25 as a hub protein for an interaction network that included pp65 [37], and 
studies demonstrating a direct interaction between ppUL97 and pp65 [103]. In spite of these changes 
to the tegument composition, the virion particles appeared indistinguishable from those resulting 
from the wild type virus, except for the absence of dense bodies. In this study, a defect in replication 
of the pp65 mutant virus in monocyte-derived macrophages was observed, although whether this is 
due to the absence of pp65 per se, or the lack of important viral proteins such as ppUL97 [63] and 
ppUL69 [104] during the initial stages of replication remains to be definitively established.  
A virus containing a 30 amino acid insertion within the pp65 open reading frame, termed  
RV-VM1, also displayed a defective growth phenotype [102]. In this case, the defect was most 
likely caused by the retention of pp65 in the nucleus at the late stages of infection, resulting in 
accumulation of the MCP in the nucleus, reduced numbers of C-capsids in the cytoplasm and a lack 
of dense body formation. The lack of pp65 relocalization resulted in the formation of large globular 
structures within the nucleus that contained the pp65 and ppUL69 proteins. Surprisingly, the 
redistribution of pp150 and pp71 to the AC were unaffected by the mutation, suggesting that these 
proteins trafficked independently of pp65 in this case. One possible explanation for this effect is that 
the insertion within pp65 disrupts the interaction with the pp71 protein. The movement of pp150 
into the AC despite the retention of immature capsids in the nucleus is harder to explain, but may 
be consistent with an independent redistribution of pp150 to the AC to facilitate completion of the 
inner tegument. The lack of C-capsids in the cytoplasm of cells infected with RV-VM1 implies a 
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direct role for pp65 and/or ppUL69 in capsid egress from the nucleus. However, the possibility that 
nonspecific effects due to the formation of the large globular structures within the nucleus also play 
a role in this phenotype cannot be excluded. Interestingly, inhibition of ppUL97 kinase activity also 
results in the accumulation of pp65 in the nucleus of infected cells where it forms large nuclear 
inclusions, presumably due to self-interaction [53].  
Cumulative evidence points to the regulation of pp65 localization and/or self-interaction as 
important for efficient virion assembly and egress. In that regard, pp65 can shuttle in and out of 
nucleus with export occurring in a CRM1 dependent manner [48,51]. As mentioned above, control 
of the rates of nuclear import and export would provide a useful mechanism for the regulation of 
pp65 localization. Interestingly, the pp65 interacting protein, ppUL69 also functions as a shuttling 
protein, although it is thought that this protein functions primarily to transport mRNA’s from the 
nucleus to the cytoplasm [105]. Other tegument proteins also regulate the relocalization of pp65, 
including pUL35, pTRS1 and pUL96 [31,56,64]. It is likely that phosphorylation of pp65 also 
plays a role in regulating the localization of this protein during infection. For example, the ppUL97 
kinase is clearly involved in the regulation of pp65 redistribution to the AC at the later stages of 
infection [53] and pp65 is a direct target of the ppUL97 kinase [102]. Infection in the presence of 
CDK inhibitors also affects both the phosphorylation and localization of pp65 [51]. In order to 
examine the effect of phosphorylation on pp65 localization and function, we recently used mass 
spectrometry to determine the sites on which pp65 was phosphorylated at the late stages of 
infection (Figure 1). This analysis revealed clusters of phosphorylation sites flanking the pp65 
nuclear localization signals [41,42], suggesting that phosphorylation may influence the recognition 
of these signals and alter the distribution of pp65. Interestingly, the 30 amino acid insertion in the 
RV-VM1 virus occurs at amino acid 387 [102], also in relatively close proximity to the pp65 
nuclear localization signals. Indeed, this mutation reduces the susceptibility of the mutant virus to 
ppUL97 kinase inhibitors. One model to explain this data is that phosphorylation of pp65 by 
ppUL97 blocks recognition of the nuclear localization signals, resulting in a change in distribution 
to the cytoplasm. The insertion in the RV-VM1 virus could result in a different pattern of 
phosphorylation that results in an active nuclear localization signal and subsequent accumulation 
and aggregation of the protein in the nucleus. Interestingly, two phosphorylation sites were also 
clustered in the amino terminus in proximity to the self-interaction domain, suggesting that 
phosphorylation also regulates this property of pp65. This data is certainly consistent with the large 
aggregates of pp65 that form in the absence of ppUL97 activity [53].  
Figure 1. Schematic of pp65 phosphorylation sites at the late stages of virus infection. 
The pp65 protein was purified from cells infected at 72 hpi by virtue of its association 
with the pp71 protein (See Table 2). The band corresponding to pp65 was excised from 
an SDS-PAGE and subjected to mass spectrometric analysis as previously described [43]. 
Also shown are the pp65 hydrophilic regions (green), sequences required for nuclear 
localization (red) and the self-interaction domain (blue) [41,59,106].  
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4.5. pUL94  
The product of the UL94 gene is nominally within the group of nuclear tegument proteins as it 
has been shown to be located in the nucleus of both transfected and infected cells [62,107]. Indeed, 
similar to the pp65 protein, pUL94 has nuclear:cytoplasmic shuttling activity [50]. However, the 
major functions of pUL94 during infection that have been reported are associated with its ability to 
interact with pp28, a cytoplasmic tegument protein [62]. Deletion of the UL94 gene results in 
defective replication, although viral gene expression and DNA replication are unaffected. The 
defect in replication is attributed to the accumulation of non-enveloped capsids in the cytoplasm, a 
phenotype similar to that observed upon deletion of the UL99 gene that encodes pp28 [65]. Thus, it 
has been concluded that pUL94 works with pp28 to facilitate secondary envelopment of 
tegumented capsids in the cytoplasm. It has been proposed that pUL94 may regulate the trafficking 
of the pp28 protein to the cytoplasmic AC [62,108]. This finding is in contrast to earlier analysis of 
the pp28 protein in the absence of virus infection, where it was found to localize to the endoplasmic 
reticulum-Golgi intermediate compartment, suggesting that trafficking to membranes associated 
with the AC may be an integral function of the pp28 protein [109]. Despite this discrepancy, it is 
clear that pUL94 and pp28 work in concert to facilitate secondary envelopment of HCMV virions.  
4.6. ppUL97 
The ppUL97 viral kinase was initially identified by virtue of its ability to phosphorylate the 
antiviral compound ganciclovir [110]. The kinase activity of the ppUL97 protein is critical for 
efficient virus replication and it has therefore been the subject of intense investigation as an 
antiviral target [111]. In regards to virion assembly, a notable function of the ppUL97 viral kinase 
is in the redistribution of nuclear tegument proteins to the AC, as previously mentioned [53,102]. In 
the absence of this relocalization, the tegument proteins form large nuclear aggregates, suggesting 
that ppUL97 may regulate the self-association of these tegument proteins [111]. In addition, as the 
ppUL97 protein can be incorporated into virion particles [28], it is possible that this kinase may 
modulate phosphorylation of virion components in situ, or immediately after infection. Recent 
studies also show that ppUL97 can interact with pUL50, and together with pUL53 disrupts the 
nuclear lamina, enabling efficient capsid egress from the nucleus [112,113]. The ppUL97 protein 
has also been proposed to play a direct role in the formation of the cytoplasmic AC [52,114]. 
Specifically, deletion of the HCMV UL97 gene or the use of ppUL97 kinase inhibitors results in a 
modified AC which is more diffuse than that observed in a typical infection, together with the 
formation of large perinuclear vacuoles [114]. Immuno-electron microscopy revealed that these 
cytoplasmic vacuoles were surrounded by membranes and contained accumulations of tegument 
proteins, including pp28 and pp65, as well as the gB envelope protein. The similarity of these 
vesicles to the nuclear inclusions observed upon inhibition of ppUL97 [111] add further weight to 
the contention that self-association of tegument proteins is tightly regulated within infected cells. 
Interestingly, a more severe growth defect was observed when the UL97 gene was deleted versus a 
kinase dead mutant, or in the presence of a ppUL97 kinase inhibitor [52]. Of note, the presence of 
dense bodies, tegumented cytoplasmic capsids and viral particle release were detected in the 
presence of the kinase dead mutant or when the kinase inhibitor NGIC-I was added to the infected 
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cells. However, when the UL97 gene was deleted, dense bodies were absent, as was evidence of 
particle release, and only a few C-capsids were observed in the cytoplasm. This finding suggests 
that the ppUL97 protein has non-kinase related functions in virion assembly and formation of the 
AC. However, the possibility that kinase inhibition was not 100% efficient in the ppUL97 mutant 
or in the presence of the inhibitor cannot be ruled out. Regardless, further identification of cellular 
and viral targets of ppUL97 will likely yield more insights into the precise role of this enzyme in 
virion assembly and egress.  
4.7. pTRS1 
The IRS1 and TRS1 genes located in the viral repeat sequences code for highly related, although 
not identical proteins [115]. The products of both genes are involved in immune evasion through 
inactivation of the interferon induced kinase, PKR [12]. Uniquely, the pTRS1 protein appears to 
also be involved in virion assembly. Deletion of the TRS1 gene results in the formation of abnormal 
viral particles containing decreased levels of the pp65 and pp150 tegument proteins [64]. 
Extracellular virus particles generated in the absence of pTRS1 also displayed abnormal 
sedimentation in glycerol-tartrate gradients, indicative of defective particles, with an increase in the 
formation of dense bodies. A delay in the movement of tegument proteins such as pp65 and pp71 
into the cytoplasm at the late stages of infection was also observed, although the large nuclear 
aggregates observed when ppUL97 is inhibited were not noted. Further analysis of the TRS1-deletion 
virus revealed decreased capsid formation in the nucleus, suggesting that pTRS1 influences events 
relatively early in the assembly process [116]. However, the precise function of pTRS1 in capsid 
assembly remains to be determined. One possibility is that the regulation of the interferon induced 
kinase, protein kinase R or PKR, by pTRS1 may be involved [117]. This could result in altered 
phosphorylation of the tegument proteins, either through the direct inhibition of PKR activity, or 
altered access to substrates by virtue of the relocalization of PKR to the nucleus of infected cells [118]. 
Some intriguing hints have come from recent studies examining a multiprotein complex that 
includes pUL84, the ppUL44 DNA processivity factor and the pIRS1/pTRS1 proteins [119,120]. 
Deletion of the amino-terminus of pUL84 diminishes the formation of this complex, and results in 
an unusual distribution of nuclear capsids in the nucleolar region, as well as a lack of cytoplasmic 
capsids. This finding suggests that pTRS1 may participate in a complex that regulates the 
maturation and egress of HCMV capsids. 
5. The Cytoplasmic Tegument Proteins 
5.1. pUL71 
Two independent studies have implicated a role for the pUL71 protein in secondary 
envelopment [46,121]. Specifically, deletion of the UL71 gene results in an accumulation of  
non-enveloped capsids in the AC region of infected cells. In addition, enlarged vesicular structures 
reminiscent of multi-vesicular bodies were noted, along with distinct changes in the AC including 
the redistribution of cellular AC markers. At this point, it is unclear whether these observations 
represent the result of direct effects of pUL71 on the formation of the AC, or whether these 
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changes are a secondary consequence of the defect in secondary envelopment. While the precise 
role of pUL71 in envelopment has yet to be determined, recent data shows that the oligomerization 
of pUL71 into dimers, trimers and higher-ordered multimers are important for this process [122]. 
Surprisingly, the pUL71 protein was also found to interact with pUL51 and pUL89 proteins using 
yeast two-hybrid analysis [37]. The pUL51 and pUL89 proteins are two components of the three 
subunit terminase subunits required for the cleavage and packaging of DNA within nuclear 
replication compartments [123]. This finding is inconsistent with the phenotype of the UL71 
deletion viruses [46,121], and thus may represent an aberrant result due to the artificial nature of 
the yeast two-hybrid assays.   
5.2. pp28 
The product of the UL99 gene, pp28, localizes to the cytoplasmic AC in association with 
cellular membranes as a result of myristoylation in the amino terminus of the protein [45,70]. 
Deletion of the UL99 gene revealed that it is essential for virus replication, and results in the 
accumulation of tegumented capsids in the cytoplasm, suggesting that the pp28 protein plays a 
critical role in secondary envelopment [65,124]. Detailed mutational analyses of the pp28 open 
reading frame have identified distinct domains required for both AC localization and virion assembly 
with an acidic cluster within the amino terminus being critical for the assembly functions [26,109]. 
Surprisingly, the first 50 of the 190 amino acids of pp28 was capable of conferring both AC 
localization and at least partially restored the defect in virion assembly [109,125]. Importantly, the 
incorporation of other tegument proteins into the virion particles was unaffected, suggesting that 
pp28 functions after the addition of the bulk of the virion tegument [125]. Such a role is consistent 
with the membrane association of the pp28 protein, and indeed multimerization of the pp28 protein 
has been proposed to promote membrane deformation and virion budding, akin to the matrix 
proteins of other viruses [126]. The multimerization function also maps to the first 50 amino acids of 
pp28, as does its ability to interact with the pUL94 protein that functions with pp28 to facilitate 
secondary envelopment [108].  
It is somewhat surprising that these key functions of the pp28 protein are localized to such a 
small region with the amino terminus of the protein. One possibility is that additional non-essential 
functions reside within the remaining portion of the protein. In that regard, recent analysis using 
mass spectrometry have revealed potential interactions between pp28 and additional viral proteins, 
including pp65, the major capsid protein and the pUL44 DNA processivity factor [34]. These 
interactions may represent a component of the functional redundancy of some of the tegument 
proteins as previously noted [20,40]. However, it remains to be seen whether the carboxy-terminal 
region of pp28 participates in these interactions, or has additional hitherto unknown functions. 
Another unanswered question in relation to pp28 is the role of phosphorylation in any or all of its 
functions. It was originally reported that only a hypophosphorylated form of pp28 was packaged 
into virions [26]. In contrast, deletion of the UL26 gene causes a unique hypophosphorylated form 
of pp28 to be incorporated into virions and this corresponded to decreased stability of the pp28 
protein upon infection [44]. The reason for this apparent discrepancy is unclear, but could be 
related to the differences in methodologies used for the analysis. The original observation was 
made using mobility in standard SDS-PAGE analysis [26] whereas the second study utilized 2-D 
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gel electrophoresis but did not compare the results to the proteins found within the infected cell [44]. 
Regardless, it is clear that phosphorylation of pp28 could have a major impact on its function 
during assembly. 
6. Conclusions  
Insights into the roles of HCMV tegument proteins during virion assembly have advanced in 
recent years due to enhancements in technology, most notably the ability to rapidly generate viral 
mutants, and more widespread use of sophisticated microscopy techniques. We now have a more 
complete understanding of the inner tegument components and how they interact with and stabilize 
the viral capsid. In addition, we are beginning to decipher the networks that link the nuclear 
tegument proteins and presumably facilitate their incorporation into the virion particle. We also 
have important clues regarding the role of the cytoplasmic tegument proteins in secondary 
envelopment. However, there is still much to be learned and basic questions regarding the 
mechanism of tegumentation remain unanswered. Specific questions include the potential role of 
viral and host enzymes in the regulation of virion components in situ; how the addition of the 
nuclear tegument proteins is coordinated, including the mechanism of redistribution during 
infection and the role of the capsid in this process; the role of tegument in targeting capsids to the 
assembly complex; how self-association of the tegument proteins is regulated; identification of 
specific cellular and viral targets of the ppUL97 viral kinase; and the nature of tegument protein 
redundancy. Answering these questions are not only vital to our overall understanding of HCMV 
assembly and egress, but are critical to realize the potential of the tegument proteins as therapeutic 
targets for intervention.  
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Abstract: Human cytomegalovirus (HCMV) encodes a number of viral proteins with 
homology to cellular G protein-coupled receptors (GPCRs). These viral GPCRs, 
including US27, US28, UL33, and UL78, have been ascribed numerous functions 
during infection, including activating diverse cellular pathways, binding to 
immunomodulatory chemokines, and impacting virus dissemination. To investigate the 
role of US28 during virus infection, two variants of the clinical isolate TB40/E were 
generated: TB40/E-US28YFP expressing a C-terminal yellow fluorescent protein tag, and 
TB40/E-FLAGYFP in which a FLAG-YFP cassette replaces the US28 coding region. 
The TB40/E-US28YFP protein localized as large perinuclear fluorescent structures at 
late times post-infection in fibroblasts, endothelial, and epithelial cells. Interestingly, 
US28YFP is a non-glycosylated membrane protein throughout the course of infection. US28 
appears to impact cell-to-cell spread of virus, as the US28 virus (TB40/E-FLAGYFP) 
generated a log-greater yield of extracellular progeny whose spread could be significantly 
neutralized in fibroblasts. Most strikingly, in epithelial cells, where dissemination of 
virus occurs exclusively by the cell-to-cell route, TB40/E-FLAGYFP ( US28) displayed a 
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significant growth defect. The data demonstrates that HCMV US28 may contribute at a 
late stage of the viral life cycle to cell-to-cell dissemination of virus. 
Keywords: human cytomegalovirus; BAC recombineering; viral GPCR US28; virus 
dissemination; virus growth; membrane protein biology  
 
1. Introduction 
Human cytomegalovirus (HCMV) is a widespread pathogen that infects a vast majority of the 
world’s population [1]. HCMV is the prototypic -herpesvirus, characterized by its extended 
replication cycle, restricted host range, and cytopathic effect of pronounced cell swelling [2]. 
Infection of the healthy, immunocompetent host is typically asymptomatic, with pressure from the 
immune system leading to establishment of lifelong latent infection within cells of the myeloid 
lineage [3]. Infection of the immunologically immature or reactivation of latent infection during 
times of immunosuppression can result in significant disease [4]. In fact, HCMV infection during 
solid organ or hematopoietic stem cell transplant can have severe implications for the host and can 
ultimately prove fatal [5].  
The exceptionally large HCMV genome encodes for over 200 genes [6], including four putative 
homologs of cellular G protein-coupled receptors (GPCRs): the HCMV-specific US27 and US28, and 
the -herpesviruses-conserved UL33 and UL78 [7]. GPCRs, also known as seven-transmembrane 
domain proteins, are integral membrane receptors that sense extracellular ligands to trigger signal 
transduction networks and coordinate cellular responses [8]. Once activated, these receptors 
undergo a conformational change, causing activation of an associated heterotrimeric G protein and 
leading to production of intracellular secondary messenger molecules to induce downstream signaling 
pathways. HCMV infection is known to modulate a number of host cellular responses, including 
intracellular calcium levels, cyclic AMP (cAMP) production, inositol phosphate hydrolysis, and 
activation of phosphatidylinositol-3-kinase (PI3K) [9]. As constituents of the virion [10–12], 
several of the HCMV-encoded GPCRs regulate a number of these pathways immediately following 
infection. Both US28 and UL33 signal constitutively and can alter inositol phosphate production 
and activation of NF- B and cAMP response elements (CRE) [13,14]. Furthermore, US28 can bind CC 
chemokines to induce increases in intracellular calcium levels and migration of infected cells [15,16]. 
Although it shows no constitutive activity [17], US27 was recently found to enhance signaling 
mediated by endogenous CXCR4, resulting in enhanced calcium mobilization and chemotaxis [18]. 
To date no activating ligands or signaling properties have been attributed to UL78. 
Another intriguing characteristic accorded to HCMV-encoded GPCRs is their contribution to 
dissemination of virus in vitro. UL78 appears to impact virus growth in both endothelial and 
epithelial cells [12]. Additionally, UL78 supports infection by coordinating the timely delivery of 
viral DNA into the nuclei of infected cells [12]. US27 is required for efficient spread by the 
extracellular route and influences virus growth in fibroblasts and endothelial cells [19]. Expression 
of the murine cytomegalovirus (MCMV) ortholog M33 protein was shown to be necessary for virus 
dissemination in vivo but not in tissue culture [20]. An MCMV mutant lacking the GPCR M78 
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exhibited a growth defect in culture and reduced pathogenicity in mice [21]. The implication of 
HCMV-encoded GPCRs as virulence factors to enhance infection is quite intriguing, as their 
presence within infected cell membranes [22,23] could allow cell-cell communication and 
modulation of signaling networks within neighboring cells to facilitate propagation.  
To determine the role of US28 in HCMV dissemination, mutational analysis of the TB40/E 
clinical isolate was performed. A YFP derivative of US28 (TB40/E-US28YFP) localized as large 
perinuclear structures at late times of infection in fibroblasts, endothelial, and epithelial cells. At 
these late times, US28YFP was integrated into cellular membranes, further validating its presence at 
the interface of infected cells. A US28 mutant (TB40/E-FLAGYFP) produced increased levels of 
extracellular virus as assayed by both multi-step and single-step growth kinetics. Extracellular virus 
produced by the US28 mutant could be neutralized by the addition of HCMV glycoprotein-specific 
antibodies and spread of TB40/E-FLAGYFP by the cell-to-cell route was abrogated in fibroblasts 
and epithelial cells. These findings implicate the viral GPCR US28 as a factor contributing to 
cellular dissemination of HCMV.  
2. Results 
2.1. Generation of HCMV TB40/E US28 Variants 
To extend on studies of viral GPCRs as virulence factors, derivatives of the HCMV clinical 
isolate TB40/E were generated (Figure 1a). The wild type TB40/E bacterial artificial chromosome 
(BAC) (herein termed TB40/E wt) was altered to express a chimeric protein in which the carboxy 
terminus of the US28 coding region was amended with a yellow fluorescent protein tag  
(TB40/E-US28YFP) (Figure 1a). A second variant was generated in which the US28 coding region 
was replaced with a DNA cassette encoding a FLAG-tagged YFP chimera (TB40/E-FLAGYFP) 
(Figure 1a). To confirm abrogation of US28 message in the US28 (FLAGYFP) virus, MRC5 lung 
fibroblasts were mock-infected or infected with TB40/E wt, TB40/E-US28YFP or TB40/E-FLAGYFP 
and RNA harvested at 48 hours post-infection, a time when US28 should be abundantly  
transcribed [24]. RT-PCR analysis with primers specific to a region within US28 demonstrated  
that US28 messenger RNA continued to be generated during infection with TB40/E wt and 
TB40/E-US28YFP, but not with the US28 virus (Figure 1b, lanes 1–4). To further confirm 
expression of our TB40/E YFP chimeras, fibroblasts were either mock-infected or infected with 
TB40/E-US28YFP or TB40/E-FLAGYFP, harvested at various times post-infection, and analyzed by 
immunoblot for expression of YFP (Figure 1c). Kinetic analysis confirmed US28YFP expression 
throughout the time course, with maximal expression at 72 hours post-infection (Figure 1c, lanes 
1–6). US28YFP migrated as a broad polypeptide species of approximately 65 kD (Figure 1c, lanes 
1–6). FLAGYFP followed a similar time course of expression, peaking at 72 hours post-infection 
(Figure 1c, lanes 7–11). When visualized by fluorescence microscopy, the majority of US28YFP 
localized intracellularly to vesicular structures concentrated around the nucleus (Figure 1d, center), 
confirming earlier data for US28 localization in transiently transfected cells [22]. A small portion 
of US28YFP appeared to localize to the cell surface, as US28 undergoes constitutive endocytosis 
and recycling [22]. TB40/E-FLAGYFP-infected cells expressed fluorescence throughout the cell 
(Figure 1d, right) while the TB40/E wt parental virus did not express YFP (Figure 1d, left). Taken 
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together, the data demonstrates that TB40/E variants of the US28 coding region had been generated 
to ascertain its role in HCMV virulence. 
Figure 1. Generation of TB40/E-US28 variants. (a) Using a bacterial artificial 
chromosome (BAC) recombineering approach Human cytomegalovirus (HCMV) TB40/E 
variants were generated that express either chimeric US28 containing a carboxy-terminal 
YFP tag (US28YFP) or a US28 deletion mutant where the US28 ORF has been replaced 
with an engineered FLAG-YFP cassette (FLAGYFP). YFP sequences are denoted by the 
diagonally hatched box; FLAG sequences are denoted by the horizontally striped box. 
TR, terminal repeat; U, unique sequences; IR, inverted repeat; L, long; S, short.  
(b) Fibroblasts mock-infected or infected (MOI = 5) with TB40/E wt or TB40/E-US28 
variants were harvested 48 hours post-infection and subjected to RT-PCR with primers 
specific to US28 (lanes 1–5) or -actin (lanes 6–10). A sample lacking RNA (( )RNA) 
was included as a negative control. HCMV US28, -actin, and relative DNA standards 
are indicated. (c) Fibroblasts mock-infected or infected (MOI = 5) with TB40/E-US28YFP 
or TB40/E-FLAGYFP were harvested at the indicated times and subjected to SDS-PAGE 
and immunoblot analysis. US28YFP, FLAGYFP, GAPDH, and molecular weight standards 
are indicated. (d) Fibroblasts infected (MOI = 5) with TB40/E wt, TB40/E-US28YFP or 
TB40/E-FLAGYFP were harvested 48 hours post-infection and visualized using the 
EVOS Cell Imaging Systems at 60× magnification.  
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2.2. HCMV US28YFP Localizes as Large Vesicular Structures at Late Times of Infection 
To visualize a time course of US28YFP expression, confocal microscopy was performed on 
fibroblasts infected with TB40/E-US28YFP (Figure 2a). At early times post-infection, US28YFP 
localized diffusely throughout the cell (Figure 2a, left). As infection progressed, US28YFP coalesced 
into intense fluorescent perinuclear structures focused on one side of the nucleus (Figure 2a, 48, 
72 hpi, arrows). By 72 hours post-infection, these large structures seemed to encroach on the 
nuclear space (Figure 2a, arrows). These organelles most likely represent viral assembly zones, as 
US28 has been proposed to be incorporated into assembling virions. 
To determine if US28YFP localization into large perinuclear structures late during infection was 
cell-type specific, infections of human umbilical vein endothelial cells (HUVECs), human 
microvascular endothelial cells (HMVECs), and ARPE-19 epithelial cells were performed  
(Figure 2b). Infection with TB40/E-US28YFP caused the formation of intense fluorescent granular 
structures in all cell types assayed (Figure 2b, left column). In comparison infection with  
TB40/E-FLAGYFP resulted in diffuse fluorescence throughout the cell for each cell type (Figure 2b, 
right column). US28YFP expression in endothelial cells was similar to cell surface staining on 
smooth muscles cells expressing US28, in which the viral GPCR accumulated toward the leading 
edge of migrating cells [16]. Strikingly, in epithelial cells, US28YFP also appeared to converge at 
the junction of neighboring infected cells (Figure 2b, bottom left, arrow). Taken together, the 
results demonstrate that US28 localizes to large perinuclear structures that may represent areas of 
infectious virus production.  
2.3. Characterization of US28YFP in HCMV-Infected Cells 
2.3.1. HCMV US28YFP Is Integrated into Dense Vesicular Bodies 
The viral GPCRs US27 and UL33 localize to virus-wrapping membranes on HCMV-infected 
cells [23]. To determine if US28, at late time points post-infection, also traffics to dense vesicles 
consisting of large complexes, subcellular fractionation was performed on TB40/E-US28YFP- and 
TB40/E-FLAGYFP-infected fibroblasts (Figure 3a). At 72 hours post-infection, cells were lysed 
using a ball-bearing homogenizer and subjected to two centrifugation steps: nuclei and heavy/dense 
organelles were spun down at 15,000 × g, followed by separation of cellular membrane and 
cytoplasm by high-speed centrifugation at 120,000 × g. A substantial amount of US28YFP and 
FLAGYFP localized to the 15,000 × g fraction containing heavy organelles (Figure 3a, lanes 1–3). 
As US28YFP and FLAGYFP polypeptides are being abundantly synthesized at this late time point of 
infection (Figure 1c), their localization to this fraction may represent ER membranes contiguous 
with the nucleus, large protein complexes, and large dense membrane vesicles. Considering the 
levels of US28YFP in the 15,000 × g fraction, only a small amount of two distinct US28YFP species 
were localized to cellular membranes after high-speed centrifugation (Figure 3a, lane 5), suggesting 
that US28YFP traffics with large protein complexes in dense membrane fractions. Interestingly, 
FLAGYFP was also found in this membranous fraction (Figure 3a, lane 6). This may simply 
represent contamination from the cytoplasmic fraction, as the majority of FLAGYFP, and not 
US28YFP, localizes to the cytoplasm (Figure 3a, lane 8–9). As a control, immunoblot analysis of 
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viral glycoproteins was also performed (Figure 3a, lanes 10–18). The glycoprotein gB also 
localized to the dense cellular membrane fraction (Figure 3a, lanes 10–15) and not the cytoplasmic 
fraction (Figure 3a, lanes 16–18). A similar result was found for the viral glycoprotein gH (data not 
shown). Remarkably, US28YFP trafficked within dense cellular membranes as early as 24 hours 
post-infection (Figure 3b, lane 2) probably due to active translation on large ER membranes. 
Alternatively, the localization of US28YFP to the 15,000 × g fraction may be due to integration of 
US28 from the HCMV virion into the plasma membrane following infection, but additional 
experiments are needed to confirm this. Taken together, the data demonstrates that US28YFP is 
found in mostly large membrane complexes and localizes to dense vesicles, likely virus assembly 
zones late during infection.  
Figure 2. Formation of US28-expressing structures late during HCMV infection.  
(a) Confocal microscopy was performed on fibroblasts either mock-infected or infected 
with TB40/E-US28YFP (MOI = 5). At various times post-infection cells were fixed and 
analyzed using an ImageXpress Ultra plate-scanning confocal microscope. (b) Endothelial 
and epithelial cells were infected with either TB40/E-US28YFP (left) or -FLAGYFP 
(right) (MOI = 25) and visualized at 4 days post-infection using the EVOS Cell 
Imaging Systems at 60× magnification.  
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Figure 3. HCMV US28 is a non-glycosylated membrane protein incorporated into 
infected cells. Fibroblasts mock-infected or infected (MOI = 5) with either  
TB40/E-US28YFP or TB40/E-FLAGYFP were subjected to subcellular fractionation at  
72 (a) or 24 (b) hours post-infection. Cell pellets from the 15,000 and 120,000 × g 
centrifugations (15 k × g pellet, 120 k × g pellet) and the 120,000 × g supernatant  
(120 k × g supe) were resolved by SDS-PAGE and subjected to immunoblot analysis. 
US28YFP, FLAGYFP, gB, and molecular weight standards are indicated. gB* indicates 
the mature form of glycoprotein B. (c) Fibroblasts infected with TB40/E-US28YFP 
(MOI = 5) were harvested at the indicated time points and left non-treated (NT) or 
treated with EndoH (H) or PNGaseF (F). US28YFP, glycosylated MHC class I heavy 
chains (HC(+)CHO), deglycosylated MHC class I heavy chains (HC( )CHO), 
GAPDH, and molecular weight standards are indicated. 
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2.3.2. HMCV US28 Is a Non-Glycosylated Membrane Protein 
As integral membrane proteins, the extracellular portions of GPCRs have the potential to be 
glycosylated. Both US27 and UL33 are heavily glycosylated while present in infected cell 
membranes [10,11]. The US28 protein annotated from the HCMV genome contains a possible  
N-linked glycosylation site (amino acids 30–32, NQS). Therefore, to determine if US28 is a 
glycosylated membrane protein, lysates prepared from TB40/E-US28YFP-infected fibroblasts at 
various times post-infection were subjected to digestion by either endoglycosidase H (EndoH) or 
peptide: N-glycosidase F (PNGaseF) (Figure 3c). EndoH cleaves high mannose glycans from the core 
of N-linked glycoproteins while PNGaseF hydrolyzes nearly all types of N-linked glycans from 
proteins [25]. Unexpectedly, US28YFP was insensitive to cleavage by either EndoH or PNGaseF 
throughout the time course (Figure 3c, lanes 1–9), suggesting that US28 is not glycosylated despite 
being a membrane protein and trafficking through the secretory compartment [22]. As a control, the 
sensitivity of the known glycoprotein major histocompatibility complex (MHC) class I heavy chain 
to cleavage by EndoH and PNGaseF was determined (Figure 3c, lanes 10–18). Class I heavy chains 
traffic rapidly through the ER, where high-mannose glycans are acquired and cleaved, and is 
therefore resistant to EndoH digestion [26] (Figure 3c, lanes 11, 14, 17). Class I heavy chains were 
completely sensitive to cleavage by PNGaseF, resulting in loss of its single glycan (Figure 3c, lanes 
12, 15, 18). The findings reveal that HCMV US28 is a unique non-glycosylated membrane protein.  
2.4. Functional Analysis of TB40/E US28 Variants 
2.4.1. TB40/E US28 Accumulates Increased Amounts of Extracellular Virus in Fibroblasts 
To determine the growth properties of the TB40/E US28 variants, fibroblasts were infected at 
both high multiplicity, to study single step growth, and low multiplicity, to determine multi-step 
growth, and production of infectious extracellular progeny was measured (Figure 4a,b). At high 
multiplicity of infection (MOI), TB40/E wt and TB40/E-US28YFP grew to comparable titers  
(Figure 4a, solid line vs. dotted line). In comparison, TB40/E-FLAGYFP ( US28) displayed a  
10-fold increase in the accumulation of extracellular virus (Figure 4a, dashed line). This effect was 
amplified at low multiplicity of infection, where TB40/E-FLAGYFP displayed a 100-fold increase in 
viral titers over TB40/E-US28YFP (Figure 4b, solid line vs. dashed line). The data demonstrates that 
the loss of US28 results in increased production of extracellular virus during HCMV infection. 
2.4.2. US28 Modulates HCMV Cell-to-Cell Dissemination  
An HCMV mutant virus lacking the tegument phosphoprotein pp28 fails to accumulate 
extracellular progeny yet mediates cell-to-cell spread of tegument-coated capsids [27]. The 
accumulation of extracellular virus seen during US28 infection could result from a blockade at the 
level of cell-to-cell spread, thus leading to re-routing of infectious virions into the extracellular 
milieu. To determine if the US28 virus has a defect in cell-to-cell spread of virus, infections were 
performed in epithelial cells, where spread of TB40/E is exclusively cell-associated [19]. ARPE-19 
cells were infected at low multiplicity with either TB40/E-US28YFP or TB40/E-FLAGYFP and 
infectious progeny measured by determining the titer of cell-associated virus (Figure 4c). In 
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comparison to fibroblasts, where TB40/E-FLAGYFP displayed increased growth properties, the 
US28 virus exhibited a growth defect in epithelial cells (Figure 4c, dashed line). In fact, while 
titers of cell-associated TB40/E-US28YFP increased over the time course, accumulation of 
intracellular virus became stagnant during TB40/E-FLAGYFP infection (Figure 4c, solid line vs. 
dashed line). Taken together, it appears that US28 may contribute to cell-to-cell dissemination 
during HCMV infection.  
Figure 4. HCMV US28 modulates cell-to-cell spread of virus. Infectious extracellular 
progeny from fibroblasts infected at 5 PFU/cell (a) or 0.1 PFU/cell (b) with TB40/E wt, 
TB40/E-US28YFP, or TB40/E-FLAGYFP were measured by TCID50 assay. Viral titers were 
assayed in duplicate. Error bars represent standard deviation of the mean. (c) ARPE-19 
cells were infected at 0.1 PFU/cell with TB40/E-US28YFP or TB40/E-FLAGYFP and at 
the indicated times post-infection cell-associated virus was determined by TCID50 assay. 
Viral titers were assayed in duplicate. Error bars represent standard deviation of the mean.  
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2.5. Inhibition of TB40/E US28 Dissemination by Anti-HCMV Neutralizing Antibody 
When grown in fibroblasts TB40/E-FLAGYFP produced substantial extracellular virus, suggesting 
that, in the absence of US28, the virus uses the extracellular route as the main route of dissemination. 
Therefore, an inhibition of infectious virus in the supernatant of US28-infected cells would result 
in a significant hindrance to dissemination. To determine if TB40/E-FLAGYFP spread could be 
ablated in fibroblasts, infected cells were cultured in the presence of the HCMV neutralizing 
antibody 14-4b that recognizes glycoprotein H (gH) [28]. At approximately two weeks post-infection 
cells were analyzed by a fluorescence microplate cytometer (Figure 5a) and by fluorescence 
microscopy (Figure 5b). When grown in the presence of 14-4b, TB40/E-US28YFP total fluorescence 
was slightly decreased (Figure 5a, left). In comparison, TB40/E-FLAGYFP fluorescence was 
significantly reduced in the presence of 14-4b (Figure 5a, right). Fluorescence microscopy revealed 
that although TB40/E-US28YFP grown in the presence of 14-4b created smaller plaques, cellular 
syncytia continued to be formed (Figure 5b). In contrast, TB40/E-FLAGYFP growth was restricted to 
small pockets of infection in the presence of 14-4b, with the absence of plaque formation (Figure 5b). 
These findings demonstrate that US28 impacts cell-to-cell spread of virus as TB40/E- US28 is 
hindered in its dissemination in culture upon addition of HCMV neutralizing antibodies. 
Figure 5. TB40/E US28 displays a growth defect when required to use the cell-to-cell 
route of dissemination. Fibroblasts infected (MOI = 0.01) with either TB40/E-US28YFP 
or TB40/E-FLAGYFP were cultured in the presence of the HCMV neutralizing antibody 
14-4b. Two weeks post-infection cells were analyzed by fluorescent microplate reader 
(a) or by fluorescence microscopy (b). For (a) YFP fluorescence was assayed in 





3. Experimental Section  
3.1. Cells and Viruses  
Human lung fibroblasts (MRC5) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 8% fetal bovine serum (FBS), 1 mM HEPES, 100 U/mL penicillin, and 
100 g/mL streptomycin. Human retinal pigmented epithelial cells (ARPE-19) were maintained in 
a 1:1 mixture of complete DMEM (FBS, HEPES, penicillin, streptomycin) and Ham’s F-12 
medium containing 8% FBS, 1mM HEPES, 100 U/mL penicillin, and 100 g/mL streptomycin. 
Human umbilical vein endothelial cells (HUVEC) were cultured in EBM medium supplemented 
with bovine brain extract (BBE), recombinant human epidermal growth factor (rhEGF), 
hydrocortisone, ascorbic acid, gentamicin sulfate/amphotericin-B (GA-1000) and 2% FBS (Lonza 
Clonetics). CD34+ CD31+ human microvascular endothelial cells (HMVEC) were cultured in 
EBM-2 basal medium supplemented with rhEGF, hydrocortisone, recombinant human fibroblast 
growth factor-beta (rhFGF-B), vascular endothelial growth factor (VEGF), insulin-like growth 
factor (R3-IGF-1), ascorbic acid, GA-1000, and 5% FBS (Lonza Clonetics). Cells were maintained 
at 37 °C in a humidified atmosphere (95% air/5% CO2).  
The HCMV bacterial artificial chromosome (BAC) clone of the clinical isolate TB40/E  
(TB40-BAC4) was a kind gift of Dr. Christian Sinzger (Institute of Virology, University Medical 
Center Ulm, Ulm, Germany) and Dr. Felicia Goodrum (University of Arizona, Tucson, Arizona, 
AZ, USA). TB40-BAC4 was used to generate variants expressing a chimeric US28 with a yellow 
fluorescent protein (YFP) tag (TB40/E-US28YFP) and a US28 deletion virus containing a FLAG-YFP 
cassette within the US28 open reading frame (TB40/E-FLAGYFP ( US28)). To generate these viruses 
TB40-BAC4 was modified using the galK recombineering system as previously described [29]. In 
brief, the galK gene was amplified by PCR using the following primers: Forward 5'-
GTGCGTGGACCAGGCGGTGTCCATGCACCGAGGGCAGAACTGGTGCTACCCCTGTTGACA
ATTAATCATCGGCA-3'; Reverse 5'-GAGGGGCGGACACGGGGTTTGTATGAAAAGGCCGAGGT 
AGCGATTTTTTATCAGCACTGTCCTGCTCCTT-3', where the underlined sequences correspond to 
galK. The PCR product was transformed into recombination-competent E. coli SW105 cells 
containing TB40-BAC4. GalK-expressing clones were subsequently selected and electroporated 
with a PCR cassette specific to either US28YFP or FLAGYFP amplified from pcDEF-US28YFP. 
Primers used for reversion were as follows: US28YFP Forward 5'-GTGCGTGGACCAGG 
CGGTGTCCATGCACCGAGGGCAGAACTGGTGCTACCATGACACCGACGACGACGACCG-3'; 
US28YFP/FLAGYFP Reverse 5'-GAGGGCGGACACGGGGTTTGTATGAAAAGGCCGAGGTAGCG 
CTTTTTTATTACTTGTACAGCTCGTCCATGC-3'; FLAGYFP Forward 5'-GTGCGTGGACCAGGC 
GGTGTCCATGCACCGAGGGCAGAACTGGTGCTACCATGGACTACAAGGACGACGACGACAC
TAGTGCGGCCGCCATGGTGAGC-3'. The resultant clones were chosen following counter-selection 
against galK and subsequently sequenced to ensure incorporation of YFP and FLAG. Virus stocks 
were generated by electroporating low passage MRC5s with purified BAC DNA from the 
respective variants. Cultures were allowed to progress to full cytopathic effect (CPE) and virus was 
then harvested and purified by centrifugation through a 20% sorbitol cushion. Virus stocks were 
stored at 80 °C in DMEM containing 8% FBS plus 1.5% bovine serum albumin (BSA). Virus 
stock titers were determined by tissue culture infectious dose 50 (TCID50) assay.  
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3.2. Fluorescence Microscopy 
For fluorescence microscopy, fibroblasts infected at a multiplicity of infection (MOI) of  
5 plaque forming units (PFU)/mL were visualized 2 days post-infection using the EVOS Cell 
Imaging Systems (Life Technologies, Grand Island, NY, USA). Images were analyzed using 
Adobe Photoshop CS5.1 software [30]. ARPE-19 and endothelial cells were infected at an MOI of 
25 PFU/mL and visualized 4 days post-infection. For confocal microscopy, fibroblasts infected at 
an MOI of 5 PFU/mL were harvested at various times post-infection and fixed in Cytofix/Cytoperm 
solution (BD Biosciences, Franklin Lakes, NJ, USA) for 45 minutes at 4 °C. YFP fluorescence was 
visualized using a Molecular Devices ImageXpress Ultra (IXU) plate-scanning confocal 
microscope (Integrated Screening Core, Icahn School of Medicine at Mount Sinai, New York, NY, 
USA). Images were analyzed using MetaExpress software [31].  
3.3. Cell Fractionation and Immunoblot Analysis 
Subcellular fractionation was performed as previously described [32]. In brief, mock-infected 
and TB40/E-infected fibroblasts were resuspended in 1× homogenization buffer (100 mM Tris,  
150 mM NaCl, 250 mM sucrose, 1.5 mg/mL aprotinin, and 1 M leupeptin) and mechanically 
homogenized using a 12- m ball bearing homogenizer (Isobiotec, Hiedelberg, Germany). Samples 
were centrifuged at 15,000 × g for 10 minutes at 4 °C and heavy organelles found in the pellet were 
lysed directly in 1× SDS sample buffer (50 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.02% 
bromphenol blue, 50 mM dithiothreitol). Supernatants were further centrifuged at 120,000 × g for  
1 hour at 4 °C. Pellets containing cellular membranes and supernatants containing cytoplasm were 
lysed in SDS sample buffer and resolved using SDS-PAGE. Green fluorescent protein (GFP) 
polyclonal antibody was a kind gift of Dr. Hidde Ploegh (Whitehead Institute, MIT, Cambridge, 
MA, USA). Polyclonal major histocompatiblity class I heavy chain (MHC class I HC) antibody has 
been previously described [33]. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
purchased from Upstate/Millipore. Monoclonal glycoprotein B (gB) antibody was a kind gift of  
Dr. William Britt (UAB, Birmingham, AL, USA).  
3.4. N-Linked Protein Glycosylation Analysis  
Endoglycosidase H (EndoH) and peptide: N-glycosidase F (PNGaseF) sensitivity was determined 
as per the manufacturer’s protocol (New England Biolabs, Ipswitch, MA, USA). In brief, 
polypeptide samples lysed in 1% SDS were incubated in 1× denaturing buffer (0.5% SDS, 0.04 M 
dithiothreitol) followed by the addition of 10× G5 buffer (0.5 M sodium citrate, pH 5.5, for EndoH) 
or 10× G7 buffer (0.5 M sodium citrate, pH 7.5, 10% Nonidet P-40, for PNGaseF) and 1000 units 
of EndoH or 500 units of PNGaseF. Enzymatic reactions were carried out at 37 °C for 2 hours.  
3.5. Analysis of Virus Growth and Spread 
Single step growth kinetics were determined by infecting fibroblasts at an MOI of 5 PFU/mL. 
At the indicated time points post-infection media was collected and virus titers in the supernatant 
were determined by TCID50 assay. Multistep growth kinetic analysis was performed at an MOI of 
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0.1 PFU/mL. For analysis of cell-associated virus yield, ARPE-19 cells were infected at an MOI of 
0.1 PFU/mL and samples harvested by scraping cells into media. Cells were lysed by subjecting 
them to a single freeze-thaw cycle and sonication. Cellular debris was pelleted by centrifugation 
and the amount of infectious virus in the resulting supernatant was determined by TCID50 assay. 
For neutralization of extracellular virus, fibroblasts were mock-infected or TB40/E-infected at 
an MOI of 0.01 PFU/mL for 1 hour at 37 °C and then placed into media containing 10 g/mL  
of the monoclonal anti-gH antibody 14-4b (a kind gift of Dr. William Britt (UAB)). 2 weeks  
post-infection YFP fluorescence was analyzed using an Acumen eX3 laser scanning fluorescence 
microplate cytometer (TTP LabTech, Cambridge, MA, USA) as previously described [34].  
4. Conclusions  
Many functions have been ascribed to the G protein-coupled receptors encoded by HCMV. In 
these studies we demonstrate that US28 impacts dissemination of virus by promoting cell-to-cell 
spread of infectious progeny. The generation of two fluorescent variants of the clinical isolate 
TB40/E, US28YFP and FLAGYFP ( US28), allowed us to investigate the role of US28 as a virulence 
factor during HCMV infection (Figure 1). Infection with TB40/E-US28YFP resulted in the 
formation of intense perinuclear granular structures at late times in fibroblasts, endothelial, and 
epithelial cells (Figure 2). Interestingly, in epithelial cells, where TB40/E disseminates via the  
cell-to-cell route, US28YFP localized to areas between infected cells (Figure 2b). During infection, 
US28YFP traffics with mostly large dense complexes in the membranes of infected cells (Figure 3a,b). 
Surprisingly, US28YFP did not acquire an N-linked glycan during infection (Figure 3c), ascribing a 
novel characteristic to this viral membrane protein. Infections with TB40/E-US28YFP resulted in 
growth properties comparable to TB40/E wt (Figure 4a). Strikingly, infection with TB40/E-FLAGYFP, a 
virus lacking US28, resulted in increased production of extracellular infectious progeny (Figure 4a,b). 
However, when assayed in epithelial cells, where dissemination occurs via cell-to-cell spread, 
TB40/E-FLAGYFP demonstrated a growth defect (Figure 4c) suggesting that US28 plays a role in 
inter-cellular dissemination of HCMV. Accordingly, when the virus lacking US28 was forced to 
utilize the cell-to-cell route in fibroblasts by culture in the presence of neutralizing antibodies, a 
substantial defect in dissemination was observed (Figure 5). Taken together, we can conclude that 
US28, an integral membrane protein present at the border of adjacent cells, plays a role in 
dissemination of infectious viral progeny from cell-to-cell.  
The scenario may occur during HCMV infection where, at late time points, US28 converges at 
the interface of viral assembly zones and adjoining cells in order to enhance virus spread to 
uninfected neighboring cells. The dissemination enhancing activity of US28 likely requires the 
interaction of this GPCR with a membrane component on adjacent cells. Due to US28’s high 
affinity binding to the chemokine fractalkine [35], this interaction might either promote cell-cell 
contact or membrane fusion in clinically relevant cell types expressing this CX3C membrane-bound 
chemokine (i.e., endothelial cells). In fact, fusion-enhancing activity has been reported for US28 
when expressed together with the HIV Env protein and the G protein of vesicular stomatit is virus 
(VSV-G) [36]. Heteromerization of US28 and other HCMV GPCRs [37] may alter the physical 
properties of membranes in a way favorable to fusion with neighboring infected cells. Interestingly, 
HCMV US27 and UL33 or MCMV M33 did not seem to enhance cell fusion in a way comparable 
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to US28 [36], suggesting a novel role for this GPCR in dissemination of HCMV in the host. The 
pattern of US28YFP trafficking and its membrane association would be well-suited to incorporation 
of this protein into the viral lipid envelope. As a component of the virion, US28 could have a direct 
role in HCMV entry through its ability to bind target cells and mediate dissemination. This would 
be most advantageous during latent infection of HCMV when US28, shown to be expressed during 
latency [38], could mediate adhesion of latently-infected monocytes to activated endothelial cells, 
where high levels of fractalkine are expressed [39], to potentiate dissemination in the host. 
Conceivably, virion-bound GPCR US28 could also bind to cells and induce signaling networks to 
facilitate infection. However, further experiments are necessary to define whether US28 is present 
in virions and whether it can play a role in virus-cell interaction.  
HCMV dissemination can occur via two routes: through production of extracellular virus 
progeny that subsequently bind and enter new cells to propagate infection or directly from cell to 
cell with limited exposure of virus to the extracellular environment [27]. Here we define US28 as a 
factor contributing to cell-to-cell dissemination of HCMV. Our data strongly supports the role of  
viral-encoded GPCRs as virulence factors in vitro and further adds to our understanding of the 
multifunctional US28 protein. We also identify US28 as a novel target for anti-HCMV therapeutics 
to inhibit viral dissemination in the host.  
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Abstract: Human cytomegalovirus (HCMV) particle morphogenesis in infected cells is 
an orchestrated process that eventually results in the release of enveloped virions. 
Proteomic analysis has been employed to reveal the complexity in the protein composition 
of these extracellular particles. Only limited information is however available regarding 
the proteome of infected cells preceding the release of HCMV virions. We used 
quantitative mass spectrometry to address the pattern of viral and cellular proteins in 
cells, infected with derivatives of the AD169 laboratory strain. Our analyses revealed a 
remarkable conservation in the patterns of viral and of abundant cellular proteins in 
cells, infected for 2 hours, 2 days, or 4 days. Most viral proteins increased in abundance 
as the infection progressed over time. Of the proteins that were reliably detectable by 
mass spectrometry, only IE1 (pUL123), pTRS1, and pIRS1 were downregulated at 4 days 
after infection. In addition, little variation of viral proteins in the virions of the different 
viruses was detectable, independent of the expression of the major tegument protein 
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pp65. Taken together these data suggest that there is little variation in the expression 
program of viral and cellular proteins in cells infected with related HCMVs, resulting in 
a conserved pattern of viral proteins ultimately associated with extracellular virions.  




The human cytomegalovirus (HCMV) is a pathogen of substantial clinical relevance that may 
lead to severe disease and sequelae after prenatal infection and life threating conditions in 
immunosuppressed individuals. Considerable interest thus focuses on the development of 
therapeutic strategies against HCMV infection and disease. One target area for the development of 
antiviral compounds is particle formation and particle release.  
The virions of HCMV are made up by an inner capsid structure, containing the linear  
double-stranded DNA genome of roughly 235 kbp, an attached matrix of viral and cellular proteins, 
assembled as a tegument layer, and an outer envelope [1]. The 100 nm icosahedral capsid is 
composed of the major capsid protein (MCP, pUL86), the minor capsid protein (mCP, pUL85), the 
mCP-binding protein (mCP-BP, pUL46), the smallest capsid protein (SCP; pUL48.5), and the 
portal protein (pUL104) [2]. Assembly of the capsids proceeds in the nucleus of infected cells, 
originating from scaffold-containing procapsids. The viral DNA is encapsidated and selected 
tegument proteins may become associated with the capsids already at this stage [1,2]. Capsids exit 
the nucleus by subsequent envelopment and de-envelopment at the nuclear membrane. A key 
determinant of that process is the nuclear egress complex (NEC) at the inner nuclear membrane that 
consists of the viral proteins pUL50 and pUL53 [3–6]. Nuclear capsid egress appears to be 
regulated by both cellular and viral kinases [3,7,8]. Following their release into the cytoplasm, the 
capsids are directed to perinuclear inclusions termed assembly compartments (AC) [9]. The AC 
consists of cylindrical structures that are assembled from the trans-Golgi network, the endoplasmic 
reticulum (ER), the ER-Golgi intermediate compartment (ERGIC) and from endosomal compartments, 
and contains proteins characteristic for endosomal sorting and transport (ESCRT) as well as Rab 
GTPases [1,10–12]. Tegument attachment to the capsids occurs predominantly at the AC and precedes 
envelopment. Both virions and subviral dense bodies are enveloped at AC and are subsequently 
found in cytoplasmic vesicles that are then transported to the cell surface by an exocytotic  
pathway [6,13]. This transport is influenced by the product of the viral UL103 open reading frame 
(ORF) [14]. Infectious virions and dense bodies are ultimately released at the cell surface.  
Early analyses used color staining or radioactive labeling in combination with SDS-PAGE to 
display the protein pattern of purified HCMV virions [15–18]. Subsequent microsequencing 
analyses identified a subset of viral and cellular protein components of HCMV virions [19].  
Further reports also identified cell derived proteins to be included in HCMV virions, although some 
of these results have later been challenged as being a result of contamination rather than of 
packaging [20–24]. A previous study, using mass spectrometry, revealed the high level of 
complexity of the HCMV virion [25,26]. Seventy-one viral proteins were identified to be integral 
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constituents of the particle. In addition, over 70 cell-derived proteins were found to be associated 
with purified particles. Proteomic analyses of the murine CMV virion displayed a similarly 
complex picture [27]. 
Mass spectrometry has provided a detailed insight into the protein composition of HCMV 
virions. There is, however, only limited information available about the proteomic composition of 
permissively infected fibroblasts preceding the release of particles. Furthermore, analyses of the 
protein composition of HCMV virions by mass spectrometry were focused on one single  
AD169-derivative. Up to this point, it remained unclear how culturing of related HCMVs in 
different laboratories would influence the proteomes of infected cells and virions. To begin to 
address this issue, we focused on five HCMVs that were all descendants, as bacterial artificial 
chromosome (BAC) clones, of the AD169 laboratory strain of HCMV. The viruses used for 
analysis were RV-HB5 [28], RV-HB15 (AD169-RV) [29]) and RV-BADwt [30], and the pp65 
deletion mutants RV-Hd65 [31], RV-KB14 [32]. The RV-HB5 is the first BAC-derived HCMV 
strain, originally cloned by Borst and colleagues by inserting a BAC-vector into the US2-US6 gene 
region of the AD169 strain [28]. The RV-HB15 is a modified version of RV-HB5, where the  
US2-US6 deletion was repaired and the BAC vector was removed by cre-lox recombination at 
virus reconstitution, leaving one single loxP site behind in the genome. [29]. The RV-BADwt is a 
full length AD169 strain that was cloned by inserting a self-excisable BAC-vector between the 
ORFs US28 and US29, again leaving one single loxP site behind, following the US28 ORF [30]. 
The pp65neg strain RV-Hd65 was derived by replacing the UL83 (pp65) ORF from AD169-BAC by 
a neomycin resistance cassette, leaving behind 151 5'-terminal base pairs of the pp65 ORF [31]. 
The AD169-BAC is the clone used to reconstitute RV-HB15. The neomycin resistance cassette was 
removed using FLP-recombinase mediated excision in E. coli. The BAC vector was removed by 
cre-lox recombination at virus reconstitution. The pp65neg strain RV-KB14 was generated by 
inserting a tetracycline resistance cassette into the UL83 (pp65) ORF of pAD/cre (the BAC clone 
used for reconstitution of RV-BADwt), thereby deleting all of the pp65-coding region except for 
152 5' base pairs of the ORF [32]. All viruses were characterized before with respect to their 
genomic structure and biologic properties.  
The data analyses presented here show a remarkable conservation of the overall levels of viral 
and cellular proteins in fibroblasts, infected with RV-HB15 or RV-BADwt. Most viral proteins 
increased in their steady-state levels in infected cells up to 4 days after infection (dpi). Only IE1 
(pUL123), IRS1 and TRS1 appeared to be downregulated at 4 dpi. No gross alteration of the viral 
protein content of the virions of pp65pos- or pp65neg-viruses were seen.  
2. Results and Discussion 
2.1. Conserved Pattern of Viral Protein Expression in Infected Cells 
To address the steady-state levels of viral proteins in HFF, cells were infected at an m.o.i. of 1 
with RV-HB15 and RV-BAD, respectively. Cells were collected and processed after 2 hpi, 2 dpi, 
or 4 dpi, respectively, and analyzed by mass spectrometry. 
The patterns of viral proteins that were detectable at 2 hpi were divergent between RV-HB15 
and RV-BADwt (Figure 1A). This, however, was not surprising, considering the low amounts of 
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viral proteins relative to the prevalence of cellular proteins at this early time after infection (data 
not shown). The precision of the measurement of viral proteins against this high background was 
limited, thus compromising a direct comparison in this case. It was yet remarkable that viral 
proteins could be detected at this early time after infection, underscoring the sensitivity of the 
proteomic approach. In contrast to these results, the patterns of viral proteins at 2 dpi were 
comparable between RV-HB15 and RV-BADwt (Figure 1B). This indicated that the protein 
expression of these two viruses was highly conserved over the passaging on human fibroblasts. 
This was corroborated by the patterns observed at 4 dpi (Figure 1C). As expected, the pattern 
changed from 2 to 4 dpi for both viruses. At 2 hpi and 2 dpi, regulatory proteins, like IRS1, or 
proteins for DNA replication, like UL44 were most prominent (Figure 2 and Table 1). Note that, at 
this time point, pUL44 was the most abundant protein in infected cells. The levels of the regulatory 
proteins IE1 (UL123), TRS1 and IRS1 already peaked at 2 dpi. These three were the only viral 
proteins that appeared to be downregulated, resulting in a decreased abundance at 4 dpi (Figure 2). 
At the later time point, structural proteins more prominently shaped the pattern of expression in 
HCMV infected cells, pp65 being by far the most abundant representative. Surprisingly, however, 
UL44 was also highly expressed at 4 dpi, although other proteins, involved in DNA replication did 
not reach that level. The reason for this abundance of UL44 in HCMV infected fibroblasts is 
unclear at this point. 
The proteomic approach shown here provided an impressive reflection of the long known burst 
of viral protein expression in infected fibroblasts. Whereas viral proteins constituted below 1% of 
the total protein mass in infected cells at 2 hpi, this increased to over 20% at 4 dpi (data not 
shown). Given the long half-life of many abundant cellular proteins, these results underscore the 
intensity with which HCMV diverts the cellular biosynthesis to its own use.  
2.2. Comparable Impact of RV-HB15- and RV-BADwt-Infection on the Cellular Proteome 
Proteomic analyses of the expression patterns of viral proteins in infected HFF displayed 
relatively conserved patterns between two different AD169 derived viruses. To test the influence of 
the two viruses on the levels of cell proteins in infected HFF, the mass spectrometry data of 
infected fibroblasts were analyzed with regard to cellular proteins (Figure 3 and Supplementary 
Table 1). Uninfected cells (mock) that were collected at different times after passage showed a 
proteomic pattern that displayed little change over time. This result compellingly documented the 
accuracy and the reproducibility of the method. The protein pattern of cells that were infected for 2 
hours was identical to the pattern of mock infected HFF for both tested viruses. This was not 
surprising, as no gross changes were expected to occur at this early time. The pattern started to 
change at 2 dpi, and these changes were even more pronounced at 4 dpi. The alterations were 
consistent with the results of many reports detailing the dramatic impact of HCMV infection on 
cellular gene expression [1,33,34]. Little differences were, however, seen between RV-HB15- and 
RV-BADwt-infected cells at any of the tested time points. This indicates that HCMV infection with 
AD169-derived viruses results in a rather uniform pattern of changes in the infected cell proteome 
(details of the data set can be found in Supplementary Table 1). Further analyses are, however, 
required to investigate if the pattern of cell protein expression varies, when viruses other than 
AD169-derivatives are analyzed. In addition the experimental setup chosen here can only provide a 
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pattern-analysis of the infected cell proteome. A more detailed insight into the HCMV-induced 
changes of particular host cell proteins will await further analyses.  
Figure 1. Proteomic analysis of viral proteins expressed in infected HFF. Fibroblasts 
were infected with RV-HB15 or RV-BADwt. At 2 hpi, 2 dpi, and 4 dpi, the cells were 
collected and analyzed, using nanoUPLC mass spectrometry. The relative abundance of 
individual proteins is shown in the pie charts. TOP3-Intensity was calculated as the 
average intensity of the three best ionizing peptides and is proportional to the molar 
amount of the respective protein in the sample. Proteins were sorted in decreasing 
abundance according to the values determined for four-day RV-HB15 infected 
fibroblasts and numbered accordingly, as indicated in the box. (A) samples obtained for 
analysis at 2 hpi; (B) samples obtained for analysis at 2 dpi; (C) samples obtained for 
analysis at 4 dpi.  
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Figure 2. Time course of viral protein levels in infected HFF. The data shown in the 
pie charts in Figure 1 are displayed in bar chart format to show the course for each 
individual protein. (A) and (C), viral proteins in RV-HB15 infected cells. (B) and (D), 
viral proteins in RV-BADwt infected cells. Note that the scales are different in (A) and 
(B) versus (C) and (D). TOP3-intensity was calculated as the average intensity of three 
best ionizing peptides and is proportional to the molar amount of the respective protein 











Figure 3. Proteomic analysis of cellular proteins in infected HFF. Fibroblasts were 
infected with RV-HB15 or RV-BADwt. After 2 hpi, 2 dpi or 4 dpi, the cells were 
collected and analyzed using nanoUPLC mass spectrometry. The relative frequency of 
the viral proteins in the samples is shown in the pie charts. Proteins were sorted 
according to frequencies found in four day RV-HB15 infected fibroblasts, displayed 
from left to right in the caption. The 100 most frequent proteins in RV-HB15 infected 





2.3. Conserved Stoichiometry of Viral Proteins in Virions of AD169-Derived Viruses 
Viral protein levels in HFF were comparable between the two AD169-derived viruses. We next 
asked the question, if this conservation was also reflected in the proteomes of virions from the 
different viruses. For this, also two AD169 variants were used that did not express the most 
abundant tegument protein pp65, in addition to three pp65positive (pp65-pos) viruses. Proteomic 
analyses showed a striking level of similarity in the protein pattern of the three pp65-pos viruses 
(RV-HB5; RV-HB15; RV-BADwt) and the two pp65-negative (pp65-neg) viruses (RV-Hd65;  
RV-KB14), respectively (Figure 4). As expected, the most prominent constituent of the pp65pos 
viruses was pp65, followed by the major capsid protein, pp71, pp150 and pUL94. These results 
were comparable to what has been published before for the proteome of AD169 virions [25]. There 
was some variation in the relative molarity of pp65, which is a non-essential tegument protein [18]. 
The number of pp65 molecules that are included in the tegument may thus vary. Accordingly, the 
relative copy numbers of some of the tegument proteins, known to interact with pp65 [36–38] 
showed subtle alterations which may be related to variations in pp65 content. There were also some 
differences in the ranking of abundance of some other virion proteins, compared to previously 
published data [25]. We do not know the reasons for this at this point. Different infection and 
particle purification strategies, e.g., with regard to the time point of collection of infectious 
supernatant or with regard to ultracentrifugation may account for these variations. In addition, 
different mass spectrometry protocols were used. In our study, exogenously added enolase was 
employed as an internal standard, providing a high level of confidence with respect to relative 
quantification. However, more detailed analyses of the virion composition, including different 
strains, will have to be performed to more accurately display relative abundances of individual 
proteins in HCMV virions. 
The compositions of the two pp65neg viruses and the three pp65pos viruses were virtually 
identical, except for the lack of pp65 in the former (Figure 4). Note that RV-Hd65 is a derivative of 
AD169-BAC [29], the BAC, used for reconstitution of RV-HB15 (AD169-RV), and RV-KB14 is a 
derivative of pAD/cre [30], the BAC used for reconstitution of RV-BADwt. The slight differences 
seen in the protein pattern of the two parental viruses were not detectable in the pp65neg variants.  
Taken together these results showed that the viral protein composition of extracellular virions of 
AD169 descendants is subject to only subtle variations. This argues in favor of a conserved process 
of viral protein packaging within a given strain of HCMV. Remarkably, however, the pattern did 
not change dramatically by removing pp65 which, in our analyses, comprised up to one third of the 
total mass of viral proteins in the particle. Despite the absence of pp65, tegument assembly 
appeared to follow along a controlled process that resulted in protein patterns that were comparable 
between pp65pos and pp65neg viruses. It is likely that the network of tegument protein 
interactions, as reported by others [37,39] will be instrumental to this process; yet this hypothesis 
still awaits confirmation.  
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Figure 4. Proteomic analysis of HCMV proteins from purified virions. Virions were 
purified by glycerol-tartrate-gradient-centrifugation from supernatants of 6–7 day 
infected foreskin fibroblasts. The pp65pos strains (RV-HB5, RV-HB15, and RV-BADwt) 
and the pp65neg strains (RV-Hd65 and RV-KB14) were used for analysis. Purified 
virions were analyzed using nanoUPLC mass spectrometry. The stoichiometry of 
individual proteins, normalized to exogenously added enolase is shown in the pie 
charts. Proteins were sorted in decreasing abundance according to the values obtained 




3. Experimental Section 
For proteomic analyses of infected cells, HFF were infected at a multiplicity of infection (MOI) 
of 1 in each case. For this, culture supernatants from 6–7 day infected HFF had been collected and 
stored at 80 °C. One sample was thawed and analyzed for infectivity, using IE1 (UL123) specific 
antibody staining. An MOI, based on serial dilution of the supernatants was calculated. For 
proteomic analyses of virions, cells were infected in a way that all cells showed a cytopathic effect 
at day one of infection. 
Mass spectrometry was performed as described elsewhere [32]. Briefly, sample preparation and 
protein digestion of virions were performed as described in [32]. Nanoscale LC separation of 
tryptic peptides was performed with a nanoAcquity system (Waters Corporation, Manchester, UK) 
equipped with a BEH C18 1.7 m, 75 m × 150 mm analytical reversed-phase column (Waters 
Corporation) in direct injection mode as described before [40]. Mobile phases, gradients and flow 
rates were chosen as described in [32] and 0.2 L of sample (50 ng of total protein) was injected 
per technical replicate. Running conditions were as described in [32]. 
Mass spectrometric analysis of tryptic peptides from infected cells and virions was performed in 
quintuplicate using a QTOF-Premier mass spectrometer (Waters Corporation) with a typical 
resolution of at least 10,000 FWHM (full width half maximum) as described before [32]. All 
analyses were performed in positive mode ESI using instrument settings and nanoLockspray 
calibration as described before [32]. 
Continuum LC-MS data were processed and searched using ProteinLynx GlobalSERVER 
version 2.5.2 (Waters Corporation) [41]. Protein identifications were obtained by searching a 
custom compiled database containing sequences of human and HCMV proteins from the Uniprot 
database. Sequence information of enolase 1 (S. cerevisiae) and bovine trypsin were added to the 
databases to normalize the data sets or to conduct absolute quantification as described before [42]. 
Database search was performed allowing a maximal mass deviation of 15 ppm for precursor ions and 
30 ppm for fragment ions with one missed cleavage allowed and fixed carbamidomethyl-cysteine 
and variable methionine oxidation set as the modifications. For valid protein identification, the 
following criteria had to be met: at least two peptides detected with together at least seven 
fragments. The false positive rate for protein identification was set to 1% based on search of a triple 
randomized database. Guideline identification criteria were applied for all searches.  
For the absolute quantification of proteins, we employed a well established label-free quantitative 
proteomics workflow that we have previously used both for the quantification of nanoparticle 
protein coronas [40] and also higher complexity samples such as myelin [42]. Label-free 
quantification using the TOP3-approach allows both the relative and absolute quantification of 
proteins. TOP3-Intensity was calculated as the average intensity of three best ionizing peptides 
and is proportional to the molar amount of the respective protein in the sample [43]. Values were 
normalized across technical replicates and samples using ISOQuant [44]. For the proteomic 
analysis of HFF, cells were infected at an MOI of 1 for 2 h, 2 d, or 4 d, respectively. After that, 
cells were collected by removing the culture supernatant and subsequently adding 5 mL of 50 mM 
EDTA solution in 1× PBS. They were detached from the support after an incubation time of  
5–15 minutes at 37 °C and were subsequently centrifuged at 470 g for five minutes. The pellet was 
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resuspended in 10 mL of PBS and the cells were centrifuged again as described above. This was 
repeated once. The final pellet was resuspended in 2–3 mL PBS and the cells were counted.  
0.5 millions of cells each were transferred to 1.8 mL Eppendorf tubes and the cells were again 
centrifuged at 1,300 g for three minutes. The supernatant was carefully removed and the tubes were 
stored at 80 °C until further mass spectrometry. The samples were subsequently analyzed by mass 
spectrometry as detailed above. 
Virions were purified from the culture supernatants of HCMV infected human foreskin fibroblasts 
(HFF). For this, cells were infected in a way that all cells showed a typical cytopathic effect at day 1 
after infection. Culture supernatants were collected at 6–7 days of infection and were purified by 
gradient ultracentrifugation as originally described by Irmiere and Gibson [15]. For this, the culture 
supernatants were collected and centrifuged for 10 min at 1,900 g to remove cells and debris. After 
that, the supernatant was collected and centrifuged at 95,000 × g (70 min, 10 °C) in a SW32Ti rotor 
in a Beckman Optima L-90K ultracentrifuge. Pellets were resuspended with 2 mL 1× PBS.  
Na-tartrate gradients were prepared directly before use. For this, 4 mL of 35% Na-tartrate solution 
in 0.04 M Na-phosphate buffer, pH 7.4 were applied in one, and 5 mL of 15% Na-tartrate/30% 
glycerol solution in 0.04 M Na-phosphate buffer, pH 7.4 were applied in the second column of a 
gradient mixer. The gradients were prepared by slowly dropping the solutions into Beckman 
UltraclearTM centrifuge tubes (14 × 89 mm), positioned at an angle of 45°. 1 mL of the viral 
particles was then carefully layered on top of the gradient. Ultracentrifugation was performed in 
slow deceleration mode in a Beckman SW41 swing out rotor for 60 min at 90,000 g and 10 °C. 
Particles were collected from the gradient, illuminated by light scattering. For this, the centrifuge 
tube was penetrated with a hollow needle below the band and samples were carefully drawn from 
the tube with a syringe. The particles were then washed once with 1× PBS and centrifuged in a 
SW41 swing out rotor for 90 min at 100,000 g and 10 °C. Following that centrifugation step, the 
pellets were resuspended in 120–150 L 1× PBS. The protein concentration of the purified virions 
was determined with the Pierce BCA Protein Assay Kit (Thermo Scientific, Bonn, Germany). 
Twenty g aliquots of the virions were then pelleted by ultracentrifugation for 60 min, 100,000 g at  
10 °C and stored at 80 °C for analysis by mass spectrometry.  
4. Conclusions  
We are only at the advent in our understanding of the complexity of HCMV particle 
morphogenesis. Mass spectrometry has provided a technical leap in our attempts to understand the 
molecular events that direct the formation and release of infectious progeny. The results indicate 
that there are only limited variations in both the intracellular and the virion proteome with regard to 
viral proteins in derivatives of one particular laboratory strain, AD169. This argues in favor of a 
highly ordered process of viral protein expression and interaction to ultimately result in packaging 
and virion release. In line with this, also the proteome of cellular proteins appeared to be conserved 
following infection with different viruses. However, the data also immediately foster the request 
for analogous proteomic analyses of other HCMV strains, clinical isolates being of particular 
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Abstract: Development of a vaccine against congenital infection with human 
cytomegalovirus is complicated by the issue of re-infection, with subsequent vertical 
transmission, in women with pre-conception immunity to the virus. The study of 
experimental therapeutic prevention of re-infection would ideally be undertaken in a 
small animal model, such as the guinea pig cytomegalovirus (GPCMV) model, prior to 
human clinical trials. However, the ability to model re-infection in the GPCMV model 
has been limited by availability of only one strain of virus, the 22122 strain, isolated in 
1957. In this report, we describe the isolation of a new GPCMV strain, the CIDMTR 
strain. This strain demonstrated morphological characteristics of a typical Herpesvirinae 
by electron microscopy. Illumina and PacBio sequencing demonstrated a genome of 
232,778 nt. Novel open reading frames ORFs not found in reference strain 22122 
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included an additional MHC Class I homolog near the right genome terminus. The 
CIDMTR strain was capable of dissemination in immune compromised guinea pigs, 
and was found to be capable of congenital transmission in GPCMV-immune dams 
previously infected with salivary gland-adapted strain 22122 virus. The availability of a 
new GPCMV strain should facilitate study of re-infection in this small animal model. 
Keywords: guinea pig cytomegalovirus; cytomegalovirus strain variation; CMV 
immune evasion; congenital cytomegalovirus infection; congenital CMV vaccines 
 
1. Introduction 
Development of a vaccine against human cytomegalovirus (HCMV) is a major public health 
priority [1]. The suggestion that passively transferred antibody protects the fetus against infection 
and injury [2] has driven efforts to develop recombinant subunit vaccines targeting major envelope 
glycoproteins, such as glycoprotein B (gB) [3,4]. Although clinical trials of recombinant gB 
vaccines have shown some degree of effectiveness in preventing HCMV infection and disease in 
high risk populations [5,6], vaccine mediated protection with vaccines targeting this single 
envelope glycoprotein appears to be incomplete. Moreover, the effectiveness of natural immunity 
in preventing congenital HCMV infection and its attendant sequelae is itself a matter of some 
controversy. A number of recent studies have described fetal HCMV transmission in women with 
preconception immunity, due to re-infection with new strains of HCMV [7–12]. Such infections 
can produce sequelae identical to those observed in congenitally infected infants born to women 
with primary HCMV infection in pregnancy [13,14]. These observations certainly complicate 
HCMV vaccine design, and suggest that: (1) for full protection, an HCMV vaccine may need to 
elicit responses superior to those conferred by natural immunity; (2) there may be a strong rationale 
for vaccinating women of childbearing age who are already HCMV seropositive, in addition to 
targeting and immunizing seronegative women, toward the goal of preventing re-infection with 
subsequent transmission of the “new” strain.  
Several clinical studies have documented the phenomena of re-infection in women of 
childbearing age. In one prospective study performed at the University of Alabama-Birmingham, 
serum specimens from 46 women with preconceptional immunity against HCMV obtained during a 
previous pregnancy and a new pregnancy were analyzed for antibodies against the strain-specific 
epitopes of HCMV glycoprotein H (gH), and the nucleotide sequences of the gH gene from seven 
HCMV isolates were determined. Ten of the 16 mothers with infected children (62%) acquired new 
antibody specificities against gH, as compared with only 4 of the 30 mothers of uninfected infants 
(13%), suggesting that acquisition of an infection with a virus expressing a novel strain-specific gH 
genotype during pregnancy was associated with congenital transmission [9]. In another study in 
Brazil that followed 7,848 women prospectively, sera from 40 mothers of congenitally infected 
infants and 109 mothers of uninfected control newborns were analyzed for strain-specific anti-HCMV 
antibodies, based not only on polymorphisms within gH binding sites, but also a second antibody 
reactivity site on gB [14,15]. Seven of 40 (17.5%) study women, but only 5 of 109 (4.6%) controls 
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acquired antibodies reactive with new HCMV strains during pregnancy (p = 0.002), suggesting that 
maternal reinfection by new strains of HCMV is a major source of congenital infection in this 
population. In a study of re-infection (based on acquisition of new gB and/or gH antibody 
specificities) in 205 seropositive women performed by Ross and colleagues at UAB, approximately 
one-third of the study participants (59 of 205) were noted to have reinfection, using this definition, 
during follow-up [10]. The molecular and immunological correlates of re-infection are unclear. 
There is some evidence that gB polymorphisms in clinical isolates may be less important for  
re-infection than polymorphisms in gH and other envelope glycoproteins. In a study in Brazil, 
infections in immunocompetent women with strains corresponding to more than one gB genotype 
were not common [16]. Additionally, in a study of the HCMV strains acquired longitudinally in 
women who developed infection in spite of being enrolled in the recombinant gB vaccine trial at 
UAB [5], there was no selection for or against any non-vaccine gB subtype, in spite of women 
being immunized only with gB protein corresponding to the Towne (gB1 subtype) strain [17]. 
Other evidence suggests that the response (or lack thereof) to the envelope glycoprotein N (gN) 
may play a role in predisposing to re-infection with new HCMV strains expressing heterologous gB 
and/or gH genotypes [18–20].  
Irrespective of the mechanism(s) involved, the issue of re-infection is a major challenge in 
vaccine design. There is increasing evidence that congenital HCMV infections after nonprimary 
maternal infections can lead to symptomatic disease and substantial long-term sequelae. Notably, 
recent evidence from a study at UAB indicated that the incidence of hearing loss in infants infected 
after nonprimary maternal infection was similar to that in infected infants born to women with 
primary infection [13], although in this study, infants in the primary infection group were more 
likely to demonstrate progressive and severe or profound hearing loss, compared to infants in the 
non-primary group.  
Since the consequences of re-infection and congenital transmission with a newly acquired strain 
in pregnant seropositive women can be similar to those that occur after primary infection and 
transmission in CMV-seronegative women [10,11,13,14], the study of re-infection in a small 
animal model of congenital transmission would be very useful for the modeling of vaccine strategies 
to prevent maternal re-infection [21,22]. Ideally, HCMV reinfection would be studied in an animal 
model prior to clinical vaccine trials. Unfortunately, the strict species-specificity of cytomegaloviruses 
precludes preclinical testing of HCMV vaccines in animals. However, a number of rodent and 
primate cytomegaloviruses are useful in modeling HCMV vaccines and therapies, given the 
conservation of many immunogenic structural proteins amongst the various viruses [23–25].  
Among the small animal models, the guinea pig cytomegalovirus (GPCMV) is uniquely useful, 
since, in contrast to other rodent models, transplacental infection of the fetus occurs following viral 
challenge during pregnancy [24,26]. Hence, the GPCMV model is particularly well-suited to the 
study of vaccines against congenital infection. However, until now this model has relied 
exclusively on a single strain of GPCMV, 22122, isolated by Hartley in 1957 [27]. While it has 
been feasible to study re-infection by experimentally inoculating strain 22122 virus into naturally 
seropositive guinea pigs [28], the lack of defined genetic information on other GPCMV strains 
(e.g., those presumably latent in the seropositive animals used in the above mentioned studies) has 
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made it impossible to study of the role of strain variation in fetal infection in the setting of 
preconception immunity.  
In this report, we describe the isolation of a novel strain of GPCMV, the CIDMTR strain. This 
communication represents the first report of detailed characterization of a GPCMV isolate since the 
original publication of isolation of the 22122 strain [27]. Although sequence and ORF structure 
were generally well conserved with the 22122 strain of GPCMV, the CIDMTR strain demonstrated 
some differences in genome structure, particularly in the right-hand end of the viral genome. There 
are also substantive differences in some protein coding sequences between the two strains, 
including sequences in envelope glycoproteins, suggesting that these proteins may have been the 
targets of immune selection during the evolution of GPCMV in the guinea pig host. We describe in 
this report the morphology and DNA sequence of this newly isolated strain, and report preliminary 
experiments regarding its pathogenesis in vivo. The availability of a second strain of GPCMV 
should enable the study of re-infection and, potentially, the development of vaccine strategies 
designed to protect against maternal re-infection in the guinea pig model of congenital 
cytomegalovirus infection. 
2. Results and Discussion 
2.1. Isolation of the CIDMTR Strain 
In the course of ongoing vaccine and pathogenesis studies, guinea pigs were screened at the time 
of purchase for GPCMV antibodies, using an ELISA based on GPCMV strain 22122 [29]. Within a 
group of 24 guinea pigs purchased from a commercial source, 5 (21%) were found to be  
GPCMV-seropositive by ELISA. Western blot analysis was performed using sera from 
commercially purchased, ELISA-positive animals using purified strain 22122 virions as the source 
of target antigens (Figure 1). These studies confirmed that sera from these animals were broadly 
cross-reactive with GPCMV strain 22122 virion-associated polypeptides, suggesting that these 
animals were infected with GPCMV strains that were closely related antigenically to strain 22122.  
One of the seropositive animals identified in these preliminary experiments was immunosuppressed 
with cyclophosphamide, 100 mg/kg [32], and seven days later the animal was sacrificed and 
salivary gland (SG) homogenates harvested. Presumptive virus in the SG homogenate was 
passaged in vivo by inoculation of two GPCMV seronegative inbred strain 2 guinea pigs with 1 mL 
SG homogenate by subcutaneous route in the dorsal neck. Both of these animals demonstrated 
DNAemia (3.2 and 6.9 × 103 genomes/mL of blood, respectively) at 14 days post-inoculation. 
Three weeks following inoculation, these animals were also immunosuppressed with 100 mg/kg of 
cyclophosphamide. One week later, these animals were sacrificed and SG homogenates were 
cultured on guinea pig lung fibroblast cells (GPLs). Eleven days after inoculation plaques with 
characteristic cytopathic effect (CPE) were observed in one of the SG homogenate cultures 
(designated P0). Supernatant from this flask was used to inoculate GPLs to generate a P1 stock of 
virus. When CPE was extensive (approximately 2 weeks later), an aliquot was removed for electron 
microscopy (EM) studies (described below, Section 2.2) and the remainder of this flask was 
expanded for large-scale virus propagation (20 flasks). These flasks were then incubated for an 
additional week prior to harvest of P2 viral stock (Figure 1b). Some of these infected flasks were 
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used for DNA purification for Illumina MiSeq and Pacific Biosciences PacBio RS sequencing, as 
described below. The remainder of this stock was used for in vivo challenge experiments in guinea 
pigs, as described in Section 2.4. 
Figure 1. Western blot analysis of sera from three “naturally seropositive” commercially 
purchased outbred Hartley guinea pigs. (a) Western analysis using a pooled, high-titer 
polyclonal anti-GPCMV antisera from guinea pigs immunized with adjuvanted viral 
particles [30] or sera from three “natural seropositive” guinea pigs (GP1, GP2, GP3) 
obtained from a commercial supplier, using sucrose gradient-purified virions from 
22122 strain as target antigen. Two independently derived, monospecific anti-GPCMV 
gB antibodies (moab 29-29 [31] (gB1) and moab IE321 (gB2)) are included as controls. 
(b) Photomicrographs comparing CPE of low-passage (P2) CIDMTR virus (right panel) 
to GPCMV strain 22122 (left panel) following infection of GPL cells. CIDMTR plaques 
are more rounded, with elliptical appearance, compared to the more spindle-like 
morphology of 22122-infected fibroblasts. Plaques photographed at 60× magnification. 
 
2.2. Morphological Analyses by EM 
To confirm that the isolated virus had morphological characteristics of a cytomegalovirus, EM 
was performed. Analysis of P1 virus stock by conventional microscopy (Section 2.1) revealed 20% 
of the cells showed cytopathic effect. Cells were enlarged with large intranuclear and 
intracytoplasmic basophilic inclusions visible upon examination by light microscopy on thick 
section of plastic preparation stained with Toluidine blue (data not shown). Ultrastructurally, both 
intranuclear and intracytoplasmic inclusions were noted, interpreted as representative of nuclear 
and cytoplasmic viral factories (Figure 2A,B). Nuclear inclusions were typical for the center of 
replication and assembly characteristic of Herpesvirinae (Figure 2C). These nuclear factories 
showed a large amount of fibrillary electron dense material admixed with moderate to large 
numbers of empty A-capsids, scaffold-containing B-capsids, and DNA-containing C-capsids that 
are characteristic of herpesvirus capsid formation and genome packaging (Figure 2C; most capsids 
in this image are B-capsids). By comparison, a virtually identical appearance was noted in EMs 
from strain 22122-infected fibroblasts (Figure 2H). First envelopment was acquired at the inner 
nuclear membrane. The EM morphology supports a model whereby de-envelopment of 
nucleocapsids takes place at the outer nuclear membrane during egress, with the second 
envelopment and tegumentation occurring in the cytoplasm factory (Figure 2D). Rearrangement of 
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Golgi cisterns, Golgi vesicles, multivesicular body and endoplasmic reticulum in conjunction with 
formation of nucleocapsids produced large aggregations that were often mixed with electron dense 
material. Numerous dense bodies were present in the intercellular space (Figure 2A,F). On negative 
contrast preparation, a large number of non-infectious enveloped particles (220.24 ± 48.15 nm) and 
dense bodies (357.83 ± 97.85 nm) were observed (Figure 2G). Infectious mature virions consisted 
of an envelope containing a 116.5 ± 2.68 nm in diameter icosahedral capsid with capsomeres of 
approximately 11.66 ± 1.87 nm. The CIDMTR strain of GPCMV presented similar cytopathic and 
pathogenic effects as those demonstrated by ATCC strain 22122 [33–35]. Nevertheless, some 
differences were noted between these two strains. The ATCC strain in contrast to the CIDMTR 
strain, demonstrated more efficient infection of fibroblasts, even at the same multiplicity of 
infection (MOI; MOI of 1), with over 80% of fibroblastic cells exhibiting cytopathic effect. The 
nuclear and cytoplasmic factories were less pronounced in the CIDMTR-infected cells, with 
generation of reduced quantities of infectious and non-infectious enveloped viral particles and 
dense bodies (data not shown). 
2.3. Sequencing and Sequence Analysis  
Viral DNA (P2) was purified from the CIDMTR strain after two passages in GLFs and subjected 
to sequence analysis using the MiSeq and PacBio platforms as described in Section 3. The 
CIDMTR genome was 232,778 nt in length. Overall sequence homology to strain 22122 (accession 
#KC503762.1) was 98%, consistent with the hypothesis suggested by immunoblotting that 
CIDMTR is a GPCMV and not a novel and distinct betaherpesvirus of guinea pigs. As discussed 
further in Section 4, a possibility existed that genetic diversity of GPCMV isolates could be 
restricted due to bottlenecks in the breeding history of Hartley guinea pigs, from which both 22122 
and CIDMTR are derived. Historically, HCMV strains were differentiated on the basis of 
restriction pattern polymorphisms. Epidemiologically unrelated isolates, considered unique HCMV 
strains, exhibit predominantly identical restriction patterns with occasional unique fragments. To 
compare CIDMTR to 22122 in these terms, genomic sequences for each virus were used to 
generate in silico-predicted restriction patterns for three enzymes (EcoR I, Hind III, and Xba I). As 
shown in Figure 3a, the majority of fragments matched between the two virus genomes in all three 
predicted restriction enzyme patterns, while for each restriction pattern a few unique (unmatched) 
fragments were evident. These results are consistent with CIDMTR and 22122 being distinct 
GPCMV strains in a manner similar to that of HCMV strains.  
Sequence comparison revealed three regions of striking discrepancies between the two genome 
sequences (Figure 3b). The first was located between nucleotides 199227 and 203071 of the 22122 
sequence. Within this 3,845-bp region, 1,437 bps were entirely missing from the CIDMTR 
genome, while the remainder corresponded with a poorly conserved (50% average nucleotide 
conservation) 2,366-bp region in CIDMTR. As a result, one of the three gp138 family ORFs 
previously annotated in 22122 was missing from CIDMTR (Figure 3c). Curiously, this region 
corresponds to a hot-spot for spontaneous deletions that occur in response to over length genomes 
in GPCMV that also roughly corresponds to regions of instability/rearrangements in HCMV and 
rhesus cytomegalovirus [36]. 
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The second region of discrepancy was located between nucleotides 221608 and 224743 of the 
CIDMTR sequence. Within this 3,136-bp region, 1,424 bps were entirely missing from the 22122 
genome, and the remainder correspond with a poorly conserved (68% average nucleotide conservation) 
1,684-bp region in 22122. Surprisingly, the additional sequences in CIDMTR encoded a fourth 
putative MHC class I homolog, annotated gp147.1, that lies adjacent to three MHC class I 
homologs (gp147, gp148, and gp149) that were previously identified in 22122 (Figure 3c).  
Figure 2. Transmission electron microscopy (EM) microphotographs of fibroblasts 
infected with the CIDMTR Strain of GPCMV. (A) Plastic embedded preparation 
contrasted with uranyl acetate/lead citrate of two enlarged fibroblasts showing cell 
intranuclear and cytoplasmic viral inclusions and numerous dense bodies (white 
arrowheads) in the intercellular space (bar = 10 m). (B) Magnification of another 
CIDMTR-infected cell revealed nuclear (N) viral replication and nucleocapsid assembly 
sites (small square), as well as a large maturation site (asterisk) and dense body 
formation in the cytoplasm (large square, bar = 2 m). (C) Additional magnification in 
which replication and capsid assembly in the nucleus (small square) is appreciated; note 
empty capsids (arrow) and DNA containing nucleocapsids (arrowhead; bar = 0.5 m). 
(D) Magnification of virus maturation sites within the cytoplasm (large square in panel 
(B)) reveals electron dense material formed by aggregation of nucleocapsids and cell 
organelles such as Golgi systems, endoplasmic reticulum and vesicles (bar = 0.5 m). 
(E) Capsid is demonstrated becoming coated with tegument proteins and then acquiring 
its final envelope by budding into vesicles (arrows; bar = 0.5 m). (F) Several dense 
bodies are present in the intercellular space (bar = 0.5 m). (G) Negative contrast 
preparation of enveloped B-capsid (arrow) and dense body (asterisk, bar = 0.5 m) is 
demonstrated. (H) EM of strain 22122-infected cells demonstrating virtually identical 
morphology; A, B and C capsids are identified as described in text. 
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The third region of discrepancy was located between nucleotides 230176 and 231697 of the 
22122 sequence. Within this 1,522-bp region, 107 bps were missing from the CIDMTR genome, 
and the remainder correspond with a poorly conserved (51% average nucleotide conservation) 1,383-bp 
region in CIDMTR. This discrepant region partially overlaps gp149 and results in CIDMTR- and 
22129-encoded gp149 proteins that lack amino acid homology in residues 1-134 (22122) or 1-164 
(CIDMTR) but are highly conserved within the remaining C-terminal 494 residues. 
Finally, like 22122, the CIDMTR genome was found to have direct terminal repeat sequences, 
although the CIDMTR repeats were slightly shorter (841 nt) than those in 22122 (953 nt).  
Figure 3b highlights the regions of DNA sequence dissimilarity when the CIDMTR strain is 
compared to strain 22122. Figure 3c illustrates in map format the regions of genomic discontinuity. 
To confirm that these large-scale rearrangements did not arise during passage of virus in cell 
culture, PCR and sequence analyses were performed directly on both DNA purified from the 
original salivary gland homogenate (no tissue culture passage), and on DNA from the tissue 
culture-derived isolate (P0), with identical results (see Section 2.5 and Figure 4). The sequences of 
the PCR-generated fragments were identical to the Illumina/PacBio genome sequence, confirming 
that discontinuities with strain 22122 did not arise as an artifact of tissue culture passage. It 
therefore appears that, as it appears in its natural host, the CIDMTR strain lacks the gp138.1 gene 
found in 22122. Similarly, 22122 lacks the fourth MHC class I homolog gene (gp147.1) found in 
CIDMTR. As the original SG extract from which 22122 was cultured is no longer available, it is 
not possible to conduct similar studies to determine whether gp147.1 was absent from 22122 prior 
to its initial isolation in cell culture or was lost during subsequent in vitro/in vivo passage. 
Nevertheless, these results suggest that naturally occurring strains of GPCMV may be polymorphic 
with respect to the presence or absence of entire genes. Similar findings have been observed when 
comparing the Smith strain of murine cytomegalovirus to strains isolated from wild mice [37]. 
Further analyses of other primary virus isolates from “naturally infected” guinea pigs will be 
necessary to confirm this hypothesis and to determine if such polymorphisms are limited to specific 
genes, such as gp138.1 and perhaps gp147.1, or include others. 
Table 1 summarizes the predicted ORFs identified in the CIDMTR strain. ORFs that are highly 
conserved in cytomegaloviruses are noted in the table in upper case/bold font (e.g., GP55). In 
contrast, ORFs appearing unique to GPCMV are noted in lower case (e.g., gp138). The “C” 
designation in Table 1 refers to the complimentary strand. Splicing sites are predicted based on 
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previously published reports and these need empiric confirmation in future studies unless otherwise 
indicated (Figures 4 and 5); exons are described as coding exons.  
Figure 3. Strain-specific genome structure differences between CIDMTR and 22122.  
(a) In silico analysis of predicted restriction endonuclease profiles for CIDMTR strain 
and 22122 (ATCC) strain with enzymes EcoRI, HindIII, and XbaI. Predictions and 
profile generated using program CLC Main Workbench 6 [40]. (b) Dot-matrix comparison 
of CIDMTR vs. 22122 genomic sequences. Two genome regions demonstrating 
sequence variability resulting in ORFs unique to each strain are indicated by shaded 
boxes. (c) Linear map comparison of the major areas of genome discontinuity. Linear 
maps prepared using XPlasMap [41]. Colored boxes in blue represent predicted 
conserved ORFs. Light red and green colored ORFs demonstrate discordance between 
the two strains. In the CIDMTR strain, an additional ORF not annotated in 22122, 
149.1, is also noted (dark red). Dashed lines indicate the positions where the sequences 
































































Table 1. GPCMV Strain CIDMTR Predicted ORFs. 
GPCMV Open Reading Frames (ORFs): CIDMTR Strain 
ORF Strand Begin End Codons Notes 
gp1 C 12,464 12,769 101 GPCMV MIP 1 ; CC chemokine homolog 
gp2  14,840 15,685 281 Homology to MCMV M69a 
gp3 C 17,197 19,563 788 Homology to THV T5b; US22 superfamily 
gp4 C 20,829 21,152 107 Homology to RCMV r136d 
gp5 C 26,721 27,818 365 Homology to MCMV m32a 
GP23 C 33,299 34,501 400 UL23 homolog; US22 gene superfamily 
GP24 C 34,739 35,956 405 UL24 homolog; US22 superfamily 
GP25  36,542 38,194 550 UL25 homolog; tegument protein 
GP26 C 38,360 39,043 227 UL26 homolog 
GP27 C 39,166 41,211 681 UL27 homolog 
GP28 C 41,311 42,378 355 UL28 homolog; US22 superfamily 
GP28.1 C 42,866 44,287 473 UL28 homolog; US22 superfamily 
GP29 C 44,653 46,623 656 UL29 homolog; US22 superfamily 
gp29.1 C 47,247 47,861 204 US22 superfamily 
GP30 C 49,082 50,800 572 UL30 homolog 
GP31  51,094 52,572 492 UL31 homolog 
GP32 C 52,665 54,365 566 UL32 homolog 
GP33  54,585 55,868 427 UL33 homolog; 7-TMR GPCR superfamily 
GP34  56,221 57,804 527 UL34 homolog 
GP35  58,008 59,666 552 UL35 homolog 
GP37 C 59,788 60,711 307 UL37 homolog 
GP38 C 61,068 61,988 306 UL38 homolog 
gp38.1 C 62,705 63,262 185 Positional homolog of HCMV UL40 
gp38.2 C 63,620 64,933 437 Positional homolog of HCMV UL41a 
gp38.3 C 65,624 66,478 284 Positional homolog of HCMV UL42 
gp38.4 C 66,997 67,362 121 Homology to RCMV r42d 
GP43 C 67,951 68,964 337 UL43 homolog 
GP44 C 68,952 70,175 407 UL44 homolog
GP45 C 70,887 73,673 928 UL45 homolog 
GP46 C 73,779 74,867 362 UL46 homolog 
GP47  74,674 77,787 1037 UL47 homolog 
GP48  77,784 84,155 2123 UL48 homolog 
GP48.2 C 84,238 84,468 76 UL48a homolog 
GP49 C 84,479 86,119 546 UL49 homolog 
GP50 C 86,088 87,158 356 UL50 homolog 
GP51 C 87,281 87,580 99 UL51 homolog; terminase subunit 
GP52  87,900 89,480 526 UL52 homolog 
GP53  89,473 90,459 328 UL53 homolog 
gp53.1 C 90,196 90,537 113 Homology to RhCMV rh86; YP_068179.1 
GP54 C 90,551 93,904 1117 UL54 homolog; DNA polymerase 
GP55 C 93,947 96,652 901 UL55 homolog; glycoprotein B 
GP56 C 96,549 98,816 755 UL56 homolog; terminase subunit 
GP57 C 98,967 102,650 1227 UL57 homolog 
gp57.1 C 104,411 104,926 171 Homolog to RCMV r23.1d 
GP69 C 108,260 111,430 1056 UL69 homolog 
GP70 C 112,136 115,339 1067 UL70 homolog; helicase-primase 
GP71  115,338 116,114 258 UL71 homolog 
GP72 C 116,277 117,350 357 UL72 homolog; dUTPase 
GP73  117,432 117,833 133 UL73 homolog; glycoprotein N 
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Table 1. Cont. 
GPCMV Open Reading Frames (ORFs): CIDMTR Strain 
ORF Strand Begin End Codons Notes 
GP73.5ex1  117,860 117,869 3  
GP73.5ex2  119,005 119,198 64  
GP74 C 117,780 118,904 374 UL74 homolog; glycoprotein O 
GP75 C 119,349 121,529 726 UL75 homolog; glycoprotein H 
GP76  121,694 122,533 279 UL76 homolog 
GP77  122,247 124,091 614 UL77 homolog 
GP78  124,473 125,717 414 UL78 homolog; 7-TMR GPCR superfamily 
GP79 C 125,914 126,861 315 UL79 homolog 
GP80  126,722 129,031 769 UL80 homolog; CMV protease 
GP80.5  127,610 129,031 473 UL80.5 
GP82 C 129,324 130,889 521 UL82 homolog; pp71 
GP83 C 131,109 132,809 566 UL83 homolog; pp65 
GP84 C 133,051 134,487 478 UL84 homolog 
GP85 C 134,785 135,696 303 UL85 homolog 
GP86 C 135,977 140,026 1349 UL86 homolog 
GP87  140,407 143,328 973 UL87 homolog 
GP88  143,231 144,499 422 UL88 homolog 
GP89ex2 C 144,545 145,675 376 UL89 homolog; terminase subunit, exon 2 
GP91  146,102 146,365 87 UL91 homolog 
GP92  146,362 146,991 209 UL92 homolog 
GP93  146,957 148,732 591 UL93 homolog 
GP94  148,644 149,681 345 UL94 homolog 
GP89ex1 C 150,032 150,913 291 UL89 homolog; terminase subunit, exon 1 
GP95  150,967 152,235 422 UL95 homolog 
GP96  152,468 152,830 120 UL96 homolog 
GP97  152,910 154,727 605 UL97 homolog; protein kinase 
GP98  154,747 156,531 594 UL98 homolog; alkaline nuclease 
GP99  156,444 156,965 173 UL99 homolog; pp28 
gp99.1  157,155 157,769 204 Homology to RCMV r4d 
GP100 C 157,278 158,327 349 UL100 homolog; glycoprotein M 
GP102  158,657 160,942 761 UL102 homolog 
GP103 C 161,127 161,852 241 UL103 homolog 
GP104 C 161,815 163,908 697 UL104 homolog; portal 
GP105  163,748 166,531 927 UL105 homolog; helicase-primase 
GP112ex1  176,745 177,498 315 UL112 homolog; replication accessory, ex 1 
GP112ex2  177,606 177,782  UL112 homolog; replication accessory, ex 2 
GP112ex3  178,115 178,131  UL122 homolog; replication accessory, ex 3 
GP114 C 179,126 179,920 264 UL114 homolog; uracil glycosylase 
GP115 C 179,986 180,762 258 UL115 homolog; glycoprotein L 
GP116 C 180,755 181,654 299 Homology to THV t116b; Fc receptor//Ig 
GP117 C 181,877 183,262 461 UL117 homolog 
gp119.1 C 184,418 185,167 249 Similar to MCMV in ACE95619.1 
GP121.2 C 185,160 185,834 224 Betaherpesvirus B7D8, accession AFK83957 
GP121.4 C 186,299 187,174 291 UL121 homolog; Tupaia t121.4, NP_116476 
GP122ex3 C 187,993 189,677 
677 UL122 homolog; HCMV IE2 GP122ex2 C 191,079 191,311 
§GP122ex1 C 191,403 191,518 
GP123ex3 C 189,907 190,985 
475 UL123 homolog; HCMV IE1 GP123ex2 C 191,079 191,311 
§GP123ex1 C 191,403 191,518 
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GPCMV Open Reading Frames (ORFs): CIDMTR Strain 
ORF Strand Begin End Codons Notes 
GP128  195,400 196,455 351 Similar to Bat HSV B126; US22 Family 
gp130  196,655 196,999 114  
GP129ex3 C 196,432 196,690 
178 Homolog of HCMV UL128 GP129ex2  196,768 196,890 
GP129ex1 C 196,974 197,128 
GP131ex2 C 197,133 197,469 191 Homolog of HCMV UL130  GP131ex1 C 197,550 197,788 
GP133 C 197,788 198,174 128 Homolog of HCMV UL131 
GP134 C 198,268 198,951 227  
gp138.2 C 199,367 200,875 502  
gp138.3 C 201,090 202,607 505  
gp139 C 202,706 204,793 695 THV T5; US22 superfamily 
gp140  204,522 204,929 135 Homology to CCMV UL132 
gp141 C 205,053 206,660 535 HCMV US23; US22 superfamily 
gp142 C 206,928 208,622 564 HCMV US24; US22 superfamily 
gp143 C 208,875 210,866 663 THV T5; US22 superfamily 
gp144 C 211,109 213,403 764 US26; US22 gene superfamily 
gp145 C 213,677 215,575 632 HCMV IRS1/TRS1; US22 superfamily 
gp146 C 215,932 217,914 660 HCMV IRS1/TRS1; US22 superfamily 
gp147.1 C 221,739 222,935 398 MHC class I homolog 
gp147 C 223,124 224,218 364 MHC class I homolog 
gp148 C 225,379 226,560 393 MHC class I homolog 
gp149 C 228,236 230,209 657 MHC class I homolog 
gp149.1  230,163 230,465 100 Unique ORF sequence in CIDMTR 
§ An observation of note is the codon, ATA, spanning nucleotides 191516–191518 (minus strand). This 
codon is ATG in strain 22122, which was annotated as the start codon for both IE2 (GP122; exons 3, 4 
and 5) and IE1 (GP123; exons 3, 4 and 6) [42–44]. Whether alternative splicing is occurring in the 
CIDMTR strain, or the start codon for the IE1/IE2 proteins is different between the two strains of 
GPCMV (i.e., in exon 4, not exon 3), requires further evaluation; this is described in greater detail in 
Section 2.4. 
Amino acid sequences predicted from CIDMTR genes encoding conserved envelope glycoproteins 
were compared to those from strain 22122. There was striking sequence conservation of the gB 
homolog; although 13 SNPs were noted, only 2 coding changes were observed (overall identity of 
99%). In contrast, sequence analyses of GP74 (gO) demonstrated the greatest degree of sequence 
divergence, with 303/374 (81% identity) noted, followed by GP75 (gH), with 613/726 (84%) 
identity compared to the 22122 strain. GP73, the homolog of HCMV glycoprotein N, a protein 
known to exhibit substantial sequence divergence across clinical isolates [19,38,39], demonstrated 
92% identity between the CIDMTR and 22122 strains. These results confirm that CIDMTR 
represents a GPCMV strain distinct from 22122 as the amino acid sequences of gH, gO, and gN 
clearly diverged through gradual evolutionary processes and cannot be attributed to abrupt, limited 
events such as insertions, deletions, or duplications. This further implies that despite potential 
bottlenecks imposed by selective breeding, GPCMV, as it exists within commercial breeding 
colonies, exhibits significant strain diversity of a nature similar to that of HCMV. These findings 
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suggest that GPCMV may provide a useful model to study the impact of naturally occurring strain 
variation on viral pathogenesis, particularly in the area of nonprimary infection and disease. 
2.4. Sequence Characterization of DNA from Original SG Homogenate in Region of IE1/2  
Start Codon 
A surprising finding from the DNA sequence analysis was the finding of an ATA codon as the 
putative start codon of the IE1/IE2 protein product [42]. To examine this issue, sequence analyses 
of PCR-amplified DNA from the original salivary gland homogenates, as well as salivary gland 
homogenates from further in vivo passages, were undertaken. DNA from the original salivary gland 
homogenate that was the source of the CIDMTR isolate was compared to DNA from GPL cells 
infected with CIDMTR following cell culture passage. The PCR was done with the primer pair 
designated IE splice 3' P1 (5'-TGCGAAGCGATCTCTCTCAAC-3') and IE splice 5' P1  
(5'-GTGGTTGTACGTGTCGTCGTCA-3'), which was predicted to produce an 864-bp product 
from CIDMTR DNA. The purified DNA was cloned and three clones from each reaction were 
sequenced. This analysis indicated that the original salivary gland source of the CIDMTR strain 
contained viral DNA that encoded an ATG codon (as does 22122), the putative start codon for the 
IE1/IE2 protein product, but that the tissue cultured-derived CIDMTR strain, following two 
passages in fibroblasts, had a DNA sequence corresponding to an ATA codon. 
To further examine splicing of the IE region from the CIDMTR strain (tissue culture-derived; 
CIDMTR-TC) virus, reverse-transcriptase PCR was performed on RNA harvested at immediate 
early times post-infection. RNA was extracted from GPL cells infected with 22122 or CIDTMR  
at 4 hours post-inoculation cDNA was synthesized from 1 g of total RNA. Conventional PCR  
was carried out using cDNA as template. PCR used primer pair IE exon4 F1  
(5'-CCGCATTTTCTGAGGGTGTT-3') and IE exon1 R1 (5'-CATGCCAGTTCCCTGTGCTG-3'), 
and primer pair IE exon5 F1 (5'- GGAAGATGTCCACTTGGAAG-3') and IE exon2 R1  
(5'- ACGTAGCCGAGAAGTAAAGT-3'). The expected product sizes for primer pair IE exon4 
F1/IE exon1 R1 and IE exon5 F1/IE exon2 R1 were 473 bp and 508 bp, respectively.  
A product of the expected size was purified, cloned into pCR2.1, and multiple clones with 
inserts from each reaction were sequenced. Notably, all CIDMTR-derived clones contained ATA at 
the putative (collinear) IE1/IE2 gene product start codon, confirming the DNA sequencing analysis. 
In contrast, all the 22122 clones contained an ATG at this position. The observed exon junctions 
were as described in the 22122 strain. The ATG codon in exon 3 was originally annotated as the 
putative IE1/2 start codon in 22122 [41] and the DNA sequence analysis of DNA from the 
CIDMTR strain purified directly from the salivary gland homogenate also demonstrated an ATG 
codon in exon 3. Thus, the finding of this ATA by DNA and RT-PCR sequencing in tissue  
culture-passaged CIDMTR virus was surprising. Since IE1/2 is abundantly expressed and ATA is 
known as an inefficient initiator of protein translation, we looked for ATGs that might serve as 
alternative start sites. Tissue culture-passaged CIDMTR strain may employ a start codon in exon 
four for the IE1 and IE2 gene products (Figure 4), although the Kozak consensus sequence of this 
putative start codon (T at 3, A at +4) is relatively weak [45].  
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Figure 4. RT-PCR mapping of CIDMTR strain and 22122 strain splice sites. (a) 
Cartoon representation of the IE1/2 gene locus illustrating positions of primer pairs 
used for RT-PCR. Introns are indicated by straight lines and exons are blue boxes, although 
exon 1 and 2 are non-coding. (b) Results of RT-PCR reactions e4-1, e5-2, and GAPDH 
(control) using RNA from uninfected cells or cells infected with 22122 or CIDMTR. 
(c) RT-PCR consensus sequence of CIDMTR strain. Exon junctions are highlighted in 
blue. The first gray highlighted sequence is an ATA codon; this is an ATG codon and 
the putative start codon for the 22122 IE1/2 proteins, but is not conserved in the 
CIDMTR sequence in tissue culture passaged virus. The second gray highlighted 
sequence may therefore represent the putative start codon for CIDMTR TC IE1/2. 
 
 
To further define IE transcription from the CIDMTR-TC virus, 5' RACE was performed.  
RNA was extracted and cDNA was synthesized with a specific sequence attached to the 5'  
UTR for capped mRNAs. After ligation of a specific RNA oligo to the 5'UTR of mRNAs,  
cDNA was synthesized using oligo-dT and random hexamers. The cDNA was used as  
template for a first round of PCR using GeneRacer 5' Primer and primer IE2 P5  
(5'-GGCGTCAATGGGCTCGGGTTTGAT-3'). Two nested PCR reactions were then performed 
with the GeneRacer 5' Nested Primer, per the manufacturer’s specifications, and IE2 P5 or IE 
exon3 P1 (5'-GGCAGCCCCAGTGGATGATTCTGATA-3') (Figure 5b). Purified DNA was 
cloned and sequenced. Results matched the previously described splice sites for strain 22122 [42]. 
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-RT -RT -RT +RT +RT +RT 




AGCATA GAA ACA AAC AGA GAG TCC ACT TCC CCG TCC AGA AAC TCC CCC GTA TCA GAA TCA TCC ACT GGG GCT GCC  
    I   E   T   N   R   E   S   T   S   P   S   R   N   S   P   V   S   E   S   S   T   G   A   A    
GCC ACA AGT GAT GCC GCA TCA AGC TCT CAG AAT AAT GAC ACC CGG TCA AAT GCC ACA CCG TCC CTC CTC CGA GAC  
 A   T   S   D   A   A   S   S   S   Q   N   N   D   T   R   S   N   A   T   P   S   L   L   R   D   
GAA TAC GAG AGC GTC TCC ACA TTC ATG AAA GAT GTA TTG GAG AGA GTC AAC AAC ACG TTC GAC TTA GAT CAG TTC  
 E   Y   E   S   V   S   T   F   M   K   D   V   L   E   R   V   N   N   T   F   D   L   D   Q   F   
GTA ACT AAC CCA GAC ATC GAT CTC AAT TTT CAA CCA ACA CCC TCA GAA AAT GCG GAG ATA GAA AGT TTT ACC AGT  
 V   T   N   P   D   I   D   L   N   F   Q   P   T   P   S   E   N   A   E   I   E   S   F   T   S   
GGA TCC GTC TCC AGG GGC GAT ATG TCA AAC GAT AGA CTG AGC GCT GTT GCA GTT CGC GCC CTG GTA CTC GTC ATG  
 G   S   V   S   R   G   D   M   S   N   D   R   L   S   A   V   A   V   R   A   L   V   L   V   M   
AAA CGA AAC ATT CAG GAG TTA CAA GAT AGT CTT AGG CAG CAC AGG GAA CTG GCA TG 
 K   R   N   I   Q   E   L   Q   D   S   L   R   Q   H   R   E   L   A 
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Using this primer combination, the RT-PCR product was 734 nt in size (5 nt longer than the 
homologous ATCC/22122 cDNA). The substitution of ATA for the putative ATCC/22122 IE2/3 
start codon was once again noted. We did not observe other in-frame start codons for the CIDMTR 
strain IE1/2 other than the one identified in exon 4. Further experiments will be required to identify 
the start codon for IE1/2; possibly, both 22122 and CIDMTR strains use the start codon in exon 4, 
in spite of its suboptimal Kozak consensus. Alternatively, growth of the CIDMTR strain in 
fibroblasts may select for mutation of the exon 3 start codon, even upon minimal passage. 
Development of guinea pig epithelial/endothelial cell for isolation and passage of CIDMTR virus is 
an important future priority, to determine whether in vivo and in vitro passage result in different 
selective pressure on viral sequences. 
Figure 5. 5' RACE analysis of CIDMTR IE region. (a) Schematic of IE gene indicating 
primers pair used in RACE. (b) nPCR gels for 22122 and CIDMTR using RNA 
purified under IE conditions. The CIDMTR RACE product is 734 nt compared to 729 
nt for the 22122 strain, explaining its slightly higher migration by gel electrophoresis. 
(c) RACE consensus sequence of CIDMTR IE. Exon junctions highlighted in blue. 
First gray highlighted sequence is co-linear to the start codon for 22122; second 
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CCAGACGCCCGGTTCTTCTGCCCCCCCCCCCCATCAATTCAAGCATA GAA ACA AAC AGA GAG TCC ACT TCC CCG TCC AGA AAC TCC 
                                             I   E   T   N   R   E   S   T   S   P   S   R   N   S   
CCC GTA TCA GAA TCA TCC ACT GGG GCT GCC GCC ACA AGT GAT GCC GCA TCA AGC TCT CAG AAT AAT GAC ACC CGG 
 P   V   S   E   S   S   T   G   A   A   A   T   S   D   A   A   S   S   S   Q   N   N   D   T   R   
TCA AAT GCC ACA CCG TCC CTC CTC CGA GAC GAA TAC GAG AGC GTC TCC ACA TTC ATG AAA GAT GTA TTG GAG AGA 
 S   N   A   T   P   S   L   L   R   D   E   Y   E   S   V   S   T   F   M   K   D   V   L   E   R   
GTC AAC AAC ACG TTC GAC TTA GAT CAG TTC GTA ACT AAC CCA GAC ATC GAT CTC AAT TTT CAA CCA ACA CCC TCA 
 V   N   N   T   F   D   L   D   Q   F   V   T   N   P   D   I   D   L   N   F   Q   P   T   P   S   
GAA AAT GCG GAG ATA GAA AGT TTT ACC AGT GGA TCC GTC TCC AGG GGC GAT ATG TCA AAC GAT AGA CTG AGC GCT 
 E   N   A   E   I   E   S   F   T   S   G   S   V   S   R   G   D   M   S   N   D   R   L   S   A   
GTT GCA GAC ACG CCC GAG GGA TGG CTG ACA CCT TCC ATC TCA CAG ATC AAA CCC GAG CCC ATT GAC GCC  




2.5. PCR Confirmation of GPCMV-CIDMTR Genome Structure  
To confirm the structure of the CIDMTR strain compared to the 22122 strain, PCR was 
performed on viral DNA from both strains, using primers spanning the mismatched regions 
observed in the sequence analysis comparisons (Figure 3b, boxed/shaded regions). Two primers 
pairs were used for each region of mismatch (mismatch region 1 and mismatch region 2). PCR was 
performed using primer pairs mismatch-region 1 F1/R1 and mismatch-region 1 F2/R2, that amplify 
a ~4-kb region for the 22122 strain, but a ~2.5-kb region for the CIDMTR strain. The amplification 
region using primer pairs mismatch-region 2 F1/R1 or mismatch-region 2 F2/R2 was predicted to 
be ~2.2 kb for the 22122 strain and ~3.7 kb for the CIDMTR strain. Primer sequences are indicated 
in Table 2. The results of these experiments confirmed that the genome configuration was precisely 
as predicted from the deep sequence analysis. Moreover, the PCR was also performed on DNA 
purified directly from the original salivary gland homogenate from which the CIDMTR isolate was 
obtained (data not shown). These results confirmed that the insertions and deletions identified by 
sequencing (Figure 3c) did not arise as an artifact of limited passage of virus in cell culture. The 
PCR results are shown in Figure 6.  
Table 2. Primer Sequences. 
Primer Name Primer Sequence 
Mismatch Region 1 F1 5'-GTGAGACGTAAGAATAGCTTGC-3' 
Mismatch Region 1 F2 5'-GATCCTTAGACTCTATCACGG-3' 
Mismatch Region 1 R1 5'-GTGTTGTCACAATTGGCACATG-3' 
Mismatch Region 1 R2 5'-ACATGGTCACGACAGAATC-3' 
Mismatch Region 2 F1 5'-GTGGACAGGATCCCCAAATT-3' 
Mismatch Region 2 F2 5'-CCAAATTTCTGTCGTCGGCG-3' 
Mismatch Region 2 R1 5'-TGTTTCCGTGTCTGTCTCCGT-3' 
Mismatch Region 2 R2 5'-GTCTTAGCCCGAGACCTTC-3' 
2.6. Infection In Vivo and Development of a Real-Time PCR Assay for Detection of CIDMTR DNA 
To evaluate DNAemia and end-organ infection in the course of in vivo studies, a  
strain-specific real-time PCR assay was developed in order to differentiate the  
GPCMV-CIDMTR strain from the 22122 strain. This assay focused on the amplification of 
sequences corresponding to the CIDMTR strain GP147.1 ORF (Table 1), since this sequence is 
absent in the 22122 strain. A GPCMV 147.1 specific PCR primer pair, consisting of 
CIDMTR147.1_464F (5'-ATGCAACATAGCGTGCTGAC-3') and CIDMTR147.1_583R  
(5'-GGGACAAAAGCACGATGAAC-3') was designed and utilized for the real-time PCR assay 
(described in detail in 3.5). These primers amplified a 120 bp region of the 147.1 gene specific for 
the CIDMTR strain. DNA was extracted from either 100 L citrated blood or from fresh frozen 
tissues samples, as described in the Methods section. For quantitative PCR, both previously 
validated primers for the GP83 gene [sequences shared by both strains] and novel primers for the 
GPCMV 147.1 gene [sequences only found in the CIDMTR strain] were used for real-time PCR 
assay. There was strong concordance between the viral load estimates identified by the gp147.1 and 
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GP83 real-time primers (data not shown). As a negative control, GPCMV 147.1 primers were used 
in several PCR assays of 22122 DNA, with consistently negative results (data not shown). 
Figure 6. Strain-specific PCR assays differentiate ATCC 22122 strain of GPCMV from 
CIDMTR strain. (a) Primers were designed to amplify across discontinuous/unique 
regions as demonstrated in Figure 3b. Lane 1, kb ladder; lane 2, mismatch region 1 
F1/R1, ATCC; lane 3, mismatch region 1, F1/R1, CIDMTR; lane 4, mismatch region 1, 
no template control; lane 5, mismatch region 1 F2/R2, ATCC; lane 6, mismatch region 
1 F2/R2, CIDMTR; lane 7, mismatch region 1 F2/R2, no template control; lane 8, 
mismatch region 2 F1/R1, ATCC; lane 9, mismatch region 2 F1/R2, CIDMTR; lane 10, 
mismatch region 2 F1/R1, no template control; lane 11, mismatch region 2 F2/R2, 
ATCC; lane 12, mismatch region 2 F2/R2, CIDMTR; lane 13, mismatch region 2 
F2/R2, no template control. (b) Restriction polymorphisms were as predicted by DNA 
sequence. PCR amplification products were digested with enzymes as indicated. Lane 
1, kb ladder; lane 2, mismatch region 1 F1/R1 ATCC, Bgl 2; lane 3, mismatch region 1 
F1/R1 CIDMTR, Bgl 2; lane 4, mismatch region 1 F2/R2 ATCC, Bgl 2; lane 5, 
mismatch region 1 F2/R2 CIDMTR, Bgl 2; lane 6, mismatch region 1 F1/R1 ATCC, 
BamH I; lane 7, mismatch region 1 F1/R1 CIDMTR, BamH I; lane 8, mismatch region 
1 F2/R2 ATCC, BamH I; lane 9, mismatch region 1 F2/R2, BamH I; lane 10, mismatch 
region 1 F1R1 ATCC, EcoR V; lane 11, mismatch region 1 F1/R1 CIDMTR, EcoR V; 
lane 12, mismatch region 1 F2/R2 ATCC, EcoR V; lane 13, mismatch region 1 F2/R2, 
EcoR V; lane 14, mismatch region 2 F1R1 ATCC, EcoR I; lane 15, mismatch region 2 
F1R1 CIDMTR, EcoR I; lane 16, mismatch region 2 F2/R2 ATCC, EcoR I; lane 17, 
mismatch region 2 F2/R2, EcoR I. 
 
Next, twelve young, GPCMV-seronegative outbred Hartley guinea pigs were divided into two 
groups of six/group. Each group was inoculated with CIDMTR strain virus (p1) at a dose of  
1 × 105 pfu, administered subcutaneously, as described in Section 3. Group 1 (n = 6) was treated 
with 200 mg/kg cyclophosphamide on day 1 and 50 mg/kg on day +6 following viral inoculation 
as described previously [32]; group 2 (n = 6) was sham-treated (PBS only). Whole blood and sera 



















































































































































samples were collected on day 0, 3, 7, and 21. Animals were sacrificed on day 21 and tissue, 
including lung, liver, spleen, and brain, were collected for PCR analysis. In group 1, 5/6 animals 
were DNAemic, peaking at day 7 (mean, 3.2 +/  0.3 log10 genomes/mL) while in group 2, the 
prevalence of DNAemia was lower (3/6 animals; 2.5 +/  0.35 log10 genomes/mL, p = 0.06 
compared to group 1). Viral DNA was most readily recovered from spleen upon dissection at day 
21 post-infection. All 6 animals from each group had recoverable CIDMTR strain DNA in the 
spleen. Total spleen viral load in group 1 was 2.4 +/  0.07 log10 copies/mg and was 2.4 +/  0.1 
log10 copies/mg in group 2 (p = NS compared to group 1).  
The ability of the CIDMTR strain to infect pregnant animals previously inoculated with the 
22122 strain was next assessed. A total of 6 female seronegative Hartley guinea pigs received a 
primary infection with SG homogenate GPCMV (22122) at a dose of 1 × 104 pfu, administered 
subcutaneously. A parallel group of animals were sham-treated (PBS only). Then, 5 weeks after 
inoculation, the animals in both groups were mated with GPCMV-seronegative breeders. Dams 
originally inoculated with the SG virus (22122 strain) were documented to undergo seroconversion; 
in addition, all were demonstrated to have low-level DNAemia after inoculation with 22122 virus 
(data not shown). Approximately 5 weeks after the initiation of mating, group 1 was challenged 
subcutaneously with CIDMTR strain at a titer of 6 × 105 pfu. A total of 19 pups were born in the 
experimental group; all pups were liveborn. When pup tissues were analyzed, 4/19 (21%) of these 
animals had recoverable CIDMTR strain-specific DNA isolated from the salivary gland. One of 
these animals also had detectable DNA in the brain. 
3. Experimental Section  
3.1. Cells, Virus and DNA Preparation 
GPCMV (strain 22122, ATCC VR682), and CPCMV/CIDMTR were propagated on guinea pig 
lung fibroblast cells (GPL; ATCC CCL 158) in F-12 medium supplemented with 10% fetal calf 
serum (FCS; Gibco-BRl), 10,000 IU of penicillin/liter, 10 mg of streptomycin/liter (Gibco-BRL), 
and 7.5% NaHCO3 (Gibco-BRL). When the P1 passaged CIDMTR virus exhibited extensive CPE 
in GPL cell culture, cells and virions were pelleted. Aliquots were fixed in phosphotungstic acid for 
EM studies (see below) and the remainder washed in 10 mM Tris (pH 8.0)/1 mM EDTA (TE), and 
lysis buffer (200 mM NaCl, 2% SDS, 200 g/mL proteinase K, in TE), was added. Cells and 
virions were gently suspended, inverted, and incubated at 68 °C overnight. Following transfer to a 
37 °C water bath, three successive phenol-chloroform extractions were performed, followed by 
ethanol precipitation. 
3.2. Transmission Electron Microscopy 
Cells were fixed in 1 mL of 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer and post 
fixed with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer (all reagents from Electron 
Microscopy Sciences, Hatfield, PA, USA). After three washes in distilled water, samples were 
dehydrated using a 25%–100% ethyl alcohol gradient. Samples were then infiltrated with 2:1 
ethanol: Embed 812 resin (Electron Microscopy Sciences, Hatfield, PA, USA) for 1 hour and 
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subsequently transferred to a 1:2 ethanol: Embed 812 resin mixture for 1 hour. Cells were further 
infiltrated with 100% resin and were embedded and incubated at 58 °C for 24 hours to polymerize 
the resin. Embedded samples were trimmed and sectioned on a Leica UC6 Ultramicrotome  
(Leica Microsystems, Vienna, Austria). Thin sections (60–70 nm) were obtained and collected on a 
200 mesh copper grid (Electron Microscopy Sciences, Hatfield, PA, USA) using a perfect loop. 
Grids were contrasted with 5% uranyl acetate for 20 minutes and Santos’ lead citrate for 6 minutes. 
For negative contrast, virions and dense bodies were collected from P1 supernatants of infected 
fibroblasts, transferred to airfuge tubes (Beckman-Coulter, Brea, CA, USA), and centrifuged at  
30 PSI using an airfuge (Beckman-Coulter, Brea, CA, USA) for 20 minutes on parafilm and 
formvar coated copper grids (Electron Microscopy Sciences, Hatfield, PA, USA). Excess liquid 
was wicked and the grids were stained with 1% phosphotungstic acid for one minute. All sections 
were observed under JEOL 1200 EX II transmission electron microscope (JEOL LTD, Tokyo, 
Japan). Images were obtained using a Veleta 2K × 2K camera with iTEM software (Olympus SIS, 
Munster, Germany) [46].  
3.3. Deep Sequencing and Sequence Analyses  
For sequence analysis of CIDMTR viral DNA, virions were purified as described previously [44], 
and lysis buffer (200 mM NaCl, 2% SDS, and 200 g/mL proteinase K in Tris-EDTA [TE]) was 
added. Following incubation at 68 °C overnight, three phenol-chloroform extractions were performed, 
followed by ethanol precipitation of viral DNA. Genomic sequencing was performed using 
Illumina MiSeq and Pacific Biosciences PacBio RS platforms. Approximately 5.2 million 151-bp 
paired-end MiSeq reads were generated at the University of Minnesota’s Biomedical Genomics 
Center with a nominal insert size of 400 bp. Removal of low quality reads and PhiX sequence 
resulted in a set of 4.0 million cleaned reads, approximately 11,000× coverage. Initial scaffolds 
were generated from the cleaned Illumina reads using the ABySS assembler (version 1.3.4) [47]. 
Scaffold quality was assessed manually by comparison with the reference strain, 22122 [44,48,49], 
and by remapping the reads using Bowtie 2 and scrutinizing local coverage and consensus using 
Tablet [50] and SAMtools [51]. Special attention was paid to correct alignment and orientation of 
the paired ends. Regions of weak coverage and scaffold gaps were identified and closed either by 
manual local assembly [52] or by Sanger sequencing. Independent validation of the pseudomolecule 
was also performed using the longer PacBio RS reads, validating the Sanger sequencing and 
manual assembly. SMRT Analysis software [53] produced 998 high quality (“corrected”) reads 
ranging between 509–15,898 bp, median 6,257 bp (approximately 27× coverage), as well as 
another set of scaffolds. These data were used to evaluate the Illumina assembly, specifically its 
structural correctness, and to correct misassembled repeat regions. The resulting complete genome 
was deposited with the EMBL Nucleotide Sequence Database (accession number HG531783). 
3.4. RT-PCR and RACE Analyses  
Reverse-transcriptase PCR was performed on RNA harvested at immediate early times 
post-infection. RNA was extracted from GPL cells infected with 22122 or CIDTMR, at 4 hours 
post-inoculation, using the RNeasy mini kit (Qiagen, Hilden, North Rhine-Westphalia, Germany) 
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according to the manufacturer’s instructions. RNA was treated with RNase-free DNase Set 
(Qiagen) while in the column according to manufacturer’s instructions. cDNA was synthesized 
from 1 g of total RNA using Quantitect Reverse Transcription kit (Qiagen). Conventional PCR 
was carried out using cDNA as template and AmpliTaq Gold Fast PCR Master Mix (Invitrogen, 
Carlsbad, CA, USA). Primers are as described in Section 2.4. The PCR products were run in a 
0.7% agarose gel. A band of the expected size was cut form the gel and purified using QIAquick 
Gel Extraction Kit (Qiagen). The purified DNA was cloned into pCR2.1 (Invitrogen) using the TA 
Cloning Kit (Invitrogen). Three of clones with inserts from each reaction were sequenced with T3 
promoter, M13 Reverse and the PCR primers.  
For 5' RACE analysis, RNA was used as template for cDNA synthesis using the GeneRacer kit 
(Invitrogen) in order to generate a cDNA with a specific sequence attached to the 5' UTR for only 
mRNAs that were capped. After ligation of a specific RNA oligo to the 5'UTR of mRNAs, cDNA 
was synthesized using a combination of oligo-dT and random hexamers. The cDNA was used as 
template for a first round of PCR using GeneRacer 5' Primer and primer IE2 P5  
(5'-GGCGTCAATGGGCTCGGGTTTGAT-3'). In order to increase the specificity and quantity of 
the PCR product, nested PCR (nPCR) was performed in a dilution (1:20) of the PCR product. Two 
nPCR reactions were performed with the GeneRacer 5' Nested Primer, per the manufacturer’s 
specifications, and IE2 P5 or IE exon3 P1 (5'- GGCAGCCCCAGTGGATGATTCTGATA-3'). A 
band of the expected size was cut form the gel and purified using QIAquick Gel Extraction Kit 
(Qiagen). The purified DNA was cloned into pCR4-TOPO (Invitrogen) using the TOPO TA 
Cloning. Clones were analyzed for the present of the insert by digestion with EcoR I. Three of the 
clones with insert from each reaction were sequenced with T3 promoter, M13 forward ( 20) and 
the PCR primers.  
3.5. GPCMV-CIDMTR Strain PCR Assay 
For confirmation of viral genome structural differences noted by deep sequencing, PCR was 
performed for each virus using primers indicated in Table 2. The PCR reaction was performed in 
a 50 L of total volume using GoTaq long PCR Master Mix from Promega and 1.0 M primers. 
The DNA template was total genomic and viral DNA extracted from GPL cells infected with 
22122 or CIDMTR tissue culture strain. The conditions for the PCR were: initial denaturation at  
95 °C for 2 min, followed by 95 °C for 30 s, 53 °C for 30 s, 72 °C for 4 min for a total of 35 cycles, 
and elongation at 72 °C for 10 min. The PCR product (4 L) was subjected to electrophoresis in a 
0.7% agarose gel. The PCR product from mismatch 1 F2/R2 and mismatch 2 F2/R2 were purified 
from the gel using the Geneclean® II kit (MP Biomedicals, Santa Ana, CA, USA) following the 
manufacturer’s instructions. The cleaned PCR product was then sequenced by Sanger sequencing 
(Functional Biosciences, Madison, WI, USA). Purified PCR products were also subjected to 
restriction endonuclease comparisons as indicated in Figure 5b. 
The real-time PCR assay focused on the amplification of sequences corresponding to  
the CIDMTR strain gp147.1 ORF (Table 1), since this sequence is absent in the 22122  
strain sequence. A GPCMV gp147.1 specific real-time PCR primer pair, consisting of 
CIDMTR147.1_464F (5'-ATGCAACATAGCGTGCTGAC-3') and CIDMTR147.1_583R  
(5'-GGGACAAAAGCACGATGAAC-3') was designed and utilized for the real-time PCR assay.  
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These primers amplified a 120 bp region of the gp147.1 gene specific for the CIDMTR strain.  
The specific hydrolysis probe used for detection was CIDMTR147.1_494P  
(FAM-GTGTTCGTGTCCTTGATCGTACGCA-BHQ1). A second GPCMV 147.1 specific primer 
pair, CIDMTR147.1_225F (5'-AATGGTTCGCTACGGACATC-3') and CIDMTR147.1_368R  
(5'-CGGACAACGGAACATACTTG-3') was also utilized in real-time PCR assays. These  
primers amplified a 144 bp region of 147.1 specific for the CIDMTR strain. The specific  
hydrolysis probe used for detection with this primer pair was CIDMTR147.1_262P 
(FAM-TTCCTCGACGAAGCTCGCGGTATAAT-BHQ1). In each instance, the PCR reactions 
were performed in a 25 L reaction, using LightCycler 480 Probes Master from Roche (Penzberg, 
Bavaria, Germany); as well as 0.4 M primers, 0.1 M probe and 0.4 u/ L of UNG. PCR was 
performed using the LightCycler 480 Real-Time PCR System (Roche) under the following 
conditions: initial denaturation at 95 °C for 10 min, followed by 95 °C for 10 s, 56 °C for 15 s,  
72 °C for 10 s for a total of 45 cycles, then a final hold step at 40 °C. The first primer pair (464F 
and 583R) was chosen for detection of viral genome for in vivo studies. Data were analyzed with 
the LightCycler Data Analysis Software (version 1.5; Roche) [54] using standard curves generated 
using serial dilutions of plasmid pCR2.1 with gp147.1 at known concentrations. Negative results 
were arbitrarily assigned a level of 50 for the purpose of statistical comparisons, based upon  
limit-of-detection analyses observed in other real-time PCR experiments [55]. 
3.6. Animal Challenge Studies 
All animal studies were performed with the approval of the University of Minnesota 
Institutional Animal Care and Use Committee (IACUC). Some animals were immune suppressed at 
day 1 (200 mg/kg) and day +6 (50 mg/kg) with cyclophosphamide delivered by intraperitoneal 
injection. For experiments described in Section 2.6, both cyclophosphamide-treated and untreated 
animals (n = 6/group) were challenged with CIDMTR strain virus (P1 workpool) at a dose of  
1 × 105 pfu by subcutaneous injection. Blood samples were collected at day 0, 3, 7 and  
21 post-inoculation and animals humanely sacrificed at day 21 for collection of tissue samples for 
PCR analyses. Pregnancy/challenge studies were conducted as described in Section 2.6. Liveborn 
pups were sacrificed within 72 hours of delivery for DNA extraction and subsequent PCR. 
4. Conclusions  
The 22122 strain was originally isolated by Hartley in 1957 [27]. As the only characterized 
isolate of GPCMV it was used in virtually all subsequent GPCMV research. However, GPCMV 
infection is common among animals in commercial breeding colonies. In a longitudinal study 
conducted by Hsiung and colleagues from 1974 to 1979, GPCMV-neutralizing antibody was 
observed in 25% of Hartley strain guinea pigs obtained from commercial sources while virus was 
isolated from only 6 of 204 animals [56]. The percentages of antibody-positive animals obtained 
from different sources varied from shipment to shipment, ranging from 8%–50%. It does not 
appear that any of these viral isolates were retained. Thus, given only a single characterized isolate, 
the extent to which diverse GPCMV strains have been maintained within these domesticated 
populations was not previously known. Given that Hartley guinea pigs are descended from animals 
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imported from South America to Europe in the 16th century, and that these animals subsequently 
underwent centuries of selective breeding, first as pets and later as research animals, the possibility 
existed that bottlenecks in the breeding history of Hartley guinea pigs could have limited the 
genetic diversity of GPCMV strains currently endemic in commercial breeding facilities.  
In the current study, a second virus was independently isolated and characterized, again from a 
Hartley strain guinea pig obtained from a commercial supplier in the United States. Based on a 
high degree of genetic relatedness to 22122, predominantly similar restriction endonuclease 
patterns, and an conserved overall genomic structure, we conclude that CIDMTR is a GPCMV and 
not a novel and distinct betaherpesvirus. However, based on restriction pattern polymorphisms and 
significant divergence of amino acid sequences for several envelope glycoproteins (particularly gH 
and gO), we conclude that CIDMTR and 22122 represent two distinct strains of GPCMV and are 
not minor variants of the same strain. This further suggests that GPCMV strain diversity has been 
sustained within commercial breeding colonies and that other strains exhibiting similar levels of 
divergence may exist and could potentially be exploited to further extend this important animal model.  
The passage history of 22122 is uncertain. In the original report by Hartley, two parallel 
isolations of GPCMV were reported: one, from salivary gland homogenate obtained from guinea 
pigs purchased by a commercial supplier in Yonkers, NY, and a second isolate obtained from a 
second supplier in New York state. Reactivation of virus may have been driven by allogeneic 
responses engendered from injecting SG extract into an animal with a different allotype, as has 
been suggested may drive HCMV and MCMV reactivation during transplantation [57,58]. 
Allogeneic responses may similarly have played a role, along with cyclophosphamide 
immunosuppression, in reactivation of the CIDMTR strain, since repeated tissue culture of salivary 
gland explants directly obtained from seropositive animals failed to result in growth of virus (data 
not shown). With respect to the original isolation of 22122, it is worth noting that serial in vivo 
passages may have occurred in the context, for some animals, of “mixed infection”, since Hartley 
noted that 7.7% (3/39) of “control NIH” strain guinea pigs aged 5 months or older were naturally 
infected, as evidenced by infrequent salivary gland inclusions [27]. This strain underwent  
22 additional passages in cell culture of fibroblasts, and appears to be the strain that eventually was 
deposited with ATCC. The precise date of deposit is unclear, but reports of GPCMV research from 
the 1960s [59] and early 1970s describe obtaining this strain directly from the NIH, while studies 
since the late 1970s describe obtaining the virus from ATCC [60]. Between its original isolation by 
Hartley and its submission to ATCC, it appears to have undergone 54 additional passages in guinea 
pigs, and six additional passages in cell culture (3 passages in guinea pig embryo fibroblasts, and 3 
passages in CCL 158 cells [61]. The 22122 strain derives from multiple rounds of both in vivo 
passage, some possibly occurring in the context of mixed infection, and 25–30 passages in cell 
culture. Thus, it is possible that 22122 underwent changes after isolation from the initial animal, 
either in cell culture or during in vivo passage.  
In contrast, CIDMTR was subjected to minimal passage (one passage in vivo and two passages 
in cell culture) prior to genomic characterization. Thus, the genomic structure and sequence of the 
CIDMTR strain may more likely represent a bona fide “wild-type” GPCMV sequence than does 
the 22122 strain.  
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Sequence comparison with the 22122 strain revealed generally good conservation of protein 
coding sequences, although three areas of substantial discontinuity were noted. Thus, each strain 
contains unique sequences that can be used as markers to distinguish the strains during in vivo 
coinfection experiments. One of the regions unique to CIDMTR contains an ORF encoding a 
fourth putative MHC class I homolog not found in the 22122 strain. Since the three putative MHC 
class I homologs found in 22122 appear to be important for the in vivo pathogenesis of infection [55], 
further functional comparisons of the two strains will be of interest. In spite of minimal cell culture 
passage, at least one mutation, in the IE1/IE2 start codon, was observed in the tissue culture-adapted 
CIDMTR virus, compared to sequences amplified from salivary gland homogenate. This observation 
is similar to reported nucleotide sequence comparisons between several open reading frames  
in the DNA of different laboratory-adapted strains and clinical isolates of HCMV that has  
revealed amino-terminal sequence extensions of ORFs with alternate start codon usage [62]. 
Sequence differences with respect to start codon usage have also been noted upon comparison of 
laboratory-passaged and “wild” isolates of MCMV [37]. Future sequence analysis of CIDMTR 
DNA propagated solely in vivo is therefore warranted. Studies in immune competent and immune 
compromised guinea pigs confirm the ability of the CIDMTR virus to disseminate and produce 
viremia (DNAemia). Variation in glycoprotein protein coding sequences were noted, particularly 
for the gH and gO proteins, suggesting that this virus may be useful for the study of re-infection of 
immune guinea pigs in the guinea pig model of congenital cytomegalovirus infection.  
Cross-neutralization studies examining strain-specific antibody responses to envelope glycoproteins 
would enhance the usefulness of this new strain for the modeling of vaccine-mediated protection 
against re-infection and congenital transmission in this uniquely valuable model. 
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Abstract: Development of a vaccine against congenital infection with human 
cytomegalovirus (HCMV) is a major public health priority. A potential vaccine target 
receiving considerable recent attention is the pentameric complex (PC) of HCMV 
proteins consisting of gL, gH, UL128, UL130, and UL131, since some antibodies 
against these target proteins are capable of potently neutralizing virus at epithelial and 
endothelial cell surfaces. Recently, homologous proteins have been described for 
guinea pig cytomegalovirus (GPCMV), consisting of gH, gL, and the GPCMV proteins 
GP129, GP131, and GP133. To investigate these proteins as potential vaccine targets, 
expression of GP129-GP133 transcripts was confirmed by reverse-transcriptase PCR. 
Mass spectrometry combined with western blot assays demonstrated the presence of 
GP129, GP131, and GP133 proteins in virus particles. Recombinant proteins 
corresponding to these PC proteins were generated in baculovirus, and as GST fusion 
proteins. Recombinant proteins were noted to be immunoreactive with convalescent 
392 
sera from infected animals, suggesting that these proteins are recognized in the humoral 
immune response to GPCMV infection. These analyses support the study of PC-based 
recombinant vaccines in the GPCMV congenital infection model. 
Keywords: guinea pig cytomegalovirus; cytomegalovirus vaccine; pentameric 
complex; congenital cytomegalovirus infection; baculovirus 
 
1. Introduction 
Development of a vaccine against human cytomegalovirus (HCMV) is a major public health 
priority [1]. Although a vaccine could be useful in several patient populations at risk for 
HCMV-associated disease, a vaccine that could prevent congenital infection and its attendant 
sequelae would be of particular value. HCMV infection elicits both cellular and humoral immune 
responses. The suggestion that passively transferred anti-HCMV antibody during pregnancy 
protects the fetus against infection and HCMV-induced injury [2] has driven efforts to develop 
recombinant vaccines targeting major envelope glycoproteins. Development of an optimal 
glycoprotein vaccine is complicated by the complexity of virus entry and the variety of 
mechanisms employed. HCMV uses two different entry mechanisms to infect various cell types 
(fibroblasts, epithelial cells, endothelial cells, and macrophages). Fibroblast entry is mediated by 
glycoprotein complexes gB, gH/gL/gO, and gM/gN, but entry into epithelial cells, endothelial cells, 
and macrophages requires the gH/gL/UL128/UL130/UL131 complex [3–5]. Recently, it was 
demonstrated that the majority of virus-neutralizing antibodies in hyperimmune globulin target the 
gH/gL/UL128/UL130/UL131 complex [6]. Moreover, it was recently shown that fetal CMV 
transmission was more likely in the setting of a delayed or diminished maternal antibody response 
to the gH/gL/pUL128/130/131 complex during primary infection [7], further underscoring the 
potential usefulness of targeting these proteins for vaccine development [8]. Therefore, although 
clinical trials of recombinant gB vaccines (which have shown some degree of effectiveness in 
preventing CMV infection and disease in high risk populations) are ongoing [9,10], there is also 
considerable interest in developing vaccines targeting the HCMV pentameric complex (PC). 
Ideally, a HCMV vaccine strategy would be tested in an animal model prior to clinical trials. 
Unfortunately, the strict species-specificity of CMVs precludes preclinical testing of HCMV 
vaccines in animals. However, a number of rodent and primate CMVs are useful in modeling 
HCMV vaccines and therapies, given the conservation of many immunogenic structural proteins 
amongst the various viruses [11–13]. The rhesus CMV (RhCMV) encodes highly conserved 
homologs of the UL128/UL130/UL131 members of the PC. Recently, a modified vaccinia virus 
Ankara virus (MVA) was described that stably coexpresses all five RhCMV proteins homologous 
to the HCMV PC [14]. RhCMV-naïve rhesus macaques vaccinated with the MVA construct 
developed antibodies that blocked infection of monkey kidney epithelial cells and rhesus 
fibroblasts. In addition, following subcutaneous RhCMV challenge at eight weeks post-vaccination, 
vaccinated animals demonstrated reduced plasma viral loads.  
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Although the RhCMV model is a valuable system that recapitulates many of the pathologies of 
HCMV congenital infection, the expense of rhesus macaques and the difficulty in establishing 
RhCMV seronegative animal colonies makes it difficult to conduct large-scale studies comparing 
vaccines against congenital infection. Among the small animal models, the guinea pig CMV 
(GPCMV) is uniquely useful, since, in contrast to rodent models, transplacental infection of the 
fetus occurs following viral challenge during pregnancy [12,15]. Hence, the GPCMV model is 
well-suited to the study of vaccines against congenital infection. Inoue described a region of the 
GPCMV genome that appeared to be genetically unstable, in the setting of serial virus passage in 
fibroblasts that contained homologs of the HCMV UL128/UL130/UL131 genes [16,17]. More 
recently, Feierbach [18] further defined the proteins encoded by this region and determined that the 
GPCMV genes GP129, GP131, and GP133 represented the ancillary protein members (along with 
GP75 [gH] and gp115 [gL]) of the PC (Table 1). These studies were undertaken to characterize 
these genes and express the encoded proteins in recombinant systems, toward the goal of 
examining antibody responses of naturally and experimentally infected guinea pigs to these 
proteins. Knowledge of the patterns of immune responses to these GPCMV proteins should prove 
useful in the evaluation of potential subunit vaccines targeting the PC in the GPCMV model.  





Codons Predicted Mr 
Amino Acid Similarity to 
HCMV (%) 
GP129 UL128 179 20.6 kDa 48% 
GP131 UL130 192 21.8 kDa 36% 
GP133 UL131 127 14.7 kDa 29% 
2. Results and Discussion 
2.1. Transcriptional Analyses of GP129, 131 and 133 
Initially, transcription from the GPCMV GP129, 131, and 133 locus was examined by 
reverse-transcriptase PCR (RT-PCR). Primer design was based upon published primer sequences 
reported by Inoue [17]. Primers used for these studies are summarized in Table 2. Previous reports 
indicated that these genes are encoded by single mRNAs, and the GP129 and GP131 RNAs, but not 
the GP133 RNA, are spliced (Figure 1A). To confirm and extend these findings, RNA was purified 
from GPCMV-infected GPL cells at 8, 12, 24, and 48 hours post-inoculation. A 48-hour time point 
was also collected in the presence of phosphonoacetic acid (PAA), 300 g/mL. The viral stock 
used was P1-passaged GPCMV Strain 22122 purchased directly from the American Type Culture 
Collection (ATCC; Manassas, VA, USA). As an additional control, cells were inoculated with 
vAM403, an eGFP-expressing recombinant GPCMV [19] known to lack the 1.6 kb region containing 
the GP129-133 locus [16]. The RT-PCR products predicted for each gene were: 540 base pairs (bp) 
for GP129 transcript; 515 bp for GP131; and 384 bp for GP133. Transcripts specific for GP131 and 
GP133 were apparent as early as 12 hours post-infection (Figure 1B,C). A GP129-specific transcript 
could be faintly detected as soon as 12 hours post-infection, and was abundantly present at 24 hours 
post-infection (Figure 1A). These data differ from those reported by Inoue and colleagues [17], who 
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did not note any GP129-specific transcript until ~48 hours post-infection, although this analysis 
was performed by northern blot, which may have been less sensitive than RT-PCR. Similar to 
Inoue’s findings, we noted that the spliced GP129 transcript was not identified in the presence of 
PAA, consistent with its classification as a late gene. However, we noted transcripts corresponding 
to the spliced GP131 mRNA as soon as 12 hours post-infection and continuing at high levels 
throughout 48 hours post-infection even in the presence of PAA (Figure 1B), suggesting that 
GP131 is an early gene, in contrast to the previous report by Inoue that suggested (based on 
northern blot analysis) that both GP129 and GP131 were late genes [17].  
Table 2. Primers used in GP129, 131 and 133 Cloning and Protein Expression Studies.  
ORF Primer Sequences 
GP129 (Baculovirus and 
Transcript Analysis) 
5' – TACGCTGCAGAATGCGTGTTATTGTT – 3' (F) 
5' – TACGAGATCTTTACTTCCCGTTACC – 3' (R) 
GP129 GST (R1) 
5' – TACGGGATCCTATACCCGTCCCGGTATCTTTG – 3' (F) 
5' – TACGCTCGAGTTAAGTATTCCCACATCGTACTAATC – 3' (R) 
GP129 GST (R2) 
5' – TACGGGATCCTCGCGGCAAGAACTCCAT – 3' (F) 
5' – TACGCTCGAGTTAACGGTAGGTCACCCCCAAG – 3' (R) 
GP129 GST (R3) 
5' – TACGGGATCCAACGGTTTATTATGCACCTTTC – 3' (F) 
5' – TACGCTCGAGTTACTTCCCGTTACCATCGAC – 3' (R) 
GP131 (Baculovirus) 
5' – TACGAATTCATGATGAAACGATAT – 3' (F) 
5' – TACGCTGCAGTTATCACGTCCAGTT – 3' (R) 
GP131 (Transcript 
Analysis) 
5' – ATAATGATGAAACGATAT – 3' (F) 
5' – TTATCACGTCCAGTTCCA – 3' (R) 
GP131 GST (R1) 
5' – GATAGGATCCTTTTACGCCTCGTTCGGA – 3' (F) 
5' – AATACTCGAGGTTCGTCAGGGTCAGGAC – 3' (R) 
GP131 GST (R2) 
5' – GATAGGATCCCGCCGAATAGATTACGGA – 3' (F) 
5' – AATACTCGAGCCACAAGAAGGACGAATC – 3' (R) 
GP131 GST (R3) 
5' – CGTGGGATCCTGGCATTATACGATACGG – 3' (F) 
5' – AATACTCGAGCAGGCAAGCGATAGAATC – 3' (R) 
GP133 (Baculovirus) 
5' – TACGCTGCAGTATGTTTTGGCGTCTTGTA – 3' (F) 
5' – TACGAGATCTTTATGCTCTGTCTATGC – 3' (R) 
GP133 (Transcript 
Analysis) 
5' – TATGTTTTGGCGTCTTGTA – 3' (F) 
5' – TTATGCTCTGTCTATGC – 3' (R) 
GP133 GST (R1) 
5' – GATCGGATCCACAAGAGTTAAGAAAGAAAACCAACTG – 3' (F) 
5' – GATCCTCGAGTTAGGAGTCCGCTAACGTATG – 3' (R) 
GP133 GST (R2) 
5' – GATCGGATCCAGGGGACGTTACAGGAAAGG – 3' (F) 
5' – GATCCTCGAGTTAAGTGCTTTGTTGAATAGAAATACG – 3' (R) 
GAPDH 
5' – ATCTCATCGTATTTGGCCGGT – 3' (F) 
5' – AATGGGAAGCTCACAGGTATGG – 3' (R) 
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Figure 1. Transcription of GP129, 131 and 133 as assessed by reverse-transcriptase 
PCR (RT-PCR). RNA from ATCC GPCMV-infected cells (Lanes 2, 4, 6, 8, 10) and  
vAM403-infected cells (Lanes 3, 5, 7, 9 and 11) was purified at 8 hours (Lanes 2, 3), 12 
hours (Lanes 4, 5), 24 hours (Lanes 6, 7) and 48 hours (Lanes 8, 9) post-infection.  
A 48-hour time point was also collected in the presence of phosphonoacetic acid  
(PAA) (Lanes 10, 11). Lane 1 represents RT-PCR of RNA from uninfected cells. 
Electrophoresis was performed on a 1.5% agarose gel. Molecular weights markers are 
the 1 Kb-Opti-DNA marker from ABM (Applied Biological Materials Inc., Richmond, 
BC, Canada). (a) GP129-specific transcripts. Predicted splice product of 540 nt is noted 
(arrow), but is not present in infected cells incubated with PAA. (b) GP131-specific 
transcripts. Predicted splice product of 515 nt is noted (arrow). (c) GP133-specific 
transcripts demonstrating no evidence of splicing. Predicted 384 nt product is noted 
(arrow). (d) GAPDH control. 
 
 
We saw no evidence of splicing of the GP133 transcript, and this RNA continued to be 
expressed to high levels through 48 hours post-infection. This transcript was also expressed in the 
presence of PAA. RNA species larger than we predicted were noted for the GP129 and GP131 
transcripts. Absence of any signal in the absence of reverse transcriptase makes the possibility of 
DNA contamination unlikely. These were presumed to represent larger, unspliced RNAs driven by 
promoters upstream of the GP129-133 promoter region. RNA purified from vAM403-infected cells 







































































































































































































































































































































region of the GPCMV genome encoding these ORFs. Guinea pig GAPDH cDNA was amplified to 
control for RNA recovery (1D). No bands were noted in the no-RT control (data not shown). 
2.2. Mass Spectrometry Analysis  
GPCMV virus particles were purified by sequential sucrose [20] and glycerol-tartrate density 
gradient centrifugation [21] as described in Section 3.2. Particles were examined by coomassie blue 
stain (Figure 2a) and transmission electron microscopy (EM; Figure 2b) to confirm homogeneity. 
Particles were probed with a monoclonal antibody (moab) to glycoprotein B, IE321, generated in 
our laboratory (Figure 2c), to further confirm their integrity. Particles were resolved by SDS PAGE 
followed by coomassie staining, and bands were excised from the gel for mass spectrometry. Three 
peptides corresponding to two unique sequences for GP129 were identified from a region of the gel 
with an approximate molecular weight of 25 kD. Additionally, six peptides corresponding to four 
unique sequences corresponding to GP131 were identified from a protein band excised from a 
region with a molecular weight spanning approximately 20–22 kD. Finally, seven peptides from 
four unique sequences of GP133 were identified from a protein band with an approximate molecular 
weight of 18 kD. Results are summarized in Table 3. Mass spectra data are provided in Appendix 
Figures A1–A3.  
Figure 2. Characterization of GPCMV viral particles. (a) Coomassie blue stain (5 g) 
of purified virus particles by 12% gel SDS-PAGE. (b) Transmission electron 
microscope microphotograph of purified particles. Negative contrast preparation of 
purified particles demonstrates enveloped virions (arrows). Dense bodies are also 
noted. Magnification, 150,000×. (c) Western blot analysis of viral particles probed with 
IE3-21 monoclonal antibody recognizing GPCMV gB (1:2,000 dilution; arrow). 
 
397 
Table 3. Mass spectrometry identification of peptides corresponding to GP129, 131  
and 133. Other major virion structural proteins included as controls for mass 
spectrometry analyses (protein probability calculations performed as described in 
materials and methods). 
ORF Unique Spectra Unique Peptide Sequences 
% 
Coverage Max Xcorr Probability 
GP 129 2 
MPSVQSKPEKPSILGVTYR 










39 4.51 99.9% 
GP83 74 61 59 62 100% 
GP25 78 55 77 5.9 100% 
gB 51 37 31 5.1 100% 
2.3. Characterization of GP129 and 131 Proteins 
Initially, an anti-peptide rabbit antiserum was generated targeting a GP131-specific peptide 
sequence, NH2-CYYPSTPIPKSFVKHVDTTRSLPE-COOH, conjugated with keyhole limpet 
hemocyanin (see Section 3 for details on generation of antibody). This antibody was used in 
western blot assay to examine purified virions (purified from passage 1 ATCC Strain 22122 
GPCMV), as well as infected cell lysates, for expression of the GP131 protein. Immune sera 
consistently demonstrated the appearance of a broadly migrating band at approximately 22 kDa.  
In some experiments, the band appeared to separate into two discrete bands at ~20 and ~22 kDa 
(Figure 3A). To confirm the specificity of this response for GP131, westerns were also performed 
using a recombinant, eGFP-expressing GPCMV, vAM403, known to lack the 1.6 kb region spanning 
the GP129-133 locus. Western assay targeting vAM403 proteins using the GP131 rabbit polyclonal 
antibody did not demonstrate presence of this band in purified lysates from cells infected with this 
virus, as expected (Figure 3A, Lane 2). 
The GP131-specific antibody was next examined in an immunofluorescence assay using cells 
transfected with a GP131 expression plasmid, pKTS 789. Immune, (but not pre-immune) sera 
identified a protein in GP131-transfected cells, but only under conditions of permeabilization 
(Figure 3B). This result is compatible with the known requirement of GP131 to be co-expressed 
with gH in order for cell surface localization. 
To identify GP129 in virions, a GP129-specific antibody was next generated following 
vaccination of naïve guinea pigs with a GST fusion protein, designated GST_R3_GP129 (described 
in Section 3). Three guinea pigs were immunized with fusion protein. All animals generated ELISA 
responses to GST_R3_129 (data not shown). The GST_R3_GP129 immune, but not pre-immune, 
sera identified a broadly migrating band in purified GPCMV virions (Figure 4). This result 
suggested that the GP129 protein is expressed in virions, and migrates broadly in the ~25 kDa 
range by SDS-PAGE. These data confirmed the identification of GP129-specific peptides present 
in the mass spectrometry analyses of virus particles. 
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Figure 3. Characterization of GP131 protein. (a) Western blot analysis using  
anti-peptide GP131 antibody. Virion particles were probed with either pre-immune sera 
(left panel) or immune sera (right panel) following purification of virus particles from 
cells infected either with ATCC GPCMV (Lane 1 in each panel) or vAM403 (Lane 2 in 
each panel). A band of approximately 20–22 kDa was noted with immune, but not  
pre-immune sera. On shorter exposure, this band appeared as a doublet. (b) Effect of 
cell permeabilization on detection of GP131. GPL cells were transfected with a GP131 
expression plasmid and immunofluorescence performed with anti-GP131 antibody. 
Little to no protein expression was detected in non-permeabilized cells (middle panel), 
but protein expression was readily detected following permeabilization (right panel). 
Left panel demonstrates pre-immune antibody control. 
 
(a) (b) 
Figure 4. Identification of GP129 in virus particles. Western blot analysis using an  
anti-GST/GP129 fusion protein derived antibody. Following electrophoresis with 12%  
Bis-Tris gel, western transfer was performed and virion particles were probed  
(1:200 dilution) with either pre-immune sera (left panel) or immune sera (right panel). 
GST_R3_129 immune (but not pre-immune) antisera identified a broadly migrating 
band with MW of the predominate species at ~25 kDa (arrow). Band was not identified 
in blots of vAM403 (lacking GP129-133 locus) virus particles probed with identical 
antibodies (data not shown). 
 
GP131 transfected GPL cells 
Permeabilized 




Anti-Peptide GP131  Ab 
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2.4. Characterization of Guinea Pig Antibody Reactivity to Recombinant-Expressed GP129, 131, 
and 133 
To examine the guinea pig immune response to GP129, 131, and 133, a series of GST fusion 
proteins were generated, corresponding to predicted immunogenic domains in the respective proteins. 
Primers used in the generation of these fusion proteins are indicated in Table 2. Immune responses 
in guinea pig convalescent sera from infected animals were readily demonstrable to GP129 fusion 
proteins. Three domains of GP129 (GP129 R1, R2, and R3; Figure 5) were cloned as GST fusion 
proteins and western blots probed with anti-GPCMV antisera obtained from experimentally 
infected animals. The R3 domain (Figure 6A) was the domain most highly immunoreactive with 
convalescent anti-GPCMV sera from infected animals. This region of the GP129 contains a 
cysteine residue highly conserved with HCMV and RhCMV UL128 (the homolog of GP129). 
Although interactions between UL128 and the other constituents of the pentameric complex are not 
believe to involve disulfide bond formation, this region of the UL128 protein in HCMV is known 
to be the target of neutralizing monoclonal antibodies [22,23]. When GP129 was expressed in 
recombinant baculovirus, purified recombinant protein was also immunoreactive with immune sera 
from animals challenged with salivary gland-adapted GPCMV (Figure 6B). Pre-immune sera failed 
to recognize the recombinant protein. These analyses strongly suggest that the GP129 protein is a 
target of the guinea pig antibody response following GPCMV infection. 
Figure 5. Subcloning of GP129, 131, 133 proteins. (a) Schematic map of the GPCMV 
GP129, 131 and 133 ORFs, patterned after [18]. These ORFs map to the rightward end 
of the GPCMV genome. Genome coordinates of this region are indicated (based on 
sequence Genbank KC503762 [24]). In contrast to HCMV, the GP131 (UL130) 
homolog is spliced, but the GP133 (UL131 homolog) is not. (b) GPCMV GP129, 
GP131, and GP133 ORFs. Predicted van Heinje signal sequence cleavage site is 
indicated by arrow. Cysteine residues are outlined in dark blue. Potential glycosylation 
sites (N-X-T and N-X-S) are shown in black outline. Regions of ORFs subcloned as 
GST fusion proteins are indicated. For GP129 and GP131, pink region represents R1 
region; blue, R2 region; yellow, R3. For GP133, pink region is R1 and yellow region 
R2 (see Table 2 and text for details). 
 
(a) 
 GP129                             GP131                   GP133 
198600 196600 
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Figure 5. Cont. 
 
(b) 
Figure 6. Antibodies from GPCMV-seropositive guinea pigs react with recombinant 
forms of GP129. (a) Analysis of GP129/GST fusion proteins. Three GP129 domains 
(Figure 5b) were cloned in-frame with GST using vector pGEX 6-P as described in 
materials and methods. Constructs evaluated by western blot included GST only;  
GST-GP129R1 fusion; GST-GP129R2 fusion; and GST-GP129R3 fusion, without 
IPTG induction (uninduced) and following IPTG induction (induced). Anti-GPCMV 
antisera from immune, experimentally infected guinea pigs demonstrated strongest 
immunoreactivity with GST-GP129R3 fusion protein. In some experiments, some 
signal could be observed with GP129R2 fusion protein. Data shown is a representative 
result from an experimentally infected animal. All fusion proteins expressed to high 
levels following IPTG induction as demonstrated by western analysis with anti-GST 
monoclonal antibody (data not shown). No background reactivity was noted with serum 
from GPCMV-seronegative animals or with pre-immune sera from experimentally 
infected guinea pigs (data not shown). (b) Western blot analysis of recombinant 
baculovirus-expressed GP129. The GP129 was cloned in-frame with GFP and a 6-His 
tag. This resulted in a fusion protein of ~55 kDa, made up of ~6 kDa from the 6-His tag 
and vector sequences; ~28 kDa from the GFP sequence; and ~21 kDa from the GP129 
sequences. Purified recombinant protein was subjected to SDS-PAGE and western 
assays performed as described in materials and methods section. For some western 
blots, a control baculovirus expressing a recombinant form of the GPCMV GP73.5 
glycoprotein was also evaluated. Top panel, both the anti-GFP and anti-6 His 
antibodies were immunoreactive with GP73.5 (~37 kDa) and GP129 (~55 kDa) fusion 
proteins, as expected. A higher MW band was noted at ~65–70 kDa, possibly 
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representing a glycosylated variant of the baculovirus-expressed GP129 fusion protein. 
Sera, raised against the GST-GP129-R3 fusion protein (Figure 5a), was also used to 
probe baculovirus-expressed GP129 as a control. Immune, but not preimmune, sera 
(1:200 dilution) from a guinea pig immunized with the GST fusion protein were 
reactive with the baculovirus expressed protein, but not proteins in uninfected SF9 
cells. Again, both the 55 kDa fusion protein as well as a larger species of 65–70 kDa, 
were identified. (c) Sera from experimentally infected animals were immunoreactive 
with the GP129-baulovirus fusion protein. Results shown are representative pre- and 
post-infection sera (1:200 dilution) from two GPCMV-infected guinea pigs (GP1; GP2) 
demonstrating immunoreactivity with bacolovirus-GP129 fusion protein (arrow), but 
not a pre-immune guinea pig serum (NEG).  
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Figure 6. Cont. 
 
(c) 
The guinea pig antibody response to GP131 was next evaluated, using recombinant GP131 in 
western blot assay along with sera from GPCMV-seropositive guinea pigs. As was the approach for 
GP129, the GP131 coding sequence was first subcloned as three GST fusion proteins, spanning 
potentially immunogenic domains of the GP131 protein (GP131 R1, R2 and R3). The GST fusion 
proteins were purified and, following western transfer, blots were probed with sera from 
experimentally infected GPCMV-seropositive animals (1:200 dilution; details as noted in Figure 6).  
A representative result from a GPCMV-infected animal is shown. These analyses demonstrated 
(Figure 7) that convalescent, but not pre-immune, sera from GPCMV-infected guinea pigs 
recognized the GST fusion protein corresponding to domains R1, R2 and R3 of the GP131 ORF.  
Figure 7. Characterization of antibody responses of GPCMV-infected guinea pigs to 
recombinant GP131 proteins. Western blots examining reactivity of anti-GPCMV 
antisera with uninduced and IPTG-induced GST-GP131R1, R2, and R3 fusion proteins. 
GP133R1 and GP131R3 were most consistently reactive with post-infection antisera 
(1:200 dilution), but not preimmune sera (data not shown). Representative result from an 









































































































































Finally, antibody responses to recombinant GP133 proteins were assessed. GP133 coding 
sequences were subcloned as depicted in Figure 5b. GST fusion constructs corresponding to 
Region 1 (predicted MW of 31.8 kDa) and Region 2 (predicted MW of 28.5 kDa) were evaluated, 
as well as a full-length GST fusion construct spanning both domains (R1/R2 construct; predicted 
MW of 34.8). These fusion protein clones were generated using primers as depicted in Table 2. The 
GST fusion proteins were purified from insoluble inclusion bodies and, following western transfer, 
blots were probed with convalescent sera from GPCMV seropositive animals that had been 
infected subcutaneously with SG virus. Results were confirmed with three independently  
GPCMV-infected guinea pigs; Figure 8 demonstrates representative results from one of these 
animals. These analyses demonstrated that convalescent, but not pre-immune (data not shown), 
sera from GPCMV-infected guinea pigs recognized the proteins corresponding to both the R1 and 
the R1/R2 regions of GP133 expressed as GST fusions, but not the R2 region of the GP133 protein. 
Reactivity of sera from infected animals, in contrast, was not noted with recombinant GP133 
expressed as a GFP/6-His fusion protein in recombinant baculovirus (data not shown). This may 
have been due to loss of reactive epitopes engendered by fusion of the GFP and 6-His tags on the 
amino-terminal coding sequences of the recombinant GP133 protein. Further experiments will be 
necessary to resolve this question. 
Figure 8. Characterization of antibody responses from GPCMV-immune guinea pigs to 
recombinant GP133 protein. (a) Antisera from a GPCMV-infected animal [GPCMV (+)] 
demonstrates immunoreactivity with the GST-GP133_R1_fusion protein (arrow) but not 
with purified GST protein. Sera is not reactive with GST-R2 fusion protein (right panel). 
Anti-GST moab (1:5,000 dilution) demonstrated reactivity both with the GST-GP133R1, 
R2, and R1/2 fusion proteins, as well as the purified GST protein. (b) Western analysis of 
GST-GP133R1/2 fusion protein. Both GST (GST vector) and GST-GP133R1/2 fusion 
protein are reactive with anti-GST moab; however, only sera from GPCMV-infected 
animal [GPCMV(+), 1:200 dilution] was reactive with the GST-R1/2 fusion protein. For 
both experiments, pre-immune sera from GPCMV-infected guinea pig was unreactive with 
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Table 4 summarizes the immunoreactivity of the various GST fusion constructs (depicted in 
Figure 5b) with immune sera from infected guinea pigs post-infection with SG virus. Designations: 
( ), no immunoreactivity; (+), minimal immunoreactivity; (++), moderate immunoreactivity; (+++) 
consistent, high-level immunoreactivity. 
Table 4. Summary of reactivity of sera from infected guinea pigs with GST-GP129, 
131 and 133 fusion proteins.  
GST Fusion Protein 
Domain 
Immunoreactivity with Guinea Pig Sera Post-Experimental 









3. Experimental Section  
3.1. Cells and Virus 
GPCMV (Strain 22122/VR682 from American Type Culture Collection [ATCC], Manassas, 
VA, USA), and vAM403, an enhanced green fluorescent protein (eGFP)-tagged GPCMV [19] were 
propagated on guinea pig fibroblast lung cells (GPL; ATCC CCL 158) in F-12 medium 
supplemented with 10% fetal calf serum (FCS; Gibco-BRL), 10,000 IU of penicillin/liter, 10 mg of 
streptomycin/liter, and 7.5% NaHCO3 (Gibco-BRL).  
3.2. EM and Mass Spectrometry Analyses 
For mass spectrometry analyses, GPCMV (Strain 22122; ATCC VR-682) was propagated on 
GPL cells as described previously, and virus particles were purified from culture supernatants by 
density gradient centrifugation. Virus was purchased from ATCC and subjected to only one 
passage in GPL culture to minimize selection for genome variants with deletion in the GP129-133 
locus [16]. Briefly, cellular debris was removed from the culture supernatant by repeated centrifugation 
at 4,000 × g for 15 min and supernatant was collected. GPCMV particles were separated by 
centrifugation at 11,000 × g for 30 min and pellet was washed twice in phosphate-buffered saline 
(PBS). Virion particles were resuspended in PBS and loaded onto a 20%–70% sucrose gradient  
(27 mL) in SW 32 centrifuge tubes and subjected to ultracentrifugation at 22,000 RPM/25 °C for 
60 min. The visualized band was then subjected to glycerol-tartrate gradient centrifugation as 
described elsewhere [21]. Particles were washed and protein concentration was quantified by BCA 
assay (Thermo Fisher Scientific, Waltham, MA, USA). Particles were also subjected to electron 
microscopy. First, particles were centrifuged at 30 PSI using an airfuge (Belkman-Coulter, Brea, CA, 
USA) for 20 minutes on parafilm and formvar coated copper grids (Electron Microscopy Sciences, 
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Hatfield, PA, USA). Excess liquid was wicked and the grids were stained with 1% phosphotungstic 
acid for one minute. All sections were observed under JEOL 1200 EX II transmission electron 
microscope (JEOL LTD, Tokyo, Japan). Images were obtained using a Veleta 2K × 2K camera 
with iTEM software (Olympus SIS, Munster, Germany) [25]. GPCMV particles were then resolved 
by SDS-PAGE and resolved protein bands were visualized by Coomassie stain. Visible bands were 
excised and subjected to in-gel trypsin digestion [26]. The digested peptide mixtures were analyzed 
using LTQ LC-MS/MS system or Velos Orbitrap LC-MS/MS system (ThermoFisher, San Jose, 
CA, USA) as previously described [27,28]. Tandem mass spectra were searched with Sequest 
version 2.7 (ThermoFisher, San Jose, CA, USA) and peptide and probability scores were applied in 
Scaffold 3.6.5 (Proteome Software, Inc., Portland, OR, USA) [29] as specified by Protein Prophet [30] 
and Peptide Prophet [31]. Mass spectra were searched against a combined protein FASTA database 
with sequence entries from NCBI Reference Sequence Cavia porcellus [32] NCBI nr Caviid 
herpesvirus 2 [33] and common lab contaminants from [34]. Manual inspection of all spectra 
validated the peptide assignments made by Scaffold. 
3.3. Transcriptional Analyses 
Guinea pig lung fibroblasts (GPL) were infected with ATCC GPCMV P1 virus at MOI of 0.1. 
After one hour of infection at 37 °C, cells were washed with PBS and cultured in F12 medium 
supplemented with 10% fetal calf serum, 10,000 IU/L penicillin, 10 mg/L streptomycin, and 7.5% 
NaHCO3. RNA was extracted from infected GPL cells at 8, 12, 24 and 48 hours post-infection 
using RNeasy mini kit (Qiagen, Venlo, Limburg, NL) according to the manufacturer’s instructions. 
RNA was treated with RNase-free DNase Set (Qiagen) while in the column according to 
manufacturer’s instructions. cDNA was synthesized from 1 g of total RNA using either Quantitect 
Reverse Transcription kit (Qiagen). Conventional PCR was carried out using cDNA as  
template and goTaq (Promega, Madison, WI, USA). The PCR for GAPDH were done using primer 
pair 5'-ATCTCATCGTATTTGGCCGGT-3' and 5'-AATGGGAAGCTCACAGGTATGG-3'. The 
conditions for GAPDH PCR were: initial denaturation at 95 °C for 2 min, followed by 95 °C for 30 
s, 58 °C for 30 s, 72 °C for 35 s for a total of 25 cycles, and elongation at 72 °C for 7 min. GP129 
PCR primers are listed in Table 2. The conditions of the GP129 PCR were: initial denaturation at 
95 °C for 2 min, followed by 95 °C for 30 s, 56 °C for 30 s, 72 °C for 35s for a total of  
35 cycles, and elongation at 72 °C for 7 min. The primers for GP131 PCR were  
5'-ATAATGATGAAACGATAT-3' and 5'-TTATCACGTCCAGTTCCA-3'; the conditions were 
the same as GP131 but the annealing temperature was 48 °C. GP133 PCR was done using primer 
pair 5'-TATGTTTTGGCGTCTTGTA-3' and 5'-TTATGCTCTGTCTATGC-3', and the same 
conditions as GAPDH. Amplicons from the PCR were resolved by agarose gel electrophoresis and 
visualized by ethidium bromide staining.  
3.4. Recombinant Baculovirus Expression 
To analyze the protein products encoded by GP133, GP131 and GP129 regions of the GPCMV 
genome, proteins were expressed in recombinant baculovirus. Baculovirus shuttle plasmids were 
generated. Briefly, ORF coding sequences GP129, GP131 and GP133 were amplified from cDNA 
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by PCR using the primers listed in Table 2. Amplicons were resolved by agarose gel 
electrophoresis and visualized by ethidium bromide staining. The purified amplicons were ligated 
into digested pAc-HLT-A-GFP vector (BD Biosciences, San Jose, CA, USA) at the C-terminus of 
the GFP-His tag following conventional cloning methods. The resultant clones encoding GP133, 
GP131 and GP129 were designated pKTS 824, pKTS 791 and pKTS 814, respectively. 
Recombinant baculoviruses were generated by co-transfecting Sf9 cells with aforementioned 
plasmids and BaculoGold® DNA (BD Biosciences) according to manufacturer’s instructions.  
3.5. Recombinant Antigenic GP129, GP131 and GP133 Fragment Expression 
Antigenic domains for GP129, 131 and 133 were predicted using MacVector software (version 
12.0) [35] by calculating antigenic index based on the results of Kyte-Doolittle hydrophilicity, 
surface probability, protein flexibility, and Chou-Fasman and Robson-Garnier secondary structure 
analyses. To screen for potential antigenic regions of GP129 that are recognized by the GPCMV 
guinea pig sera, three predicted antigenic fragments R1 (TYR12 through THR50), R2 (SER79 
through ARG129) and R3 (ASN146 through LYS179) were expressed as GST fusion proteins.  
Briefly, R1, R2 and R3 coding sequences of GP129 were amplified from cDNA by PCR using the 
primers listed in Table 2. The purified amplicons were ligated into linearized pGEX-6P vector  
(GE Healthcare Biosciences, Pittsburgh, PA, USA) at the C-terminus of the GST following 
conventional cloning methods. The resultant clones encoding R1-GP129, R2-GP129, R3-GP129 
were designated pKTS 828, 829 and 830, respectively. For GP131, the clones were designated as 
pKTS 818, 819, and 820 (domains R1, R2, and R3, respectively). For GP133, clones encoding  
R1-GP133 and R2-GP133 were designated as pKTS 831 and pKTS 832 respectively. 
The aforementioned plasmids corresponded to these fusion proteins were sequenced, and then 
were transformed into MAX EFFICIENCY® DH5  chemically competent cells (Invitrogen, 
Carlsbad, CA, USA) and screened on LB plates containing ampicillin (100 g/mL). DH5  cells 
harboring the above plasmids were selected to express GST fusion proteins under IPTG induction 
(0.5 mM). GST-fusion proteins were extracted and purified using Glutathione agarose beads 
(Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. 
3.6. Western Blot 
Recombinant GP129, GP131 and GP133 proteins were characterized by western blot. Briefly, 
80% confluent monolayer of Sf9 cells were infected with recombinant baculovirus and after  
120 hours of infection, the cells were harvested and washed twice with PBS. Cellular proteins were 
extracted and recombinant GP129, GP131 and GP133 fusions proteins were purified using Ni-NTA 
agarose beads according to the manufacturer’s instruction (Qiagen). Either purified recombinant 
GP129, GP131 or GP133-expressing Sf9 cell lysates were resolved by SDS PAGE (Novex-10%–20% 
Tris-HCl, Life Technologies, Carlsbad, CA, USA) and electro blotted to PVDF membrane. Blots 
were blocked with 5% skim milk solution in PBS containing 0.1% Tween-20 for 2 hours. Blots 
were probed with anti-GFP monoclonal (1:3,000 dilution), anti-6-His monoclonal (1:2,000 
dilution), anti-GST monoclonal (1:5,000 dilution), preimmune and post-infection sera from guinea 
pigs (1:200 dilution for most experiments as indicated in individual figure legends), pre-immune 
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rabbit sera (both at 1:2,000 dilution), anti R3-GP129 guinea pig sera (1:2,000 dilution) or rabbit 
affinity-purified, GP131 anti-peptide antibody (concentration 1 g/mL) for one hour, followed by 
incubation with either horseradish peroxidase (HRP)-conjugated anti-guinea pig (1:10,000 dilution, 
Sigma, St. Louis, MO, USA), HRP-conjugated anti-rabbit (1:2,000 dilution; Cell Signaling 
Technology, Danvers, MA, USA) or HRP-conjugated anti mouse (1:10,000; GE Healthcare 
Biosciences) secondary antibody. Anti-GPCMV gB moab IE321 was used at a 1:2,000 dilution. 
Binding of antibody was detected by adding enhanced chemiluminescent substrate (GE Healthcare 
Biosciences) for HRP and bands were visualized by exposing the blot to an X-ray film.  
3.7. Generation of Antibodies 
GP131-specific anti-peptide antibodies were raised in rabbits (US Biological, Salem, MA, 
USA). A synthetic peptide, NH2-CYYPSTPIPKSFVKHVDTTRSLPE-COOH, was generated and 
conjugated with keyhole limpet hemocyanin (KLH). Rabbits were immunized with 200 g of the 
conjugate and complete Freunds adjuvant (CFA), followed by three subsequent doses of the 
conjugate (100 g) and incomplete Freunds adjuvant (IFA) at 21, 42 and 72 days following  
initial immunization. Serum was collected seven days after final immunization. GP131-specific 
anti-peptide antibodies were purified from the aforementioned rabbit serum by affinity  
column chromatography using cyanogen bromide-activated sepharose 4B gel coupled to  
NH2-CYYPSTPIPKSFVKHVDTTRSLPE-COOH. 
R3-GP129 antibodies were raised in Strain 2 guinea pigs (University of Minnesota RAR facility, 
Minneapolis, MN, USA). GPCMV-seronegative guinea pigs were immunized with 50 g of the 
purified GST_R3_GP129 and incomplete Freunds adjuvant (IFA), followed by three subsequent 
doses of the GST_R3_GP129 (30 g) and incomplete Freunds adjuvant (IFA) at 21, 42 and 72 days 
following initial immunization. Sera were collected seven days after final immunization.  
GPCMV sera were generated by infecting seronegative Hartley strain guinea pigs (Elm Hill 
laboratories, Chelmsford, MA, USA) with salivary gland-adapted GPCMV. Infection was by 
subcutaneous route with a dose of 5 × 105 pfu. Animals were monitored for seroconversion by 
ELISA assay and western blot, and preimmune and immune (post-infection) sera were used to 
probe GP129, 131 and 133 recombinant proteins at dilutions of 1:200 as described in individual 
figure legends. 
4. Conclusions  
These results confirm and extend the observations of Feierbach by identifying the GP129, 131 
and 133 proteins in virus particles purified from GPCMV-infected cells [18]. There are potential 
limitations to our analyses. We performed these studies using strain 22122 of GPCMV from the 
ATCC. This strain is known to harbor two genomic variants of GPCMV, with the second variant 
containing a 1.6 kb genome deletion that lacks the GP129-133 locus. It is possible that our studies 
underestimated the presence of GP129-133 proteins by selecting for the deletion variant in cell 
culture in fibroblasts [16]. However, we used virus passaged only one time in GPL cells, and by 
PCR analysis we were able to confirm that the majority of the genome variants in cell culture were 
full-length, compatible with our finding of the GP129-133 proteins by mass spectrometry. Another 
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potential limitation of these studies was the lack of full characterization of whether there were 
dense bodies co-purifying with virions in our purified virus. A more detailed characterization of 
GPCMV virions and dense bodies will be required in future studies to elucidate what differences 
exist in the proteome of these respective particles. 
Using anti-peptide antisera (GP131) and an anti-GST fusion protein antibody (GP129), we were 
able to identify both the GP131 and GP129 proteins in purified virus particles by western blot. The 
GP131 was found to migrate as a doublet at ~20 and 22 kDa. The virion-associated GP129 
migrated at ~25 kDa, compatible with its predicted potential to undergo more extensive 
glycosylation (Figure 5b). The GP129 protein also appeared to migrate as a double (at ~55 and  
~65 kDa) in Sf9 cells infected with a recombinant baculovirus expressing GP129 as a GFP/6-His 
fusion, also compatible with differential glycosylated isoforms of the protein in insect cells. 
Experiments with glycosylation inhibitors will be required to examine this question in further 
detail. We were unable to identify GP133 in virions using an anti-GST antibody raised against a 
GP133-GST fusion protein (data not shown). However, the finding of GP133 by mass spectrometry 
analysis of viral particles provides assurance that this protein is expressed in the mature virion. 
Using GST fusions and, for GP129, a recombinant baculovirus-expressed protein, we were able 
to identify antibody responses in serum from guinea pigs experimentally infected with GPCMV. 
We were unable to identify immunoreactivity of sera from GPCMV-infected animals with 
recombinant insect cell-expressed forms of GP131 and 133. Both the GP131 and GP133 
baculovirus-expressed proteins were reactive with anti-6-His and anti-GFP antibodies at the 
predicted MWs of ~56 and ~49 kDa, respectively (data not shown), indicating that the recombinant 
baculovirus fusion protein was being expressed in insect cells. It may be that fusion of GFP and/or 
6-His at the amino-terminus of these fusion proteins rendered relevant epitopes inaccessible. Our 
study was also limited by examination of a relatively small number of sera from infected animals. 
In summary, GPCMV encodes homologs of HCMV PC complex proteins, GP129, 131, and 133, 
and these proteins are expressed and can be identified in virions by mass spectrometry. Furthermore, 
using recombinant GST and baculovirus expressed proteins, we observe that the GP129/131/133 
constituents of the GPCMV PC appear to elicit an antibody response in the context of viral 
infection in animals. These observations reinforce interest in studying the GPCMV PC as a 
potential target of protective subunit vaccination in the GPCMV model of congenital infection. The 
precise protein-protein interactions in this complex remain to be elucidated. In a model of the 
protein-protein interactions that make up the gH/gL/UL128/UL130/UL131 complex, the HCMV 
gH protein is predicted to be inserted in the viral envelope, and interacts with gL through disulfide 
bond formation. Johnson et al. characterized the HCMV PC using a system of HCMV mutants 
lacking UL128-131, differentially reconstituted with non-replicating adenovirus vectors expressing 
gH, gL, UL128, UL130, and UL131 [4]. The assembly of a pentameric structure was further 
suggested by the observation of increased export of gH/gL complexes from the endoplasmic 
reticulum (ER) to the Golgi apparatus and cell surface when UL128, UL130, and UL131 were 
expressed with gH/gL [4]. Direct covalent disulfide bonds between HCMV gH/gL and 
UL130/UL131 were suggested by differential immunoprecipitation of heterodimers in reducing and 
non-reducing environments; direct non-covalent interactions between gH/UL130, gL/UL128, and 
UL128/UL130 were also observed. These complex interrelationships remain to be elucidated for 
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the GPCMV PC. Evaluation of GPCMV neutralization following immunization with GPCMV 
pentameric complex constituents should help clarify which of these proteins are most important in 
elucidation of a protective immune response, and subunit vaccine studies in guinea pigs should 
help provide a useful proof-of-concept for the potential usefulness of a PC-based HCMV vaccine. 
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Figure A1. Mass spectrometry data for GP129. Representative mass spectra for each of 
the unique peptides identified using Velos Orbitrap LC-MS/MS system for GP129.  
B peaks are labeled in red. Y peaks are labeled in blue. Additional charge variants  








Figure A2. Mass spectrometry data for GP131. Representative mass spectra for each of 
the unique peptides identified using Velos Orbitrap LC-MS/MS system for GP131.  
B peaks are labeled in red. Y peaks are labeled in blue. Additional charge variants are 
marked in green. (a) Spectrum for RIDYGSTGTAASTLPSLTSLR. (b) Spectrum  
for TYFGDRDSSFLWHYTIR. (c) Spectrum for TLDCDVYVTSR. (d) Spectrum  









Figure A2. Cont. 
 
(d) 
Figure A3. Mass spectrometry data for GP133. Representative mass spectra for each of 
the unique peptides identified using Velos Orbitrap LC-MS/MS system for GP133. B 
peaks are labeled in red. Y peaks are labeled in blue. Additional charge variants are 
marked in green. (a) Spectrum for EDEGIDTWWLGGVTDNTR. (b) Spectrum for 
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Abstract: Human cytomegalovirus (HCMV) gene expression during infection is 
characterized as a sequential process including immediate-early (IE), early (E), and late 
(L)-stage gene expression. The most abundantly expressed gene at the IE stage of 
infection is the major IE (MIE) gene that produces IE1 and IE2. IE1 has been the focus 
of study because it is an important protein, not only for viral gene expression but also 
for viral replication. It is believed that IE1 plays important roles in viral gene regulation 
by interacting with cellular proteins. In the current study, we performed protein array 
assays and identified 83 cellular proteins that interact with IE1. Among them, seven are 
RNA-binding proteins that are important in RNA processing; more than half are 
nuclear proteins that are involved in gene regulations. Tumorigenesis-related proteins 
are also found to interact with IE1, implying that the role of IE1 in tumorigenesis might 
need to be reevaluated. Unexpectedly, cytoplasmic proteins, such as Golgi autoantigen and 
GGA1 (both related to the Golgi trafficking protein), are also found to be associated with 
IE1. We also employed a coimmunoprecipitation assay to test the interactions of IE1  
and some of the proteins identified in the protein array assays and confirmed that the 
results from the protein array assays are reliable. Many of the proteins identified by the 
protein array assay have not been previously reported. Therefore, the functions of the 
IE1-protein interactions need to be further explored in the future. 
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1. Introduction 
Human cytomegalovirus (HCMV) has been defined as one of the major infectious agents related to 
AIDS. HCMV infects large populations in general and causes serious diseases in immunocompromised 
individuals [1–3]. A sequential process of viral events is characterized for CMV infection in 
permissive host cells [3], including viral entry, immediate-early (IE) and early gene expression, 
DNA replication, late (L) gene expression, viral packaging and release. Major immediate-early 
(MIE) gene expression is one of the earliest events during CMV infection. MIE genes are the most 
abundantly expressed viral genes at the IE stage and give rise to several nuclear phosphoproteins 
that are critical for the next stage of gene expression and viral replication [4–14]. Hence, the 
HCMV MIE gene has been the focus of study. IE1 is believed to be the first de novo viral protein 
produced after HCMV infection and is essential for HCMV replication when HCMV is infected at 
a low multiplicity of infection (MOI).  
In general, IE1 has been considered as a gene activator. How IE1 activates gene expression is 
not fully understood. Several mechanisms that are involved in this activation (by IE1) have been 
described by different groups. First, IE1 interacts with nuclear corepressors such as PML, Daxx, 
and Sp100, thereby reducing their repressive effects on gene expression [15,16]. It was found by 
different groups independently that IE1 interacts with HDAC and inhibits HDAC’s activity [15,17]. 
Second, IE1 disperses ND10, a nuclear domain that contains many different nuclear suppressive 
proteins and responds to interferon stimulation [18–21]. In addition, innate cellular defense directed 
by interferons was disrupted by IE1 via inhibiting JAK-STAT signaling and by interacting with 
STAT1 [22–24]. The IE1 protein counteracts virus- or type I IFN-induced ISG activation via 
complex formation with STAT1 and STAT2 resulting in the reduced binding of ISGF3 to  
ISREs [22–25]. Last, IE1 is important for HCMV to arrest the cell cycle in the G1 phase that favors 
the infected HCMV for the cellular microenvironment. IE1 binds the Rb-related p107 protein and 
relieves its repression of E2F-responsive promoters [26]; IE1 also induces p53 accumulation 
through activating the p53 pathway by increasing the levels of p19Arf and by inducing the 
phosphorylation of p53 at Ser15 [27], which might also relate to the HCMV-caused “G1 arrest” of 
infected cells. The mechanisms used by IE1 to activate viral gene expression perhaps all depend on 
IE1-protein interactions. Therefore, it is important to identify the cellular proteins interacting with 
IE1 at a global level. 
2. Results 
One of the major challenges in the post-genomic era is to explore the functional elements in the 
human genome. It also applies to the virus-host interaction. Identifying the cellular proteins that 
interact with the important virus proteins will certainly contribute to the understanding of the 
mechanisms that the virus uses for its gene expression and replication. Protein arrays constitute a 
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powerful tool for high throughput and multiplexed protein analysis, including protein detection, the 
investigation of protein interactions with various types of molecules, and the determination of 
protein functions [28]. Protein array technology is highly sensitive and generates large amounts of 
data in a single experiment with comparatively low sample consumption; therefore, it is highly 
economical [28]. In current studies, we used protein array assays to screen cellular proteins that 
interact with HCMV IE1. Here we report our experimental results. 
First, we isolated the IE1 from an IE1-producing cell line (previously called U373-IE1, now 
called U-251 MG-IE1) [29] using a specific anti-IE1 antibody that was later incubated with  
beads-conjugated secondary antibody after which the beads were washed in binding/wash buffer 
(20 mM Na2HPO4, 0.15 M NaCl, pH 7.0). The pulled-down IE1 was washed off from the 
secondary antibody-bound beads with elution buffer (0.1 M glycine, pH 2–3), and the eluted 
solution was immediately neutralized with neutralization buffer (1 M Tris, pH 8.5). The isolated 
IE1 was confirmed by Western blot assay as shown in the top of Figure 1. Then the isolated IE1 
was incubated at room temperature for 1 hour with the 22 cm × 22 cm PVDF membranes 
presenting up to 7390 in situ expressed human proteins (Cat# Unipex_1, _2, library # 9027, #9028, 
imaGenes GmbH, Berlin, Germany). After 24 h of incubation with primary anti-IE1 antibody at  
4 °C, the membrane was washed with the buffer 2 times followed by incubation with a horseradish 
peroxidase-coupled secondary antibody (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and 
detection with enhanced chemiluminescence (Pierce, Rockford, IL, USA), according to standard 
methods. As can be seen in Figure 1A,B, 83 cellular proteins were found to bind to IE1. In the PVDF 
membrane, each in situ expressed cellular protein is presented in doublets, which is why we can see 
2 dots together for each protein. We set up cutoffs according to the background index. Figure 1A,B 
represents 2 PVDF membranes that were processed at the same time with the same samples. The 
83 proteins are listed in the Table 1 with their Gene bank #, name, function, and references.  
Further analysis of the 83 proteins revealed some important information: First, some of them 
have already been reported to interact with IE1. These are ATRX (#13) [15], splicing factor, 
arginine/serine-rich 2 (#40) [18], and Daxx (#65) [30]. Second, some of them are reported to be 
important for CMV infection but they have not been shown to interact with IE1, these are CDC25A 
(#10) [31], ATF4 (#41) [32], BCL-2 (#46) [33], and Ataxin (#39) [34]. In addition, 7 of the 
proteins that interact with IE1 are RNA binding proteins: RNA binding motif protein 10 (RBM10) 
(#5), RNA binding motif protein 5 (#20), Staufen, RNA binding protein (#26), splicing factor, 
arginine/serine-rich 2 (#40), heterogeneous nuclear ribonucleoprotein F (#52), RD RNA binding 
protein (#59), and PRP40 pre-mRNA processing factor 40 B (#60). All the RNA-bonding proteins 
are important for pre-mRNA processing. To our surprise, neither HDAC1, 2, or 3 nor TRIM19 
(PML) is on the list; however, HDAC10 (#15) and TRIM33 (#57) are both detected as IE1-binding 
proteins with high signals (Figure 1). 
Since most of the IE1-interacting proteins in the Table 1 have not been reported, we need to 
validate the reliability of the results from the protein arrays. For that purpose, we performed a 
coimmunoprecipitation (coIP) assay using antibodies on hand to examine whether the proteins can 
be pulled down by the anti-IE1 antibody. The IE1-producing cell line (U-251 MG-IE1) [29] was 
cultured at 37 °C until it reached 95% confluence. The nuclear extract was prepared according to 
the protocol as described in Material and Method section. The nuclear extracts were incubated with 
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anti-IE1 antibody or with normal IgG and then secondary antibody-conjugated beads. After several 
washings, the eluted complexes from the beads were examined by Western blot assay using 
antibodies against the proteins as indicated in Figure 2. All the proteins from the list that are 
examined by Western blot assay were positive. We also examined the tubulin as control and it was 
negative. Therefore, the results from the protein arrays are reliable.  
Figure 1. Protein Array. The isolated IE1 was incubated with the two PVDF 
membranes, which was followed by incubation with a horseradish peroxidase-coupled 
secondary antibody (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and detection 
with enhanced chemiluminescence (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA), 







Table 1. List of the Human Cytomegalovirus (HCMV) IE1 Protein-Protein Interactions 
(PPIs) by Protein Array Assay. The positive spots in Figure 1A,B were listed in this 
table according to the manufacturer’s annotation table. The dots are all in doublets. 
Some genes overlap between the two PVDF membranes. Cellular Proteins Interacting 
with Human Cytomegalovirus IE1 (Identified by Protein Array Assays). 
GenBank entry# Name of the protein Function Ref. 
AF217982 CDK5 regulatory subunit associated protein Tumorigenesis and metastasis [35] 
D84294 TPRDI (tetratricopeptide repeat) Down syndrome [36] 
BC069268 Golgi autoantigen, golgin subfamily a Tentacular matrix [37] 
NM_007144 Polycomb group ring Finger 2 (PCGF2) Embryogenesis and tumorigenesis [38] 
NM_005676 RNA binding motif protein 10 (RBM10) RNA-related apoptosis [39] 
Z11584 NuMA protein Spindle orientation [40] 
BC022880 Breast carcinoma amplified sequence 2 Negative regulator of p53 [41] 
BC057387 LSM14B, SCD6 homolog B Regulation of translation [42] 
BG354577 CDCA4 Cell division cycle associated gene 4 Transcription regulation [43] 
NM_001789 Cell division cycle 25 homolog A (CDC25A) Cell cycle regulation [44] 
NM_003026 SH3-domain GRB2-like 2 (SH3GL2) Tumorigenesis [45] 
NM_203505 GTPase activating protein binding protein 2 Stress granule formation [46] 
XM_001128623 Transcriptional regulator ATRX Transcriptional repression [47] 
NM_153273 Inositol hexaphosphate kinase 1 (IHPK1) Type 2 diabetes [48] 
NM_032019 Histone deacetylase 10 (HDAC10) Cancer metastasis [49] 
NM_001040653 ZXD family zinc finger C (ZXDC) MHC gene transcription [50] 
NM_138383 




Adrenocortical dysplasia homolog (mouse) 
(ACD), transcript variant 1 
Tumorigenesis [52] 
AK122898 ADP-ribosylation factor binding protein GGA1 Trans-olgi network [53] 
AB208813 RNA binding motif protein 5 Gene splicing factor [39] 
NM_170677 Meis homeobox 2 (MEIS2) Unknown [54] 
NM_000038 Adenomatosis polyposis coli (APC) Tumor supresor [55] 
NM_003660 
Protein tyrosine phosphatase, receptor type f 
polypeptide (PTPRF), interacting protein (liprin), 
alpha 3 (PPFIA3) 
Unknown [56] 
NM_012398 
Phosphatidylinositol-4-phosphate 5-kinase, type 
I, gamma (PIP5K1C) 
Lethal contractural syndrome [57] 
NM_003861 WD repeat domain 22 (WDR22) Unknown N/A 
NM_017453 Staufen, RNA binding protein mRNA traffic [58] 
BC017222 Sequestosome 1 Signal transduction [59] 
NM_152586 Ubiquitin specific peptidase 54 (USP54) Unknown [60] 
NM_014868 Ring finger protein 10 (RNF10) Type 2 diabetes [61] 
BC041897 
SplA/ryanodine receptor domain and SOCS box 
containing 3 
Inflammation [62] 
AB209534 Tumor rejection antigen (gp96) 1 Unknown N/A 
NM_001080424 Jumonji domain containing 3 (JMJD3) Histone demethylation [63] 
NM_006312 Nuclear receptor co-repressor 2 (NCOR2) Gene suppressor [64] 
AK124656 Gamma enolase (EC 4.2.1.11) Neural tissue development [65] 
422 
Table 1. Cont. 
GenBank entry# Name of the protein Function Ref. 
AK123065 Sperm acrosomal protein Motility of the spermatozoon [66] 
NM_001098800 Melanoma antigen family D 4 (MAGED4) Renal cell carcinoma [67] 
NM_021098 
Calcium channel, voltage-dependent, T type, alpha 
1H subunit (CACNA1H) 
T-type Ca(2+) channel activity [68] 
NM_001417 Eukaryotic translation initiation factor 4B (EIF4B) Translation control [69] 
NM_002973 Ataxin 2 (ATXN2) Spinocerebellar ataxia type 2 [70] 
BC070086 Splicing factor, arginine/serine-rich 2 Gene splicing [18] 
NM_001675 Activating transcription factor 4 (ATF4) Gene transcription [71] 
AB209149 Phenol-sulfating phenol sulfotransferase 1 Transfer of a sulfonate moiety [72] 
AY509035 Roundabout-like protein 3 (ROBO3) Horizontal gaze palsy [73] 
NM_014751 Metastasis suppressor 1 (MTSS1) Metastasis [74] 
AY335491 GON4L isoform C (GON4L) Hematopoiesis [75] 
NM_014739 BCL2-associated transcription factor 1 Transcriptional repression [76] 
AB067518 KIAA1931 protein Unknown N/A 
NM_003200 
Transcription factor 3 (E2A immunoglobulin 
enhancer binding factors E12/E47) (TCF3) 
Transcription regulation [77] 
AB209197 Protein phosphatase 1 (PP1) Multiple functions [78] 
NM_020226 PR domain containing 8 (PRDM8) Gene repressor [79] 
XM_166659 OTU domain containing 1 (OTUD1) Unknown N/A 
NM_001098208 Heterogeneous nuclear ribonucleoprotein F (HNRPF) Gene splicing [80] 
AB209441 Fibroblast growth factor receptor 3 isoform 1 precursor Development [81] 
NM_152643 
Kinase non-catalytic C-lobe domain (KIND) 
containing 1 (KNDC1) 
Unknown N/A 
NM_001982 
V-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3 (ERBB3) 
Cell proliferation or 
differentiation 
[82] 
NM_015695 Bromodomain and PHD finger containing, 3 (BRPF3) Fetal liver erythropoiesis [83] 
NM_015906 Tripartite motif-containing 33 (TRIM33) Tumor suppressors [84] 
NM_032127 Chromosome 11 open reading frame 56 (C11orf56) 
FTS and Hook-interacting 
protein 
[85] 
NM_002904 RD RNA binding protein (RDBP) Repress RNA polymerase II N/A 
NM_012272 PRP40 pre-mRNA processing factor 40 B (PRPF40B) Gene splicing [86] 
NM_020967 Nuclear receptor coactivator 5 (NCOA5) Gene regulator [87] 
NM_001080495 KIAA1856 protein (KIAA1856) Unknown N/A 
NM_022748 Tensin 3 (TNS3) Signal transduction [88] 
BC063642 
Phosphodiesterase 4D interacting protein 
(myomegalin) 
Control microtubules [89] 
AB209493 Death-associated protein 6 (DAXX) Development and Cancer [90] 
NM_003482 
Myeloid/lymphoid or mixed-lineage leukemia 2 
(MLL2) 
Lymphomagenesis [91] 
NM_033396 Tankyrase 1 binding protein 1, (TNKS1BP1) Unknown [92] 
AY729650 Intersex-like protein Unknown [93] 
BC110647 Immediate-early response 2 Unknown N/A 
AB014581 KIAA0681 protein Unknown N/A 
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NM_004235 Kruppel-like factor 4 (gut) (KLF4) 
Transactivation and growth 
suppression 
[94] 
AB051455 KIAA1668 protein Unknown N/A 
AF045458 Serine/threonine kinase ULK1 (ULK1) Autophagy activation [95] 
NM_001003694 Bromodomain and PHD finger containing, 1 (BRPF1) Unknown N/A 
NM_003626 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 1 (PPFIA1) 
Unknown N/A 
NM_006291 
tumor necrosis factor, alpha-induced protein 2 
(TNFAIP2) 
Unknown N/A 
AB209643 smoothelin isoform b Unknown N/A 
NM_002857 peroxisomal biogenesis factor 19 (PEX19) Peroxisomal assembly [96] 
AB061669 receptor for advanced glycation end-products Signaling and inflammation [97] 
NM_014678 SAPS domain family, member 2 (SAPS2) Unknown N/A 
NM_006887 zinc finger protein 36, C3H type-like 2 (ZFP36L2) Unknown N/A 
AB208876 axin 1 isoform Wnt signaling pathway [98] 
NM_004530 matrix metallopeptidase 2 (MMP2) Metastasis and inflammation [99] 
Figure 2. Validation of some IE1 PPIs by coIP. The nuclear extract from the  
IE1-producing cell line was prepared and incubated with anti-IE1 antibody followed by 
incubation with secondary bound beads. The pulled-down complexes were examined 
by Western blot using antibodies against the protein, as indicated on the right hand side. 
 
3. Discussion 
HCMV infects a large part of the population and has serious consequences for immunocompromised 
persons with AIDS or who have received organ transplants and for newborns after congenital 
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infection. In fact, HCMV is the leading viral cause of congenital birth defects [1]. More than 30% 
of primary HCMV infections in pregnant women result in placental transmission and clinical 
syndromes. Congenital infection is not uncommon [100–102]. Of symptomatic newborns, about 
12% die and half of the survivors develop mental retardation, vision loss, and/or sensorineural 
deafness [103]. Interference strategies commonly target the early events of the replication cycle by 
using approved nucleoside analogs such as ganciclovir, the nucleotide analog cidofovir, and 
foscarnet. However, these can lead to resistance [104]. In vitro anti-sense oligonucleotides against 
the HCMV immediate-early protein 2 (IE2) have proven effective [105], as has targeting the UL36 
and UL37 sites [105,106]. These attempts show that targeting the HCMV IE part of the 
propagation cycle may be effective; however, none of these treatments are permissible or feasible 
for use on a potentially infected fetus. The lack of suitable treatment modalities has especially 
serious consequences for the congenitally infected fetus and for patients with impaired immune 
systems. The challenge is to find treatment modalities that do not depend on the inhibition of the 
DNA replication process. This has attracted our investigation to the immediate-early (IE) stage of 
HCMV infection. Understanding IE1’s function is our first step in the development of a practical 
strategy against HCMV replication via interfering with IE1 function. 
In many cases, proteins play their biological role through interactions with other proteins. 
Especially for viral infection, viruses need to manipulate cellular function via interacting with 
cellular proteins. Therefore, the systematic identification and characterization of protein-protein 
interactions (PPIs) is considered a key strategy to understand protein function. In the case of 
HCMV viral immediate-early products, IE1 might be the most important protein that initiates the 
early interactions between the virus and cells. The number of possible contacts between protein 
surfaces is astronomical. In this context, protein array technology opens up new avenues for  
the characterization of viral proteins and the identification of molecular partners involved in  
virus-mediated regulatory networks in cells. The array technology used in the present study started 
with incubation of IE1 with the PVDF membranes that carry GST-tagged human fusion proteins. 
Those fusion proteins were expressed in E. coli, and after native lysis with lysozyme, crude protein 
extracts were prepared under non-denaturing conditions in a 384-well plate format. The crude 
bacterial cell extracts were used for incubation overnight with the high-density spotted PVDF 
membranes, which were used to detect IE1-interacting proteins.  
Using the protein array, eighty-three cellular proteins in total were identified to be PPIs of 
HCMV IE1. Most of them were gene regulators. Only 3 IE1 PPIs from the list have been reported. 
However, many HCMV-mediated cell biological activities have been linked to IE1 (which link is 
also shown in these array assays); these activities include, among others, the interaction of IE1 with 
BCL-2, CDC25A, which interaction might be important for HCMV-induced “G1 arrest”. Some 
cellular proteins reported to interact with IE1 are not on the list, they might interact with IE1 only 
indirectly or the printed proteins are in different isoforms. For example, some isoforms of PML 
was found to interact with IE1 [15] but is not on the list because the other isoforms of PML are 
printed on the PVDF membranes. As shown on the Table 1, 7 RNA binding proteins are found to 
interact with IE1, implying that IE1 has a novel function in viral mRNA processing.  
In conclusion, our current effort in characterizing IE1’s PPIs resulted in the identification of 83 
cellular proteins that directly interact with HCMV IE1. The results have been partially validated by 
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coIP assay. With the data listed in the Table 1, we will further investigate the function of the PPIs 
of IE1. 
4. Experimental  
4.1. Tissue Culture and Viruses  
The IE1-producing cell lines (U-251 MG-IE1) [29] were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin.  
4.2. Antibodies  
The monoclonal antibody against IE1 (MAB810) and the rabbit antibodies against cellular 
proteins were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The rabbit 
antibodies included anti-SC35 (sc-28720), -TRIM33 (sc-68424), -HDAC10 (sc-130775), and -tubulin 
(sc-5546). Rabbit antibodies against RBM5 (ab69970) and RBM 10 (ab126112) were bought from 
Abcam (Cambridge, MA, USA) 
4.3. Preparation of Nuclear Extracts  
Nuclear extracts were obtained essentially as described previously [15]. Briefly, monolayer cells 
were washed with PBS and scraped into fresh Eppendorf tubes. Cell pellets were resuspended in 
cold buffer A (10 mM HEPES-KOH, pH 7.9, at 4 °C, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride) and incubated for 10 min at 4 °C. Then the 
cells were dounced with 10–20 plunges in a Kontes-B (Wheaton, DC, USA) Dounce Homogenizer 
(Pestle B) and poured into new bottles after centrifugation. The pellets were resuspended in cold 
buffer C (20 mM HEPES-KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride) by vortexing and incubated 
for 30 min at 4 °C. The pellets were dounced again with 10–20 plunges in Kontes-B (Wheaton) 
Dounce Homogenizer (Pestle B), and clarified extracts were transferred to fresh tubes and stored at 
70 °C until use.  
4.4. Coimmunoprecipitation  
Antibodies were coupled to protein G-Sepharose beads (GE Healthcare Bio-Sciences, Pittsburgh, 
PA, USA), according to the manufacturer’s instructions. After a wash with PBS-0.1% bovine 
serum albumin, the beads were incubated overnight at 4 °C with clarified extracts, washed again  
in PBS-0.1% bovine serum albumin, and resuspended in a mixture of PBS and 2× Laemmli buffer 
(20 L of each). After being heated for 5 min at 95 °C, the beads were removed by centrifugation 
and supernatants were analyzed by SDS-PAGE and immunoblotting. 
4.5. Immunoblot Analysis  
Proteins were separated by sodium dodecyl sulfate-7.5% polyacrylamide gel electrophoresis [107] 
(10 to 20 g loaded in each lane), transferred to nitrocellulose membranes (Amersham Inc., 
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Piscataway, NJ, USA), and blocked with 5% nonfat milk for 60 min at room temperature. 
Membranes were incubated overnight at 4 °C with primary antibody followed by incubation with a 
horseradish peroxidase-coupled secondary antibody (Amersham Inc.) and detection with enhanced 
chemiluminescence (Pierce, Rockford, IL, USA), according to standard methods. Membranes were 
stripped with stripping buffer (100 mM -mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.8), 
washed with PBS-0.1% Tween 20, and used to detect additional proteins. 
5. Conclusions 
We currently used a protein array assay to identify HCMV IE1 interacting proteins. There are 83 
cellular proteins that are PPIs of IE1 and most of the PPIs have not been reported previously. The 
interactions have been partially validated by coIP method which confirmed that the protein array  
assay is reliable.  
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Abstract: Human cytomegalovirus (HCMV) has a large 240 kb genome that may 
encode more than 700 gene products with many of them remaining uncharacterized. 
Mutagenesis of bacterial artificial chromosome (BAC)-cloned CMV genomes has 
greatly facilitated the analysis of viral gene functions. However, the roles of essential 
proteins often remain particularly elusive because their investigation requires the 
cumbersome establishment of suitable complementation systems. Here, we show that 
HCMV genomes can be introduced into cells with unprecedented efficiency by 
applying a transfection protocol based on replication-defective, inactivated adenovirus 
particles (adenofection). Upon adenofection of several permissive cell types with 
HCMV genomes carrying mutations in essential genes, transfection rates of up to 60% 
were observed and viral proteins of all kinetic classes were found expressed. This 
enabled further analyses of the transfected cells by standard biochemical techniques. 
Remarkably, HCMV genomes lacking elements essential for viral DNA replication, 
such as the lytic origin of replication, still expressed several late proteins. In 
conclusion, adenofection allows the study of essential HCMV genes directly in BAC-
transfected cells without the need for sophisticated complementation strategies.  
Keywords: human cytomegalovirus; bacterial artificial chromosomes; essential viral 




Human cytomegalovirus (HCMV) is still a serious threat for immunocompromised individuals 
such as AIDS patients and transplant recipients [1,2]. HCMV is also the leading viral cause of birth 
defects, resulting in severe long-term sequelae, e.g., hearing loss or mental retardation [3]. 
Currently, there is no effective CMV vaccine in use and the available medication has severe side 
effects (myelosuppression, nephrotoxicity) and can lead to the emergence of drug-resistant virus 
strains [4,5]. Understanding HCMV gene functions is necessary to identify new antiviral drug 
targets and for the rational design of a CMV vaccine. The 240-kbp HCMV genome is the largest 
among all mammalian DNA viruses, and according to a recent study it has the potential to encode 
more than 700 gene products [6]. The cloning of cytomegalovirus genomes as infectious bacterial 
artificial chromosomes (BAC) in E. coli and the establishment of suitable mutagenesis techniques 
has tremendously advanced the investigation into HCMV gene products [7]. Still, especially the 
roles of essential viral proteins remain largely elusive, which is mainly due to the lack of 
appropriate complementation systems. Random mutagenesis of HCMV genomes indicated that 
approximately 40 of the proposed 165 canonical open reading frames (ORF) [8,9] are essential for 
viral growth in vitro [10,11]. Yet, several features of HCMV, e.g., its slow replication cycle and the 
limited range of cell types supporting efficient growth, have impeded attempts to complement 
mutants with mutations in essential viral genes. Successful examples include a few cell lines 
expressing the essential protein of interest [12–16], as well as inducible systems based on 
tetracycline-regulated transcription [17,18], or the fusion of essential HCMV proteins to a 
destabilizing domain [19–23]. However, each of these procedures has limitations, such as low virus 
productivity on the complementing cells, occurrence of escape mutants (rescuants), insufficient 
tightness of conditional gene regulation, or impairment of viral protein function upon fusion to 
regulatory domains.  
We therefore asked whether it is possible to analyze the phenotypic consequences of the 
disruption of an essential viral ORF directly in cells transfected with the respective mutant HCMV 
BACs. Transfection of permissive primary cells with the 240-kbp HCMV BACs is very inefficient, 
resulting in few transfected cells only, and immortalized cell lines widely employed for 
complementation of -herpesvirus mutants do not support the full replication cycle of HCMV. 
Utilizing commercially available transfection reagents, infectious viral progeny can be 
reconstituted from HCMV BACs, because few successfully transfected cells will give rise to 
infectious progeny that finally spreads throughout the cultures. However, the transfection 
efficiencies achieved so far did not allow the analysis of the transfected cells by common 
virological and biochemical techniques. In this study, we evaluated an alternative method to 
introduce HCMV BACs into permissive cells, namely an adenovirus-based gene delivery protocol 
that was pioneered by Matthew Cotten and coworkers [24–27]. Adenovirus particles derived from a 
replication-deficient mutant are chemically and physically inactivated and serve as carriers for the 
HCMV BACs, which results in the uptake of the BACs via the natural infection route of the 
adenovirus. Firstly, the BAC DNA is condensed with cationic low molecular weight 
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polyethyleneimine (PEI), yielding a BAC-PEI complex with an overall positive charge. Secondly, 
this complex is bound to the adenovirus (Ad) particles, presumably through interaction with the 
negatively charged hexon protein of the viral capsid. By receptor-mediated endocytosis, the  
BAC-PEI-Ad complexes are then taken up by the cells, and the ability of PEI to act as a proton 
sponge together with the endosomolytic activity of adenovirus capsid proteins enable the escape of 
the transfected DNA into the cytosol.  
We applied this method, which we termed adenofection, to different HCMV-permissive cell 
types and used various HCMV BACs in which essential genomic regions had been deleted. The 
excellent delivery rates of the mutated HCMV genomes, particularly into an epithelial cell line, 
made it possible to examine the transfected cells for expression, localization, and interactions of 
viral proteins, as well as for testing of viral DNA replication. In summary, by using the 
adenofection technique, essential viral gene functions can be assessed immediately after 
transfection of the HCMV BAC mutants, which obviates the requirement to develop individual 
complementation strategies. 
2. Results and Discussion 
2.1. Adenovirus-Mediated Delivery of HCMV BACs into Different Cell Types and Optimization of  
the Procedure 
Previously, we had already set up the adenofection method (Figure 1A) to reconstitute virus 
from HCMV BACs in primary human foreskin fibroblasts (HFF) [28]. HFF is the prototype cell 
type for propagating HCMV, however, these primary cells are particularly difficult to transfect. In 
these previous experiments, adenofection gave better results than all commercially available 
transfection reagents we had tried before, yielding approximately 100–200 transfected cells  
per 3.5 cm dish. Here, we examined the transfection efficiency of other human cell types after 
adenofection with an EGFP-expressing HCMV BAC (pHG-13) that does not give rise to infectious 
progeny due to a deletion in the essential ORF UL104 (see Table 1). Since primary HFF originate 
from various sources and may therefore vary in their properties, we instead used commercially 
available primary fetal lung fibroblasts (MRC-5), which in addition are also easier to transfect than 
HFF [29]. Besides MRC-5, we tested two epithelial cell lines, retinal pigmented epithelial cells 
having an extended life span due to expression of human telomerase reverse transcriptase  
(hTERT-RPE-1 cells, further referred to as RPE-1), and A549 cells (a lung adenocarcinoma 
epithelial cell line) as well as the human glioblastoma cell line U373. All of these cells can be 
infected with HCMV and support replication of the virus, although with different efficacy. Because 
the adenofection protocol is sensitive to bacterial lipopolysaccharide (LPS) that is potentially 
present in plasmid preparations and interferes with DNA-PEI complex formation and can also 
provoke cytotoxicity in the presence of adenovirus [30], we first compared BAC DNA purified by 
standard protocols to that obtained by a method removing most of the LPS. Indeed, when using 
endotoxin-free BAC DNA, transfection rates increased twofold over those obtained with  
LPS-containing DNA (data not shown), even though the LPS-chelating substance polymyxin B 
was added during adenofection, which alleviates LPS-mediated toxicity [31]. Therefore, all of the 
following experiments were done with endotoxin-free BAC DNA. The different cell types were 
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adenofected with 1 g of pHG-13 each, and EGFP expression was analyzed the following day by 
flow cytometry. As can be seen in Figure 1B, transfection of RPE-1 cells was most efficient, with 
64% of cells scoring positive for EGFP, followed by MRC-5 (13%), A549 (6.5%) and U373 cells 
(2%). To our knowledge, such high delivery rates of HCMV BACs into permissive cells have not 
been achieved previously by applying any other transfection technique. It is conceivable that by 
optimizing parameters even higher transfection efficiencies can be achieved. It has for instance 
been reported that the success of the method greatly depends on the formation of a DNA-PEI 
complex which is of optimal size and has a positive net charge [27]. The size of these complexes 
can be tuned by varying the sodium chloride concentration of the HBS solution employed to dilute 
both DNA and PEI (see Experimental Section), and the charge of the complex is given by the 
molar ratio of the anionic DNA to polyethylenimine (a polycation). We performed all adenofection 
experiments in the presence of 150 mM sodium chloride as initially proposed [24,26], which results 
in larger complexes compared to that prepared in the absence of sodium chloride [27]. If smaller 
complexes are beneficial to transfection of HCMV BACs remains to be tested. Related to that, we 
noticed that the transfection of HCMV BACs is enhanced when increasing the amount of PEI 2000. 
For smaller DNA molecules, maximum delivery was reported when the molar ratio of PEI nitrogen 
to DNA phosphate (N:P) was around 10, and was not further improved using higher N:P ratios [27]. 
However, there is some evidence that larger DNA molecules may require a higher N:P ratio than 
smaller plasmids [26]. In our HCMV BAC transfection protocol the N:P ratio is 50 (1 g of DNA 
equals 3 nmol of phosphate, and 15 L of 10 mM PEI 2000 solution correspond to 150 nmol of 
nitrogen). We also tried N:P ratios of 33 and 67 (see below) and did not see a major effect on 
transfection efficiency, yet lowering the N:P ratio to 20 resulted in a markedly decreased delivery 
rate (not shown). Therefore, by determining the best relation between sodium chloride, HCMV 
BAC DNA, PEI 2000, and also the amount of adenovirus particles (i.e., the size and charge  
of the final PEI-DNA-adenovirus complex that is taken up by the cells) the procedure may be 
further improved. 
Since RPE-1 cells were most efficiently transfected by adenofection, all subsequent experiments 
were performed with this cell type. Next we tested whether the amount of BAC DNA and the cell 
confluence have an impact on transfection efficiency. Six different HCMV BACs harboring 
deletions in essential genomic regions (pHG-11 to pHG-14, pHG- 3.7, and pHG- 1.5; see  
Table 1) and the parental BAC pHG were used to transfect either 80% or 100% confluent RPE-1 
cells with 0.75 g (N:P = 67) or 1.5 g (N:P = 33) of each BAC DNA, respectively (Figure 2A). 
One day post transfection, the number of EGFP-expressing cells was determined by flow 
cytometry. The DNA amounts used had little influence on the number of EGFP-positive cells, 
whereas (as also true for other transfection protocols) there was a slight improvement in 
transfection efficiency when using subconfluent cell cultures. Occasionally we observed variable 
transfection efficiencies (e.g., compare pHG-14 to pHG, white bars in Figure 2A, right part), which 
is perhaps due to the fact that preparations of high molecular weight DNA such as of the 240 kb 
HCMV BACs tend to be inhomogeneous, resulting in differing DNA contents during handling of 
the samples. Still, in general adenofection allowed the uptake of the HCMV BACs into 40%–60% 
of the RPE-1 cells, which represents an outstanding delivery rate not obtained with any other 
transfection reagent tested so far [32].  
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Figure 1. (A) Principle of the adenofection method. BAC DNA is condensed with low 
molecular weight polyethylenimine (PEI 2000). Addition of replication-incompetent, 
chemically and physically inactivated adenovirus particles leads to binding of the  
BAC-PEI complexes to the virions. The DNA-loaded adenovirus particles are taken up 
by the cells, and the endosomolytic activity of virion protein helps to release the DNA 
into the cytosol; (B) Adenofection of different human cell types with the EGFP-expressing 
HCMV BAC pHG-13. RPE-1: retinal pigmented epithelial cell line, A549: lung 
adenocarcinoma epithelial cell line, MRC-5: primary embryonic lung fibroblasts, U373: 
human astrocytoma cell line. Transfection efficiency is given as percentage of  
EGFP-positive cells on day 1 post transfection. Transfections were done in 
quadruplicates, and standard deviations are indicated. Inlay: example of FACS analysis 
of adenofected RPE-1 cells. 
 
Table 1. HCMV BACs used in this study.  
Name of HCMV BAC Mutation 
pHG 
(parental BAC) 
EGFP ORF under control of HCMV MIEP 
deletion of UL1-10 [28] 
pHG-11 deletion in UL77 
pHG-12 deletion in UL93 
pHG-13 deletion in UL104 
pHG-14 deletion in UL44 
pHG- 1.5 1.5 kb deletion in oriLyt [28] 
pHG- 3.7 3.7 kb deletion in oriLyt [28] 
pHG- 52 deletion in UL52 [14] 
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Figure 2. Evaluation of adenofection conditions and late protein expression in 
adenofected cells. (A) Subconfluent or confluent RPE-1 cells were transfected with 750 
or 1,500 ng of the HCMV BACs indicated. On day 1 post transfection the percentage of 
EGFP-expressing cells was determined by flow cytometry. Each bar represents the 
mean value of two transfections; (B) RPE-1 cells transfected with the HCMV BACs 
indicated were stained on day 4 post transfection with DAPI and an antibody against 
the major capsid protein (MCP). Ten random images were taken per setting, and the 
percentages of EGFP-positive cells (white bars) and MCP-expressing cells (grey bars) 
were determined. The index numbers following the names of the BACs (/1 and /2) 
indicate that 750 and 1,500 ng of BAC DNA were used for adenofection, respectively. 
 
2.2. Viral Gene Expression in Adenofected Cells 
So far, we measured the outcome of adenofection by detection of EGFP, which is under control 
of the HCMV major immediate-early promoter (MIEP) [33]. EGFP-expression thus directly 
represents transfection efficiency, because gene expression driven by the HCMV MIEP occurs very 
early after transfection (and infection) and is independent of the synthesis of other viral proteins. 
However, most experiments to be performed with HCMV BAC-transfected cells will not only 
require the initiation of viral gene expression, but also progression to the early and late phases of 
the HCMV life cycle. Therefore, we analyzed how many of the EGFP-positive cells proceed to the 
late phase of the infection cycle. A portion of the cells transfected with pHG or pHG-11 to pHG-13 
(cf. Figure 2A, left part) was seeded onto cover slips and examined on day four post transfection 
for the presence of EGFP and the major capsid protein (MCP; a late viral protein) by 
immunofluorescence (Figure 2B). Compared to the data obtained by FACS analysis, transfection 
efficiency evaluated by fluorescence microscopy gave slightly lower values, probably because the 
latter technique is the less sensitive one. We found that in the majority of the EGFP-expressing 
cells MCP was detected as well, and also displayed the expected nuclear localization, with the 
percentage of MCP-positive cells (related to the EGFP-expressing cells) ranging from 50%  
(pHG-11/2) to 75% (pHG-12/2). This result is similar to what is observed after infection with 
HCMV, where it is known that not all cells expressing immediate-early proteins also make it into 
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the late phase and lead to plaque formation, which can be explained by defective virus particles 
and/or an unfavorable cellular environment (e.g., failure of viral genomes to overcome intrinsic 
cellular defense mechanisms such as sequestration at PML bodies). Likewise, it is conceivable that 
not all of the 240 kb HCMV BAC molecules remain intact during the DNA preparation and 
transfection procedure. Moreover, progression through the productive infection cycle may be 
impaired in the absence of tegument proteins that usually counteract the function of cellular 
restriction factors early in infection [34,35]. This may be overcome by simultaneously transfecting 
the cells with plasmids encoding the respective tegument proteins, such as pp71 which is known to 
enhance gene expression from HCMV DNA [36]. 
Next, we aimed at detecting expression of other viral proteins following adenofection and also 
included early and additional late proteins. Furthermore, we wanted to investigate late gene 
expression in the absence of HCMV genome replication. The kinetics of herpesviral protein 
expression is typically analyzed by keeping infected cells in the presence of inhibitors that interfere 
with protein synthesis (e.g., cycloheximide, CHX) or DNA replication (phosphonoacetic acid, 
PAA). Viral genes transcribed in the presence of CHX are classified as immediate-early, and those 
expressed despite the presence of PAA are considered to be early genes. In contrast, it is believed 
that late proteins are synthesized only in the absence of any inhibitor, i.e., following viral genome 
replication. Cells were adenofected with HCMV BACs pHG-14, pHG- 1.5 or pHG- 3.7 to 
investigate whether late protein synthesis strictly relies on viral replication. pHG-14 has a deletion 
in the UL44 open reading frame (ORF), whose gene product pUL44 is the accessory factor of the 
viral DNA polymerase and is required for HCMV lytic origin (oriLyt)-dependent genome 
replication [37,38]. In pHG- 1.5 and pHG- 3.7, a 1.5 kb or 3.7 kb region of oriLyt was deleted, 
and upon transfection these BACs do not produce infectious progeny [28]. We first ensured that 
these BACs have indeed a defect in viral genome replication. Adenofected RPE-1 cells were 
harvested on days 4 and 5 post transfection, and total DNA was extracted from the cells. The DNA 
samples were examined by dot blot as well as by restriction analysis, followed by Southern blotting. 
As is obvious from Figure 3A, viral DNA was only detected in cells transfected with the parental 
BAC pHG, but not after transfection of pHG-14, pHG- 1.5, or pHG- 3.7. We conclude from this 
data that these HCMV genomes are deficient for viral DNA replication. 
We then checked viral protein expression in the adenofected cells by immunoblotting (Figure 3B). 
The 72 kDa IE1 protein (Figure 3B, panel IE1, lower band) was detected in comparable amounts 
with all of the mutants as well as with the parental BAC. Interestingly, the higher molecular mass 
form of IE1, presumably representing sumoylated IE1, was markedly reduced when viral replication 
was impaired, in line with observations of others which showed that this version of IE1 is rather 
made during the late phase of the HCMV life cycle [39]. UL44, an early gene product, was 
expressed by all BACs except pHG-14, in which the UL44 ORF was disrupted. Remarkably, 
compromising viral replication had different effects on the levels of the other proteins tested, 
ranging from almost complete absence (UL50, UL53, UL104, SCP, pp150: all late proteins) to 
more or less reduced, but still clearly detectable amounts (UL52, UL99, MCP, pp65: late proteins, 
and UL56, UL89: early-late proteins). It is also of note that UL52, which was previously designated 
as a true late protein due to its complete lack of expression in the presence of PAA [14,40] was 
found in considerable amounts after transfection of the replication-defective genomes. These data 
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may be explained by recent results of Nitzsche and colleagues, who found that viral DNA 
replication is needed to mark the HCMV genome with methylated histones that define 
transcriptionally active chromatin, namely H3K4me2 [23]. Most interestingly, the tested HCMV 
genomic regions were differentially influenced by impairing viral replication, for instance 
occupancy of UL32 sequences (coding for pp150) with H3K4me2 was much more dependent on 
HCMV genome replication than that of the UL99 gene, which was still labeled with this activating 
histone mark quite efficiently in both the presence of ganciclovir and after knock-down of the viral 
polymerase. This is consistent with the expression of the UL99 protein and the absence of pp150 
(UL32) in cells transfected with HCMV BACs defective for genome replication. A similar 
mechanism may apply to the other HCMV proteins tested by us in this study.  
Figure 3. Analysis of viral genome replication and protein expression in adenofected 
cells. (A) Viral DNA levels in RPE-1 cells adenofected with the indicated HCMV 
BACs. Total DNA was isolated on days four and five post transfection and analyzed by 
dot blot hybridization using a UL93-specific probe (left part). Right part: the DNA 
samples obtained on day five were treated with HindIII and DpnI, followed by 
Southern blotting. The 32P-labelled probe specific for the UL93 ORF detects a 7.5 kb 
HindIII fragment; (B) Viral protein expression after adenofection with the depicted 
HCMV BACs. Cell lysates were prepared on day four post transfection and analyzed 
for the given proteins by immunoblotting. 
 
2.3. Impact of UL52 on HCMV Terminase Proteins 
Besides genome replication, the nuclear phase of the HCMV life cycle comprises the assembly 
of capsid shells, as well as packaging of viral genomes into these preformed capsids. HCMV 
proteins mediating genome cleavage and encapsidation are the terminase subunits UL56 and UL89. 
We have recently demonstrated that UL51 is also essential for cleavage of viral concatemeric DNA 
and the generation of DNA-filled capsids. Moreover, UL51 forms a complex with UL56 and UL89 
and seems to be required for the correct localization of UL56 and UL89 to nuclear  
replication compartments [40,41]. Likewise, we have identified an essential role of UL52 in 
genome cleavage-packaging, but there was no evidence for UL52 being also part of the terminase 
complex [14,40]. The precise function of UL52 thus remains elusive. 
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Figure 4. Investigation into RPE-1 cells adenofected with the UL52-deleted genome  
pHG- 52. (A) Transfected cells were harvested on days zero to six post transfection 
(dpt) and expression of the indicated proteins was analyzed by immunoblotting. Please 
note that the pp65 antibody exhibits some cross-reactivity with cellular proteins as 
observed previously [42]; (B) Interaction of the terminase subunits UL56 and UL89 in 
the absence of UL52. RPE-1 cells adenofected with pHG- 52 were subjected to 
immunoprecipitation with -UL56 and -UL89 monoclonal antibodies on day 4 post 
transfection, followed by immunoblotting using the same antibodies. Input: whole cell 
lysate before IP, hc: IgG heavy chain; (C) Subcellular localization of HCMV terminase 
subunits in the presence or absence of UL52. RPE-1 cells were adenofected with pHG 
or pHG- 52 and analyzed on day 4 post transfection by confocal laser scanning 
microscopy using monoclonal antibodies against UL51, UL56, and UL89. 
 
We now asked whether the absence of UL52 may influence the interactions among the 
terminase subunits or their subnuclear localization. To this end, RPE-1 cells were adenofected with 
the BAC genome pHG- UL52, which carries a disrupted UL52 ORF. First, we checked the 
expression kinetics of representative immediate-early (IE1), early (UL44) and late proteins (pp65) 
in the transfected cells. Cells were harvested on days 0 to 6 post transfection, and viral proteins 
were analyzed by immunoblotting. As is obvious from Figure 4A, IE1, UL44 and pp65 were 
expressed with the expected kinetics, with IE1 already being detectable on day 1, UL44 coming up 
on day 2, and pp65 being clearly visible on day 4 and later. The higher molecular mass form of IE1 
was detected in distinct amounts on day 3 and later only, which is in agreement with our finding 
that the abundance of this version of IE1 seems to be increased following viral replication  
(cf. Figure 3B). To investigate the interaction of the terminase subunits, pHG- UL52-transfected 
cells were lysed on day four and subjected to immunoprecipitation using monoclonal antibodies 
(mAb) directed against UL56 and UL89 [40]. Figure 4B shows that the binding of UL56 to UL89 
was still seen when UL52 was missing, since immunoprecipitation of UL56 also brought down 
UL89 (Figure 4B, second lane), and vice versa (Figure 4B, third lane). We could not test for 
binding to UL51 in this setting, because the UL51 mAb exhibits no distinct reactivity in 
immunoblotting. Since the UL51 antibody performs well in immunofluorescence experiments, we 
examined the subcellular distribution of UL51, UL56 and UL89 in the absence of UL52 by 
confocal laser scanning microscopy in RPE-1 cells transfected with pHG- UL52 or the parental 
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BAC pHG. As can be seen in Figure 4C, the terminase subunits were all found in the cell nucleus 
and were enriched within the replication compartments, despite the lack of UL52 (Figure 4C, right 
part), as is the case in cells transfected with the parental BAC genome pHG (Figure 4C, left part). 
Thus, UL52 does not seem to play a role in the interactions among the HCMV terminase proteins 
or their correct intracellular localization. 
3. Experimental Section  
3.1. Cells 
hTERT-RPE-1 cells were obtained from Clontech and were cultivated in Dulbecco’s modified 
Eagle’s medium (DMEM)/Ham’s F-12 (Sigma, Saint Louis, MO, USA, D6421), supplemented 
with 5% fetal calf serum (FCS), 100 U/mL of penicillin, 100 g/mL of streptomycin sulfate, 2 mM 
glutamine, and 0.348% sodium bicarbonate. A549 and MRC-5 cells (ATCC) were kept in DMEM 
(Sigma, D5796), containing 10% FCS and the mentioned antibiotics. The U-373 MG (Uppsala) cell 
line was purchased from Sigma (Cat. No. 08061901) and corresponds to a new deposit of the cells 
from the laboratory in Uppsala, Sweden, where they were originally isolated. U-373 MG cells were 
cultivated according to the instructions of the supplier.  
3.2. HCMV Bacterial Artificial Chromosomes 
The parental HCMV BAC pHG, carrying the enhanced green fluorescent protein (EGFP) ORF 
under control of the major immediate-early promoter (MIEP) and containing a deletion of the  
non-essential genes UL1 to UL10 was described before [28,33]. The construction of pHG- 52 
lacking most of the UL52 open reading frame (ORF) was reported elsewhere [14], and pHG- 1.5 
and pHG- 3.7 harboring deletions in the HCMV lytic origin region have also been described [28].  
pHG-11, pHG-13 and pHG-14, having deletions in essential viral genes UL77, UL104 and UL44, 
respectively, were generated by red -mediated recombination in E. coli as described [43]. 
Oligonucleotides used for mutagenesis are given in Table 2, and comprised sequences homologous 
to the desired integration site in the BAC, as well as priming regions to the kanamycin resistance 
(KnR) gene flanked by mutant FRT sites [28]. The KnR sequence was subsequently removed from 
all BACs by Flp-mediated recombination as reported [43]. pHG-12, in which UL93 is disrupted, 
was constructed by en passant mutagenesis using the primers indicated in Table 2, with a KnR 
cassette carrying an I-SceI site as a template [44]. Further details on the construction of these BACs 
will be available from the authors upon request. Large-scale purification of HCMV BACs was done 
either with the Nucleobond PC 100 columns, or by using the Nucleobond PC 500 EF kit (both 
Macherey & Nagel, Düren, Germany), which yields mostly endotoxin-free DNA. BAC DNA was 
resuspended in TE buffer (10 mM Tris-HCl pH 8.0/1 mM EDTA) and DNA concentrations were 
determined by measuring each preparation three times using a Nanodrop device. 
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Table 2. Oligonucleotides used for HCMV BAC mutagenesis. 













3.3. Preparation of Adenovirus Stocks and Transfection by Adenofection 
The adenovirus dl1014 mutant [45], having a deletion in the E4 region, and the complementing 
cell line W162 [46] were kindly provided by Gary Ketner, Johns Hopkins University School of 
Medicine, MD, USA. To produce the adenovirus stock, ten T175 flasks of W162 cells were 
infected at an MOI of 0.01–0.1. At approximately day three post infection, when all cells were 
rounded and detached, cells were collected by centrifugation and the pellet was transferred to  
80 °C. Virus was released by adding 5 mL of serum-free DMEM, followed by two freeze-thaw 
cycles. Cellular debris was removed by centrifugation at 3,800 × g for 20 min, and virus in the 
supernatant was purified by two rounds of isopycnic cesium chloride gradient centrifugation. For 
the first centrifugation step, 3 mL of a CsCl solution with a density of 1.2 g/mL was carefully 
added to a tube containing 3 mL of a CsCl solution with a density of 1.4 g/mL. Virus-containing 
supernatant was layered on top, and centrifugation was done for 90 min at 100,000 × g, 20 °C in an 
SW41 Ti rotor, without deceleration. The virus-containing band was identified by light scattering 
and removed by puncturing the tube with a hollow needle, and was then diluted to a total volume of 
2 mL with 10 mM Tris-HCl/1 mM EDTA pH 7.5. The second purification step was done via a 
continuous CsCl gradient prepared by mixing 5.4 mL of CsCl solution density 1.2 with 4.6 mL of 
CsCl solution density 1.4 using a gradient maker, and centrifugation took place for 24 h at 100,000 × g, 
20 °C without deceleration. After harvesting of the virus band as described above, the samples 
were desalted using PD-10 columns (GE Healthcare, Uppsala, Sweden), and fractions of 0.5 mL 
each were collected by elution in HBS/40% glycerol (HBS is 20 mM HEPES, 150 mM NaCl  
pH 7.4). Virus-containing fractions were identified by measuring protein concentrations with the 
Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA), and protein-positive 
fractions were pooled. To inactivate the virus, 8-methoxy-psoralen (Sigma, M-3501) was added to 
a final concentration of 0.33 mg/mL, the sample was transferred on ice and exposed to UV light  
(366 nm) for 30 min, with rotation of the dish every 10 min. The inactivated virus particles were 
again purified by PD-10 columns, and fractions scoring positive in the BCA protein assay were 
pooled and stored at 80 °C in HBS/40% glycerol. Concentration of adenovirus particles was 
determined by calculating 0.3 mg/mL of (capsid) protein being equivalent to 1 × 1012 particles/mL. 
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For adenofection of HCMV BACs, the DNA amounts indicated in the figures were diluted  
in 250 L of HBS. 15 L of 10 mM PEI 2000 stock solution (polyethylenimine MW 2000, Sigma, 
Cat. No. 40870-0, 0.9 mg/mL H2O), mixed before usage, was diluted in 250 L of HBS and mixed 
vigorously again. The diluted PEI 2000 solution was slowly added to the diluted DNA, with 
constant gentle flicking of the tube, and the sample was incubated for 20 min at room temperature 
(RT). 3 × 109 particles of inactivated adenovirus were added, and the sample was incubated at RT  
for another 20 min. Cells cultured in six-well plates were washed with PBS, and 1.5 mL/well of 
serum-free DMEM containing polymyxin B (30 g/mL) was added. The transfection complexes 
were added to the cells, which were then incubated for 5 h at 37 °C, 5% CO2. After that, the cells 
were washed twice with PBS and further cultivated in complete growth medium with polymyxin B 
(30 g/mL).  
3.4. Flow Cytometry 
Cells were adenofected with the HCMV BAC genomes indicated in the figure legends. One day 
later, cells were trypsinized, washed with PBS containing 2 mM EDTA, and fixed with 3% 
paraformaldehyde (w/v) in PBS/2mM EDTA. One-color flow cytometry was applied to detect  
GFP-positive cells. A total of 30,000 events were collected by a Beckman Coulter FC500 flow 
cytometer and analyzed using the Kaluza software (Beckman Coulter, Brea, CA, USA) [47].  
3.5. Viral DNA Replication Assay 
RPE-1 cells adenofected with the respective HCMV BACs were trypsinized on days four or five 
post transfection, and total DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen, 
Hilden, Germany). For dot blot, 5 L of each sample (corresponding to approximately 30 ng of 
total DNA each) was applied to a nylon membrane. Denaturing of the DNAs was achieved by 
exposing the membrane to filter paper soaked with 0.5 M NaOH/1.5 M NaCl twice for three min 
each, followed by neutralization of the membrane four times for three min each using 0.5 M  
Tris-HCl/1.5 M NaCl pH 7.2. For restriction analysis, 40 L of each DNA sample obtained on day 
five (corresponding to approximately 240 ng of total DNA each) was treated with DpnI to cut 
residual transfected BAC DNA, followed by treatment with HindIII. After gel electrophoresis, the 
DNAs were transferred to a nylon membrane by Southern blotting, and hybridized to a 32P-labelled 
probe generated by PCR amplification of HCMV UL93 sequences using primers UL93-N.for  
(5'-cgcggatccttctatgccgtcttcactacg-3') and UL93-N.rev (5'-cgcaagcttgcgactgcgccaaaaggaatt-3') with 
HCMV BAC pHG as a template. 
3.6. Protein Biochemistry 
Immunofluorescence microscopy of adenofected cells was done as described previously [14], 
and immunoprecipitation as well as immunoblotting was performed as reported recently [40]. 
Additionally, the SuperSignal Western Blot Enhancer reagents (Thermo Scientific, Cat. No. 46640) 
and the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Cat. No. 
34096) were applied. Antibodies commercially available were directed against HCMV IE1  
(NEA-9221, PerkinElmer, Boston, MA, USA), UL99 (Fitzgerald, MA, USA, Cat. No. 10-C50), 
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and pp65 (Novus Biologicals, Littleton, CO, USA, Cat. No. NB110-57244). The antibody 
recognizing the major capsid protein was kindly provided by Klaus Radsak, UL44 and pp150 
monoclonal antibodies were a gift of Bodo Plachter, University of Mainz, Germany, UL50 and 
UL53 antibodies were obtained from Manfred Marschall, University of Erlangen, Germany, and 
the monoclonal antibody directed against the HCMV small capsid protein was provided by William 
Britt, Birmingham, Alabama. The monoclonal antibodies specific for UL51, UL52, UL56, and 
UL89 are described elsewhere [40]. The UL104-specific antibody was generated by immunization 
of mice as described [40], using a recombinant protein comprising the N-terminal part of pUL104. 
Primers for amplification of UL104 sequences were UL104-N.for (5'-cgcaagcttggcgtactgatataaaatgt-3') 
and UL104-N.rev (5'-cgcggatccgagcgaaaccactggaacga-3'). The resulting PCR product was cut  
with HindIII and BamHI and cloned into the bacterial expression vector pQE-30 via the same 
restriction sites.  
4. Conclusions  
In this work, we present a novel approach to analyze essential HCMV gene functions by 
transfecting cells with BACs that are deleted for the gene of interest. Transfection is based on 
applying replication-deficient, inactivated adenovirus particles as carriers, a method that was 
initially developed by Cotten and coworkers for BACs of up to 170 kb, and that proved to be 
superior to commercially available transfection reagents [26,27]. We now show that this approach 
works also perfectly well with HCMV BACs, which are of larger size (240 kbp). We used particles 
of an adenovirus mutant that has a deletion in the essential E4 region and is propagated on a 
complementing cell line. However, other adenovirus mutants may be employed as well, such as 
dl312 lacking E1a sequences and which can be grown on 293 cells [24], although under certain 
conditions cellular factors can substitute for E1a functions, resulting in toxicity due to low level 
adenoviral gene expression [25]. Due to the natural tropism of human adenovirus the adenofection 
method is currently restricted to human cells. However, it is conceivable that the protocol can be 
extended to BAC-cloned herpesviruses of other species, for instance mouse adenovirus mutants 
could be generated and tested for adenofection of murine cells. Transfection can also be performed 
through double condensation of BAC DNA with low and high molecular weight PEI only [48].  
In our hands, this approach also gave good transfection efficiencies (data not shown), although  
the high transfection rates described here (40%–60%) were only reached upon including 
adenovirus particles.  
The excellent transfection efficiencies with HCMV BACs found after adenofection have not  
been possible before with other transfection methods applied so far. RPE-1 cells performed best in 
these experiments, which is of note because this cell type is also useful to propagate clinical 
HCMV isolates [49]. This enables faster reconstitution of viral progeny from HCMV BAC 
genomes, which could be of advantage for high throughput analysis of a library of HCMV mutants. 
Furthermore, the new delivery approach allows the study of the phenotypic consequences of the 
lack of given essential proteins by various techniques such as immunofluorescence, immunoblotting, 
or immunoprecipitation. Other assays, for instance pulsed field gel electrophoresis of viral DNA  
or electron microscopy, are also feasible, especially when the adenofected cells are sorted for 
EGFP-positive cells before applying the respective techniques. We think that virtually any 
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investigation can be done with BAC-transfected cells, at least as steps of the infection cycle 
subsequent to delivery of the viral genomes into the nucleus are concerned. Although RNAs and 
virion proteins delivered by the HCMV particle, which can enhance viral gene expression are 
absent following adenofection, all viral proteins tested were produced in sufficient amounts to 
perform downstream analyses. We consider the adenofection procedure as safe since infectious 
adenovirus was not observed in the transfection experiments. Moreover, recombination between 
adenoviral and HCMV DNA appears highly unlikely, because (i) the genomes do not share 
significant homologous regions; (ii) the adenovirus DNA is cross-linked by treatment with  
psoralen and UV light and is thus inert; and (iii) there is no selection pressure on the occurrence  
of recombination. 
In summary, adenofection of HCMV BACs enables the analysis of essential viral genes directly 
after transfection, without the need to establish complementing systems for the HCMV mutants  
of interest.  
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Abstract: The human cytomegalovirus (HCMV) viral mitochondria-localized inhibitor 
of apoptosis (vMIA) protein, traffics to mitochondria-associated membranes (MAM), 
where the endoplasmic reticulum (ER) contacts the outer mitochondrial membrane 
(OMM). vMIA association with the MAM has not been visualized by imaging. Here, 
we have visualized this by using a combination of confocal and superresolution 
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imaging. Deconvolution of confocal microscopy images shows vMIA localizes away 
from mitochondrial matrix at the Mitochondria-ER interface. By gated stimulated 
emission depletion (GSTED) imaging, we show that along this interface vMIA is 
distributed in clusters. Through multicolor, multifocal structured illumination 
microscopy (MSIM), we find vMIA clusters localize away from MitoTracker Red, 
indicating its OMM localization. GSTED and MSIM imaging show vMIA exists in 
clusters of ~100–150 nm, which is consistent with the cluster size determined by 
Photoactivated Localization Microscopy (PALM). With these diverse superresolution 
approaches, we have imaged the clustered distribution of vMIA at the OMM adjacent 
to the ER. Our findings directly compare the relative advantages of each of these 
superresolution imaging modalities for imaging components of the MAM and  
sub-mitochondrial compartments. These studies establish the ability of superresolution 
imaging to provide valuable insight into viral protein location, particularly in the  
sub-mitochondrial compartments, and into their clustered organization.  
Keywords: HCMV vMIA; MAM; mitochondria; OMM; matrix; confocal microscopy; 
superresolution microscopy; GSTED; MSIM; PALM 
 
1. Introduction 
The mitochondria-associated membrane (MAM) sub-compartment of the endoplasmic reticulum 
(ER) plays critical roles in ER-mitochondrial cross-talk by allowing efficient transfer of calcium 
(Ca2+) from the ER to mitochondria without elevating cytosolic Ca2+ levels [1–3]. A macromolecular 
complex, composed of MAM inositol 1,4,5 trisphosphate receptors (IP3R), cytosolic glucose 
response protein 75 (GRP75) and outer mitochondrial membrane (OMM)-localized voltage 
dependent anion channel (VDAC) generates the high Ca2+ microdomains needed for Ca2+ transfer 
from ER to mitochondria (Figure 1) [4]. Constitutive low level IP3R-mediated Ca2+ transfer, 
needed for Ca2+ dependent mitochondrial enzymes, maintains normal cellular metabolism [5]. 
Nonetheless, continued mitochondrial Ca2+ influx drives the adaptive metabolic phase of early ER 
stress and can result in mitochondrial-mediated apoptosis [6,7]. Lipids, including phospholipids, 
cholesterol, and ceramide, are synthesized in the MAM and transferred to the OMM [1,8,9]. In 
addition, the MAM is enriched in internal lipid rafts [10], which can serve to connect extrinsic and 
intrinsic apoptotic pathways [11]. Finally, mitochondrial antiviral responses have also been 
recently linked to the MAM [7,12,13].  
The viral mitochondria-localized inhibitor of apoptosis (vMIA), encoded by the human 
cytomegalovirus (HCMV) UL37 exon 1 (UL37x1) immediate early gene, inhibits mitochondrial- 
mediated programmed cell death and increases viral progeny production during permissive 
infection [14–19]. vMIA traffics sequentially from the ER to mitochondria and is present at 
ER-mitochondria contact sites known as MAM [20–24]. At the ER, vMIA causes ER Ca2+  
efflux [15]. It associates with MAM lipid rafts in close proximity to sigma 1 receptor (Sig-1R) [25], 
which is a chaperone affecting Ca2+ efflux from the ER. Additionally, vMIA recruits Bax to MAM 
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lipid rafts and induces Bax proteasome-mediated degradation, thereby augmenting vMIA’s 
antiapoptotic activity [26,27]. Because of its sequential trafficking [20,23], vMIA can relocalize a 
cellular defense protein, viperin, from the ER to mitochondria where viperin assumes a new  
role of a major effector to induce lipogenesis metabolism during HCMV infection [28,29].  
At mitochondria, vMIA blocks Bax-mediated permeabilization of the OMM [17,18,30,31], reduces 
ATP synthesis [28,29,32], causes mitochondrial fragmentation [12,30,33,34], and controls 
HtrA2/Omi-induced cell death through very late times of HCMV infection [35].  
Figure 1. Endoplasmic reticulum (ER), mitochondria-associated membranes (MAM), 
and mitochondrial sub-compartments visualized. Viral mitochondria-localized inhibitor 
of apoptosis (vMIA) localization in the MAM and mitochondrion sub-compartments 
was imaged using the following markers: preprolactin signal sequence (ss) fused to the  
N-terminus of the red fluorescent protein (RFP) with a KDEL ER retention signal at its  
C-terminus (ss-RFP-KDEL, for ER) [36] and mitochondrial Cox 4 leader fused to Tag 
blue fluorescent protein (Mito-BFP)/mitochondrial targeting sequence from human 
cytochrome c oxidase subunit VIII to the N-terminus of Discosoma RFP (DsRed-Mito, 
for mitochondrial matrix) [37]. We use MitoTracker Red as an intermembrane space 
(IMS) marker based upon the superresolution imaging of MitoTracker by others [38,39] 
and our own results herein. Contacts between the ER and mitochondria are shown, with 
the MAM Ca2+ signaling complex components on the ER (IP3R3), cytosol (GRP75) 
and outer mitochondrial membrane (OMM) (voltage dependent anion channel 
(VDAC)). MAM Ca2+ efflux from the ER is regulated by chaperones (BiP, Sig-1R) as 
well as vMIA. Lipid rafts (blue) containing the Ca2+ signaling complex and vMIA are 
shown. These components are shown in the figure. 
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vMIA is N-terminally anchored to ER and mitochondrial membranes by an uncleaved 
hydrophobic leader and its downstream C-terminal sequences are cytosolic [20]. This topology was 
confirmed by vMIA’s sensitivity to protease digestion in ER and mitochondrial fractions [22]. 
Immune electron microscopy (EM) of stably transfected HeLa cells has localized vMIA-myc using 
anti-myc antibody primarily at the OMM [16]. However, fixation, embedding and staining of 
specimens for EM severely compromise membrane morphology. Moreover, immune EM limits 
identifying the distribution of the protein populations such that only a fraction of the molecules in a 
given cellular organelle can be detected, thereby offering limited information about spatial distribution 
of the targeted molecule. Thus, the exact pattern of vMIA distribution and functional organization 
along the mitochondria was not detected by immune EM analysis. This EM analysis aside, vMIA 
imaging has primarily utilized conventional confocal microscopy [15–18,20,23,24,30–32,35,40]. 
Using multicolor confocal microscopy, we have previously found that enhanced green fluorescent 
protein (EGFP) tagged vMIA partially co-localizes with MAM, lipid raft, and mitochondrial 
markers [20,21,23]. Further, vMIA has been co-localized with mitochondrial markers from the 
OMM and matrix [17,18,20,21,23–25,32].  
A major challenge in precisely defining vMIA’s localization in the ER, MAM and  
sub-mitochondrial compartments by confocal microscopy results from the close proximities of the 
ER and OMM membranes (10–25 nm) and of the OMM and inner mitochondrial membrane (IMM) 
at the MAM, which are below its diffraction limit. While confocal microscopy can theoretically 
produce a resolution down to ~200 nm, this resolution of visible light is seldom achieved in 
practice due to numerous optical aberrations associated with biological specimens as well as noise 
associated with the detected fluorescence. Some of this can be corrected by deconvolution of 
confocal images [41]. Mitochondria typically have a diameter of 200–500 nm [38]. Thus, it is not 
possible to determine vMIA distribution within sub-mitochondrial compartments using 
conventional confocal microscopy. For this, we turned to superresolution microscopy, which 
allows imaging beyond the limitations imposed by diffraction, to improve insight into vMIA’s 
distribution in sub-mitochondrial compartments.  
Superresolution microscopy overcomes the physical limit imposed by diffraction. Multiple 
approaches have been developed to resolve fluorescent signals below diffraction limit and these 
include structured illumination (e.g., structured illumination microscopy, SIM; multifocal SIM, 
MSIM), reduction of point spread function by grounding emissions outside of the excitation center 
(e.g., stimulated emission depletion, STED; gated STED, GSTED) or activation of single fluorophores 
(e.g., photoactivated localization microscopy, PALM; stochastic optical reconstruction microscopy, 
STORM). Each of these approaches has its own strengths and weaknesses. In this study, we 
examined the localization of vMIA by deconvolved confocal microscopy and three superresolution 
microscopy techniques namely MSIM, single-color GSTED, and PALM.  
MSIM uses sparse 2D excitation patterns [42] moved in sequential steps to fully illuminate the 
specimen. Images are collected at each step and used in post processing to derive a superresolution 
image. Superresolution is achieved by first defining the precise location of the illumination spots. 
Once the focal spots in each of the images are defined, these are digitally pinholed followed by 
scaling the spots by a factor of 0.5 and then summing these images over all positions. The pinholed, 
scaled, and summed images are then subjected to Richardson-Lucy deconvolution to gain ~2-fold 
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improvement in resolution. Although MSIM sacrifices speed compared to confocal microscopy, it 
maintains the optical sectioning and was shown to provide resolution-doubling characteristics of 
SIM to ~140 nm [42].  
Further improvement in resolution over MSIM is obtained using STED microscopy, where a 
592 nm wavelength doughnut shaped beam is used to drive the fluorochromes in the doughnut to 
ground state by stimulated emission resulting in <50 nm resolution [43,44]. Time gating of the 
short fluorescent lifetimes caused by stimulated emission results in the GSTED approach further 
improves the spatial resolution. STED microscopy has previously shown that the mitochondrial 
inner membrane organizing system (MINOS) forms clusters within mitochondria of primary 
human fibroblasts [45] while two color STED found VDAC type 3 and hexokinase I clusters on the 
OMM of human osteosarcoma cells [46]. Similarly, cytochrome c oxidase subunit 2 and VDAC1 
were found in clusters in purified mitochondria from murine heart [47]. 
Pointillistic imaging based superresolution microscopy approach, PALM offers the highest 
resolution microscopy (~25 nm) used in these studies. PALM uses photoactivatable fluorescent 
proteins and precise localization of single molecules to overcome diffraction limitations. PALM is 
based on high density, single molecule localization in which single molecule signals are fitted with 
2D Gaussian functions to provide a more precise estimate of the molecule’s location. PALM and 
several related techniques use photoactivatable, photoswitchable, or photoconvertible fluorescent 
proteins [48], which initially have little fluorescence or their fluorescence can be turned “off” in the 
spectral region under detection before they are actively turned “on” during imaging. Conservatively 
setting the precision cutoff at ~50 nm can often produce images resolved at that value which is  
~3-fold improvement over the MSIM images and comparable to the GSTED images. Similar to 
MSIM, PALM provides the ability to image multiple colors and better resolution than confocal, but 
slower imaging speed. 
2. Results and Discussion 
2.1. Conventional Confocal Imaging of vMIA Localization with Mitochondrial Markers 
We first used confocal microscopy to monitor mitochondrial distribution of vMIA in HCMV 
permissive cells, human foreskin fibroblasts (HFFs) expressing vMIA-EGFP, which traffics 
indistinguishably from untagged vMIA [15,21,23,26]. We labeled the mitochondrial matrix by using 
S. cerevisiae mitochondrial Cox 4 leader fused to Tag blue fluorescent protein (Mito-BFP) [37] 
(Figure 2). As we previously found [20,21,23,24], vMIA-EGFP fluorescence substantially 
co-localized with a matrix marker, Mito-BFP [37] (Figure 2A). The zoom of one of the larger 
mitochondrion (Figure 2C) shows an example of the level of detail available when imaging these 
markers with confocal microscopy. With the spatial resolution we obtained for this image (FWHM 
for vMIA-EGFP = 298 nm), vMIA-EGFP distribution was only marginally distinguishable from 
Mito-BFP. With the image acquired 3-times below the Nyquist limit, deconvolution of the confocal 
Z-stack images improved the spatial resolution (FWHM for vMIA-EGFP = 182 nm) (Figure 2B). 
This improved resolution allowed us to distinguish the presence of vMIA at the rim of the 
mitochondria, away from the matrix marker Mito-BFP (Figure 2D). This is quantified by the 
intensity profile for the dotted line marked along the deconvolved image of the mitochondrion 
458 
(Figure 2E). This imaging also demonstrated that vMIA is not uniformly distributed along the 
mitochondrial periphery, hinting at the possibility of clustering of vMIA on the mitochondrial 
surface (Figure 2D); however, the clusters of molecules were not clearly resolvable even after 
deconvolution of the confocal microscopy images. In summary, confocal microscopy showed the 
presence of vMIA at the periphery of mitochondria and partially resolved it from the matrix marker.  
Figure 2. Monitoring mitochondrial localization of vMIA by confocal microscopy. 
Primary human foreskin fibroblasts (HFFs) lipofected with vectors expressing  
vMIA-EGFP and Mito-BFP were fixed with 4% paraformaldehyde (PFA) at 22 hours 
after transfection as described in the methods. (A) Images show a single optical plane 
for a cell expressing vMIA-EGFP (green) and Mito-BFP (pseudocolored red) imaged 
using confocal microscopy and (B) the same image plane following deconvolution of 
the entire Z-stack. (C,D) The boxed region of interest is enlarged on the right.  
(E) Intensity profile of vMIA-EGFP (green) and Mito-BFP (red) emissions along the 
pixels marked by the dotted line on the deconvolved image are shown by the plot. For 
higher resolution images, see Supplemental Figure S1.  
 
In these studies, we detected altered mitochondrial morphology in HFFs expressing vMIA 
consistent with previous literature [30,33,34,49]. To determine if the altered mitochondrial 
morphology correlated with vMIA levels, we examined mitochondria morphology in cells 
expressing vMIA (Figure 3). We found that mitochondria (red) not expressing vMIA or expressing 
low levels of vMIA (R1) maintained tubular morphology (Figure 3A). Conversely, mitochondria 
expressing higher levels of vMIA (R2) showed fragmented, vesicular morphology. Multiple tubular 
mitochondria (blue arrows) not expressing or expressing low levels of vMIA were also observed in 
another cell (Figure 3B). These results suggest that threshold levels of vMIA are required for 
mitochondrial fragmentation and vesiculation.  
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With the ability of the deconvolved confocal image to resolve vMIA distribution from the 
mitochondrial matrix marker (Mito-BFP), we next examined the distribution of these markers with 
respect to that of the ER (ss-RFP-KDEL), which has the bovine preprolactin signal sequence (ss) 
fused to monomeric red fluorescent protein (RFP) with the KDEL ER retention [36] sequence 
(graciously provided by Dr. J. Lippincott-Schwartz) (Figure 4A). HFFs expressing the three 
fluorophore-tagged proteins showed that vMIA partially colocalized with ER and mitochondrial 
markers as we previously found [20,21,23,24,26,50]. Moreover, the intensity profile (Figure 4B) of 
the pixels along the line shown in the zoomed boxed region of interest (Figure 4C) showed that 
vMIA-EGFP is located at the interface of Mito-BFP and ss-RFP-KDEL. Although there is 
detection of the interfaces between the ER and mitochondria, there is substantial overlap of the 
mitochondrial OMM (green) and matrix (blue) sub-compartments, which limits the ability of 
confocal microscopy to compellingly resolve the sub-mitochondrial distribution of vMIA.  
Figure 3. Mitochondrial fragmentation by vMIA exhibits a threshold effect. Primary 
HFFs transfected with vectors to express vMIA-EGFP and Mito-BFP were fixed with 
4% PFA at 22 hours after transfection as described in the methods and visualized by 
confocal deconvolution microscopy. (A) Maximal intensity projection of a 3-D image 
showing a pair of cells expressing differing levels of vMIA-EGFP (green), but 
comparable level of Mito-BFP (pseudocolored red). Insets showing the zoom of 
regions R1 and R2 highlights the change in mitochondrial morphology (as shown by 
Mito-BFP) in cells expressing low level (R1) or high level (R2) of vMIA-GFP (B) 
Maximal intensity 3-D projection of another cell expressing Mito-BFP 
(pseudocolored red in the merge) and showing varying levels of vMIA-EGFP (green 
in the merge) on the individual mitochondria. While most of the mitochondria in this 
cell have lost their tubular appearance, red arrows point to the individual 
mitochondrion that show low or no vMIA-GFP expression have remained tubular. 
Scale bars represent 5 m. For higher resolution images, see Supplemental Figure S2. 
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Figure 4. Confocal microscopy imaging of ER-mitochondria interface. HFFs were 
lipofected with vectors expressing vMIA-EGFP (OMM), ss-RFP-KDEL (ER) and 
Mito-BFP (matrix) and fixed with 4% PFA at 25 hours after transfection as described 
below and previously published [23]. (A) Cells expressing vMIA-EGFP (green),  
ss-RFP-KDEL (red) and Mito-BFP (blue) were imaged using confocal microscopy. 
(C) The boxed region of interest from the merged image is enlarged. (B) Line scans of 
vMIA-EGFP (green), ss-RFP-KDEL (red) and Mito-BFP (blue) emissions are shown. 




2.2. Single Color GSTED Imaging of vMIA Localization 
To image vMIA beyond the diffraction limit imposed by the visible light, we used GSTED, an 
earlier variant, STED, has been used to study clustered distribution of several mitochondrial 
proteins at the OMM and IMM by immune localization of intact or isolated mitochondria [45–47]. 
As use of antibody affects precision of localization due to increased distance added on by the 
presence of primary and fluorescently tagged secondary antibodies and imaging isolated mitochondria 
provides localization outside the biologically relevant subcellular context, we undertook in situ 
imaging of vMIA-EGFP in permissive HFFs (Figure 5A). Following deconvolution of the GSTED 
image, we detected vMIA-EGFP (green) in the periphery of a tubular mitochondrion (Figure 5B), 
which is consistent with the above suggestion of OMM localization by the confocal microscopy 
and of biochemical literature [16,20,22]. Intensity profile of pixels marked by the line shown in the 
zoomed GSTED image of the region R2 confirmed that vMIA is localized at the periphery of 
mitochondria, distinguishable from DsRed-Mito, used as a matrix marker and imaged by confocal 
microscopy (Figure 5D,E). GSTED showed improved resolution of vMIA (FWHM = 75 nm) 
OMM location compared to confocal imaging of vMIA (Figure 5B). This increase in spatial 
resolution also offered conclusive evidence to support clustered distribution of vMIA along the 
OMM (Figure 5C). Thus, superresolution GSTED resolved the presence of vMIA at the OMM and 
its clustered distribution in mitochondria in permissive HFFs. It also showed that vMIA exists as 
<100 nm clusters at the OMM irrespective of if the mitochondrion is tubular (Figure 5B) or 
fragmented (Figure 5D).  
As clustering of vMIA along the OMM is an unprecedented phenotype for a viral protein, we 
performed GSTED imaging of vMIA-EGFP in another permissive (human astrocytoma) cell line, 
U373-Tet-ON cells [51] (Figure 6A). GSTED imaging detected vMIA-EGFP (green) in U373-Tet-ON 
cells also showed that similar to HFFs, vMIA is present at the rim of the mitochondria (Figure 6B). 
This rim-like distribution of vMIA-EGFP was confirmed by the intensity profile of pixels marked 
by the line shown in the zoomed region (R2, Figure 6B). GSTED showed improved resolution of 
vMIA location (<50 nm) compared to confocal imaging (200 nm) (Figure 6C). Similar to our 
findings in HFFs (Figure 5), vMIA was present in clusters on the mitochondria in transfected 
U373-Tet-ON cells (Figure 6D,E). However, mitochondria of the U373-Tet-ON cells expressing 
vMIA are considerably less tubular (Figure 6) than mitochondria from transfected HFFs expressing 
vMIA (Figure 5). These differences in mitochondrial morphology likely represent cell-type specific 
differences in the effects of vMIA, which is known to alter mitochondrial morphology [30,32,33,52].  
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Figure 5. Gated stimulated emission depletion (GSTED) microscopy of vMIA-EGFP 
in human fibroblasts. (A) HFFs were lipofected with vectors expressing vMIA-EGFP 
and DsRed-Mito. At 24 hours post transfection, cells were methanol fixed as described 
as below and elsewhere [23] and imaged using GSTED (vMIA-EGFP) and confocal 
microscopy (DsRed-Mito, vMIA-EGFP) followed by deconvolution of both the images. 
(B) Zoomed, merged image of a tubular mitochondrion in the boxed region (R1) is 
shown. This includes DsRed-Mito confocal (red), vMIA-EGFP confocal (blue) and 
vMIA-EGFP GSTED (green). Each channel is also presented individually. (C) Intensity 
profile of the pixels marked by the dotted line on the GSTED panel demonstrates the 
clustered distribution of vMIA along the entire length of the OMM of this 
mitochondrion. (D) The zoomed, merged image of a mitochondrion in the boxed region 
(R2) is shown. (E) The normalized intensity profile along the line shown on the R2 
image, which demonstrates the significant improvement in visualizing the vMIA 
distribution along OMM by GSTED as compared to confocal imaging and its improved 
resolution of its localization away from the matrix and at the OMM. For higher 




Figure 6. GSTED microscopy of vMIA-EGFP in human astrocytoma cells. U373-Tet-ON 
cells expressing the tetracycline controlled transactivator (tTA) [51] were lipofected 
with the tetracycline responsive element (TRE-Tight) promoter driving expression of 
vMIA-EGFP. At 24 hours post transfection, cells were treated with doxycycline (Dox) 
for 60 minutes, labeled with MitoTracker Red (0.5 M) and imaged live using 
Confocal (vMIA-GFP and MitoTracker Red) and GSTED (vMIA-GFP). (A) An optical 
slice showing deconvolved confocal image of a cell expressing vMIA-EGFP and a zoom 
of the region corresponding to the boxed region (R1) are shown in the left panel. Right 
panel presents the zoom of the R1 region showing the deconvolved GSTED (bottom) 
and deconvolved confocal MitoTracker (top) channels. (B) Zoomed confocal images of 
the mitochondrion in the region R2 showing the various channels acquired—Confocal 
images of MitoTracker Red and vMIA-EGFP as well as GSTED image of vMIA-EGFP. 
(C) Normalized intensity profile along the dotted line shown on the confocal and 
GSTED images of R2 demonstrate the improved resolution of vMIA localization by 
GSTED imaging as compared to confocal imaging. (D) Zoom of region R3 showing 
GSTED image of vMIA (E) Intensity profile of the pixels marked by the red line in 
panel (D). For higher resolution images, see Supplemental Figure S5. 
 
2.3. MSIM Imaging of vMIA and Mitochondrial Marker 
With a restricted set of compatible fluorophores that can be used for multicolor superresolution 
imaging by GSTED, for simultaneous superresolution imaging of vMIA-EGFP in context of 
organelle markers we made use of an alternative superresolution imaging approach—MSIM. We 
performed MSIM imaging of doxycycline (Dox) treated HFFs dually transfected with the 
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tetracycline transactivator [53] and the TRE-Tight promoter driving vMIA-EGFP (Figure 7). We 
observed that vMIA localized distinctly from the mitochondrial marker we used here—MitoTracker 
Red, which appears to localize to the IMS [38]. As expected, widefield imaging of vMIA-EGFP 
and MitoTracker Red showed predominant colocalization of the two fluorophores (Figure 7A). 
With the observed spatial resolution of 302 nm for this image there was little resolution of the 
vMIA and MitoTracker labeling (Figure 7B). The overlap of the signals was documented by the 
intensity profile of each fluorophore along the pixels marked by the dotted line shown in the zoom 
of the region R3 (Figure 7B). MSIM images of the two fluorophores for this cell showed improved 
resolution of vMIA-EGFP and MitoTracker Red (Figure 7C). Intensity profile of MSIM image of 
each fluorophore along the pixels marked by the dotted line shown in the zoom of the region R3 
showed partial separation of the vMIA-EGFP fluorescence peaks from those of the MitoTracker 
fluorescence peaks such that the bimodal vMIA peaks are farther away to the outside of the 
bimodal MitoTracker peaks (FWHM = 120nm) (Figure 7D). This distribution of the two markers is 
in agreement with the vMIA localization to the OMM, surrounding the IMS localized MitoTracker 
Red. Furthermore, MSIM imaging in individual mitochondrion (R1 and R2 in Figure 7E) 
confirmed our previous observations of vMIA localization in clusters at the OMM. The presence of 
vMIA clusters was verified by intensity profile of MSIM image of each fluorophore along the 
pixels marked by the dotted line drawn along the rim of a mitochondrion in R2 (Figure 7F). These 
vMIA clusters were obscured by diffraction in widefield imaging (Figure 7B) and confocal 
microscopy (Figures 2–4) but detected by superresolution GSTED imaging (Figures 5 and 6). 
Together, these results show that MSIM partially resolves vMIA location at mitochondria 
periphery, away from IMS, and in clusters of diffraction limited size. The ER and OMM make 
contacts at the MAM. In addition, using superresolution microscopy multiple mitochondrial 
proteins including the OMM VDAC1, VDAC3 and Tom 20 proteins have been shown to exist in 
clusters as functional mitochondrial complexes [46,47,54]. vMIA clustering could represent the 
contact sites between the ER and OMM or could indicate the vMIA association with functional 
complexes at the OMM. Use of above approaches allowed us to narrow down the size of vMIA 
clusters to be in the range of 100 nm, but this is close to the resolution of imaging modalities used. 
2.4. PALM Imaging of PA-mCherry-vMIA 
To visualize vMIA clusters by yet another independent superresolution approach and obtain a 
better estimate of the size of vMIA clusters, we made use of the pointillistic imaging 
superresolution imaging approach PALM. Here, we expressed vMIA tagged with PAmCherry, a 
photoactivatable red fluorescent protein [55], in HFFs and visualized them using 2D PALM 
imaging (Figure 8). Most of the molecules in this image localized with precision better than 25nm, 
but here we have conservatively rendered all molecules which have been localized to <25 nm 
precision as 2D Gaussian distributions with 25 nm sigmas. Similar to our MSIM and GSTED 
results above, qualitative observations suggest a non-uniform distribution of vMIA-PAmCherry on 
the periphery of the mitochondria when rendered in this manner. PALM imaging also affords a 
second, rather straightforward analysis of molecule distributions, which is relevant to this work, 
cluster analysis. Several methods are developed for this sort of analysis, but we opted for pair 
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correlation analysis in quantitatively determining which regions of each mitochondrion displayed 
increased vMIA protein densities.  
Figure 7. Imaging vMIA localization using widefield microscopy and MSIM. HFFs 
were transfected with vectors expressing TRE-tight promoter-vMIA-EGFP (green) and 
its tetracycline controlled transactivator (tTA) [53]. Transfected cells were Dox-treated 
(0.2 g/mL) for one hour, MitoTracker Red treated (0.5 M for 5 min, red) and 
methanol fixed as described [23]. 25 slices (0.2 m step size) were collected using  
488 nm and 561 nm excitation lasers. For each channel, 256 multifocal excited images 
were collected as the excitation array was stepped ~1 pixel in a 16 × 16 grid pattern. 
(A) Summation of the images produces the widefield fluorescence image, which shows 
high degree of co-localization between vMIA-EGFP and MitoTracker Red. (B) Zoomed 
images of mitochondria in the region marked R3 are shown and the plot below shows 
the intensity profile through the region marked by dotted line. (C) The MSIM image is 
shown. (D) The zoomed images of region R3 and the line scan for the region marked by 
dotted line show the improved ability to resolve the vMIA-EGFP and MitoTracker Red 
staining through the use of MSIM. (E) MSIM images of two mitochondria (R1 and R2) 
are shown. (F) Intensity profile through the perimeter of mitochondrion in R2 marked 
by dotted line is shown in the plot. This indicates non-uniform distribution of vMIA-GFP 




Figure 8. PALM imaging of vMIA-PAmCherry1. HFFs were transfected with  
vMIA-PAmCherry and imaged by PALM. (A) The image shows 301666 molecules that 
were localized to 25 nm precision out of 515207. Molecules are plotted as  
two-dimensional Gaussian distributions with 25 nm standard deviations. (B) The image 
shows a small region in (A) indicated by the red square. The molecule positions in a 
binary image were used in pair correlation analysis and the maximum g(r) derived from 
using each molecule as a reference point was plotted as the pixel values. (C) The image 
shows the same region in the red square color-coded to display the varying degrees of 
molecule densities. The Look Up Table (LUT) and calibration bar are included in the 
upper right corner. The distributions of cluster sizes (D) and the number of particles per 
cluster (E) were determined from the pair correlation analysis results. The maximum 
cluster radius was limited to 500 nm and the minimum number of particles per cluster 
was limited to 20. Please note that the Y axis in (E) is a log scale to better indicate the 
lower percentages at the higher particle numbers. The scale bar in (A) is 5 m and in 
(B,C) is 1 m. High resolution images of the entire field of view are available in the 
SOM (see Supplemental Figures S7, S10 and S11). 
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In these analyses, the function g(r) is determined by comparing the protein density in a local 
“shell” region around each position with the average density of all molecules of interest (see 
Supplemental Figure S8). Simulated images containing various levels of clustering are shown in 
Supplemental Figure S9A–D. For these, the factor g is plotted as a function of the radius and for 
images containing no clusters, this remains close to 1 as the radius decreases toward zero 
(Supplemental Figure S9E). However, in images with clusters, the g(r) deviates from 1 at 
approximately the diameter of the clusters (Supplemental Figure S9E). If the cluster radii increase, 
the g(r) deviates at a higher value of r. If the molecule density in the cluster increases, the 
maximum g(r) increases. Thus, the maximum g(r) can reflect the relative amplitude of the molecule 
density surrounding each reference particle. This is important for our simple analysis in which we 
compare the local protein density with the whole image density. With these criteria, the entire 
mitochondrion could be considered a cluster. In our analyses, we used the average density of all 
molecules in the image localized to <25 nm precision. We plotted the g(r) maximum value 
obtained for each reference molecule in a new image at the appropriate location (Supplemental 
Figure S10). Indeed, we find that most of the molecules localized to the mitochondria show g(r) 
values greater than 1, but we also note that regions resembling the clusters observed with MSIM 
and GSTED have much higher g(r) values than surrounding peripheral regions (Figure 8). Using 
the results from pair correlation analysis, the cluster sizes (Figure 8D) and the number of particles 
per cluster (Figure 8E) were determined. Cluster radii show a broad distribution with a mean radius 
of approximately 95 nm and suggest that a majority are <100 nm. The number of particles per 
cluster is also broadly distributed and indicates that a majority of the clusters (approximately 60%) 
contain 50 particles or less.  
3. Experimental Section  
3.1. Cell Culture and Lipofection  
HFFs were cultured in Dulbecco’s Modified Eagle’s medium containing 10% fetal calf serum 
(FCS, Hyclone, Logan, UT), 100 U/mL of penicillin, 100 g/mL of streptomycin, 2 mM L-Glutamine 
(Life Technologies, Grand Island, NY) as previously described [56]. U373-Tet-ON cells were also 
cultured in the 10% FCS, 100 U/mL of penicillin, 100 g/mL of streptomycin, 2 mM L-Glutamine 
but maintained under selective pressure using 0.6 mg/mL Geneticin (Life Technologies).  
Cells were seeded at 20%–50% confluency on sterile 18 mm (for confocal or GSTED) or 25 mm 
(for PALM and MSIM) cover slips in six-well plates (9.72 cm2 per well). Twenty-four hours later 
cells were transiently transfected using Lipofectamine 2000 (Life Technologies) suspended in  
Opti-MEM (Life Technologies), according to the manufacturer’s protocols. DNA ( g):lipid ( L) 
ratios for transfection were at 1:1.77, with approximately 0.5 g total DNA used per cm2 of 
available plating surface area. Cells were harvested 22-25 hours after transfection by fixation with 
methanol or 4% PFA in PBS and mounted with Prolong Gold Antifade. GSTED imaging was 
performed on live U373-Tet-ON cells treated with Dox (0.5 M).  
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3.2. Construction of pTRE-Tight Promoter-vMIA-EGFP 
The vMIA/UL37x1 protein-EGFP open reading was isolated from p1242 [15] by restriction 
enzyme digestion with EcoRI and NotI. The fragment was ligated into EcoRI/NotI digested 
TRE-Tight vector (Clontech, Mountain View, CA, USA) and the ligation product was transformed 
into competent E. coli (strain DH5 alpha). 
3.3. Confocal Microscopy 
The confocal images were acquired using the Olympus FV1000 confocal microscope. An 
UPlanSApo100x/1.40NA oil objective was used to obtain an oversampled 1024 × 1024 image with 
49 nm pixel and a z-stack with a step size of 120 nm. The Mito-BFP and the vMIA-EGFP were 
sequentially excited using a 405nm diode laser and a 488nm Argon laser, respectively, and 
collected between 425 nm–475 nm and 500 nm–545 nm in the spectral detectors. In the triple 
labeled cells, ss-RFP-KDEL was also sequentially collected using 575 nm–675 nm filter after 
excitation with a 559 nm diode laser. 
3.4. GSTED Microscopy 
The GSTED images were acquired using a Leica TCS SP5 gated STED (GSTED) microscope 
that was equipped with a super continuum white light laser (WLL) and hybrid detectors adapted for 
time gated imaging which allow elimination of low spatial frequency from the final super resolved 
image [57]. The 592 nm depletion laser delivers 0.3W at the focal plane. A HCX PL APO  
100× 1.40 NA oil objective was used to obtain a 1600 × 1600 image with a 24.2 nm pixel.  
The DsRed-Mito confocal image was acquired using the 560 nm excitation and collected between 
569 nm–665 nm. A sequential GSTED image of UL37-EGFP was obtained using a 488 nm 
excitation, 592 nm depletion, time gating from 1–8 ns, and collected between 500 nm–544 nm. 
Using the tunability of the white light laser and prism based spectral emission. “Lambda lambda” 
scans were acquired for an excitation range of 470 nm–590 nm and an emission range of  
485 nm–605 nm. Both excitation and emission scans were taken with 10 nm wavelength steps 
between measurements and was used to confirm the excitation and emission properties of the 
EGFP fluorophore imaged on this microscope in the GSTED or confocal mode. 
3.5. Deconvolution Analysis  
Blurring due to out of focus signal and Poisson noise in the confocal and GSTED images was 
removed by carrying out deconvolution using the Huygens Essential software supplied by Scientific 
Volume Imaging B.V. (Hilversum, The Netherlands). For confocal images, deconvolution was 
done using 3D images acquired as described above. For GSTED images, 2D deconvolution was 
done on the using images acquired as discussed below. For generating pixel intensity plots images 
were imported and analyzed in the Metamorph Premier (7.7.0) software supplied by Molecular 




The MSIM microscope used for these experiments is a homebuilt machine using an Olympus 
IX-71 widefield microscope as previously described [58] and with modifications detailed below.  
A 100 mW 405 nm Cube laser (Coherent, Inc., Santa Clara, CA, USA), 50 mW 488 laser (Oxxius, 
Lannion, France, LBX-488-50-CIR-PP), 50 mW 561 Sapphire laser (Coherent, Inc.), and 100 mW 
640 nm Cube laser (Coherent, Inc.) served as illumination sources for blue, green, red, and far-red 
fluorophores, respectively. The light from each laser was filtered by placing a 405/10 nm 
BrightLine single-band bandpass filter (Semrock Inc., Rochester, NY, USA, FF01-405-10/25) at 
the aperture of the 405 laser, a 488/6 nm BrightLine single-band bandpass filter (Semrock Inc., 
FF01-488-6/25) at the aperture of the 488 laser, a 561/4 nm BrightLine single-band bandpass filter 
(Semrock Inc., FF01-561-6/25) at the aperture of the 561 laser, and a 640/8 nm MaxDiode laser 
clean-up filter (Semrock Inc., LL01-640-8/12.5) at the aperture of the 640 laser. The laser beams 
were collimated or expanded and collimated with insertion of pairs of lenses after the clean-up 
filters. The 405 laser has a 2× telescope consisting of a 50 mm focal length lens (Thorlabs Inc., 
Newton, NJ, USA, LA1131-A) and a 100 mm focal length lens (Thorlabs Inc., LA1509-A). The 
488 laser has a 1× telescope consisting of a pair of 100 mm focal length lenses (Thorlabs Inc., 
LA1509-A). The 561 laser has a 3× telescope consisting of a 50 mm focal length lens (Thorlabs 
Inc., LA1131-A) and a 150 mm focal length lens (Thorlabs Inc., LA1433-A). The 640 laser has a 
2× telescope consisting of a 50 mm focal length lens (Thorlabs Inc., LA1131-A) and a 100 mm 
focal length lens (Thorlabs Inc., AC254-100-A). Mechanical shutters along with acousto-optic 
tunable filter (AA Opto-electronic Inc., Orsay, France, AOTFnC-400.650) controlled by  
Micro-Manager [59] allowed for laser wavelength selection, laser power tuning and laser 
shuttering. The laser beams were expanded 5× using a 40 mm focal length lens (Thorlabs Inc., 
AC254-40-A) and a 200 mm focal length lens (Thorlabs Inc., AC254-200-A). Collected fluorescence 
was filtered through a 480/40 bandpass filter (Chroma Technology Corp, Bellows Falls, VT, USA 
D480/40m) for 405 nm excitation, a 525/45 bandpass filter (Semrock, FF01-525/45-25) for 488 nm 
excitation, a 600/37 bandpass filter (Semrock, FF01-600/37-25) for 561 nm excitation, and a 
EdgeBasic 635 longpass filter (Semrock, BLP01-635R-25) for 640 nm excitation. All other 
components in the excitation and emission paths, such as optical components, 2D galvanometer, 
z-stage and camera, are the same as previously published [58].  
3.7. MSIM Data Collection and Analysis 
MSIM data were collected for each slice as previously published [58] except the galvanometer 
was stepped in a 16 × 16 grid to collect 256 frames for each 512 × 512 pixel wide field of view.  
Post-processing was performed as previously published [58] on freely available software [60]. 
Deconvolution was performed on the MPSS images using a program written in Python (freely 
available at [60] implementing Richardson–Lucy deconvolution [58,61–63].  
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3.8. PALM Data Analysis 
Single molecule images were analyzed as previously described [64] using PeakSelector (a 
program written in IDL by Harald Hess and Gleb Shtengel, Howard Hughes Medical Institute, 
Janelia Farms, Ashburn, VA, USA). The molecule localization data were output as an Ascii file 
which was used by an ImageJ macro (available upon request) [65] to plot the molecule positions 
and precisions on images with 5 nm pixels. 
Pair correlation analysis was performed on binary images displaying peak positions rendered as 
single 5 nm pixels. The g(r) function was determined for each particle by using the equation  
g(r) = ( r)/ (AN) 
where each particle is treated as a reference particle. The particle density in a “shell” region of r is 
determined and then divided by the particle density in a region containing all of the particles of 
interest, AN. In these analyses, the entire image was used as AN (Supplemental Figure S8). The 
analysis was performed using an ImageJ macro (available upon request) run in FIJI [66]. Briefly, 
the particle density  in region AN, ( r), was determined by dividing the total number of rendered 
molecules by the area of the image. The particle density  in region r, ( r), was determined by 
first counting the number of particles in areas r1 and r2 (Supplemental Figure S8). The number of 
particles in region r was determined by subtracting the r1 count from the r2 count. The area of r 
was determined using r2 by subtracting the area the r1 region from the area of the r2 region. The 
( r) was calculated by dividing the r count by the area of r. 
The g(r) as a function of the radius r1 for each peak was fit with an exponential equation  
g(r) = A × exp(–(1/B) × r) + C 
where A is the amplitude, B is the radius of the cluster, and C is the offset. Only peaks with g(r) 
fitted with a correlation coefficient R2 > 0.9 were rendered in the g(r) image. To display these data, 
the molecule peak position image was rendered by setting the pixel values for each particle to the 
maximum g(r) determined for that peak when using it as a reference in the analysis (Supplemental 
Figure S10). A color coded LUT with calibration is included for comparison of different regions of 
the cell. Additional processing on this image included a Gaussian blur with a 25 nm sigma to 
represent the uncertainty in molecule localization (Supplemental Figure S11).  
4. Conclusions  
Because superresolution microscopy is an emerging technology, it has had very limited use in 
the study of viruses. To date, superresolution imaging has primarily focused on RNA viruses including 
imaging of rotavirus virions [67], influenza hemagglutinin clusters [68], HIV assembly [64,69,70] 
and HIV transfer [71]. More recently, single copy viral genomes including those of DNA viruses 
have been imaged using superresolution microscopy [72]. To our knowledge, our studies are the 
first superresolution imaging of any human herpesvirus protein, in particular of a HCMV vMIA.  
HCMV vMIA imaging by confocal/deconvolution microscopy indicated its OMM localization, 
which was confirmed by GSTED, MSIM, and PALM imaging. Additionally these imaging 
modalities all demonstrate that at the OMM vMIA is present in clusters, indicating nanoscale 
localization of HCMV vMIA at the mitochondrial periphery, away from IMS and matrix. While 
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this clustering is also suggested by deconvolved images obtained by the confocal microscopy, 
diffraction limits the ability to visualize the distribution of MAM clusters. This indicates that the 
vMIA domains are generally spaced closer than the diffraction limit. This inference has been 
supported by the ability to resolve them by each of the superresolution imaging approaches used 
here. Use of PALM imaging allowed us to estimate the sizes of these clusters at approximately 95 
nm, which is in agreement with the cluster sizes indicated by the GSTED and MSIM approaches.  
Intriguingly, clusters of cellular mitochondrial proteins have been observed using superresolution 
microscopy. STED microscopy found that MINOS, which maintains IMM morphology, forms 
clusters often in an ordered inner mitochondrial distribution [45]. Tom 20 and Tom22, components 
of the translocase of the outer mitochondrial membrane, are clustered at the OMM with densities 
that correlate with mitochondrial membrane potential [73]. VDAC1 and VDAC3 have also been 
found by superresolution imaging to be distributed in clusters in the OMM. Cytosolic hexokinase I 
which associates with VDAC3 is partly also localized in clusters with VDAC3 [46,47]. Our 
superresolution imaging suggests that vMIA may target and associate with clustered OMM 
proteins. Alternatively, vMIA traffics efficiently to the MAM [20–23,26,74]. vMIA clustering may 
represent sites of contacts between the ER and OMM, where vMIA could be transferred between 
the two organelles. The use of vMIA mutants and known cellular markers of MAM should allow us 
to distinguish these possibilities.  
Superresolution imaging has the clear potential to provide valuable insight into the nanoscale 
organization of viral machineries, which provide essential replicative processes. Case in point is the 
detection of non-uniform distribution of vMIA at the OMM. This distribution was not detectable by 
conventional microscopy because of its diffraction limited resolution. Further, this technology 
allows virologists to study how viruses alter cellular organelles to establish replication 
compartments and virus assembly. However, the superresolution approach to be used should be 
carefully selected. Our approach here involved three techniques with complementary advantages in 
nanoscale studies of vMIA localization. GSTED relies primarily on imaging of one fluorophore 
impacting on the ability to place the viral proteins in the in situ biological context of cellular 
organelles or structures. Secondary markers can be imaged by GSTED using the appropriately labeled 
secondary antibodies (e.g., Alexa 532). GSTED provides greater resolution (<50 nm) than MSIM. 
However, use of primary and secondary antibodies can adversely affect precision of protein 
localization at the nanoscale resolution. Nonetheless, because of its resolution, GSTED provided 
compelling evidence for vMIA clustering in mitochondria and localization at the OMM. 
Conversely, MSIM is lower resolution than GSTED microscopy. However, MSIM makes use of 
the same fluorophores used for conventional confocal microscopy. This enables imaging of viral 
proteins in the context of multiple fluorophore tagged proteins from different sub-cellular 
compartments. For our experiments, MSIM provided sufficient resolution to confirm the location 
and clustering of vMIA at the OMM. 
PALM imaging provides the highest resolution used in these studies but imaging sufficient 
molecules to obtain meaningful information requires hours of acquisition and post-acquisition 
processing. This limits most PALM imaging to fixed specimens. Given the increasing palette of 
photoactivatable fluorophores and increasing availability of these powerful microscopy techniques 
much can be learned by their application to multiple viruses and their processes.  
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Here, we have used three different superresolution techniques with multiple markers to image 
the localization and clustering of vMIA. These all confirm the presence of the clusters on the outer 
membranes of mitochondria and are helping to define the cluster physical characteristics. In 
general, the clusters are found closer together than the limits of resolution by widefield and 
confocal microscopy. Examples of these include the plot profiles in Figures 5–7 compared with the 
widefield or confocal counterparts. These results show that given time, the imaging techniques 
used here will help discern on a sub-mitochondria scale where are the components of MAMs 
located in relation to each other as well as other cellular players.  
A second important finding here is that we may put a conservative upper limit on the  
diffraction-limited vMIA cluster size of approximately 150 nm. Since this comes from the data 
collected with three independent imaging techniques, it provides a more reasonable estimate than 
simply relying on a single technique. 
Why is the size of importance? At these scales, small cluster sizes dictate the maximum number 
of molecules which can fit inside. Given the number of processes in which MAMs are known to 
play a role, this imposes limits on the number of molecules which can participate in signaling 
events. Thus, every MAM may not have all of the components to initiate all processes and this 
brings up another nagging question in the MAM field. Are the MAMs homogeneous or have 
differing compositions which imply different functions? Now that these structures can be readily 
imaged with optical techniques using multiple color markers, answers to this question will be far 
more straightforward to derive than with previous efforts. In summary, our studies show that 
superresolution imaging provides valuable insight into sub-diffraction resolution of viral protein 
location, particularly in the sub-mitochondrial compartments, and into their clustered arrangement. 
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Abstract: The complete genome of human cytomegalovirus (HCMV) was elucidated 
almost 25 years ago using a traditional cloning and Sanger sequencing approach. 
Analysis of the genetic content of additional laboratory and clinical isolates has lead to 
a better, albeit still incomplete, definition of the coding potential and diversity of  
wild-type HCMV strains. The introduction of a new generation of massively parallel 
sequencing technologies, collectively called next-generation sequencing, has profoundly 
increased the throughput and resolution of the genomics field. These increased possibilities 
are already leading to a better understanding of the circulating diversity of HCMV 
clinical isolates. The higher resolution of next-generation sequencing provides new 
opportunities in the study of intrahost viral population structures. Furthermore, deep 
sequencing enables novel diagnostic applications for sensitive drug resistance mutation 
detection. RNA-seq applications have changed the picture of the HCMV transcriptome, 
which resulted in proof of a vast amount of splicing events and alternative transcripts. 
This review discusses the application of next-generation sequencing technologies, 
which has provided a clearer picture of the intricate nature of the HCMV genome. The 
continuing development and application of novel sequencing technologies will further 
augment our understanding of this ubiquitous, but elusive, herpesvirus. 
Keywords: cytomegalovirus; genomics; transcriptomics; next-generation sequencing;  




Human cytomegalovirus (HCMV), the prototype member of the herpesvirus subfamily 
Betaherpesvirinae, has a worldwide distribution and infections with this virus are extremely 
common. Seroprevalences in the adult population vary from 45% to 100%, increasing with age and 
varying with geographic location and socio-economic background [1]. HCMV causes only mild to 
no symptoms in immunocompetent individuals, but the virus is never cleared and establishes a 
latent infection for the lifetime of its host [2]. Primary infection, reactivation, or reinfection of 
immunocompromised individuals, such as transplant recipients and AIDS patients, results in 
considerable morbidity and mortality [3]. Furthermore, it is the most important congenital  
infection in both developed and developing countries, causing sensorineural hearing loss and 
neurodevelopmental delays [4]. The double-stranded DNA (dsDNA) genome of wild-type HCMV 
strains has a size of around 235 kb, which is longer than all other human herpesviruses and one of 
the longest genomes of all human viruses in general. It has the characteristic herpesvirus class E 
genome architecture, consisting of two unique regions (unique long UL and unique short US), both 
flanked by a pair of inverted repeats (terminal/internal repeat long TRL/IRL and internal/terminal 
repeat short IRS/TRS). Both sets of repeats share a region of a few hundred bps, the so-called  
“a sequence”; the other regions of the repeats are sometimes referred to as “b sequence” and  
“c sequence” (Figure 1). The genome exists as an equimolar mixture of four genomic isomers by 
inversion of UL and US regions [5]. 
Figure 1. Class E genome of HCMV. The unique long and unique short regions are 
indicated as UL and US. Repeat regions are indicated as a, b and c sequences, where 
primes designate inverted orientations. Sequences ab and b’a’ correspond to the 
terminal/internal repeat long (TRL/IRL); sequences a’c’ and ca correspond to the 
internal/terminal repeat short (IRS/TRS). Top: typical genome arrangement of  
wild-type strains; bottom: genome arrangement of strain AD169 is given as  
an example of a laboratory-adapted strain. Genome rearrangements (deletion of  
UL 3’ end and replacement by an inverted copy of UL 5’ end) that have occurred 
during extensive passaging are indicated in red between the wild-type and  
laboratory-adapted configurations. 
 
The commercial introduction of new DNA sequencing technologies, referred to as next-generation 
sequencing (NGS), has immensely impacted the field of genomics. These novel technologies 
generate a massive throughput at a considerably lower per base cost than traditional Sanger 
sequencing, and obviate the need for laborious cloning procedures [6–8]. NGS has already shown 
its promise in virological research with applications in virus discovery and metagenomics, whole 
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genome analysis, deep sequencing of viral populations, novel diagnostic assays, and studies of 
virus-host interactions through transcriptome and epigenome studies [9–11]. In this review, we will 
highlight the recent progress that has contributed to the understanding of HCMV genomics through 
the application of NGS technologies. 
2. HCMV Genomics before the Introduction of NGS 
2.1. Genome Alterations during Cell Culture Adaptation  
When the first complete genome sequence of HCMV was published in 1990, it was the largest 
contiguous sequence generated at the time [12,13]. The authors estimated that the effort to 
sequence the genome of the laboratory-adapted strain AD169 with M13 shotgun cloning and 
Sanger sequencing was equivalent to a 12-year workload for one person. The laboratory-adapted 
strains AD169 and Towne had been passaged extensively in human fibroblast cell lines and were 
found to cause no or very low virulence in seronegative individuals during vaccine studies [14–16]. 
In contrast, the Toledo strain had been passaged significantly less and produced mononucleosis 
syndromes when administered to seropositive individuals [17]. When genome regions of AD169, 
Towne, and Toledo were compared through restriction enzyme profiles, hybridization, and 
sequencing techniques, it was observed that AD169 and Towne had lost genome segments of 15 kb 
and 13 kb, respectively. These segments were situated at the 3’ end of the UL region (sometimes 
referred to as the UL/b’ region) and were replaced by an inverted copy of the 5’ end of the UL 
region, leading to an enlargement of the b repeats (Figure 1). This missing UL/b’ segment was also 
found to be present in an additional set of five low-passage clinical isolates like Toledo, confirming 
that it is a universal hallmark of wild-type HCMV strains and clearly contains factors that are 
dispensable for fibroblast replication, but essential for virulence in vivo [18,19]. 
In addition to these genome rearrangements, strains AD169 and Towne display more subtle 
alterations of their coding capacity in genes inside—variants of AD169 and Towne with a more or 
less intact UL/b’ region exist [20]—and outside the UL/b’ region. AD169 has open reading frame 
(ORF) disrupting mutations in genes RL5A, RL13, UL36, and UL131A; Towne is affected in 
genes RL13, UL1, UL40, UL130, US1, and US9 [20–24]. Even the low-passage strain Toledo is 
mutated in genes RL13, UL9 and UL128 [25]. Almost all strains passaged in fibroblast cell 
cultures display one or more mutations in the UL128 locus (UL128L) and in the genes of the RL11 
family, indicating a role in cell tropism for these gene products. UL128L consists of genes UL128, 
UL130, and UL131A (Figure 2). and its products form a complex with the viral glycoproteins gH 
and gL. While this complex is dispensable for growth in fibroblasts, it is essential for endothelial 
and epithelial cell tropism [26–28]. The RL11 gene family contains 14 genes at the 5’ end of the 
UL region (RL5A, RL6, RL11-UL1, UL4-UL11, Figure 2) that are dispensable for growth in 
fibroblasts and are functionally poorly characterized [23,29,30]. Several of these genes show a 
remarkable genetic variability between different clinical isolates [25,31]. The majority of the RL11 
genes have a characteristic domain (RL11D) that shares homology with the CR1 domain of the 
adenovirus E3 genes [23]. These proteins could function as modulators of a set of variable host 
proteins, and similarities to the immunoglobulin IgD family have been proposed [12]. Recently, 
some RL11 genes have indeed been implicated in immune evasive functions [32–34]. 
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Figure 2. Genome annotation of the low-passage HCMV strain Merlin (GenBank 
accession NC_006273). The dsDNA genome is visualized as a single line; nucleotide 
positions are given in bps. Terminal and internal repeat regions (TRL, IRL/IRS and 
TRS) are indicated with white boxes. Arrows represent genes; different gene families 
are designated with different color codes, as illustrated below the genome. The four 
large non-coding RNAs and the origin of lytic replication are also represented. 
 
While the consensus sequence of the low-passage strain Merlin only has a mutation in gene 
UL128, cloning of the strain into a bacterial artificial chromosome (BAC) vector showed that it 
was also defective in gene RL13 [25,35]. Since RL13 mutations were present at different sites in 
different clones, this was not noticeable in the consensus sequence. Repair of UL128 in the Merlin 
BAC repressed replication in fibroblast cells, but not in epithelial cells and, consequently, novel 
mutations only emerged in fibroblasts. On the contrary, repair of RL13 impaired replication in 
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fibroblast cells as well as in epithelial cells, and mutants appeared rapidly in both cell types. 
Mutational dynamics of clinical HCMV isolates were further analyzed in fibroblasts, epithelial, and 
endothelial cells by recording all mutations in four isolates up to passage 50 or more [36]. Several 
additional genes were mutated in some strains, but only UL128L and RL13 invariably mutated in 
fibroblast cells (RL13 in all cell types). Taken together, these studies stress the inherent instability 
of HCMV isolates when passaged in cell culture. Thus, in vitro studies with HCMV strains should 
allow for these limitations, and researchers should be mindful of the genetic changes that have 
altered the coding capacity and functionality of the strain under study. 
2.2. Genome Annotation  
The publication of the first complete genome sequence of HCMV was accompanied by a first 
genome annotation, predicting 208 ORFs that were potentially protein encoding [12]. Only ORFs 
encoding for proteins with a minimum length of 100 amino acids were considered, with a maximal 
overlap of 60% between ORFs. As the authors expected, this preliminary annotation wrongly 
predicted some ORFs and at the same time excluded genuine ORFs that were either too small or 
highly spliced. Since the results were based on the laboratory-adapted strain AD169, the ORFs 
encoded by the UL/b’ region (Figure 1) were also missed [18,19]. The annotation was further 
refined by comparison with chimpanzee, rhesus and murine cytomegalovirus genomes [37,38] and 
by sequence analysis of additional clinical isolates of HCMV [25,39]. The low-passage strain 
Merlin has become the reference strain for wild-type HCMV, and its sequence entry (NCBI 
GenBank accession NC_006273, Table 1) currently contains a set of 170 genes. Several sets of 
genes share some sequence similarity and are thought to have originated from duplication events 
and subsequent divergence of structure and function [12,13]. These 15 gene families are indicated 
on the genome map in Figure 2. 
Table 1. HCMV complete genome sequences available on NCBI GenBank, listed in 
order of submission date. 
GenBank 
accession 
Strain name Clinical source Passage history Ref. 
Submission 
date 
X17403 AD169 Adenoids of a 7-year old girl 








Adenoids of a 7-year old girl 
Passaged extensively in 
human fibroblasts 




Urine from a congenitally 
infected infant 





AY315197 Towne varS 
Urine of a 2-month-old 
infant with microcephaly and 
hepatosplenomegaly 
Passaged extensively in 
human fibroblasts 
[30] June 6, 2003 
AC146851 Towne-BAC 
Urine of a 2-month-old 
infant with microcephaly and 
hepatosplenomegaly 
BAC clone from a plaque 






Transplant patient with 
HCMV disease 
BAC clone from isolate PH 






Table 1. Cont. 
GenBank 
accession 




Urine from a congenitally 
infected infant 
BAC clone from a plaque 





AIDS patient with CMV 
retinitis 




Cervical secretions of a 
pregnant woman with a 
primary HCMV infection 





AC146999 AD169-BAC Adenoids of a 7-year old girl 
BAC clone from a plaque 








Throat wash of a bone 
marrow transplant recipient 
BAC clone from TB40/E 
passaged 5 times in human 
fibroblasts and 22 times in 







Adenoids of a 7-year old girl 





FJ616285 Towne varL 
Urine of a 2-month-old 
infant with microcephaly and 
hepatosplenomegaly 





GQ221973 HAN13 Bronchoalveolar lavage 






Urine from a congenitally 
infected infant 






Post mortem prostate tissue 




GQ396662 HAN38 Bronchoalveolar lavage 





GQ396663 HAN20 Bronchoalveolar lavage 


















Cervical secretions of a 
pregnant woman with a 














Urine from a congenitally 
infected infant 






Blood from a bone marrow 
transplant patient 
Plaque purified and 







Table 1. Cont. 
GenBank 
accession 




Urine from a congenitally 
infected infant 






Liver biopsy from a 
congenitally infected infant 





JX512199 HAN1 Bronchoalveolar lavage No information - 
August 21, 
2012 
JX512200 HAN2 Bronchoalveolar lavage 





JX512201 HAN3 Bronchoalveolar lavage 





JX512202 HAN8 Bronchoalveolar lavage 





JX512203 HAN12 Bronchoalveolar lavage 





JX512204 HAN16 Urine from an infant 





JX512205 HAN19 Bronchoalveolar lavage 





JX512206 HAN22 Bronchoalveolar lavage 





JX512207 HAN28 Bronchoalveolar lavage 





JX512208 HAN31 Bronchoalveolar lavage 





KC519319 BE/9/2010 Urine from an infant 






Urine from a congenitally 
infected infant 





KC519321 BE/11/2010 Urine from an infant 












Urine from a renal transplant 
recipient 






Vitreous humor from eye of 
HIV-positive male 
Passaged several times in 
human fibroblasts 




Throat wash of a bone 
marrow transplant recipient 
Generated on human 
fibroblasts by passaging 
strain TB40/E once, plaque 
purifying 3 times and 




°NCBI GenBank release file 199.0; search performed on 15 January 2014; patent sequences, transgenic 
strains, and incomplete sequences were not included; *NCBI Reference Sequence (RefSeq); “Update 
from AD169 entry X17403 by the addition of the 929 bp missing region, encompassing UL42 and UL43, 
and the correction of sequencing errors. 
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2.3. Genetic Diversity 
Complete sequence analysis of several clinical isolates not only assisted the refinement of the 
genome annotation, but also led to the understanding that several regions of the HCMV genome are 
variable between different isolates [25,39]. Studies of individual gene sequences from viral 
glycoprotein genes [46–48], virulence-determining genes from the UL/b’ region [49–51], and 
RL11 genes [31,52,53] have been conducted to establish the existence of separate clusters of 
polymorphisms or genotypes (reviewed in [54–56]). Despite their variability, individual genotypes 
display remarkable sequence stability both within the host as in the population, and most genotypes 
seem to have a worldwide distribution [50,57–60]. Based on these data, it is hypothesized that the 
selective forces that have shaped the currently circulating genotypes were active during the 
evolution of early humans or even earlier and were modulated by founder and bottleneck events. In 
more recent times, migrations of human populations have redistributed and mixed these genotypes 
on a worldwide scale [56,59,61]. Furthermore, the very low incidence of gene linkage in the 
HCMV genome probably illustrates the predominant role of recombination in the generation of the 
existing genetic diversity [31,50,62–64]. 
The existence of distinct genotypes of several genes has attracted interest because of the 
potential differences in pathogenicity. If such correlations would be observed, this could provide 
novel diagnostic tools to tailor medical interventions. While some studies investigating genes UL55 
(glycoprotein B) [65,66], UL73 (glycoprotein N) [67,68], and UL144 (TNF- -like receptor) [69–71] 
have presented data involving specific genotypes with different disease outcomes, there is no 
overall consensus on these correlations yet (reviewed in [54–56]). To establish the feasibility of 
using viral genotype data as prognostic markers in patient follow-up, more comprehensive studies 
that include larger sets of variable genes, if not complete genome sequences, will be necessary. In 
this regard, a study making use of gene sequences from only four genes (UL144, UL146, UL147 
and US28) could train an artificial neural network to correctly predict congenitally-infected infants 
to be symptomatic or asymptomatic at birth in 90% of cases [72]. Considering the progress in 
sequencing technology and its implementation in HCMV genomics, this type of investigation 
should now become more feasible on a full genome scale. 
3. Characterization of Complete HCMV Genomes Using NGS 
Table 1 gives an overview of all complete HCMV genome sequences that are currently publicly 
available. If each individual strain is only counted once—some strains have multiple isolate 
sequences published—, this amounts to a total of 35 strains; 31 of these strains can be considered 
low-passage (or unpassaged) clinical isolates. While a considerable proportion of these sequences 
were still deduced using traditional Sanger sequencing, the labor intensity of these approaches 
precludes routine and high-throughput application of complete genome sequencing. Over the past  
5 years, NGS technologies have begun to show their promise in becoming a novel, scalable,  
cost-effective, and time-efficient way of characterizing HCMV genome diversity. 
The first application of NGS to HCMV genomics was published in 2009 and investigated the 
genome architecture of laboratory-adapted strains AD169 and Towne in detail (Table 2) [20]. 
While the published sequences of AD169 (varUK and AD169-BAC/varATCC) and Towne 
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(varS/varRIT3) missed the entire UL/b’ region (Table 1), it had already been noted that some 
variants did seem to contain this region [73,74]. For AD169, this variant constituted a separate 
stock (varUC), but it was unclear whether this was an AD169 variant with an intact UL/b’ or a 
different strain altogether. For Towne, the original stock was a mixture of the varS/varRIT3 
variant, that was cloned into a BAC and sequenced [30,39], and an apparently intact varL variant, 
for which the UL/b’ region had been characterized [25]. The exact nature of the AD169 varUC 
stock and the mixed Towne stock containing both varS and varL was determined by generating 
sequencing reads with the Genome Analyzer (Illumina) and mapping these onto appropriate 
reference sequences with or without the UL/b’ region. The results showed that AD169 varUC was 
indeed an AD169 variant with a nearly intact UL/b’ region, only missing a 3.2 kb region affecting 
genes UL144, UL142, UL141, and UL140. Furthermore, the presence of both varS and varL variants 
in the Towne stock was experimentally confirmed. In a similar fashion, other studies have sequenced 
specific transgenic BAC clones of strains Merlin and Towne using NGS to characterize genetic 
changes that have occurred during passaging and cloning of these BACs (Table 2) [35,75,76]. 
Table 2. Overview of studies on the HCMV genome making use of NGS technology, 
ranked in chronological order. 






Bradley et al. 
High-throughput sequence analysis of variants of 
human cytomegalovirus strains Towne and AD169. 





Sequences of complete human cytomegalovirus 
genomes from infected cell cultures and clinical 
specimens. 
J. Gen. Virol. IGA° [42] 
November 
11, 2009 
Görzer et al. 
Deep sequencing reveals highly complex dynamics 
of human cytomegalovirus genotypes in transplant 
patients over time. 
J. Virol. GSF* [77] 
May 12, 
2010 
Stanton et al. 
Reconstruction of the complete human 
cytomegalovirus genome in a BAC reveals RL13 to 
be a potent inhibitor of replication. 
J. Clin. Investig. IGA° [35] 
August 2, 
2010 
Görzer et al. 
The impact of PCR-generated recombination on 
diversity estimation of mixed viral populations by 
deep sequencing. 
J. Virol. Methods GSF* [78] 
August 4, 
2010 
Jung et al. 
Full genome sequencing and analysis of human 
cytomegalovirus strain JHC isolated from  
a Korean patient. 
Virus Res. GSF* [43] 
January 19, 
2011 
Renzette et al. 
Extensive genome-wide variability of human 
cytomegalovirus in congenitally infected infants. 
PLoS Pathog. IGA° [79] 
May 19, 
2011 
James et al. 
Cyclopropavir inhibits the normal function of the 







Stark et al. 
High-resolution profiling and analysis of viral and 
host small RNAs during human  
cytomegalovirus infection. 












Gatherer et al. 
High-resolution human cytomegalovirus 
transcriptome. 
Proc. Natl. Acad. 






Genetic analysis of cytomegalovirus in  
malignant gliomas. 
J. Virol. IGA° [83] 
April 11, 
2012 
Meshesha et al. 
The microRNA Transcriptome of Human 
Cytomegalovirus (HCMV). 




Ginossar et al. 






Rossetto et al. 
Cis and trans acting factors involved in human 
cytomegalovirus experimental and natural  
latent infection of CD14 (+) monocytes and  
CD34 (+) cells. 
PLoS Pathog. MiSeq’ [86] 
May 23, 
2013 
Sahoo et al. 
Detection of cytomegalovirus drug resistance 






Renzette et al. 
Rapid intrahost evolution of human 
cytomegalovirus is shaped by demography and 
positive selection. 
PLoS Genet. IGA° [88] 
September 
26, 2013 
Brechtel et al. 
Complete Genome Sequence of a Cytomegalovirus 
Towne-BAC (Bacterial Artificial Chromosome) 
Isolate Maintained in Escherichia coli for 10 Years 






Brechtel et al. 
Complete Genome Sequence of a UL96 Mutant 
Cytomegalovirus Towne-BAC (Bacterial Artificial 
Chromosome) Isolate Passaged in Fibroblasts To 






° Genome Analyzer (Illumina); * 454 GS FLX (Roche); ^ HiSeq (Illumina); ‘ MiSeq (Illumina); “ 454 
GS Junior (Roche). 
The previous studies made proper use of NGS technology to elucidate the stock composition of 
laboratory-adapted strains, but, then again, they could employ the existing sequence information to 
direct the assembly of the millions of sequencing reads that are generated during a typical Illumina 
run. In order to apply NGS to the genome characterization of novel clinical isolates, this assembly 
approach needed some adjustment. Because of the sequence variability in substantial regions of the 
HCMV genome, direct mapping of NGS reads from unknown isolates to existing reference 
sequences leads to a lack of coverage in these areas, simply because the novel sequences are too 
divergent from the chosen reference strain. To assemble the sequence information from novel clinical 
isolates, alternative approaches were devised that start with a de novo or reference-independent 
assembly of sequence reads (Table 2) [42]. The longer sequences formed by de novo assembly, the 
so-called contigs, are scaffolded against a reference sequence to produce a strain-specific reference 
that can be used for a mapping or reference-dependent assembly like before. The final strain 
sequence is optimized through manual inspection of the read alignment and correction of 
misassemblies by iterative mapping and/or PCR sequencing. 
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A comparative analysis was made of the effectiveness of sequencing complete HCMV genomes 
from clinical isolates through both Sanger sequencing of overlapping PCR products and NGS 
analysis of infected cell cultures and unamplified clinical material with the Genome Analyzer [42]. 
Both approaches were successful, but the PCR and Sanger sequencing method proved to be much 
more labor-intensive and, by consequence, less amenable to high-throughput application. However, 
the NGS approach is not specifically directed towards viral DNA and analyzes the total DNA 
present in an isolate. Whole cell culture extracts are heavily contaminated with cellular DNA and 
the viral loads in unamplified clinical material can be very low. This was illustrated for strain 3301 
(Table 1); only 3% of sequence reads that were collected directly from the sample were of viral 
origin. While it was possible to reconstruct the complete genome using these 3% of reads, such an 
approach also precludes any high-throughput prospect. This limitation was recently confirmed when 
strain BE/21/2010 (Table 1) was amplified using undirected whole genome amplification and only 
yielded 12% HCMV-specific NGS reads (Sijmons et al, unpublished results). This study did realize 
higher levels of viral DNA (mostly >90%) by combining limited cell culture amplification, 
nuclease digestion of unencapsidated (cellular) DNA, purification of viral DNA, and whole 
genome amplification. A series of validation experiments showed that the generated genome 
sequences did not undergo major alterations during these procedures and were still representative 
for the strain in the original clinical isolate. 
As discussed previously, cell culture passaging leads to disruptive mutations in genes that are 
inhibitory or non-essential for growth in that cell type. Genes RL13 and UL128L seem to be the 
first that are affected when passaging a strain in fibroblast cells [35,36]. Interestingly, RL13 and 
UL128L genes do not show obvious disruptive mutations in most of the clinical isolates analyzed 
by NGS after limited culturing [42,43]. This suggests that these strains are still in a very early 
phase of genetic adaptation to fibroblast replication; although it cannot be ruled out that these genes 
are mutated at different sites in different clones of the population, like in the case of RL13 in strain 
Merlin [35]. Several observations imply that some ORF-disrupting mutations may be present in the 
original clinical isolate and are not an artifact of culturing [42]. Most importantly, the sequence 
characterization of strains JP and BE/21/2010 directly from clinical material (Table 1) has  
shown disruptive mutations in genes RL5A, UL9, UL111A, and UL150 that are definitely  
culture-independent. Furthermore, identical indels and point mutations were shared between 
unrelated isolates, which suggests that these could be derived from a common ancestor circulating 
in the human population. Finally, the presence of individual mutations in RL5A, UL1, UL9, and 
UL111A in passaged strains was confirmed by PCR sequencing of the original sample (Sijmons et al, 
unpublished results). Analysis of a larger number of clinical isolates will reveal the complete set of 
genes that can be disabled in clinical isolates, their occurrence in different patient populations, and 
potential implications for strain pathogenicity. 
4. Deep Sequencing of Intrahost HCMV Populations  
Accumulating data shows that infections with multiple HCMV strains are no exceptions, neither 
in immunocompromised nor in immunocompetent hosts (reviewed in [56]). This could probably be 
the product of both simultaneous and consecutive virus transmission events [89,90]. Multiple 
infections could result in a higher pathogenic potential because of trans-complementation between 
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strains [91]. This prediction is confirmed by data about the effect of strain multiplicity in transplant 
patients [92–95]. Because of the large amounts of sequence reads that are generated by NGS 
technologies, these are ideally suited to characterize the dynamics of mixed viral populations in 
greater depth (reviewed in [96,97]). The first study to apply this approach to HCMV populations 
analyzed PCR amplicons of the hypervariable genes UL73, UL74, and UL139 in lung transplant 
recipients using 454 GS FLX (Roche) technology (Table 2) [77]. Viral populations consisted of 
mixtures of up to six genotypes, with one or two types accounting for the majority of the 
population and the other genotypes present at frequencies of 0.1%–10%. When serial samples of 
patients were compared, the genotype frequencies fluctuated in a seemingly stochastic fashion. The 
authors speculated these fluctuations could be caused by sporadic and stochastic events that lead to 
differential reactivation of latent genomes. While the abundance of the individual genotypes changed, 
their sequences did not, confirming the stability of hypervariable HCMV genes [44,51,53]. In a 
follow-up study, the authors warned against the formation of artificial recombinants during PCR 
amplification when interpreting results from amplicon deep sequencing experiments [78]. 
The previous studies characterized intrahost population diversity by analyzing a set of genes that 
are highly variable between hosts. However, applying such a deep sequencing approach to a 
complete genome does not suffer from a selection bias towards certain genome regions and can 
provide a more comprehensive picture of the diversity and dynamics of viral populations inside the 
host. Sequencing complete genomes from unamplified clinical material, results in a low proportion 
of viral NGS reads, which would impair any deep sequencing effort [42]. Cell culture amplification 
on the other hand would almost certainly alter the composition of viral populations. Therefore, a 
workflow was devised that characterized complete HCMV genomes using overlapping PCR 
amplicons [79,83,88]. As an internal control, BAC clones of AD169 and Toledo strains were 
resequenced to establish a set of quality filtering thresholds that helped distinguishing genuine 
intrahost variants from PCR and sequencing errors. In a first study, the viral populations of three 
congenitally infected infants were characterized [79]. Surprisingly, for a dsDNA virus encoding a 
polymerase with proofreading capacity, estimates of the genetic diversity of these populations were 
comparable to quasispecies RNA viruses like HIV and dengue virus. Population variants were 
clustered in two groups. Variants present at high frequencies ( 90%) accounted for 20% of reads, 
while low-frequency variants ( 10%) represented 73% of reads. This population structure is 
comparable to the study of UL73, UL74 and UL139 amplicons in lung transplant recipients, which 
also found one or two variants present at higher frequencies and a set of low-frequency variants 
(0.1%–10%) [77]. Interestingly, when ORF-specific intrahost diversities were estimated, ORFs 
encoding glycoproteins or immune-evasive functions showed the lowest intrahost diversity 
estimates. While they are considered to have the highest interhost diversity, studies focusing on 
these ORFs may underestimate intrahost diversity. Compared to the results in congenitally infected 
infants, intrahost diversity estimates were lower in malignant gliomas [83]. A potential explanation for 
this discrepancy could be the higher levels of replication during congenital infection, which would 
lead to a higher accumulation of de novo mutations. More data from different patient groups is 
warranted to provide a broader view of the range of intrahost diversity estimates, the mechanisms 
that shape them, and potential implications for patient health. 
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To better understand the dynamics of these genome populations, serial urine and plasma isolates 
were sampled from five infants with a symptomatic HCMV infection at birth [88]. When serial 
isolates of the same compartment were compared, the majority of SNPs had a similar frequency, 
and consensus sequences differed only by 0.2% at the nucleotide level, demonstrating the overall 
stability of the populations. This result is in clear accordance with previous results that have 
illustrated the stability of HCMV genotypes in vivo [50,57,59]. However, comparison of isolates of 
different compartments (urine and plasma) at the same time point showed that consensus sequences 
differed by approx. 1%; comparable to the divergence of HCMV strains from different hosts. 
Subsequently, the observed dynamics were modeled using both demographic variables (population 
size and structure) and selective pressures. Intercompartment differentiation was shaped by strong 
bottleneck events and the calculation of bottleneck timing enabled estimation of the timing of 
infection and compartment colonization. While the effects of positive selection in the same 
compartment were small, strong evidence of positive selection was found when comparing 
different compartments. The large differences between viral populations in plasma and urine pose 
important questions about how representative the secreted virus (urine) is for the virus that 
circulates (plasma). It is conceivable that other compartments might show other diversification 
dynamics. However, the total number of patients analyzed in this study is relatively low and the 
data about intercompartment diversification are only based on one patient. From the presented data, 
it is unclear whether this patient was infected by a single strain or multiple strains. Rephrasing the 
issue: are we looking at the differentiation of one single quasispecies cloud or the segregation of 
multiple quasispecies clouds that could have had inherent differences in their respective cell 
tropisms? Analysis of the intercompartment diversity in additional patients will be needed to 
improve the understanding of the dynamics of these virus populations, which obviously could have 
very important implications for diagnostics, treatment, and vaccine development. 
The deep sequencing capabilities of NGS technology show great promise for the sensitive 
detection of drug resistance mutations. This approach has already proven its use in drug resistance 
testing for HIV, HCV, and HBV (reviewed in [10]). While Sanger sequencing of UL54 and UL97 
PCR amplicons is still the gold standard for detection of drug resistance mutations in HCMV 
isolates, this method suffers from a lack of sensitivity, often failing when plasma viral loads drop 
below 1,000 copies/mL and/or mutant frequencies are lower than 10%–20%. Recently, the use of 
NGS technology in resistance mutation detection was evaluated for the first time for HCMV [87]. 
Using the benchtop 454 GS Junior system (Roche), the study showed the ability to reproducibly 
detect resistance mutations at frequencies lower than 20% and at viral loads lower than 1000 
copies/mL. This improvement in sensitivity will help studying the abundance, dynamics, and 
importance of low-frequency drug-resistant variants. The high throughput of NGS could result in a 
decrease of the time and cost of resistance detection. In addition, full genome characterization of 
drug-resistant variants with NGS can potentially lead to the discovery of new resistance mutations 
in other genome regions. 
5. NGS in HCMV Transcriptome Studies 
The high throughput of NGS provided new opportunities for the field of transcriptomics; the 
study of the total coding and non-coding RNA that is transcribed in a given cell type [98]. NGS, 
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often referred to as RNA-Seq in this context, has now surpassed microarrays as the method of 
choice for transcriptomic research, since it is much better at detecting rare variants and does not 
depend on a priori sequence knowledge. Transcriptomic analysis of HCMV in an infected cell can 
contribute to the genome annotation by revealing complex transcriptional processes that often 
cannot be predicted based on the genome sequence alone. HCMV transcription is characterized by 
the presence of multiple transcripts sharing common 5’ or 3’ ends, complex and adaptable splicing 
patterns, antisense transcription, and transcription of non-coding and miRNAs (reviewed in [99]). 
Several NGS-based studies have added important insights into these processes. 
The first study to use RNA-Seq in HCMV transcriptome research characterized the polyA RNA 
content of human fetal foreskin fibroblast cells, 72h after infection with the Merlin strain, when 
virion production is underway [82]. The four large non-coding RNAs that are encoded in the 
HCMV genome (RNA2.7, RNA1.2, RNA4.9, and RNA5.0; Figure 2) accounted for a staggering 
65.1% of viral transcription. These RNAs probably do not function via translation, since they do 
not overlap significantly with potential ORFs. Large non-coding RNAs are implicated in gene 
regulation in eukaryotes [100]. Especially RNA2.7 was transcribed massively, making up almost 
half of the viral transcripts. RNA2.7 inhibits apoptosis by regulation of mitochondria-induced cell 
death [101]. Furthermore, antisense transcripts were found throughout the genome, but are 
generally present at a lower level than their sense counterparts. Antisense transcription is 
increasingly being recognized as being involved in gene regulation, both in pro- and eukaryotes 
(reviewed in [102]). It can be hypothesized that the antisense transcripts of HCMV provide the 
virus with an additional mechanism of regulating its expression. Because of the high levels of 
transcription from non-coding and antisense regions, coding regions only made up one third of 
transcription. Within these coding regions, splicing patterns were found to be more numerous and 
complex than previously appreciated. While some of these splicing events are essential for proper 
expression, others probably have more subtle regulatory roles or could be non-functional by-
products of normal transcription. Four new HCMV genes were identified based on this 
transcriptome study (RL8A, RL9A, UL150A, and US33A; Figure 2), indicating the added value of 
this kind of study for genome annotation. 
The added complexity that is caused by transcription and translation was further illustrated by a 
study that made use of a novel technique, i.e., ribosome profiling [85]. This technique characterizes 
the “translatome” by generating libraries of ribosome-protected mRNA fragments. Examining 
these ribosome footprints, the authors identified 751 ORFs, only 147 of which were previously 
recognized. ORFs were positioned within existing ORFs (both in-frame and out of frame), 
upstream of existing ORFs, antisense of existing ORFs, and within presumably non-coding regions. 
Multiple translation products were also identified on the long non-coding RNAs RNA2.7, RNA1.2, 
and RNA4.9. Tandem mass spectrometry and protein tagging experiments confirmed the 
translation of a large proportion of these novel ORFs. Furthermore, this study highlighted the use 
of alternative 5’ ends, enabling the virus to express different proteins from overlapping coding 
regions in a temporally regulated fashion. 
The discovery that microRNAs (miRNAs), small RNAs that target and silence complementary 
mRNAs, are not restricted to eukaryotes, but also present in several viruses, including HCMV, 
added yet another weapon to the viral armory [103–107]. While miRNAs are non-immunogenic 
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and only require minimal space in the genome, they offer the virus an efficient way of regulating 
both viral and host gene expression. Two studies have used NGS technology to characterize the 
profile of small RNAs that are expressed in HCMV-infected cells [81,84]. These studies used 
different HCMV strains (Towne vs. AD169), harvested RNA at different time points post-infection 
(72 h vs. 96 h), and assigned and verified novel miRNAs in different ways. The fraction of small 
RNAs encoding viral miRNAs was 20% and 5%, respectively. The seven miRNAs with the highest 
expression levels were identical in both, although in a different order. While the second study 
identified more novel miRNAs from NGS data, the functionality of the only two novel miRNAs 
reported in the first study was confirmed in transfection assays. The first study also reported that all 
22 characterized miRNAs were incorporated into the endogenous host silencing machinery, further 
highlighting their functionality [81]. Additionally, the authors identified novel small viral RNAs, 
distinct from miRNAs that were especially observed across the long non-coding RNAs, such as 
RNA2.7. These could be related to the ribosome footprints that were found on these RNAs [85]. 
Recently, the HCMV transcriptome of CD14+ and CD34+ cells in experimental and natural 
latency was characterized through deep sequencing, identifying transcripts that had not previously 
been related to latency [86]. These include UL44 and UL84 transcripts, normally involved in lytic 
DNA replication, and the large non-coding RNAs RNA2.7 and RNA4.9. 
In addition to providing insights into the viral expression profile during productive and latent 
infection, NGS-based transcriptome studies can also study the virus-host interface by 
simultaneously monitoring the changes in cellular transcription. Two studies have already 
illustrated this for murine cytomegalovirus, but similar studies on HCMV have not yet been 
published [108,109]. 
It has to be noted that the complex set of transcripts that were identified through deep 
sequencing still await further characterization to identify their potential functions. As the authors 
admit, some of the predicted RNAs and proteins could be aberrant byproducts of normal 
transcription/translation without further function and/or could be rapidly degraded [82,85]. These 
studies do offer the first glance at a complex regulatory network that the virus can use to finely 
balance its replication, including alternative splicing, antisense transcription, large and small  
non-coding RNAs, and miRNAs. 
6. Conclusions 
A quarter of a century has now passed since the publication of the first complete HCMV 
genome sequence ushered in the age of HCMV genomics. In the meantime, insights have 
accumulated regarding the genetic alterations of laboratory-adapted strains, the genome annotation 
has been progressively fine-tuned, and regions of high nucleotide diversity have been identified. 
The advent of NGS technology has changed the scope and pace of genomic research and is 
beginning to show its promise in the HCMV field. However, NGS is still a relatively recent 
technology and the interpretation of the massive amounts of sequence data requires considerable 
bioinformatics expertise. Error identification and correction protocols are not completely 
standardized yet and this precludes the routine application in clinical settings. 
Sequencing the complete genome of a clinical HCMV isolate is now possible in a considerably 
higher throughput and speed than a few years ago. Analysis of a large set of genomes from a 
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diverse group of patients will improve our understanding of the circulating genetic diversity and 
variability in coding capacity of wild-type HCMV. This could lead to novel insights into the 
association of genetic diversity and viral pathogenicity, which has eluded the field for years. 
Furthermore, routine sequencing of transgenic strains to identify unintended genetic alterations 
should now be possible. 
Deep sequencing has shown that intrahost populations of HCMV are remarkably diverse. A 
better understanding of the dynamics of these populations could have important implications for 
treatment and vaccine development. The sensitivity of NGS will also improve the standard of drug 
resistance mutation detection. 
RNA-Seq applications have already altered our understanding of the transcriptional complexity 
during HCMV-infection. Further characterization of these transcripts is warranted and could 
provide novel insights into mechanisms of viral pathogenicity and potential treatment options. 
Additionally, simultaneous characterization of the changes in the host transcriptome during 
infection will reveal currently unknown virus-host interactions. 
Meanwhile, a new generation of single-molecule sequencing technologies are being developed [110] 
or have already found their way to the market [111] (reviewed in [112]). These technologies 
require much less input material than NGS, making them more attractive for sequencing directly 
from clinical material. They do not need a library amplification step, ruling out possible artifacts 
caused by this step. Furthermore, they provide considerable longer read lengths, which facilitate 
genome assembly and could provide insights into the mutual relations of single variants in intrahost 
populations. Finally, these technologies can characterize DNA modifications, enabling the direct 
analysis of epigenetic changes in the genome [113,114]. Undoubtedly, application of single-molecule 
sequencing to HCMV genomics will aid in deciphering this complex herpesvirus. 
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Abstract: RNase P ribozyme can be engineered to be a sequence-specific gene-targeting 
agent with promising application in both basic research and clinical settings. By using 
an in vitro selection system, we have previously generated RNase P ribozyme variants 
that have better catalytic activity in cleaving an mRNA sequence than the wild type 
ribozyme. In this study, one of the variants was used to target the mRNA encoding 
human cytomegalovirus (HCMV) essential transcription factor immediate-early protein 
2 (IE2). The variant was able to cleave IE2 mRNA in vitro 50-fold better than the wild 
type ribozyme. A reduction of about 98% in IE2 expression and a reduction of 3500-fold 
in viral production was observed in HCMV-infected cells expressing the variant 
compared to a 75% reduction in IE2 expression and a 100-fold reduction in viral 
production in cells expressing the ribozyme derived from the wild type sequence. These 
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results suggest that ribozyme variants that are selected to be highly active in vitro are 
also more effective in inhibiting the expression of their targets in cultured cells. Our 
study demonstrates that RNase P ribozyme variants are efficient in reducing HCMV gene 
expression and growth and are potentially useful for anti-viral therapeutic application. 
Keywords: ribozyme; RNase P; gene targeting; cytomegalovirus 
 
1. Introduction 
Human cytomegalovirus (HCMV) is a common herpesvirus and usually affects individuals with 
compromised immune system [1]. This virus causes birth defects including mental problems [2]. 
Furthermore, HCMV can cause debilitating symptoms in AIDS patients, such as blindness and 
gastrointestinal diseases [3,4]. New therapeutic approaches are needed to combat and control this 
important opportunistic pathogen. 
Gene targeting approaches using nucleic acid-based molecules to target specific mRNA sequences 
of choice represent promising therapeutic strategies [5,6]. One example is small interfering RNAs 
(siRNAs), which were used to target several human viruses effectively [5,7,8]. Ribozymes can also 
inactivate viral mRNA sequences and diminish viral infection in human cells [9–12].  
RNase P functions in cells to process tRNA precursors (ptRNA) into mature tRNAs [13–15]. In 
Escherichia coli, RNase P forms a holoenzyme containing a protein (C5 protein) and a catalytically 
active RNA (M1 RNA) [16]. Previous studies have shown that the enzyme recognizes its substrate 
through the tertiary structure and not the primary sequence. (Figure 1A) [13,14,17]. Any mRNA 
substrate can be targeted and hydrolyzed by M1 ribozyme through the binding of a complementary 
external guide sequence (EGS) to the substrate to resemble the structure of the tRNA module  
that includes the 5’ leader sequence, the acceptor stem, the T-stem, and the 3' CCA sequence 
(Figure 1) [18,19]. A ribozyme targeting any mRNA sequence of choice, M1GS RNA, can be 
designed by linking a guide sequence (GS) to the 3' terminus of M1 RNA (Figure 1C) [20,21]. The 
guide sequence can basepair with an mRNA target and thus, allows M1GS to bind to the mRNA. 
Previous studies had designed M1GS ribozymes to target cellular genes and the essential genes of 
herpes simplex virus 1 (HSV-1) and HCMV [22–24]. The ribozymes were effective in reducing 
HSV-1 and HCMV growth 1000-fold and 150-fold, respectively [22,23].  
Compared to other gene-targeting approaches such as RNAi, the M1GS ribozyme has several 
advantages. Ribozymes have not been shown to saturate the cellular machinery required for their 
processing while high levels of siRNAs can overwhelm the RNAi machinery that contains various 
cellular factors and may affect the normal cellular functions of these factors [5,25–28]. Furthermore, 
by interacting with specific cellular proteins including the RNase P protein subunits [14,29], RNase 
P ribozymes may improve their intracellular stability and catalytic activities in cells. RNase P 




Figure 1. Schematic presentation of RNase P/M1GS ribozyme’s substrates.  
(A–C) pre-tRNA (ptRNA), a natural substrate (A); EGS:mRNA complex (B);  
and M1GS binding to its substrate (C). Filled arrows denote the cleavage sites.  
(D) Substrate ie2-39 with boxed region representing the complementary sequence to the 
guide sequence of M1GS. 
 
Increasing the catalytic efficiency of the RNase P ribozyme is essential for M1GS technology to 
be used as an effective gene-targeting approach. Previously, we have generated RNase P ribozyme 
variants through an in vitro selection system that have better catalytic activity in cleaving an 
mRNA sequence than the wild type M1 RNA ribozyme [31]. For the study, a highly active 
ribozyme variant was designed to hydrolyze the exon 5 region of the mRNA encoding HCMV 
immediate-early 2 (IE2) protein. IE2 encodes a HCMV major transcription regulatory factor and its 
expression is needed for the expression of viral early ( ) and late ( ) genes [1,32–34]. Thus, IE2 
protein expression is essential for HCMV replication in cultured cells. Inhibition of IE2 expression 
would result in shutting down gene expression and replication of HCMV. We investigated the 
activity of the constructed ribozyme in generating cleavage of IE2 mRNA sequence in vitro and in 
shutting down HCMV infection in cells. Our data showed that the ribozyme variant cleaved the 
target IE2 mRNA sequence at least 50-fold more efficiently than the wild type ribozyme. More 
importantly, greater reduction in IE2 expression and HCMV growth was observed in cells 
expressing the variant. Our results suggest that RNase P ribozyme variants can be used as 




2.1. Targeting and Cleavage Activities of the M1GS RNAs in Vitro 
Since most mRNA species inside cells form complex secondary structures and are associated 
with proteins, a targeting region must be accessible for ribozyme binding and catalytic cleavage of 
the target mRNA. We used dimethyl sulphate (DMS) [21,35] to map the accessible regions of IE2 
mRNA in vivo [36]. To map these regions, we infected human U373MG cells with HCMV and 
then incubated these cells with culture media that contained DMS [36]. It is expected that DMS 
would enter the cells and modify the nucleotides of the accessible mRNA regions. We then isolated 
the total mRNAs. Primer extension assays using reverse transcriptase were used to map the IE2 
mRNA regions that were modified by DMS [36]. A position, 30 nucleotides downstream from the 5' 
terminus of exon 5, was selected as the targeting site. The chosen targeting region (designated as IE2 
RNA) was extensively modified by DMS and was predicted to be accessible for M1GS binding and 
cleavage (data not shown). 
We had previously carried out an in vitro selection procedure and isolated M1GS RNA variants 
that have higher catalytic activity in cleaving HSV-1 thymidine kinase (TK) mRNA than the wild 
type M1 RNA [31]. However, little research has been done to examine whether these variants are 
also effective in targeting HCMV mRNAs to shut down viral infection. To investigate these issues, 
we chose variant 661 (designated as V661) for the study because this selected variant is highly 
active in cleaving target RNAs in vitro (e.g., IE2 and TK and mRNA) (Table 1) [31]. This variant 
contains two point mutations (i.e., A94  G94 and G194  C194) [31]. Little is known about the 
contribution of these nucleotides to the activity of M1GS RNAs in cleaving an mRNA substrate. 
The effect of the point mutations on the activity of RNase P ribozymes has not been studied. 
Table 1. Overall cleavage rate [(kcat/Km)s] and binding affinity (Kd) of RNase P 
ribozymes with substrate ie2-39. 
Enzyme 
(kcat/Km)s 
( M 1·min 1) 
Kd  
(nM) 
M1-IE2 0.20 ± 0.05 0.34 ± 0.06 
V661-IE2 10.5 ± 0.5 0.30 ± 0.05 
M1-IE2-C <5 × 10 6 0.33 ± 0.07 
V661-IE2-C <5 × 10 6 0.32 ± 0.07 
M1-TK <5 × 10 6 ND 
The values shown are the average derived from triplicate experiments. p < 0.01. “ND”, not determined.  
To construct IE2 mRNA-cleaving ribozymes from the variant and wild type M1 sequence, 
V661-IE2 and M1-IE2, the 3' termini of V661 and M1 RNA were covalently linked with an 18 
nucleotides guide sequence that binds to the IE2 mRNA sequence, respectively. We included two 
control RNase P ribozymes, M1-IE2-C and V661-IE2-C. M1-IE2-C was generated from C102 
RNA, an M1 mutant with mutations (A347C348  C347U348, C353C354C355G356  G353G354A355U356) 
at the catalytic P4 domain that rendered it inactive in cleaving a pre-tRNA [37]. V661-IE2-C was 
generated from V661-IE2 and contained the mutations found in C102. While sharing identical 
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guide sequence with M1-IE2 and V661-IE2, both M1-IE2-C and V661-IE2-C were not expected to 
be functional because of the P4 mutations. 
We measured the catalytic activity (kcat/Km)s with kinetic analyses for these ribozymes in 
cleaving substrate ie2-39 of the 39 nucleotide long IE2 mRNA target sequence (Figure 1D). These 
results, shown in Table 1, indicate that V661-IE2 is about 50-fold more active than M1-IE2 in 
cleaving substrate ie2-39 (p < 0.01). As expected, V661-IE2-C and M1-IE2-C were at least  
104-fold less active than M1-IE2 RNA in cleaving substrate ie2-39, possibly because the P4 
mutations abolished the catalytic activity of the ribozymes (p < 0.01).  
Detailed gel-shift assays indicate that the binding affinities of V661-IE2-C and M1-IE2-C to 
substrate ie2-39, as measured by the dissociation constant (Kd), are similar to those of V661-IE2 
and M1-IE2 (Table 1). Since V661-IE2-C and M1-IE2-C are non-functional but contain identical 
guide sequence complementary to ie2-39 and exhibit similar affinity to ie2-39 as V661-IE2 and 
M1-IE2, these ribozymes serve as controls for the antisense effect in our experiments. 
2.2. Expression of Ribozymes in Human Cell Culture  
The DNA sequences coding for V661-IE2, M1-IE2, V661-IE2-C, and M1-IE2-C were 
subcloned into LXSN retroviral vector and placed under the constitutively expressed U6 RNA 
promoter [19,21,38]. To construct cell lines that express M1GS RNAs, we generated retroviral 
vectors that contained the genes for M1GS RNAs by transfecting LXSN-M1GS DNAs into the 
amphotropic packaging cells (PA317). We subsequently infected human U373MG cells with the 
retroviruses and generated stable cell lines expressing the M1GSs. A cell line expressing ribozyme 
M1-TK, which targeted HSV-1 TK mRNA, was constructed to control for M1GS RNA with a 
mismatched guide sequence [22]. No cleavage of substrate ie2-39 by M1-TK was observed in vitro 
(data not shown, Table 1). 
Northern blot analysis was performed to assay M1GS RNA expression in individual cell clones 
(Figure 2, lanes 5–8). Human H1 RNA was used as the loading and internal control (Figure 2,  
lanes 1–4) [14,36]. No difference in cell growth and viability was observed for up to two months 
between cell lines expressing M1GS and a control line with empty vector LXSN DNA, suggesting 
that ribozymes did not result in significant cytotoxicity (data not shown). For subsequent 
experiments, only cell lines exhibiting similar ribozyme expression levels were used. 
Figure 2. M1GS ribozymes expression with Northern blot analysis in parental 
U373MG cells (-, lanes 1 and 5) and cells with M1-IE2-C (lanes 2 and 6), M1-IE2 
(lanes 3 and 7), and V661-IE2 (lanes 4 and 8). H1 RNA control (lanes 1–4).  
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2.3. Enhanced Reduction of HCMV IE2 Expression in Cells Expressing the Engineered Ribozymes  
Cells were infected with HCMV at a multiplicity of infection (MOI) of 1. Total RNAs were then 
isolated from these cells. HCMV immediate early 5kb RNA, which is expressed from the region 
spanning viral UL106 and UL111 with its 5' end at nucleotide position 159627 and its putative 3’ 
end at position 154829 of the HCMV (AD169) genome [1,39], was used as an internal loading 
control for IE2 mRNA expression.  
Figure 3 shows northern analysis of IE2 mRNA levels, which are quantitated in Table 2. A 
reduction of about 98% and 75% (p < 0.04) in IE2 mRNA expression was detected in cells that 
expressed V661-IE2 and M1-IE2, respectively (Figure 3, lanes 5 and 8).  
Figure 3. Northern analysis of the levels of human cytomegalovirus (HCMV) mRNAs. 
Cells (n = 1 × 106) were infected with HCMV (MOI = 1) and were harvested at either 8 
(A–B) or 24 h (C) post-infection. We used RNAs isolated from parental U373MG cells  
(-, lanes 3, 7, and 11) and cell lines that expressed V661-IE2 (lanes 1, 5, and 9),  
M1-IE2-C (lanes 2, 6, and 10), and M1-IE2 (lanes 4, 8, and 12). RNA samples were 
hybridized to a DNA probe coding for HCMV 5 kb RNA (lanes 1–4), IE2 mRNA 
(lanes 5–8), and US2 mRNA (lanes 9–12). 
 
In comparison, cells that expressed M1-IE2-C and V661-IE2-C showed little reduction (<10%) 
(Figure 3, lane 6, data not shown) (Table 2). An antisense effect could explain the low level of 
inhibition found in cells that expressed M1-IE2-C and V661-IE2-C. This is because these control 
ribozymes contained the same guide sequence as M1-IE2 and V661-IE2 but did not exhibit 
catalytic activity. These observations suggest that the significant reduction of IE2 mRNA 
expression in cells that expressed V661-IE2 and M1-IE2 was due to the catalytic cleavage of the 
target mRNA by these ribozymes. IE2 mRNA cleavage products were not detected in our northern 
analyses possibly due to degradation by intracellular RNases. 
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Table 2. HCMV mRNA and protein expression in cells expressing M1-TK, M1-IE2-C, 
V661-IE2-C, M1-IE2, or V661-IE2, and cells not expressing any ribozyme (U373MG). 
The values represent the levels of inhibition of gene expression as compared to the 





U373MG M1-IE2-C V661-IE2-C M1-IE2 V661-IE2 M1-TK 
IE2 mRNA  0% 6% 5% 75% ± 7% 98% ± 7% 1% 
US2 mRNA  0% 1% 1% 70% ± 6% 96% ± 8% 0% 
IE2 protein  0% 4% 5% 75% ± 8% 98% ± 8% 0% 
UL44 protein ,  0% 1% 0% 71% ± 8% 95% ± 7% 1% 
UL99 protein  0% 0% 1% 72% ± 7% 94% ± 6% 0% 
gH protein  0% 0% 0% 71% ± 8% 98% ± 7% 1% 
The values represent arithmetic means of three independent experiments performed in triplicate. p < 0.04. 
The values of standard deviation that were less than 5% are not shown.  
IE2 protein levels in M1GS-expressing cells are expected to decrease due to the corresponding 
reduction in the level of IE2 mRNA. Proteins were isolated from cells, separated in gels, and 
transferred to membranes. The membranes were stained with an anti-IE2 antibody (anti-IE2)  
(Figure 4, lanes 5–8), and the expression levels of HCMV IE2 protein were determined. Actin was 
used as an internal and loading control (Figure 4, lanes 1–4). The results are summarized in Table 2 
from three independent experiments: 98% and 75% reduction in IE2 protein expression (p < 0.04) 
was found in cells with V661-IE2 and M1-IE2 RNA, respectively. In comparison, little reduction 
(<10%) was detected in cells with V661-IE2-C, M1-IE2-C, and M1-TK RNAs (Table 2). 
2.4. Increased Reduction of HCMV Infection by the Ribozymes 
The expressions of HCMV  (early) and  (late) genes are expected to be decreased due to the 
inhibition of IE2 expression [1,33]. To explore this, US2 mRNA level (a  mRNA) (Figure 3,  
lanes 9–12) as well as UL99 protein level (a  protein) (Figure 4, lanes 9–12) were determined. We 
used HCMV 5 kb RNA and human actin as the internal loading controls. Our results demonstrated 
95%–96% and 71%–73% reduction (p < 0.04) in the expression levels of these genes in cells  
with V661-IE2 and M1-IE2, respectively. Limited inhibition was found in cells with M1-IE2-C, 
V661-IE2-C, and M1-TK (Figures 3 and 4, Table 2). Similar results were also observed in the 
expression of HCMV polymerase processivity factor UL44 (a  protein) and viral glycoprotein H 
(gH) (a  protein) (Table 2). Thus, V661-IE2 and M1-IE2 expressing cells appeared to exhibit 
overall viral  and  gene expression inhibition. 
The ribozymes also appeared to inhibit viral growth. After 5 days post-infection, we observed a 
3500- and 100-fold reduction (p < 0.04) in viral titers in cells that expressed V661-IE2 and  
M1-IE2, respectively (Figure 5). In comparison, we observed no reduction in cells with control 
M1-IE2-C, V661-IE2-C, or M1-TK ribozymes (Figure 5, data not shown). 
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Figure 4. Levels of HCMV proteins observed by Western Blot. Actin control  
(lanes 1–4), IE2 (lanes 5–8), and UL99 (lanes 9–12). Cells (n = 1 × 106) were  
infected with HCMV (MOI = 1) and were harvested at either 24 (lanes 1–8) or 72 h 
(lanes 9–12) post-infection.  
 
 
Figure 5. HCMV growth in various cell lines expressing M1GS and the parental 
U373MG cells. These values are the average from three experiments with error bars 
showing the standard deviation. p < 0.04. 
 
3. Discussion 
Ribozyme-based gene targeting represents a promising therapeutic approach [5]. For  
ribozyme-mediated gene targeting to work efficiently, M1GS needs to be highly specific, catalytically 
efficient, and easily delivered to the target of choice. We have constructed M1GS RNAs that target 
the exon 5 region of HCMV IE2 mRNA and have shown that the ribozymes target the substrate 
efficiently in vitro. Moreover, 98% reduction in the expression level of IE2 and 3,500-fold reduction 
in viral growth were observed in cells with a ribozyme variant (i.e., V661-IE2). In comparison, we 
detected little reduction (<10%) in IE2 expression and HCMV growth in cells with V661-IE2-C 
and M1-IE2-C. While non-functional, V661-IE2-C and M1-IE2-C contained identical guide 
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sequence and showed similar binding affinity to the targeting mRNA as V661-IE2 and M1-IE2. 
Thus, our results imply that the overall observed inhibition of HCMV infection with M1-IE2 and 
V661-IE RNA was primarily due to specific ribozyme-mediated cleavage of the target mRNA.  
Limited information is available about what limits M1GS-mediated gene-targeting efficacy in 
cultured cells [30]. Not much is known about how to improve the efficacy of M1GS RNA in 
blocking HCMV infection in vivo. In this report, M1GS was designed to target a DMS-accessible 
sequence of IE2 mRNA and was constitutively expressed by the U6 promoter. Our design should 
enhance the chance for M1GS to find the mRNA target. With the design, we postulated that the 
efficacy of RNase P ribozyme cleavage in cultured cells is dictated by its catalytic efficiency 
[(kcat/Km)s]. It is conceivable that enhancing catalytic activity of M1GS may reduce target mRNA 
expression more effectively in vivo. Indeed, V661-IE2, which was more efficient in cleaving ie2-39 
in vitro, blocked IE2 expression and viral growth in cultured cells more effectively than M1-IE2, 
the wild type M1GS (Tables 1 and 2). The difference between the in vivo efficacies of V661-IE2 
and M1-IE2 (e.g., 98% vs. 75%) is less than the difference of in vitro cleavage efficiencies (more 
than 50-fold difference). A possible explanation is that about 1%–2% of the target mRNA 
substrates are unavailable for ribozyme cleavage because they may be bound by ribosome for 
translation prior to being bound by the ribozymes. Our work implies that increasing catalytic 
efficiencies [(kcat/Km)s] correlates with better ribozyme-mediated effect in reducing HCMV growth, 
and further suggests that improving the in vitro catalytic efficiencies of the ribozymes should lead 
to increased anti-HCMV efficacies in tissue culture. Thus, our study provides a guideline for the 
generation of highly effective RNase P ribozyme variants.  
The antiviral effect of RNase P ribozymes appears to be specifically induced by the cleavage of 
the IE2 mRNA. First, cells expressing the ribozymes appeared normal with no toxicity for up to 
two months (data not shown). Second, the antiviral effect of the ribozyme (inhibition of viral 
growth) appears to be due to the decrease of IE2 expression. We detected overall reduction of viral 
 and  gene expression (e.g., US2, UL44, UL99, and gH) in cells expressing functional M1-IE2 
and V661-IE2 but not control M1-IE2-C or V661-IE2-C. The levels of reduction of IE2 expression 
correlate well with the levels of reduction in viral  and  gene expression. In comparison, we 
detected no reduction in other viral immediate-early RNA (e.g., 5 kb RNA and UL36 mRNA) 
expression in these cells (Figure 3A, Table 2, data not shown) [22,40]. Thus, the antiviral effect of 
M1GS ribozyme may be induced by the cleavage of the IE2 mRNA. 
Our study showed that variant V661-IE2 is more active in cleaving IE2 mRNA sequence than  
M1-IE2 in vitro (Table 1). Furthermore, a ribozyme targeting the HSV-1 TK mRNA sequence,  
V661-TK, was derived from variant V661. V661-TK also cleaved the TK mRNA sequence in vitro 
more efficiently than M1-TK, which was derived from the wild type ribozyme [31]. Thus, V661 
may be used to construct highly efficient ribozymes to target any specific mRNAs. This variant has 
two point mutations: A94  G94 and G194  C194. Little is known about the roles of these two 
nucleotides in the M1GS-mediated cleavage of an mRNA substrate. Our study indicated that the 
point mutations at these two positions increased the overall cleavage rate (kcat/Km) without 
affecting the binding affinity (Kd) to the mRNA substrate (Table 1). These results imply that the 
mutations may have no effect on the interactions of the ribozyme to the target mRNA. Perhaps 
these mutations increase the overall cleavage rate by stabilizing the active site and facilitating the 
512 
folding of the overall structure of the ribozyme. Further biochemical characterization of V661 and 
other ribozyme variants will elucidate the mechanism by which mutations found in the variants 
increase the gene-targeting activity of the ribozymes and provide insight into the construction of 
highly effective ribozymes for gene targeting applications. 
HCMV is a member of the human herpesvirus family [41,42]. Like other herpesviruses, HCMV 
can actively replicate or enter into latency [1]. When HCMV reactivates from latent infection and 
initiates lytic infection, IE2 is among the first proteins expressed and is essential for viral 
replication [1]. To study the functionality of M1GS ribozyme in HCMV latent infection, M1GS can 
be delivered into latently infected cells including CD34+ bone marrow progenitor cells. These 
studies will determine if RNase P ribozymes diminish IE2 expression and block HCMV reactivation. 
One potential challenge is to develop appropriate vectors for effective delivery and efficient 
expression of the ribozymes in CD34+ bone marrow progenitor cells. These and further studies should 
provide insight into the development of M1GSs as potentially effective anti-HCMV therapeutics.  
4. Experimental Section 
4.1. Viruses, Cells and Antibodies 
HCMV (strain AD169) was grown in human astrocytoma U373MG cells and foreskin 
fibroblasts in Dulbecco’s modified Eagle medium (DMEM) [22,32]. The anti-UL44 and UL99 
monoclonal antibodies were obtained from Virusys (Taneytown, MD, USA). Other antibodies were 
described previously [22,32].  
4.2. Mapping of the Accessible Regions of HCMV IE2 mRNA in Cells 
Detailed protocol for using dimethyl sulfate (DMS) to map the accessible regions of mRNA was 
described previously [36]. Briefly, DMS was incubated with HCMV-infected cells for 5–10 min. 
The cells were then lysed and the supernatant containing the cellular lysate was transferred to 
another tube for total RNA isolation with phenol-chloroform extraction and ethanol precipitation. 
Primer extension assays were performed with radiolabeled oligonucleotides in order to map the 
DMS modification sites [21,35], following the procedure described previously [36]. Phenol 
chloroform was used to extract the primer extension products followed by ethanol precipitation and 
separation in 8% denaturing gels. Sites that blocked primer extension, which represent potential 
locations modified by DMS, were identified in denaturing gels and analyzed using a STORM840 
Phosphorimager [36]. 
4.3. Ribozyme Studies in Vitro 
The ie2-39 DNA template was obtained by annealing oligonucleotide AF25 (5'-
GGAATTCTAATACGACTCACTATAG-3') that contains a T7 promoter with oligonucleotide sie2-39 
(5'-CGGGATCCTACTGGAATCGATACCGGCATGATTGACACCTATAGTGAGTCGTATTA-
3'). Plasmid pFL117, pV661, and pC102, which encode M1 RNA, variant V661, and mutant  
C102, respectively, have been described previously [31,37]. C102 contains point mutations 
(A347C348  C347U348, C353C354C355G356  G353G354A355U356), which render it inactive [37]. 
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Plasmids pFL117, pV661, and pC102 were used as templates to construct ribozymes M1-IE2, 
V661-IE2, and M1-IE2-C, respectively. Plasmid pV661-C, which was derived from pV661  
and contained the mutations found in C102, was used as the template to construct ribozyme  
V661-IE2-C. The 5' PCR primer was AF25 while the 3' primer was M1IE23 (5'-
CCCGCTCGAGAAAAAATGGTGCCGGTATCGATTCCAGTTGTGGAATTGTG-3'). Ribozymes 
and RNA substrate ie2-39 were synthesized with T7 RNA polymerase [12]. Kinetic analyses and 
gel shift assays were performed as described previously [31,43,44].  
4.4. Construction of the M1GS-Expressing Cell Lines 
The DNA sequences coding for the M1GSs were subcloned into retroviral vector LXSN and 
placed under the control of the U6 RNA promoter [12,21,45]. The retroviral vector DNAs containing 
the M1GS sequence were transfected into amphotropic PA317 cells. Culture supernatants 
containing retroviruses were used to infect human U373MG cells, and neomycin-resistant cells 
were selected in the presence of neomycin (600 g/mL) (GE Healthcare, Piscataway, NJ) and were 
eventually cloned [12,21,45]. 
4.5. Assaying of Gene Expression and Viral Infection 
Cells (n = 1 × 106) were either mock-infected or infected with HCMV at a multiplicity of 
infection (MOI) of 1. Viral mRNA or protein samples were isolated from the infected cells at 
various time points as described previously [22,44]. Specifically, the samples used for the detection 
of the IE2 mRNA and protein expression were harvested at 8 and 24 h post-infection, respectively. 
Similarly, the samples used for the detection of the HCMV immediate-early UL36 mRNA were 
harvested at 8 h post-infection. The samples used for the detection of the US2 mRNA expression 
were harvested at 24 h post-infection while those used for the detection of the protein expression of 
UL44, UL99, and gH were harvested at 72 h post-infection. For controls, the samples for the 
detection of the 5kb RNA expression were harvested at 8 and 24 h post-infection while the samples 
for the detection of the actin protein expression were harvested at 24 and 72 h post-infection.  
Western and northern blot analyses for the expression levels of HCMV proteins and mRNAs 
and ribozymes were performed as described previously [12,22,40]. In the northern blot analysis 
experiments, the RNA samples were separated in 1% agarose gels that contained formaldehyde, 
transferred to membranes, hybridized with the [32P]-radiolabeled DNA probes that contained the 
HCMV DNA sequences or the DNA sequences coding for M1 RNA and H1 RNA, and analyzed 
with a STORM840 Phosphorimager [12,22,40]. The radiolabeled DNA probes used in the northern 
blot analysis experiments were synthesized from plasmids using a random primed labeling kit 
(Roche Applied Science, Indianapolis, IN).  
In the western blot analysis experiments, the protein samples were separated on 9% (v/v)  
SDS-polyacrylamide gels cross-linked with N,N-methylenebisacrylamide. The separated proteins 
were transferred electrically to nitrocellulose membranes and reacted with the antibodies against 
human actin and HCMV proteins. The membranes were subsequently stained with a 
chemiluminescent substrate with the aid of a Western chemiluminescent substrate kit (GE 
Healthcare) and quantitated with a STORM 840 Phosphorimager [12,22,40].  
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In order to accurately assay the viral mRNA/protein expression and increase the sensitivities of 
our detection assays, a series of diluted RNA and protein samples (1–100-fold dilution) were used 
and quantitation was performed in the linear range of RNA and protein detection. For example, 
two-fold changes in RNA and protein samples resulted in a two-fold change in signal bracketing 
the range of experimental values in our experiments. Furthermore, to obtain an accurate 
measurement of the expression level of a specific mRNA or protein, we carried out three separate 
and independent experiments. In each of these three experiments, cells were grown in triplicate and 
samples were collected from these cultures and analyzed. The results were the arithmetic average 
of the three experiments [12,22,40].  
To study the M1GS-mediated inhibition of viral replication, U373MG cells (n = 5 × 105) 
expressing M1GS were infected with HCMV at an MOI of 1. Viral stocks were prepared from cells 
harvested at 1 day interval for 7 days post-infection, and viral titers in the stocks were assayed by 
infecting human foreskin fibroblasts in triplicate, following previously described procedures [12,22].  
4.6. Statistical Analysis 
Statistical significance was determined using Student’s t test for paired samples [46]. All the 
experiments were carried out in triplicate, and repeated three times. We considered differences 
statistically significant at a value of p  0.05. 
5. Conclusions 
HCMV represents a significant global public health concern and developing novel anti-HCMV 
strategies is critical for the treatment and prevention of HCMV infection and associated diseases. 
RNase P ribozyme can act as a sequence-specific gene-targeting agent with promising applications 
in clinical settings. Here, we report the anti-HCMV activity of a ribozyme derived from a novel 
RNase P variant in cultured cells. The ribozyme variant cleaved the target IE2 mRNA in vitro and 
shut down IE2 expression in human cells more efficiently than the wild type ribozyme. 
Furthermore, cells expressing the variant exhibited more than a 3500-fold reduction in HCMV 
growth. Our study demonstrates that RNase P ribozyme variants are efficient in reducing HCMV 
infection and are potentially useful for anti-viral therapeutic applications. 
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